<SEC-DOCUMENT>0001575872-25-000012.txt : 20250107
<SEC-HEADER>0001575872-25-000012.hdr.sgml : 20250107
<ACCEPTANCE-DATETIME>20250107172553
ACCESSION NUMBER:		0001575872-25-000012
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		46
FILED AS OF DATE:		20250107
DATE AS OF CHANGE:		20250107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Advanced Biomed Inc.
		CENTRAL INDEX KEY:			0001941029
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NV

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-272110
		FILM NUMBER:		25515850

	BUSINESS ADDRESS:	
		STREET 1:		401 RYLAND ST
		STREET 2:		STE 200-A
		CITY:			RENO
		STATE:			NV
		ZIP:			89502
		BUSINESS PHONE:		86-21-20510823

	MAIL ADDRESS:	
		STREET 1:		401 RYLAND ST
		STREET 2:		STE 200-A
		CITY:			RENO
		STATE:			NV
		ZIP:			89502
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>vc051_s1a.htm
<DESCRIPTION>FORM S-1A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the United States Securities and
Exchange Commission on January 7, 2025.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-272110</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDMENT NO. 14 TO</B></P>
<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>UNDER</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Advanced Biomed Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>8071</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>87-2177170</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>incorporation or organization)</B></P></TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Primary Standard Industrial</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Classification Code Number)</B></P></TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification Number)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>No. 689-85 Xiaodong Road, Yongkang District</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tainan City, Taiwan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: 886-6-3121716</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Cogency Global Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>122 East 42nd Street, 18th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, NY 10168</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(212) 947-7200</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies of all communications to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Fang Liu, Esq.</B></FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>VCL Law LLP</B></FONT></P></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><B>William S. Rosenstadt, Esq.</B></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><B>Mengyi &ldquo;Jason&rdquo; Ye, Esq.</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>1945 Old Gallows Road</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>Ortoli Rosenstadt LLP</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Suite 260</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>366 Madison Avenue, 3rd Floor</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Vienna, VA 22182</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>New York, NY 10017</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Telephone: (703) 919-7285</B></FONT></TD>
    <TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center"><B>Telephone: (212) 588-0022</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate date of commencement of proposed
sale to the public: As soon as practicable after the effective date of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
box: <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large
accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; text-align: left"><FONT STYLE="font-size: 10pt">Large Accelerated Filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: left"><FONT STYLE="font-size: 10pt">Accelerated Filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: justify"><FONT STYLE="font-size: 10pt">Non-Accelerated Filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: justify"><FONT STYLE="font-size: 10pt">Smaller Reporting Company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Emerging Growth Company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>The registrant hereby amends this registration statement on such date or
dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that
this registration statement shall hereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the
registration statement shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to
said Section 8(a), may determine.</B>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Registration Statement contains two prospectuses, as set forth
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Primary
                                    Offering Prospectus. A prospectus to be used for the initial primary underwritten public offering
                                    of 1,875,000 Common Stock of the Registrant through the underwriter named on the cover page of the
                                    Primary Offering Prospectus. The initial primary underwritten public offering is referred to as the
                                    &ldquo;Primary Offering.&rdquo;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Resale
                                            Prospectus. A prospectus to be used for the resale by the selling stockholders &nbsp;of up
                                            to 1,875,000 Common Stock of the Registrant (the &ldquo;Resale Shares&rdquo; and each a &ldquo;Resale
                                            Share&rdquo;). &nbsp;Each of the two selling stockholders identified in the Resale Prospectus
                                            is referred to as a &ldquo;Selling Stockholder&rdquo; and together, &ldquo;Selling Stockholders.&rdquo;
                                            The offering of the Resale Shares is referred to as the &ldquo;Resale Offering.&rdquo;</FONT></P>

</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Resale Prospectus is substantively identical
to the Primary Offering Prospectus, except for the following principal points:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">they contain different outside and inside front covers and back covers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Offering section in the Prospectus Summary section from the Primary Offering Prospectus on page 12 is deleted and replaced with a revised the Offering section on page Alt-1;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Use of Proceeds section from the Primary Offering Prospectus on page 47 is deleted and replaced with a revised the Use of Proceeds section on page Alt-5;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">a Selling Shareholder section is included in the Resale Prospectus on page Alt-2; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Underwriting section from the Primary Offering Prospectus on page 106 is deleted and replaced with a Selling Stockholders Plan of Distribution section on page Alt-3; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Legal Matters section from the Primary Offering Prospectus on page 114 is deleted and replaced with a revised the Legal Matters section on page Alt-5.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant has included in this Registration
Statement a set of alternate pages after the back-cover page of the Primary Offering Prospectus (the &ldquo;Alternate Pages&rdquo;) to
reflect the foregoing differences in the Resale Prospectus as compared to the Primary Offering Prospectus. The Primary Offering Prospectus
will exclude the Alternate Pages and will be used for the Resale Offering by the Registrant and the Selling Stockholders. The Resale Prospectus
will be substantively identical to the Primary Offering Prospectus except for the addition or substitution of the Alternate Pages and
will be used for the resale offering by the Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>The information in
this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed
with the United States Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does
it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Red">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0"><FONT STYLE="color: Red"><B>PRELIMINARY
PROSPECTUS</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Subject to Completion, dated January 7,
2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Advanced Biomed Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc051_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>1,875,000 Shares
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the offer and sale of 1,875,000 shares of common stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;), of Advanced Biomed Inc.
(&ldquo;Advanced Biomed&rdquo;). We expect that the Primary Offering price will be between $4.00 to $6.00 per share of Common Stock. Prior
to this offering, there has been no public market for our Common Stock. We have applied to list our Common Stock on the Nasdaq Capital
Market under the symbol &ldquo;ADVB.&rdquo; We cannot guarantee that we will be successful in listing our Common Stock on the Nasdaq Capital
Market; however, we will not complete this offering unless we are so listed on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Advanced Biomed Inc. is not
an operating company but a holding company incorporated in the State of Nevada. Substantially all of the business operations are conducted
in Taiwan by our Taiwan subsidiary. And we also have a subsidiary in Hong Kong and a Shanghai subsidiary in Mainland China.&nbsp;<B>Shares
of Common Stock offered in this offering are shares of a U.S. holding company</B>,&nbsp;<B>which does not conduct operations</B>. As used
in this prospectus, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company&rdquo; refers to Advanced Biomed, the
U.S. holding company. While our subsidiaries in Mainland China and Hong Kong do not operate with a variable interest entity (&ldquo;VIE&rdquo;)
structure, the Chinese regulatory authorities could disallow our current operating structure, which would likely result in a material
change in our operations and/or a material change in the value of the securities we are registering for sale, including that it could
cause the value of such securities to significantly decline or become worthless. See &ldquo;Risk Factors &mdash; Changes in the policies,
regulations, rules, and the enforcement of laws of the PRC government may be quick with little advance notice and could have a significant
impact upon our ability to operate profitably in the PRC.&rdquo;; and &ldquo;Risk Factors &mdash; The Chinese government may intervene
in or influence our operations in the Mainland China and Hong Kong at any time or may exert more control over offerings conducted overseas
and/or foreign investment in us, which could result in a material change in our operations and and/or the value of the securities we are
registering for sale.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; text-align: justify; margin: 0"><I>Although the majority of our
operations are not conducted in Mainland China, we face various legal and operational risks and uncertainties relating to our Shanghai
subsidiary, Shanghai Sglcell Biotech Co., Ltd., and such legal and operational risks and uncertainties also apply to our holding company,
Advanced Biomed HK Limited (&ldquo;Advanced Biomed HK&rdquo;), in Hong Kong. The Chinese government may intervene or influence the operation
of our Shanghai subsidiary and Advanced Biomed HK and exercise significant oversight and control over the conduct of their business and
may intervene in or influence their operations at any time, or may exert more control over securities offerings conducted overseas and/or
foreign investment in us, which could result in a material change in our operations and/or the value of our Common Stock. Further, any
actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment
in us could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the
value of such securities to significantly decline or be worthless.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I></I></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 40pt; text-align: justify"><I>Recently, the PRC government initiated a series of regulatory actions and
statements to regulate business operations in China with little advance notice, including cracking down on illegal activities in the securities
market, adopting new measures to extend the scope of cybersecurity reviews, and expanding the efforts in&nbsp;anti-monopoly&nbsp;enforcement.
As advised by our PRC counsel, AllBright Law Offices (&ldquo;AllBright&rdquo;), we do not believe that we are directly subject to these
regulatory actions or statements, as our Shanghai subsidiary does not have a VIE structure and their operations are not subject to cybersecurity
review requirements, or involve any type of foreign investment restricted industry. Because these statements and regulatory actions are
new, it is highly uncertain how soon legislative or administrative rule making bodies in China will respond to them, or what existing
or new laws or regulations will be modified or promulgated, if any, or the potential impact such modified or new laws and regulations
will have on our subsidiaries&rsquo; daily business operations or ability to accept foreign investments and list on an U.S. exchange.
In July 2021, the Cyberspace Administration of China (&ldquo;CAC&rdquo;) opened cybersecurity probes into several U.S.-listed technology
companies focusing on anti-monopoly regulation, and how companies collect, store, process and transfer data, among other things. On October
23, 2021, the Standing Committee of the National People&rsquo;s Congress issued a discussion draft of the amended Anti-Monopoly Law, which
proposes to increase the fines for illegal concentration of business operators to &ldquo;no more than ten percent of its last year&rsquo;s
sales revenue if the concentration of business operator has or may have an effect of excluding or limiting competition; or a fine of up
to RMB5 million if the concentration of business operator does not have an effect of excluding or limiting competition.&rdquo; On December
24, 2021, nine government agencies jointly issued the Opinions on Promoting the Healthy and Sustainable Development of Platform Economy,
which provides that, among others, monopolistic agreements, abuse of dominant market position and illegal concentration of business operators
in the field of platform economy will be strictly investigated and punished in accordance with the relevant laws. We do not hold a dominant
market position in our product markets and we have not entered into any monopolistic agreement. We have not received any inquiry from
the relevant governmental authorities. On July 10, 2021, the CAC published a revised draft revision to the Cybersecurity Review Measures
for public comment, or the Draft Cybersecurity Measures, and together with 12 other Chinese regulatory authorities, released the final
version of the Revised Measures for Cybersecurity Review, or the Revised Cybersecurity Measures, in December 2021, which took effect on
February 15, 2022. Pursuant to the Revised Cybersecurity Measures, critical information infrastructure operators procuring network products
and services and online platform operators carrying out data processing activities, which affect or may affect national security, shall
conduct a cybersecurity review pursuant to the provisions therein. In addition, online platform operators possessing personal information
of more than one million users seeking to be listed on foreign stock markets must apply for a cybersecurity review. Further, an expert
interpretation of the Revised Cybersecurity Measures published at the CAC&rsquo;s website on February 17, 2022 indicated no application
review is required for operators that have been listed abroad before the implementation of the Revised Cybersecurity Measures. The Revised
Cybersecurity Measures apply to companies going abroad for secondary listing, dual primary listing and other new foreign listings and
subject to the reporting requirements. As advised by AllBright, we do not believe that we are an &ldquo;online platform operator&rdquo;
within the meaning of the Revised Cybersecurity Measures, and, we currently do not have over one million users&rsquo; personal information
and do not anticipate that we will be collecting over one million users&rsquo; personal information in the foreseeable future. The Regulation
on Network Data Security Management (the &ldquo;Network Data Regulation&rdquo;) was promulgated by the State Council on September 24,
2024, and will become effective as of January 1, 2025. The Network Data Regulation restates and further specifies the legal requirements
for personal information, important data, cross-border data transfer, network platform services, and data security. Among others, if the
network data processing activities have or may have impacts on national security, such activities shall be subject to national security
review in accordance with relevant laws and regulations. Any failure to comply with such requirements may subject us to, among others,
suspension of services, fines, revoking relevant business permits or business licenses and penalties. We are also not subject to Network
Data Regulation, since we currently do not collect data that affects or may affect national security and we do not anticipate that we
will be collecting data that affects or may affect national security in the foreseeable future.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 40pt; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"><I>On December&nbsp;24, 2021,&nbsp;China
Securities Regulatory Commission (the&nbsp;&ldquo;CSRC&rdquo;)&nbsp;issued the Administrative Provisions of the State Council Regarding
the Overseas Issuance and Listing of Securities by Domestic Enterprises (the &ldquo;Draft Administrative Provisions&rdquo;) and the Measures
for the Overseas Issuance of Securities and Listing Record-Filings&nbsp;by Domestic Enterprises (Draft for Comments) (the &ldquo;Draft
Filing Measures&rdquo;), collectively, the Draft Overseas Listing Rules. On February 17, 2023, the CSRC&nbsp;released Trial Administrative
Measures of Overseas Securities Offering and Listing by Domestic Companies with five interpretive guidelines (the &ldquo;Trial Measures&rdquo;)
which came into effect on March 31, 2023. Pursuant to the Trial Measures, a PRC domestic company that seeks to offer and list securities
in overseas markets, either in direct or indirect overseas offering, shall fulfill the filing procedure with the CSRC per requirement
of the Trial Measures, submit relevant materials that contain a filing report and a legal opinion, and provide truthful, accurate and
complete information on the shareholder and etc. Direct overseas offering and listing by domestic companies refers to such overseas offering
and listing by a joint-stock company incorporated domestically. Any overseas offering and listing made by an issuer that meets both the
following conditions will be determined as indirect offering and listing in overseas market and, therefore, be subject to filing requirement:
(i) 50% or more of the issuer&rsquo;s operating revenue, total profit, total assets or net assets as documented in its audited consolidated
financial statements for the most recent accounting year is accounted for by domestic companies; and (ii) the main parts of the issuer&rsquo;s
business activities are conducted in the Mainland China, or its main places of business are located in the Mainland China, or the senior
managers in charge of its business operation and management are mostly Chinese citizens or domiciled in the Mainland China. The determination
as to whether or not an overseas offering and listing by domestic companies is indirect, shall be made on substance over form basis. As
of the date of this prospectus, as advised by AllBright, we are not required to obtain the approval from or complete the filing with the
CSRC for this offering and thus we have not submitted an application for approval for this offering with the CSRC pursuant to the Trial
Measures based on the facts that (i) we are a holding company incorporated in the State of Nevada, not a company incorporated under the
PRC law; (ii) based on the report on the Shanghai subsidiary from a third party accounting firm in China, the Shanghai subsidiary contributed
less than 50% to our operating revenue, total profit, total assets or net assets as documented in the audited consolidated financial statements
for the fiscal year ended June 30, 2024; (iii) the business activities are primarily conducted in Taiwan, with minimal operation in Mainland
China, and (iv) most of our officers and directors are non-Chinese citizens or domiciled outside Mainland China. Thus, we do not meet
the explicit conditions set out in the Trial Measures to determine whether an overseas offering shall be deemed as a direct or an indirect
overseas offering and listing by a domestic company. However, as the Trial Measures was newly published and the determination as to whether
or not an overseas offering and listing by domestic companies is indirect, shall be made on a substance over form basis, there are substantial
uncertainties as to the implementation and interpretation, and the CSRC may take a view that is contrary to our understanding of the Trial
Measures. If we are required by the CSRC to submit and complete the filing procedures of this offering and listing, we cannot assure you
that we will be able to complete such filings in a timely manner, or even at all. Any failure by us to comply with such filing requirements
under the Trial Measures may result in rectification, warnings, and a fine between RMB1 million and RMB10 million on our Shanghai subsidiary,&nbsp;which
could adversely and materially affect our business operations and financial outlook, and significantly limit or completely hinder our
ability to offer or continue to offer our Common Stock to investors and could cause the value of our Common Stock to significantly decline
or such shares to become worthless.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 40pt; text-align: justify"><I></I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 6pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>As of the date of this prospectus,
we and our only subsidiaries in the Mainland China and Hong Kong (1) are not required to obtain permissions from any PRC authorities to
operate or issue our Common Stock to foreign investors, (2) are not subject to permission requirements from the CSRC, CAC or any other
entity that is required to approve of our PRC subsidiary&rsquo;s operations, and (3) have not received or were denied such permissions
by any PRC authorities. As of the date of this prospectus, these new laws and guidelines have not impacted our ability to conduct our
business, accept foreign investments, or continue to list on a U.S. or other foreign exchange; however, if (i) we inadvertently conclude
that permissions or approvals are not required from applicable PRC authorities, (ii) applicable laws, regulations, or interpretations
change, and we are required to obtain such permissions or approvals in the future, or (iii) we fail to file or were denied any required
permission from the PRC authorities to this offering, any follow-up offerings or transactions, our ability to conduct our business may
be materially impacted, and we will not be able to continue listing on any U.S. exchange, continue to offer securities to investors, the
interest of the investors may be materially and adversely affected and our Common Stock may significantly decrease in value or become
worthless. To date, there are uncertainties in the interpretation and enforcement of these new laws and guidelines, which could materially
and adversely impact our business and financial outlook and may impact our ability to accept foreign investments, or continue to list
on a U.S. or other foreign exchange. See &ldquo;Risk Factors &mdash; The Chinese government may intervene in or influence our operations
in the Mainland China or Hong Kong at any time or may exert more control over offerings conducted overseas and/or foreign investment in
us, which could result in a material change in our operations and and/or the value of the securities we are registering for sale;&rdquo;
&ldquo;Risk Factors &mdash; If the Chinese government were to exert more oversight and control over or impose new requirements for approval
from the PRC authorities to issue our Common Stock to foreign investors or list on a foreign exchange, such action could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to
significantly decline or be worthless;&rdquo; &ldquo;Risk Factors &mdash; If the Chinese government chooses to exert more oversight and
control over offerings that are conducted overseas and/or foreign investment in China-based issuers, such action could significantly limit
or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly
decline or be worthless;&rdquo; and &ldquo;Risk Factors &mdash; The M&amp;A Rules and certain PRC regulations may make it more difficult
for us to pursue growth through acquisitions.&rdquo;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Cash may be transferred
within our organization in the following manners: (i) Advanced Biomed may transfer funds to our subsidiaries, including our Shanghai subsidiary,
by way of capital contributions or loans, through intermediate holding subsidiaries or otherwise; (ii) we and our intermediate holding
subsidiaries may provide loans to our operating subsidiaries and vice versa; and (iii) our subsidiaries, including our Shanghai subsidiary,
may make dividends or other distributions to us through intermediate holding companies or otherwise. As of the date of this prospectus,
Advanced Biomed made nine capital contributions to Advanced Biomed Inc. (Taiwan) (&ldquo;Advanced Biomed Taiwan&rdquo;) and Advanced
Biomed HK to support their research and development.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I></I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>Date</I></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>Receiving Entity</I></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>Amount (US$)</I></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 29, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2,500,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 11, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">86,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">100,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 26, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">500,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 7, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">122,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 2, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">110,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 14, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">85,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 10, 2023</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">70,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 5, 2023</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">300,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center">April 9, 2024</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Advanced Biomed HK</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">150,000</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="text-indent: 0.5in; text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Other than the transfers
in the table above, we have not made any distribution of dividends or assets, cash transfers, capital contributions or loans among the
holding company or any of our subsidiaries. Any loans from us or our holding subsidiaries outside of Mainland China to our Shanghai subsidiary,
which is treated as a foreign-invested enterprise (&ldquo;FIE&rdquo;) under PRC law, are subject to PRC regulations and foreign exchange
loan registrations. Such loans to our FIE subsidiary to finance its activities must be registered with the State Administration of Foreign
Exchange (&ldquo;SAFE&rdquo;) or its local counterparts. As advised by AllBright, our PRC counsel, PRC laws, regulations and judicial
interpretations thereof do not prohibit using cash generated from one subsidiary to fund another subsidiary&rsquo;s operations by way
of short term interest free loans as long as they comply with relevant laws and procedures. </I><I>In the future, cash proceeds
raised from overseas financing activities, including this offering, may be transferred by us to our Taiwan and Hong Kong subsidiaries
and Shanghai subsidiary via capital contributions or shareholder loans. As of the date of this prospectus, Advanced Biomed has not made
dividend or other distributions to our shareholders. Advanced Biomed may pay dividends to our shareholders subject to our ability to service
our debts as they become due and provided that our assets will exceed our liabilities after the payment of such dividends. As a holding
company, Advanced Biomed may rely on dividends and other distributions on equity paid by our subsidiaries for our cash and liquidity requirements,
including payment of any debt we may incur outside of China and our expenses. If any of our subsidiaries incurs debt on its own behalf
in the future, the instruments governing such debt may restrict their ability to pay dividends to us. To the extent cash or assets in
the business is in the PRC or a PRC subsidiary, the cash or assets may not be available to fund operations or for other use outside of
the PRC due to interventions in or the imposition of restrictions and limitations on our or our subsidiaries&rsquo; ability by the PRC
government to transfer cash or assets or distribute earnings within our group or to U.S. investors. PRC laws and regulations applicable
to our Shanghai subsidiary permit payments of dividends only out of their retained earnings, if any, determined in accordance with applicable
accounting standards and regulations. Our Shanghai subsidiary may pay dividends only out of their respective accumulated after-tax profits
as determined in accordance with PRC accounting standards and regulations. In addition, our subsidiaries are required to set aside at
least 10% of its accumulated after-tax profits each year, if any, to fund certain statutory reserve funds, until the aggregate amount
of such funds reaches 50% of its registered capital. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its
after-tax profits to discretionary funds. These reserve funds and discretionary funds are not distributable as cash dividends. Furthermore,
dividends paid by our Shanghai subsidiary to its parent companies will be subject to a 10% withholding tax, which can be reduced to 5%
if certain requirements are met. The PRC government also imposes restrictions on the conversion of RMB into foreign currencies and the
remittance of currencies out of the PRC. As such, we may experience difficulties in completing the administrative procedures necessary
to obtain and remit foreign currency for the payment of dividends from our profits, if any, or transfer cash within our group, across
border, or to U.S. investors. Additionally, current Taiwan regulations only permit our Taiwan subsidiary to pay dividends to its shareholders
out of its accumulated profits, and Advanced Biomed Taiwan must set aside at least 10% of its accumulated profits each year and use it
to make up previous losses, if any. The statutory reserve cannot be distributed as cash dividends. As of the date of this prospectus,
no dividends, transfers, or distributions have been made within our group or to shareholders. We presently intend to retain all earnings
to fund our operations and business expansions and have no plan to distribute earnings to shareholders. We do not anticipate paying dividends
or other distributions to our shareholders, including U.S. investors, in the foreseeable future. See the relevant discussions in &ldquo;Risk
Factors &mdash; Risks Related to Doing Business in China&rdquo; on page 31; &ldquo;Risk Factors &mdash; PRC regulation on loans to, and
direct investment in, PRC entities by offshore holding companies and governmental control in currency conversion may delay or prevent
us from making loans to or making additional capital contributions to our Shanghai subsidiary&rdquo; on page 35; &ldquo;Risk Factors &mdash;
Our Shanghai subsidiary is subject to restrictions on paying dividends or making other payments to us, which may restrict our ability
to satisfy our liquidity requirements in the future&rdquo; on page 35; &ldquo;Risk Factors &mdash; Payment of dividends is subject to
restrictions under PRC laws&rdquo; on page 39; and &ldquo;Risk Factors &mdash; Advanced Biomed Taiwan is subject to restrictions on paying
dividend or making other payments to us, which may restrict our ability to satisfy its liquidity requirements&rdquo; on page 29.&rdquo;</I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Our Common Stock may be prohibited from trading on a national exchange
or &ldquo;over-the-counter&rdquo; markets under the Holding Foreign Companies Accountable Act (the &ldquo;HFCAA&rdquo;) if the Public
Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) determines it is unable to inspect or investigate completely our auditors for
three consecutive years beginning in 2021. Further, on June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies
Accountable Act (&ldquo;AHFCAA&rdquo;). If the AHFCAA is enacted into law, it would amend the HFCAA and require the United States Securities
and Exchange Commission (&ldquo;SEC&rdquo;) to prohibit an issuer&rsquo;s securities from trading on any U.S. stock exchanges if its auditor
is not subject to PCAOB inspections or complete investigations for two consecutive years instead of three. On December 29, 2022, a legislation
entitled &ldquo;Consolidated Appropriations Act, 2023&rdquo; (the &ldquo;Consolidated Appropriations Act&rdquo;), was signed into law
by President Biden. The Consolidated Appropriations Act contained, among other things, an identical provision to HFCAA, which reduces
the number of consecutive non-inspection years required for triggering the prohibitions under the HFCAA from three years to two. Pursuant
to the HFCAA, the PCAOB issued a Determination Report on December 16, 2021, which found that the PCAOB is unable to inspect or investigate
completely registered public accounting firms headquartered in Mainland China and Hong Kong because of positions taken by the authorities
in those jurisdictions. In addition, the PCAOB&rsquo;s report identified the specific registered public accounting firms which are subject
to these determinations. On August 26, 2022, the PCAOB signed a Statement of Protocol Agreement with the CSRC and the Ministry of Finance
(the &ldquo;MOF&rdquo;) of the PRC governing inspections and investigations of audit firms based in China or Hong Kong. On December 15,
2022, the PCAOB announced in the 2022 Determination its determination that the PCAOB was able to secure complete access to inspect and
investigate accounting firms headquartered in Mainland China and Hong Kong, and the PCAOB Board voted to vacate previous determinations
to the contrary. Should the PCAOB again encounter impediments to inspections and investigations in Mainland China or Hong Kong as a result
of positions taken by any authority in either jurisdiction, including by the CSRC or the MOF, the PCAOB will make determinations under
the HFCAA as and when appropriate. Our auditor, WWC, P.C., is headquartered in California and, as a PCAOB-registered public accounting
firm, is required to undergo regular inspections by the PCAOB to assess its compliance with the laws of the U.S. and professional standards.
WWC, P.C. has been subject to PCAOB inspections and is not among the PCAOB-registered public accounting firms headquartered in the PRC
or Hong Kong that are subject to PCAOB&rsquo;s determination of having been unable to inspect or investigate completely. Notwithstanding
the foregoing, if it is later determined that the PCAOB is unable to inspect or investigate our auditor completely, if there is any regulatory
change or step taken by PRC regulators that does not permit WWC, P.C. to provide audit documentations located in China or Hong Kong to
the PCAOB for inspection or investigation, or the PCAOB expands the scope of the Determination so that we are subject to the HFCAA, as
the same may be amended, you may be deprived of the benefits of such inspection. Any audit reports not issued by auditors that are completely
inspected or investigated by the PCAOB, or a lack of PCAOB inspections of audit work undertaken in China that prevents the PCAOB from
regularly evaluating our auditors&rsquo; audits and their quality control procedures, could result in a lack of assurance that our financial
statements and disclosures are adequate and accurate, which could result in limitation or restriction to our access to the U.S. capital
markets, and trading of our securities, including trading on the national exchange and trading on &ldquo;over-the-counter&rdquo; markets,
may be prohibited under the HFCAA and our securities may be delisted by an exchange. See &ldquo;Risk Factors &mdash; Recent joint statement
by the SEC and the PCAOB, rule changes by Nasdaq, and the Holding Foreign Companies Accountable Act all call for additional and more stringent
criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors
who are not inspected by the PCAOB. These developments could add uncertainties to our continued listing or future offerings of our securities
in the U.S.&rdquo;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>We are also registering
1,875,000 Common Stock for the resale of our Common Stock owned by the Selling Stockholders. No sales of the Resale Shares shall occur
until the closing of our Primary Offering. The Selling Stockholders may sell all or a portion of the Resale Shares from time to time
directly or through one or more transactions that may take place in ordinary brokers&rsquo; transactions, privately negotiated transactions
or through sales to one or more dealers for resale of such securities as principals. Usual and customary or specifically negotiated brokerage
fees or commissions may be paid by the Selling Stockholders. The offering by the Selling Stockholders will remain open for 180 days following
the date of the Resale Prospectus, and following the expiration of such 180 days period, we no longer intend to keep the resale registration
statement effective. See &ldquo;Selling Stockholders Plan of Distribution.&rdquo; We expect the initial offering price of the Resale
Shares will be between $4.00 and $6.00 per Resale Share until our Common Stock is listed on the Nasdaq Capital Market and there is an
established market for the Resale Shares. There are risks associated with having two offerings. See &ldquo;Risk Factors &mdash; Risks
Related to this Offering.&rdquo;</I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><I></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><I>Although our Hong Kong subsidiary
is a holding company with no operations, it may be subject to similar risks faced by our Shanghai subsidiary if the Chinese government
exert more control over or impose new laws or regulations on business activities in Hong Kong. See &ldquo;Risk Factors &mdash; Chinese
government may exert more control over Hong Kong business or impose new laws or regulations on business activities in Hong Kong.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are an &ldquo;emerging growth
company&rdquo; under applicable U.S. federal securities laws and are eligible for reduced public company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 15.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Share</B><SUP>(5)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B><SUP>(3)(4)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 70%"><FONT STYLE="font-size: 10pt">Assumed Primary Offering price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;4.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">7,500,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions <SUP>(1)(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">562,500</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Proceeds to us, before expenses<SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.70</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,937,500</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) We have agreed to pay the underwriters a commission equal to 7.50% of the
gross proceeds of the offering. Underwriting discounts and commissions do not include a non-accountable expense allowance equal to 1%
of the gross proceeds of this offering payable to the representative of the underwriters. We have also agreed to reimburse certain accountable
expenses to the representative, including, but no limited to, the representative&rsquo;s legal fees, background check expenses and other
expenses related to the offering, up to $200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) We have also agreed to issue to the representative of underwriters
warrants to purchase 112,500 shares of Common Stock (or 129,375 shares of Common Stock if the representative of underwriters exercises
its over-allotment option in full) equal to 6% of the shares sold in this offering, at a per share exercise price equal to 125% of the
per share offering price. The representative&rsquo;s warrants are exercisable at any time and from time to time, in whole or in part,
during the four-and-a-half-year period commencing six months following the date of commencement of sales of securities issued in this
offering. For a description of other terms of the representative&rsquo;s warrants and other compensation to be received by the underwriters,
see &ldquo;Underwriting&rdquo; beginning on page 106.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Excludes fees and expenses payable to the
representative. The maximum amount of the representative&rsquo;s expenses that we are required to reimburse related to this offering is
set forth in the section entitled &ldquo;Underwriting.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(4) Assumes the underwriters do not exercise any portion
of their over-allotment option as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Assumes that the Primary Offering price is
$4.00 per share, which is the lower end of the price range set forth on the cover page of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This offering is being conducted on a firm commitment basis. The underwriters
are obligated to take and pay for all of the shares offered by this prospectus if any such shares are taken. The underwriters are not
required to take or pay for the shares covered by the underwriters&rsquo; over-allotment option to purchase additional shares of Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have granted a 45-day option
to the underwriters to purchase up to 281,250 additional shares of Common Stock (equal to 15% of the shares sold in the offering) at the
same offering price to cover over-allotments, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Neither the United States Securities
and Exchange Commission nor any other regulatory body has approved or disapproved these securities or determined if this prospectus is
truthful or complete. Any representation to the contrary is a criminal offense.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The underwriters expect to deliver the Shares
to purchasers on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc051_img18.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Craft Capital Management LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></P>
                                                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_001" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_001" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_002" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_002" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">15</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_003" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Cautionary Note Regarding
    Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_003" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">46</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_004" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_004" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">47</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_005" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_005" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">48</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_006" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_006" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">49</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_017" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_017" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">50</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#b_001"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion
    and Analysis of Financial Conditions and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_001">51<FONT STYLE="font-size: 10pt"></FONT></A></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#v_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Industry</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#v_001">60</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#za_001">Business</A></TD>
    <TD STYLE="text-align: center"><A HREF="#za_001">62</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Management</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">95</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_009" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Security Ownership of Certain
    Beneficial Owners and Management</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_009" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">100</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_010" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Description of Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_010" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">101</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_011" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Shares Eligible for Future
    Sale</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_011" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">102</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_012" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Underwriting</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_012" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">106</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#a_013" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_013" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">114</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_014" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_014" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">114</FONT></A></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#c_001" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Enforceability of Civil Liabilities</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#c_001" STYLE="-sec-extract: exhibit">114</A></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#a_015" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Where You Can Find More
    Information</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_015" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">115</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><A HREF="#index"><FONT STYLE="font-size: 10pt">Index to Consolidated Financial
    Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#index"><FONT STYLE="font-size: 10pt">F-1</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025 (25 days after the commencement of this offering), all dealers effecting transaction in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver
a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MARKET, INDUSTRY AND OTHER DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About this Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">You should rely only on the information contained in this prospectus and
any free writing prospectus we may authorize to be delivered to you. We have not, and the underwriters have not, authorized anyone to
provide you with information different from, or in addition to, that contained in this prospectus and any related free writing prospectus.
We and the underwriters take no responsibility for, and can provide no assurances as to the reliability of, any information that others
may give you. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any jurisdiction where the
offer or sale is not permitted. The information contained in this prospectus is only accurate as of the date of this prospectus, regardless
of the time of delivery of this prospectus and any sale of our Common Stock. Our business, financial condition, results of operations
and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>For investors outside of
the United States:</B>&nbsp;Neither we nor any of the underwriters have done anything that would permit this offering or possession or
distribution of this prospectus or any free writing prospectus we may provide to you in connection with this offering in any jurisdiction
where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession
of this prospectus and any free writing prospectus must inform themselves about and observe any restrictions relating to this offering
and the distribution of this prospectus outside of the United States. See &ldquo;Underwriting&mdash; Offer restrictions outside the United
States&rdquo; on page 109.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Industry and Market Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This prospectus includes estimates regarding market
and industry data. Unless otherwise indicated, information concerning our industry and the markets in which we operate, including our
general expectations, market position, market opportunity, and market size, are based on our management&rsquo;s knowledge and experience
in the markets in which we operate, together with currently available information obtained from various third-party sources, including
publicly available information, industry reports and publications, surveys, our customers, trade and business organizations, and other
contacts in the markets in which we operate. Some data is also based on our good faith estimates. The industry in which we operate is
subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled &ldquo;Risk
Factors.&rdquo; These and other factors could cause results to differ materially from those expressed in these publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<DIV STYLE="padding: 5pt; border: Black 1pt solid">




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary contains basic information about
us and the offering contained elsewhere in this prospectus. Because it is a summary, it does not contain all the information that you
should consider before investing in our securities. You should read and carefully consider the entire prospectus before making an investment
decision, especially the information presented under the headings &ldquo;Risk Factors,&rdquo; &ldquo;Cautionary Note Regarding Forward-Looking
Statements,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation&rdquo; and all other
information included in this prospectus in its entirety before you decide whether to purchase any shares offered by this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Unless the context requires otherwise, the
words &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company,&rdquo; &ldquo;the Company,&rdquo; and &ldquo;Advanced
Biomed&rdquo; refer to Advanced Biomed Inc., a holding company incorporated in the State of Nevada.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Our Mission</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are committed to the application research of integrating semiconductor
technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker
cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services
include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a holding company incorporated in the State of Nevada. We operate
through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and
development of the company's primary technologies and products. Since our establishment in 2014, we have been focusing on the integration
of multiple interdisciplinary technologies and established our own microfluidic technology platform. Utilizing the physical and molecular
biological characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor
technology and biotechnology. This includes complex precision structures, dielectric detection, functional microfluidic biochips, microfluidic
integrated semiconductor sensors, related application modules, and key components of medical testing equipment. We have also developed
a series of medical testing equipment and related products by integrating various functions of microfluidic modules, automation software,
and hardware. Our technologies and products can be used for early screening and detection, diagnosis and staging, and treatment of cancer
through the detection of circulating tumor cells and related tumor markers in blood samples, capture of single circulating tumor cells,
and single-cell sorting and determination. These products provide assistance in treatment selection and patient prognosis intervention
once the required licenses and approvals have been obtained. Advanced Biotech HK is our first localized operation company, mainly responsible
for market operation and management in China, localized production, product registration, and future local market sales of our products
in accordance with relevant local regulations in China. Our Shanghai subsidiary owns some of our R&amp;D equipment and patents and will
be responsible for operations related to clinical trials in Mainland China through contract research organizations (&ldquo;CROs&rdquo;).
In the future, we also plan to establish operation centers in countries and regions in North America and Europe.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our devices, A<SUP>+</SUP>Pre,
AC-1000, A<SUP>+</SUP>CellScan, and A<SUP>+</SUP>SCDrop, and three corresponding microfluidic biochips, A<SUP>+</SUP>Pre Chip and AC-1000
CTC Enrichment Chip and A<SUP>+</SUP>CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer
patients. Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation
and enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A+CellScan is mainly
used for fluorescent labeling and automatic scanning judgment of targeted cells while A+SCDrop preserves the original viability of single
cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, we have finished
the research and development stage for four matching immunostaining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM,
and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different
colors to bind to specific proteins on the cell surface or inside the cells. The presence and intensity of fluorescent signals can be
observed through a separate fluorescent imaging system, and the expression of the target protein and the cell type can be judged and determined
accordingly. Different cell types can be distinguished using multiplexed combined staining with different antibodies. The A<SUP>+</SUP>CTCE
kit is mainly used to identify epithelial circulating tumor cells, the A<SUP>+</SUP>CTCM kit is used to identify mesenchymal circulating
tumor cells, the A<SUP>+</SUP>EMT kit is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, and the A<SUP>+</SUP>CM
kit is used to identify tumor-associated macrophages (cancer-associated macrophage-like cells).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also developed a product
for early screening of lung cancer, the A<SUP>+</SUP>LCGuard Lung Cancer Early Screening Kit (&ldquo;A<SUP>+</SUP>LCGuard&rdquo;), which
is used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the
research, design, and development of A<SUP>+</SUP>LCGuard. A<SUP>+</SUP>LCGuard is a Class III medical device and is required to conduct
clinical trials before completing the registration process, and we plan to begin A+LCGuard&rsquo;s clinical research by the end of June
2025. We believe clinical research serves as the foundation for clinical trials, bridging the gap between preclinical studies and large-scale
clinical trials. We&nbsp; believe clinical trials enables an understanding of subject recruitment, facilitates the development of appropriate
inclusion and exclusion criteria for later stages, and helps verify trial procedures. Additionally, we believe it increases familiarity
with the trial products. In June 2025, the Company and the CRO plan to collaborate to draft the clinical research protocol and begin preparing
the necessary equipment, consumables, reagent kits, and other materials for the study. By the end of September 2025, we expect that the
clinical research protocol may pass ethical review and receive ethics committee approval. Thereafter, we plan to initiate the trial stage
of the clinical research, with completion anticipated within six months of October 2025. We believe the results of the clinical research
will inform the work plan for future large-scale clinical trials, minimizing waste from an excessively large sample size or insufficient
statistical power due to a sample size that is too small. We recognize that the clinical research results may differ from expectations
and may not support our expected progression to clinical trials. If so, we plan to promptly optimize the product, adjust participant group
selection, and modify the final protocol for large-scale clinical trials. However, we cannot guarantee that any clinical research or trial
will meet our anticipated outcomes. Furthermore, delays in obtaining ethical approval or recruiting participants could prevent the clinical
research from being completed on schedule. Such delays could subsequently postpone the large-scale clinical trial and ultimately the product
launch date.</P>



</DIV>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must go through
three steps to receive the required clearance from the National Medical Products Administration of China (&ldquo;NMPA&rdquo;) before they
can be sold to customers. The three steps are research and development, registration application, and registration review, which must
be done in that order. At the registration application stage, we have to assemble all the required application materials, complete clinical
trials (if required by NMPA), and work with an NMPA accredited third-party organization to examine our products in accordance with NMPA
rules. NMPA will review our application during the registration review period and may request additional information before officially
approving or denying our applications. Currently, A<SUP>+</SUP>Pre and AC-1000 and their corresponding chips have been cleared by the
NMPA; the four matching immunostaining kits and A<SUP>+</SUP>SCDrop are under registration review; A<SUP>+</SUP>CellScan,
A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>LCGuard are ready to start their registration applications. As of the date of this prospectus,
we have not applied for similar clearances from other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We participated in a scientific
research project at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies to test
A<SUP>+</SUP>Pre, AC-1000 and A<SUP>+</SUP>LCGuard. In the study, we selected 123 individuals, and among them, 75 were surgical patients
with nodular changes or shadows in the lungs reported by imaging studies and 48 healthy patients without lung nodules reported by imaging
studies. 7ml blood samples were taken from test subjects either before the clinical operation (for cancer patients) or after the physical
examination (for healthy individuals), and A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>LCGuard kits were used to determine whether there
were circulating tumor cells and other tumor markers in the blood samples. Finally, the pathological and physical examination results
of the tested individuals were compared with the test results of our products. Our test results achieved 96% sensitivity and 99.9% specificity,
which provides the research and development basis for our products. Specifically, A<SUP>+</SUP>Pre and AC-1000 were at the research and
development stage, and we completed their effectiveness and performance indicators testing through this project. At the same time, A<SUP>+</SUP>LCGuard
finished its feasibility and functional verification testing. All three products were tested together throughout the entire project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must be approved
by applicable regulatory authorities before being sold to customers. A<SUP>+</SUP>Pre and A<SUP>+</SUP>CellScan can work with third-party
products to achieve their designed objectives. AC-1000 and A<SUP>+</SUP>SCDrop may be used together with other devices according to different
application scenarios below. For the A<SUP>+</SUP>LCGuard early screening kit, it has to be used in combination with A<SUP>+</SUP>Pre
and AC-1000. Our four staining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CM, A<SUP>+</SUP>CTCM, and A<SUP>+</SUP>EMT, can be used independently
or with third-party products. A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>CellScan require the use of our supporting microfluidic chips.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the analysis of high-viscosity blood samples: A<SUP>+</SUP>Pre
can be independently used for pretreatment, retaining the original cell activity while preventing blood samples from clogging the equipment
pipeline after entering the detection equipment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the identification and counting application of circulating tumor cells:
blood samples are diluted with A<SUP>+</SUP>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells and related tumor
markers. The enriched samples are stained, calibrated, and finally identified and counted. We can provide this service to the public if
using third-party staining reagents already on the market in China. However, we plan to officially roll out this service once our in-house
developed staining reagents, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM, complete the registration process.
The identification and counting of circulating tumor cells and related tumor marker cells can provide auxiliary references for relevant
clinical applications.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">The capture of circulating tumor cells: we follow the same process
as the identification of circulating tumor cells to obtain enriched samples with A<SUP>+</SUP>Pre and AC-1000, and then the samples are
captured and separated by A<SUP>+</SUP>SCDrop to isolate single circulating tumor cells. This service can provide tumor cells with high
purity and high activity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For early screening of lung cancer: peripheral blood samples
of the subjects are first obtained, and the target cells are enriched and captured sequentially by A<SUP>+</SUP>Pre and AC-1000. After
that, A<SUP>+</SUP>LCGuard performs cell fluorescence staining on the enriched samples to determine the number of targeted cells, and
finally makes a judgment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the different regulatory
requirements for the marketing of medical device products and in-vitro diagnostics (&ldquo;IVD&rdquo;) products in various regions/countries,
it is necessary to complete the registration application and obtain the corresponding license in accordance with the local regulations
before engaging in commercial activities in the respective regions/countries (&ldquo;localization registration&rdquo;). Afterward, marketing
and sales can be carried out. We follow the principle of modularization when design and develop all of our products and equipment so that
products and equipment can be produced locally to meet different regulatory requirements. Based on the current development of the early
tumor screening and preventive treatment industry and the characteristics of the products we are planning to register and apply in the
future, we have adopted the operation model of centralized research and development and localized management. We have started the registration process with the NMPA in China for all of our products. Later on, the Company may establish subsidiaries
in the United States and Europe to produce products and carry out product registration. To achieve that, our products must be cleared
by the United States Food and Drug Administration and go through the conformity assessment process to obtain the Conformite Europeenne
marking (&ldquo;CE marking&rdquo;) from competent authority in each European Union member state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are looking for suitable locations
in the states of California and Washington for our planned expansion to the North America market. We aim to complete site selection and
personnel recruitment in the United States by the end of 2024 and start product registration, testing and production afterward. Our US
subsidiary will be responsible for the production and registration of our equipment and related products in the US. Production, testing,
and clinical trials in our US market will be conducted in accordance with US regulations, and clinical data from trials conducted in China
will not be used to establish product standards. In addition, we plan to break into the European market in 2025 and conduct localized
management and operations in accordance with European regulations. In 2025, we also plan to begin the localized registration of our IVD
products in Europe. As of the date of this prospectus, we have not conducted any clinical trials for our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
we have not commenced sales of our products nor have any revenue-generating products and do not expect sales of revenue-generating product
candidates until we have completed clinical development, submitted regulatory filings, and received applicable regulatory approvals for
candidate products. Due to differences in regulatory and clinical registration requirements, we may not be able to obtain device and product
approvals or provide product service on time. We expect to be in a state of continuous loss for the next two to three years.</P>



</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>Market Opportunities in Early Cancer
Detection Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The early cancer
detection market has huge potential. Early tumor screening and related diagnosis are the most active directions in the industry.
According to Grand View Research, Inc.&rsquo;s market analysis report, Liquid Biopsy Market Size, Share &amp; Trends Analysis
Report, the global liquid biopsy market size was valued at USD8,937.68 million in 2022 and is anticipated to grow at a CAGR of
12.46% from 2023 to 2030, resulting in sales worth USD22,865.56 million in 2030. The report provides market value for the base year
2022 and a yearly forecast till 2030 in terms of revenue in US dollars. It uses the bottom-up approach for market sizing, analyzing
key regional markets, dynamics, and trends for various services, and end-uses. The forecast of the global market is calculated by
integrating the regional markets&rsquo; amounts. The report has also considered factors including impact of COVID-19 up to 2023,
supply chain disruptions and demand dynamics. According to the report, liquid biopsy is a revolutionary technique that has created
various opportunities that were previously unexplored. It aids in detection and isolation of circulating tumor DNA, exosomes, and
circulating tumor cells and is a source of proteomics and genomics information in cancer patients. It is an easy, rapid, and
minimally invasive test for cancer genetic status based on circulating tumor cells, circulating tumor DNA, and other tumor-derived
substances in blood plasma samples. Rapid development in digital Polymerase Chain Reaction (PCR) and NGS-based technology has
improved accuracy of liquid biopsy. It can be performed repeatedly for disease monitoring and is anticipated to help overcome
limitations of tissue biopsies. It is worth noting that these are estimates of the global market, and we intend to initially focus
on developing our cancer screening market in China and plan to expand our operations to other markets in the following years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Oncology Detection Solutions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The current market uses positive
antibody-labeling selection to capture CTCs out of the blood by a specific epithelial cell adhesion molecule (EpCAM). This method could
detect tumor cells in the patient&rsquo;s blood for diagnosing lung, prostate, pancreatic, and breast cancers. However, this technology
costs approximately $1,000 per chip, and the processing time per patient is up to 12 hours. Besides, antibody-based methods such as immunomagnetic
methods are highly dependent on antigen expression of CTC. Some CTCs may show low or no EpCAM expression on the cell membrane, and thus
cannot be effectively captured using the proposed biomarkers and makes it difficult to detect cancer in the early stage. More importantly,
the capture of dying or dead CTCs cannot provide meaningful information to doctors for diagnosis or treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products use pure physical
mechanisms (antigen-independent) and can effectively enrich and detect the CTCs with high or low antigen expressions with high viability.
Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation and
enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A<SUP>+</SUP>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<SUP>+</SUP>SCDrop preserves the original
viability of single cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For three corresponding microfluidic
biochips, A<SUP>+</SUP>Pre Chip and AC-1000 CTC Enrichment Chip have been cleared by NMPA and can be mass-produced and sold to customers.
A<SUP>+</SUP>CellScan Chip is expected to start the registration application by the end of March 2024. The A<SUP>+</SUP>CellScan Chip
and A<SUP>+</SUP>CellScan will enrich our product chain by upgrading our immunochromogenic kits to tumor cell assay equipment. Specifically,
A<SUP>+</SUP>CellScan, together with A<SUP>+</SUP>Pre and AC-1000, can serve as a liquid biopsy IVD product to accelerate downstream assay
and reduce the amount of labor required for assaying tumor cells.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use our own product features
combined with different application scenarios to achieve the corresponding work objectives. To identify CTCs in liquid biopsy, blood
samples are first diluted through equipment A<SUP>+</SUP>Pre, then AC-1000 is used to separate and enrich circulating tumor cells, and
then the obtained cells are stained for identification and counting. We have been cleared by NMPA to provide this service to customers
in China and plan to do so once our matching immunostaining kits pass the NMPA&rsquo;s registration review. The counting of circulating
tumor cells can provide auxiliary reference for clinical diagnosis, treatment evaluation, prognosis evaluation, recurrence, and metastasis
detection, etc. In the future, we can also use our A<SUP>+</SUP>LCGuard early screening kit combined with two devices, A<SUP>+</SUP>Pre
and AC-1000, for early screening of lung cancer. In addition, we use A<SUP>+</SUP>SCDrop together with A<SUP>+</SUP>Pre and AC-1000 to
complete the capture of a single circulating tumor cell, which retains the original activity of the cell and can provide high-purity,
high-activity tumor cells for relevant clinical applications. It can be applied to various applications such as single-cell sequencing,
whole gene sequencing, protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, and individualized
drug sensitivity testing. The above product applications need to be approved by the local regulatory authorities before they can be provided
to customers.&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Commercialization Preparation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are committed to the development
of microfluidic chips, reagents and detectors for capturing circulating tumor cells in blood. We have integrated various complex precision
structures, dielectric detection and functional microfluidic biochips. Our devices include a variety of expensive semiconductor manufacturing
and precision micro-manufacturing related equipment. We signed a research project equipment use contract with Taiwan Semiconductor Research
Institute of National Applied Research Laboratories (&ldquo;TSRI&rdquo;) and used their semiconductor manufacturing equipment and precision
micro-nano processing equipment for chip technology research and development such as concept presentation of each R&amp;D process, cross-scale
composite structure production, rapid wafer trial production, material testing, and thin film production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As for the designed microfluidic
detector, since 2020, we have developed various functional microfluidic biomedical testing devices for microfluidic modules, automation
software, and hardware. We also designed, manufactured and processed an increasing number of key components of our testing devices. All
of our products must go through three steps to receive the required clearance from the National Medical Products Administration of China
(&ldquo;NMPA&rdquo;) before they can be sold to customers. The three steps are research and development, registration application, and
registration review, which must be done in that order. At the registration application stage, we have to assemble all the required application
materials, complete clinical trials (if required by NMPA), and work with an NMPA accredited third-party organization to examine our products
in accordance with NMPA rules. NMPA will review our application during the registration review period and may request additional information
before officially approving or denying our applications. Currently, A<SUP>+</SUP>Pre and AC-1000 and their corresponding chips have been
cleared by the NMPA; A<SUP>+</SUP>SCDrop, A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>LCGuard are at the registration
application stage; the four matching immunostaining kits are under registration review. As of the date of this prospectus, we have not
applied for similar clearances from other jurisdictions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although none of the chips has
been mass produced as of the date of this prospectus, we have been cooperating with the injection molding machine manufacturer Riva and
the mold manufacturer Unimold to conduct pre-mass production trial test for our A<SUP>+</SUP>Pre Chip and AC-1000 Enrichment Chip. During
the mass production trial test, we examine the following factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">whether the tested chip can work with its corresponding product,
and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">whether chips&rsquo; flatness, roughness, water leakage, critical
size and thickness match the original design.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A Chip is ready for mass-production
if each individual production line can produce at least 2,500 pieces per month and pass the quality control examination. During the quality
control examination, one chip out of every 48 chips will be randomly selected for verification and must achieve designed objectives when
working with their corresponding products and meet all the product specifications to pass the examination. The product specifications
are listed in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 10%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Flatness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Roughness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">No Water leakage </FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Critical size compared with original design</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Thickness</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif"><SUP>+</SUP></FONT>Pre Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.1 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R&lt;1.5 um /mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2 mm &plusmn;10%</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">AC<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">-</FONT>1000 Enrichment Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.3 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R &lt; 1.5 um/mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.5 mm &plusmn;10%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon completion of the pre-mass
production trial test, all of the randomly selected A<SUP>+</SUP>Pre Chips and AC-1000 Enrichment Chips can work with their corresponding
A<SUP>+</SUP>Pre and AC-1000 products and meet or exceed the production specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">One of every 48 chips was randomly selected and tested for performance
verification by using A549 lung cancer cells spiked into human blood. In May 2023, a total of 20 A+Pre chips were tested, with
a result of average tumor cell recovery rate of 94%, which exceeded the target rate of 90%, with the highest and lowest rates of 99% and
91.6%, respectively. The liquid and blood cells removal rate by A+Pre chip was between 90-92.5%, which is in line with the target rate
of 90-94%. A total of 12 AC-1000 chips were examined and the average recovery rate is 79.5%, which exceeded the target rate of 75%, with
the highest and lowest recovery rates of 88.6% and 76.8%, respectively. The blood cells depletion rate was &gt;2.5 logs, exceeding the
target rate of 2 logs, with the highest and lowest rate of 4 and 2.5 logs, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The specifications of the randomly
selected A<SUP>+</SUP>Pre and AC-1000 chips produced during the pre-mass production trial test can be found in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 10%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Flatness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Roughness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">No Water leakage </FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Critical size compared with original design</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Thickness</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif"><SUP>+</SUP></FONT>Pre Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.05 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R&lt;1.5 um /mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 3%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2 mm &plusmn;5%</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">AC<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">-</FONT>1000 Enrichment Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.08 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R &lt; 1 um/mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.5 mm &plusmn;10%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Riva is a mold manufacturing and
injection molding machine manufacturer. We have purchased a Riva injection molding machine at the end of October 2022 and completed the
mass production trial test for AC-1000 chips, and the production samples met our product specifications. The special structure mold core
we made combined with the Riva injection molding machine has repeatedly produced hundreds of pieces of AC-1000 chips. The quality of the
products is consistent and meet the product specifications of the microstructure characteristics. The operation on the equipment has achieved
the expected efficiency and cell enrichment efficiency. Each equipment is expected to produce 2,000 pieces AC-1000 chips per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unimold is a mold manufacturer and an ISO9001 plastic
injection molding foundry. We cooperate with Unimold to embed our specially manufactured mold core for A+Pre Chip into the mold cavity,
which will be employed at our future production facility. Although there is no formal cooperation agreement between Unimold and us, Unimold
produces custom-made molds for us on a make-to-order basis. Each time, we first discuss the mold specification with a Unimold representative,
then receive an offer from Unimold with the price, and Unimold will produce the customized mold for us to test. To protect our intellectual
property, Unimold and us entered into a Non-Disclosure Agreement (the &ldquo;NDA&rdquo;) with a term of three years. The NDA prohibits
both parties from disclosing confidential information without authorization and hiring the other party&rsquo;s employees during the term
of the NDA or within two years of the termination of the NDA. The NDA is governed by the laws of Taiwan, and any disputes arising from
the NDA must be resolved before Taiwan Tainan District Court. The chips produced by Unimold&rsquo;s mold have met the specifications set
by us, and a batch of small-scale trial production of 5,000 pieces was carried out in October 2022. Our A<SUP>+</SUP>Pre is operating
to expected efficacy and performance specifications using the in-house produced A<SUP>+</SUP>Pre Chip. One injection-type production equipment
is expected to produce 50,000 pieces of A<SUP>+</SUP>Pre Chip per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have built our microfluidic
technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines
our patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor
fabrication technology, and integrated application patented technology. Each geographic territory will establish clean rooms for chip
production in compliance with local regulations to meet local market demand. While performing its designed duties, our microfluidic technology
platform can provide customized services to third parties for a fee. We envision providing services such as OEM production of microfluidic
chips, micro-electromechanical components, biochips, sensors, and other components, customized product design, and commissioned development
and research services to customers. Different from the general Integrated Circuit (&ldquo;IC&rdquo;) wafer OEM production, our production
is based on our micro-nano manufacturing technology platform developed by professionals in various fields that integrates cross-field
knowledge, including Micro Electro Mechanical Systems (MEMS), lithography-assisted micromachining (LIGA), semiconductor process, and
soft materials such as silicone gel and polydimethylsiloxane. We boast the ability to develop, design, and manufacture micro-electromechanical
components and sensors, including three-dimensional microstructures or micro-optical-electromechanical integrated components. The material
of the microstructure can be multi-layer stacking of alloys and insulating materials, which may be used in a wide range of fields, such
as pressure or environment detection, MEMS oscillators, optical actuators, biomedical components, passive components, silicon optical
integration platforms, and microfluidic structures.&nbsp;&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The platform integrates our
AC-1000 and A<SUP>+</SUP>SCDrop devices. Our rare cell enrichment device AC-1000 integrates the A<SUP>+</SUP>Pre chip and AC-1000 CTC
enrichment chip. AC-1000 uses semiconductor nano ultra-sensitive biosensors and patented microfluidic chip technology to isolate rare
cells with complete cell activity. It has great potential to be applied to routine liquid biopsy and companion diagnosis in the future.
AC-1000 can satisfy different applications with corresponding special chip products. Our products also have the potential to provide application
services in tumor screening, auxiliary diagnosis, treatment evaluation, prognosis evaluation, recurrence and metastasis detection, individualized
medication guidance, and companion diagnosis. In terms of tumor screening, we have developed a complete set of service models for early
screening of lung cancer, and plan to begin the clinical research process by the end of June 2025. Our application services for the identification
of CTCs have matured, and the identification of CTCs can be used for tumor screening, auxiliary diagnosis, and treatment evaluation, etc.
Our CTCs single cell capture device A<SUP>+</SUP>SCDrop is used in combination with A<SUP>+</SUP>Pre and AC-1000. It preserves the original
activity of single cells and polymer microfluidic chips combined with cell dielectric sensing technology. With the technical advantages
combined with our IVD kit products, A<SUP>+</SUP>SCDrop can be used in a variety of applications, such as single-cell sequencing, whole
gene sequencing, protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, individualized drug susceptibility
testing, and other aspects of individualized precision medicine. We are also working on prognosis assessment, recurrence and metastasis
detection, individualized medicine, and companion diagnosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although no services have been provided to customers yet, we believe the application services using our products and devices will be an essential part of our future
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we have not received
any regulatory approvals necessary to commercialize our products, we believe that the following competitive strengths enable us to compete
effectively in and capitalize on the growing oncology detection market:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Own microfluidic technology platform</B>. We can quickly complete the product development and improvement we need on our own platform.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Proprietary Ultra-Sensitive Biosensor Technology</I></B><I>.
    </I>Our self-developed proprietary semiconductor nano ultra-sensitive biosensor technology integrates various composite precision
    structures, dielectric detection and functional microfluidic biochips to complete the microfluidic chips and reagents for capturing
    circulating tumor cells in a patient&rsquo;s blood. Our technology also enables a fast and inexpensive method for early cancer diagnosis
    because we mainly rely on self-developed equipment and products, including the microfluidic chips and the related reagents. Specifically,
    with the start and expansion of mass-production, the cost and price of microfluidic chips will drop multiple times. Also, since we
    estimate that we will enrich all the targeted cells, the amount of reagents required in the process will decrease correspondingly.
    Additionally, we are able to complete the detection and analysis in a short period of time while ensuring the accuracy of the results
    and reducing the death number of targeted cells throughout the process by employing our microfluidic technology platform, which uses
    self-developed microfluidic chips to separate and detect CTCs. By using automatic and efficient microfluidic chips, we can reduce
    human errors when capturing, releasing, counting, and detecting CTCs. For example, AC-1000 and its corresponding chip can achieve
    high throughput (800-1000 drops/s) and high flow rate (&gt;0.7ml/hr) while completely removing red blood cells in peripheral blood
    samples within 30 minutes. Due to the non-destructive nature of the rare cell enrichment system, it can maintain the original characteristics
    of the desired target cells through purely physical and high-purity enrichment processes, improving the accuracy of the results and
    reducing the number of target cells that die during the entire process<I>.</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><B><I>On Track to Commercialization.</I></B> All of our products must go through
    three steps to receive the required clearance from NMPA before they can be sold to customers. The three steps are research and development,
    registration application, and registration review, which must be done in that order. Currently, A+Pre and AC-1000 and their corresponding
    chips have been cleared by the NMPA; A+SCDrop, A+CellScan, A+CellScan Chip, and A+LCGuard are at the registration application stage;
    the four matching immunostaining kits are under registration review. We expect to submit the A+CellScan, and A+CellScan Chip&rsquo;s
    registrations to the NMPA in December 2024 while completing preliminary works for A+SCDrop&rsquo;s application. We have been cooperating
    with the injection molding machine manufacturer Riva Machinery Co., Ltd. (&ldquo;Riva&rdquo;) and the mold manufacturer Unimold Technology
    Inc. (&ldquo;Unimold&rdquo;) to conduct mass production mode testing and trial production. Although none of the chips has been mass-produced
    as of the date of this prospectus, we have purchased a Riva injection molding machine at the end of October 2022 and completed the
    mass production trial test of AC-1000 CTC Enrichment chip. We also cooperate with Unimold to embed our specially manufactured mold
    core for A+Pre Chip into the mold cavity made by Unimold. The chips produced have met the specifications set by us, and a batch of
    small-scale trial production of 5,000 pieces has been carried out in October 2022. Our equipment is operating to expected efficacy
    and performance specifications using in-house produced chips. Moreover, the prototype of A+CellScan and its corresponding chip have
    completed the performance study. You can find more information on page 66 under the heading &ldquo;A+CellScan.&rdquo; We are refining
    the production method of A+CellScan chip and have submitted the results of our medical device safety test to a third party for independent
    evaluation. In addition, we have completed the mass production trial test using the mold manufactured by Unimold in December 2023,
    and an independent third-party is evaluating the test result. The A+CellScan and its corresponding chip will enrich our product chain
    by upgrading our immunochromogenic kits to tumor cell assay equipment. Specifically, A+CellScan, together with A+Pre and AC-1000,
    can serve as a liquid biopsy IVD product to accelerate downstream assay time and reduce the amount of labor required for assaying
    tumor cells. In addition, we are actively carrying out registration application for our A+LCGuard kit products, as well as work related
    to research programs.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Multi-Disciplinary Management Team</I></B>. We have a multi-disciplinary management team, an R&amp;D team and strategic cooperation units composed of interdisciplinary and cross-field professionals and well-known experts. The R&amp;D team has the ability to combine semiconductor/integrated circuits and biomedical expertise. Our team has accumulated valuable experience from chip development and design, manufacturing, mass production, design and development of detectors, research and development of system modules, and the operation of clinical laboratory personnel.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will strive to be a leading
provider of precision oncology detection solutions by the following growth strategies:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Increase the market penetration
                                            </I></B>of our oncology auxiliary products and expand our product portfolio to actively focus
                                            on in vitro early diagnosis, rapid evaluation of chemotherapy drugs, individualized treatment
                                            including clinical screening of drugs, detection of drug resistance, and monitoring of tumor
                                            recurrences.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Develop cancer screening market
                                            in China and further expand to other regions</I></B>. We plan to initially focus on developing our cancer screening market in China. We also plan to expand to North American and European market
by setting up subsidiaries and localize production and operation to meet specific market demand and compliance requirements in the relevant
market.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Expand our R&amp;D</I></B>
                                            to strength and develop pipeline products. In the future, we will actively promote the research
                                            and development, application and registration of other cancer early screening products</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate History and Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Nevada
in July 2021 as a holding company. We started operations in 2014 through Advanced Biomed Taiwan as a research and development center
for technology research and product development. In August 2021, we established Advanced Biomed HK to integrate market development and
commercialization in the PRC. On January 1, 2022, Advanced Biomed HK acquired 100% equity interest of Shanghai Sglcell and its subsidiaries
from its shareholders for a consideration of RMB12 million. In March 2022, Advanced Biomed HK established Sglcell (Huangshan) Biotech
Co., Ltd.&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In July 2022, we consummated
a reorganization pursuant to which we acquired 100% equity interest of Advanced Biomed Taiwan, making it our wholly owned subsidiary.
On November 7, 2022, we obtained the approval of the Investment Commission of the Ministry of Economic Affairs (&ldquo;Taiwan Investment
Commission&rdquo;) for the reorganization, the Issue No. of which is &ldquo;<FONT STYLE="font-family: MS Mincho">&#32147;&#23529;&#19968;&#23383;&#31532;</FONT>11100116890<FONT STYLE="font-family: MS Mincho">&#34399;</FONT>&rdquo;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
June 8, 2023, pursuant to the Share Transfer Agreement entered into by Ting Wang and Haifeng Zhang, who are independent third-party individuals,
and Shanghai Sglcell on June 2, 2023, Shanghai Sglcell transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and
its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd., to Ting Wang and Haifeng Zhang at aggregate consideration of RMB500,000 (approximately
US$72,780) without any other obligations arising from the transfers.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
June 9, 2023, pursuant to the Share Transfer Agreement entered into by Ting Wang and Haifeng Zhang, who are independent third-party individuals,
and Shanghai Sglcell on May 31, 2023, Shanghai Sglcell transferred its wholly owned subsidiary, Shandong Sglcell Medical Devices Co.,
Ltd., to Ting Wang and Haifeng Zhang at zero consideration without any other obligations arising from the transfers.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On June 15, 2023, pursuant to the Share
Transfer Agreement entered into by Quantum Capital (Hong Kong) Limited, who is an independent third-party corporation, and Advanced Biomed
HK on June 9, 2023, Advanced Biomed HK transferred its wholly owned subsidiary, Sglcell (Huangshan) Biotech Co., Ltd., to Quantum Capital
(Hong Kong) Limited at zero consideration without any other obligations arising from the transfers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus, our Shanghai subsidiary is the only
operating entity we have in the mainland China and owns all of our patents and some of our R&amp;D equipment while the rest of our R&amp;D
equipment are owned by Advanced Biomed Taiwan. Our Shanghai subsidiary will also be responsible for operations related to clinical trials
in Mainland China through CROs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The chart below depicts the
corporate structure of the Company as of the date of this prospectus.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc051_img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company was incorporated in the State of
Nevada on July 16, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at No. 689-85, Xiaodong Rd., Yongkang Dist., Tainan City 710, Taiwan. Our telephone number is 886-6-3121716. We maintain a
corporate website at www.advanbiomed.com. Information on our website, and any downloadable files found there, are not part of this prospectus
and should not be relied upon with respect to this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Implications of Being an Emerging Growth
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify as an &ldquo;emerging
growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &ldquo;JOBS Act&rdquo;). An
emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally
to public companies in the United States. These provisions include:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a requirement to have only two&nbsp;years of audited financial statements and only two&nbsp;years of related Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations disclosure in this prospectus;&nbsp;</TD></TR>
                                                                                                                       </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduced executive compensation disclosure; and&nbsp;</TD></TR>
                                                                                                                                                                                </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant
to the Sarbanes-Oxley Act of 2002.&nbsp;</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may choose to take
advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and
may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide
to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may take advantage
of these provisions for up to five years or such an earlier time that we are no longer an emerging growth company. We would cease
to be an emerging growth company if we have more than $1.235 billion in annual revenue, have more than $700 million in the market
value of our shares held by non-affiliates, or issue more than $1 billion of non-convertible debt over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Transfers of Cash to and from Our Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash may be transferred within
our organization in the following manners: (i) Advanced Biomed may transfer funds to our subsidiaries, including our Shanghai subsidiary,
by way of capital contributions or loans, through intermediate holding subsidiaries or otherwise; (ii) we and our intermediate holding
subsidiaries may provide loans to our operating subsidiaries and vice versa; and (iii) our subsidiaries, including our Shanghai subsidiary,
may make dividends or other distributions to us through intermediate holding companies or otherwise. As of the date of this prospectus,
Advanced Biomed made nine capital contributions to Advanced Biomed Taiwan and Advanced Biomed HK to support their research and
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>Date</I></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>Receiving Entity</I></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><I>Amount (US$)</I></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 29, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2,500,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 11, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">86,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">100,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 26, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">500,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 7, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">122,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 2, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">110,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 14, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">85,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center">October 10, 2023</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">70,000</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">December 5, 2023</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">300,000</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center">April 9, 2024</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Advanced Biomed HK</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">150,000</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than the transfers in
the table above, we have not made any distribution of dividends or assets, cash transfers, capital contributions or loans among the holding
company or any of our subsidiaries. Any loans from us or our holding subsidiaries outside of Mainland China to our Shanghai subsidiary,
which is treated as a FIE under PRC law, are subject to PRC regulations and foreign exchange loan registrations. Such loans to our FIE
subsidiary to finance its activities must be registered with the SAFE or its local counterparts. As advised by AllBright, our PRC counsel,
PRC laws, regulations and judicial interpretations thereof do not prohibit using cash generated from one subsidiary to fund another subsidiary&rsquo;s
operations by way of short term interest free loans <I>as long as subject to applicable [--] and requires procedures</I>. In the future,
cash proceeds raised from overseas financing activities, including this offering, may be transferred by us to our Taiwan and Hong Kong
subsidiaries and Shanghai subsidiary via capital contributions or shareholder loans. As of the date of this prospectus, Advanced Biomed
has not made dividend or other distributions to our shareholders. Advanced Biomed may pay dividends to our shareholders subject to our
ability to service our debts as they become due and provided that our assets will exceed our liabilities after the payment of such dividends.
As a holding company, Advanced Biomed may rely on dividends and other distributions on equity paid by our subsidiaries for our cash and
liquidity requirements, including payment of any debt we may incur outside of China and our expenses. If any of our subsidiaries incurs
debt on its own behalf in the future, the instruments governing such debt may restrict their ability to pay dividends to us. To the extent
cash or assets in the business is in the PRC or the Shanghai subsidiary, the cash or assets may not be available to fund operations or
for other use outside of the PRC due to interventions in or the imposition of restrictions and limitations on our or our subsidiaries&rsquo;
ability by the PRC government to transfer cash or assets or distribute earnings within our group or to U.S. investors. PRC laws and regulations
applicable to our Shanghai subsidiary permit payments of dividends only out of their retained earnings, if any, determined in accordance
with applicable accounting standards and regulations. Our Shanghai subsidiary may pay dividends only out of their respective accumulated
after-tax profits as determined in accordance with PRC accounting standards and regulations. In addition, our subsidiaries are required
to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund certain statutory reserve funds, until the aggregate
amount of such funds reaches 50% of its registered capital. At its discretion, a wholly foreign-owned enterprise may allocate a portion
of its after-tax profits to discretionary funds. These reserve funds and discretionary funds are not distributable as cash dividends.
Furthermore, dividends paid by our Shanghai subsidiary to its parent companies will be subject to a 10% withholding tax, which can be
reduced to 5% if certain requirements are met. The PRC government also imposes restrictions on the conversion of RMB into foreign currencies
and the remittance of currencies out of the PRC. As such, we may experience difficulties in completing the administrative procedures necessary
to obtain and remit foreign currency for the payment of dividends from our profits, if any, or transfer cash within our group, across
border, or to U.S. investors. Additionally, current Taiwan regulations only permit our Taiwan subsidiary to pay dividends to its shareholders
out of its accumulated profits, and Advanced Biomed Taiwan must set aside at least 10% of its accumulated profits each year and use it
to make up previous losses, if any. The statutory reserve cannot be distributed as cash dividends. As of the date of this prospectus,
no dividends, transfers, or distributions have been made within our group or to shareholders. We presently intend to retain all earnings
to fund our operations and business expansions and have no plan to distribute earnings to shareholders. We do not anticipate paying dividends
or other distributions to our shareholders, including U.S. investors, in the foreseeable future. See the relevant discussions in &ldquo;Risk
Factors &mdash; Risks Related to Doing Business in China&rdquo; on page 31; &ldquo;Risk Factors &mdash; PRC regulation on loans to, and
direct investment in, PRC entities by offshore holding companies and governmental control in currency conversion may delay or prevent
us from making loans to or making additional capital contributions to our Shanghai subsidiary&rdquo; on page 35; &ldquo;Risk Factors &mdash;
Our Shanghai subsidiary is subject to restrictions on paying dividends or making other payments to us, which may restrict our ability
to satisfy our liquidity requirements in the future&rdquo; on page 35; &ldquo;Risk Factors &mdash; Payment of dividends is subject to
restrictions under PRC laws&rdquo; on page 39; and &ldquo;Risk Factors &mdash; Advanced Biomed Taiwan is subject to restrictions on paying
dividend or making other payments to us, which may restrict our ability to satisfy its liquidity requirements&rdquo; on page 29.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Risk Factor Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Our Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">We may not be able to develop or commercialize early cancer detection products
and compete with our competitors. See &ldquo;<I>Risk Factors &ndash; Risks Related to Our Business and Industry &ndash; We may be unable
to develop and commercialize our early cancer detection devices, chips or immunochromogenic kits on a timely basis, or at all</I>&rdquo;
on page 15; &ldquo;<I>If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue or achieve
and sustain profitability</I>&rdquo; on page 17; &ldquo;<I>If we do not launch new products in a timely manner, our products may become
obsolete and our results of operations may suffer</I>&rdquo; on page 18; &ldquo;<I>As of the date of this prospectus, we have not conducted
any clinical trials for our products. Uncertainties or failures in clinical trials of our product candidates could materially and adversely
affect our business operations</I>&rdquo; on page 19; and &ldquo;<I>We are an early stage cancer diagnostics company with a limited operating
history, which may make it difficult to evaluate our current business and predict our future </I>performance&rdquo; on page 15.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Associated with Government Regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We, our products and any future products may be adversely affected by uncertainties
and changes in China&rsquo;s regulations on the cancer screening industry and may fail to obtain, complete or maintain the required regulatory
approvals, licenses, registrations or filings. See &ldquo;<I>Risk Factors &ndash; Risks Associated with Government Regulations &ndash;
We may be adversely affected by uncertainties and changes in China's regulations on the cancer screening industry, and the lack of necessary
approvals, licenses, registrations or filings in relation to our business may adversely affect our business, results of operations and
prospects material adverse effects</I>&rdquo; on page 20; &ldquo;<I>If we fail to obtain, complete or maintain the required regulatory
approvals, licenses, registrations or filings, or if there is a delay in obtaining, complete or maintain the required regulatory approvals,
licenses, registrations or filings, we will not be able to commercialize our product candidates change, and our ability to generate revenue
will be significantly compromised</I>&rdquo; on page 20; and &ldquo;<I>Our products and any future products will be subject to ongoing
regulatory obligations and ongoing regulatory scrutiny, which may result in significant additional expenses, and if we fail to comply
with regulatory requirements or if there are unexpected issues with our products and/or product candidates, we may will be punished</I>&rdquo;
on page 21.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Associated with Our Testing and the Manufacture
and Supply of Our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">We plan to test and manufacture our products and future products around
the world and may be subject to various risks related to regulatory schemes, intellectual properties, data privacy. See &ldquo;<I>Risk
Factors &ndash;Risks Associated with Our Testing and the Manufacture and Supply of Our Products &ndash; Delays in the completion and obtaining
regulatory approvals of our manufacturing facilities, or damage, destruction or interruption of production at such facilities may delay
our development plans or commercialization efforts</I>&rdquo; on page 24; &ldquo;<I>Security threats to our information technology infrastructure
and unauthorized use of data by third parties could expose us to liability or damage our reputation and business</I>&rdquo; on page 25;
and &ldquo;<I>We may be subject to intellectual property infringement or misappropriation claims by third parties, which may force us
to incur substantial legal expenses and, if determined adversely against us, could disrupt our business</I>&rdquo; on page 26.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Relating to Our Financial Prospects and
Need for Additional Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">We have not generated positive cash income and any failure to raise
additional capital will significantly hinder our ability to continue our operations and developing new products. See &ldquo;<I>Risk Factors
&ndash; Risks Relating to Our Financial Prospects and Need for Additional Capital &ndash; We incurred net losses for the years ended June
30, 2024 and 2023 and the three-month period ended September 30, 2024, and may not be able to generate sufficient operating cash flows
and working capital to continue as a going concern. Failure to manage our liquidity and cash flows may materially and adversely affect
our financial condition and results of operations. As a result, we may need additional capital, and financing may not be available on
terms acceptable to us, or at all&rdquo; </I>on page 27<I>; &ldquo;We require substantial funding for our operations. If we cannot raise
sufficient additional capital on acceptable terms, our business, financial condition and prospects may be adversely affected&rdquo; </I>on
page 27<I>; </I>and <I>&ldquo;Raising additional capital may lead to dilution of shareholdings by our existing shareholders, restrict
our operations, and may further result in fair value loss adversely affecting our financial results&rdquo; </I>on page 28<I>.</I></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Doing Business in Taiwan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Our subsidiary in Taiwan is subject to risks related to complying with
Taiwan laws and regulations. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in Taiwan &ndash;Advanced Biomed Taiwan
is subject to restrictions on paying dividend or making other payments to us, which may restrict our ability to satisfy its liquidity
requirements</I>&rdquo; on page 29; and &ldquo;<I>Taiwanese investors holding more than 10% of Advanced Biomed Common Stock will be subject
to Taiwan regulations on investment or technical cooperation in China for its investment or technical cooperation in China</I>&rdquo;
on page 30.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The geopolitical tension between Taiwan and China that could negatively affect our business and hence the value of your investment. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in Taiwan &ndash; We face economic and political risks associated with doing business in Taiwan, particularly due to the geopolitical tension between Taiwan and China that could negatively affect our business and hence the value of your investment</I>&rdquo; on page 29.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The imposition of foreign exchange restrictions in Taiwan may have an adverse effect on foreign investors&rsquo; abilities to acquire securities of a Taiwan company, including the shares of our subsidiaries in Taiwan, or to repatriate the interest, dividends or sale proceeds from those securities. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in Taiwan &ndash; The imposition of foreign exchange restrictions in Taiwan may have an adverse effect on foreign investors&rsquo; abilities to acquire securities of a Taiwan company, including the shares of our subsidiaries in Taiwan, or to repatriate the interest, dividends or sale proceeds from those securities&rdquo; </I>on page 30.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Doing Business in China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We, through our Shanghai and Hong Kong subsidiaries, are subject to unique legal risks, and the enforcement of Chinese laws and regulations can change quickly with little advance notice. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in China &ndash; Changes in the policies, regulations, rules, and the enforcement of laws of the PRC government may be quick with little advance notice and could have a significant impact upon our ability to operate profitably in the PRC</I>&rdquo; on page 31; <I>&nbsp;Uncertainties in the interpretation and enforcement of PRC laws and regulations could limit the legal protections available to you and the Company&rdquo; </I>on page 33<I>; </I>and <I>&ldquo;You may experience difficulties in effecting service of legal process, enforcing foreign judgments, or bringing actions in PRC against us&rdquo; </I>on page 34<I>.</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Because we have subsidiaries in Shanghai and Hong Kong, the Chinese government
may intervene or influence our operations at any time or may exert more control over offerings conducted overseas and/or foreign investment
in &nbsp;us, which could result in a material change in our operations and/or the value of our securities we are registering to offer
and/or significantly limit or completely hinder our abilities to offer or continue to offer securities to investors and cause the value
of such securities to significantly decline or be worthless. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in China
&ndash; The Chinese government may intervene in or influence our operations in the Mainland China or Hong Kong at any time or may exert
more oversight or control over offerings conducted overseas and/or foreign investment in us, which could result in a material change in
our operations and and/or the value of the securities we are registering for sale</I>&rdquo; on page 31; &ldquo;<I>If the Chinese government
chooses to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers,
such action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause
the value of such securities to significantly decline or be worthless&rdquo; </I>on page 32; and &ldquo;<I>If the Chinese government were
to exert more oversight and control over or impose new requirements for approval from the PRC authorities to issue our Common Stock to
foreign investors or list on a foreign exchange, such action could significantly limit or completely hinder our ability to offer or continue
to offer securities to investors and cause the value of such securities to significantly decline or be worthless</I>&rdquo; on page 32.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">You may face difficulties enforcing liabilities against our directors and officers in China. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in China &ndash; Uncertainties in the interpretation and enforcement of PRC laws and regulations could limit the legal protections available to you and the Company</I>&rdquo; <I>on page 33 and <B>&ldquo;</B>You may experience difficulties in effecting service of legal process, enforcing foreign judgments, or bringing actions in PRC against us&rdquo; </I>on page 34.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Legal and operational risks associated with operating in China also apply to any operations in Hong Kong. See &ldquo;<I>Risk Factors &ndash; Risks Related to Doing Business in China &ndash; Chinese government may exert more control over Hong Kong business or impose new laws or regulations on business activities in Hong Kong&rdquo; </I>on page 36.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">You may experience extreme stock price volatility. See &ldquo;<I>Risk
Factors &ndash; Risks Related to this Offering &ndash;The market price of our Common Stock may be volatile or may decline regardless of
our operating performance, and you may not be able to resell your shares at or above the Primary Offering price</I>&rdquo; on page 43.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the majority of our operations are not conducted in Mainland China,
we face various legal and operational risks and uncertainties relating to our Shanghai subsidiary, Shanghai Sglcell Biotech Co., Ltd.,
and such legal and operational risks and uncertainties also apply to our holding company, Advanced Biomed HK, in Hong Kong. The Chinese
government may intervene or influence the operation of our Shanghai subsidiary and Advanced Biomed HK and exercise significant oversight
and control over the conduct of their business and may intervene in or influence their operations at any time, or may exert more control
over securities offerings conducted overseas and/or foreign investment in us, which could result in a material change in our operations
and/or the value of our Common Stock. Further, any actions by the Chinese government to exert more oversight and control over offerings
that are conducted overseas and/or foreign investment in us could significantly limit or completely hinder our ability to offer or continue
to offer securities to investors and cause the value of such securities to significantly decline or be worthless.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, the PRC government initiated a series of regulatory actions and
statements to regulate business operations in China with little advance notice, including cracking down on illegal activities in the securities
market, adopting new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. As
advised by our PRC counsel, AllBright, we do not believe that we are directly subject to these regulatory actions or statements, as our
Shanghai subsidiary does not have a VIE structure and their operations are not subject to cybersecurity review requirements, or involve
any type of <I>foreign investment</I> restricted industry. Because these statements and regulatory actions are new, it is highly uncertain
how soon legislative or administrative rule making bodies in China will respond to them, or what existing or new laws or regulations will
be modified or promulgated, if any, or the potential impact such modified or new laws and regulations will have on our subsidiaries&rsquo;
daily business operations or ability to accept foreign investments and list on an U.S. exchange. In July 2021, the CAC opened cybersecurity
probes into several U.S.-listed technology companies focusing on anti-monopoly regulation, and how companies collect, store, process and
transfer data, among other things. On October 23, 2021, the Standing Committee of the National People&rsquo;s Congress issued a discussion
draft of the amended Anti-Monopoly Law, which proposes to increase the fines for illegal concentration of business operators to &ldquo;no
more than ten percent of its last year&rsquo;s sales revenue if the concentration of business operator has or may have an effect of excluding
or limiting competition; or a fine of up to RMB5 million if the concentration of business operator does not have an effect of excluding
or limiting competition.&rdquo; On December 24, 2021, nine government agencies jointly issued the Opinions on Promoting the Healthy and
Sustainable Development of Platform Economy, which provides that, among others, monopolistic agreements, abuse of dominant market position
and illegal concentration of business operators in the field of platform economy will be strictly investigated and punished in accordance
with the relevant laws. We do not hold a dominant market position in our product markets and we have not entered into any monopolistic
agreement. We have not received any inquiry from the relevant governmental authorities. On July 10, 2021, the CAC published a revised
draft revision to the Cybersecurity Review Measures for public comment, or the Draft Cybersecurity Measures, and together with 12 other
Chinese regulatory authorities, released the final version of the Revised Measures for Cybersecurity Review, or the Revised Cybersecurity
Measures, in December 2021, which took effect on February 15, 2022. Pursuant to the Revised Cybersecurity Measures, critical information
infrastructure operators procuring network products and services and online platform operators carrying out data processing activities,
which affect or may affect national security, shall conduct a cybersecurity review pursuant to the provisions therein. In addition, online
platform operators possessing personal information of more than one million users seeking to be listed on foreign stock markets must apply
for a cybersecurity review. Further, an expert interpretation of the Revised Cybersecurity Measures published at the CAC&rsquo;s website
on February 17, 2022 indicated no application review is required for operators that have been listed abroad before the implementation
of the Revised Cybersecurity Measures. The Revised Cybersecurity Measures apply to companies going abroad for secondary listing, dual
primary listing and other new foreign listings and subject to the reporting requirements. As advised by AllBright, we do not believe that
we are an &ldquo;online platform operator&rdquo; within the meaning of the Revised Cybersecurity Measures, and, we currently do not have
over one million users&rsquo; personal information and do not anticipate that we will be collecting over one million users&rsquo; personal
information in the foreseeable future. The Regulation on Network Data Security Management (the &ldquo;Network Data Regulation&rdquo;)
was promulgated by the State Council on September 24, 2024, and will become effective as of January 1, 2025. The Network Data Regulation
restates and further specifies the legal requirements for personal information, important data, cross-border data transfer, network platform
services, and data security. Among others, if the network data processing activities have or may have impacts on national security, such
activities shall be subject to national security review in accordance with relevant laws and regulations. Any failure to comply with such
requirements may subject us to, among others, suspension of services, fines, revoking relevant business permits or business licenses and
penalties. We are also not subject to Network Data Regulation, since we currently do not collect data that affects or may affect national
security and we do not anticipate that we will be collecting data that affects or may affect national security in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 24, 2021, China Securities
Regulatory Commission (the &ldquo;CSRC&rdquo;) issued the Administrative Provisions of the State Council Regarding the Overseas Issuance
and Listing of Securities by Domestic Enterprises (the &ldquo;Draft Administrative Provisions&rdquo;) and the Measures for the Overseas
Issuance of Securities and Listing Record-Filings by Domestic Enterprises (Draft for Comments) (the &ldquo;Draft Filing Measures&rdquo;),
collectively, the Draft Overseas Listing Rules. On February 17, 2023, the CSRC released Trial Administrative Measures of Overseas Securities
Offering and Listing by Domestic Companies with five interpretive guidelines (the &ldquo;Trial Measures&rdquo;) which came into effect
on March 31, 2023. Pursuant to the Trial Measures, a PRC domestic company that seeks to offer and list securities in overseas markets,
either in direct or indirect overseas offering, shall fulfil the filing procedure with the CSRC per requirement of the Trial Measures,
submit relevant materials that contain a filing report and a legal opinion, and provide truthful, accurate and complete information on
the shareholder and etc. Direct overseas offering and listing by domestic companies refers to such overseas offering and listing by a
joint-stock company incorporated domestically. Any overseas offering and listing made by an issuer that meets both the following conditions
will be determined as indirect offering and listing in overseas market and, therefore, be subject to filing requirement: (i) 50% or more
of the issuer&rsquo;s operating revenue, total profit, total assets or net assets as documented in its audited consolidated financial
statements for the most recent accounting year is accounted for by domestic companies; and (ii) the main parts of the issuer&rsquo;s
business activities are conducted in the Mainland China, or its main places of business are located in the Mainland China, or the senior
managers in charge of its business operation and management are mostly Chinese citizens or domiciled in the Mainland China. The determination
as to whether or not an overseas offering and listing by domestic companies is indirect, shall be made on substance over form basis.
As of the date of this prospectus, as advised by AllBright, we are not required to obtain the approval from or complete the filing with
the CSRC for this offering and thus we have not submitted an application for approval for this offering with the CSRC pursuant to the
Trial Measures based on the facts that (i) we are a holding company incorporated in the State of Nevada, not a company incorporated under
the PRC law; (ii) based on the report on the Shanghai subsidiary from a third party accounting firm in China, the Shanghai subsidiary
contributed less than 50% to our operating revenue, total profit, total assets or net assets as documented in the audited consolidated
financial statements for the fiscal year ended June 30, 2024; (iii) the business activities are primarily conducted in Taiwan, with minimal
operation in Mainland China, and (iv) most of our officers and directors are non-Chinese citizens or domiciled outside Mainland China.
Thus, we do not meet the explicit conditions set out in the Trial Measures to determine whether an overseas offering shall be deemed
as an indirect overseas offering and listing by a domestic company. However, as the Trial Measures was newly published <I>and the determination
as to whether or not an overseas offering and listing by domestic companies is indirect, shall be made on a substance over form basis</I>,
there are substantial uncertainties as to the implementation and interpretation, and the CSRC may take a view that is contrary to our
understanding of the Trial Measures. If we are required by the CSRC to submit and complete the filing procedures of this offering and
listing, we cannot assure you that we will be able to complete such filings in a timely manner, or even at all. Any failure by us to
comply with such filing requirements under the Trial Measures may result in rectification, warnings, and a fine between RMB1 million
and RMB10 million on our Shanghai subsidiary, which could adversely and materially affect our business operations and financial outlook,
and significantly limit or completely hinder our ability to offer or continue to offer our Common Stock to investors and could cause
the value of our Common Stock to significantly decline or such shares to become worthless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt">As of the date of this prospectus, these new laws and guidelines have not
impacted our ability to conduct its business, accept foreign investments, or continue to list on a U.S. or other foreign exchange; however,
if (i) we inadvertently conclude that permissions or approvals are not required from applicable PRC authorities, (ii) applicable laws,
regulations, or interpretations change, and we are required to obtain such permissions or approvals in the future, or (iii) we fail to
file or were denied any required permission from the PRC authorities to this offering, any follow-up offerings or transactions, our ability
to conduct our business may be materially impacted, and we will not be able to continue listing on any U.S. exchange, continue to offer
securities to investors, the interest of the investors may be materially adversely affected and our Common Stock may significantly decrease
in value or become worthless. To date, there are uncertainties in the interpretation and enforcement of these new laws and guidelines,
which could materially and adversely impact our business and financial outlook and may impact our ability to accept foreign investments,
or continue to list on a U.S. or other foreign exchange. See &ldquo;Risk Factors &mdash; The Chinese government may intervene in or influence
our operations in the Mainland China or Hong Kong at any time or may exert more oversight or control over offerings conducted overseas
and/or foreign investment in us, which could result in a material change in our operations and and/or the value of the securities we are
registering for sale&rdquo;; &ldquo;Risk Factors &mdash; If the Chinese government were to exert more oversight and control over or impose
new requirements for approval from the PRC authorities to issue our Common Stock to foreign investors or list on a foreign exchange, such
action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the
value of such securities to significantly decline or be worthless&rdquo;; and &ldquo;Risk Factors &mdash; The M&amp;A Rules and certain
PRC regulations may make it more difficult for us to pursue growth through acquisitions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B></B></P>



<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Prospectus Conventions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Except where the context otherwise requires and for
purposes of this prospectus only:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Advanced Biomed
    Taiwan&rdquo; refers to Advanced Biomed Inc. (Taiwan);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Advanced Biomed HK&rdquo; refers to Advanced Biomed HK Limited;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;China&rdquo; or &ldquo;PRC&rdquo; refer to the People&rsquo;s
    Republic of China, including Hong Kong, Macau and Taiwan; however the only time such jurisdictions are not included in the definition of PRC
    and China is when we reference to the specific laws that have been adopted by the PRC; The term &ldquo;Chinese&rdquo; has a
    correlative meaning for the purpose of this prospectus; The term &ldquo;Mainland China&rdquo; refers to the People&rsquo;s Republic
of China, excluding Hong Kong, Macau and Taiwan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CRO&rdquo; refers to contract research organization, a type of third-party entity that is engaged by medical device research and manufacturing companies to conduct all or part of the required scientific or medical trials before a medical device can be sold to the public;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Common stock&rdquo; prior to the completion of this offering refers to shares our common stock of par value US$0.001 per share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;NMPA&rdquo; refers to National Medical Products Administration, formerly known as China Food and Drug Administration;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;NTD&rdquo; or &ldquo;NT$&rdquo; refers to New Taiwan Dollar, the legal currency of Taiwan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;RMB&rdquo; or &ldquo;Renminbi&rdquo; refers to the legal currency of the People&rsquo;s Republic of China;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Shanghai
    Sglcell&rdquo; or &ldquo;Shanghai subsidiary&rdquo; refers to Shanghai Sglcell Biotech Co., Ltd., a company incorporated in the
    People&rsquo;s Republic of China and our wholly foreign owned entity 100% owned by Advanced Biomed HK. Shanghai subsidiary is our
    only subsidiary in Mainland China; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Taiwan&rdquo; refers to Taiwan, Penghu, Kinmen, Matsu, and any other areas under the effective control of the government of Republic of China;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;US$,&rdquo; &ldquo;$&rdquo; or &ldquo;U.S. dollars&rdquo; refers to the legal currency of the United States; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our
    company,&rdquo; and &ldquo;our group&rdquo; refer to Advanced Biomed Inc., a Nevada company and its subsidiaries.</FONT></TD></TR>


  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise noted, all
translations from NTD to U.S. dollars and from U.S. dollars to RMB in this prospectus are made at NTD31.65 to US$1.00, the exchange rate
set forth in the H.10 statistical release of the Federal Reserve Board on September 30, 2024. We make no representation that any NTD or
U.S. dollar amounts could have been, or could be, converted into U.S. dollars or RMB, as the case may be, at any particular rate, the
rates stated below, or at all. On September 30, 2024, the exchange rate as set forth in the H.10 statistical release of the Federal Reserve
Board for New Taiwan Dollar was NTD31.65 to US$1.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The industry in which we operate
is subject to a high degree of uncertainty and risk due to variety of factors, including those described in the &ldquo;Risk Factors&rdquo;
section. These and other factors could cause results to differ materially from those expressed in these publications and reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Shares of Common Stock to be Offered:</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 59%"><FONT STYLE="font-size: 10pt">1,875,000 shares of Common Stock (or 2,156,250 shares of Common Stock if the representative of the underwriters exercises its over-allotment option in full) on a firm commitment basis.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Offering Price per Share:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The purchase price for the Common Stock being sold in this offering
is expected to be between $4.00 and $6.00 per share of Common Stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Shares of Common Stock Outstanding prior to this Offering (1)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">20,000,000 shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Shares of Common Stock Outstanding after this Offering (1)(2)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">21,875,000 shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Lock-up Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed that, without the prior written
consent of the underwriters, subject to certain exceptions, we will not, for a period of 180 days after the date of the prospectus, will
not issue, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Shares of the Company
or any securities convertible into or exercisable or exchangeable for shares of Common Stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">All of our directors, officers, and certain shareholders holding more
than 5% of our Common Stock as of the effective date of this prospectus, have agreed not to offer, sell, contract to sell, encumber, grant
any option for the sale of or otherwise dispose of any securities of the Company without the underwriters&rsquo; prior written consent
of any Common Stock for a period of 180 days from the date of the prospectus, subject to certain exceptions. The Resale Shares are not
subject to the lock-up agreement inclusive of certain Selling Stockholder holding more than 5% of our Common Stock.</P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Proposed Nasdaq Capital Market Symbol</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have applied to list our Common Stock on the Nasdaq Capital Market under the symbol &ldquo;ADVB&rdquo;.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Underwriter&rsquo;s Over-Allotment Option</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have granted the underwriters an option for 45 days after the closing
date of this offering to purchase up to an additional 281,250 shares of our Common Stock at the Primary Offering price, less the underwriting
discounts and commissions, to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Representative&rsquo;s Warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the closing of this offering, we will issue to the representative
of the underwriters, representative&rsquo;s warrants entitling the representative of the underwriters to purchase 112,500 shares of Common
Stock (or 129,375 shares of Common Stock if the representative of the underwriters exercises its over-allotment option in full) equal
to 6% of the aggregate number of shares of Common Stock sold in this offering. The representative&rsquo;s warrants are exercisable at
any time and from time to time, in whole or in part, during the four and a half year period commencing six months following the date of
commencement of sales of securities issued in this offering, at a price per share equal to 125% of the per share offering price (and shall
provide for adjustments to the exercise price and number of shares of Common Stock for which the warrant is exercisable in the event of
stock dividends, splits and recapitalizations). For additional information, please refer to the &ldquo;Underwriting&rdquo; section beginning
on page 106.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We estimate that we will receive net proceeds, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us, of approximately $5.20 million from this offering
assuming no exercise of the representative&rsquo;s warrants or underwriters&rsquo; over-allotment option and completion of the offering.
We intend to use the net proceeds of this offering as follows after we complete the remittance process:</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 58%"><FONT STYLE="font-size: 10pt">Approximately 60% for invitro diagnosis (IVD) clinical research, chip design and development, upgrade facilities, and expansion to other markets;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">20% for marketing and sales; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">20% for general working capital. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Transfer Agent</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Transhare Corporation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 59%; text-align: justify"><FONT STYLE="font-size: 10pt">See &ldquo;Risk Factors&rdquo; below and the other information
    included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The number of shares of Common Stock to be outstanding
immediately after this offering is based upon 20,000,000 shares outstanding as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Except as otherwise indicated, the number of shares
of Common Stock presented in this prospectus excludes shares of our Common Stock issuable if the underwriters exercise their over-allotment
option and shares of our Common Stock underlying warrants to be issued to the representative of the underwriters in connection with this
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY CONSOLIDATED FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following selected historical
statements of operations for the fiscal years ended June 30, 2024 and 2023 and three-month periods ended September 30, 2024 and 2023,
and balance sheet data as of September 30, 2024, June 30, 2024 and 2023 have been derived from our audited consolidated financial statements
and unaudited interim condensed consolidated financial statements for those periods included elsewhere in this prospectus. Our historical
results are not necessarily indicative of the results that may be expected in the future. You should read this data together with our
consolidated financial statements and related notes appearing elsewhere in this prospectus as well as &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations,&rdquo; appearing elsewhere in the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Selected Consolidated Results of Operations
Data&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the years ended June 30,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Operating expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 74%; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Research and development expenses</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(880,193</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(1,383,181</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">General and administrative expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,661,379</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,688,042</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,541,572</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(3,071,223</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Other income (expense):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Interest income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">53,495</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21,402</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Other expense, net</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(294,201)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(682,956</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total other expense, net</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(240,706)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(661,554</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Loss before tax expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2,782,278)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,732,777</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Income tax expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>Net loss</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,782,278</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(3,732,777</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For Three-month Periods<BR> ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(181,703</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(169,185</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(338,324</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(271,060</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(520,027</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(440,245</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">254,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(331,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">254,447</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(331,071</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss before tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(265,580</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(771,316</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(265,580</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(771,316</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selected Consolidated Balance Sheet Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: justify">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,646,992</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,607,973</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,622,279</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Working capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(176,636</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318,650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(489,595</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,473,771</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,460,247</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,599,977</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,379,941</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,796,989</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,294,389</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,093,830</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,663,258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,305,588</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B></B></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our securities involves a high
degree of risk. Before making any investment decision, you should consider carefully the following risks and other information in this
prospectus, including our consolidated financial statements and related notes. The risks and uncertainties we describe are not the only
ones facing us. Additional risks and uncertainties that we are unaware of or that we believe are not material at the time could also
materially adversely affect our business, financial condition or results of operations. In any case, the value of our Common Stock could
decline, and you could lose all or part of your investment. Please also see the section entitled &ldquo;Cautionary Note Regarding Forward-Looking
Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an early stage cancer diagnostics
company with a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are at the early
stage of commercializing our business. We have not started manufacturing or sales of any products or services. Our limited operating
history may make it difficult to evaluate our current business and predict our future performance. Any assessment of our profitability
or prediction about our future success or viability is subject to significant uncertainty.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Taiwan and China&rsquo;s
precision oncology detection market is still in its early stage of development and rapidly evolving, and companies operating in this
industry face a variety of risks. We may not have sufficient experience or resources to address risks frequently encountered in this
industry, which include, among other things, our potential failure to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">acquire and retain customers and increase
                                            adoption of our precision oncology detection products and services by hospitals, physicians,
                                            patients, pharmaceutical companies and others in the medical community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">timely respond to changing market conditions
                                            and keep up with evolving industry and technological standards and regulatory developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtain and maintain the regulatory
                                            approvals required for us to further market and sell our precision oncology detection products
                                            and services and commercialize our early cancer detection products and services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">manage our relationships with our suppliers,
                                            customers and research partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">protect proprietary technologies and
                                            intellectual property rights; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">attract, train, motivate and retain
                                            research and development and other qualified personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unsuccessful in
addressing any one or more of these risks, our business, financial condition and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to develop and commercialize
our early cancer detection devices, chips or immunochromogenic kits on a timely basis, or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing early
cancer detection products and may develop and commercialize our cancer diagnostics products from time to time in the future. Developing
early cancer detection and new cancer diagnostics products is a lengthy and complex process. New products may take time to commercialize,
and their launch could be delayed or may not be successful.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product development process
involves various risks, and we may not be able to develop and commercialize any early cancer detection products or new precision oncology
detection products on a timely basis, or at all. A product candidate that appears promising in the early phases of development may fail
to reach the market for a number of reasons. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our product candidates may fail to
                                            demonstrate clinical utility, or the development process may produce negative or inconclusive
                                            results, and we may decide, or regulators may require us to conduct additional clinical trials
                                            or we may decide to abandon our development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our employees, or third-party clinical investigators, medical institutions
and CROs, may fail to comply with their contractual duties or obligations or meet expected deadlines, and if the quality, completeness
or accuracy of the clinical data they obtain are compromised due to any failure to adhere to our clinical protocols or for other reasons,
our clinical trials may have to be extended, delayed or terminated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">we may fail to obtain approvals for
                                            our product candidates from relevant regulatory authorities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure to generate additional data
                                            and insights from our existing products to advance the research and development of new products
                                            as quickly, or at all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our competitors
may develop and commercialize competing products faster than we are able to, in which case our results of operations could be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to keep up with industry and
technology developments in a timely and cost-effective manner, we may be unable to compete effectively and our business and prospects
could suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cancer early detection market
is characterized by rapid changes, including technological and scientific breakthroughs, increasing amounts of data, frequent introductions
of new tests, constant emergence of alternative diagnostic methods, and evolving industry standards. If we are not able to keep pace
with these advances and increased customer expectations as a result of these advances and capture new market opportunities that develop
as a result of these advances, our proprietary technologies could be rendered obsolete, our existing products and services and products
and services we are developing could be rendered less clinically effective, and our future operations and prospects could suffer. To
remain competitive, we must continuously upgrade our existing products and services and launch new products and services, to keep pace
with these developments. We cannot assure you that these efforts will be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we must expend
significant resources in order to continuously upgrade our existing products and services or launch new ones to keep pace with industry
and technological advances. We may never realize a return on investment on these efforts, especially if the improved or new products
and services fail to perform as expected, in which case our business, financial condition and results of operations could be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our products or services do not perform
as expected, our operating results, reputation and business could suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends on the
market confidence that we can provide reliable, high-quality cancer early detection products and services that will provide physicians
with real-time clinically actionable diagnostic information. However, there is no assurance that our products and services will perform
as expected at all times. Our tests may fail to accurately detect gene variants or incompletely or incorrectly identify the significance
of genomic alterations, or contain other errors or mistakes due to a variety of reasons (such as malfunction of our laboratory equipment
and degraded liquid biopsy or tissue samples provided by our delivery service providers), which may result in negative perception of
our tests. In addition, inaccurate results or misunderstandings of, or inappropriate reliance on, the diagnostic information our tests
provide could lead to, or be associated with, side effects or adverse events in patients who use our tests, including treatment-related
death, and could lead to termination of our services or claims against us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face risks related to natural disasters,
health epidemics, civil and social disruption and other outbreaks, which could significantly disrupt our operations. In particular, the&nbsp;COVID-19&nbsp;outbreak
in China and worldwide has adversely affected, and may continue to adversely affect, our business, results of operations and financial
condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are vulnerable to social
and natural catastrophic events that are beyond our control, such as natural disasters, health epidemics, and other catastrophes, which
may materially and adversely affect our business. Since December 2019, a novel strain of coronavirus, or&nbsp;COVID-19,&nbsp;has become
widespread in China and around the world. In March 2020, the World Health Organization declared&nbsp;COVID-19&nbsp;a pandemic, given
its threat beyond a public health emergency of international concern that the organization had declared in January 2020. Since the beginning
of 2020, China, Taiwan and many other countries have taken various restrictive measures to contain the virus&rsquo; spread, such as quarantines,
travel restrictions and home office policies to avoid large-scale population movement and gathering. These restrictions had certain degree
of impact on our research and development and production plan in Taiwan and China. COVID-19 has reduced the availability of labor and
led to difficulties for employees to return to work and constraints of service chain interruption. Because of the uncertainty surrounding
the COVID-19 outbreak, the business disruption and the related financial impact related to the outbreak of and response to the coronavirus
cannot be reasonably estimated at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, the COVID-19 situation has improved in Taiwan and China. With
Taiwan relaxing its mask mandate on April 17, 2023, and China no longer enforcing the &ldquo;zero-COVID&rdquo; policy, our research and
development have started to recover. However, the potential downturn brought by the COVID-19 outbreak is difficult to assess or predict
and the full impact of the virus on our operations will depend on many factors beyond our control. The extent to which the&nbsp;COVID-19
outbreak impacts our business, results of operations and financial condition&nbsp;remains uncertain, and we are closely monitoring its
impact on us. Our business, results of operations, financial conditions and prospects could be materially adversely affected to the extent
that&nbsp;COVID-19&nbsp;harms the Chinese and global economy in general, and the trading price of our shares of Common Stock may be adversely
affected. To the extent the&nbsp;COVID-19&nbsp;pandemic and the outbreak of other health epidemics adversely affect our business and financial
results, they may also have the effect of heightening many of the other risks described in this &ldquo;Risk Factors&rdquo; section.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we cannot compete successfully with
our competitors, we may be unable to increase or sustain our revenue or achieve and sustain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cancer early detection and
screening market has become increasingly competitive, and we expect this competition to intensify further in the future. Some of our
existing and potential future competitors may have longer operating histories, larger customer bases, more expansive brand recognition
and deeper market penetration, substantially greater financial, technological and research and development resources and selling and
marketing capabilities, and more favorable terms from suppliers. As a result, they may be able to respond more quickly to changes in
customer requirements or preferences, develop faster, better and more expansive advancements for their technologies and tests, create
and implement more successful strategies for the promotion and sale of their tests, adopt more aggressive pricing policies for their
tests, secure supplies from vendors on more favorable terms or devote substantially more resources to infrastructure and system development.
In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established
and well-financed companies as the use of precision oncology detection increases. In addition, if we expand into international markets
in the future, we could face competition from the companies in these markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to compete
successfully with current and future competitors for these or any other reasons, we may be unable to increase market acceptance and sales
volume of our tests, which could prevent us from maintaining or increasing our revenue levels or achieving or sustaining profitability
or could otherwise negatively affect our performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our future success depends on our ability
to promote our brand and protect our reputation. If we are unable to effectively promote our brand, our business may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that enhancing and
maintaining awareness of our trademarks <FONT STYLE="font-family: Times New Roman, Times, Serif">&#27427;&#25096;&#36187; </FONT>and sglcell
are critical to achieving widespread acceptance of our microfluidic biochip products, gaining trust for our testing devices and attracting
customers. Successful promotion of our brand depends largely on the quality of the products and services we offer and the effectiveness
of our branding and marketing efforts. Currently, we rely primarily on our own sales and marketing team to promote our brand and our precision
oncology detection products and testing services. We expect that our branding and marketing efforts will require us to incur significant
expenses and&nbsp;devote substantial resources. We cannot guarantee that our sales and marketing efforts will be successful. Brand promotion
activities may not lead to increased revenue in the near term, and, even if they do, any revenue increases may not offset the expenses
we incur to promote our brand. Our failure to establish and promote our brand and any damage to our reputation will hinder our growth.
In addition, our reputation may be undermined as a result of the negative publicity about our company or our industry in general. If precision
oncology detection products or services provided by us or our competitors do not perform to customers&rsquo; expectations, it may result
in lower confidence in precision oncology detection in general, which may in turn impair our operating results and our reputation. You
can find more information regarding our intellectual properties in &ldquo;Business &ndash; Intellectual Property.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to attract and retain our senior
management and other key employees could adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success is significantly
dependent upon the continued service of our senior management, such as Dr.&nbsp;Yi Lu, our chairman of the board of directors and chief
executive officer. If we lose their services, we may not be able to locate suitable or qualified replacements, and we may incur additional
expenses to recruit new senior management team members, which could severely disrupt our business and growth. In addition, if these personnel
join our competitors or form a competing business, our business and prospects could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities and laboratory operations depend upon our ability to attract and retain highly skilled scientists and technicians. We are
also in strong need of sales and marketing personnel with the relevant technology background and industry expertise in order to effectively
conduct our sales and marketing activities and increase our hospital network. We face intense competition for qualified individuals from
numerous biotechnology and pharmaceutical companies, universities, governmental entities and other research institutions. We may be unable
to attract and retain suitably qualified individuals, and our failure to do so could adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we experience difficulties in recruiting
subjects for clinical trials, our clinical development activities may be delayed or otherwise adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Completion of a clinical
trial on time according to the trial plan depends, among other things, on our ability to recruit a sufficient number of subjects to participate
in the trial until the end of the trial. We may encounter difficulties in recruiting subjects for clinical trials for a variety of reasons,
including the base and nature of the subject population and the eligibility criteria for subjects defined in the trial plan. Our clinical
trials will likely compete with other clinical trials, which will reduce the number and categories of subjects we can recruit, as some
subjects who may choose to participate in our trials may instead choose to participate in trials conducted by other companies. Due to
the limited number of qualified clinical investigators and clinical trial sites, we expect that some of our clinical trials will be conducted
at the same clinical trial sites used by some of our competitors, which will result in subjects eligible to participate in our clinical
trials at those clinical trial sites decrease in the number of people. Even if our clinical trials are able to enroll a sufficient number
of subjects, delays in enrolling subjects may increase costs or affect the timing or outcomes of planned clinical trials, hindering the
completion of those trials and hindering our progress adversely affect the ability of product candidates to develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not launch new products in a timely
manner, our products may become obsolete and our results of operations may suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Technology in the cancer
screening industry is constantly changing, new products are emerging, and industry standards continue to evolve. If new and improved
products are not introduced in a timely manner, our products may become technologically obsolete or vulnerable to competition, and our
revenue and results of operations could be impaired. Even if we develop new or improved products, our ability to bring those products
to market may be limited by a variety of factors, including regulatory approvals and market demand. We invest significant financial and
other resources in our research and development activities. The research and development process are lengthy and uncertain. The products
we are currently developing may not be able to complete the development process or obtain the regulatory or other approvals required
to bring such products to market in a timely manner or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Technological innovations
often require significant time and investment before their commercial viability can be determined. We may not have the necessary financial
resources to fund all such projects. In addition, even if we are able to successfully develop new or improved products, those products
may not generate revenue in excess of development costs or achieve desirable financial returns and may become obsolete or due to changes
in customer preferences or the introduction of advanced technology or functionality by competitors. Products or other factors resulting
in a decline in competitiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>As of the date of this prospectus, we have
not conducted any clinical trials for our products. Uncertainties or failures in clinical trials of our product candidates could materially
and adversely affect our business operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We must conduct various
clinical trials to demonstrate the sensitivity and specificity of our test prior to regulatory approval for marketing of our product
candidates and depending on the type of our relevant product candidates, clinical trials may require large-scale prospective clinical
studies, and such studies are far more rigorous and expensive than other existing tests or auxiliary diagnostic products. We have planned
to conduct a multicenter registry trial in China to evaluate the performance of the pulmonary nodule benign and malignant determination
kit. We may encounter a variety of contingencies while conducting or as a result of clinical trials that may delay or prevent us from
obtaining regulatory approval or commercializing our product candidates, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Regulatory agencies, institutional review boards or ethics committees may refuse to authorize us or investigators to conduct clinical trials or conduct clinical trials at the intended trial site;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">We are unable to reach agreement on admissible terms with prospective CROs and hospitals (as trial centers), which may require extensive negotiation and may vary significantly between different CROs and hospitals (as trial centers);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Production issues, including issues with the quality of production, supply, or obtaining sufficient quantities of the product candidate for use in clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Insufficient testing capacity to meet the needs of clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Our products fail to demonstrate superior results than competitors&rsquo; or alternative products (if applicable);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Clinical trials of our product candidates may fail to demonstrate the expected cancer screening sensitivity and specificity, and we may decide or regulatory authorities may require us to conduct additional clinical trials or abandon product development programs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The number of subjects required for clinical trials of our product candidates may be larger than expected, recruitment may be insufficient or slower than we expect, or the rate of subjects dropping out of trials may be higher than expected;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Our third-party contractors may fail to comply with regulatory requirements or perform in a timely manner or at all of their contractual obligations to us;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">We may have to suspend or terminate clinical trials of our product candidates for a variety of reasons, including the discovery of a lack of clinical response or other unexpected characteristics; and preliminary or interim results of clinical trials may not be indicative of final results.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
such trials will be completed in a timely or cost-effective manner, or that they will result in a commercially viable product. If clinical
trials of any of our product candidates are delayed or terminated, the commercial prospects of that product candidate will be impaired
and our ability to generate revenue from any such product candidate will be delayed. In addition, any delay in the completion of our
clinical trials would increase our costs, slow down the development and approval process of our product candidate, and impair our ability
to initiate product sales and generate related revenue for that product candidate. The occurrence of any of the above events could materially
damage our business, financial condition and prospects.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have contracts with third parties for the
future manufacturing, supply and registration applications of certain of our products, which supply could become limited or interrupted
or may not be of satisfactory quality and quantity.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently rely on third parties
in the PRC for certain supplying, registration applications and future manufacturing of certain of our products. Any such reliance may
increase the risk that we will not have sufficient quantities of our products, or such quantities at an acceptable cost or quality, which
could delay, prevent or impair our development or commercialization efforts. Furthermore, all the contract manufacturers in the PRC for
our products are subject to extensive PRC laws and regulations. These PRC laws and regulations govern manufacturing processes and procedures,
including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational
products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent
changes in the properties or stability of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Associated with Government Regulations</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be adversely affected by uncertainties
and changes in China's regulations on the cancer screening industry, and the lack of necessary approvals, licenses, registrations or
filings in relation to our business may adversely affect our business, results of operations and prospects material adverse effects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the relatively short
history of the cancer screening industry in China, a comprehensive regulatory framework to regulate the industry has not yet been established.
The possibility cannot be ruled out that certain industry practices, which we have also adopted, may be deemed to fail to fully comply
with the existing laws and regulations in the PRC. As China's laws and regulations on medical devices are still developing, and it is
uncertain whether new laws, regulations or interpretations will be promulgated or adopted in the future, we cannot assure you that our
early stage cancer detection devices will not be construed as non-compliance with applicable laws and regulations in the future. If the
PRC government issues clear requirements for the approval of our devices, we intend to take the necessary steps to comply with those
requirements. Our business and results of operations may be adversely affected if we fail to comply with existing or future requirements
or are found to be otherwise non-compliant in the conduct of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to obtain, complete or maintain
the required regulatory approvals, licenses, registrations or filings, or if there is a delay in obtaining, complete or maintain the
required regulatory approvals, licenses, registrations or filings, we will not be able to commercialize our product candidates change, and our ability to generate revenue will be significantly compromised.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the relatively short history of the cancer screening industry in
China, a comprehensive regulatory framework to regulate the industry has not yet been established. However, the significant aspects of
the development and commercialization of our products have been strictly regulated in China. The process of obtaining regulatory approvals
and complying with applicable laws and regulations requires significant time and financial resources. Applicants may face administrative
or judicial sanctions if they fail to comply with applicable regulations during the product development process, the approval process,
or at any time after approval. Such sanctions may include regulatory refusals to approve pending applications, revocation of approvals,
revocation of licenses, clinical restrictions, voluntary or compulsory product recalls, product seizures, suspensions of production or
distribution in whole or in part, injunctions, fines, refusals to government contracts, compensation, Hand over money or civil or criminal
penalties. Failure to comply with these regulations may affect our business, financial business conditions and prospects are materially
and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Before
obtaining regulatory approval for commercial sale of some of our products, we must demonstrate its effectiveness in a well-controlled
clinical trial and, for approval in China, must be satisfied by NMPA that the product candidate is safe and effective for its intended
use, and appropriate manufacturing and testing facilities, procedures and controls are in place. For now, only A</FONT><SUP>+</SUP><FONT STYLE="font-size: 10pt">LCGuard
is required by NMPA to complete clinical trial. Obtaining regulatory approval is a long, expensive and uncertain process, and approval
may not be obtained. When we submit a registration application to NMPA, it will decide whether to accept or reject the submitted registration
application. We cannot be certain that any submission will be approved by NMPA for registration review. NMPA may also slow down, suspend
or terminate the review of our application, and any such circumstance will prolong the registration process for our products. Our product
candidates may not receive regulatory approval for a number of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The clinical trial
                                            results cannot reach the level of statistical significance required for approval or the clinical
                                            trial cannot be conducted in accordance with regulatory regulations or clinical trial plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Approval policy or
                                            regulatory changes that make our preclinical and clinical data insufficient to obtain approval
                                            or require us to revise our clinical trial plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Regulatory requirements
                                            requiring additional analysis, reporting, data, non-clinical studies and clinical trials,
                                            or questions regarding interpretation of data and results and the emergence of new information
                                            about our product candidates or other products; and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The relevant authority
                                            refuses to approve a pending application submitted by us or a supplementary application to
                                            an approved application, or suspends, withdraws or withdraws the approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory requirements
and guidelines may also change, and we may, among other things, need to revise clinical trial plans submitted to applicable regulatory
authorities to reflect such changes. We may make revisions that necessitate resubmission of the clinical trial proposal to the Institutional
Review Board or Ethics Committee for reconsideration, which may affect the outcome of the clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of developing,
obtaining regulatory approval, and commercializing medical device candidates is long, complex, and costly, both within China and abroad.
Even if our product candidates are successful in obtaining regulatory approval, such approval may impose significant restrictions on
the approved use, or require product labels to contain precautions or warnings, or require expensive and time-consuming post-approval
clinical trials or surveillance as approval conditions of. If we are unable to obtain regulatory approvals for our product candidates
in one or more jurisdictions, or any approvals come with significant restrictions, our target market will be reduced and our ability
to realize the full market potential of our product candidates will be impaired. In addition, we may not be able to obtain sufficient
financing or generate sufficient revenue and cash flow to continue developing any other product candidates in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our products and any future products will
be subject to ongoing regulatory obligations and ongoing regulatory scrutiny, which may result in significant additional expenses, and
if we fail to comply with regulatory requirements or if there are unexpected issues with our products and/or product candidates, we may
will be punished.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
regulatory agency-approved testing services, products and any other product candidates are subject to and will be subject to compliance
with manufacturing, testing, labelling, packaging, storage, advertising, promotion, sampling, record keeping, post-marketing studies,
submission of safety, efficacy and other ongoing regulatory requirements for post-listing materials, and other requirements from regulatory
authorities in the PRC and/or other jurisdictions. Our testing and manufacturing facilities are subject to numerous regulatory requirements
from the China Food and Drug Administration (&ldquo;CFDA&rdquo;) and/or other similar authorities. Accordingly, we have been and will
be subject to ongoing scrutiny and inspection by regulatory agencies to assess our compliance with applicable laws and regulations and
our commitments made in any application materials submitted to the CFDA or other authorities. Therefore, we must continue to invest time,
money and effort in all aspects of regulatory compliance.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Regulatory
approvals for our products and any approvals we obtain for product candidates are subject to and may be limited by the use of our marketable
products. Our approvals may also be subject to other conditions that may result in the need for potentially costly post-market testing
and surveillance to monitor the safety and efficacy of our products or product candidates. Such restrictions and conditions may adversely
affect the commercial potential of our products.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">After
our product candidates are approved for commercialization, certain changes to the products, such as changes in manufacturing processes
and additional claims, may require additional review and approval by the CFDA and/or similar regulatory authorities. Regulatory
approval of any of our product candidates may also be withdrawn. If we fail to maintain compliance with these ongoing regulatory requirements
or if problems arise after the product is launched, the CFDA or similar regulatory authorities may seek to enforce a consent order or
withdraw marketing approval. Late discovery of our products or product candidates or issues previously unknown to us in our manufacturing
process may lead to revisions to approved labels or regulations to add new safety information; conduct clinical studies to evaluate new
safety risk; or impose distribution restrictions or other restrictions. Other potential consequences include (among others):</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 12pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Restrictions on the listing or manufacture of our
    products, withdrawal of products from the market, or voluntary or mandatory product recalls;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fines, untitled letters or warning letters, or suspension of clinical
    trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The CFDA or similar regulatory authorities refuse to approve our pending
    applications or supplements to approved applications, or suspend or revoke licensing approval or withdraw approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Product seizure or
                                            detention, or denial of permission to import or export our products and candidate products;
                                            and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Injunction or Civil
                                            or Criminal Penalty</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CFDA and other regulatory authorities strictly supervise the listing,
labelling, advertising and promotion of medical products and services introduced to the market. Our products and testing services may
only be marketed for their approved uses in accordance with approved labels. The CFDA and other regulatory authorities actively enforce
laws and regulations that prohibit the promotion of off-label uses, and companies found to improperly promote off-label uses may bear
significant responsibility. The policies of the CFDA and other regulatory authorities may change and other government regulations may
be issued to prevent, limit or delay regulatory approval of our product candidates. Given the changing regulatory environment, we cannot
predict the likelihood, nature or scope (whether in China or abroad) of government policies or regulations that may result from future
legislative or administrative actions. If we are slow or unable to adapt to changes in existing regulations or adopt new regulations or
policies, or if we are unable to maintain regulatory compliance, we may lose any regulatory approvals we have obtained and may not be
able to achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our existing and new products fail to
meet the quality standards required by applicable laws, our business and reputation could be damaged, and our revenue and profitability
could be materially and adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our production and manufacturing
processes are subject to certain quality standards. We have established quality control and assurance systems and adopted standardized
operating procedures to prevent quality issues related to our products and operating processes. For further details of our quality control
and assurance system, please refer to &ldquo;Business &mdash; Quality Control System&rdquo;. Although we have quality control and assurance
systems and procedures, we cannot eliminate the risk of product defects or malfunctions. Quality defects may not be detected or remedied
due to a number of factors, many of which are beyond our control, including:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 12pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 12pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Manufacturing error;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Technical or mechanical failures in the manufacturing process;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Human error or malfeasance by our quality control personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third party intervention; and/or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The raw materials we produce or purchase have quality problems.</FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0; font: 11pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our failure
to detect quality defects in our products or to prevent such defective products from being delivered to end users may result in injury
or death, product recalls or withdrawals, revocation of licenses or fines by regulatory agencies, product and professional liability
or other problems, which could seriously damage our reputation and business, expose us to the risk of liability, and materially and adversely
affect our revenue and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>In addition to the Chinese market, we are planning
to expand to North American and European markets. We cannot give any assurance that any of our products will receive regulatory approval
in North America or Europe, which is necessary before they can be commercialized.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot be certain that any
of our product candidates will be successful in clinical studies or receive regulatory approval. Applications for our products could fail
to receive regulatory approval for many reasons, including but not limited to the following:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the Food and Drug Administration (FDA), the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical or clinical studies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the data collected from clinical studies of our products in China may not be sufficient or accepted to obtain regulatory approval in the U.S. or elsewhere;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be unable to demonstrate to the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities that a product&rsquo;s benefit-risk ratio for its proposed indication is acceptable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or other regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the approval policies or regulations of the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities may change significantly in a manner rendering our clinical data&nbsp;insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, we plan to seek regulatory
approval to commercialize our product candidates in the U.S., the EU and in additional countries where we obtain commercial and IP rights.
To obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of such other countries
regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing, marketing and distribution
of our products. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in
any other jurisdictions. Failure to obtain marketing authorization for our products will result in our being unable to market and sell
such products, which would materially adversely affect our business, financial condition and results of operations. If we fail to obtain
approval in any jurisdiction, the geographic market for our products could be limited.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to obtain the broad market acceptance
or maintain a good reputation necessary for our current products and any future products could materially and adversely affect our results
of operations and profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our current and future products depends on their market acceptance, especially among customers, hospitals and physicians. As a diagnostic
method recently developed and introduced into the Chinese market, our products may not be widely recognized by the intended target customers,
doctors or end users. If our products and any future approved product candidates fail to gain sufficient market acceptance from physicians,
end users, third-party payers and other industry players, our product sales will be adversely affected. In addition, customers, physicians,
end users and third-party payers may prefer other new products over our products. If our products and product candidates fail to achieve
an adequate level of recognition, we may not generate significant revenue and may not be profitable. The failure of our products, product
candidates and our testing services to achieve an adequate level of recognition or to increase market visibility could adversely affect
our financial condition, business and results of operations. Once approved for commercial sale, the market acceptance of our products
and product candidates and their services will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Physicians, end users
                                            and hospitals consider our products and product candidates to be safe and effective;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Potential and visible
                                            advantages of our products and product candidates over other alternatives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our continuous cooperation
                                            with existing commercialization channels;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We further validate
                                            the product's capabilities through clinical studies and accompanying publications;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The timing and scope of the approval of our other cancer screening products
by the CFDA;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our ability to maintain
                                            laboratory accreditation, accreditation and regulatory approval and to complete required
                                            inspections;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Defects or errors that lead to negative reports about our or our competitors&rsquo;
testing and technology influences;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Changes in government
                                            policies or guidelines regarding cancer screening;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Development of cancer
                                            treatments that may diminish or reduce the need for cancer screening;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our competitors accelerate
                                            R&amp;D progress;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The effectiveness
                                            of our sales and marketing efforts.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If any of our commercialized products
and services fail to gain market acceptance among doctors, end users, hospitals or other customers, or if we fail to maintain good relationships
with them, we will not be able to generate significant revenue. Our ability to market our products and product candidates may be limited
by regulatory approval requirements, restrictions on approved uses, inherent patterns of clinical practice, uncertainty about third-party
compensation or other factors. Even if our products gain market acceptance, we may not be able to maintain market acceptance all the time
if new products or technologies are introduced that are more popular, cost-effective or make our products obsolete. We believe that maintaining
and enhancing our brand image and increasing the market awareness of our company and our products are critical to gaining broad recognition
for our services and products, strengthening our relationships with existing customers and our ability to attract new customers. The successful
promotion of our brand will largely depend on our ability to continue to provide high-quality products, as well as our research and development
efforts. However, there is no guarantee that our branding activities and research and development efforts will be successful or contribute
to our growth. In addition, even if such activities increase revenue, such revenue may not be sufficient to offset the increase in expenses
we incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>There is no guarantee that our products will
be covered by the National Medical Insurance Program in China.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">China maintains a National Medical
Insurance Program that can reimburse certain residents in urban cities and rural areas for, among other things, fees associated with diagnostic
and treatment devices and diagnostic tests covered by such Program through the basic medical insurance scheme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
our products are not covered by any national or provincial medical insurance programs. Although we strive to make our products covered
by the national medical insurance programs in the future, there is no guarantee that the responsible government agency, the National Healthcare
Security Administration, will approve our applications. Furthermore, even if our products may be covered by the Program in the future,
uncertainties still exist around reimbursement coverage and rates as we need to negotiate such terms with government entities in the PRC,
and we cannot guarantee that we will receive favorable coverage and rates. In the absence of reimbursement or favorable coverage and rates
from the National Medical Insurance Program, end users have to bear all or the majority part of their expenses to use our products, which
may reduce consumers&rsquo; interest in our products or cause our products to be less competitive when compared with other products that
are covered by such Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have relatively limited experience in product
promotion and sales. There is no assurance that we will be able to successfully commercialize our products and, as a result, our revenue
and profitability could be materially and adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relatively limited
experience in launching and commercializing product candidates and in the sales and marketing of products, and limited experience in
market analysis or managing sales teams for product candidates. As a result, our ability to successfully commercialize our product candidates
may involve more inherent risks, require more time and cost more than would be the case if we were a company with extensive experience
in launching product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market size of existing and future
products has not been precisely established and may be lower than our estimates, and we may not fully grasp the target population of
our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our estimates of the total
addressable market and target population for our existing products and product candidates are based on a number of internal and third-party
estimates, including but not limited to the size of the target population, the number of people at higher risk of developing cancer,
and the availability of the hypothetical price at which the established market sells the relevant candidate product. Although we believe
that our assumptions and data relating to estimates are reasonable, such assumptions and estimates may not be correct, and the conditions
supporting our assumptions or estimates may change at any time, reducing the accuracy of forecasts for these relevant factors. Accordingly,
our estimates of the total addressable market for current or future products may prove to be incorrect. If the target population that
will benefit from our products, the price at which we can sell our products or the total addressable market for our products is lower
than our estimates, it could harm our sales growth and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Associated with Our Testing and the Manufacture
and Supply of Our Products</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delays in the completion
and obtaining regulatory approvals of our manufacturing facilities, or damage, destruction or interruption of production at such facilities
may delay our development plans or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future manufacturing
facilities will be global. The facility may incur unanticipated expenses due to a number of factors including regulatory requirements.
Our manufacturing facilities are subject to ongoing periodic inspections by various NMPA or other comparable regulatory agencies to ensure
compliance with current drug manufacturing practices. Failure to comply with applicable regulations may also result in us being subject
to penalties, including fines, injunctions, civil penalties, requests to suspend or stop one or more of our clinical trials, failure
to obtain regulatory approvals for our product candidates, delays, Suspension or withdrawal of approvals, supply interruptions, revocation
of licenses, seizure or recall of products or product candidates, operational restrictions and criminal prosecutions, any of which can
cause harm to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our facilities may be damaged
or rendered inoperable due to physical damage caused by fire, flood, earthquake, typhoon, tornado, power outage, telecommunications failure,
intrusion and similar events. If our production facilities or equipment are damaged or destroyed, we may not be able to replace our production
capacity quickly or cheaply or at all. In the event of temporary or long-term damage to facilities or equipment, we may not be able to
transfer manufacturing to third parties. Even if we could transfer manufacturing to a third party, that transfer could be expensive and
time-consuming, especially since the new facility has to meet the necessary regulatory requirements and we have to obtain regulatory
approvals before selling any products manufactured at that facility. This event could delay our clinical trials or reduce sales of our
products. Any disruption to our manufacturing operations at our manufacturing facilities may result in us being unable to meet our clinical
trial or commercialization needs. Any disruption to our ability to manufacture products or product candidates in a timely manner could
materially damage our business, financial condition and results of operations. We currently insure against damage to our property and
equipment for an amount we believe is reasonable. However, our insurance coverage may not compensate us or may not be sufficient to cover
any expenses or losses we may incur. In the event of a catastrophic event or the failure of our production facilities or processes, we
may not be able to meet our requirements for products and product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The manufacturing and testing process of
our products is complex and subject to strict quality control. If we or any of our suppliers or logistics partners experience manufacturing,
logistics or quality problems, including as a result of natural disasters, our business may be damaged.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Partly due to stringent regulatory requirements, the manufacturing and
testing process for products is complex and subject to strict quality control. Additionally, quality is paramount as product or test defects
can have serious and costly consequences. Manufacturing and testing processes can go wrong for a number of reasons, including equipment
failure, non-compliance with codes and procedures, raw material issues, software issues, sample contamination or human error. In addition,
if contaminants are found in our product or product candidate supply, or in our production and testing facilities, such production and
testing facilities may need to be shut down for an extended period of time to investigate the contamination and remediate it. Stability
and other issues may arise in the future related to the manufacture and testing of our products or product candidates. While well-managed,
disruptions can occur during the introduction of new equipment and systems to replace aging equipment, as well as production line transfers
and expansions. As we increase market penetration, we may face unexpected surges in demand for our products, which could put pressure
on our production capacity or testing capabilities. If these problems arise, or if we otherwise fail to meet our internal quality standards
or the standards of the CFDA or other applicable regulatory agencies, including detailed record-keeping requirements, our reputation may
be damaged and we Safety warnings or recalls may apply, we may incur product and professional liability and other costs, product approvals
may be delayed, and our business may otherwise be adversely affected. In addition, our manufacturing, testing and warehousing facilities,
as well as those of our suppliers and logistics partners, may be severely damaged by earthquakes, hurricanes, volcanoes, fires and other
natural disasters or catastrophic circumstances, could materially and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Security threats to our information technology
infrastructure and unauthorized use of data by third parties could expose us to liability or damage our reputation and business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our information technology
systems store and process a variety of sensitive data, including our proprietary business information, as well as patients&rsquo; personal
data such as health information and personally identifiable information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is essential that our
information technology infrastructure remains secure and is perceived by hospitals, patients and our research partners to be secure.
Despite our security measures, we may face cyber-attacks that attempt to penetrate our network security, sabotage or otherwise disable
our research, tests and services, misappropriate our proprietary business information or cause interruptions of our internal systems
and services. Any cyber-attacks could negatively affect our reputation, damage our network infrastructure and our ability to deploy our
products and services, harm our relationship with customers and research partners, and expose us to significant financial liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we may not be
able to prevent third parties from illegally obtaining and misappropriating personal data of the tested patients that we collect. Concerns
about data leakage or unauthorized use of data by third parties, even if unfounded, could damage our reputation and negatively affect
our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to effectively protect
our intellectual property, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on patents,
software copyrights, trademarks, trade secrets and other intellectual property rights protection and contractual restrictions to
protect our products, services and technologies. We have registered a number of patents and trademarks in China and the United States. However, such
protection is limited and may not adequately protect our rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also be subject to
infringement claims by third parties. We may be subject to fines and other legal or administrative sanctions, and it may also be costly
to defend such claims. In addition, competitors could purchase our products and attempt to replicate and/or improve some or all of the
competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, and design their
devices and tests around our protected technologies or develop their own competitive technologies that fall outside of our intellectual
property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Monitoring unauthorized
disclosure and uses of our trade secrets is difficult, and we do not know whether the steps we have taken to prevent such disclosure
and uses are, or will be, adequate. If we resort to litigation to enforce or protect our intellectual property rights, such litigation
could result in substantial costs and a diversion of our managerial and financial resources, while the outcome would be unpredictable,
and any remedy may be inadequate. Our contractual agreements may be breached by our counterparties, and there may not be adequate remedies
available to us for any such breach. In addition, our trade secrets may be leaked or otherwise become available to, or be independently
discovered by, our competitors, and we would have no right to prevent others from using them. Moreover, if a party having an agreement
with us has an overlapping or conflicting obligation to a third party, our rights in and to certain intellectual property could be undermined.
If we fail to effectively protect our intellectual property, our competitive position and prospects could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to intellectual property
infringement or misappropriation claims by third parties, which may force us to incur substantial legal expenses and, if determined adversely
against us, could disrupt our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain
that our products, tests and technologies do not or will not infringe patents, software copyrights, trademarks or other intellectual
property rights held by third parties, especially when they are in China, as the validity, enforceability and scope of intellectual
property rights protection in China are uncertain and still evolving. From time to time, we may be subject to legal proceedings and
claims alleging infringement of patents, trademarks or copyrights, or misappropriation of creative ideas or formats, or other
infringement of proprietary intellectual property rights. Any such proceedings and claims could result in significant costs to us
and divert the time and attention of our management and technical personnel from the operation of our business. These types of
claims could also potentially adversely impact our reputation and our ability to conduct business and raise capital, even if we are
ultimately absolved of all liability. Moreover, third parties making claims against us may be able to obtain injunctive relief
against us, which could block our ability to offer one or more devices or tests and could result in a substantial award of damages
against us. In addition, since we sometimes indemnify our customers or collaboration partners, we may have additional liability in
connection with any infringement or alleged infringement of third-party intellectual property. Intellectual property litigation can
be very expensive, and we may not have the financial means to defend ourselves or our customers or collaboration partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because patent applications
can take many years to issue, there may be pending applications, some of which are unknown to us, that may result in issued patents upon
which our products, tests or proprietary technologies may infringe. Moreover, we may fail to identify issued patents of relevance or
incorrectly conclude that an issued patent is invalid or not infringed by our technology or any of our devices or tests. There is a substantial
amount of litigation involving patents and other intellectual property rights in our industry. If a third-party claims that we infringe
upon a third-party&rsquo;s intellectual property rights, we may have to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">seek to obtain licenses that may not
                                            be available on commercially reasonable terms, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">abandon any product alleged or held
                                            to infringe, or redesign our products or processes to avoid potential assertion of infringement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">pay substantial damages including,
                                            in exceptional cases, treble damages and attorneys&rsquo; fees, if a court decides that the
                                            device, test or proprietary technology at issue infringes upon or violates the third-party&rsquo;s
                                            rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">pay substantial royalties or fees or
                                            grant cross-licenses to our technology; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">defend litigation or administrative
                                            proceedings that may be costly whether we win or lose, and which could result in a substantial
                                            diversion of our financial and management resources.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to litigation and other
claims and legal proceedings, and may not always be successful in defending ourselves against these claims or proceedings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to lawsuits
and other claims in the ordinary course of our business. We may from time to time be subject to lawsuits and other legal proceedings
brought by our customers, competitors, employees, business partners, investors, other shareholders of the companies we invest, or other
entities against us in the ordinary course of our business. We may also be subject to regulatory proceedings in the ordinary course of
our business. We may not be successful in defending ourselves, and the outcomes of these lawsuits and proceedings may be unfavorable
to us. Lawsuits and regulatory proceedings against us may also generate negative publicity that significantly harms our reputation, which
may adversely affect our customer base, market position and our relationships with our research partners and other business partners.
In addition to the related costs, managing and defending litigation and other legal proceedings and related indemnity obligations can
significantly divert our management&rsquo;s attention from operating our business. We may also need to pay damages or settle lawsuits
or other claims with a substantial amount of cash, negatively affecting our liquidity. As a result, our business, financial condition
and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Relating to Our Financial Prospects
and Need for Additional Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We incurred net losses for the three-month
period ended September 30, 2024 and the years ended June 30, 2024 and 2023 and may not be able to generate sufficient operating cash flows
and working capital to continue as a going concern. Failure to manage our liquidity and cash flows may materially and adversely affect
our financial condition and results of operations. As a result, we may need additional capital, and financing may not be available on
terms acceptable to us, or at all.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incurred net losses of
$265,580, $2,782,278 and $3,732,777 and for three-month period ended September 30, 2024 and the years ended June 30, 2024 and 2023. Our
ability to continue as a going concern depends upon our ability to develop, register and obtain regulatory approval for commercial sell
of our products to generate positive operating cash flows. As of September 30, 2024 and June 30, 2024, the Company&rsquo;s working capital
was in deficit of $176,636 and $318,650. In addition, the Company had net cash outflows of $29,680 and $2,126,340 from operating activities
for the three-month period ended September 30, 2024 and financial year ended June 30, 2024. These conditions give rise to substantial
doubt as to whether the Company will be able to continue as a going concern. Management has commenced a strategy to raise debt and equity.
However, there can be no certainty that these additional financings will be available on acceptable terms or at all. If management is
unable to execute this plan, there would likely be a material adverse effect on the Company&rsquo;s business.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We can offer no assurance that
we will operate profitably or that we will generate positive cash flows in the next twelve months, given our substantial expenses in relation
to our revenue at this stage of our Company. Inability to collect our accounts receivable in a timely and sufficient manner, or the inability
to offset our expenses with adequate revenue, may adversely affect our liquidity, financial condition and results of operations. Although
we believe that our cash on hand will be sufficient to meet our anticipated working capital requirements and capital expenditures in the
ordinary course of business for the next 6 months, we cannot assure you this will be the case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If and when we are unable to meet
our working capital requirements and various operating needs, we may need to raise additional funds for our operations and such funds
may not be available on commercially acceptable terms, if at all. If we are unable to raise funds on acceptable terms, we may not be able
to execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements.
This may seriously harm our business, financial condition and results of operations. If we are unable to achieve or maintain profitability,
the market price of our shares may significantly decrease. In the event that the Company requires additional funding to finance its operations,
the Company&rsquo;s major shareholders have indicated their intent and ability to provide such financial support, however, there is no
assurance such funding will be available when the Company needs it in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have recorded negative cash flows from operating activities historically
and may have a current liabilities position in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have experienced significant
cash outflow from operating activities since our inception. We had net cash outflow in operating activities of $29,680, $2.1 million and
$3.0 million for the three-month period ended September 30, 2024 and for the years ended June 30, 2024 and 2023, respectively. The cost
of continuing operations could further reduce our cash position, and an increase in our net cash outflow from operating activities could
adversely affect our operations by reducing the amount of cash available to meet the cash needs for operating our business and to fund
our investments in our business expansion.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had net current asset (liabilities)
of $(0.2) million, $0.3 million and $ (0.5) million as of September 30, 2024, June 30, 2024 and 2023. We cannot guarantee that we will
turnaround into a net current assets position in future, which would expose us to liquidity risk. Our future liquidity and ability to
make additional capital investments necessary for our operations and business expansion will depend primarily on our ability to maintain
sufficient cash and to obtain adequate external financing. There can be no assurance that we will be able to obtain any sources of financing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif"><B><I>We require substantial funding for our operations. If we cannot
raise sufficient additional capital on acceptable terms, our business, financial condition and prospects may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We require substantial capital
to fund our existing operations, commercialize new products, expand our business and pursue strategic investments. In particular, we
require substantial capital to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">advance our early cancer detection
                                            technologies and develop early cancer detection product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">increase our sales and marketing efforts
                                            to drive market adoption of our products and services and address competitive developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">seek regulatory and marketing approvals
                                            for our tests;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">maintain, expand and protect our intellectual
                                            property portfolio;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">hire and retain additional personnel,
                                            such as scientists and sales and marketing personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">develop, acquire and improve operational,
                                            financial and management information systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">add equipment and physical infrastructure
                                            to support our research and development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">finance general and administrative
                                            expenses; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">operate as a public company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current business
plan, we believe our cash and cash equivalents, together with our financing activities, our Primary Offering will be sufficient to meet
our current and anticipated needs for general corporate purposes for at least the next 6&nbsp;months. If our available cash balances are
insufficient to satisfy our liquidity requirements, in particular, for the development and commercialization of our products, we may seek
to obtain further funding through public or private equity offerings, debt financings or other sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further financing may not
be available to us on acceptable terms, or at all. If we fail to raise capital as and when needed it would have a negative impact on
our financial condition and our ability to pursue our business strategy. In addition, if we raise funds by issuing debt securities or
incurring additional borrowings, the terms of debt securities issued or borrowings could impose significant restrictions on our operations,
and we may be unable to repay the indebtedness when due. If we raise funds by issuing equity securities, your investment in our company
could be diluted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Raising additional capital may lead to dilution
of shareholdings by our existing shareholders, restrict our operations, and may further result in fair value loss adversely affecting
our financial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional funding
through a combination of equity and debt financings and collaborations. To the extent that we raise additional capital through the sale
of equity or convertible debt securities, the ownership interest of existing holders of our shares will be diluted, and the terms may
include liquidation or other preferences that adversely affect the rights of our existing shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The incurrence of additional
indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in
certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations
on our ability to acquire or license IP rights and other operating restrictions that could adversely impact our ability to conduct our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have only a limited accounting personnel
and have corrected an error in application of the accounting principle for business combinations accounted for an acquisition of an entity
during the year ended June 30, 2022.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to the completion of this
offering, we have been a private company with limited accounting personnel mainly engage in financial reporting. On January 1, 2022, the
Company, through Advanced Biomed HK, acquired 100% equity interest of Shanghai Sglcell. The Company carefully considered the appropriate
accounting guidance in accordance with its application of the accounting principle related to accounting for business combinations. However,
we did not engage outside experts to assist in the detailed analysis.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon further assessment, the Company
has corrected an error in its application of the accounting principle for business combinations where the Company previously incorrectly
accounted for an acquisition of an entity as a business combination; the Company has amended its consolidated financial statements for
the year ended June 30, 2022 to account for the transaction as purchase of assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Management
concluded that the <FONT STYLE="background-color: white">above correction</FONT> identified in connection with the accounting treatment for the acquisition was a significant deficiency
that did not rise to the level of a material weakness. The deficiency identified was narrow as it focused on the interpretation of accounting
literature to a specific transaction structure which is not expected to be recurring nature. For future material acquisitions, the Company
will engage outside experts to assist in the transaction, including legal and accounting advisors, to advise on complex accounting issues
in order to prevent potential differences in the accounting for business combinations. As a result, the Company does not believe that
the significant deficiency rose to the level of a material weakness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Risks Related to Doing Business in Taiwan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Advanced Biomed Taiwan does not currently
own any trademark or patent.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No trademark or patent has been
registered by Advanced Biomed Taiwan so far in Taiwan. It also has no pending intellectual property right contracts, including license, transfer or sublicense.
Its primary business is research and development of various advanced and innovative microfluidic biochip technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based on Article 7 of Taiwan&rsquo;s
Patent Act, where a fund provider appoints another party to conduct research and development, the ownership of the right to apply for
a patent and the patent right in connection with the outcome of such research and development shall be vested in the party as mutually
agreed upon in an agreement between both parties, or such rights shall be vested in the inventor, utility model creator or designer in
the absence of such agreement. However, the fund provider shall be entitled to exploit such invention, utility model or design. Advanced
Biomed Taiwan signed a research project equipment use contract with TSRI and used their
semiconductor manufacturing equipment and precision micro-nano processing equipment for chip technology research and development such
as concept presentation of each R&amp;D process, cross-scale composite structure production, rapid wafer trial production, material testing,
and thin film production. Both parties agree
to keep the test data, process and materials confidential. Advanced Biomed Taiwan agrees that TSRI may
quote the test data in its research paper with the consent of Advanced Biomed Taiwan. The contract also provides that any intellectual
property rights of one party should only be used in the test by licensing to the other party and that any intellectual property rights
derived from the test will belong to the developer. Both parties will jointly own the intellectual property right if it cannot be clearly
identified who the developer is. The ownership of patent application rights and patent rights may be obscure in such practice and raise
disputes on who the developers are. We cannot assure you that the patents owned or applied by Advanced Biomed Taiwan will not be subject
to disputes under Taiwan&rsquo;s Patent Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face economic and political risks associated
with doing business in Taiwan, particularly due to the geopolitical tension between Taiwan and China that could negatively affect our
business and hence the value of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, we rely on Advanced
Biomed Taiwan for microfluidic biochip technology and its application in precision medicine in the field of oncology. Accordingly, our
business, financial condition and results of operations and the market price of our securities may be affected by changes in governmental
policies, taxation, growth rate, inflation rate or interest rates and by social instability and diplomatic and social developments in
or affecting Taiwan. In particular, the unique political status of Taiwan and its internal political movement cause sustained tension
between China and Taiwan. Past developments related to the interactions between China and Taiwan, especially in relation to trade activities
such as bans on exports of goods from time to time, have on occasions depressed the transactions and business operations of certain Taiwanese
companies and overall economic environment. We cannot predict whether there will be escalation of the tensions between China and Taiwan
which would lead to new bans or tariffs on exports or even conflict. Any conflict which threatens the military, political or economic
stability in Taiwan could have a material adverse effect on our current or future business and financial conditions and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Advanced Biomed Taiwan is subject to restrictions
on paying dividend or making other payments to us, which may restrict our ability to satisfy its liquidity requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company incorporated
under the laws of the State of Nevada structured as a holding company, we may need dividends and other distributions on equity from our
Taiwan subsidiary to satisfy our liquidity requirements. Current Taiwan regulations permit our Taiwan subsidiary to pay dividends to
its shareholders only out of its accumulated profits, if any, which shall first make up previous losses and set aside at least 10% of
its accumulated profits each year. These reserves are not distributable as cash dividends. Furthermore, if our Taiwan subsidiary incurs
debt on its own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments
to us. Any limitation on the ability of our Taiwan subsidiary to distribute dividends or to make payments to us may restrict our ability
to satisfy our liquidity requirements. In addition, the dividend payments by our Taiwan subsidiary to us shall be subject to the withholding
tax of 21% since January&nbsp;1, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Advanced Biomed Taiwan is subject to foreign
exchange control imposed by Taiwan authorities, which may affect the paying dividends, repatriating the interest or making other payments
to us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently Taiwan regulates
only those foreign exchange transactions that involve the conversion of the New Taiwan Dollar into foreign currencies. Pursuant to the
relevant provisions of Taiwan Foreign Exchange Control Act, foreign exchange transactions of a value of NTD 500,000 or more shall be
declared to the Central Bank of Republic of China (Taiwan). Further, for a remittance by a company as follows, relevant testimonials
shall be submitted and such remittance shall be subject to the approval of the Central Bank of Taiwan: (i)&nbsp;a single remittance of
an amount over USD1&nbsp;million; or (ii)&nbsp;annual accumulated settlement amount of foreign exchange purchased or sold has exceeded
USD50&nbsp;million. Nevertheless, Taiwan government may impose further foreign exchange restrictions in certain emergency situations,
where Taiwan government experiences extreme difficulty in stabilizing the balance of payments or where there are substantial disturbances
in the financial and capital markets in Taiwan. If the dividend payments or other payments by our Taiwan subsidiary and branches to us
involves the currency conversion from New Taiwan Dollar to US&nbsp;Dollar, such conversion would be subject to the foregoing foreign
exchange control imposed by Taiwan authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Taiwan laws and regulations of loans to
and direct investment in Taiwan entities by offshore holding companies may delay or prevent us from using the proceeds of this offering
to make loans or additional contributions to Advanced Biomed Taiwan, which could materially and adversely affect our ability to fund and
expand our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an offshore holding
company conducting our R&amp;D operations substantially in Taiwan through our Advanced Biomed Taiwan. We may make loans to Advanced Biomed
Taiwan, or we may make additional capital contributions to Advanced Biomed Taiwan, or we may establish new Taiwan subsidiaries and make
capital contributions to these new Taiwan subsidiaries, or we may acquire offshore entities with business operations in Taiwan in an offshore
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most of these ways are
subject to Taiwan regulations and approvals or registration. For example, investment, including lending long-term loans, in Taiwan
entities require Foreign Investment Approval (as defined below) from the Taiwan Investment Commission. Furthermore, foreign entities
are prohibited from investing in some industries which are relating to national security and environmental protection, as specified
in the negative list provided by Taiwan authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Advanced Biomed Taiwan will collaborate and
share its R&amp;D efforts with us and our Shanghai subsidiary and is subject to Taiwan regulations on investment or technical cooperation
in China. It may affect its technical cooperation with the Shanghai subsidiary and more seriously its acquisition by Advanced Biomed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the cross-strait relations become more and more sensitive recently, Taiwan authorities incline to prohibit Taiwan technology companies
from selling their subsidiaries or assets to mainland Chinese investors to prevent leak of sensitive technologies, including semiconductors.
Pursuant to the Taiwan Permission Regulations for Investment or Technical Cooperation in the PRC and the Review Principles for Investments
or Technical Cooperation in China (&ldquo;Permission Regulations&rdquo;), an investment or technical cooperation made by a Taiwanese investor
in China is subject to the restrictions thereunder and requires the approval by the competent Taiwan authority, Taiwan Investment Commission.
The restrictions under the Permission Regulations include a negative list in which investment or technical cooperation is prohibited.
Currently, Advanced Biomed Taiwan&rsquo;s technical cooperation with the Shanghai subsidiary is not on such negative list. However, we
cannot preclude the possibility that the negative list will be amended to restrict Advanced Biomed Taiwan&rsquo;s cooperation with the
Shanghai subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Taiwanese investors holding more than 10%
of Advanced Biomed Common Stock will be subject to Taiwan regulations on investment or technical cooperation in China for its investment
or technical cooperation in China.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Permission Regulations,
for an investment made by a Taiwanese individual or entity (&ldquo;Taiwanese Investor&rdquo;) in a &ldquo;third region&rdquo; company
which conducts the investments or technical cooperation in China defined therein and such Taiwanese Investor (i)&nbsp;acts as director,
supervisor, manager or equivalent position or (ii)&nbsp;has a shareholding or capital contribution of 10% or more in such third region
company, the investment in such a third region company would also be deemed a defined investment in China and therefore be subject to
the Permission Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, for our future investment or technical cooperation in China, our Taiwanese shareholders holding 10% or more of our Common Stock
will need to apply for the foreign investment approval with the competent Taiwan authority, the Taiwan Investment Commission in accordance
with the Permission Regulations (the &ldquo;Foreign Investment Approval&rdquo;). There are restrictions on the investment or technical
cooperation with China, including, without limitation, the annual investment amount in China shall be capped at USD5 million per year
for Taiwan individuals or NTD 80 million or 60% of the higher of its stand-along net worth or consolidated net worth for a Taiwan small-medium
enterprise. Your indirect investment in the PRC via the Company under the Permission Regulations will be calculated on the portion of
your shareholdings in the Company. If your aggregate investments in the PRC exceed the annual ceiling amount, the Taiwan Investment Commission
will reject your application for the exceeding investment in the PRC. If the Taiwanese Investor fails to obtain applicable approvals from
the Taiwan Investment Commission in respect of its investment in China, an administrative fine ranging NTD 50 thousand to 25 million or
imprisonment may be imposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The imposition of foreign exchange restrictions
in Taiwan may have an adverse effect on foreign investors&rsquo; abilities to acquire securities of a Taiwan company, including the shares
of our subsidiaries in Taiwan, or to repatriate the interest, dividends or sale proceeds from those securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Taiwan government may impose
foreign exchange restrictions in certain emergency situations, including situations where there are sudden fluctuations in interest rates
or exchange rates, where the Taiwan government experiences extreme difficulty in stabilizing the balance of payments or where there are
substantial disturbances in the financial and capital markets in Taiwan. These restrictions may require foreign investors to obtain the
Taiwan government&rsquo;s approval before acquiring securities of a Taiwan company, including the shares of our subsidiaries in Taiwan,
repatriating the interest or dividends from those securities or repatriating the proceeds from the sale of those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our operations are subject to the effects
of a rising rate of inflation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Taiwan experienced historically
high levels of inflation in 2022 and 2023. Although the inflation rate peaked in June 2022 at 3.59%, there is no guarantee that the inflation
will not accelerate again. If the inflation rate continues to remain at a relatively high level or increases drastically, for example,
due to increases in the costs of labor and supplies, it will affect our expenses, such as employee compensation and research and development
charges. Additionally, Taiwan is experiencing an acute workforce shortage, which, in turn, has created a very competitive wage environment
that may increase our operating costs. To the extent inflation results in rising interest rates and has other adverse effects on the market,
it may adversely affect our consolidated financial condition and results of operations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>You may experience difficulties in effecting
service of legal process, enforcing foreign judgments, or bringing actions in Taiwan against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company incorporated under
the laws of the State of Nevada, it may be difficult for you to enforce judgments obtained in U.S. courts based on civil liability provisions
of the U.S. federal securities laws against us in Taiwan. In addition, there is uncertainty as to whether the courts of Taiwan would recognize
or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of
the U.S. or any state, if the following circumstances occurs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Where the foreign court lacks jurisdiction pursuant to the Taiwan laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Where a default judgment is rendered against the losing defendant, except in the case where the notice
or summons of the initiation of action had been legally served in a reasonable time in the foreign country or had been served through
judicial assistance provided under the Taiwan laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Where the performance ordered by such judgment or its litigation procedure is contrary to Taiwan public
policy or morals; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Where there exists no mutual recognition between the foreign country and the Taiwan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Doing Business in China</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A downturn in China or global economy,
and economic and political policies of the PRC could materially and adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the different regulatory
requirements for the marketing of medical device products and invitro diagnosis (&ldquo;IVD&rdquo;) products in different regions/countries,
it is necessary to complete the registration application and obtain the corresponding license in accordance with the local regulations
before engaging in commercial activities in the respective regions/countries (&ldquo;localization registration&rdquo;). Afterwards, marketing
and sales can be carried out. All the products and equipment we research and develop are designed following the principle of modularization
so that products and equipment can be produced locally to meet different regulatory requirements. The Chinese market has a great potential
and is our one of the main markets in the future. At present, we have applied for product registration in China in accordance with relevant
Chinese laws and regulations. Meanwhile, we have established subsidiaries in Mainland China and Hong Kong. Accordingly, our business,
prospects, financial condition and results of operations may be influenced by political, economic and social conditions in the PRC generally
and by continued economic growth in the PRC as a whole. The Chinese economy differs from the economies of most developed countries in
many respects, including the amount of government involvement, level of development, growth rate, control of foreign exchange and allocation
of resources. While the Chinese economy has experienced significant growth over the past decades, growth has been uneven, both geographically
and among various sectors of the economy, and we cannot assure you that such growth is sustainable. The Chinese government has implemented
various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall Chinese
economy but may have a negative effect on us. For example, the Chinese government may direct resources to industries other than the one
we operate in and potentially reduce the investors&rsquo; interest in our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Economic conditions in China are
sensitive to global economic conditions. Any prolonged slowdown in the global or Chinese economy may affect potential clients&rsquo; confidence
in financial market as a whole and have a negative impact on our business, results of operations and financial condition. Additionally,
continued turbulence in the international markets may adversely affect our ability to access the capital markets to meet liquidity needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Changes in the policies, regulations, rules,
and the enforcement of laws of the PRC government may be quick with little advance notice and could have a significant impact upon our
ability to operate profitably in the Mainland China and Hong Kong.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since we have our subsidiaries
in Shanghai and Hong Kong, economic, political and legal developments in the PRC will affect our business, financial condition, results
of operations and prospects. Policies, regulations, rules, and the enforcement of laws of the PRC government can have significant effects
on economic conditions in the PRC and the ability of businesses to operate profitably. Our ability to operate profitably in the PRC may
be adversely affected by changes in policies by the PRC government, including changes in laws, regulations or their interpretation, particularly
those dealing with the Internet, including censorship and other restriction on material which can be transmitted over the Internet, security,
intellectual property, money laundering, taxation and other laws that affect our ability to operate business in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The Chinese government may intervene in or influence our operations
in the Mainland China or Hong Kong at any time or may exert more control over offerings conducted overseas and/or foreign investment in
us, which could result in a material change in our operations and and/or the value of the securities we are registering for sale.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Chinese government has significant oversight and discretion over the conduct of our business and may intervene or influence our operations
in the Mainland China or Hong Kong as the government deems appropriate to further regulatory, political and societal goals. The Chinese
government has recently published new policies that significantly affected certain industries such as the education and Internet industries,
and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry that could require
us to seek permission from Chinese authorities to commence to operate our business, which may adversely affect our business, financial
condition and results of operations. Furthermore, recent statements made by the Chinese government have indicated an intent to increase
the government&rsquo;s oversight and control over offerings of companies with significant operations in China that are to be conducted
in foreign markets, as well as foreign investment in PRC-based issuers. There is no guarantee that we will not be subject to such direct
influence or intervention in the future due to changes in laws or other unforeseeable reasons. There is always a risk that the Chinese
government may, in the future, seek to affect operations of any company with any level of operations in the Mainland China and Hong Kong.
Any such action, once taken by the Chinese government, could cause the value of our Common Stock to significantly decline or become worthless.
In addition, if we were to become subject to the direct intervention or influence of the PRC government at any time due to changes in
laws or other unforeseeable reasons, it may require a material change in our operations and/or result in increased costs necessary to
comply with existing and newly adopted laws and regulations or penalties for any failure to comply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I></I></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-size: 10pt"><B><I>If the Chinese government chooses
to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, such
action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the
value of such securities to significantly decline or be worthless.</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We face risks arising from China including risks and uncertainties regarding the enforcement of laws and that rules and regulations in
China can change quickly with little advance notice. The Chinese government may intervene or influence the operations of our subsidiaries
in Shanghai and Hong Kong at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based
issuers, which could result in a material change in the operations of our subsidiaries in Shanghai and Hong Kong and/or the value of our
Common Stock.</FONT></P>

<P STYLE="margin: 0pt; font: 11pt Times New Roman, Times, Serif; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in">The Chinese government has exercised and continues to exercise substantial
control over virtually every sector of the Chinese economy through regulation and state ownership. Our ability to operate in China through
our subsidiaries in Shanghai and Hong Kong may be harmed by changes in laws and regulations in China, including those relating to securities
regulation, data protection, cybersecurity and mergers and acquisitions and other matters. The PRC central or local governments may impose
new, stricter regulations or interpretations of existing regulations that would require additional expenditures and efforts on our part
to ensure our and our subsidiaries&rsquo; compliance with such regulations or interpretations.</P>

<P STYLE="text-align: justify; margin: 0pt; font: 11pt Times New Roman, Times, Serif; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Government actions
in the future could significantly affect economic conditions in China or particular regions thereof, and could require our subsidiaries
in Shanghai and Hong Kong to materially change their operating activities or divest ourselves of any interests we hold in Chinese assets.
Our subsidiaries in Shanghai and Hong Kong may be subject to various government and regulatory interference. We may incur increased costs
necessary to comply with existing and newly adopted laws and regulations or penalties for any failure to comply. Such subsidiaries&rsquo;
operations could be adversely affected, directly or indirectly, by changes to existing laws or implementation of future laws and regulations
relating to their business or industry.</FONT></P>

<P STYLE="text-align: justify; margin: 0pt; font: 11pt Times New Roman, Times, Serif; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
we and our subsidiaries in the Mainland China and Hong Kong (1) are not required to obtain permissions from any PRC authorities to operate
or issue our Common stock to foreign investors, (2) are not subject to permission requirements from the CSRC, CAC or any other entity
that is required to approve their operations in the Mainland China and Hong Kong, and (3) have not received or were denied such permissions
by any PRC authorities. Nevertheless, the General Office of the Central Committee of the Communist Party of China and the General Office
of the State Council jointly issued the &ldquo;Opinions on Severely Cracking Down on Illegal Securities Activities According to Law,&rdquo;
which were made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal
securities activities, and the need to strengthen the supervision over overseas listings by Chinese companies. The regulatory agencies
like CSRC or CAC may impose fines and penalties on our operations in the Mainland China or Hong Kong, limit our ability to pay dividends
outside of the Mainland China or Hong Kong, limit our operations in the Mainland China or Hong Kong, delay or restrict the repatriation
of the proceeds from this offering into the Mainland China or Hong Kong or take other actions that could have a material adverse effect
on our business, financial condition, results of operations and prospects, as well as the trading price of our securities. The CSRC, the
CAC, or other PRC regulatory agencies also may take actions requiring us, or making it advisable for us, to halt this offering before
settlement and delivery of our Common Stock. Consequently, if you engage in market trading or other activities in anticipation of and
prior to settlement and delivery, you do so at the risk that settlement and delivery may not occur. In addition, if the CSRC, the CAC
or other regulatory PRC agencies later promulgate new rules requiring that we obtain their approvals for this offering, we may be unable
to obtain a waiver of such approval requirements, if and when procedures are established to obtain such a waiver. Any uncertainties and/or
negative publicity regarding such an approval requirement could have a material adverse effect on the trading price of our securities.</P>
<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0pt; font: 11pt Times New Roman, Times, Serif; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Any actions by the
Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based
issuers could significantly limit or complete hinder our ability to offer or continue to offer our securities and cause the value of
such securities to significantly decline or be worthless.&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If the Chinese government were to exert more
oversight and control over or impose new requirements for approval from the PRC authorities to issue our Common Stock to foreign investors
or list on a foreign exchange, such action could significantly limit or completely hinder our ability to offer or continue to offer securities
to investors and cause the value of such securities to significantly decline or be worthless.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B><I></I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recent statements by the Chinese
government have indicated an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investments
in PRC based issuers. PRC has recently promulgated new rules that require companies collecting or holding large amounts of data to undergo
a cybersecurity review prior to listing in foreign countries, a move that will significantly tighten oversight over PRC-based internet
giants. The Measures for Cybersecurity Review (2021 version) was promulgated on December 28, 2021 and became effective on February 15,
2022. These measures specify that any &ldquo;online platform operators&rdquo; controlling the personal information of more than one million
users which seek to list on a foreign stock exchange are subject to prior cybersecurity review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On September 24, 2024, the State Council promulgated the Regulation on
Network Data Security Management (the &ldquo;Network Data Regulation&rdquo;), which will become effective as of January 1, 2025. The Network
Data Regulation restates and further specifies the legal requirements for personal information, important data, cross-border data transfer,
network platform services, and data security. Among others, if the network data processing activities have or may have impacts on national
security, such activities shall be subject to national security review in accordance with relevant laws and regulations. Any failure to
comply with such requirements may subject us to, among others, suspension of services, fines, revoking relevant business permits or business
licenses and penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The PRC Data Security Law,
which was promulgated by the Standing Committee of the National People's Congress (the &ldquo;SCNPC&rdquo;) on June 10, 2021 and took effect on September 1, 2021, requires data collection to be conducted in
a legitimate and proper manner, and stipulates that, for the purpose of data protection, data processing activities must be conducted
based on data classification and hierarchical protection system for data security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On August 20, 2021, the SCNPC
promulgated the Personal Information Protection Law of the People&rsquo;s Republic of China, or the Personal Information Protection Law,
which integrates the scattered rules with respect to personal information rights and privacy protection and took effect on November 1,
2021.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business does not involve the collection of user data, implicate cybersecurity,
or involve any other type of <I>foreign investment</I> restricted industry. Based on the advice of PRC counsel and our understanding of
currently applicable PRC laws and regulations, our registered public offering in the U.S. is not subject to the review or prior approval
of the CAC. As of the date of this prospectus, we have not received any notice from any authorities identifying the operating entities
as CIIOs or requiring us to go through cybersecurity review or network data security review by the CAC. Uncertainties still exist, however,
due to the possibility that laws, regulations, or policies in the PRC could change rapidly in the future. Any future action by the PRC
government expanding the categories of industries and companies whose foreign securities offerings are subject to review by the CAC could
significantly limit or completely hinder our ability to offer or continue to offer securities to investors and could cause the value of
such securities to significantly decline or be worthless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 17, 2023, the CSRC
released Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies with five interpretive guidelines
(the &ldquo;Trial Measures&rdquo;), which came into effect on March 31, 2023. Pursuant to the Trial Measures, a PRC domestic company that
seeks to offer and list securities in overseas markets, either in direct or indirect overseas offering, shall fulfill the filing procedure
with the CSRC and report relevant information to the CSRC. Direct overseas offering and listing by domestic companies refers to such overseas
offering and listing by a joint-stock company incorporated domestically. Any overseas offering and listing made by an issuer that meets
both the following conditions will be determined as indirect offering and listing in overseas market and, therefore, be subject to filing
requirement: (i) 50% or more of the issuer&rsquo;s operating revenue, total profit, total assets or net assets as documented in its audited
consolidated financial statements for the most recent accounting year is accounted for by domestic companies; and (ii) the main parts
of the issuer&rsquo;s business activities are conducted in the Mainland China, or its main places of business are located in the Mainland
China, or the senior managers in charge of its business operation and management are mostly Chinese citizens or domiciled in the Mainland
China. The determination as to whether or not an overseas offering and listing by domestic companies is indirect, shall be made on substance
over form basis. As of the date of this prospectus, as advised by AllBright, we are not required to obtain the approval
from or complete the filing with the CSRC for this offering and thus we have not submitted an application for approval for this offering
with the CSRC pursuant to the Trial Measures based on the facts that (i) we are a holding company incorporated in the State of Nevada,
not a company incorporated under the PRC law; (ii) based on the report on the Shanghai subsidiary from a third party accounting firm in
China, the Shanghai subsidiary contributed less than 50% to our operating revenue, total profit, total assets or net assets as documented
in the audited consolidated financial statements for the fiscal year ended June 30, 2024; (iii) the business activities are primarily
conducted in Taiwan, with minimal operation in Mainland China, and (iv) most of our officers and directors are non-Chinese citizens or
domiciled outside Mainland China. Thus, we do not meet the explicit conditions set out in the Trial Measures to determine whether an overseas
offering shall be deemed as an indirect overseas offering and listing by a domestic company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">However, as the Trial Measures
was newly published <FONT STYLE="font-style: normal; font-weight: normal">and the determination as to whether or not an overseas offering
and listing by domestic companies is indirect, shall be made on a substance over form basis,</FONT> there are substantial uncertainties
as to the implementation and interpretation, and the CSRC may take a view that is contrary to our understanding of the Trial Measures.
If we are required by the CSRC to submit and complete the filing procedures of this offering and listing, we cannot assure you that we
will be able to complete such filings in a timely manner, or even at all. Any failure by us to comply with such filing requirements under
the Trial Measures may result in rectification, warnings, and a fine between RMB1 million and RMB10 million on our Shanghai subsidiary,
which could adversely and materially affect our business operations and financial outlook, and significantly limit or completely hinder
our ability to offer or continue to offer our Common Stock to investors and could cause the value of our Common Stock to significantly
decline or such shares to become worthless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 24, 2023, the
CSRC, together with other PRC government authorities, released the Provisions on Strengthening the Confidentiality and Archives Administration
Related to the Overseas Securities Offering and Listing by Domestic Enterprises (the &ldquo;Confidentiality and Archives Administration
Provisions&rdquo;), which came into effect on March 31, 2023. The Confidentiality and Archives Administration Provisions require, among
others, that PRC domestic enterprises seeking to offer and list securities in overseas markets, either directly or indirectly, shall establish
the confidentiality and archives system, and shall complete approval and filing procedures with competent authorities, if such PRC domestic
enterprises or their overseas listing entities provide or publicly disclose documents or materials involving state secrets and work secrets
of PRC government agencies to relevant securities companies, securities service institutions, overseas regulatory agencies and other entities
and individuals. It further stipulates that providing or publicly disclosing documents and materials which may adversely affect national
security or public interests, and accounting files or copies of important preservation value to the state and society shall be subject
to corresponding procedures in accordance with relevant laws and regulations. As of the date of this prospectus, our Shanghai subsidiary
has established the confidentiality and archives system and we are not subject to the approval to the competent authorities since we do
not possess any documents or materials involving state secrets and work secrets of PRC government agencies.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus and as advised by AllBright, we and our subsidiaries in the Mainland China and Hong Kong, (1) are not
required to obtain permissions from any PRC authorities to operate or issue our Common Stock to foreign investors, (2) are not subject
to permission requirements from the CSRC, CAC or any other entity that is required to approve of our PRC Subsidiaries&rsquo; operations,
and (3) have not received or were denied such permissions by any PRC authorities. Nevertheless, the General Office of the Central Committee
of the Communist Party of China and the General Office of the State Council jointly issued the &ldquo;Opinions on Severely Cracking Down
on Illegal Securities Activities According to Law,&rdquo; or the Opinions, which were made available to the public on July 6, 2021. The
Opinions emphasized the need to strengthen the administration over illegal securities activities, and the need to strengthen the supervision
over overseas listings by Chinese companies.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have been closely monitoring regulatory developments in PRC regarding
any necessary approvals from the CSRC or other PRC governmental authorities required for overseas listings, including this offering. As
of the date of this prospectus, we have not received any inquiry, notice, warning, sanctions or regulatory objection to this offering
from the CSRC or other PRC governmental authorities. However, there remains significant uncertainty as to the enactment, interpretation
and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities. Given the
current PRC regulatory environment, it is uncertain when and whether we or our subsidiaries in Shanghai and Hong Kong will be required
to obtain permission from the PRC government to list on U.S. exchanges in the future, and even when such permission is obtained, whether
it will be denied or rescinded. Such significant uncertainty could materially and adversely impact our business and financial outlook
and may impact our ability to accept foreign investments, or continue to list on a U.S. or other foreign exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;<B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Uncertainties in the interpretation and enforcement
of PRC laws and regulations could limit the legal protections available to you and the Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are subject to
various PRC laws and regulations generally applicable to companies in the PRC because we have subsidiaries in Shanghai and Hong Kong.
The PRC legal system is based on written statutes. Unlike common law systems, it is a system in which legal cases have limited value as
precedents. In the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic
matters in general. The overall effect of legislation over the past four decades has significantly increased the protections afforded
to various forms of foreign or private-sector investment in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, the PRC has not developed
a fully integrated legal system and recently enacted laws and regulations may not sufficiently cover all aspects of economic activities
in the PRC. In particular, the interpretation and enforcement of these laws and&nbsp;regulations involve uncertainties. In addition,
the PRC legal system is based in part on government policies and internal rules (some of which are not published on a timely basis or
at all) that may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until sometime
after the violation. Such uncertainties, including uncertainty over the scope and effect of our contractual, property (including intellectual
property) and procedural rights, and any failure to respond to changes in the regulatory environment in the PRC could materially and
adversely affect our business and impede our ability to continue our operation in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if certain PRC
laws and regulations were to become applicable to us in the future, the application of such laws and regulations may have a material
adverse impact on our business, financial condition and results of operations, any of which may cause the value of our securities to
significantly decline or become worthless. In addition, the laws and regulations in the PRC are evolving, and their enactment timetable,
interpretation and implementation involve significant uncertainties. To the extent any PRC laws and regulations become applicable to
our business, it may be subject to the risks and uncertainties associated with the legal system in the PRC, including with respect to
the enforcement of laws and the possibility of changes of rules and regulations with little or no advance notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience difficulties in effecting
service of legal process, enforcing foreign judgments, or bringing actions in PRC against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company incorporated under the laws of the State of Nevada, it may
be difficult for you to enforce judgments obtained in U.S. courts based on civil liability provisions of the U.S. federal securities laws
against us in the PRC. In addition, there is uncertainty as to whether the courts of the PRC would recognize or enforce judgments of U.S.
courts against us or such persons predicated upon the civil liability provisions of the securities laws of the U.S. or any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The recognition and enforcement
of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance
with the requirements of the PRC Civil Procedures Law based either on treaties between PRC and the country where the judgment is made
or on principles of reciprocity between jurisdictions. PRC does not have any treaties or other forms of written arrangement with the
United States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil
Procedures Law, the PRC courts will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment
violates the basic principles of PRC laws or national sovereignty, security, or public interest. As a result, it is uncertain whether
and on what basis a PRC court would enforce a judgment rendered by a court in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Non-compliance with the PRC Labor Contract
Law and other labor-related regulations in the PRC may adversely affect our business and our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been subject to stricter
regulatory requirements in terms of entering into labor contracts with our employees and paying various statutory employee benefits,
including pensions, housing fund, medical insurance, work-related injury insurance, unemployment insurance and childbearing insurance
to designated government agencies for the benefit of our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the PRC Labor Contract
Law, or the Labor Contract Law, which was released on January&nbsp;1, 2008, was amended on December&nbsp;28, 2012 and became effective
on July 1, 2013 employees have the right, among others, to enter into written labor contracts, minimum wages, paying remuneration, determining
the term of employees&rsquo; probation and unilaterally terminating labor contracts. In the event that we decide to terminate some of
our employees or otherwise change our employment or labor practices, the Labor Contract Law and its implementation rules may limit our
ability to effect those changes in a desirable or cost-effective manner, which could adversely affect our business and results of operations.
In addition, according to the PRC Social Insurance Law, which was released on July&nbsp;1, 2011, amended on December&nbsp;29, 2018 and
became effective on the same day, and the Administrative Regulations on the Housing Provident Funds, which was released on April 3, 1999,
amended on March 24, 2019 and became effective on the same day, companies operating in the PRC are required to participate in pension
insurance, work-related injury insurance, medical insurance, unemployment insurance, maternity insurance and housing provident fund plans,
and the employers must pay all or a portion of the social insurance premiums and housing provident funds for their employees.&nbsp;We
believe our current practice complies with the Labor Contract Law and its amendments. However, the relevant governmental authorities
may take a different view and impose fines on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interpretation and
implementation of these laws and regulations are still evolving, our employment practices may not at all times be deemed in compliance
with the new laws and regulations. If we incur significant liabilities in connection with labor disputes or investigations, our businesses
and results of operations may be adversely affected.<B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I></I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Changes in the PRC&rsquo;s economic, political
or social conditions or government policies could have a material adverse effect on our businesses and operations in Mainland China and
Hong Kong.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><B><I></I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The PRC&rsquo;s economy differs
from the economies of the PRC&rsquo;s counterpart countries in many respects, including the level of government involvement, level of
development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures
since the late 1970s emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive
assets, and the establishment of improved corporate governance in business enterprises, which are generally viewed as a positive development
for foreign business investment, a substantial portion of productive assets in the PRC is still owned by the PRC government. In addition,
the PRC government continues to play a significant role in regulating industry development by imposing industrial policies. The PRC government
also exercises significant control over the PRC&rsquo;s economic growth through allocating resources, controlling payments of foreign
currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">While the PRC&rsquo;s economy has experienced significant growth over the past decades, such growth has been uneven,
both geographically and among various sectors of the economy, and the rate of growth has been slowing down. In addition, in the past,
the PRC government has implemented certain measures to control the pace of economic growth. These measures may cause decreased economic
activity, which in turn could lead to a low demand for our products and services.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Our Shanghai subsidiary is subject to restrictions
on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Although currently our Shanghai subsidiary are inactive, in the future, we may need dividends and other distributions on equity from our Shanghai subsidiary to satisfy
our liquidity requirements. Current PRC regulations permit our Shanghai subsidiary to pay dividends to their respective shareholders only
out of their accumulated profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, such companies
are required to set aside at least 10% of its accumulated profits each year, if any, to fund certain reserve funds until the total amount
set aside reaches 50% of its registered capital. Our Shanghai subsidiary may also, at the respective subsidiary&rsquo;s discretion,
allocates a portion of its&nbsp;after-tax profits based on its articles of association and PRC accounting standards to certain reserve
funds. These reserves are not distributable as cash dividends. Furthermore, if our Shanghai subsidiary incur debt on their own behalf in
the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments to us. Any limitation
on the ability of our Shanghai subsidiary to distribute dividends or to make payments to us may restrict our ability to satisfy our future
liquidity requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, the Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up
to 10% will be applicable to dividends payable by PRC companies to&nbsp;non-PRC-resident&nbsp;enterprises unless otherwise exempted or
reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the&nbsp;non-PRC-resident&nbsp;enterprises
are incorporated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we are deemed by the PRC tax authorities as a PRC tax resident enterprise
for tax purposes, any dividends we pay to our non-PRC resident shareholders may be regarded as China-sourced income and as a result, may
be subject to PRC withholding tax at a rate of up to 10%. Pursuant to the Arrangement between Mainland China and the Hong Kong Special
Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, or the Double Tax Avoidance Arrangement, the 10%
withholding tax rate may be reduced to 5% if a Hong Kong resident enterprise owns no less than 25% of a PRC entity. However, the 5% withholding
tax rate does not automatically apply and certain requirements must be satisfied, including, without limitation, that (a) the Hong Kong
entity must be the beneficial owner of the relevant dividends; and (b) the Hong Kong entity must directly hold no less than 25% share
ownership in the PRC entity during the 12 consecutive months preceding its receipt of the dividends. In practice, a Hong Kong entity must
obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC withholding tax rate. As the Hong Kong
tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot be certain that we will be able to obtain
the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential withholding tax rate of 5% under the
Double Taxation Arrangement with respect to any dividends to be paid by our Shanghai subsidiary to our Hong Kong subsidiary, Advanced
Biomed HK. Moreover, Advanced Biomed HK may be subject to additional restrictions and government regulations if the Chinese government
were to impose new laws and regulations or exert more control over Hong Kong&rsquo;s business activities. Our Shanghai subsidiary currently
does not have any plan to declare and pay dividends, and we have not applied for the tax resident certificate from the relevant Hong Kong
tax authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We can give no assurance that
we will declare dividends of any amounts, at any rate or at all in the future. The declaration of future dividends, if any, will be at
the discretion of our board of directors and will depend upon our future operations and earnings, capital requirements, general financial
conditions, legal and contractual restrictions and other factors that our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PRC regulation on loans to, and direct investment
in, PRC entities by offshore holding companies and governmental control in currency conversion may delay or prevent us from making loans
to or making additional capital contributions to our Shanghai subsidiary.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any funds we transfer to
the Shanghai subsidiary, either as a shareholder loan or as an increase in registered capital, are subject to approval by or registration
with relevant governmental authorities in China. According to the relevant PRC regulations on foreign invested enterprises in China,
capital contributions to our Shanghai subsidiary are subject to the registration with the State Administration for Market Regulation
or its local counterpart and registration with a local bank authorized by the SAFE. In addition, (i) any foreign loan procured by our
Shanghai subsidiary is required to be registered with the SAFE or its local branches and (ii) any of our Shanghai subsidiary may not
procure loans which exceed the difference between its total investment amount and registered capital or, as an alternative, only procure
loans subject to the calculation approach and limitation as provided by the People&rsquo;s Bank of China. Additionally, any medium or
long-term loans to be provided by us to the Shanghai subsidiary must be registered with the National Development and Reform Commission
and SAFE or its local branches. We may not be able to obtain these government approvals or complete such registrations in a timely manner,
or at all, with respect to future capital contributions or loans by us to our Shanghai subsidiary. Moreover, Advanced Biomed HK may be
subject to additional restrictions and government regulations if the Chinese government were to impose new laws and regulations or exert
more control over Hong Kong&rsquo;s business activities. If we fail to receive such approvals or complete such registration or filing,
our ability to use the proceeds of future offerings to capitalize our PRC operations may be negatively affected, which could adversely
affect our liquidity and our ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SAFE promulgated the Notice
of the State Administration of Foreign Exchange on Reforming the Administration of Foreign Exchange Settlement of Capital of Foreign-invested
Enterprises, or SAFE Circular 19, effective on June&nbsp;1, 2015 and was amended on December 30, 2019, in replacement of the Circular
on the Relevant Operating Issues Concerning the Improvement of the Administration of the Payment and Settlement of Foreign Currency Capital
of Foreign-Invested Enterprises, the Notice from the State Administration of Foreign Exchange on Relevant Issues Concerning Strengthening
the Administration of Foreign Exchange Businesses, and the Circular on Further Clarification and Regulation of the Issues Concerning
the Administration of Certain Capital Account Foreign Exchange Businesses. According to SAFE Circular 19, the flow and use of the RMB
capital converted from foreign currency-denominated registered capital of a foreign-invested company is regulated such that RMB capital
may not be used for the issuance of RMB entrusted loans, the repayment of inter-enterprise loans or the repayment of bank loans that
have been transferred to a third party. Although SAFE Circular 19 allows RMB capital converted from foreign currency-denominated registered
capital of a foreign-invested enterprise to be used for equity investments within the PRC, it also reiterates the principle that RMB
converted from the foreign currency-denominated capital of a foreign-invested company may not be directly or indirectly used for purposes
beyond its business scope. Thus, it is unclear whether the SAFE will permit such capital to be used for equity investments in the PRC
in actual practice. The SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the
Foreign Exchange Settlement Management Policy of Capital Account, or SAFE Circular 16, effective on June&nbsp;9, 2016, which reiterates
some of the rules set forth in SAFE Circular 19, but changes the prohibition against using RMB capital converted from foreign currency-denominated
registered capital of a foreign-invested company to issue RMB entrusted loans to a prohibition against using such capital to grant loans
to&nbsp;non-associated enterprises. Violations of SAFE Circular 19 and SAFE Circular 16 could result in administrative penalties. SAFE
Circular 19 and SAFE Circular 16&nbsp;may significantly limit our ability to transfer any foreign currency it holds, including the net
proceeds from the offering to our Shanghai subsidiary, which may adversely affect our liquidity and our ability to fund and expand our business
in the PRC.&nbsp;On October 23, 2019, SAFE issued the Notice of the State Administration of Foreign Exchange on Further Facilitating
Cross-border Trade and Investment, or &ldquo;SAFE Circular 28,&rdquo; which, among other things, expanded the use of foreign exchange
capital to domestic equity investment area. Non-investment foreign-funded enterprises are allowed to lawfully make domestic equity investments
by using their capital if (i) such investments do not violate the current Negative List and (ii) the domestic investment projects are
authentic and are in compliance with relevant regulations. However, since SAFE Circular 28 is newly promulgated, it is unclear how SAFE
and competent banks will carry it out in practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the various requirements
imposed by PRC regulations on loans to, and direct investment in, PRC entities by offshore holding companies, we cannot assure you that
we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if
at all, with respect to future loans or future capital contributions by us to our Shanghai subsidiary. If we fail to complete such registrations
or obtain such approvals, our ability to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially
and adversely affect our liquidity and our ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I></I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>PRC regulations relating to offshore investment activities by
PRC residents may subject our PRC resident beneficial owners or our Shanghai subsidiary to liability or penalties, limit our ability to inject
capital into our Shanghai subsidiary, limit our Shanghai subsidiary&rsquo;s ability to increase its registered capital or distribute profits to
us, or may otherwise adversely affect us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In July 2014, SAFE promulgated
the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&rsquo; Offshore Investment and Financing and
Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37, to replace the Notice on Relevant Issues Concerning Foreign
Exchange Administration for Domestic Residents&rsquo; Financing and Roundtrip Investment Through Offshore Special Purpose Vehicles, or
SAFE Circular 75, which ceased to be effective upon the promulgation of SAFE Circular 37. SAFE Circular 37 requires PRC residents (including
PRC individuals and PRC corporate entities) to register with SAFE or its local branches in connection with their direct or indirect offshore
investment activities. SAFE Circular 37 may be applicable to any offshore acquisitions that we make in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Under SAFE Circular 37, PRC
residents who make, or have prior to the implementation of SAFE Circular 37 made, direct or indirect investments in offshore special purpose
vehicles, or SPVs, will be required to register such investments with SAFE or its local branches. In addition, any PRC resident who is
a direct or indirect shareholder of an SPV is required to update its filed registration with the local branch of SAFE with respect to
that SPV, to reflect any material change. Moreover, any subsidiary of such SPV in China is required to urge the PRC resident shareholders
to update their registration with the local branch of SAFE. If any PRC shareholder of such SPV fails to make the required registration
or to update the previously filed registration, the subsidiary of such SPV in China may be prohibited from distributing its profits or
the proceeds from any capital reduction, share transfer or liquidation to the SPV, and the SPV may also be prohibited from making additional
capital contributions into its subsidiary in China. On February 13, 2015, the SAFE promulgated a Notice on Further Simplifying and Improving
Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June 1, 2015. Under SAFE Notice
13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments, including
those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks will directly examine the
applications and accept registrations under the supervision of SAFE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As of the date of this prospectus, none of our shareholders are subject
to the SAFE Circular 37. We may not be informed of the identities of all the PRC residents holding direct or indirect interest in our
company, however, and we have no control over any of our future beneficial owners. Thus, we cannot provide any assurance that our current
or future PRC resident beneficial owners will comply with our request to make or obtain any applicable registrations or continuously comply
with all registration procedures set forth in these SAFE regulations. Such failure or inability of our PRC residents beneficial owners
to comply with these SAFE regulations may subject us or our PRC resident beneficial owners to fines and legal sanctions, restrict our
cross-border investment activities, or limit our Shanghai subsidiary&rsquo;s ability to distribute dividends to or obtain foreign-exchange-dominated
loans from us, or prevent us from being able to make distributions or pay dividends, as a result of which our business operations and
our ability to distribute profits to you could be materially and adversely affected. Moreover, Advanced Biomed HK may be subject to additional
restrictions and government regulations if the Chinese government were to impose new laws and regulations or exert more control over Hong
Kong&rsquo;s business activities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>The Chinese government may exert more
control over Hong Kong business or impose new laws or regulations on business activities in Hong Kong</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although Advanced Biomed HK
is a holding company with no operations and is in compliance with current Mainland China and Hong Kong laws and regulations, it may be
subject to similar risks faced by our Shanghai subsidiary in the future if the Chinese government were to exert more control over Hong
Kong business or impose new laws or regulations on business activities in Hong Kong, which often comes with little advance notice. In
that case, we cannot guarantee you that we can timely comply with any new laws and regulations, which could materially affect our operations
and significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of
such securities to significantly decline or be worthless.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent joint statement by the SEC and the
PCAOB, rule changes by Nasdaq, and the Holding Foreign Companies Accountable Act all call for additional and more stringent criteria
to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are
not inspected by the PCAOB. These developments could add uncertainties to our continued listing or future offerings of our securities
in the U.S.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 21, 2020, SEC Chairman
Jay Clayton and PCAOB Chairman William D. Duhnke III, along with other senior SEC staff, released a joint statement highlighting the
risks associated with investing in companies based in or have substantial operations in emerging markets including China. The joint statement
emphasized the risks associated with lack of access for the PCAOB to inspect auditors and audit work papers in China and higher risks
of fraud in emerging markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 18, 2020, Nasdaq filed
three proposals with the SEC to (i) apply minimum offering size requirement for companies primarily operating in &ldquo;Restrictive Market&rdquo;,
(ii) adopt a new requirement relating to the qualification of management or board of director for Restrictive Market companies, and (iii)
apply additional and more stringent criteria to an applicant or listed company based on the qualifications of the company&rsquo;s auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 20, 2020, the U.S. Senate
passed the Holding Foreign Companies Accountable Act requiring a foreign company to certify it is not owned or controlled by a foreign
government if the PCAOB is unable to audit specified reports because the company uses a foreign auditor not subject to PCAOB inspection.
If the PCAOB is unable to inspect the company&rsquo;s auditors for three consecutive years, the issuer&rsquo;s securities are prohibited
to trade on a national exchange. On December 2, 2020, the U.S. House of Representatives approved the Holding Foreign Companies Accountable
Act. On December 18, 2020, the Holding Foreign Companies Accountable Act was signed into law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 24, 2021, the SEC
announced the adoption of interim final amendments to implement the submission and disclosure requirements of the Holding Foreign Companies
Accountable Act. In the announcement, the SEC clarifies that before any issuer will have to comply with the interim final amendments,
the SEC must implement a process for identifying covered issuers. The announcement also states that the SEC staff is actively assessing
how best to implement the other requirements of the Holding Foreign Companies Accountable Act, including the identification process and
the trading prohibition requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 22, 2021, the U.S.
Senate passed the AHFCAA, which, if passed by the U.S. House of Representatives and signed
into law, would reduce the number of consecutive non-inspection years required for triggering the prohibitions under the Holding Foreign
Companies Accountable Act from three years to two. On December 29, 2022, a legislation entitled &ldquo;Consolidated Appropriations Act, 2023&rdquo; (the &ldquo;Consolidated
Appropriations Act&rdquo;), was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things,
an identical provision to HFCAA, which reduces the number of consecutive non-inspection years required for triggering the prohibitions
under the HFCAA from three years to two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 22, 2021, the
PCAOB adopted a final rule implementing the Holding Foreign Companies Accountable Act, which provides a framework for the PCAOB to use
when determining, as contemplated under the Holding Foreign Companies Accountable Act, whether the board of directors of a company is
unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position
taken by one or more authorities in that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 2, 2021, the SEC
issued amendments to finalize rules implementing the submission and disclosure requirements in the Holding Foreign Companies Accountable
Act. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered
public accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely because
of a position taken by an authority in foreign jurisdictions. The final amendments are effective on January 10, 2022. The SEC will begin
to identify and list Commission-Identified Issuers on its website shortly after registrants begin filing their annual reports for 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 16, 2021, PCAOB
announced the PCAOB Holding Foreign Companies Accountable Act determinations (the &ldquo;PCAOB determinations&rdquo;) relating to the
PCAOB&rsquo;s inability to inspect or investigate completely registered public accounting firms headquartered in China of the PRC or
Hong Kong, a Special Administrative Region and dependency of the PRC, because of a position taken by one or more authorities in the PRC
or Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 26, 2022, PCAOB
signed a Statement of Protocol with the CSRC and the Ministry of Finance of the People&rsquo;s Republic of China governing inspections
and investigations of audit firms based in Mainland China and Hong Kong.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 15, 2022, the
PCAOB announced in the 2022 Determination its determination that the PCAOB was able to secure complete access to inspect and investigate
accounting firms headquartered in Mainland China and Hong Kong, and the PCAOB Board voted to vacate previous determinations to the contrary.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should the PCAOB again encounter
impediments to inspections and investigations in Mainland China or Hong Kong as a result of positions taken by any authority in either
jurisdiction, including by the CSRC or the MOF, the PCAOB will make determinations under the HFCAA as and when appropriate. The inability
of the PCAOB to conduct inspections of auditors in PRC makes it more difficult to evaluate the effectiveness of these accounting firm&rsquo;s
audit procedures or quality control procedures as compared to auditors outside of PRC that are subject to the PCAOB inspections, which
could cause investors and potential investors in our Common stock to lose confidence in our audit procedures and reported financial information
and the quality of our financial statements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our auditor WWC, P.C., the independent registered public accounting firm
that issues the audit report included elsewhere in this prospectus, as an auditor of companies that are traded publicly in the United
States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections
to assess its compliance with the applicable professional standards Our auditor, WWC, P.C. is headquartered in San Mateo, California and
has been inspected by the PCAOB on a regular basis, with the last inspection conducted in December 2021. It is not subject to the determinations
announced by the PCAOB on December 16, 2021 or the Statement of Protocol with the China Securities Regulatory Commission and the Ministry
of Finance of the People&rsquo;s Republic of China on August 26, 2022. However, if the PCAOB is unable to inspect our accounting firm
in the future, our Common Stock may be delisted from or prohibited from trading on a national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The recent developments would
add uncertainties to our offering and we cannot assure you whether Nasdaq or regulatory authorities would apply additional and more stringent
criteria to us since we are an emerging growth company and substantially all of our operations are conducted in China. The Holding Foreign
Companies Accountable Act, which requires that the PCAOB be permitted to inspect an issuer&rsquo;s public accounting firm within three
years, may result in the delisting of our Company or prohibition of trading in our Common stock in the future if the PCAOB is unable to
inspect our accounting firm at such future time. Further, the AHFCAA which was later signed into law in the Consolidated Appropriations
Act, reduces the period for foreign companies to comply with PCAOB audits to two consecutive years instead of three, thus reducing the
time period for triggering the prohibition on trading, and this ultimately could result in our Common Stock being delisted by an exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>The M&amp;A Rules and certain PRC regulations
may make it more difficult for us to pursue growth through acquisitions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: .5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Among other things, the Regulations on Mergers and Acquisitions of Domestic
Enterprises by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009, and some other
regulations and rules concerning mergers and acquisitions, established&nbsp;additional procedures and requirements that could make merger
and acquisition activities by foreign investors more time-consuming and complex. Such regulation requires, among other things, that the
Ministry of Commerce of the PRC, or the MOFCOM, be notified in advance of any&nbsp;change-of-control transaction in which a foreign investor
acquires control of a PRC domestic enterprise or a foreign company with substantial PRC operations, if certain thresholds under the Provisions
on Thresholds for Prior Notification of Concentrations of Undertakings, issued by the State Council in 2008, are triggered. Moreover,
the Anti-Monopoly Law promulgated by the Standing Committee of the National People&rsquo;s Congress which became effective in 2008 requires
that transactions which are deemed concentrations and involve parties with specified turnover thresholds must be cleared by the Anti-Monopoly
Bureau of State Administration for Market Regulation, or the Anti-Monopoly Bureau, before they can be completed. Therefore, our acquisitions
of other entities that we make in the future (whether by ourselves or our subsidiaries) and that meets the thresholds for clearance, may
be required to be report to and approved by the anti-monopoly law enforcement agency in the PRC, and we may be subject to penalty including
but not limited to a fine of no more than RMB500,000 if we fail to comply with such requirement. In addition, PRC national security review
rules which became effective in September 2011 require acquisitions by foreign investors of PRC companies engaged in military related
or certain other industries that are crucial to national security be subject to security review before consummation of any such acquisition.
On December 19, 2020, the Measures for the Security Review for Foreign Investment was jointly issued by National Development and Reform
Commission (&ldquo;NDRC&rdquo;) and MOFCOM and took effect from January 18, 2021. The Measures for the Security Review for Foreign Investment
specified provisions concerning the security review mechanism on foreign investment, including the types of investments subject to review,
review scopes and procedures, among others.&nbsp;We may pursue potential strategic acquisitions that are complementary to our business
and operations in the future. Complying with the requirements of these regulations to complete such transactions could be time-consuming,
and any required approval processes, including obtaining approval or clearance from the MOFCOM or the Anti-Monopoly Bureau or its local
counterparts or other relevant governmental authorities, may delay or inhibit our ability to complete such transactions, which could affect
our ability to expand our business or maintain our market share. Moreover, Advanced Biomed HK may be subject to additional restrictions
and government regulations if the Chinese government were to impose new laws and regulations or exert more control over Hong Kong&rsquo;s
business activities.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>Enhanced scrutiny over acquisition
transactions by the PRC tax authorities may have a negative impact on potential acquisitions we may pursue in the future.</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant
to the Notice on Strengthening Administration of Enterprise Income Tax for Share Transfers by&nbsp;Non-PRC&nbsp;Resident Enterprises,
or SAT Circular 698, issued by the PRC&rsquo;s State Administration of Taxation (&ldquo;SAT&rdquo;) on December&nbsp;10, 2009, where
a foreign investor transfers the equity interests of a resident enterprise indirectly via disposition of the equity interests of an overseas
holding company, or an &ldquo;indirect transfer,&rdquo; and such overseas holding company is located in a tax jurisdiction that (i)&nbsp;has
an effective tax rate less than 12.5% or (ii)&nbsp;does not tax foreign income of its residents, the foreign investor shall report the
indirect transfer to the competent PRC tax authority. The PRC tax authority will examine the true nature of the indirect transfer, and
if the tax authority considers that the foreign investor has adopted an &ldquo;abusive arrangement&rdquo; to avoid PRC tax, it may disregard
the existence of the overseas holding company and&nbsp;re-characterize&nbsp;the indirect transfer and as a result, gains derived from
such indirect transfer may be subject to PRC withholding tax at a rate of up to 10%.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
February&nbsp;3, 2015, the SAT issued the Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise
Income Tax on Indirect Property Transfer by&nbsp;Non-Resident&nbsp;Enterprises, or SAT Bulletin 7, to supersede existing provisions in
relation to the &ldquo;indirect transfer&rdquo; as set forth in SAT Circular 698, while the other provisions of SAT Circular 698 remain
in force. Pursuant to SAT Bulletin 7, where a&nbsp;non-resident&nbsp;enterprise indirectly transfers properties such as equity in PRC
resident enterprises without any justifiable business purposes and aiming to avoid the payment of enterprise income tax, such indirect
transfer must be reclassified as a direct transfer of equity in PRC resident enterprise. To assess whether an indirect transfer of PRC
taxable properties has reasonable commercial purposes, all arrangements related to the indirect transfer must be considered comprehensively
and factors set forth in SAT Bulletin 7 must be comprehensively analyzed considering the actual circumstances. SAT Bulletin 7 also provides
that, where a&nbsp;non-PRC&nbsp;resident enterprise transfers its equity interests in a resident enterprise to its related parties at
a price lower than the fair market value, the competent tax authority has the power to make a reasonable adjustment to the taxable income
of the transaction.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
October&nbsp;17, 2017, the SAT issued the Announcement of the State Administration of Taxation on Matters Concerning Withholding of Income
Tax of&nbsp;Non-resident&nbsp;Enterprises as Source, or SAT Bulletin 37, which repealed the entire SAT Circular 698 and the provision
in relation to the time limit for the withholding agent to declare to the competent tax authority for payment of such tax of SAT Bulletin
7. Pursuant to SAT Bulletin 37, the income from a property transfer, as stipulated in the second item under Article 19 of the Enterprise
Income</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Tax
Law, shall include the income derived from transferring such equity investment assets as stock equity. The balance of deducting the equity&rsquo;s
net value from the total income from equity transfer shall be taxable income from equity transfer. Where a withholding agent enters into
a business contract, involving the income specified in the third paragraph of Article 3 in the Enterprise Income Tax Law, with a&nbsp;non-resident&nbsp;enterprise,
the&nbsp;tax-excluding&nbsp;income of the&nbsp;non-resident&nbsp;enterprise will be treated as the&nbsp;tax-including&nbsp;income, based
on which the tax payment will be calculated and remitted, if it is agreed in the contract that the withholding agent shall assume the
tax payable.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During the effective period of SAT Circular
698 and by the application of SAT Bulletin 7 and SAT Bulletin 37, some intermediary holding companies were looked through by the PRC
tax authorities, and consequently the&nbsp;non-PRC&nbsp;resident investors were deemed to have transferred the PRC Subsidiary and PRC
corporate taxes were assessed accordingly. It is possible that we or our&nbsp;non-PRC&nbsp;resident investors may at some point be at
risk of being taxed under SAT Bulletin 7 and SAT Bulletin 37 and may be required to expend valuable resources to comply with SAT Bulletin
7 and SAT Bulletin 37 or to establish that we or our&nbsp;non-PRC&nbsp;resident investors should not be taxed under SAT Bulletin 7 and
SAT Bulletin 37, which may have an adverse effect on our financial condition and results of operations or such&nbsp;non-PRC&nbsp;resident
investors&rsquo; investment in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>It may be difficult for overseas shareholders
and/or regulators to conduct investigations or collect evidence within the PRC.</I></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Shareholder
claims or regulatory investigation that are common in the United States generally are difficult to pursue as a matter of law or practicality
in the PRC. For example, in the PRC, there are significant legal and other obstacles to providing information needed for regulatory investigations
or litigation initiated outside the PRC or otherwise with respect to foreign entities. Although the authorities in the PRC may establish
a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border
supervision and administration, such cooperation with the securities regulatory authorities in the Unities States may not be efficient
in the absence of mutual and practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, which
became effective in March 2020, or Article 177, the securities regulatory authority of the State Council may collaborate with securities
regulatory authorities of other countries or regions in order to monitor and oversee cross border securities activities. Article 177
further provides that no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities
within the territory of the PRC, and that PRC entities and individuals are not allowed to provide documents or materials related to securities
business activities to overseas agencies without prior consent of the securities regulatory authority of the State Council and the competent
departments of the State Council. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated,
the inability for an overseas securities regulator to directly conduct investigation or evidence collection activities within the PRC
may further increase difficulties faced by you in protecting your interests.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 11pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Regulation
and censorship of information disseminated over the Internet in the PRC may adversely affect our business, and we may be liable for content
that is displayed on our website.</I></B></FONT></P>

<P STYLE="margin: 0pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
PRC has enacted laws and regulations governing internet access and the distribution of products, services, news, information, audio-video
programs and other content through the Internet. In the past, the PRC government has prohibited the distribution of information through
the Internet that it deems to be in violation of PRC laws and regulations. If any of our Internet information is deemed by the PRC government
to violate any content restrictions, we would not be able to continue to display such content and could become subject to penalties,
including confiscation of income, fines, suspension of business and revocation of required licenses, which could materially and adversely
affect our PRC businesses, financial condition and results of operations. We may also be subject to potential liability for any unlawful
actions of our customers or users of our website or for content we distribute that is deemed inappropriate. It may be difficult to determine
the type of content that may result in liability to us, and if we are found to be liable, we may be prevented from operating our website
in the PRC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Additional factors outside of our control related
to doing business in the Mainland China and Hong Kong could negatively affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Additional factors that could negatively affect our
business include a potential significant revaluation of the RMB, which may result in an increase in the cost of operating in the PRC.
Natural disasters or health pandemics impacting the PRC can also have a significant negative impact on our PRC businesses. Further, the
imposition of trade sanctions or other regulations against products imported by us from, exported by us into, or the loss of &ldquo;normal
trade relations&rdquo; status with the PRC could significantly increase our cost of products exported outside of or imported into the
PRC and harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt"><B><I>Payment
of dividends is subject to restrictions under PRC laws.</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 10pt">Because of a variety of rules applicable to our operations in the PRC and the regulations on foreign investments as well as
the applicable tax law, we may be subject to limitations on our ability to declare and pay dividends to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">As a holding company, we may rely on dividends and
other distributions from our Shanghai subsidiary for cash requirements. If our Shanghai subsidiary incurs any debts, the instruments governing
such debts may restrict its ability to pay dividends to us. To the extent cash or assets in the business is in the PRC or the Shanghai
subsidiary, the cash or assets may not be available to fund operations or for other use outside of the PRC due to interventions in or
the imposition of restrictions and limitations on our or Shanghai subsidiary&rsquo;s ability by the PRC government to transfer cash or
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Current PRC regulations permit
Chinese operating subsidiaries to pay dividends to foreign parent companies only out of their accumulated profits, if any, determined
in accordance with Chinese accounting standards and regulations. In addition, our subsidiary in China is required to set aside at least
10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital.
The Shanghai subsidiary is also required to further set aside a portion of its after-tax profits to fund the employee welfare fund, although
the amount to be set aside, if any, is determined at the discretion of its board of directors. While the statutory reserves can be used,
among other ways, to increase the registered capital and eliminate future losses in excess of retained earnings of the respective companies,
the reserve funds are not distributable as cash dividends except in the event of liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash dividends, if any, on our
Common Stock will be paid in U.S. dollars. The PRC government also imposes restrictions on the conversion of RMB into foreign currencies
and the remittance of currencies out of the PRC. As such, we may experience difficulties in completing the administrative procedures necessary
to obtain and remit foreign currency for the payment of dividends from our profits, if any. Furthermore, if the Shanghai subsidiary incurs
any debts, the existence of debts evidenced by the debt instruments may significantly limit its ability to pay dividends or make other
payments. If we are unable to receive earnings distributions from the operating subsidiary in China, we would be unable to pay dividends
on our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">If we are deemed by the PRC tax authorities as a PRC
tax resident enterprise for tax purposes, any dividends we pay to our non-PRC resident shareholders may be regarded as China-sourced income
and as a result, may be subject to PRC withholding tax at a rate of up to 10%. Pursuant to the Arrangement between Mainland China and
the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, or the Double Tax Avoidance
Arrangement, the 10% withholding tax rate may be reduced to 5% if a Hong Kong resident enterprise owns no less than 25% of a PRC entity.
However, the 5% withholding tax rate does not automatically apply and certain requirements must be satisfied, including, without limitation,
that (a) the Hong Kong entity must be the beneficial owner of the relevant dividends; and (b) the Hong Kong entity must directly hold
no less than 25% share ownership in the PRC entity during the 12 consecutive months preceding its receipt of the dividends. In practice,
a Hong Kong entity must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC withholding tax
rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot be certain that we
will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential withholding tax
rate of 5% under the Double Taxation Arrangement with respect to any dividends to be paid by our Shanghai subsidiary to our Hong Kong
subsidiary, Advanced Biomed HK. Moreover, Advanced Biomed HK may be subject to additional restrictions and government regulations if the
Chinese government were to impose new laws and regulations or exert more control over Hong Kong&rsquo;s business activities. Our Shanghai
subsidiary currently does not have any plan to declare and pay dividends, and we have not applied for the tax resident certificate from
the relevant Hong Kong tax authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">As of the date of this prospectus, we have not paid,
and do not anticipate paying in the foreseeable future, dividends or other distributions to our shareholders. Our Shanghai subsidiary
has never paid any dividends or distributions outside of China. We presently intend to retain all earnings to fund our operations and
business expansions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">We can give no assurance that we will declare dividends
of any amounts, at any rate or at all in the future. The declaration of future dividends, if any, will be at the discretion of our board
of directors and will depend upon our future operations and earnings, capital requirements, general financial conditions, legal and contractual
restrictions and other factors that our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Risks Related to
our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Common Stock may not develop an active trading
market and the price and trading volume of our shares may fluctuate significantly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following this offering, our Common
Stock will be listed on the Nasdaq Capital Market. We cannot predict whether investor interest in us will lead to the development of an
active and liquid trading market. In addition, no assurances can be given regarding when, and if, we will be able to list on a national
exchange, including whether or not we will be able to meet applicable listing standards for any such exchange. If an active trading market
does not develop, holders of our shares of Common Stock may have difficulty selling our shares that may now be owned or may be purchased
later. In addition, until we are able to be listed on a national exchange, the number of investors willing to hold or acquire our shares
may be reduced, we may receive decreased news and analyst coverage, and we may be limited in our ability to issue additional securities
or obtain additional financing in the future on terms acceptable to us, or at all. Even if an active trading market develops for our shares,
the market price of our shares may be highly volatile and could be subject to wide fluctuations. In addition, the trading volume of our
shares may fluctuate and cause significant price variations to occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>We do not anticipate
paying cash dividends on our Common Stock in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We do
not anticipate paying cash dividends in the foreseeable future. Presently, we intend to retain all our earnings, if any, to finance development
and expansion of our business. Consequently, your only opportunity to achieve a positive return on your investment in us will be if the
market price of our Common Stock appreciates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Our Chairman Dr. Yi
Lu owns a substantial portion of our outstanding shares of Common Stock and could significantly influence the outcome of our corporate
matters.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our Chairman
and Chief Executive Officer Dr. Yi Lu beneficially owns 33.54% of our outstanding shares of Common Stock, and our Director Dr. Hung To
Pau beneficially owns 17.62% of our outstanding shares of Common Stock. As a result, Messrs. Lu and Pau are collectively able to exercise
significant influence over all matters that require us to obtain shareholder approval, including the election of directors to our board
and approval of significant corporate transactions that we may consider, such as a merger or sale of our company or its assets. This concentration
of ownership in our shares by Messrs. Lu and Pau will limit other shareholders&rsquo; ability to influence corporate matters and may have
the effect of delaying or preventing a third party from acquiring control over us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The price of our Common Stock may be volatile
or may decline regardless of our operating performance, and stockholders may not be able to resell their shares.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our stock
may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">actual or anticipated fluctuations
                                            in our revenue and other operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the financial projections we may provide
                                            to the public, any changes in these projections or our failure to meet these projections;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actions of securities analysts who
                                            initiate or maintain coverage of us, changes in financial estimates by any securities analysts
                                            who follow our company, or our failure to meet these estimates or the expectations of investors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">announcements by us or our competitors
                                            of significant products, acquisitions, strategic partnerships, joint ventures, or capital
                                            commitments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">price and volume fluctuations in the
                                            overall stock market, including as a result of trends in the economy as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">lawsuits threatened or filed against
                                            us; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">other events or factors, including
                                            those resulting from health pandemics, war or incidents of terrorism, or responses to these
                                            events.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the stock markets
have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of securities of many
companies. Stock prices of many companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If
you purchase our Common Stock in this offering, you will experience immediate dilution in the Common Stock included in the Common Stock
you purchase. You will experience further dilution because of the Resale Shares </I></B>&nbsp;<B><I>offered by certain of the Selling
Stockholders of the Company or if we issue additional equity securities in future financing transactions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchasers
of Common Stock in this offering will pay a price per share of Common Stock included in the Common Stock you purchase that exceeds the
net tangible book value per share of our Common Stock. Investors participating in this offering will incur immediate and substantial
dilution. Giving effect to our receipt of approximately $5.20 million of estimated net proceeds, after deducting underwriting discounts
and commissions and estimated offering expenses payable by us from our sale of Common Stock in this offering at an assumed Primary Offering
price of $4.00 per share (assuming no exercise of the underwriters&rsquo; over-allotment option), our pro forma as adjusted net tangible
book value as of September 30, 2024 would be $0.31 per share. This amount represents an immediate increase in net tangible book value
of $0.23 per share of our Common Stock to existing stockholders and an immediate dilution in net tangible book value of $3.69 per share
of our Common Stock to new investors purchasing in this offering. You could also experience dilution if the warrants issued in this offering
are exercised. In addition, we are registering 1,875,000 Resale Shares for certain Selling Stockholders of the Company alongside the
Primary Offering, and the sale of the Resale Shares will cause further and significant dilution to your investment. See the section entitled
&ldquo;Dilution&rdquo; for a more detailed illustration of the dilution you would incur if you purchase our Common Stock in this offering
and information related to the resale in the Resale Prospectus.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
if we issue additional shares of Common Stock, or securities convertible into or exchangeable or exercisable for Common Stock, our stockholders,
including investors who purchase shares of Common Stock in this offering, may experience additional dilution, and any such issuances
may result in downward pressure on the price of our Common Stock. We also cannot assure you that we will be able to sell shares or other
securities in any future offering at a price per share that is equal to or greater than the price per share paid by investors in this
offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Nasdaq
may apply additional and more stringent criteria for our initial and continued listing because we plan to have a small public offering
and insiders will hold a large portion of the company&rsquo;s listed securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nasdaq
Listing Rule 5101 provides Nasdaq with broad discretionary authority over the initial and continued listing of securities in Nasdaq and
Nasdaq may use such discretion to deny initial listing, apply additional or more stringent criteria for the initial or continued listing
of particular securities, or suspend or delist particular securities based on any event, condition, or circumstance that exists or occurs
that makes initial or continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though
the securities meet all enumerated criteria for initial or continued listing on Nasdaq. In addition, Nasdaq has used its discretion to
deny initial or continued listing or to apply additional and more stringent criteria in the instances, including but not limited to:
(i) where the company engaged an auditor that has not been subject to an inspection by the Public Company Accounting Oversight Board
(&ldquo;PCAOB&rdquo;), an auditor that PCAOB cannot inspect, or an auditor that has not demonstrated sufficient resources, geographic
reach, or experience to adequately perform the company&rsquo;s audit; (ii) where the company planned a small public offering, which would
result in insiders holding a large portion of the company&rsquo;s listed securities. Nasdaq was concerned that the offering size was
insufficient to establish the company&rsquo;s initial valuation, and there would not be sufficient liquidity to support a public market
for the company; and (iii) where the company did not demonstrate sufficient nexus to the U.S. capital market, including having no U.S.
stockholders, operations, or members of the board of directors or management. Our public offering will be relatively small, and our company&rsquo;s
insiders will hold a large portion of the company&rsquo;s listed securities. Nasdaq might apply the additional and more stringent criteria
for our initial and continued listing, which might cause delay or even denial of our listing application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we cannot satisfy, or continue to satisfy,
the initial listing requirements and other rules of Nasdaq Capital Market, our securities may not be listed or may be delisted, which
could negatively impact the price of our securities and your ability to sell them.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will seek to have our
securities approved for listing on the Nasdaq Capital Market upon consummation of this offering. We cannot assure you that we will be
able to meet those initial listing requirements at that time. Even if our securities are listed on the Nasdaq Capital Market, we cannot
assure you that our securities will continue to be listed on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, following this
offering, in order to maintain our listing on the Nasdaq Capital Market, we will be required to comply with certain rules of Nasdaq Capital
Market, including those regarding minimum stockholders&rsquo; equity, minimum share price, and certain corporate governance requirements.
Even if we initially meet the listing requirements and other applicable rules of the Nasdaq Capital Market, we may not be able to continue
to satisfy these requirements and applicable rules. If we are unable to satisfy the Nasdaq Capital Market criteria for maintaining our
listing, our securities could be subject to delisting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Nasdaq Capital Market
does not list our securities or subsequently delists our securities from trading, we could face significant consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">limited
                                            availability fo</FONT>r <FONT STYLE="font-size: 10pt">market quotations for our securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">reduced liquidity with respect to our
                                            securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">a determination that our Common Stock is a &ldquo;penny stock,&rdquo; which
will require brokers trading in our Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity
in the secondary trading market for our Common Stock;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">limited amount of news and analyst coverage;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">a decreased ability to issue additional
                                            securities or obtain additional financing in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B><I></I>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The market price of our Common Stock may be
volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the public
offering price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, there have been
instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with a number of recent initial
public offerings, especially among companies with relatively smaller public floats. The offering price for our Primary Offering will be
determined through negotiations between the underwriters and us and may vary from the market price of our Common Stock following our Primary
Offering. If you purchase our Common Stock in our Primary Offering and Resale Offering, you may not be able to sell those shares at or
above the Primary Offering price or the Resale Offering price. In particular, our Common Stock may be subject to rapid and substantial
price volatility, low volumes of trades and large spreads in bid and ask prices, given that we will have relatively small public floats
after this offering, and the Selling Stockholders of the Company are offering Resale Shares through the Resale Prospectus. Such
volatility, including any stock-run up, may be unrelated to our actual or expected operating performance, financial condition or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
the Primary Offering price of our Common Stock, or the market price following our Primary Offering, will equal or exceed prices in privately
negotiated transactions of our shares that have occurred from time to time prior to our Primary Offering. The market price of our Common
Stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated fluctuations
                                            in our revenue and other operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the sale of Resale Shares by the Selling Stockholders of the Company
in the open market;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the financial projections we may
                                            provide to the public, any changes in these projections or our failure to meet these projections;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actions of securities analysts who
                                            initiate or maintain coverage of us, changes in financial estimates by any securities analysts
                                            who follow our company, or our failure to meet these estimates or the expectations of investors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">announcements by us or our competitors
                                            of significant services or features, technical innovations, acquisitions, strategic relationships,
                                            joint ventures, or capital commitments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">price and volume fluctuations in
                                            the overall stock market, including as a result of trends in the economy as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">lawsuits threatened or filed against
                                            us; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">other events or factors, including
                                            those resulting from war or incidents of terrorism, or responses to these events.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">In addition, the stock markets have
                                            experienced extreme price and volume fluctuations that have affected and continue to affect
                                            the market prices of equity securities of many companies. Stock prices of many companies
                                            have fluctuated in a manner unrelated or disproportionate to the operating performance of
                                            those companies. In the past, stockholders have filed securities class action litigation
                                            following periods of market volatility. In the event that we were to become involved in securities
                                            litigation, it could subject us to substantial costs, divert resources and the attention
                                            of management from our business, and adversely affect our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Holders of our Common Stock may
also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. Broad market
fluctuations and general economic and political conditions may also adversely affect the market price of our Common Stock. As a result
of this volatility, investors may experience losses on their investment in our Common Stock. Furthermore, the potential extreme volatility
may confuse the public investors of the value of our stock, distort the market perception of our stock price and our company&rsquo;s financial
performance and public image, negatively affect the long-term liquidity of our Common Stock, regardless of our actual or expected operating
performance. If we encounter such volatility, including any rapid stock price increases and declines seemingly unrelated to our actual
or expected operating performance and financial condition or prospects, it will likely make it difficult and confusing for prospective
investors to assess the rapidly changing value of our Common Stock and understand the value thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The purchase price of our Common Stock in
the resale offering could be higher or lower than the primary offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock is offered
in two different offerings: the primary underwritten offering and the resale offering. Although our Common Stock will be offered at a
fixed price in the primary offering determined by the underwriters and us, we cannot guarantee that the Selling Stockholders will also
offer their shares at the same price. As a result, if you participate in the resale offering, you could pay more or less than the price
in our primary offering, depending on the actual price of the Resale Shares &nbsp;at the time of the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have broad discretion in the use of the net proceeds from
our Primary Offering and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent (i) we raise
more money than required for the purposes explained in the section titled &ldquo;Use of Proceeds&rdquo; or (ii) we determine that the
proposed uses set forth in that section are no longer in the best interests of our Company, we cannot specify with any certainty the particular
uses of such net proceeds that we will receive from our Primary Offering. Our management will have broad discretion in the application
of such net proceeds, including working capital, possible acquisitions, and other general corporate purposes, and we may spend or invest
these proceeds in a way with which our stockholders disagree. The failure by our management to apply these funds effectively could harm
our business and financial condition. Pending their use, we may invest the net proceeds from our Primary Offering in a manner that does
not produce income or that loses value. As of the date of this prospectus, the management team has not determined the types of businesses
that the Company will target or the terms of any potential acquisition.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Shares eligible for future sale may adversely
affect the market price of our Common Stock, as the future sale of a substantial amount of outstanding Common Stock in the public marketplace
could reduce the price of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">The market price of our shares
could decline as a result of sales of substantial amounts of our shares in the public market or the perception that these sales could
occur, including the sale of Resale Shares by the Selling Stockholders of the Company through the Resale Prospectus. In addition,
these factors could make it more difficult for us to raise funds through future offerings of our Common Stock. Shares will be outstanding
immediately after this offering if the firm commitment is completed and the underwriters do not exercise their over-allotment option and
shares if exercised in full. All of the shares sold in the offering will be freely transferable without restriction or further registration
under the Securities Act. The remaining shares will be &ldquo;restricted securities&rdquo; as defined in Rule 144. These shares may be
sold in the future without registration under the Securities Act to the extent permitted by Rule 144 or other exemptions under the Securities
Act. See &ldquo;Shares Eligible for Future Sale&rdquo; On page 103.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur additional costs as a result
of becoming a public company, which could negatively impact our net income and liquidity.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon completion of this offering,
we will become a public company. As a public company, we will incur significant legal, accounting and other expenses that we did not
incur as a private company. In addition, Sarbanes-Oxley and rules and regulations implemented by the SEC and the Nasdaq Capital Market
require significantly heightened corporate governance practices for public companies. We expect that these rules and regulations will
increase our legal, accounting and financial compliance costs and will make many corporate activities more time-consuming and costly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not expect to incur materially
greater costs as a result of becoming a public company than those incurred by similarly sized U.S. public companies. In the event that
we fail to comply with these rules and regulations, we could become the subject of a governmental enforcement action, investors may lose
confidence in us and the market price of our Common Stock could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The obligation to disclose information
publicly may put us at a disadvantage to competitors that are private companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon completion of this offering,
we will be a publicly listed company in the United States. As a publicly listed company, we will be required to file annual reports with
the Securities and Exchange Commission. In some cases, we will need to disclose material agreements or results of financial operations
that we would not be required to disclose if we were a private company. Our competitors may have access to this information, which would
otherwise be confidential. This may give them advantages in competing with our company. Similarly, as a U.S.-listed public company, we
will be governed by U.S. laws that our competitors, which are mostly private Chinese companies, are not required to follow. To the extent
compliance with U.S. laws increases our expenses or decreases our competitiveness against such companies, our public listing could affect
our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Information in this prospectus includes
&ldquo;forward-looking statements&rdquo;. All statements, other than statements of historical fact included in this prospectus,
regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans
and objectives of management are forward-looking statements. When used in this prospectus, the words &ldquo;could,&rdquo; &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;project&rdquo; and similar
expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying
words. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements described
under the heading &ldquo;Risk Factors&rdquo; included in this prospectus. These forward-looking statements are based on our current
expectations and assumptions about future events and are based on currently available information as to the outcome and timing
of future events. Nevertheless, and despite the fact that management&rsquo;s expectations and estimates are based on assumptions
management believes to be reasonable and data management believes to be reliable, our actual results, performance or achievements
are subject to future risks and uncertainties, any of which could materially affect our actual performance. These forward-looking
statements include, but are not limited to, statements about our future financial performance, including the following:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to generate revenue and
                                            profit;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to expand our business
                                            model;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to manage or expand operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to maintain adequate control
                                            of our expenses as we seek to grow;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to establish or protect
                                            our intellectual property;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">the impact of significant government
                                            regulations in Taiwan and PRC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our ability to implement marketing
                                            and sales strategies and adapt and modify them as needed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">our implementation of required financial,
                                            accounting and disclosure controls and procedures and related corporate governance policies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Although the forward-looking statements included
herein, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction
of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions
or other future performance suggested herein. Except as required by applicable law, including by the securities laws of the United States,
we do not intend to update any of the forward-looking statements to conform these statements to actual results.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After deducting the underwriting
discounts and commissions and estimated expenses of this offering payable by us, we expect net proceeds from this offering of approximately
$5.20 million based on an assumed offering price of $4.00 per share (which is the lower end of the price range set forth on the cover
page of this prospectus), assuming no exercise of the underwriters&rsquo; over-allotment option. If the underwriters fully exercise the
over-allotment option, net proceeds from this offering of approximately $5.68 million. The net proceeds from this offering must be remitted
to Taiwan and Hong Kong before we will be able to use the funds to grow our business. The procedure to remit funds may take several months
after completion of this offering, and we will be unable to use the offering proceeds in Taiwan and Hong Kong until remittance is completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We intend to use the net proceeds of this offering
as follows after we complete the remittance process:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 60% for IVD clinical research, chip design and development, laboratory upgrade, and our planned expansion to the U.S. and European market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Approximately 20% for marketing and sales; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Approximately 20% for general working capital.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that 60% of the
net proceeds of the Primary Offering &nbsp;will be sufficient for us to complete IVD clinical research, design work plans for IVD clinical
trials, warp up chip development and production preparation, and upgrade our current laboratories without raising additional capital.
We believe clinical &nbsp;research serves as the foundation for clinical trials, bridging the gap between preclinical studies and large-scale
clinical trials. We believe clinical trials enables an understanding of subject recruitment, facilitates the development of appropriate
inclusion and exclusion criteria for later stages, and helps verify trial procedures. Additionally, we believe clinical trials increases
familiarity with the trial products. Specifically, we believe 20% of the net proceeds will be enough to cover the planned clinical research
of IVD products, which is expected to start by the end of June 2025. The clinical research aims to involve 200 individuals, and the average
cost is estimated to be approximately $6,500 per person. See also &ldquo;Our Business &ndash; Overview&rdquo; for a more detailed discussion
of our planned clinical research. Other expenses include experimental equipment, reagents, CRO fees, clinical trial fees, testing fees,
subject fees, etc. We plan to allocate 10% of the net proceeds to support us in completing the design, development, registration, and
production preparation of our products and chips. Finally, 30% of the net proceeds will be used to modernize our laboratories in PRC and
Taiwan and support our expansion to the United States and European markets.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each $1.00 increase or decrease
in the assumed Primary Offering price per share of $4.00 (which is the lower end of the price range set forth on the cover page of this
prospectus) would increase or decrease the net proceeds to us from this offering by approximately $1.7 million, assuming the number of
shares of Common Stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
precise amounts and percentage of proceeds we devote to particular categories of activity and their priority of use will depend on prevailing
market and business conditions as well as on the nature of particular opportunities that may arise from time to time. Accordingly, we
reserve the right to change the use of proceeds that we presently anticipate and describe herein. Pending remitting the offering proceeds
to Taiwan, we intend to invest our net proceeds in short-term, interest bearing, and investment-grade obligations.</FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our shares and we do not anticipate paying any cash dividends on our shares in the foreseeable future. It
is presently intended that we will retain our earnings for future operations and expansion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within the organization,
investor cash inflows have all been received by Advanced Biomed Inc., the parent Nevada entity. Cash to fund Advanced Biomed&rsquo;s
operations is transferred from: (i)&nbsp;the Nevada parent to its operating companies through capital contributions; and (ii)&nbsp;operating
companies to other operating companies through capital contributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a holding company, Advanced
Biomed Inc. may rely on dividends and other distributions on equity paid by its subsidiaries for its cash and financing requirements.
If any of Advanced Biomed&rsquo;s subsidiaries incur debt on its own behalf in the future, the instruments governing such debt may restrict
their ability to pay dividends to Advanced Biomed Inc. As of the date of this prospectus, neither Advanced Biomed nor any of its subsidiaries
have ever paid dividends or made distributions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advanced Biomed had a net
loss in fiscal year 2023 and does not expect to distribute earnings in the near future. Going forward, Advanced Biomed intends to continue
to invest profit generated from its business operations to invest in new markets or business lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2024, the following
cash transfers have been made from the holding company Advanced Biomed Inc. to its subsidiaries to support research and development in
Taiwan and Hong Kong:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On June 29, 2022, Advanced Biomed made a $2.5&nbsp;million capital contribution to Advanced Biomed Taiwan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On October 11, 2022, Advanced Biomed made a $86,000 capital contribution to Advanced Biomed Taiwan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On October 24, 2022, Advanced Biomed made a $100,000 capital contribution to Advanced Biomed HK;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On October 26, 2022, Advanced Biomed made a $500,000 capital contribution to Advanced Biomed HK;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On November 7, 2022, Advanced Biomed made a $122,000 capital contribution to Advanced Biomed Taiwan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On December 2, 2022, Advanced Biomed made a $110,000 capital contribution to Advanced Biomed HK;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On December 14, 2022, Advanced Biomed made a $85,000 capital contribution to Advanced Biomed Taiwan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On October 10, 2023, Advanced Biomed made a $70,000 capital contribution to Advanced Biomed HK;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                    December 5, 2023, Advanced Biomed made a $300,000 capital contribution to Advanced Biomed HK;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt Symbol">&middot;</P></TD>
    <TD STYLE="text-align: justify">On April 9, 2024, Advanced Biomed made a $150,000 capital contribution to Advanced Biomed HK.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advanced Biomed&rsquo;s subsidiaries
have not made any dividend distributions to the holding company Advanced Biomed. Advanced Biomed has not made any dividend distribution
to its U.S. or&nbsp;non-U.S.&nbsp;stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Besides the aforementioned paragraph &ldquo;Advanced Biomed Taiwan
is subject to foreign exchange control imposed by Taiwan authorities, which may affect the paying dividends, repatriating the interest
or making other payments to us.&rdquo;, NTD is freely convertible
into other currencies. As result, Advanced Biomed Taiwan has the ability to use their potential future NTD net profits to pay dividends
to Advanced Biomed after deducting tax withheld at source. The proceeds of this offering from Advanced Biomed to Advanced Biomed Taiwan
should be approved by Taiwan Investment Commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">RMB is not freely convertible
into other currencies. As result, any restriction on currency exchange may limit the ability of Advanced Biomed&rsquo;s Shanghai subsidiary
to use their potential future RMB revenues to pay dividends to Advanced Biomed. The PRC government imposes controls on the convertibility
of RMB into foreign currencies and, in certain cases, the remittance of currency out of China. Shortages in availability of foreign currency
may then restrict the ability of our Shanghai subsidiary to remit sufficient foreign currency to our offshore entities for our offshore
entities to pay dividends or make other payments or otherwise to satisfy our foreign-currency- denominated obligations. Currently, our
Shanghai subsidiary does not purchase any foreign currency for settlement. However, if such needs arise in the future, the SAFE and other relevant PRC governmental authorities may limit or eliminate our ability
to purchase foreign currencies in the future to settle transactions. The PRC government may continue to strengthen its capital controls,
and additional restrictions and substantial vetting processes may be instituted by SAFE for cross-border transactions. Any existing and
future restrictions on currency exchange may limit our ability to utilize revenue generated in RMB to fund our business activities outside
of PRC, pay dividends in foreign currencies to holders of our securities or to obtain foreign currency through debt or equity financing
for our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the current corporate
structure, Advanced Biomed does not believe that there are restrictions and limitations on its ability to: (i)&nbsp;remit offering proceeds
to its subsidiaries outside China; (ii) distribute earnings from its businesses, including subsidiaries outside China, to the parent
company and U.S. investors; and (iii)&nbsp;settle amounts owed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our cash and cash
equivalents and total capitalization as of September 30, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: left">on an actual basis; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">a pro forma basis giving effect to the sale of 1,875,000 shares of Common
Stock in this offering at an assumed offering price of $4.00 per share (which is the lower end of the price range set forth on the cover
page of this prospectus), after deducting the commissions and discounts payable to the underwriter and estimated offering expenses payable
by us (assuming the over-allotment is not exercised).</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The pro forma information below
is illustrative only and our capitalization following the completion of this offering is subject to adjustment based on the offering price
of our Common Stock and other terms of this offering determined at pricing. You should read this table in conjunction with our financial
statements and notes thereto included in this prospectus, and the information under &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of September 30, 2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pro Forma <BR>
Adjusted for&nbsp;this <BR>
Offering (Over-allotment option not exercised)<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,646,992</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">7,847,492</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Long-term debt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Stockholders&rsquo; equity:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Common Stock, $0.001 par value per share, 400,000,000 shares authorized; 20,000,000 shares issued and outstanding on an actual basis; 21,875,000 shares of Common Stock issued and outstanding on a pro forma basis*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16,493,989</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21,694,489</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Accumulated deficits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(16,239,655</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(16,239,655</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Accumulated other comprehensive income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">819,496</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">819,496</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Stockholders&rsquo; equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,093,830</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,294,330</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Non-controlling interests</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total stockholders&rsquo; equity</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,093,830</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6,294,330</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total capitalization</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,093,830</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">6,294,330</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">*</TD><TD STYLE="text-align: justify">Gives retroactive effect to the 4 for 1 share split effected on
May 16, 2023, and 5 for 1 reverse share split effected on October 15, 2024.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left"><B><SUP>(1)</SUP></B></TD><TD STYLE="text-align: justify">Reflects the issuance and sale of 1,875,000 shares of Common Stock
in the Primary Offering at an assumed initial public offering price of $4.00 per share, which is the lower end of the estimated Primary
Offering price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and estimated
offering expenses payable by us in the total amount of $2,299,500. The pro forma as adjusted information is illustrative only, and we
will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing.
We estimate that such net proceeds will be approximately $5,200,500, assuming the underwriters do not exercise their over-allotment option.
And the pro forma (i) Common Stock would be 21,875,000 shares, (ii) cash would be $7,847,492, (iii) additional paid-in capital would
be $21,694,489, (iv) total stockholders&rsquo; equity would be $6,294,330 and (v) total capitalization would be $6,294,330.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the underwriters&rsquo;
over-allotment option to purchase additional shares of Common Stock from us is exercised in full, pro forma (i) Common Stock would be
21,987,500 shares, (ii) additional paid-in capital would be $22,110,756, (iii) total stockholders&rsquo; equity would be $6,710,597 and
(iv) total capitalization would be $6,710,597 after deducting the underwriting discount and commission payable to the underwriter and
estimated offering expenses payable by us in the amount of $2,333,423.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each $1.00 increase or decrease
in the assumed Primary Offering price per share of $4.00 (which is the lower end of the price range set forth on the cover page of this
prospectus) would increase or decrease as applicable, the pro forma as adjusted amount of each of additional paid-in capital, total stockholders&rsquo;
equity and total capitalization by approximately $1,875,000, assuming that the number of shares of Common Stock offered by us, as set
forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The dilution in net tangible
book value per share to new investors, represents the difference between the amount per share paid by in purchasers of shares this offering
and the pro forma net tangible book value per share immediately after completion of this offering. After giving effect to the sale of
the 1,875,000 shares being sold pursuant to this offering at an assumed Primary Offering price of $4.00 per share (without over-allotment
option) and after deducting the underwriting discount and commission payable by us in the amount of $562,500 and estimated offering expenses
in the amount of approximately $1,737,000, our pro forma as adjusted net tangible book value as of September 30, 2024 would be approximately
$0.29 per share of Common Stock. This represents an immediate increase in net tangible book value of $0.24 per share to existing stockholders
and an immediate and substantial dilution in net tangible book value of $3.71 per share to new investors purchasing shares in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the underwriters exercise
their over-allotment option in full, our pro forma as adjusted net tangible book value as of September 30, 2024 would be approximately
$0.31 per share of Common Stock, the increase in net tangible book value of $0.26 per share to existing stockholders and an immediate
and substantial dilution in net tangible book value of $3.670 per share to new investors purchasing shares in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the estimated net tangible book value per share of Common Stock after the offering and the dilution to persons purchasing Common Stock
based on the foregoing offering assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering<BR> without</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Over-<BR> allotment</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering<BR> with Full</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exercise of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Over-<BR> allotment</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%">Assumed Primary Offering price per share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book value per share as of September 30, 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in pro forma net tangible book value per share attributable to price paid by new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.26</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Pro forma net tangible book value per share after this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dilution in pro forma net tangible book value per share to new investors in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.69</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
on an as adjusted basis as of September 30, 2024, the difference between the number of Common Stock purchased from us, the total consideration
paid, and the average price per share paid by our existing stockholders and by new public investors before deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us, using an assumed Primary Offering price of $4.00 per share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares Purchased</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consideration</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Average</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Price Per</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Share</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Existing stockholders</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">20,000,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">91</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">21,714,506</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">74</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1.09</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">New investors from Primary Offering</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,875,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">7,500,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">26</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">4.00</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">21,875,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">29,214,506</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">0.97</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to the
sale of Common Stock in this offering by us, if the underwriters do not exercise their over-allotment option, our existing stockholders
would own 91% and purchasers of Common Stock in this offering would own 9% of the total number of shares of Common Stock outstanding upon
completion of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="b_001"></A>&nbsp;MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The following discussion and analysis of our financial
condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included
elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based
upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of selected
events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those
set forth under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus. You should carefully read the &ldquo;Risk Factors&rdquo;
section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from
our forward-looking statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 26.65pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a holding company incorporated
in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the
main operation and the design and development of the company&rsquo;s primary technologies and products. Since our establishment in 2014,
we have been focusing on the integration of multiple interdisciplinary technologies and established our own microfluidic technology platform.
Utilizing the physical and molecular biological characteristics of tumor cells, we have developed various advanced and original research
through the joint application of semiconductor technology and biotechnology. This includes complex precision structures, dielectric detection,
functional microfluidic biochips, microfluidic integrated semiconductor sensors, related application modules, and key components of medical
testing equipment. We have also developed a series of medical testing equipment and related products by integrating various functions
of microfluidic modules, automation software, and hardware. Our technologies and products can be used for early screening and detection,
diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers in blood samples,
capture of single circulating tumor cells, and single-cell sorting and determination. These products provide assistance in treatment selection
and patient prognosis intervention once the required licenses and approvals have been obtained. Advanced Biotech HK is our first localized
operation company, mainly responsible for market operation and management in China, localized production, product registration, and future
local market sales of our products in accordance with relevant local regulations in China. Our Shanghai subsidiary owns some of our R&amp;D
equipment and patents and will be responsible for operations related to clinical trials in Mainland China through CROs. In the future,
we plan to also establish operation centers in countries and regions in North America and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our devices, A<SUP>+</SUP>Pre,
AC-1000, A<SUP>+</SUP>CellScan, and A<SUP>+</SUP>SCDrop, and three corresponding microfluidic biochips, A<SUP>+</SUP>Pre Chip and AC-1000
CTC Enrichment Chip and A<SUP>+</SUP>CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer
patients. Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation
and enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A<SUP>+</SUP>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<SUP>+</SUP>SCDrop preserves the original
viability of single cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we have finished
the research and development stage for four matching immunostaining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM,
and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different
colors to bind to specific proteins on the cell surface or inside the cells. The presence and intensity of fluorescent signals can be
observed through a separate fluorescent imaging system, and the expression of the target protein and the cell type can be judged and determined
accordingly. Different cell types can be distinguished using multiplexed combined staining with different antibodies. The A<SUP>+</SUP>CTCE
kit is mainly used to identify epithelial circulating tumor cells, the A<SUP>+</SUP>CTCM kit is used to identify mesenchymal circulating
tumor cells, the A<SUP>+</SUP>EMT kit is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, and the A<SUP>+</SUP>CM
kit is used to identify tumor-associated macrophages (cancer-associated macrophage-like cells).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also developed a product
for early screening of lung cancer, the A<SUP>+</SUP>LCGuard Lung Cancer Early Screening Kit (&ldquo;A<SUP>+</SUP>LCGuard&rdquo;), which
is used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the
research, design, and development of A<SUP>+</SUP>LCGuard. A<SUP>+</SUP>LCGuard is Class III medical devices and is required to conduct
clinical trials before completing the registration process. We plan to begin A+LCGuard&rsquo;s clinical research by the end of June 2025.
Specifically, in June 2025, the Company and the CRO plan to collaborate to draft the clinical research protocol and begin preparing the
necessary equipment, consumables, reagent kits, and other materials for the study. By the end of September 2025, we expect that the clinical
research protocol may pass ethical review and receive ethics committee approval. Thereafter, we plan to initiate the trial stage of the
clinical research, with completion anticipated within six months of October 2025. We believe the results of the clinical research will
inform the work plan for future large-scale clinical trials, minimizing waste from an excessively large sample size or insufficient statistical
power due to a sample size that is too small. We recognize that the clinical research results may differ from expectations and may not
support our expected progression to clinical trials. If so, we plan to promptly optimize the product, adjust participant group selection,
and modify the final protocol for large-scale clinical trials. However, we cannot guarantee that any clinical research or trial will meet
our anticipated outcomes. Furthermore, delays in obtaining ethical approval or recruiting participants could prevent the clinical research
from being completed on schedule. Such delays could subsequently postpone the large-scale clinical trial and ultimately the product launch
date.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our products must go
through three steps to receive the required clearance from the NMPA before they can be sold to customers. The three steps are research
and development, registration application, and registration review, which must be done in that order. At the registration application
stage, we have to assemble all the required application materials, complete clinical trials (if required by NMPA), and work with an NMPA
accredited third-party organization to examine our products in accordance with NMPA rules. NMPA will review our application during the
registration review period and may request additional information before officially approving or denying our applications. Currently,
A<SUP>+</SUP>Pre and AC-1000 and their corresponding chips have been cleared by the NMPA; A<SUP>+</SUP>SCDrop, A<SUP>+</SUP>CellScan,
A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>LCGuard are at the registration application stage; the four matching immunostaining kits
are under registration review. As of the date of this prospectus, we have not applied for similar clearances from other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We participated in a scientific
research project at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies to test
A+Pre, AC-1000 and A<SUP>+</SUP>LCGuard. In the study, we selected 123 individuals, and among them, 75 were surgical patients with nodular
changes or shadows in the lungs reported by imaging studies and 48 healthy patients without lung nodules reported by imaging studies.
7ml blood samples were taken from test subjects either before the clinical operation (for cancer patients) or after the physical examination
(for healthy individuals), and A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>LCGuard kits were used to determine whether there were circulating
tumor cells and other tumor markers in the blood samples. Finally, the pathological and physical examination results of the tested individuals
were compared with the test results of our products. Our test results achieved 96% sensitivity and 99.9% specificity, which provides the
research and development basis for our products. Specifically, A+Pre and AC-1000 were at the research and development stage, and we completed
their effectiveness and performance indicators testing through this project. At the same time, A<SUP>+</SUP>LCGuard finished its feasibility
and functional verification testing. All three products were tested together throughout the entire project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our products must be
approved by applicable regulatory authorities before being sold to customers. A<SUP>+</SUP>Pre and A<SUP>+</SUP>CellScan can work with
third-party products to achieve their designed objectives. AC-1000 and A<SUP>+</SUP>SCDrop may be used together with other devices according
to different application scenarios below. For the A<SUP>+</SUP>LCGuard early screening kit, it has to be used in combination with A<SUP>+</SUP>Pre
and AC-1000. Our four staining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CM, A<SUP>+</SUP>CTCM, and A<SUP>+</SUP>EMT, can be used independently
or with third-party products. A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>CellScan require the use of our supporting microfluidic chips.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">For the analysis of high-viscosity blood samples: A<SUP>+</SUP>Pre can be independently used for pretreatment, retaining the original cell activity while preventing blood samples from clogging the equipment pipeline after entering the detection equipment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">For the identification and counting application of circulating tumor cells: blood samples are diluted with A<SUP>+</SUP>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells and related tumor markers. The enriched samples are stained, calibrated, and finally identified and counted. We can provide this service to the public if using third-party staining reagents already on the market in China. However, we plan to officially roll out this service once our in-house developed staining reagents, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM, complete the registration process. The identification and counting of circulating tumor cells and related tumor marker cells can provide auxiliary references for relevant clinical applications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The capture of circulating tumor cells: we follow the same process as the identification of circulating tumor cells to obtain enriched samples with A<SUP>+</SUP>Pre and AC-1000, and then the samples are captured and separated by A<SUP>+</SUP>SCDrop to isolate single circulating tumor cells. This service can provide tumor cells with high purity and high activity.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">For early screening of lung cancer: peripheral blood samples of the subjects are first obtained, and the target cells are enriched and captured sequentially by A<SUP>+</SUP>Pre and AC-1000. After that, A<SUP>+</SUP>LCGuard performs cell fluorescence staining on the enriched samples to determine the number of targeted cells, and finally makes a judgment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the different regulatory
requirements for the marketing of medical device products and in-vitro diagnostics (&ldquo;IVD&rdquo;) products in various regions/countries,
it is necessary to complete the registration application and obtain the corresponding license in accordance with the local regulations
before engaging in commercial activities in the respective regions/countries (&ldquo;localization registration&rdquo;). Afterward, marketing
and sales can be carried out. We follow the principle of modularization when design and develop all of our products and equipment so that
products and equipment can be produced locally to meet different regulatory requirements. Based on the current development of the early
tumor screening and preventive treatment industry and the characteristics of the products we are planning to register and apply in the
future, we have adopted the operation model of centralized research and development and localized management. We have started the registration
process with the NMPA in China for all of our products. Later on, the Company may establish subsidiaries in the United States and Europe
to produce products and carry out product registration. To achieve that, our products must be cleared by the United States Food and Drug
Administration and go through the conformity assessment process to obtain the Conformite Europeenne marking (&ldquo;CE marking&rdquo;)
from competent authority in each European Union member state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are looking for suitable
locations in the states of California and Washington for our planned expansion to the North America market. We aim to complete site selection
and personnel recruitment in the United States by the end of 2024 and start product registration, testing and production afterward. Our
US subsidiary will be responsible for the production and registration of our equipment and related products in the US. Production, testing,
and clinical trials in our US market will be conducted in accordance with US regulations, and clinical data from trials conducted in China
will not be used to establish product standards. In addition, we plan to break into the European market in 2025 and conduct localized
management and operations in accordance with European regulations. In 2025, we plan to also start the localized registration of our IVD
products in Europe. As of the date of this prospectus, we have not conducted any clinical trials for our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, as of the date of
this prospectus, we have not commenced sales of our products nor have any revenue-generating products and do not expect sales of revenue-generating
product candidates until we have completed clinical development, submitted regulatory filings, and received applicable regulatory approvals
for candidate products. Due to differences in regulatory and clinical registration requirements, we may not be able to obtain device and
product approvals or provide product service on time. We expect to be in a state of continuous loss for the next two to three years.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.65pt"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended June 30,
2024 and 2023 and three-month periods ended September 30, 2024 and 2023, the Company conducted its business through Advanced Biomed Taiwan
and Shanghai Sglcell&rsquo;s subsidiaries as research and development centers for technology research and product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Comparison of Results of Operations for the Fiscal Years Ended June
30, 2024 and 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Operating expenses:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(880,193</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,383,181</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">502,988</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,661,379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,688,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">26,663</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,541,572</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,071,223</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">529,651</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,495</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,402</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(294,201</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(682,956</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">388,755</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">57</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss before tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,782,278</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,732,777</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">950,499</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">nm </FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,782,278</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,732,777</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">950,499</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Comparison of Results of Operations for the
Three Months Periods Ended September 30, 2024 and 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three-month Periods</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ended September 30</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(181,703</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(169,185</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(12,518</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(7</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(338,324</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(271,060</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(67,264</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(520,027</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(440,245</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(79,782</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">254,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(331,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">585,522</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">177</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(265,580</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(771,316</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">516,869</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">67</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we do
not have any products approved for sale, we have not generated any revenue from the sale of products, and we do not expect to generate
revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and receive approvals
from the applicable regulatory bodies for such product candidates, if ever. Our main activities through September 30, 2024 have been re-organizational
and capital raising activities and the research and development of three automated devices A<SUP>+</SUP>Pre, AC-1000 and A<SUP>+</SUP>SCDrop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses are primarily related to research and development of microfluidic biochip technology and its application in precision medicine
in the field of oncology, including early cancer screening and detection, diagnosis and staging, treatment selection, and patient prognosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended June 30,
2024 and 2023, we incurred research and development expenses of $0.9 million and $1.4 million, respectively. The research and development
expenses decreased by approximately $0.5 million or 36% for the year ended June 30, 2024 mainly due to slow down of clinical development
activities as all of the Company&rsquo;s products are in the regulatory registration process. We do not plan to begin the clinical research
for A<SUP>+</SUP>LCGuard until June 2025, and we anticipate the clinical research will end in April 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three-month periods
ended September 30, 2024 and 2023, we incurred research and development expenses of $0.2 million and $0.2 million, respectively. The research
and development expenses increased by approximately $0.01 million or 7% mainly due to increase in clinical development activities during
the three-month period ended September 30, 2024.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 26.65pt; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our general and administrative
expenses primarily consist of (i) staff cost; (ii) depreciation and amortization; (iii) office supplies and upkeep expenses; (iv) travelling
and entertainment; (v) legal and professional fees; (vi) property and related expenses; and (vii) miscellaneous expenses. The following
table sets forth the breakdown of our general and administrative expenses for the years ended June 30, 2024 and 2023 and the three-month
periods ended September 30, 2024 and 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Staff costs</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">761,257</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">743,291</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">17,966</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">399,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">365,231</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,371</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Travelling and entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,843</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,129</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(38,286</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(67</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal and professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">380,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,853</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,381</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,528</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Office supplies and upkeep expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">297</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,381</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,864</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">19,517</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">73</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,661,379</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,688,042</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">(26,663</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">(2</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three-month Periods Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30,</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Staff costs</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">148,778</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">160,214</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(11,436</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(7</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,853</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,933</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,920</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Travelling and entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,604</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,164</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,440</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal and professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,037</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Office supplies and upkeep expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,704</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">663</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,041</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1514</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">66,847</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62,736</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">4,111</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">338,324</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">271,060</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">67,264</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">(25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended June 30,
2024 and 2023 and three-month periods ended September 30, 2024 and 2023, our general and administrative expenses amounted to $1.7 million,
$1.7 million, $0.3million and $0.3million, respectively. The slight decrease in administrative expenses by approximately $0.03 million
or 2% for the year ended June 30, 2024, is mainly attributable to the decrease in the travelling and entertainment expenses, legal and
professional fees and property and related expenses which offset by the increase in staff costs, depreciation and amortization and miscellaneous
expenses. The increase in administrative expenses by approximately $0.1 million or 25% for the period ended September 30, 2024, is mainly
attributable to the increase in the depreciation and amortization, travelling and entertainment expenses, legal and professional fees
and office suppliers and upkeep expenses which offset by the decrease in staff costs and property and related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended June 30,
2024 and 2023, our other expense, net amounted to $0.3 million and $0.7 million respectively. The decrease in other expense was due to
an ad hoc loss on disposal of subsidiaries of $0.2 million and higher foreign exchange loss of $0.2 million in the year ended June 30,
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the three-months period
ended September 30, 2024 and 2023, our other income (expense), net amounted to $0.3 million and $(0.3) million respectively. The increase
in other income, net by approximately $0.6 million for the three-month period ended September 30, 2024, is mainly attributable to the
exchange gain resulted from revaluation of the foreign currency balances of approximately $0.3 million for the three-month period ended
September 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Net Loss for the Year</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing,
our net loss for the year ended June 30, 2024 was $2.8 million, compared to a loss from operations of $3.7 million for the year ended
June 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our loss from operations for
the three-month period ended September 30, 2024 was $0.3 million for the three-month period ended September 30, 2024 and 2023 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><B>Liquidity and Capital
Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our liquidity and working
capital requirements are primarily related to our research and development and operating expenses. Historically, we have met our working
capital and other liquidity requirements primarily through a combination of cash generated from stockholders&rsquo; advances to the company.
Going forward, we expect to fund our working capital and other liquidity requirements from various sources, including but not limited
to cash generated from our operations, loans from banking facilities, the net proceeds from this offering and other equity and debt financings
as and when appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s ability
to continue as a going concern depends upon its ability to develop, register and obtain regulatory approval for commercial sell of its
products to generate positive operating cash flows. For the financial year ended June 30, 2024 and the three-month period ended September
30, 2024, the Company reported net loss of $2,782,278 and $265,580, respectively. As of June 30, 2024 and September 30, 2024, the Company&rsquo;s
working capital surplus (deficit) was $318,650 and $ (176,636) respectively. In addition, the Company had net cash outflows of $2,126,340
and $29,680 from operating activities for the financial year ended June 30, 2024 and the three-month period ended September 30, 2024.
These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As circumstances warrant and
to sustain its ability to support the Company&rsquo;s operating activities, the Company may consider supplementing its available sources
of funds through the following sources:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">cash generated from operations; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">financial support from the Company&rsquo;s related party and stockholders
as well as third parties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management has commenced a
strategy to raise debt and equity. Our director and former Chief Executive Officer, Hung To Pau, Ph.D. paid the initial public offering
costs and certain expenditures, amounted $1,233,764, on behalf of the Company and committed to the disbursement of the remaining initial
public offering costs. Advanced Biomed Taiwan entered into an unsecured, interest-free loan with Yi Lu, our Chairman of the Board and
current Chief Executive Officer, of NTD3,578,212 (approximately $110,268) for general working capital in January 2023. As of June 30,
2024, the loan balance due to Yi Lu amounted to $110,268. Advanced Biomed Taiwan entered into ten unsecured, interest-free loans with
Well Fancy Development Ltd amounting to NTD2,967,700 (approximately $91,455), NTD2,989,873 (approximately $92,138), NTD4,270,200 (approximately
$131,593), NTD1,945,000 (approximately $59,938), NTD1,858,120 (approximately $57,261), NTD2,912,200 (approximately $89,744), NTD2,890,065
(approximately $89,062), NTD5,857,750 (approximately $180,516) and NTD4,356,145 (approximately $134,242) and NTD3,732,100 (approximately
US$115,011) for general working capital in August 2022, April 2023, May 2023, June 2023, July 2023, August 2023, October 2023, December
2023, February 2024 and April 2024, respectively. As of June 30, 2024, the loan balance due to Well Fancy Development Ltd totally amounted
to $1,040,960 and amounted to $545,900 for general working capital. Shanghai Sglcell entered into four unsecured, interest-free loans
with Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$68,802) in April 2023, May 2023, June 2023
and September 2023, respectively, and RMB700,000 (approximately US$96,323) and RMB1,500,000 (approximately US$206,407) and RMB700,000
(approximately US$96,323) in January 2024, March 2024 and June 2024, respectively, for general working capital. As of June 30, 2024, the
loan balance due to Shanghai Sglcell Biotech Co., Ltd totally amounted to US$674,262.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the amount due
to Dr. Pau of US$1,233,764 has been waived off by Dr. Pau as of June 30, 2024. And the total amount due to Well Fancy Development Ltd
of US$1,586,860 have also been waived off by Well Fancy Development Ltd as of June 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we acknowledge that
unforeseen circumstances or changes in market conditions could impact our liquidity, we remain committed to monitoring our financial health
and will take necessary actions to secure additional financing if needed. In the event of unforeseen circumstances that disrupt the above-mentioned
financial projection and strategies, the Company believes that our existing cash $2,646,992 as of September 30, 2024 will be sufficient
to meet our research and development and operating expenditures for a minimum period of approximately 2 months until February 28,&nbsp;2025
from the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, there can be no certainty
that these additional financings will be available on acceptable terms or at all. If management is unable to execute this plan, there
would likely be a material adverse effect on the Company&rsquo;s business. All of these factors raise substantial doubt about the ability
of the Company to continue as a going concern. The consolidated financial statements for the financial years ended June 30, 2024 and 2023
have been prepared on a going concern basis and do not include any adjustments to reflect the possible future effects on the recoverability
and classifications of assets or the amounts and classifications of liabilities that may result from the inability of the Company to continue
as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Material Cash Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cash requirements consist
primarily of day-to-day operating expenses, research and development expenses, capital expenditures and contractual obligations with respect
to facility leases and other operating leases. We lease our R&amp;D center and office. We expect to make future payments on existing leases
from cash generated from operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had the following contractual
obligations and lease commitments as of June 30, 2024:&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Contractual Obligations</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Less than</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1 year</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">1-3 years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">3-5 years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>More than 5</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>years</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Operating lease commitment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">126,740</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">62,211</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">64,529</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total obligations</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">126,740</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">62,211</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">64,529</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had the following contractual
obligations and lease commitments as of September 30, 2024&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Contractual Obligations</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Less than 1<BR>
 year</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">1-3 years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">3-5 years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">More than 5<BR>
 years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Operating lease commitment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">126,614</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">56,045</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">70,569</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,614</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,045</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,569</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Working Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September&nbsp;30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Total current assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,132,736</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,051,110</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">81,626</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,309,372</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,732,460</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">(576,912</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net current assets (liabilities)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(176,636</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">318,650</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">(495,286</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2024 and
June 30, 2024, the Company&rsquo;s working capital surplus and (deficit) was ($176,636) and $318,650. Management has commenced a strategy
to raise debt and equity, including financial supports from the Company&rsquo;s related party and stockholders as well as third parties,
which will enable that we have sufficient working capital for our requirements for at least the next 2 months from the date of this prospectus,
in the absence of unforeseen circumstances, taking into account the cash and financial resources presently available to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Cash flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">The
following table summarizes our cash flows for the fiscal years ended June 30, 2024 and 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-style: italic; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-style: italic; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash at beginning of the year</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">2,622,279</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">4,783,864</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,126,340</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,963,625</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(74,110</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(263,009</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,866,820</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">458,137</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency effect</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">319,324</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">606,912</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net decrease in cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(14,306</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,161,585</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash at end of the year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,607,973</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,622,279</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">The
following table summarizes our cash flows for the three-month period ended September 30, 2024 and 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three-month period ended<BR>
 September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-style: italic; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD><TD STYLE="font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-style: italic; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of the period</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">2,607,973</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">2,622,279</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,680</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(619,138</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,978</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">392,525</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">313,206</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency effect</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(303,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">270,871</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net decrease in cash and cash equivalents</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">39,019</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(35,061</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents as at end of the period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,646,992</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,587,218</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Cash Flow from Operating
Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended June
30, 2024 and 2023, the operating activities were primarily comprised the research and development activities, staff costs and administrative
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our net cash used in operating
activities primarily reflected our net loss, as adjusted for non-operating items, such as non-cash depreciation and amortization and effects
of changes in working capital such as decrease in prepaid expenses and other current assets and increase or decrease in accounts payables,
accruals and other current liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2024, our net cash used in operating activities was approximately $2.1 million, which primarily reflected our net loss of approximately
$2.8 million, as primarily adjusted by the (i) non-cash depreciation and amortization of approximately $0.4 million positively offset
by (ii) increase in accounts payable, accrual and other current liabilities of approximately $0.5 million and negatively impacted by increase
in prepaid expenses and other current assets of approximately $0.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2023, our net cash used in operating activities was approximately $3.0 million, which primarily reflected our net loss of approximately
$3.7 million, as primarily adjusted by the (i) non-cash depreciation and amortization of approximately $0.4 million, positively offset
by (ii) increase in accounts payable, accrual and other current liabilities of approximately $0.4 million and increase in prepaid expenses
and other current assets of approximately $0.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;For the year ended September
30, 2024, our net cash used in operating activities was approximately $0.03 million, which primarily reflected our net loss of approximately
$0.3 million, as primarily adjusted by the (i) non-cash depreciation and amortization of approximately $0.1 million positively offset
by (ii) increase in accounts payable, accrual and other current liabilities of approximately $0.2 million and negatively impacted by increase
in prepaid expenses and other current assets of approximately $0.04 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flow from Investing Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cash flows used in investing
activities primarily consisted of (i) the purchase of intangible assets; (ii) the purchase of equipment, furniture and fixtures and leasehold
improvements; and (iii) acquisition of assets of the subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2024, our net cash used in investing activities was approximately $0.08 million, primarily attributable to the purchase of equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2023, our net cash used in investing activities was approximately $0.26 million, primarily attributable to the purchase of equipment,
furniture and fixtures and leasehold improvements of approximately $0.21 million and net cash outflow of approximately $0.05 million from
the disposal of subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the period ended September
30, 2024, our net cash used in investing activities was approximately $0.02 million, primarily attributable to the purchase of equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flow from Financing Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cash flows from financing
activities primarily consists of proceeds from issuance of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2024, our Company recorded net cash generated from financing activities of approximately $1.9 million, which was mainly attributable to
the initial public offering costs and certain expenditures paid on behalf by the related parties and loans from the related parties totalling
of approximately $1.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30,
2023, our Company recorded net cash generated from financing activities of approximately $0.4 million, which was mainly attributable to
the proceeds from issuance of shares of approximately $1 million and offsetting the payment of deferred initial public offering costs
of approximately $0.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;For the period ended
September 30, 2024, our Company recorded net cash generated from financing activities of approximately $0.2 million, which was mainly
attributable to the certain expenditures paid on behalf by the related parties and loans from the related parties totalling of approximately
$0.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Critical Accounting
Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements
and accompanying notes requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and
expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other
assumptions that are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about
the carrying values of assets and liabilities that are not readily apparent from other sources. We have identified certain accounting
policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding
of our financial condition and results of operation. Critical accounting policies are those that are most important to the portrayal of
our financial conditions and results of operations and require management&rsquo;s difficult, subjective, or complex judgment, often as
a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.
Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility
that future events affecting the estimate may differ significantly from management&rsquo;s current judgments. While our significant accounting
policies are more fully described in Note 3 to the consolidated financial statements included elsewhere in this prospectus, we believe
the following critical accounting policies involve the most significant estimates and judgments used in the preparation of our financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are an &ldquo;emerging growth company&rdquo; as defined under the federal securities laws and, as such, will be subject to reduced public
company reporting requirements. Section 107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage
of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards.
We have elected to take advantage of the extended transition period for complying with new or revised accounting standards and acknowledge
such election is irrevocable pursuant to Section 107 of the JOBS Act. As a result of our election, our financial statements may not be
comparable to those of companies that comply with public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Use of Estimates
and Assumptions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience, when available,
and on other various assumptions that are believed to be reasonable under the circumstances. Actual results could differ significantly
from those estimates under different assumptions and conditions. Significant accounting estimates reflected in our consolidated financial
statements include the useful lives for equipment and intangible assets, fair value of financial instruments, assumptions used in assessing
right of use assets, impairment of equipment and intangible assets. We continue to evaluate these estimates and assumptions that we believe
to be reasonable under the circumstances. We rely on these evaluations as the basis for making judgments about the carrying values of
assets and liabilities that are not readily apparent from other sources. Since the use of estimates is an integral component of the financial
reporting process, actual results could differ from these estimates. Some of our accounting policies require higher degrees of judgment
than others in their application. We believe critical accounting policies as disclosed in this prospectus reflect the more significant
judgments and estimates used in preparation of our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following accounting policies
are significant to the preparation of our consolidated financial statements. The areas involving a higher degree of judgement or complexity,
or areas where estimates and assumptions are significant to the financial statements are disclosed in Critical, Accounting Judgements
and Key Sources of Estimation Uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intangible assets, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s intangible
assets are stated at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated
useful lives of the assets. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances
warrant revised estimates of useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 68%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Software</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Patents</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Software represents purchased
software and is amortized straight-line over the Company&rsquo;s estimates to generate economic benefits from such software, generally
three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents represent the estimated
fair value assigned to finite-lived intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather
than a business combination are initially recognized in accordance with other application GAAP. Any consideration transferred in excess
of the fair value of the assets acquired is allocated to each asset acquired on a relative fair value basis. Amortization is computed
using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally six years.
Intangible assets are reviewed for impairment at least annually or more frequently if indicators of potential impairment exist. The Company
reviews finite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate
that the carrying value of the assets might not be recoverable. An impairment allowance of approximately US$1.6 million was recognized
at the balance sheet date for the intangible assets related to the patents as management assessed that there were changes in circumstances
indicate that the carrying value of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an impairment is determined,
the actual impairment recognized is the difference between the carrying amount and the fair value as estimated using one of the following
approaches: income, cost and/or market. Assets which are to be disposed of are reported at the lower of the carrying amount or fair value
less costs to sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying amount of a long-lived
asset or asset group is considered impaired when the anticipated undiscounted cash flows from such asset or asset group is less than its
carrying amount. In that event, a loss is recorded in &ldquo;Impairment of long-lived assets&rdquo; on our Consolidated Statements of
Operations and Comprehensive Income (Loss) based on the amount by which the carrying amount exceeds the fair value of the long-lived asset
or asset group. Fair value, using the income approach, is determined primarily using a discounted cash flow model that uses the estimated
cash flows associated with the asset or asset group under review, discounted at a rate commensurate with the risk involved. Fair value,
utilizing the cost approach, is determined based on the replacement cost of the asset reduced for, among other things, depreciation and
obsolescence. Fair value, utilizing the market approach, benchmarks the fair value against the carrying amount. As of September 30, 2024
and June 30, 2024, the Company had finite-lived intangible assets of US$1.6 million of purchased patents from the acquisition of Shanghai
Sglcell. The accumulated impairment allowance recognised was approximately US$1.6 million as of September 30, 2024 and June 30, 2024,
respectively, as management assessed that there were changes in circumstances indicate that the carrying value of the assets might not
be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Equipment, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Equipment, net are stated
at cost less accumulated depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives
of the assets. Cost represents the purchase price of the asset and other costs incurred to bring the asset into its intended use. The
estimated useful lives are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 68%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Lab equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Computer equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Furniture and fixtures</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Leasehold improvements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Expenditure for repair and
maintenance costs, which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure
for major renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to
the related assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment
with any resulting gain or loss recognized in the consolidated statements of income. The Company also re-evaluates the periods of depreciation
to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash consist of cash on hand,
the Company&rsquo;s demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted
as to withdrawal and use. Deposits are held at highly liquid and well capitalized financial institutions. As of September 30, 2024, cash
balances of $2,617,436 and $24,825 were maintained at financial institutions in Taiwan and the PRC. PRC and Taiwan laws and regulations
impose certain restrictions on our ability to transfer cash between countries and between our subsidiaries. See &ldquo;Prospectus Summary
&mdash; Transfers of Cash to and from Our Subsidiaries&rdquo; for detailed discussions. Risk of loss is not expected by management. A
hypothetical 10% change in average interest rates during 2024 would not have a material impact in annual interest income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Impairment of long-lived assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Long-lived assets, including
equipment and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant
adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not
be recoverable. We assess the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate
and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds
expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, we would
reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate,
to comparable market values. As of September 30, 2024 and 2023, except for the impairment loss on intangible assets recognized, no further
impairment of long-lived assets was recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an impairment is determined,
the actual impairment recognized is the difference between the carrying amount and the fair value as estimated using one of the following
approaches: income, cost and/or market. Assets which are to be disposed of are reported at the lower of the carrying amount or fair value
less costs to sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying amount of a long-lived
asset or asset group is considered impaired when the anticipated undiscounted cash flows from such asset or asset group is less than its
carrying amount. In that event, a loss is recorded in &ldquo;Impairment of long-lived assets&rdquo; on our Consolidated Statements of
Operations and Comprehensive Income (Loss) based on the amount by which the carrying amount exceeds the fair value of the long-lived asset
or asset group. Fair value, using the income approach, is determined primarily using a discounted cash flow model that uses the estimated
cash flows associated with the asset or asset group under review, discounted at a rate commensurate with the risk involved. Fair value,
utilizing the cost approach, is determined based on the replacement cost of the asset reduced for, among other things, depreciation and
obsolescence. Fair value, utilizing the market approach, benchmarks the fair value against the carrying amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating leases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company adopted ASC 842
on July 1, 2020. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use
(&ldquo;ROU&rdquo;) assets, operating lease liability, and operating lease liability, non-current in the Company&rsquo;s consolidated
balance sheets. ROU assets represent the Company&rsquo;s right to use an underlying asset for the lease term and lease liabilities represent
the Company&rsquo;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized
at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Company includes
options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company&rsquo;s
leases do not provide an implicit rate, the Company used an incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments. The Company has elected to adopt the following lease policies in conjunction
with the adoption of ASU 2016-02: (i) for leases that have lease terms of 12 months or less and does not include a purchase option that
is reasonably certain to exercise, the Company elected not to apply ASC 842 recognition requirements; and (ii) the Company elected to
apply the package of practical expedients for existing arrangements entered into prior to July 1, 2020 to not reassess (a) whether an
arrangement is or contains a lease, (b) the lease classification applied to existing leases, and(c) initial direct costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value Measurement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accounting standard regarding
fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair
value of financial instruments held by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accounting standards define
fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements
for fair value measures. The three levels are defined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 1 inputs to the valuation methodology are quoted prices
(unadjusted) for identical assets or liabilities in active markets.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 2 inputs to the valuation methodology include quoted prices
for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or
indirectly, for substantially the full term of the financial instruments.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 3 inputs to the valuation methodology are unobservable
and significant to the fair value.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments included
in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair
value because of the short period of time between the origination of such instruments and their expected realization and their current
market rates of interest.&nbsp;The Company accounts for bank loans and lease payables at amortized cost and has elected NOT to account
for them under the fair value hierarchy. Fair value estimates are made at a specific point in time based on relevant market information
about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant judgment
and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2024,
and 2023, the carrying amount for cash and cash equivalents, trade accounts receivable (net of allowance for credit losses) and current
liabilities (excluding the &ldquo;Current portion of long-term debt and finance lease obligations&rdquo;) was equal to or approximated
fair value due to their short-term nature or proximity to current market rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of private
debt are based on, among other things, available trade information, and/or an analysis in which we evaluate market conditions, related
securities, various public and private offerings, and other publicly available information. In performing this analysis, we make various
assumptions regarding, among other things, credit spreads, and the impact of these factors on the value of the debt securities. See Note
10 for the fair value of our long-term debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Concentration of Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments
that potentially subject the Company to credit risk consist of cash on hand, the Company&rsquo;s demand deposit placed with
financial institutions and other receivables. Bank and cash balances are maintained with high credit quality institutions, the
composition and maturities of which are regularly monitored by management. As of June 30, 2024 and September 30,2024, bank and cash
balances of $2.6 million and 2.7 million respectively were maintained at financial institutions in Taiwan and China, of which
approximately $2.6 million and $2.7 million respectively was subject to credit risk. While management believes that these financial
institutions are of high credit quality, it also continually monitors their credit worthiness. The maximum exposure to credit risk
is the carrying amounts of cash and bank balances presented on the consolidated statements of financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidity Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Liquidity risk is the risk
that the Company will not be able to meet its financial obligations as they become due. The Company&rsquo;s policy is to ensure that it
has sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without incurring unacceptable
losses or risking damage to the Company&rsquo;s reputation. A key risk in managing liquidity is the degree of uncertainty in the cash
flow projections. If future cash flows are fairly uncertain, the liquidity risk increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Impact of Inflation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The types of inflationary
pressures that affected the Company has primarily related to research and development costs, staff salaries and related costs. Inflation
in Taiwan and China has not materially affected our profitability and operating results. However, we can provide no assurance that we
will be unaffected by higher inflation rates in Taiwan and China or globally in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Seasonality </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not observed any significant
seasonal trends. Our directors believe that there is no apparent seasonality factor affecting the industry that our Company is operating
in.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Trend Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as disclosed elsewhere
in this prospectus, we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably likely to have
a material effect on our profitability, liquidity, or capital resources, or that would cause reported financial information not necessarily
indicative of future operating results or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Quantitative and Qualitative Disclosures about
Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Interest Rate Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not exposed to interest
rate risk while we have no bank loans outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2024 and September
2024, bank and cash balances of approximately $2.6 million and $2.6 million respectively were maintained at financial institutions. A
hypothetical 10% decrease in average interest rates during 2024 would not have a material impact in annual interest income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Credit risk is the potential
financial loss to the Company resulting from the failure of a customer or a counterparty to settle its financial and contractual obligations
to the Company, as and when they fall due. As the Company does not hold any collateral, the maximum exposure to credit risk is the carrying
amounts of other receivables (exclude prepayments), financial instrument and cash presented on the consolidated statements of financial
position. The Company has no other financial assets which carry significant exposure to credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Foreign Exchange Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our reporting currency is
the United States Dollar. The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility
that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually
post higher or lower profit depending on exchange rate of NT$ and RMB converted to US$ on that date. The exchange rate could fluctuate
depending on changes in political and economic environments without notice. However, the Company assessed that a hypothetical 10% decrease
in exchange rates during 2024 would not have a material impact in exchange gain/loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical, Accounting Judgements and Key Sources
of Estimation Uncertainty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no critical judgements, apart from those
involving estimation (see below) that the management has made in the process of applying the Group&rsquo;s accounting policy and that
has the most significant effect on the amounts recognized in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: -27.35pt"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: -27.35pt"><B><I>Key sources
of estimation uncertainty</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The key assumptions concerning
the future and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing
a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are disclosed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Impairment of intangible assets</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company reviews finite-lived
intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying
value of the assets might not be recoverable. Accounting standards require that if the sum of the future cash flows expected to result
from a company&rsquo;s asset, undiscounted and without interest charges, is less than the reported value of the asset, an asset impairment
must be recognized in the financial statements. The amount of impairment to recognize is calculated by subtracting the fair value of the
asset from the reported value of the asset. As disclosed in note 7 to the consolidated financial statements for the years ended June 30,
2024 and 2023, the intangible asset related to acquired patents are carried forward through the acquisition of Shanghai Sglcell since
the year ended June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company believe that the
accounting estimate related to asset impairment is a &quot;critical accounting estimate&quot; because: (1) it is susceptible to change
from period to period because it requires company management to make assumptions about future sales and cost of sales over the life of
the products arising from the patents acquired (generally six years); and (2) the impact that recognizing an impairment would have on
the assets reported on our balance sheet as well as our net loss would be material. Management&rsquo;s assumptions about future sales
prices and future sales volumes of the products arising from the patents acquired require significant judgment because actual sales prices
and volumes have fluctuated in the past and are expected to continue to do so. Management has discussed the development and selection
of this critical accounting estimate with our board of directors and the board has reviewed the Company&rsquo;s disclosure relating to
it in this MD&amp;A. In estimating future sales, we use our internal budgets. We develop our budgets based on estimated sales data for
new products, planned timing of new product launches, customer commitments related to newly developed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have assessed the accumulated
impairment allowance of approximately US$1.6 mil recognized at the balance sheet date for the intangible assets related to the patents
acquired as of June 30, 2024, we determined that, based on our assumptions, the sum of the expected future cash flows, undiscounted and
without interest charges, below the reported value and therefore the accumulated impairment allowance was adequately recognized at the
balance sheet date as management assessed that there were changes in circumstances indicate that the carrying value of the assets might
not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The management has assessed that risk related
to using different assumptions and analyze their sensitivity to change based on outcomes that are deemed reasonably likely to occur and
concluded any change would not have affected our liquidity and capital resources with the impairment allowance recognized as of June 30,
2024 and September 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent accounting pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers the
applicability and impact of all accounting standards updates (&ldquo;ASUs&rdquo;). Management periodically reviews new accounting standards
that are issued. Under the Jump start Our Business Start-ups Act of 2012, as amended (the &ldquo;JOBS Act&rdquo;), the Company meets the
definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting
standards, which delays the adoption of these accounting standards until they would apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2020, the Financial
Accounting Standard Board (&ldquo;FASB&rdquo;) issued ASU 2020-05, which is an update to ASU Update No. 2016-13, &ldquo;Financial Instruments
&mdash; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&rdquo;, which introduced the expected credit
losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred
loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments &mdash; Credit Losses, and made several consequential
amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually
assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments
&mdash; Credit Losses &mdash; Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders&rsquo; concerns
by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis.
For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option
to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs
for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful
information. In November 2020, the FASB issued ASU No. 2020-10, which to update the effective date of ASU No. 2016-02 for private companies,
not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new
effective date for these preparers is for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact
of this new standard on Company&rsquo;s consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, the FASB
issued ASU 2021-08, Codification Improvements to Subtopic 310-20, Receivables &mdash; Nonrefundable Fees and Other Costs. The amendments
in this Update represent changes to clarify the Codification. The amendments make the Codification easier to understand and easier to
apply by eliminating inconsistencies and providing clarifications. ASU 2021-08 is effective for the Company for annual and interim reporting
periods beginning July 1, 2021. Early application is not permitted. All entities should apply the amendments in this Update on a prospective
basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. These amendments do not
change the effective dates for Update 2017-08. The Company is currently evaluating the impact of this new standard on Company&rsquo;s
consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, the FASB
issued ASU 2021-10, Codification Improvements. The amendments in this Update represent changes to clarify the Codification or correct
unintended application of guidance that are not expected to have a significant effect on current accounting practice or create a significant
administrative cost to most entities. The amendments in this Update affect a wide variety of Topics in the Codification and apply to all
reporting entities within the scope of the affected accounting guidance. ASU 2021-10 is effective for annual periods beginning after December
15, 2021 for public business entities. Early application is permitted. The amendments in this Update should be applied retrospectively.
The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as mentioned above,
the Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material
effect on the Company&rsquo;s consolidated balance sheets, statements of income and comprehensive income and statements of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="v_001"></A>OUR INDUSTRY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in"><I>This section includes estimates regarding market and industry data. Unless otherwise indicated, information concerning
our industry and the markets in which we operate is based on a research report commissioned by us and independently prepared by Grand
View Research Inc. (&ldquo;Grand View&rdquo;), our management&rsquo;s knowledge and experience, together with currently available information
obtained from various third-party sources, including publicly available information, industry reports and publications, surveys, our customers,
trade and business organizations, and other contacts in the markets in which we operate. Some data is also based on our good faith estimates.
The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described
in the section entitled &ldquo;Risk Factors.&rdquo; These and other factors could cause the estimates to differ materially from those
expressed in these publications.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cancer is the second leading
cause of death in the world, and the number of deaths and cases is increasing year by year. The World Health Organization&rsquo;s International
Agency for Research on Cancer (IARC) has released the Biennial Report 2020-2021, which shows 19.29 million new cancer cases worldwide
and 10.0 million cancer deaths in 2020. Among the 2020 new cancer cases, there were 4.57 million new cancer cases in China, accounting
for 23.7% of the world. Since China is the most populous country in the world, the number of new cancer cases far exceeds that of other
countries in the world. The top ten countries with new cancer cases are: China 4.57 million, the United States 2.28 million, India 1.32
million, Japan 1.03 million, Germany 630,000, Brazil 590,000, Russia 590,000, France 470,000, the United Kingdom 460,000, and Italy 420,000.
IARC predicts that by 2040 cancer incidence will almost double, to 30.2 million new cases, with 16.3 million cancer deaths worldwide predicted
in 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">According to Grand
View&rsquo;s market analysis report, Liquid Biopsy Market Size, Share &amp; Trends Analysis Report, the global liquid biopsy market
size was valued at USD8,937.68 million in 2022 and is anticipated to grow at a CAGR of 12.46% from 2023 to 2030, resulting in sales
worth USD22,865.56 million in 2030. The report provides market value for the base year 2022 and a yearly forecast till 2030 in
terms of revenue in US dollars. It uses the bottom-up approach for market sizing, analyzing key regional markets, dynamics, and
trends for various services, and end-uses. The forecast of the global market is calculated by integrating the regional
markets&rsquo; amounts. The report has also considered factors including impact of COVID-19 up to 2023, supply chain disruptions and
demand dynamics. According to the report, liquid biopsy is a revolutionary technique that has created various opportunities that
were previously unexplored. It aids in detection and isolation of circulating tumor DNA, exosomes, and circulating tumor cells and
is a source of proteomics and genomics information in cancer patients. It is worth noting that these are estimates of the global
market, and we intend to initially focus on developing our cancer screening market in China and will expand our operations to other
markets in the following years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In recent years, from the
diversification of early tumor screening and early detection technologies to the transformation and application of products based on
different re-examination technologies, the early cancer screening industry is on the fast track of development and has broad prospects.
Liquid biopsy is a diagnostic technology for tumor analysis which collects body fluid samples such as blood, effusion, urine, and saliva
and detects biomarkers in the body fluid samples. Liquid biopsy technology has been widely used in lung cancer, breast cancer, prostate
cancer, head and neck squamous cell carcinoma, colorectal cancer, gastrointestinal cancer, leukemia and other tumors, musculoskeletal
system and connective tissue diseases. It provides molecular-level diagnosis for tumor patients, enabling tumor patients to receive more
precise treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Traditional Screening vs. Liquid Biopsy Screening</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Traditional cancer screening
methods mainly focus on imaging screening (color Doppler, CT, MRI), endoscopy screening (gastroscopy, colonoscopy), tumor marker screening
(Prostate specific antigen, alpha fetoprotein), which are highly invasive with poor sensitivity, low compliance and other defects. The
5-year survival rate of lung cancer with the highest mortality rate in the world is only 15%-18%. But if lung cancer can be detected
and treated early, the 5-year survival rate can exceed 80%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The vast majority of early-stage
lung cancers are asymptomatic, and most of the lung cancer patients who have symptoms and seek medical attention are in the advanced
stages. However, early-stage lung cancers with ground-glass nodules are all missed by chest X-ray screening; early-stage lung cancers
with soft-tissue nodules are too small, and a considerable part of them are missed by chest X-ray examination. Only intermediate and
advanced lung cancer can be detected by chest X-ray. Low-dose helical CT can detect tiny tumors less than 1 cm in diameter and plays
a much greater role in early lung cancer screening. For people who are under the age of 40 and have no family history of lung cancer,
it is generally not recommended to do low-dose spiral CT. But if a chest X-ray is included in the physical examination, it is better
to do a low-dose spiral CT than a chest X-ray, because the chest X-ray will miss more than 80% of early lung cancer. Many people are
very concerned after finding pulmonary nodules in their physical examination and choose to perform CT examinations multiple times. It
is not advisable by most doctors as CT examination has a certain amount of radiation and its use should be Minimized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Compared with the existing
cancer screening technology, liquid biopsy technology for early cancer screening has three advantages of &ldquo;non-invasive&rdquo;, &ldquo;efficient&rdquo;
and &ldquo;accurate&rdquo;. The test samples of liquid biopsy are usually blood, saliva, urine and other body fluids. The sampling process
is convenient and fast, and it is less invasive to the human body and has good compliance. The entire testing process is simple to operate,
less dependent on medical resources, and samples are highly accessible for multiple sampling. The testing cycle is usually 1-2 weeks.
Compared with traditional screening methods, liquid biopsy technology has significantly improved sensitivity and specificity. It can also
enable doctors to evaluate the overall tumor situation for early detection of tumors. In the future, it will be a clear path for large-scale
adoption of liquid biopsy technology as a tool for early cancer screening and diagnosis, which has obvious benefits to patients and can
reduce overall medical costs. Further, the detection results can effectively guide the clinical decision-making process for oncologists.
In conclusion, the future of liquid biopsy technology can increase the options for molecular diagnosis of tumors and enhance the personalized
treatment of tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Market Opportunities in Early Cancer Detection
Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The early cancer detection
market has huge potential. Early tumor screening and related diagnosis are the most active directions in the industry. According to Grand
View Research, Inc.&rsquo;s market analysis report, Liquid Biopsy Market Size, Share &amp; Trends Analysis Report, the global liquid biopsy
market size was valued at USD8,937.68 million in 2022 and is anticipated to grow at a CAGR of 12.46% from 2023 to 2030, resulting in sales
worth USD22,865.56 million in 2030. The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of
revenue in US dollars. It uses the bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various
services, and end-uses. The forecast of the global market is calculated by Integrating the regional markets&rsquo; amounts. The report
has also considered factors including impact of COVID-19 up to 2023, supply chain disruptions and demand dynamics. According to the report,
liquid biopsy is a revolutionary technique that has created various opportunities that were previously unexplored. It aids in detection
and isolation of circulating tumor DNA, exosomes, and circulating tumor cells and is a source of proteomics and genomics information in
cancer patients. It is an easy, rapid, and minimally invasive test for cancer genetic status based on circulating tumor cells, circulating
tumor DNA, and other tumor-derived substances in blood plasma samples. Rapid development in digital Polymerase Chain Reaction (PCR) and
NGS-based technology has improved accuracy of liquid biopsy. It can be performed repeatedly for disease monitoring and is anticipated
to help overcome limitations of tissue biopsies. It is worth noting that these are estimates of the global market, and we intend to initially
focus on developing our cancer screening market in China and plan to expand our operations to other markets in the following years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_002"></A><B><A NAME="za_001"></A>OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a holding company incorporated in the State of Nevada. We operate
through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and
development of the company's primary technologies and products. Since our establishment in 2014, we have been focusing on the integration
of multiple interdisciplinary technologies and established our own microfluidic technology platform. Utilizing the physical and molecular
biological characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor
technology and biotechnology. This includes complex precision structures, dielectric detection, functional microfluidic biochips, microfluidic
integrated semiconductor sensors, related application modules, and key components of medical testing equipment. We have also developed
a series of medical testing equipment and related products by integrating various functions of microfluidic modules, automation software,
and hardware. Our technologies and products can be used for early screening and detection, diagnosis and staging, and treatment of cancer
through the detection of circulating tumor cells and related tumor markers in blood samples, capture of single circulating tumor cells,
and single-cell sorting and determination. These products provide assistance in treatment selection and patient prognosis intervention
once the required licenses and approvals have been obtained. Advanced Biotech HK is our first localized operation company, mainly responsible
for market operation and management in China, localized production, product registration, and future local market sales of our products
in accordance with relevant local regulations in China. Our Shanghai subsidiary owns some of our R&amp;D equipment and patents and will
be responsible for operations related to clinical trials in Mainland China through CROs. In the future, we also plan to establish operation
centers in countries and regions in North America and Europe.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our devices, A<SUP>+</SUP>Pre,
AC-1000, A<SUP>+</SUP>CellScan, and A<SUP>+</SUP>SCDrop, and three corresponding microfluidic biochips, A<SUP>+</SUP>Pre Chip and AC-1000
CTC Enrichment Chip and A<SUP>+</SUP>CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer
patients. Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation
and enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A<SUP>+</SUP>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<SUP>+</SUP>SCDrop preserves the original
viability of single cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, we have finished
the research and development stage for four matching immunostaining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM,
and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different
colors to bind to specific proteins on the cell surface or inside the cells. The presence and intensity of fluorescent signals can be
observed through a separate fluorescent imaging system, and the expression of the target protein and the cell type can be judged and determined
accordingly. Different cell types can be distinguished using multiplexed combined staining with different antibodies. The A<SUP>+</SUP>CTCE
kit is mainly used to identify epithelial circulating tumor cells, the A<SUP>+</SUP>CTCM kit is used to identify mesenchymal circulating
tumor cells, the A<SUP>+</SUP>EMT kit is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, and the A<SUP>+</SUP>CM
kit is used to identify tumor-associated macrophages (cancer-associated macrophage-like cells).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also developed a product
for early screening of lung cancer, the A<SUP>+</SUP>LCGuard Lung Cancer Early Screening Kit (&ldquo;A<SUP>+</SUP>LCGuard&rdquo;), which
is used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the
research, design, and development of A<SUP>+</SUP>LCGuard. A<SUP>+</SUP>LCGuard is a Class III medical device and is required to conduct
clinical trials before completing the registration process, and we plan to begin A+LCGuard&rsquo;s clinical research by the end of June
2025. We believe clinical research serves as the foundation for clinical trials, bridging the gap between preclinical studies and large-scale
clinical trials. We believe clinical trials enables an understanding of subject recruitment, facilitates the development of appropriate
inclusion and exclusion criteria for later stages, and helps verify trial procedures. Additionally, we believe it increases familiarity
with the trial products. In June 2025, the Company and the CRO plan to collaborate to draft the clinical research protocol and begin preparing
the necessary equipment, consumables, reagent kits, and other materials for the study. By the end of September 2025, we expect that the
clinical research protocol may pass ethical review and receive ethics committee approval. Thereafter, we plan to initiate the trial stage
of the clinical research, with completion anticipated within six months of October 2025. We believe the results of the clinical research
will inform the work plan for future large-scale clinical trials, minimizing waste from an excessively large sample size or insufficient
statistical power due to a sample size that is too small. We recognize that the clinical research results may differ from expectations
and may not support our expected progression to clinical trials. If so, we plan to promptly optimize the product, adjust participant group
selection, and modify the final protocol for large-scale clinical trials. However, we cannot guarantee that any clinical research or trial
will meet our anticipated outcomes. Furthermore, delays in obtaining ethical approval or recruiting participants could prevent the clinical
research from being completed on schedule. Such delays could subsequently postpone the large-scale clinical trial and ultimately the product
launch date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must go through
three steps to receive the required clearance from the NMPA before they can be sold to customers. The three steps are research and development,
registration application, and registration review, which must be done in that order. At the registration application stage, we have to
assemble all the required application materials, complete clinical trials (if required by NMPA), and work with an NMPA accredited third-party
organization to examine our products in accordance with NMPA rules. NMPA will review our application during the registration review period
and may request additional information before officially approving or denying our applications. Currently, A<SUP>+</SUP>Pre and AC-1000
and their corresponding chips have been cleared by the NMPA; A<SUP>+</SUP>SCDrop, A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and
A<SUP>+</SUP>LCGuard are at the registration application stage; the four matching immunostaining kits are under registration review. A<SUP>+</SUP>LCGuard
is a Class III medical device and is required to conduct clinical trials before completing the registration process. As of the date of
this prospectus, we have not applied for similar clearances from other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We participated in a scientific
research project at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies to test
A+Pre, AC-1000 and A<SUP>+</SUP>LCGuard. In the study, we selected 123 individuals, and among them, 75 were surgical patients with nodular
changes or shadows in the lungs reported by imaging studies and 48 healthy patients without lung nodules reported by imaging studies.
7ml blood samples were taken from test subjects either before the clinical operation (for cancer patients) or after the physical examination
(for healthy individuals), and A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>LCGuard kits were used to determine whether there were circulating
tumor cells and other tumor markers in the blood samples. Finally, the pathological and physical examination results of the tested individuals
were compared with the test results of our products. Our test results achieved 96% sensitivity and 99.9% specificity, which provides the
research and development basis for our products. Specifically, A+Pre and AC-1000 were at the research and development stage, and we completed
their effectiveness and performance indicators testing through this project. At the same time, A<SUP>+</SUP>LCGuard finished its feasibility
and functional verification testing. All three products were tested together throughout the entire project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of our products must be approved
by applicable regulatory authorities before being sold to customers. A<SUP>+</SUP>Pre and A<SUP>+</SUP>CellScan can work with third-party
products to achieve their designed objectives. AC-1000 and A<SUP>+</SUP>SCDrop may be used together with other devices according to different
application scenarios below. For the A<SUP>+</SUP>LCGuard early screening kit, it has to be used in combination with A<SUP>+</SUP>Pre
and AC-1000. Our four staining kits, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CM, A<SUP>+</SUP>CTCM, and A<SUP>+</SUP>EMT, can be used independently
or with third-party products. A<SUP>+</SUP>Pre, AC-1000, and A<SUP>+</SUP>CellScan require the use of our supporting microfluidic chips.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the analysis of high-viscosity blood samples: A<SUP>+</SUP>Pre can be independently used for pretreatment,
retaining the original cell activity while preventing blood samples from clogging the equipment pipeline after entering the detection
equipment.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For the identification and counting application of circulating tumor cells:
blood samples are diluted with A<SUP>+</SUP>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells and related tumor
markers. The enriched samples are stained, calibrated, and finally identified and counted. We can provide this service to the public if
using third-party staining reagents already on the market in China. However, we plan to officially roll out this service once our in-house
developed staining reagents, A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CTCM, A<SUP>+</SUP>EMT and A<SUP>+</SUP>CM, complete the registration process.
The identification and counting of circulating tumor cells and related tumor marker cells can provide auxiliary references for relevant
clinical applications.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">The capture of circulating tumor cells: we follow the same process as the identification of circulating
tumor cells to obtain enriched samples with A<SUP>+</SUP>Pre and AC-1000, and then the samples are captured and separated by A<SUP>+</SUP>SCDrop
to isolate single circulating tumor cells. This service can provide tumor cells with high purity and high activity.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">For early screening of lung cancer: peripheral blood samples of the subjects are first obtained, and the
target cells are enriched and captured sequentially by A<SUP>+</SUP>Pre and AC-1000. After that, A<SUP>+</SUP>LCGuard performs cell fluorescence
staining on the enriched samples to determine the number of targeted cells, and finally makes a judgment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the different regulatory
requirements for the marketing of medical device products and in-vitro diagnostics (&ldquo;IVD&rdquo;) products in various regions/countries,
it is necessary to complete the registration application and obtain the corresponding license in accordance with the local regulations
before engaging in commercial activities in the respective regions/countries (&ldquo;localization registration&rdquo;). Afterward, marketing
and sales can be carried out. We follow the principle of modularization when design and develop all of our products and equipment so that
products and equipment can be produced locally to meet different regulatory requirements. Based on the current development of the early
tumor screening and preventive treatment industry and the characteristics of the products we are planning to register and apply in the
future, we have adopted the operation model of centralized research and development and localized management. We have started the registration process with the NMPA in China for all of our products. Later on, the Company may establish subsidiaries
in the United States and Europe to produce products and carry out product registration. To achieve that, our products must be cleared
by the United States Food and Drug Administration and go through the conformity assessment process to obtain the Conformite Europeenne
marking (&ldquo;CE marking&rdquo;) from competent authority in each European Union member state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are looking for suitable locations in the states of California and Washington
for our planned expansion to the North America market. We aim to complete site selection and personnel recruitment in the United States
by the end of December 2024 and start product registration, testing and production afterward. Our US subsidiary will be responsible for
the production and registration of our equipment and related products in the US. Production, testing, and clinical trials in our US market
will be conducted in accordance with US regulations, and clinical data from trials conducted in China will not be used to establish product
standards. In addition, we plan to break into the European market in 2025 and conduct localized management and operations in accordance
with European regulations. In 2025, we also plan to start the localized registration of our IVD products in Europe. As of the date of
this prospectus, we have not conducted any clinical trials for our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, as of the date of this prospectus, we have
not commenced sales of our products nor have any revenue-generating products and do not expect sales of revenue-generating product candidates
until we have completed clinical development, submitted regulatory filings, and received applicable regulatory approvals for candidate
products. Due to differences in regulatory and clinical registration requirements, we may not be able to obtain device and product approvals
or provide product service on time. We expect to be in a state of continuous loss for the next two to three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Corporate History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Nevada
in July 2021 as a holding company. We started operations in 2014 through Advanced Biomed Taiwan as a research and development center for
technology research and product development. In August 2021, we established Advanced Biomed HK as the wholly owned subsidiary of Advanced
Biomed Taiwan to integrate market development and commercialization in the PRC. On January 1, 2022, Advanced Biomed HK acquired 100% equity
interest of Shanghai Sglcell from its stockholders for a consideration of RMB12 million. In March 2022, Advanced Biomed HK established
Sglcell (Huangshan) Biotech Co., Ltd.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In July 2022, we consummated a reorganization
pursuant to which we acquired 100% equity interest of Advanced Biomed Taiwan, making it our wholly owned subsidiary. On November 7, 2022,
we obtained the approval of Taiwan Investment Commission for the reorganization, the Issue No. of which is &ldquo;</FONT><FONT STYLE="font-family: MS Mincho">&#32147;&#23529;&#19968;&#23383;&#31532;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">11100116890</FONT><FONT STYLE="font-family: MS Mincho">&#34399;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 8, 2023, pursuant to the Share Transfer Agreement entered into
by Ting Wang and Haifeng Zhang, who are independent third-party individuals, and Shanghai Sglcell on June 2, 2023, Shanghai Sglcell transferred
its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd., to Ting Wang
and Haifeng Zhang at aggregate consideration of RMB500,000 (approximately US$72,780) without any other obligations arising from the transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 9, 2023, pursuant to the Share Transfer
Agreement entered into by Ting Wang and Haifeng Zhang, who are independent third-party individuals, and Shanghai Sglcell on May 31, 2023,
Shanghai Sglcell transferred its wholly owned subsidiary, Shandong Sglcell Medical Devices Co., Ltd., to Ting Wang and Haifeng Zhang
at zero consideration without any other obligations arising from the transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 15, 2023, pursuant to
the Share Transfer Agreement entered into by Quantum Capital (Hong Kong) Limited, who is an independent third-party corporation, and
Advanced Biomed HK on June 9, 2023, Advanced Biomed HK transferred its wholly owned subsidiary, Sglcell (Huangshan) Biotech Co., Ltd.,
to Quantum Capital (Hong Kong) Limited at zero consideration without any other obligations arising from the transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
our Shanghai subsidiary is the only operating entity we have in the PRC and owns all of our patents and some of our R&amp;D equipment
while the rest of our R&amp;D equipment are owned by Advanced Biomed Taiwan. Our Shanghai subsidiary will also be responsible for operations
related to clinical trials in Mainland China through CROs.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Corporate Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The chart below depicts the
corporate structure of the Company as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc051_img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Our Oncology Detection Solutions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The current market uses positive
antibody-labeling selection to capture CTCs out of the blood by a specific epithelial cell adhesion molecule (EpCAM). This method could
detect tumor cells in the patient&rsquo;s blood for diagnosing lung, prostate, pancreatic, and breast cancers. However, this technology
costs approximately $1,000 per chip, and the processing time per patient is up to 12 hours. Besides, antibody-based methods such as immunomagnetic
methods are highly dependent on antigen expression of CTC. Some CTCs may show low or no EpCAM expression on the cell membrane, and thus
cannot be effectively captured using the proposed biomarkers and makes it difficult to detect cancer in the early stage. More importantly,
the capture of dying or dead CTCs cannot provide meaningful information to doctors for diagnosis or treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our products use pure physical
mechanisms (antigen-independent) and can effectively enrich and detect the CTCs with high or low antigen expressions with high viability.
Among them, A<SUP>+</SUP>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation and
enrichment of circulating tumor cells (&ldquo;CTCs&rdquo;) and tumor-related targeted cells in blood samples. The A<SUP>+</SUP>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<SUP>+</SUP>SCDrop preserves the original
viability of single cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For three corresponding microfluidic
biochips, A<SUP>+</SUP>Pre Chip and AC-1000 CTC Enrichment Chip have been cleared by NMPA and can be mass-produced and sold to customers.
A<SUP>+</SUP>CellScan Chip is expected to start the registration application by the end of March 2024. The A<SUP>+</SUP>CellScan Chip
and A<SUP>+</SUP>CellScan will enrich our product chain by upgrading our immunochromogenic kits to tumor cell assay equipment. Specifically,
A<SUP>+</SUP>CellScan, together with A<SUP>+</SUP>Pre and AC-1000, can serve as a liquid biopsy IVD product to accelerate downstream assay
and reduce the amount of labor required for assaying tumor cells.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We use our own product features
combined with different application scenarios to achieve the corresponding work objectives. To identify CTCs in liquid biopsy, blood samples
are first diluted through equipment A<SUP>+</SUP>Pre, then AC-1000 is used to separate and enrich circulating tumor cells, and then the
obtained cells are stained for identification and counting. We have been cleared by NMPA to provide this service to customers in China
and plan to do so once our matching immunostaining kits pass the NMPA&rsquo;s registration review. The counting of circulating tumor cells
can provide auxiliary reference for clinical diagnosis, treatment evaluation, prognosis evaluation, recurrence, and metastasis detection,
etc. In the future, we can also use our A<SUP>+</SUP>LCGuard early screening kit combined with two devices, A<SUP>+</SUP>Pre and AC-1000,
for early screening of lung cancer. In addition, we use A<SUP>+</SUP>SCDrop together with A<SUP>+</SUP>Pre and AC-1000 to complete the
capture of a single circulating tumor cell, which retains the original activity of the cell and can provide high-purity, high-activity
tumor cells for relevant clinical applications. It can be applied to various applications such as single-cell sequencing, whole gene sequencing,
protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, and individualized drug sensitivity testing.
The above product applications need to be approved by the local regulatory authorities before they can be provided to customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>A<SUP>+</SUP>Pre</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A<SUP>+</SUP>Pre is a fully
automated sample preparation system that enables to pre-concentrate diluted blood sample and it is able to deplete approximately 90 %
blood cells in 10 minutes and reduce sample volume with a lower blood cell density (hematocrit approximately 4%). A<SUP>+</SUP>Pre provides
dual channels to simultaneously process two patients&rsquo; samples per run, and 8 samples could be done in an hour. A<SUP>+</SUP>Pre
is easy to operate with two simple steps: 1. dilute the samples by 10-fold; 2. insert the samples and A<SUP>+</SUP>Pre chips into A<SUP>+</SUP>Pre
system and press &lsquo;START&rsquo;. Our A<SUP>+</SUP>Pre sample-pretreatment could provide clotting-free and clogging-free samples
for downstream microfluidic applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>A<SUP>+</SUP>Pre Chip</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Blood sample includes several
billions blood cells and millions white blood cells with a hematocrit of approximately 45% (&ldquo;Hct&rdquo;). The high-density blood
cells in microfluidic chip typically induces clotting or clogging in microchannel and microstructs, causing trail failure or unstable
system. Sample dilution can effectively reduce the clotting and clogging. However, dilution may increase sample volume and prolong the
processing time for downstream precise separation and makes analysis more difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">A<SUP>+</SUP>Pre chip utilizes microfluidic inertial forces to rapidly
pre-enrich (deplete approximately 90% blood cells) and pre-concentrate (reduce over 90% sample volume) the diluted blood sample in 10
minutes. We can dilute a 5ml blood sample with approximately 45% by a factor of 10 and obtain a 50ml blood sample. After concentration
and enrichment using the A<SUP>+</SUP>Pre chip, the total volume of the 50ml blood sample can be reduced by 10-13 times to around 4 ml
while maintaining low red blood cell density (Hct approximately 4.5%), and we can recover more than 90% of the targeted tumor cells.
It reduces blood cell density of oncology patients to make it possible for clotting-free downstream precise separation, A<SUP>+</SUP>Pre
treated sample provide AC-1000 with high purity rare tumor cells in 20 minutes (12 mL/hour). A<SUP>+</SUP>Pre chip plays an important
role to reduce sample volume and density to make downstream applications much faster and more stable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%">&nbsp;<IMG SRC="vc051_img03.jpg" ALT=""></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><IMG SRC="vc051_img10.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">A<SUP>+</SUP>Pre</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">A<SUP>+</SUP>Pre Chip</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>AC-1000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AC-1000 is a rare cell enrichment
device to solve the problem of detection of hypercoagulable state samples of tumor patients. Our rare cell enrichment system uses semiconductor
fabrication method to implant high-aspect-ratio functional microstructures inside the microchannel and patented microfluidic chip technology
to separate rare cells with complete cell activity. The system is convenient and efficient. We take 5 mL of blood from a patient and
the whole process takes only 20 minutes. Compatible to A<SUP>+</SUP>Pre, AC-1000 also provides dual channels to simultaneously process
two patients&rsquo; samples per run, and 8 samples could be done with high-purity enrichment of tumor cells in one and half hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The blood sample enriched
by AC-1000 can maintain the capture rate of 76-90% of the targeted cells, and the isolated product after blood sample separation can
achieve a leukocyte removal rate of 99.9%, which is convenient for downstream detection. Because the rare cell enrichment system is non-destructive,
highly active and label-free, it can carry out pure physical and high-purity enrichment, completely maintain the original characteristics
of the desired target cells and improve accuracy. What we get is highly active cells, which can be used for different applications in
the future, and can be used for tumor screening, auxiliary diagnosis, treatment evaluation, prognosis evaluation, recurrence and metastasis
detection, individualized medication guidance, and companion diagnosis. Our rare cell enrichment system is low-cost, and the cost will
be further reduced after mass production. It has great potential to be applied to routine liquid biopsy and companion diagnostic platforms
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>AC-1000 CTC Enrichment Chip</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">AC-1000 chip utilizes a hybrid
mechanism with microfluidics induced lateral displacement to combine the difference in cell deformability and to remove all of red blood
cells (&ldquo;RBCs&rdquo;) and deplete over three logs White Blood Cell (&ldquo;WBCs&rdquo;). The remaining cells, including few WBCs
and rare cell-based cancer biomarkers, are all sorted out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt">&nbsp;<IMG SRC="vc051_img04.jpg" ALT=""></TD>
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt">&nbsp;<IMG SRC="vc051_img11.jpg" ALT=""></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>A<SUP>+</SUP>SCDrop</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A<SUP>+</SUP>SCDrop is a
CTCs single cell capture device. It preserves the original viability of single cells. The polymer microfluidic chip combines the cell
dielectric sensing technology, without the need for antibody fluorescence calibration and image recognition. CTC sorting combined with
AC-1000 achieves tandem for complete label-free live cell sorting. A<SUP>+</SUP>SCDrop can sort single circulating tumor cells into nanoliter
droplet collection samples while maintaining single cell biological activity: a. Precise counting of CTCs while separating and capturing
single cells; b. In vitro culture and expansion of non-destructive Single-CTC; drug sensitivity test; c. Single-CTC encapsulated in oil
droplets, single-cell sequencing or genetic screening d. Single CTCs were independently sorted into 96-well plates in suspension liquid
mode for CTC proteomic study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc051_img05.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>A<SUP>+</SUP>CellScan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Currently, A<SUP>+</SUP>CellScan
are developed as an analyzer with immunostaining chip for reducing hands-on time, manual discrimination, and accelerating immunostaining/analysis
of the AC-1000 product. A<SUP>+</SUP>CellScan provides a novel approach for rapid on-chip immunofluorescence staining, which may take
approximately 30 minutes, and artificial intelligence analysis of enriched sample for detecting, identification, and counting of rare
CTCs/clusters from white blood cells with four color immune-fluorescent images. The prototype we designed can (a) autofocus for capturing
and analyzing images of four colors fluoresces in A<B><I><SUP>+</SUP></I></B>CellScan chip, (b) perform on-chip immunostaining, and (c)
automatically count tumor cells and labeling them on each image. We also completed A<B><I><SUP>+</SUP></I></B>CellScan&rsquo;s performance
study, which examine (i) its autofocus ability and precision for automatically capturing and analyzing cell images, (ii) whether it can
detect and analyze 3-1000 cancer cells in &lt;106 WBCs, and (iii) its maximum on-chip immunostaining ability. Performance study (i) to
(iii) were completed in December 2022, January 2023, and March 2023, respectively. During the performance study, we have thoroughly evaluated
A<B><I><SUP>+</SUP></I></B>CellScan&rsquo;s autofocus precision in capturing cell images. Out of 6,400 cell pictures that were captured
through a non-stop and fully automated process, less than 2 pictures were found to be out-of-focus. We also analyzed the presence of 3-1,000
cancer cells stained with fluorescence within samples containing 104, 105, and 106 WBCs, resulting in reliable detection of cancer cells.
We have optimized the antibody concentrations for CK+, DAPI, and CD14/45 combination, resulting in a maximum on-chip immunostaining ability
with high specificity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>A<SUP>+</SUP>CellScan Chip</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Conventional immuno-staining is
labor-intensive with multiple processes, and its reaction is based on diffusion-dominated mechanism, thus causing a long operating time
(about 4-5 hours per sample). A<SUP>+</SUP>CellScan chip consists of fluid device and 5 &mu;m micro-pores membrane that is used as a filter
to trap nucleated cells on the membrane surface form the through-flow. Only fluid and RBCs are allowed to pass through the pores. Captured
cells are kept in wells during flowing staining and washing. The active through-flow plays two important roles: 1. carrying antibodies
to cells rapidly, thus accelerating the reaction rate of specific binding between reporting antibody and cells; 2. simplifying the operation
processes in reagent spiking and repeated washing steps. A<SUP>+</SUP>CellScan chip stains rare cells such as CTCs and CTC clusters without
cell loss during fixation, permeabilization, blocking, incubation and washing. The device provides flexibility to process up to eight
samples per run. On-chip immunostaining only need 30 minutes for one sample, and batch process for eight samples can be completed in one
and half hours. After cell staining, A<SUP>+</SUP>CellScan and A<SUP>+</SUP>CellScan chips automatically captures cell images and analyses
the stained cells in 30 minutes. Compared to conventional methods, A<SUP>+</SUP>CellScan chip significantly reduces the total detection
time by 4-5 hours per 1 sample.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt"><IMG SRC="vc051_img14.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 50%; font-size: 10pt"><IMG SRC="vc051_img12.jpg" ALT="">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following diagrams illustrate
the procedures using our devices for diagnostic detection of blood samples from oncology patients:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Diagram 1: A<SUP>+</SUP>Pre reduces blood density
of oncology patients.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U></U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;<IMG SRC="vc051_img07.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the analysis of high-viscosity
blood samples, the A<SUP>+</SUP>Pre equipment can be used for pretreatment, retaining the original cell activity while preventing blood
samples from clogging the equipment pipeline after entering the detection equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Diagram 2: AC-1000 completes targeted cell
enrichment work.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I><IMG SRC="vc051_img08.jpg" ALT="">&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A<SUP>+</SUP>Pre and AC-1000 equipment
can be combined for the identification and counting application of circulating tumor cells purposes. First, blood samples are diluted
with A<SUP>+</SUP>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells and related tumor markers. The enriched
samples are stained, calibrated, and finally identified and counted. A<SUP>+</SUP>Pre combined with AC-1000 provide the purified solution
of cell-based cancer biomarkers, which can be easily identified, analyzed and tested. The total purification process can be completed
in only 40 minutes. A<SUP>+</SUP>Pre combined with AC-1000 capture multi-cell-based cancer markers simultaneously with a high recovery
rate (76~90%), and therefore making it possible to diagnose cancer and predict cancer progression in very early stage. This application
service can already be commercialized in the Chinese market. Calibration and staining currently use staining reagents that are already
on the market. Once our products are registered, we will start using our own developed reagents. The identification and counting of circulating
tumor cells and related tumor marker cells can provide auxiliary reference for relevant clinical applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Diagram 3: A<SUP>+</SUP>SCDrop completes
single targeted cell capture.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="vc051_img09.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">The capture of circulating tumor cells requires the use of A<SUP>+</SUP>Pre,
AC-1000, and A<SUP>+</SUP>SCDrop in combination. First, the user needs to follow the same process as the identification of circulating
tumor cells to obtain enriched samples, and then the samples are captured and separated by A<SUP>+</SUP>SCDrop equipment to isolate single
circulating tumor cells. This combined application can provide tumor cells with high purity and high activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Four Immunochromogenic Kits</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The four immunochromogenic kits,
A<SUP>+</SUP>CTCE, A<SUP>+</SUP>CM, A<SUP>+</SUP>CTCM and A<SUP>+</SUP>EMT, are currently under NMPA registration review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="vc051_img13.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the four immunochromogenic
kits, the basic principle is to use antibodies combined with different colored fluorophores to bind to specific proteins on the cell surface
or inside the cells and observe the presence or absence of fluorescent signals through a fluorescent imaging system (to be obtained separately).
Afterwards, the expression of the target protein can be examined, and the cell type can be determined accordingly. Different cell types
can be distinguished using multiplexed combined staining with different antibodies. The A<SUP>+</SUP>CTCE kit is mainly used to identify
epithelial circulating tumor cells, and is determined by immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies. The A<SUP>+</SUP>CTCM
kit is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies.
A<SUP>+</SUP>EMT is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, which are determined by immunochromogenicity
of Cell-Surface Vimentin (CSV), CD45 antibody, and CD14 antibody. A<SUP>+</SUP>CM is used to identify tumor-associated macrophages (cancer-associated
macrophage-like cells) based on immunochromogenicity of PD-L1, CD45, and CD14 antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With the assistance of the four
kits, targets are stained using antibodies conjugated with different fluorophores that specifically bind to antigens in cells. In immunohistochemical
reaction or in situ hybridization reaction, it is combined with the primary antigen antibody, and the target is marked by staining. It
is suitable for the staining of blood cells enriched by A<SUP>+</SUP>Pre and AC-1000 hemocytometer. We transfer the cell suspension separated
and obtained by A<SUP>+</SUP>Pre and AC-1000 into a centrifuge tube, use the kits to stain the cell suspension, and observe and count
the fluorescently stained cells under a fluorescence microscope or a fluorescence scanner. Observed under a fluorescence microscope, all
nuclei are stained blue, and the cell membrane of leukocytes is red, and the color of the cell membrane we observe under the fluorescence
microscope is the marked color, which is the target cell we want to obtain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Product in the Pipeline</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our A<SUP>+</SUP>LCGuard was
designed for early screening of lung cancer. In order to detect lung cancer, peripheral blood samples of the subjects are first obtained,
and the target cells are enriched and captured sequentially by A<SUP>+</SUP>Pre and AC-1000. Then, A<SUP>+</SUP>LCGuard performs cell
fluorescence staining on the enriched samples to determine the number of targeted cells, and finally makes a judgment. We completed A<SUP>+</SUP>LCGuard&rsquo;s
research and development in China between August 2020 and September 2022. A<SUP>+</SUP>LCGuard is a Class III medical device and is required
to conduct clinical trials before completing the registration process. We plan to begin A+LCGuard&rsquo;s clinical research by the end
of June 2025. Specifically, in June 2025, the Company and the CRO plan to collaborate to draft the clinical research protocol and begin
preparing the necessary equipment, consumables, reagent kits, and other materials for the study. By the end of September 2025, the clinical
research protocol is expected to pass ethical review and receive ethics committee approval. In October 2025, we plan to initiate the trial
stage of the clinical research, with completion anticipated within six months. Based on the results of clinical research, we plan to formulate
a work plan for large-scale clinical trials and proceed with the clinical trial. We believe the registration declaration will be made
after we complete the clinical trials.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following diagrams illustrate
the procedures using our detection solutions for CTC enriched samples:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc051_img15.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We participated in scientific
research projects at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies. In the
study, we selected 123 individuals, and among them, 75 were surgical patients with nodular changes or shadows in the lungs reported by
imaging studies and 48 healthy patients without lung nodules reported by imaging studies. 7ml blood samples were taken from test subjects
either before the clinical operation (for cancer patients) or after the physical examination (for healthy individuals), and A<SUP>+</SUP>Pre,
AC-1000, and A<SUP>+</SUP>LCGuard kits were used to determine whether there were circulating tumor cells and other tumor markers in the
blood samples. Finally, the pathological and physical examination results of the tested individuals were compared with the test results
of our products. Our test results achieved 96% sensitivity and 99.9% specificity, which provides the research and development basis for
our kit products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Below are two comparable blood
testing methods in the current market. We have not tested the sensitivity of our products against these two comparable blood testing products
in head-to-head comparisons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Universal Diagnostics (UDX), a
Spanish vitro diagnostic company, announced the preliminary research data of its liquid biopsy method for early detection of lung cancer
at the International Association for the Study of Lung Cancer 2020 World Conference. In a preliminary study, UDX detected 37 lung cancer
patients and 71 asymptomatic control subjects with a panel of 10 methylation sites. The results showed that lung cancer patients could
be detected with a sensitivity of 73% (27/37) with 90% (64/71) specificity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The &ldquo;Aifeiming&rdquo;
gene methylation detection kit (P)R-fluorescent probe method) by Beijing Akron Medical Technology Co., Ltd. won the NMPA Class III certification.
The clinical sensitivity of this product is 86.83%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Quality Control System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have established quality control
system in accordance with the following regulations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Medical Device Quality Management System for Regulatory Requirements</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Quality Management System Requirements</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Regulations on the Supervision and Administration of Medical Devices</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Measures for the Supervision and Administration of Medical Device Production</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">Appendix of Good Manufacturing Practice for Medical Devices In Vitro Diagnostic Reagents</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">Guiding Principles for Clinical Trial of In Vitro Diagnostic Reagents</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our quality control system includes
quality manuals specifically designed for each product, procedure documents, supporting documents and quality records. We implement, maintain
and improve the quality control system to ensure that product quality can be effectively and compliantly controlled throughout the entire
process of procurement, production, formation and realization. Specifically, our quality control team (&ldquo;QC&rdquo;) consists of three
members who are responsible to examine the entire production process from raw materials to finished products. QC also collaborate with
various internal departments of the Company to conduct periodic review on all aspects of our research, development, and production process
and provide their recommendations to the management to ensure our products and processes adhere to the regulations apply to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Commercialization Preparation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are committed to the development
of microfluidic chips, reagents and detectors for capturing circulating tumor cells in blood. We have integrated various complex precision
structures, dielectric detection and functional microfluidic biochips. Our devices include a variety of expensive semiconductor manufacturing
and precision micro-manufacturing related equipment. We signed a research project equipment use contract with TSRI and used their semiconductor manufacturing equipment and precision
micro-nano processing equipment for chip technology research and development such as concept presentation of each R&amp;D process, cross-scale
composite structure production, rapid wafer trial production, material testing, and thin film production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The contract between Advanced
Biomed Taiwan and TSRI was executed on August 1, 2022 and expired on July 31, 2023. The total cost of the study, including tax, is NTD
1,300,000. Advanced Biomed Taiwan will pay the research fee to the National Institute of Experimental Research in two installments. The
first installment of NTD 650,000 was paid on September 23, 2022, and the second installment of NTD650,000 was paid on April 18, 2023.
The agreement can be unilaterally terminated only if a party fails to fulfil its obligations, if Advanced Biomed Taiwan declares bankruptcy,
or if its business activities are disrupted by the government. The agreement can only be terminated by mutual agreement in all other circumstances.
The parties agree to take the Taiwan Taipei District Court as the jurisdiction court of first instance for any disputes arising from the
execution of this agreement, which shall be subject to the laws of Taiwan.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As for the designed microfluidic
detector, since 2020, we have developed various functional microfluidic biomedical testing devices for microfluidic modules, automation
software, and hardware. We also designed, manufactured and processed an increasing number of key components of our testing devices. All
of our products must go through three steps to receive the required clearance from the NMPA before they can be sold to customers. The
three steps are research and development, registration application, and registration review, which must be done in that order. At the
registration application stage, we have to assemble all the required application materials, complete clinical trials (if required by NMPA),
and work with an NMPA accredited third-party organization to examine our products in accordance with NMPA rules. NMPA will review our
application during the registration review period and may request additional information before officially approving or denying our applications.
Currently, A<SUP>+</SUP>Pre and AC-1000 and their corresponding chips have been cleared by the NMPA; A<SUP>+</SUP>SCDrop, A<SUP>+</SUP>CellScan,
A<SUP>+</SUP>CellScan Chip, and A<SUP>+</SUP>LCGuard are at the registration application stage; the four matching immunostaining kits
are under registration review. A<SUP>+</SUP>LCGuard is a Class III medical device and is required to conduct clinical trials before completing
the registration process. As of the date of this prospectus, we have not applied for similar clearances from other jurisdictions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although none of the chips has
been mass produced as of the date of this prospectus, we have been cooperating with the injection molding machine manufacturer Riva and
the mold manufacturer Unimold to conduct pre-mass production trial test for our A<SUP>+</SUP>Pre Chip and AC-1000 Enrichment Chip. During
the mass production trial test, we examine the following factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">whether the tested chip can work with its corresponding product, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">whether chips&#8217; flatness, roughness, water leakage, critical size and thickness match the original
design.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A Chip is ready for mass-production
if each individual production line can produce at least 2,500 pieces per month and pass the quality control examination. During the quality
control examination, one chip out of every 48 chips will be randomly selected for verification and must achieve designed objectives when
working with their corresponding products and meet all the product specifications to pass the examination. The product specifications
are listed in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 10%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Flatness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Roughness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">No Water leakage </FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Critical size compared with original design</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Thickness</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif"><SUP>+</SUP></FONT>Pre Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.1 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R&lt;1.5 um /mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2 mm &plusmn;10%</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">AC<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">-</FONT>1000 Enrichment Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.3 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R &lt; 1.5 um/mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.5 mm &plusmn;10%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon completion of the pre-mass
production trial test, all of the randomly selected A<SUP>+</SUP>Pre Chips and AC-1000 Enrichment Chips can work with their corresponding
A<SUP>+</SUP>Pre and AC-1000 products and meet or exceed the production specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">One of every 48 chips was randomly selected and tested for performance
verification by using A549 lung cancer cells spiked into human blood. In May 2023, a total of 20 A+Pre chips were tested, with
a result of average tumor cell recovery rate of 94%, which exceeded the target rate of 90%, with the highest and lowest rates of 99% and
91.6%, respectively. The liquid and blood cells removal rate by A+Pre chip was between 90-92.5%, which is in line with the target rate
of 90-94%. A total of 12 AC-1000 chips were examined and the average recovery rate is 79.5%, which exceeded the target rate of 75%, with
the highest and lowest recovery rates of 88.6% and 76.8%, respectively. The blood cells depletion rate was &gt;2.5 logs, exceeding the
target rate of 2 logs, with the highest and lowest rate of 4 and 2.5 logs, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The specifications of the randomly
selected A<SUP>+</SUP>Pre and AC-1000 chips produced during the pre-mass production trial test can be found in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 10%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Flatness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Roughness</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">No Water leakage </FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Critical size compared with original design</FONT></TD>
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Thickness</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif"><SUP>+</SUP></FONT>Pre Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.05 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R&lt;1.5 um /mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 3%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">2 mm &plusmn;5%</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">AC<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">-</FONT>1000 Enrichment Chip</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;F &lt; 0.08 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">&Delta;R &lt; 1 um/mm<SUP>2</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Under 2 bar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">within 5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">1.5 mm &plusmn;10%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Riva is a mold manufacturing and
injection molding machine manufacturer. We have purchased a Riva injection molding machine at the end of October 2022 and completed the
mass production trial test for AC-1000 chips, and the production samples met our product specifications. The special structure mold core
we made combined with the Riva injection molding machine has repeatedly produced hundreds of pieces of AC-1000 chips. The quality of the
products is consistent and meet the product specifications of the microstructure characteristics. The operation on the equipment has achieved
the expected efficiency and cell enrichment efficiency. Each equipment is expected to produce 2,000 pieces AC-1000 chips per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Unimold is a mold manufacturer and an ISO9001 plastic injection molding
foundry. We cooperate with Unimold to embed our specially manufactured mold core for A+Pre Chip into the mold cavity, which will be employed
at our future production facility. Although there is no formal cooperation agreement between Unimold and us, Unimold produces custom-made
molds for us on a make-to-order basis. Each time, we first discuss the mold specification with a Unimold representative, then receive
an offer from Unimold with the price, and Unimold will produce the customized mold for us to test. To protect our intellectual property,
Unimold and us entered into a Non-Disclosure Agreement (the &ldquo;NDA&rdquo;) with a term of three years. The NDA prohibits both parties
from disclosing confidential information without authorization and hiring the other party&rsquo;s employees during the term of the NDA
or within two years of the termination of the NDA. The NDA is governed by the laws of Taiwan, and any disputes arising from the NDA must
be resolved before Taiwan Tainan District Court. The chips produced by Unimold&rsquo;s mold have met the specifications set by us, and
a batch of small-scale trial production of 5,000 pieces was carried out in October 2022. Our A<SUP>+</SUP>Pre is operating to expected
efficacy and performance specifications using the in-house produced A<SUP>+</SUP>Pre Chip. One injection-type production equipment is
expected to produce 50,000 pieces of A<SUP>+</SUP>Pre Chip per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have built our microfluidic
technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines
our patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor
fabrication technology, and integrated application patented technology. Each geographic territory will establish clean rooms for chip
production in compliance with local regulations to meet local market demand. While performing its designed duties, our microfluidic technology
platform can provide customized services to third parties for a fee. We envision providing services such as OEM production of microfluidic
chips, micro-electromechanical components, biochips, sensors, and other components, customized product design, and commissioned development
and research services to customers. Different from the general IC wafer OEM production, our production is based on our micro-nano manufacturing
technology platform developed by professionals in various fields that integrates cross-field knowledge, including Micro Electro Mechanical
Systems (MEMS), lithography-assisted micromachining (LIGA), semiconductor process, and soft materials such as silicone gel and polydimethylsiloxane.
We boast the ability to develop, design, and manufacture micro-electromechanical components and sensors, including three-dimensional microstructures
or micro-optical-electromechanical integrated components. The material of the microstructure can be multi-layer stacking of alloys and
insulating materials, which may be used in a wide range of fields, such as pressure or environment detection, MEMS oscillators, optical
actuators, biomedical components, passive components, silicon optical integration platforms, and microfluidic structures.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The platform integrates our
AC-1000 and A<SUP>+</SUP>SCDrop devices. Our rare cell enrichment device AC-1000 integrates the A<SUP>+</SUP>Pre chip and AC-1000 CTC
enrichment chip. AC-1000 uses semiconductor nano ultra-sensitive biosensors and patented microfluidic chip technology to isolate rare
cells with complete cell activity. It has great potential to be applied to routine liquid biopsy and companion diagnosis in the future.
AC-1000 can satisfy different applications with corresponding special chip products. Our products also have the potential to provide application
services in tumor screening, auxiliary diagnosis, treatment evaluation, prognosis evaluation, recurrence and metastasis detection, individualized
medication guidance, and companion diagnosis. In terms of tumor screening, we have developed a complete set of service models for early
screening of lung cancer, and plan to begin the clinical research by the end of June 2025. Our application services for the identification
of CTCs have matured, and the identification of CTCs can be used for tumor screening, auxiliary diagnosis, and treatment evaluation, etc.
Our CTCs single cell capture device A<SUP>+</SUP>SCDrop is used in combination with A<SUP>+</SUP>Pre and AC-1000. It preserves the original
activity of single cells and polymer microfluidic chips combined with cell dielectric sensing technology. With the technical advantages
combined with our IVD kit products, A<SUP>+</SUP>SCDrop can be used in a variety of applications, such as single-cell sequencing, whole
gene sequencing, protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, individualized drug susceptibility
testing, and other aspects of individualized precision medicine. We are also working on prognosis assessment, recurrence and metastasis
detection, individualized medicine, and companion diagnosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although no services have been provided to customers yet, we believe the application services using our products and devices will be an essential part of our future
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we have not received
any regulatory approvals necessary to commercialize our products, we believe that the following competitive strengths enable us to compete
effectively in and capitalize on the growing oncology detection market:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Our microfluidic technology
    platform.</B> We can quickly complete the product development and improvement we need on our own platform. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Proprietary Ultra-Sensitive Biosensor Technology. </B>Our self-developed
    proprietary semiconductor nano ultra-sensitive biosensor technology integrates various composite precision structures, dielectric
    detection and functional microfluidic biochips to complete the microfluidic chips and reagents for capturing circulating tumor cells
    in a patient&rsquo;s blood. Our technology also enables a fast and inexpensive method for early cancer diagnosis because we mainly
    rely on self-developed equipment and products, including the microfluidic chips and the related reagents. Specifically, with the
    start and expansion of mass-production, the cost and price of microfluidic chips will drop multiple times. Also, since we estimate
    that we will enrich all the targeted cells, the amount of reagents required in the process will decrease correspondingly. Additionally,
    we are able to complete the detection and analysis in a short period of time while ensuring the accuracy of the results and reducing
    the death number of targeted cells throughout the process because we have a complete microfluidic technology platform, which uses
    self-developed microfluidic chips to separate and detect CTCs. By using automatic and efficient microfluidic chips, we can reduce
    human errors when capturing, releasing, counting, and detecting CTCs. For example, AC-1000 and its corresponding chip can achieve
    high throughput (800-1000 drops/s) and high flow rate (&gt;0.7ml/hr) while completely removing red blood cells in peripheral blood
    samples within 30 minutes. Due to the non-destructive nature of the rare cell enrichment system, it can maintain the original characteristics
    of the desired target cells through purely physical and high-purity enrichment processes, improving the accuracy of the results and
    reducing the number of target cells that die during the entire process.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><B>On Track to Commercialization.</B> All of our products must go through three
    steps to receive the required clearance from NMPA before they can be sold to customers. The three steps are research and development,
    registration application, and registration review, which must be done in that order. Currently, A+Pre and AC-1000 and their corresponding
    chips have been cleared by the NMPA; A+SCDrop, A+CellScan, A+CellScan Chip, and A+LCGuard are at the registration application stage;
    the four matching immunostaining kits are under registration review. We expect to submit the A+CellScan, and A+CellScan Chip&rsquo;s
    registrations to the NMPA in December 2024 while completing preliminary works for A+SCDrop&rsquo;s application. We have been cooperating
    with the injection molding machine manufacturer Riva Machinery Co., Ltd. (&ldquo;Riva&rdquo;) and the mold manufacturer Unimold Technology
    Inc. (&ldquo;Unimold&rdquo;) to conduct mass production mode testing and trial production. Although none of the chips has been mass-produced
    as of the date of this prospectus, we have purchased a Riva injection molding machine at the end of October 2022 and completed the
    mass production trial test of AC-1000 CTC Enrichment chip. We also cooperate with Unimold to embed our specially manufactured mold
    core for A+Pre Chip into the mold cavity made by Unimold. The chips produced have met the specifications set by us, and a batch of
    small-scale trial production of 5,000 pieces has been carried out in October 2022. Our equipment is operating to expected efficacy
    and performance specifications using in-house produced chips. Moreover, the prototype of A+CellScan and its corresponding chip have
    completed the performance study. You can find more information on page 66 under the heading &ldquo;A+CellScan.&rdquo; We are refining
    the production method of A+CellScan chip and have submitted the results of our medical device safety test to a third party for independent
    evaluation. In addition, we have completed the mass production trial test using the mold manufactured by Unimold in December 2023,
    and an independent third-party is evaluating the test result. The A+CellScan and its corresponding chip will enrich our product chain
    by upgrading our immunochromogenic kits to tumor cell assay equipment. Specifically, A+CellScan, together with A+Pre and AC-1000,
    can serve as a liquid biopsy IVD product to accelerate downstream assay time and reduce the amount of labor required for assaying
    tumor cells. In addition, we are actively carrying out registration application for our A+LCGuard kit products, as well as work related
    to research programs.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B>Multi-Disciplinary Management
                                            Team.</B> We have a multi-disciplinary management team, an R&amp;D team and strategic cooperation
                                            units composed of interdisciplinary and cross-field professionals and well-known experts.
                                            The R&amp;D team has the ability to combine semiconductor/integrated circuits and biomedical
                                            expertise. Our team has accumulated valuable experience from chip development and design,
                                            manufacturing, mass production, design and development of detectors, research and development
                                            of system modules, and the operation of clinical laboratory personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will strive to be a leading
provider of precision oncology detection solutions by the following growth strategies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B>Increase the market penetration
                                            </B>of our oncology auxiliary products and expand our product portfolio to actively focus
                                            on in vitro early diagnosis, rapid evaluation of chemotherapy drugs, individualized treatment
                                            including clinical screening of drugs, detection of drug resistance, and monitoring of tumor
                                            recurrences.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B>Develop cancer screening market
                                            in China and further expand to other regions.</B> We plan to initially focus on developing
                                            our cancer screening market in China. We also plan to expand to North American and European
                                            market by setting up subsidiaries and localize production and operation to meet specific
                                            market demand and compliance requirements in the relevant market.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B>Expand our R&amp;D</B> to strength
                                            and develop pipeline products. In the future, we will actively promote the research and development,
                                            application and registration of other cancer early screening products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 20.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2024 we
had registered or applied with China Patent and Trademark Office 8 patents on novel separation technologies for antibody-free and label-free
enrichment of rare cell-based cancer biomarkers (such as CTC, CTC cluster, tumor marker expressed cells) from very dense blood cells,
6 patents on high throughput droplet microfluidic chips for nano-liter scale reagent preparation and single-cell, 3 patents for the device
of water phase single-cell isolation and capturing for single cell applications, 6 patents on single-CTC detection/discrimination and
delivery for single-CTC sorting and downstream single-CTC analysis, and 3 patents on target cells pre-concentration and enrichment. Meanwhile,
we also applied 2 of abovementioned patents with PCT and 2 of abovementioned patents with the U.S., and one of the U.S. application has
been granted on October 11, 2022. As of the date of this prospectus, we own 17 patents and additional 9 patent applications are pending.
Several smart and key chip fabrication techniques/methods with mass production level are protected by commercial confidential to reduce
exposed risk.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our ability to obtain and maintain proprietary or intellectual property protection for our detection solutions and other commercially
important products, technologies, invention and&nbsp;know-how,&nbsp;to operate without infringing, misappropriating or otherwise violating
the proprietary or intellectual property rights of others and to prevent others from infringing, misappropriating or otherwise violating
our proprietary or intellectual property rights. Our patent strategy is focused on seeking coverage for our core technologies and specific&nbsp;follow-on&nbsp;applications,
implementations for detecting and monitoring cancer by determining genomic alterations and evaluating the status of specific biomarkers
in liquid biopsy or tissue samples. In addition, we file for patent protection on our&nbsp;on-going&nbsp;research and development, particularly
into early-stage cancer screening.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,&nbsp;know-how&nbsp;and
continuing technological innovation to develop and maintain our proprietary and intellectual property position. We generally require
our R&amp;D personnel to enter into confidentiality agreements. These agreements provide that all confidential information developed
or made known to the individual during the course of the individual&rsquo;s relationship with us is to be kept confidential and not disclosed
to third parties except under specific circumstances. In the case of our R&amp;D personnel, the agreements provide that all of the technology
which is conceived by the individual during the course of employment is our exclusive intellectual property. Furthermore, as a matter
of company policy, our R&amp;D personnel have entered into agreements that generally require disclosure and assignment to us of ideas,
developments, discoveries and inventions made by them which relate to their employment with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; width: 19%; border-bottom: black 1pt solid; padding-right: 3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Patent Number</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 11%; border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Patent Type*</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 20%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Patent Description</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 11%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Jurisdiction</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 11%; border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiration Date</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Product Application</B></FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-size: 10pt">ZL201821544689.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Target cells pre-concentration and enrichment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-size: 10pt">ZL201811418768.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Target cells pre-concentration and enrichment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11/26/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201811098975.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Target cells pre-concentration and enrichment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">PCT/CN2018/103116</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">International</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US11467081B216/639,117</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/30/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544716.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544498.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811099053.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre Chip, AC-1000 CTC Enrichment Chip, and A<SUP>+</SUP>CellScan Chip</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201810381143.X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-CTC detection/discrimination</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">04/25/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">PCT/CN2018/103171</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">International</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US20200086320A1<BR>
16/617,634</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">USA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/30/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544718.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544717.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811098985.0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811098981.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center">ZL<FONT STYLE="font-size: 10pt">201810169100.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">02/28/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">202110753142.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Separation technologies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">02/28/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">AC-1000</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201921425592.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/29/2029</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201910807870.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">08/30/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821961715.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11/26/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>CellScan Chip &amp; A<SUP>+</SUP>SCDrop</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821544526.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811470094.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">11/26/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center">ZL<FONT STYLE="font-size: 10pt">201811099052.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Droplet microfluidics</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ZL201821562851.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Utility Models</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Single-cell isolation and capturing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2028</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>Pre Chip, AC-1000 CTC Enrichment Chip, and A<SUP>+</SUP>CellScan Chip</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811098968.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-cell isolation and capturing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">201811098887.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Invention</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Single-cell isolation and capturing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">09/20/2038</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A<SUP>+</SUP>SCDrop chip&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">* Chinese Patent Law defines three different types
of patents for protecting invention-creation: invention, utility model, and design. &ldquo;Invention&rdquo; means any new technical solution
proposed for a product, a process or the improvement thereof. &ldquo;Utility Model&rdquo; means any new technical solution proposed for
the shape, the structure, or their combination, of a product, which is fit for practical use. &ldquo;Design&rdquo; means, with respect
to an overall or partial product, any new design of the shape, the pattern, or their combination, or the combination of the colour with
shape or pattern, which is rich in an aesthetic appeal and is fit for industrial application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2024,
we had registered 8 trademarks in China, including <FONT STYLE="font-family: Times New Roman, Times, Serif">&#27427;&#25096;&#36187;</FONT>
and sglcell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own 11 registered
domain names in China, including our official website, <U>www.advanbiomed.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Item</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Trademarks</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 87%; font-weight: bold; text-align: center; padding-left: 5.4pt">&#27427;&#25096;&#36187;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">sglcell</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Item</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Domain Names</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 87%; text-align: center; padding-left: 5.4pt">advanbiomed.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">sglcell.cn</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">sglcell.net</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">sglcell.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">singlecellbiomed.com.cn</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">singlecellbiomed.cn</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">singlecellbiomed.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">cell-biomed.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">abi-cell.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">abi-singlecell.com</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">yitiancell.com</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Employees</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2024,
we had 40 employees. Most of our employees are located in Mainland China, with a small number located in Taiwan. The following table sets
forth the number of our employees by function as of September 30, 2024.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As&nbsp;of&nbsp;September 30, 2024</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>%&nbsp;of&nbsp;Total&nbsp;Employees</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Functions:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-size: 10pt">Technology, Research and Development</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">53</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Medical Affairs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Operations and Quality Assurance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sales and Marketing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">General and Administration</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Total number of employees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">40</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">100.0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our R&amp;D personnel are
imperative to our technological development. They are responsible for the early stage of biochip design and production, design improvement
and optimization, self-developed microfluidic system, design and development of biomedical testing instruments, and establishment of
biochip mass production mode. They also test the electrical safety of our medical devices, assist us to prepare FDA medical device regulatory
certification and registration application documents. The R&amp;D personnel are also responsible for the training of clinical laboratory
personnel, the training of assembly, testing and maintenance of medical equipment production line personnel, and future chip mass production
and packaging production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our Shanghai subsidiary is required
by law to make contributions equal to certain percentages of each employee&rsquo;s salary for his or her pension insurance, medical insurance,
unemployment insurance and other statutory benefits and a housing provident fund. Our Shanghai subsidiary also
enters into standard labor contracts with its employees. The labor contract typically includes a confidentiality covenant that requires
employees to protect the company confidential information during their employment. In addition, employees are prohibited from entering
into another employment relationship with a third party, which may adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Advisors and Industry-Academia Cooperation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We focus on the research and development of various advanced and original
microfluidic biochips and strive to provide tumor precision diagnosis and treatment technology and early cancer detection service. In
order to strengthen our strategic development and research, we have worked with the following advisors (&ldquo;Advisors&rdquo;) and the
National Taiwan University (the &ldquo;NTU&rdquo;) pursuant to certain advisory agreements and industry-academia cooperation agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B>Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Lin Jianhuang</I></B>
is currently President of Taipei Medical University, Director of National Applied Research Laboratory, Director of Biotechnology and Pharmaceutical
Industry Research Institute, Executive Director of Taiwan Pharmacological Society, and Director of International Cooperation Foundation.
Dr. Lin is mainly engaged in the field of molecular pharmacology signal transduction new drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Zhou Caicun</I></B>
Director of the Institute of Oncology, Tongji University School of Medicine, Director of the Department of Oncology. Director of Oncology
Department of Shanghai Pulmonary Hospital, Director of Lung Cancer Immunology Research Office, Director of Clinical Pharmacology Institute.
Mainly engaged in early diagnosis of lung cancer, comprehensive treatment, targeted therapy and individualized therapy, molecular imaging
of tumor, phage vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Advisors attend quarterly
meetings and provide professional advice to the Company. Advisors make recommendations and offer guidance on the Company&rsquo;s long-term
development strategy and major decisions, including providing consultation and suggestions on the Company&rsquo;s development plans,
research directions, scientific partnerships, and academic exchanges based on their abundant clinical experience to help the Company
stay on the right track. For example, we used to focus on counting tumor cells, and our Advisors suggested to capture active single cells
for further clinical application. Based on the suggestion, we eventually developed A<SUP>+</SUP>SCDrop. Furthermore, our Advisors suggested
that we adopt the method of taking blood samples at multiple times, as the number of targeted cells contained in samples at different
times is different, so as to ensure the accuracy of the obtained results. Accordingly, we adjusted our clinical plan regarding our prospective
clinical trials.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Below are the material terms of
the advisory agreements (the &ldquo;Advisory Agreement&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Terms</I></B>.
The Advisory Agreement for Mr. Lin Jianhuang went into effect on November 1, 2022, and will end on October 31, 2025, unless terminated
earlier in accordance with the provisions of the Advisory Agreement. The Advisory Agreement for Mr. Lin Jianhuang may be renewed if the
parties start the renewal process three months prior to the end of this agreement and agree on the terms and conditions of the new agreement.
The Advisory Agreement for Mr. Zhou Caicun went into effect on July 1, 2022, and will end on June 30, 2025, unless terminated earlier
in accordance with the provisions of the Advisory Agreement. The Advisory Agreement for Mr. Zhou Caicun may be renewed if the parties
start the renewal process one months prior to the end of this agreement and agree on the terms and conditions of the new agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Services</I></B>.
The Advisor is hired by us as its advisor (&ldquo;Advisor&rdquo;) and provide consulting service to us regarding our development plans
and strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Compensation</I>.</B>
We will reimburse Mr. Zhou Caicun any work-related expenses. We will reimburse Mr. Lin Jianhuang any work-related expenses and we agreed
to grant Mr. Lin 0.5% of the total number of shares of this Offering. The Common Stock will be distributed evenly among Mr. Lin&rsquo;s
three years of service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Termination</I></B>.
This Advisory Agreement can only be modified by both parties&rsquo; written consents and will remain in effect if either Party does not
agree on the proposed modification. This Advisory Agreement is terminated once the end date has been reached or in accordance with the
terms and conditions of this Advisory Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Industry-Academia Cooperation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advanced Biomed Taiwan entered
into two industry-academia cooperation agreements with the National Taiwan University under identical terms and conditions for identifying
novel biomarkers for early detection of lung cancer (together the &ldquo;Cooperation Agreements&rdquo;). Advanced Biomed Taiwan
renewed one of the two Cooperation Agreements on November 30, 2024 (the &ldquo;Renewed Cooperation Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below are the material terms
of the Cooperation Agreements&nbsp;and the Renewed Cooperation Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Terms.</I></B> The Cooperation
Agreements went into effect on April 15, 2023 and expired on October 14, 2024. The Renewed Cooperation Agreement went into effect on December
1, 2024 and will expire on November 30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Scopes</I>.</B> Research
and development works stipulated in the Cooperation Agreements and the Renewed Cooperation Agreement focus on improving the accuracy of
early lung cancer detection and exploring more novel biomarkers in that regard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Payment</I>.</B> Under
the Cooperation Agreements, Advanced Biomed Taiwan is required to pay the NTU NTD6 million in two equal installments, with the first one
been paid on April 24, 2023. The second installment of NTD3 million was paid in February 2024. Under the Renewed Cooperation Agreement,
Advanced Biomed Taiwan is required to pay the NTU NTD3 million in two installments, with the first one due on December 15, 2024. As of
the date of this prospectus, we have not received the required invoice from the NTU for the first installment and thus no payment has
been made. The second installment of NTD1.5 million is due on June 1, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Ownership</I>.</B> The
parties recognize that the services provided by the advisor are advisory and consulting in nature and do not involve actual research activities.
The NTU shall own the copyrights of any and all reports and works produced under the Cooperation Agreements, while Advanced Biomed Taiwan
has the license to use any and all reports and works produced under the Cooperation Agreements freely. The Renewed Cooperation Agreement
does not permit Advanced Biomed Taiwan to use any results or products under that agreement directly for profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Termination</I>.</B>
Either party to the Cooperation Agreements and the Renewed Cooperation Agreement has the power to terminate such agreement if the NTU
cannot perform its duties and obligations due to force majeure events or if Advanced Biomed Taiwan cannot perform its duties and obligations,
provided that the NTU shall refund Advanced Biomed Taiwan any portion of the payment to the extent not actually spent.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">We currently lease three properties
for our Taiwan R&amp;D center, which covers an area of 450 square meters. The lease of Haihuan Street expires on May 29, 2025;&nbsp;the
lease of 689-86 Xiaodong Street expires on July 14, 2027; and the lease of 689-85 Xiaodong Road expires on July 14, 2026. Pursuant to
an equipment use contract with the adjacent TSRI, Taiwan R&amp;D center can use the TSRI&rsquo;s various semiconductor manufacturing equipment
manufacturing and precision micro-nano processing equipment to carry out concept presentation and cross-scale composite structure of each
R&amp;D process, chip technology research and development, rapid chip trial production, material testing, and thin film production. We
believe that we will be able to obtain adequate facilities, principally through leasing, to accommodate our future expansion.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shanghai office is located
in Shanghai Bay Valley Science and Technology Park (&ldquo;Bay Valley&rdquo;), adjacent to Shanghai Pulmonary Hospital and Fudan University
Life Research Institute. The leased area is 1267.98 square meters, and the lease term is from October 16, 2024 to October 15, 2025.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The geographic location of
our Taiwan R&amp;D center provides access to supply of graduates from the local Chenggong University for R&amp;D personnel. Its vicinity
to Taiwan Semiconductor Research Center, Yongkang Industrial Zone, and Chengda Hospital enables us to form a good research and development
ecosystem for biomedical testing of our devices and chips. The location also enables us to integrate nearby resources of the semiconductor
micro-manufacturing related facilities, precision processing industry community, hospital biological treatment and preservation facilities
and other resources required for our research and development process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Licenses and Approvals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
licenses and approvals that our subsidiaries are required to obtain for our operations in Taiwan and China as of the date of this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 30%; border-bottom: black 1pt solid; padding-right: 3pt"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 22%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Licenses and <BR>
Approvals</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 26%; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PRC and Taiwan Regulatory</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Authority</B></P></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 18%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Expiration Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Business Registration Certificate</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Tainan City Government</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">indefinite</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Certificate of Incorporation</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrar of Companies,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Hong Kong Special Administrative Region</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">indefinite</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Business Registration Certificate</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrar of Companies,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Hong Kong Special Administrative Region</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">August 9, 2025</FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">&nbsp;Shanghai Sglcell</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Business License</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Shanghai Administration for Market Regulation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">indefinite</FONT></TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may from time to time
be subject to legal and administrative proceedings and claims that arise in the ordinary course of business. We are not aware of any
pending or threatened material legal or administrative proceedings against us. We do not believe that any claims exist where the outcome
of such matters would have a material adverse effect on our consolidated financial position, operating results or cash flows. However,
there can be no assurance such legal proceedings will not have a material impact on future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This section summarizes the
principal Taiwan and PRC laws, rules and regulations related to our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulations in Taiwan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to Taiwan Companies Going
to The Mainland to Engage in Technical Cooperation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 1, 1993, the Ministry
of Economic Affairs promulgated the Regulations Governing the Examination of Investment or Technical Cooperation in Mainland China (&ldquo;Examination
of Investment or Technical Cooperation&rdquo;) which became effective immediately. The regulations were amended and took effect on December
30, 2020. On March 1, 1993, the Ministry of Economic Affairs also promulgated the Regulations Governing the Approval of Investment or
Technical Cooperation in Mainland China (&ldquo;Approval of Investment or Technical Cooperation&rdquo;). The regulations were amended
and took effect on April 21, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If a Taiwan company intends to
go to Mainland China for technical cooperation, in principle, it must submit an application to the Taiwan Investment Commission in advance.
According to the instructions of the Taiwan Investment Commission, the average review time for each case is 15-30 days. During the review,
the competent authority will consider factors such as the impact on the core competitiveness of other Taiwanese companies, the layout
of R&amp;D and innovation, and the infringement of intellectual property rights of other companies to comprehensively determine whether
to approve or not. If a Taiwan company and a Chinese company engage in technical cooperation without permission, the competent authority
may impose a fine of not less than NTD50,000 but not more than NTD25,000,000 in accordance with Paragraph 1 of Article 86 of the Taiwan
-Mainland People&rsquo;s Relations Act, and may terminate it within a time limit, or require the companies to make corrections. Those
who do not comply or make corrections within the time limit may be punished continuously. However, if a Taiwan company goes to Mainland
China to engage in technical cooperation that does not involve substantial technology outflow, for example, if the Chinese company has
no substantial involvement in product design and related R&amp;D processes, it is not necessary to apply to the Investment Review Committee
in advance. The competent authority may make alterations to the general and prohibited technical cooperation projects either by conducting
regular reviews annually or by conducting special reviews on a case-by-case basis.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to Exchange Control or
Currency Regulations or any Registration Requirements Under Anti-Money Laundering Laws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 23, 1996, the
Ministry of Justice promulgated the Money Laundering Control Act (the &ldquo;Act&rdquo;), which became effective on April 23, 1997. The
Act was amended and became effective on November 7, 2018. The Act is enacted to prevent money laundering activities and combat-related
crimes; bolster anti-money laundering systems; maintain financial stability; increase transparency in money flows; and strengthen international
cooperation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Act, inward and
outward remittances involving currency exchange between NTD and another foreign currency are subject to an annual ceiling of: USD5 million
for individuals and USD50 million for businesses. Any total annual remittance exceeding these thresholds requires approval by the Central
Bank of the Republic of China (CBC). Individual foreign exchange transactions over NTD500,000 must be reported to the CBC.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no other foreign
exchange controls on trade, insurance, and authorized investment transactions, and no limit on repatriation of capital or profits from
portfolio investments. There are also no registration requirements under anti-money laundering laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to Anti-bribery or Corruption</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Bribery and corruption of public
officials in Taiwan are mainly regulated by the Anti-Corruption Act. The Anti-Corruption Act was promulgated by the Ministry of Justice
and took effect on July 15, 1963. It was later amended on June 22, 2016 and became effective on July 1, 2016. The Anti-Corruption Act
lists various behaviors that constitute bribery of public officials. Public officials who commit bribery may be punished by up to life
imprisonment together with a fine of up to NTD100 million. Any private individual who commits bribery of public officials may be punished
by up to seven years of imprisonment together with a fine of up to NTD3 million.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hospitality accepted by a public official is only
allowed under limited circumstances specified in the Integrity and Ethics Directions for Civil Servants. The value of gifts received by
a public official cannot exceed NTD500. Gifts received due to visits to companies cannot exceed NTD3,000. The total value of gifts received
from the same source in one year cannot exceed NTD10,000.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Ethical Corporate Management
Best Practice Principles were promulgated by the Taipei Exchange and became effective on September 3, 2010. The principles were amended
and took effect on May 23, 2019. These principles are applicable to companies, their subsidiaries, any foundation to which the companies&rsquo;
direct or indirect contribution of funds exceeds 50 percent of the total funds received, and other institutions or juridical persons
which are substantially controlled by such companies. The purpose of the principles is to foster a corporate culture of ethical management
and sound development and offer a reference framework for establishing good commercial practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to employment relationships</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Employment Service Act was
promulgated by the Ministry of Labor and became effective on May 8, 1992. It was amended and became effective on November 28, 2018. The
Act is enacted to promote the employment of nationals with a view to enhance social and economic development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Labor Standards Act was promulgated
by the Ministry of Labor and became effective on July 30, 1984. It was amended and took effect on June 10, 2020. The Act is enacted to
provide minimum standards for working conditions, protect workers' rights and interests, strengthen employee-employer relationships and
promote social and economic development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations Relating to Intellectual Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I><U>Patents</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in">The Patent
Act was promulgated by the Ministry of Economic Affairs and took effect on May 29, 1944. It was amended and took effect on May 4, 2022.
The Patent Act is formulated to encourage, protect and utilize the creations of invention, utility model and design in order to promote
industrial development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I><U>Trademarks</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Trademark Act was promulgated
by the Ministry of Economic Affairs and became effective on May 6, 1930. Articles 68, 70, 95, 96 and 97 were amended on May 4, 2022, which
shall take effect on the date designated by Executive Yuan. This Act is enacted for protection of the rights of trademark, certification
mark, collective membership mark, collective trademark and the interests of consumers, maintenance of fair competition, and promotion
of development of the industry and commerce.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I><U>Copyright</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in">The Copyright
Act was promulgated by the Ministry of Economic Affairs and took effect on May 14, 1928. It was amended and took effect on June 15, 2022.
This Act is specifically enacted for the purposes of protecting the rights and interests of authors with respect to their works, balancing
different interests for the common good of society, and promoting the development of national culture. Matters not provided for herein
shall be governed by the provisions of other acts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I><U>Trade Secrets</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in">The Trade
Secrets Act was promulgated by the Ministry of Economic Affairs and became effective on January 17, 1996. It was amended and took effect
on January 15, 2020. This Act is enacted to protect trade secrets, maintain industrial ethics and order in competition, and balance societal
and public interests. Matters not provided for in this Act shall be governed by other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I><U>Regulations Relating to Data Protection</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Personal Data Protection Act was promulgated by the National Development
Council on August 11, 1995 and became effective on January 17, 1996. It was amended on December 30, 2015, and became effective on March
15, 2016. The Personal Data Protection Act (hereinafter, the &ldquo;PDPA&rdquo;) is enacted to regulate the collection, processing and
use of personal data so as to prevent harm on personality rights, and to facilitate the proper use of personal data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Regulations on Taxation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Income Tax Act was promulgated
by the Ministry of Finance and became effective on February 17, 1943. It was amended on April 28, 2021 and became effective on July 1,
2021. Income tax is classified into consolidated income tax and profit-seeking enterprise income tax. For any individual having income
from sources in the Republic of China, consolidated income tax shall be levied in accordance with this Act on his income derived from
sources in the Republic of China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Tax Collection Act was promulgated
by the Ministry of Finance and became effective on October 22, 1976. It was amended on December 17, 2021 and became effective on January
1, 2022. Collection of taxes shall be governed by this Act. Where a profit-seeking enterprise ceases to exist after a merger, the surviving
or newly incorporated profit-seeking enterprise shall pay in full the taxes originally payable by the dissolved enterprise prior to the
merger. Major taxes on corporations <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I><U>Corporate income tax (&ldquo;CIT&rdquo;)</U></I></B></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the total taxable income of
a profit-seeking enterprise is NTD120,000 or less, the profit-seeking enterprise is exempt from tax. If the total taxable income of a
profit-seeking enterprise is more than NTD120,000 but not more than NTD 200,000, the income tax payable is computed based on the following
formula: (Profit-NTD120,000) x 50%. As for a profit-seeking enterprise with the total taxable income of more than NTD200,000, the income
tax rate shall be: Profit x 20%.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><I><U>Profit retention tax</U></I></B></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">An additional profit retention
tax of 5% is imposed on any current earnings of a corporation that remain undistributed by the end of the following year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Bio Industry in
Taiwan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Act for the Development of Biotech and
Pharmaceutical Industry</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2007, Act for the Development
of Biotech and Pharmaceutical Industry (the &ldquo;Statute&rdquo;) was enacted in order to promote the development of the biotech and
pharmaceutical industry in Taiwan so that it can bring about changes in the economic structure of the country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By 2022, the scope of the
Statute covers industries that deals in new drugs, new dosage forms, high-risk medical devices, regenerative medicine, precision medicine,
digital medicine, innovative technology platforms dedicated to biotech and pharmaceutical industry and other strategic biotech and pharmaceutical
products used by human beings, animals and plants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Statute permits biotech
and new pharmaceutical companies to offset up to 30% of their expenses for personnel training and R&amp;D against enterprise income tax
over a period of five years. Up to five percent (5%) of the annual investment amount may be credited against the profit-seeking enterprise
income tax payable by it in the then current year from the first year the biotech and pharmaceutical company has payable profit-seeking
income tax; or up to three percent (3%) of the annual investment amount may be credited against the profit-seeking enterprise&rsquo;s income
tax payable in each of the three years from the first year the biotech and pharmaceutical company has payable profit-seeking income tax.
In addition, based on Article 5, up to 25% of the research and development investment of the biotech companies that engage in research,
development, and manufacturing may be deducted from the amount of profit-seeking enterprise income tax payable for each year within five
years from the year in which the payable profit-seeking enterprise income tax is incurred with the annual deduction capped at 50% of
the tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Statute provides for tax incentives
to high-level professionals and technology investors to participate in company operations and R&amp;D (Art. 7), to elaborate, up to 20%
of the price paid for the shares may be deducted from the payable profit-seeking enterprise income tax for each year within five years
from the year a payable profit-seeking enterprise income tax is incurred with the annual deduction capped at 50% of the tax. Moreover,
if the senior professional staff or technology investors of the biotech companies receive newly issued stock or stock options as a result
of reward or due to technology invested as capital stock and have held shares or stock options, been employed, or provided technical services
cumulatively for two years, they may choose to be taxed at the lower of the &ldquo;transfer price&rdquo; or the &ldquo;current price or
price at which the stock was acquired.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, researchers of schools
and institutions who are the main technology providers of the start-up biotech companies are exempted from the prohibitions against business
operation and part-time employment and the restrictions on shareholding percentage under Article 34 of the Act Governing the Appointment
of Educators and Articles 13 and 14 of the Civil Servants Work Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulations in the PRC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Medical Devices
in the PRC</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Regulations Relating to Classification
of Medical Devices</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulations on the Supervision and Administration of Medical
Devices promulgated on January 4, 2000, effective on June 1, 2014, amended by the State Council on May 4, 2017 and now effective, and
then amended on February 9, 2021 but not yet effective until June 1, 2021 (&ldquo;Regulation on Supervision and Administration of Medical
Devices&rdquo;), the China Food and Drug Administration (&ldquo;CFDA&rdquo;) of the State Council shall be responsible for the national
administration and supervision of medical devices of the PRC and its local counterparts take charge of the local administration and supervision
of medical devices of the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under this regulation, medical
devices have been classified into three categories based on the degree of risk. Class I medical devices shall refer to those devices
with low level of risks and whose safety and effectiveness can be ensured through routine administration. Class II medical devices shall
refer to those devices with moderate risks that must be strictly controlled and regulated to ensure their safety and effectiveness. Class
III medical devices shall refer to those devices with relatively high risks that must be strictly controlled and regulated through special
measures to ensure their safety and effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, the products we are approved by NMPA to manufacture and sell
are Class I medical device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Registration and Filings of Medical
Devices</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt; text-align: justify">Pursuant to the Regulations on the Supervision and Administration of Medical
Devices (&ldquo;the Supervision and Administration of Medical Devices&rdquo;), which was amended and came into effect on May 4, 2017.
Then it was amended on February 9, 2021 and came into effect on June 1, 2021, Class I medical devices are subject to filing administration,
and Class II and Class III medical devices are subject to pre-approval registration administration. A registration certificate for Class
II and Class III medical devices are issued upon approval, which is valid for five years and may be renewed six months prior to its expiration
date. In addition, a registrant or record-filing party of medical devices may manufacture medical devices on its own or entrust enterprises
that meet the provisions hereof and have corresponding conditions to manufacture medical devices. In the event of entrusted manufacture
of medical devices, the registrant or record-filing party of medical devices shall be responsible for the quality of medical devices manufactured
under entrustment, and strengthen management of the manufacturing activities of the entrusted manufacturers to ensure that they carry
out manufacturing in accordance with statutory requirements. The registrant or record-filing party of medical devices shall enter into
an entrustment agreement with the entrusted manufacturer to specify the rights, obligations and responsibilities of both parties. The
entrusted manufacturer shall organize manufacture of medical devices in accordance with laws and regulations, GMP, compulsory standards,
product technical requirements and the entrustment agreement, be responsible for the manufacturing activities and accept the supervision
of the entrusting party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Clinical trials are not required
for the filing of the Class I medical devices, but necessary for the registration of Class II and Class III medical device with certain
exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among our products, A<SUP>+</SUP>Pre
and AC-1000 are Class I medical devices and have passed NMPA registration review. A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and
A<SUP>+</SUP>SCDrop are Class II medical devices but do not need to conduct clinical trials. A<SUP>+</SUP>LCGuard is Class III medical
device and is required to conduct clinical trials before completing the registration process. We have already started the registration
process and plan to begin the clinical research by the end of June 2025. Specifically, in June 2025, the Company and the CRO plan to collaborate
to draft the clinical research protocol and begin preparing the necessary equipment, consumables, reagent kits, and other materials for
the study. By the end of September 2025, the clinical research protocol is expected to pass ethical review and receive ethics committee
approval. In October 2025, we plan to initiate the trial stage of the clinical research, with completion anticipated within six months.
Based on the results of clinical research, we plan to formulate a work plan for large-scale clinical trials and proceed with the clinical
trial. We anticipate that we will obtain the required registration certificate by October 2027.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Production License for Medical Devices</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulation on the Supervision and Administration of Medical
Devices promulgated on July 30, 2014 and came into effect on October 1, 2014, as amended in 2017 and came into effect on May 4, 2017 (amended
on February 9, 2021, came into effect on June 1, 2021), and the Administrative Measures on the Production Supervision of Medical Devices
promulgated on July 30, 2014 and came into effect on October 1, 2014, as amended in March 10, 2022 and came into effect on May 1, 2022,
manufacturers engaged in the manufacturing of Class I medical devices are subject to production filing administration and receive production
filing certificates upon satisfaction of filing requirements; while those engaged in the manufacturing of Class II and Class III medical
devices are subject to pre-approval licensing administration and receive medical device production licenses upon receipt of approval for
licensing. A medical device production license is valid for five years and may be renewed six months prior to its expiration date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining production
licenses from local government authorities, our product must pass NMPA&rsquo;s registration review. Among our products, A<SUP>+</SUP>Pre
and AC-1000 and their corresponding chips have passed NMPA registration review, A<SUP>+</SUP>CellScan, A<SUP>+</SUP>CellScan Chip, and
A<SUP>+</SUP>SCDrop are at the registration application stage, the four matching immunostaining kits are under NMPA registration review.
A<SUP>+</SUP>LCGuard is required to conduct clinical trials before completing the registration process. We have already started the registration
process and plan to begin clinical research by the end of June 2025. Specifically, in June 2025, the Company and the CRO plan to collaborate
to draft the clinical research protocol and begin preparing the necessary equipment, consumables, reagent kits, and other materials for
the study. By the end of September 2025, the clinical research protocol is expected to pass ethical review and receive ethics committee
approval. In October 2025, we plan to initiate the trial stage of the clinical research, with completion anticipated within six months.
Based on the results of clinical research, we plan to formulate a work plan for large-scale clinical trials and proceed with the clinical
trial. We anticipate that we will obtain the required registration certificate by October 2027.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a manufacturer
of medical devices shall satisfy the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">possessing production sites, environmental conditions, production equipment and professional technicians
that are suitable for such medical device produced;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">possessing organizations or professional examination staff and examination equipment that carry out quality
examination for such medical device produced;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">formulating a management system which ensures the quality of such medical device;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">having capability of after-sale services that is suitable for such medical device produced; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">satisfying the requirements as prescribed in production R&amp;D and production technique documents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus, we have obtained the license for the
production of the Class I medical device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Production and Quality Management of
Medical Devices</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the
Administrative Measures on the Supervision of the Production of Medical Devices promulgated on December 29, 2014 and came into
effect on March 1, 2015, as amended in March 10, 2022 and came into effect on May 1, 2022, and the Standards on Production and
Quality Management of Medical Devices promulgated by the CFDA on December 29, 2014 and came into effect on March 1, 2015, an
enterprise engaged in the production of medical devices shall establish and effectively maintain a quality control system in
accordance to the requirements of the Standards on Production and Quality Management of Medical Devices. The enterprise engaged in
the production of medical devices shall regularly conduct comprehensive self-inspection on the operation of quality management
system and submit this report to the local food and drug supervision and administration authorities before the end of every year.
The enterprise shall also establish its procurement control procedure and assess its suppliers by establishing an examination system
to ensure the purchased products are in compliance with the statutory requirements. The enterprise shall apply risk management to
the whole process of design and development, production, sales and after-sale services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to The Notice of Four
Guidelines including On-site Inspection Guidelines for the standards on Production and Quality Management of Medical Devices promulgated
by the CFDA on September 25, 2015 and came into effect on September 25, 2015, during the course of on-site verification of the registration
of medical devices and on-site inspection of production license t(including change production license), the inspection team shall, in
accordance with the guidelines, issue recommended conclusions for on-site inspections, which shall be divided into &ldquo;Passed,&rdquo;
&ldquo;Failed&rdquo; and &ldquo;Reassessment after rectification.&rdquo; During the supervision and inspection, if it is found that the
requirements of the key items or ordinary items that may have direct impact on product quality are not satisfied, the enterprise shall
suspend production and go through rectification. If it is found that the requirements of the ordinary items are not satisfied, and it
does not directly affect product quality, the enterprise shall rectify in a prescribed time. The regulatory authorities will examine
and verify the recommended conclusions and on-site inspection materials submitted by the inspection group and issue the final inspection
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Good Clinical Practice for Medical Devices</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 24, 2022, the CFDA and the National Health and Family Planning
Commission jointly promulgated the Good Clinical Practice for Medical Devices, which became effective as of May 1, 2022. The regulation
includes full procedures of clinical trial of medical devices, including, among others, the protocol design, conduction, monitoring, verification,
inspection, and data collection, recording, analysis and conclusion and reporting procedure of a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt; text-align: justify">For conducting clinical trials
of medical devices, an applicant shall organize to formulate scientific and reasonable clinical trial protocol based on the categories,
risks and intended use of the medical devices for the clinical study. The applicant shall be responsible for organizing to develop and
revise of the researcher&rsquo;s manual, clinical trial protocol, informed consent form, case report form, relevant standard operating
procedures and other relevant documents, and shall be responsible for organizing necessary trainings for the clinical trials. The applicant
shall select the clinical trial institutions and its researchers from the qualified medical device clinical trial institutions according
to the characteristics of the medical devices to be used in the clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an applicant for clinical
trials of medical devices, we are responsible for initiating, applying, organizing and monitoring such clinical trials, and shall be
responsible for the authenticity and reliability of the clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Operation License for Medical Device</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Supervision and Administration of Medical Devices, filing
and licensing are not required for the operation of Class I medical devices. Operators engaged in the operation of Class II medical devices
are subject to filing administration and will receive medical device operation filing certificate upon satisfaction of filing requirement,
while operators engaged in the operation of Class III medical devices are subject to pre-approval licensing administration and will receive
medical device operation license upon receipt of approval for licensing. A medical device operation license is valid for five years and
may be renewed six months prior to its expiration date</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">To engage in business operations
of medical devices, the following requirements shall be met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Having a quality control institution or staff corresponding to the business scope and scale, and the staff
shall have relevant education or professional titles certified by the state;</TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Having an operation and storage premises corresponding to the business scope and scale;</TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Having storage conditions corresponding to the business scope and scale; warehouses are not required if
all storage is commissioned to other operators of medical devices;</TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Having a quality control system corresponding to the medical devices concerned; and</TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possessing
                                            the capability of professional guidance, technical training and after-sale service corresponding
                                            to the medical devices it operates; or it has come into an agreement on technical support
                                            with a relevant institution.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An enterprise to be engaged
in business operations of Category III medical devices shall also have a computerized information management system compliant with quality
standards to ensure traceability of products. An enterprise to be engaged in business operations of Category I or Category II medical
devices is encouraged to set up such a system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Special Procedures for Examination and
Approval of Innovative Medical Devices</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 2017, the General
Office of the CPC Central Committee and the General Office of the State Council issued the Opinions on Deepening the Reform of the Evaluation
and Approval Systems and Encouraging Innovation on Drugs and Medical Devices, which aims to encourage the innovation for medical devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Opinions, the
priority review and approval will be applicable to innovative medical devices supported by the National Science and Technology Major
Projects and the National Key R&amp;D Program of China, and the clinical trials of which having been conducted by the National Clinical
Research Center and approved by the management department of National Clinical Research Center. Pursuant to the Special Procedures for
Examination and Approval of Innovative Medical Devices which were promulgated by the NMPA on November 2, 2018 and came into effect on
December 1, 2018, special procedures shall be applicable to the examination and approval for medical devices in the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">if the applicant legally owns the invention patent of the core technology of the product through its technological
innovation activities in the PRC, or legally obtained the invention patent or the right of use thereof through transfer in the PRC, and
that the interval between the date of application for the special examination and approval of innovative medical devices to the date of
authorized publication should not exceed five years; or the patent administration department of the State Council has disclosed the application
for the invention patent of the core technology and the Patent Search and Consultation Center of the National Intellectual Property Administration
of the PRC has issued the patent search report setting out the novelty and innovation of the core technology solution of the product;</TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">the applicant has developed the prototype product and completed the preliminary research under a true
and controllable process that generated complete and traceable data; and</TD></TR></TABLE>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"><FONT STYLE="font-family: Symbol"></FONT></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the product has major working mechanism
or mechanism of action which is the first of its kind in the PRC, has fundamental improvement in product performance or safety compared
with similar products, is of an internationally leading standard in terms of techniques and has significant clinical value. The Center
for Medical Device Evaluation of the NMPA should give priority to the innovative medical devices in their technical review upon receiving
the registration application, after which the NMPA will give priority to the product in their administrative approval.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I><U>Advertisements of Medical Devices</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulations
on Tentative Measures for the Censorship of Advertisement for Drugs, Medical Devices, Dietary Supplements, Food Formula for Special Medical
Purpose promulgated by SAMR on December 24, 2019 and came into effect on March 1, 2020, the State Administration for Market Regulation
is responsible for organizing and guiding the review of advertisements for drugs, medical devices, health foods and formula foods for
special medical purposes. The administrations for market regulation and drug administrations (hereinafter referred to as the &ldquo;advertisement
review authorities&rdquo;) of all provinces, autonomous regions and centrally administered municipalities shall be responsible for the
review of advertisements for drugs, medical devices, health food and formula food for special medical purposes, and may entrust other
administrative authorities to implement review of advertisements pursuant to the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity period of the advertisement
approval number for drugs, medical devices, health food and formula food for special medical purposes shall be consistent with the shortest
validity period of the product registration certificate, filing certificate or production license. If no valid period is prescribed in
the product registration certificate, filing certificate or production license, the valid period of the advertisement approval number
shall be two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advertisements for drugs, medical
devices, health food and formula food for special medical purposes shall be true and legitimate and shall not contain any false or misleading
contents. Advertisers shall be responsible for the veracity and legitimacy of the contents of advertisements for drugs, medical devices,
health food and formula food for special medical purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I><U>National Medical Insurance Program</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Medical Insurance
Program (NMIP) was adopted pursuant to the Decision of the State Council on the Establishment of the Urban Employee Basic Medical Insurance
Program issued by the State Council on December 14, 1998, under which all employers in urban cities are required to enroll their employees
in the Urban Employee Basic Medical Insurance Program and the insurance premium is jointly contributed by the employers and employees.
Pursuant to the Opinions on the Establishment of the New Rural Cooperative Medical System forwarded by the General Office of the State
Council on January 16, 2003, China launched the New Rural Cooperative Medical System to provide medical insurance for rural residents
in selected areas which has since spread to the whole nation. The State Council promulgated the Guiding Opinions of the State Council
about the Pilot Urban Resident Basic Medical Insurance on July 10, 2007, under which urban residents of the pilot district, rather than
urban employees, may voluntarily join Urban Resident Basic Medical Insurance. In 2015, the PRC government announced the Outline for the
Planning of the National Medical and Health Service System (2015-2020) which aims to establish a basic medical and health care system
that covers both rural and urban citizens by 2020. On January 3, 2016, the State Council issued the Opinions on Integrating the Basic
Medical Insurance Systems for Urban and Rural Residents to integrate the Urban Resident Basic Medical Insurance and the New Rural Cooperative
Medical System and the establishment of a unified Basic Medical Insurance for Urban and Rural Residents, which will cover all urban and
rural non-working residents expect for rural migrant workers and persons in flexible employment arrangements who participate in the basic
medical insurance for urban employees. The National Healthcare Security Administration (NHSA) is the responsible agency that makes the
final determination on whether a product may be covered by the NMIP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With regard to reimbursement for medical devices
and diagnostic tests, the Notice of Opinion on the Diagnosis and Treatment Management, Scope and Payment Standards of Medical Service
Facilities Covered by the National Urban Employees Basic Medical Insurance Scheme (Lao She Bu Fa [1999] No. 22) prescribes the coverage
of diagnostic and treatment devices and diagnostic tests where part of the fees is paid through the basic medical insurance scheme. It
also includes a negative list that precludes certain devices and medical services from governmental reimbursement, which includes (i)
examination and treatment items by applying large medical devices such as positron emission tomography (PET), electron beam CT, ophthalmic
excimer laser therapy instruments, etc.; (ii) rehabilitation appliances such as spectacles, artificial dentures, artificial eyes, artificial
limbs and hearing aids, etc.; (iii) medical devices for health care, massage, physical examination and treatment for own use; and (iv)
disposable materials for medical use that cannot be charged separately as stipulated by price authorities of all provinces. Detailed reimbursement
coverage and rate for medical devices and medical services (including diagnostic tests and kits) are subject to each province&rsquo;s
local policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, every covered individual
is eligible to request reimbursement from the NMIP for medical expenses, but the reimbursement rate and coverage are determined on a case-by-case
basis. Based on our understanding of applicable PRC laws and regulations, the reimbursement rate and coverage for certain products are
different for each individual and are subject to the following factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Whether the product is covered by the NMIP or whether the product is part of a procedure or service that
is covered by the NMIP. If not covered, the NMIP may deny the request for reimbursement or reduce the reimbursement rate and coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40pt; text-align: justify; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">The region and status of individuals seeking reimbursement. NMIP varies in different regions and types,
leading to different reimbursement ratios. For instance, the basic medical insurance for urban employees generally covers around 50% to
80% of basic medical expenses, while the rural resident medical insurance typically covers around 60% to 80%;</TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Hospital level. The reimbursement ratio of NMIP is related to the level and grade of hospitals performing
services. For example, a level 3 hospital&#8217;s service is generally more expensive than primary healthcare institutions, and the reimbursement
ratio for level 3 hospitals is lower than for primary healthcare institutions. Typically, an individual who received services from a primary
care provider can get a relatively high reimbursement rate and coverage for medical expenses;</TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Individual payment status. The reimbursement ratio of NMIP is also related to the individual payment status.
If an individual contributes more and for a longer period of time, the reimbursement ratio will correspondingly increase; and</TD></TR></TABLE>

<P STYLE="margin: 0pt 0pt 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Special diseases or major illnesses. For certain special diseases or major illnesses, the reimbursement
ratio of medical insurance may be correspondingly increased, or special medical subsidies or assistance may be provided to alleviate the
financial burden on patients by NHSA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus, our products are not covered by any
national or provincial medical insurance programs. Currently, A+LCGuard is the only product we are applying for NMIP coverage. There is
no fixed timeline to get a product covered by NMIP, as the application process involves multiple procedures and interactions with NHSA
that are beyond the applicant&rsquo;s control. To our knowledge, the application process may take one to two years to complete. Currently,
A+LCGuard is the only product we are applying for NMIP coverage. Although we strive to make our products covered by the NMIP in the future,
there is no guarantee that the NHSA will approve our applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Export Registration</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Administrative Measures on the Supervision of the Production
of Medical Devices promulgated on December 29, 2014 and came into effect on March 1, 2015, as amended in March 10, 2022 and came into
effect on May 1, 2022, in accordance with the spirit of the Notice of Guo Ban Fa [94] No. 66 of the State Council, conducts inspections
of safety and legality of the exported products manufactured by domestic enterprises, grants legitimate production license in China (if
these products are sold within Chinese territory) and files the relevant product information by its branches at the level of a districted
city for recordation. In accordance with international practice, the quality of exported medical devices is mainly supervised by the importing
countries. However, some importing countries/regions may require exporting enterprises to provide Medical Device Product Export Sales
Certificates issued by the CFDA. Pursuant to Announcement on Issuing the Provisions on the Administration of Medical Device Product Export
Sales Certificates, promulgated by the CFDA and effective on September 1, 2015, such exporting enterprises may apply to the provincial
departments of the CFDA at the places where enterprises are located for Medical Device Product Export Sales Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The premise of obtaining Medical
Device Product Export Sales Certificates is that the relevant production enterprises have obtained medical device product registration
certificates and production licenses or have undergone the formalities for recordation and production recordation of medical device products
in China. The valid period of Medical Device Product Export Sales Certificates, except being specified for one time use, shall not expire
after the earliest deadline of any certificate among various certificates submitted by the enterprise amid the application materials,
and shall be no longer than two years. Where the relevant materials submitted by an enterprise change, the enterprise shall report to
the certificate issuing department in a timely manner. Where the relevant materials change, or the Medical Device Product Export Sales
Certificate still needs to be used after its expiration, the enterprise shall apply for a new Medical Device Product Export Sales Certificate.
Where the CFDA find that any relevant enterprises fail to meet the requirements of relevant regulations on production, they shall downgrade
the credit ratings of such enterprises to lower levels; or, when any enterprises are considered failing to meet the requirements for
issuance of certificates anymore, or the relevant materials submitted by the enterprises change, the provincial CFDA departments shall
notify the relevant information in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to M&amp;A Rules and
Overseas Listings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2006, six PRC
regulatory agencies, including the China Securities Regulatory Commission, or the CSRC, adopted the Regulations on Mergers of Domestic
Enterprises by Foreign Investors, or the M&amp;A Rules, which became effective on September 8, 2006 and was amended on June 22, 2009.
Foreign investors shall comply with the M&amp;A Rules when they purchase equity interests of a domestic company or subscribe the increased
capital of a domestic company, thus changing the nature of the domestic company into a foreign-invested enterprise; or when the foreign
investors establish a foreign-invested enterprise in the PRC, purchase the assets of a domestic company and operate the assets; or when
the foreign investors purchase the asset of a domestic company, establish a foreign-invested enterprise by injecting such assets and
operate the assets. The M&amp;A Rules purport, among other things, to require offshore special purpose vehicles formed for overseas listing
purposes through acquisitions of PRC domestic companies and controlled by PRC companies or individuals, to obtain the approval of the
CSRC prior to publicly listing their securities on an overseas stock exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Anti-Monopoly
Law which took effect as of August 1, 2008, where the concentration of business operators reaches the filing thresholds stipulated by
the State Council, business operators shall file a declaration with the SAMR, and no concentration shall be implemented until the SAMR
clears the anti-monopoly filing. Pursuant to the Notice of the General Office of the State Council on the Establishment of the Security
Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors and the Security Review Rules issued by the General
Office of the State Council on February 3, 2011 and became effective on March 3, 2011, mergers and acquisitions by foreign investors
that raise &ldquo;national defense and security&rdquo; concerns, and mergers and acquisitions through which foreign investors may acquire
de facto control over domestic enterprises that raise &ldquo;national security&rdquo; concerns, are subject to strict review by the PRC
government authorities. On August 25, 2011, the MOFCOM issued the Provisions of the Ministry of Commerce for the Implementation of the
Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, which provides that if a foreign investor&rsquo;s
merger or acquisition of a domestic enterprise falls within the scope of security review specified in the Notice of the General Office
of the State Council on the Establishment of the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign
Investors, the foreign investor shall file an application with MOFCOM for security review. Whether a foreign investor&rsquo;s merger
or acquisition of a domestic enterprise falls within the scope of security review or not shall be determined based on the substance and
actual influence of the merger or acquisition transaction. No foreign investor is allowed to substantially avoid the security review
in any way, including but not limited to, holding shares on behalf of others, trust arrangements, multi-level reinvestment, leasing,
loans, contractual control, or overseas transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2023, the
CSRC released Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the &ldquo;Trial Measures&rdquo;)
which came into effect on March 31, 2023. Pursuant to Trial Measures, a PRC domestic company that seeks to offer and list securities
in overseas markets, either in direct or indirect overseas offering, shall fulfil the filing procedure with the CSRC per requirement
of the Trial Measures, submit relevant materials that contain a filing report and a legal opinion, and provide truthful, accurate and
complete information on the shareholder and etc. Direct overseas offering and listing by domestic companies refers to such overseas offering
and listing by a joint-stock company incorporated domestically. Any overseas offering and listing made by an issuer that meets both the
following conditions will be determined as indirect offering and listing in overseas market and, therefore, be subject to filing requirement:
(i) 50% or more of the issuer&rsquo;s operating revenue, total profit, total assets or net assets as documented in its audited consolidated
financial statements for the most recent accounting year is accounted for by domestic companies; and (ii) the main parts of the issuer&rsquo;s
business activities are conducted in the Mainland China, or its main places of business are located in the Mainland China, or the senior
managers in charge of its business operation and management are mostly Chinese citizens or domiciled in the Mainland China. The determination
as to whether or not an overseas offering and listing by domestic companies is indirect, shall be made on substance over form basis.
In addition, initial public offerings or listings in overseas markets or subsequent securities offerings and listing of an issuer in
overseas market other than where it has offered and listed shall be filed with the CSRC within 3 working days after the relevant application
is submitted overseas. Subsequent securities offerings of an issuer in the same overseas market where it has previously offered and listed
securities shall be filed with the CSRC within 3 working days after such offering is completed. A PRC domestic company that seeks to
directly or indirectly list its domestic assets in overseas markets through single or multiple acquisitions, share swaps, transfers of
shares or other means, shall also fulfil the filing procedure as prescribed above. Furthermore, upon the occurrence of any of the material
events specified below after an issuer has offered and listed securities in an overseas market, the issuer shall submit a report thereof
to CSRC within 3 working days after the occurrence and public disclosure of the event: (i) change of control; (ii) investigations or
sanctions imposed by overseas securities regulatory agencies or other relevant competent authorities; (iii) change of listing status
or transfer of listing segment; (iv) voluntary or mandatory delisting. Where an issuer&rsquo;s main business undergoes material changes
after overseas offering and listing, and is therefore beyond the scope of business stated in the filing documents, such issuer shall
submit to the CSRC an ad hoc report and a relevant legal opinion issued by a domestic law firm within 3 working days after occurrence
of the changes. However, the PRC Companies already listed overseas before effectiveness of Trial Measures are not required to submit
any records with the CSRC until they have successive refinancing demand or other filing requirement. A six-month transition will be given
to PRC domestic enterprises that have obtained the approval of overseas regulatory bodies or exchanges since implementation date of the
Trial Measure but have not completed the overseas listing. If they fail to complete the overseas listing within six months, they should
file records with CSRC according to the requirements. The Trial Measure further stipulate that CSRC may order rectification, issue warnings,
and impose a fine between RMB1 million and RMB10 million if an applicant fails to fulfill the filing requirements with the CSRC or conducts
an overseas offering or listing in violation of the Trial Measure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 24, 2023, the
CSRC, together with other PRC government authorities, released the Provisions on Strengthening the Confidentiality and Archives Administration
Related to the Overseas Securities Offering and Listing by Domestic Enterprises (the &ldquo;Confidentiality and Archives Administration
Provisions&rdquo;), which came into effect on March 31, 2023. The Confidentiality and Archives Administration Provisions require, among
others, that PRC domestic enterprises seeking to offer and list securities in overseas markets, either directly or indirectly, shall establish
the confidentiality and archives system, and shall complete approval and filing procedures with competent authorities, if such PRC domestic
enterprises or their overseas listing entities provide or publicly disclose documents or materials involving state secrets and work secrets
of PRC government agencies to relevant securities companies, securities service institutions, overseas regulatory agencies and other entities
and individuals. It further stipulates that providing or publicly disclosing documents and materials which may adversely affect national
security or public interests, and accounting files or copies of important preservation value to the state and society shall be subject
to corresponding procedures in accordance with relevant laws and regulations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Foreign Investment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investment activities in the PRC by foreign investors are principally governed
by the Industry Guidelines of Encouraged Foreign Investment, or the Industry Guidelines, effective on January 27, 2021, and the Special
Administrative Measures for Entrance of Foreign Investment (Negative List), or the Negative List, most recently amended on April 8, 2024
and effective on September 6, 2024, and together with the PRC Foreign Investment Law, which took effect on January 1, 2020, and its respective
implementation rules and ancillary regulations. The Industry Guidelines and the Negative List lay out the basic framework for foreign
investments in China, classifying businesses into three categories with regard to foreign investments: &ldquo;encouraged&rdquo;, &ldquo;restricted&rdquo;
and &ldquo;prohibited&rdquo;. Industries not listed in the Industry Guidelines or the Negative List are generally deemed as falling into
a fourth category &ldquo;permitted&rdquo; unless specifically restricted by other PRC laws. The Negative List specifies that Investment
in Internet news service, Internet publishing service, Internet audio-visual program service, cyber culture operation (except for music)
and Internet information dissemination service (except for contents opened up in China&rsquo;s WTO commitments) shall be prohibited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the PRC Foreign
Investment Law, foreign investments shall enjoy pre-entry national treatment, except for those foreign-invested entities that operate
in industries deemed to be either &ldquo;restricted&rdquo; or &ldquo;prohibited&rdquo; in the &ldquo;negative list.&rdquo; While foreign
investors shall refrain from investing in any of the foreign &ldquo;prohibited&rdquo; industries, foreign-invested entities operating
in foreign &ldquo;restricted&rdquo; industries shall require market entry clearance and other approvals from relevant PRC governmental
authorities. Furthermore, the PRC Foreign Investment Law provides that foreign-invested enterprises that have been established before
the implementation of PRC Foreign Investment Law according to the then existing laws regulating foreign investments may maintain their
structure and corporate governance within five years after the implementation of the PRC Foreign Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 19, 2020, MOFCOM
and NDRC released the Measures for the Security Review of Foreign Investments, which took effect on January 18, 2021. For foreign investments
within the following scope, foreign investors or the relevant parties in China (hereinafter referred to collectively as the &ldquo;parties
concerned&rdquo;) shall take the initiative to declare to the office of the working mechanism prior to implementation of the investments:&hellip;(II)
investments in important agricultural products, important energy and resources, important equipment manufacturing, important infrastructure,
important transport services, important cultural products and services, important information technology and Internet products and services,
important financial services, key technologies and other important fields relating to national security, and obtaining the actual controlling
stake in the investee enterprise. Prior to a decision made by the office of the working mechanism, the parties concerned shall not make
the investment. The parties concerned shall not make the investment unless the office of the working mechanism decides that security
review is not required. Where the declared foreign investment affects national security, a decision on prohibiting the investment shall
be made. Foreign-invested entities of the group have businesses that conduct Internet services, but not related to national security
within the scope of the regulations above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 26, 2019, the
State Council promulgated the Regulations for Implementing the PRC Foreign Investment Law, which took effect on January 1, 2020. The
implementation regulations further clarified that the State encourages and promotes foreign investments, protects the lawful rights and
interests of foreign investors, regulates foreign investment administration, continues to optimize foreign investment environment, and
advances a higher-level opening.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2019, MOFCOM
and SAMR jointly promulgated the Measures for Information Reporting on Foreign Investment, which became effective on January 1, 2020.
Pursuant to the Measures for Information Reporting on Foreign Investment, where a foreign investor carries out investment activities
in China directly or indirectly, the foreign investor or the foreign-invested enterprise shall submit the investment information to the
competent commerce department.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations relating to Anti-Monopoly and
Competition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 11, 2020, the
Anti-Monopoly Commission of the State Council issued Anti-Monopoly Compliance Guideline for Business Operators, which requires business
operators to establish anti-monopoly compliance management systems under the PRC Anti-Monopoly Law to manage anti-monopoly compliance
risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 17, 2021, the State
Administration for Market Regulation, or the SAMR, issued a discussion draft of Provisions on the Prohibition of Unfair Competition on
the Internet, under which business operators should not use data or algorithms to hijack traffic or influence users&rsquo; choices, or
use technical means to illegally capture or use other business operators&rsquo; data. Furthermore, business operators are not allowed
to (i)&nbsp;fabricate or spread misleading information to damage the reputation of competitors, or (ii)&nbsp;employ marketing practices
such as fake reviews or use coupons or &ldquo;red envelopes&rdquo; to entice positive ratings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 7, 2021, the
Anti-Monopoly Commission of the State Council published Anti-Monopoly Guidelines for the Internet Platform Economy Sector that specified
circumstances where an activity of an internet platform will be identified as monopolistic act as well as concentration filing procedures
for business operators. According to the PRC Anti-Monopoly Law, if a business operator carries out a concentration in violation of the
law, the relevant authority shall order the business operator to terminate the concentration, dispose of the shares or assets or transfer
the business within a specified time limit, or take other measures to restore the pre-concentration status, and impose a fine of up to
RMB500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 23, 2021, the
Standing Committee of the National People&rsquo;s Congress issued a discussion draft of the amended Anti-Monopoly Law, which proposes
to increase the fines for illegal concentration of business operators to no more than ten&nbsp;percent of its last&nbsp;year&rsquo;s
sales revenue if the concentration of business operator has or may have an effect of excluding or limiting competitions, or a fine of
up to RMB5 million if the concentration of business operator does not have an effect of excluding or limiting competition. The draft
also proposes that the relevant authority shall investigate a transaction where there is any evidence that the concentration has or may
have the effect of eliminating or restricting competitions, even if such concentration does not reach the filing threshold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>Regulations Relating to Cybersecurity
and Privacy Protection</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC Constitution states
that PRC law protects the freedom and privacy of communications of citizens and prohibits infringement of these rights. In recent years,
PRC government authorities have enacted legislation on the Internet use to protect personal information from any unauthorized disclosure.
Under the Several Provisions on Regulating the Market Order of Internet Information Services which was promulgated by MIIT on December
29, 2011, an Internet content service operator may not collect any user personal information or provide any such information to third
parties without the consent of a user, unless otherwise stipulated by laws and administrative regulations. An Internet content service
operator must expressly inform the users of the method, content and purpose of the collection and processing of such user personal information
and may only collect such information necessary for the provision of its services. An Internet content service operator is also required
to properly keep the user personal information, and in case of any leak or likely leak of the user personal information, the Internet
content service operator must take immediate remedial measures and, in severe circumstances, to make an immediate report to the telecommunication
regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Decision
on Strengthening Network Information Protection, which was promulgated by the Standing Committee of NPC on December 28, 2012, provides
that electronic information that is able to identify personal identities of citizens or is concerned with personal privacy of citizens
is protected by law and shall not be unlawfully obtained or provided. Internet content service operators collecting or using personal
electronic information of citizens shall specify purposes, manners and scopes of information collection and use, obtain the consent of
citizens concerned, and strictly keep confidential personal information collected. Internet content service operators are prohibited
from disclosing, tampering with, damaging, selling or illegally providing others with personal information collected. Technical and other
measures are required to be taken by Internet content service operators to prevent personal information collected from unauthorized disclosure,
damage or being lost. Internet content service operators are subject to legal liability, including warnings, fines, confiscation of illegal
gains, revocation of licenses or filings, closing of websites concerned, public security administration punishment, criminal liabilities,
or civil liabilities, if they violate relevant provisions on Internet privacy.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Order for
the Protection of Telecommunication and Internet User Personal Information which was promulgated by MIIT on July 16, 2013, any collection
and use of users&rsquo; personal information must be subject to the consent of the users, abide by the principles of legality, rationality
and necessity and be within the specified purposes, methods and scopes. Pursuant to the Ninth Amendment to the Criminal Law which was
issued by the Standing Committee of NPC on August 29, 2015 and became effective on November 1, 2015, any Internet service provider that
fails to fulfil obligations to manage information and network security as required by applicable laws and refuses to rectify upon orders
from government authorities, will be subject to the criminal penalty if such failure (i) causes dissemination of illegal information in
large scale; (ii) causes user information leaks resulting in severe consequences; (iii) causes serious loss of evidence to criminal investigations;
or (iv) implicates other severe circumstances. Moreover, any individual or entity that (i) sells or provides personal information to others
in violation of applicable laws, or (ii) steals or illegally obtains any personal information, in either case implicating severe circumstances,
will be subject to the criminal penalty. The PRC government, however, has the power and authority to order Internet content service operators
to turn over personal information if an Internet user posts any prohibited content or engages in illegal activities on the Internet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To further regulate cybersecurity
and privacy protection, the PRC Cybersecurity Law which was promulgated by the Standing Committee of NPC on November 7, 2016 and took
effect on June 1, 2017, provides that: subject to certain exceptions, (i) to collect and use personal information, network operators
must follow the principles of legitimacy, rightfulness, and necessity, disclose their rules of data collection and use, clearly express
the purposes, means, and scope of collecting and using the information, and obtain the consent of the persons whose data is gathered;
(ii) network operators can neither gather personal information unrelated to the services they provide, nor gather or use personal information
in violation of the provisions of laws and administrative regulations or the scopes of consent given by the persons whose data is gathered,
and must dispose of personal information they have saved in accordance with the provisions of laws and administrative regulations and
agreements reached with users; (iii) network operators cannot divulge, tamper with, or damage the personal information they have collected,
and cannot provide the personal information to others without the consent of persons whose data is collected. According to the PRC Cybersecurity
Law, personal information refers to all kinds of information that are recorded electronically or that can otherwise be used to independently
identify or be combined with other information to identify natural persons&rsquo; personal information, including but not limited to
natural persons&rsquo; names, dates of birth, identification numbers, biologically identified personal information, addresses, and telephone
numbers. Any Internet information services provider that violates these privacy protection requirements under the PRC Cybersecurity Law
and related laws and regulations may be ordered to turn in illegal gains generated from unlawful operations and pay a fine of no less
than one but no more than ten times of the illegal gains and may be ordered to cease the relevant business operations when the violation
is serious.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2016, the CAC
issued the Administrative Provisions on Mobile Internet Applications Information Services, which became effective on August 1, 2016,
to further strengthen the regulation of the mobile app information services. Pursuant to these provisions, owners or operators of mobile
apps that provide information services are required to be responsible for information security management, establish and improve the
protective mechanism for user information, observe the principles of legality, rightfulness and necessity, and expressly state the purpose,
method and scope of, and obtain user consent to, the collection and use of users&rsquo; personal information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 8, 2017, the Supreme
People&rsquo;s Court and the Supreme People&rsquo;s Procuratorate issued the Interpretations of the Supreme People&rsquo;s Court and
the Supreme People&rsquo;s Procuratorate on Several Issues Concerning the Application of Law in the Handling of Criminal Cases Involving
Infringement of Citizens&rsquo; Personal Information, or the Personal Information Interpretations, which became effective on June 1,
2017. The Personal Information Interpretations provides more practical conviction and sentencing criteria for the infringement of citizens&rsquo;
personal information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 23, 2019, the
PRC Office of the Central Cyberspace Affairs Commission and other three authorities jointly issued the Circular on the Special Campaign
of Correcting Unlawful Collection and Usage of Personal Information via Apps. Pursuant to this circular, (i) app operators are prohibited
from collecting any personal information irrelevant to their services; (ii) information collection and usage policy should be presented
in a simple and clear way, and such policy should be consented by the users voluntarily, and; (iii) authorization from users should not
be obtained by coercing users with default or bundling clauses or making consent a condition of service. App operators violating these
rules can be ordered by authorities to correct their noncompliance within a given period of time, be publicly reported, or ordered to
quit its operation or cancel its business license or operational permits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2019, the Ministry
of Public Security promulgated the Guidelines for Internet Personal Information Security Protection, which establishes the management
mechanism, security technical measures and business workflows for personal information security protection. On August 22, 2019, the CAC
promulgated the Provisions on the Cyber Protection of Children&rsquo;s Personal Information which requires, among others, that network
operators who collect, store, use, transfer and disclose personal information of children under the age of 14 shall establish special
rules and user agreements for the protection of children&rsquo;s personal information, inform the children&rsquo;s guardians in a noticeable
and clear manner, and shall obtain the consent of the children&rsquo;s guardians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 28, 2019, the
CAC, MIIT, the Ministry of Public Security and SAMR jointly promulgated the Measures for the Determination of the Collection and Use
of Personal Information by Apps in Violation of Laws and Regulations, which provides guidance for the regulatory authorities to identify
the illegal collection and use of personal information through mobile apps, and for the app operators to conduct self-examination and
self-correction and social supervision by citizens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 28, 2020, the NPC
approved the Civil Code of the PRC or the Civil Code, which came into effect on January 1, 2021. Pursuant to the Civil Code, the personal
information of a natural person shall be protected by the law. Any organization or individual that needs to obtain personal information
of others shall obtain such information legally and ensure the safety of such information, and shall not illegally collect, use, process
or transmit personal information of others, or illegally purchase or sell, provide or make public personal information of others. Furthermore,
information processors shall not divulge or tamper with personal information collected or stored by them; without the consent of a natural
person, information processors shall not illegally provide personal information of such person to others, except for information that
has been processed so that specific persons cannot be identified and that cannot be restored. In addition, an information processor shall
take technical measures and other necessary measures to ensure the security of the personal information that is collected and stored
and to prevent the information from being divulged, tampered with or lost; where personal information has been or may be divulged, tampered
with or lost, the information processor shall take remedial measures in a timely manner, inform the natural person concerned in accordance
with the provisions and report the case to the relevant competent department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 20, 2021, the SCNPC
adopted the Personal Information Security Law, which took effect on November 1, 2021. The Personal Information Protection Law includes
the basic rules for personal information processing, the rules for cross-border provision of personal information, the rights of individuals
in personal information processing activities, the obligations of personal information processors, and the legal responsibilities for
illegal collection, processing, and use of personal information. As the first systematic and comprehensive law specifically for the protection
of personal information in the PRC, the Personal Information Protection Law provides, among others, that (i) an individual&rsquo;s consent
shall be obtained to use sensitive personal information, such as biometric characteristics and individual location tracking, (ii) personal
information operators using sensitive personal information shall notify individuals of the necessity of such use and impact on the individual&rsquo;s
rights, and (iii) where personal information operators reject an individual&rsquo;s request to exercise his or her rights, the individual
may file a lawsuit with a People&rsquo;s Court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 14, 2021, the
CAC published the Regulations of Internet Data Security Management (Draft for Comments), which further regulate the internet data processing
activities and emphasize the supervision and management of network data security, and further stipulate the obligations of internet platform
operators, such as to establish a system for disclosure of platform rules, privacy policies and algorithmic strategies related to data.
Specifically, the draft regulations require data processors to, among others, (i) adopt immediate remediation measures when finding that
network products and services they use or provide have security defects and vulnerabilities, or threaten national security or endanger
public interest, and (ii) follow a series of detailed requirements with respect to processing of personal information, management of
important data and proposed overseas transfer of data. In addition, the draft regulations require data processors handling important
data or the data processors to be listed overseas to complete an annual data security assessment and file a data security assessment
report to applicable regulators. Such annual assessment, as required by the draft regulations, would encompass areas including, but not
limited to, the status of important data processing, data security risks identified and the measures adopted, the effectiveness of data
protection measures, the implementation of national data security laws and regulations, data security incidents that occurred and their
handling, and a security assessment with respect to sharing and provision of important data overseas. As of the date of this prospectus,
the draft regulations have been released for public comment only and have not been formally adopted. The final provisions and the timeline
for its adoption are subject to changes and uncertainties.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, our business does not involve the collection of user data, implicate
cybersecurity, or involve any other type of <I>foreign investment</I> restricted industry. Based on the advice of PRC counsel and our
understanding of currently applicable PRC laws and regulations, our registered public offering in the U.S. is not subject to the review
or prior approval of the CAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Intellectual Property
Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Patent</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents in the PRC are principally
protected under the Patent Law of the PRC. The duration of a patent right is either 10 years or 15 year or 20 years from the date of
application, depending on the type of patent right. The Patent Law of the PRC and its implementation rules provide for three types of
patents, namely, &ldquo;invention&rdquo;, &ldquo;utility model&rdquo; and &ldquo;design&rdquo;. Invention patents are valid for twenty
years, utility model patents are valid for fifteen years, while design patents are valid for ten years, from the date of application.
The Chinese patent system adopts a &ldquo;first-to-file&rdquo; principle, which means that where more than one person files a patent
application for the same invention, a patent will be granted to the person who files the application first. To be patentable, invention
or utility models must meet three criteria: novelty, inventiveness and practicability. A third party must obtain consent or a proper
license from the patent owner to use the patent. Otherwise, the use constitutes an infringement of the patent rights.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Copyright</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copyright in the PRC, including
copyrighted software, is principally protected under the Copyright Law of the PRC and related rules and regulations. Under the Copyright
Law, promulgated in September 1990, implemented in June 1991, amended in October 2001, February 2010 and November 2020, and effective
on June 1, 2021 the term of protection for copyrighted software is 50 years. The Regulation on the Protection of the Right to Communicate
Works to the Public over Information Networks, as most recently amended on January 30, 2013, provides specific rules on fair use, statutory
license, and a safe harbor for use of copyrights and copyright management technology and specifies the liabilities of various entities
for violations, including copyright holders, libraries and Internet service providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Trademark</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Registered Trademarks are
protected by the PRC Trademark Law which was adopted by the Standing Committee of NPC on August 23, 1982 and most recently amended on
April 23, 2019 as well as the Implementation Regulation of the PRC Trademark Law which was adopted by the State Council on August 3,
2002 and amended on April 29, 2014. The Trademark Office of the National Intellectual Property Administration under SAMR handles trademark
registrations and grants a term of ten years to registered trademarks which may be renewed for consecutive ten-year periods upon request
by the trademark owner. For licensed use of a registered trademark, the licensor shall file record of the licensing of the said trademark
with the Trademark Office, otherwise it may not defend against a bona fide third party. The PRC Trademark Law has adopted a &ldquo;first-to-file&rdquo;
principle with respect to trademark registration. Where a trademark for which a registration has been made is identical or similar to
another trademark which has already been registered or been subject to a preliminary examination and approval for use on the same kind
of or similar commodities or services, the application for registration of such trademark may be rejected. Any person applying for the
registration of a trademark may not prejudice the existing right first obtained by others, nor may any person register in advance a trademark
that has already been used by another party and has already gained a &ldquo;sufficient degree of reputation&rdquo; through such party&rsquo;s
use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under PRC law, any of the
following acts will be deemed as an infringement to the exclusive right to use a registered trademark: (i) use of a trademark that is
the same as or similar to a registered trademark for identical or similar goods without the permission of the trademark registrant; (ii)
sale of any goods that have infringed the exclusive right to use any registered trademark; (iii) counterfeit or unauthorized production
of the label of another&rsquo;s registered trademark, or sale of any such label that is counterfeited or produced without authorization;
(iv) change of any trademark of a registrant without the registrant&rsquo;s consent, and selling goods bearing such replaced trademark
on the market; or (v) other acts that have caused any other damage to another&rsquo;s exclusive right to use a registered trademark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the PRC Trademark
Law, in the event of any of the foregoing acts, the infringing party will be ordered to stop the infringement immediately and may be
imposed a fine; the counterfeit goods will be confiscated. The infringing party may also be held liable for the right holder&rsquo;s
damages, which will be equal to the losses suffered by the right holder as a result of the infringement, including reasonable expenses
incurred by the right holder for stopping the infringement, or the gains obtained by the infringing party if the losses are difficult
to be ascertained. If both gains and losses are difficult to be ascertained, the damages may be determined by referring to the amount
of royalties for the license of such trademarks, which will be one to five times of the royalties in the case of any serious infringement
with malicious intent. If the gains, losses and royalties are all difficult to be ascertained, the court may render a judgment awarding
damages no more than RMB5 million. Notwithstanding the above, if a distributor does not know that the goods it sells infringe another&rsquo;s
registered trademark, it will not be liable for infringement provided that the seller shall prove that the goods are lawfully obtained
and identify its supplier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Domain Name</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Domain names are protected
under the Administrative Measures on Internet Domain Names promulgated by the MIIT on August 24, 2017 and effective as of November 1,
2017. Domain name registrations are handled through domain name service agencies established under the relevant regulations, and applicants
become domain name holders upon successful registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;<B>&nbsp;</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations on Foreign Currency Exchange</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The principal regulations governing
foreign currency exchange in China are the Foreign Exchange Administration Regulations, most recently amended on August 5, 2008. Under
PRC foreign exchange regulations, payments of current account items, such as profit distributions, interest payments and trade and service-related
foreign exchange transactions, can be made in foreign currencies without prior approval from the State Administration of Foreign Exchange,
or SAFE, by complying with certain procedural requirements. By contrast, approval from or registration with appropriate government authorities
is required where RMB is to be converted into foreign currency and remitted out of China to pay capital account items, such as direct
investments, repayment of foreign currency-denominated loans, repatriation of investments and investments in securities outside of China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 19, 2012, SAFE
promulgated the Circular of Further Improving and Adjusting Foreign Exchange Administration Policies on Foreign Direct Investment, or
Circular 59, which substantially amends and simplifies the current foreign exchange procedure. Pursuant to Circular 59, the opening of
various special purpose foreign exchange accounts, such as pre-establishment expenses accounts, foreign exchange capital accounts and
guarantee accounts, the reinvestment of RMB proceeds derived by foreign investors in the PRC, and remittance of foreign exchange profits
and dividends by a foreign-invested enterprise to its foreign stockholders no longer require the approval or verification of SAFE, and
multiple capital accounts for the same entity may be opened in different provinces, which was not possible previously. In 2013, SAFE specified
that the administration by SAFE or its local branches over direct investment by foreign investors in the PRC must be conducted by way
of registration and banks must process foreign exchange business relating to the direct investment in the PRC based on the registration
information provided by SAFE and its branches. In February 2015, SAFE promulgated the Notice on Further Simplifying and Improving the
Administration of the Foreign Exchange Concerning Direct Investment, or SAFE Notice 13. Instead of applying for approvals regarding foreign
exchange registrations of foreign direct investment and overseas direct investment from SAFE, entities and individuals may apply for such
foreign exchange registrations from qualified banks. The qualified banks, under the supervision of SAFE, may directly review the applications
and conduct the registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, SAFE promulgated
the Circular of the SAFE on Reforming the Management Approach regarding the Settlement of Foreign Capital of Foreign-invested Enterprise,
or Circular 19, which expands a pilot reform of the administration of the settlement of the foreign exchange capitals of foreign-invested
enterprises nationwide. Circular 19 replaced both the Circular of the SAFE on Issues Relating to the Improvement of Business Operations
with Respect to the Administration of Foreign Exchange Capital Payment and Settlement of Foreign-invested Enterprises, or Circular 142,
and the Circular of the SAFE on Issues concerning the Pilot Reform of the Administrative Approach Regarding the Settlement of the Foreign
Exchange Capitals of Foreign-invested Enterprises in Certain Areas, or Circular 36. Circular 19 allows all foreign-invested enterprises
established in the PRC to settle their foreign exchange capital on a discretionary basis according to the actual needs of their business
operation, provides the procedures for foreign invested companies to use RMB converted from foreign currency-denominated capital
for equity investments and removes certain other restrictions that had been provided in Circular 142. However, Circular 19 continues
to prohibit foreign-invested enterprises from, among other things, using RMB funds converted from their foreign exchange capital for
expenditure beyond their business scope and providing entrusted loans or repaying loans between non-financial enterprises. SAFE promulgated
the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management
Policy of Capital Account, or Circular 16, effective June 2016, which reiterates some of the rules set forth in Circular 19. Circular
16 provides that discretionary foreign exchange settlement applies to foreign exchange capital, foreign debt offering proceeds and remitted
foreign listing proceeds, and the corresponding RMB capital converted from foreign exchange may be used to extend loans to related parties
or repay inter-company loans (including advances by third parties). However, there are substantial uncertainties with respect to Circular
16&rsquo;s interpretation and implementation in practice. Circular 19 or Circular 16 may delay or limit us from using the proceeds of
offshore offerings to make additional capital contributions to our Shanghai subsidiary and any violations of these circulars could result
in severe monetary or other penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2017, SAFE promulgated
the Circular on Further Improving Reform of Foreign Exchange Administration and Optimizing Genuineness and Compliance Verification, or
Circular 3, which stipulates several capital control measures with respect to the outbound remittance of profits from domestic entities
to offshore entities, including (i) banks must check whether the transaction is genuine by reviewing board resolutions regarding profit
distribution, original copies of tax filing records and audited financial statements, and (ii) domestic entities must retain income to
account for previous years&rsquo; losses before remitting any profits. Moreover, pursuant to Circular 3, domestic entities must explain
in detail the sources of capital and how the capital will be used, and provide board resolutions, contracts and other proof as a part
of the registration procedure for outbound investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 23, 2019, SAFE
issued Circular of the State Administration of Foreign Exchange on Further Promoting the Facilitation of Cross-border Trade and Investment,
or the Circular 28, which took effect on the same day. Circular 28 allows non-investment foreign-invested enterprises to use their capital
funds to make equity investments in China, provided that such investments do not violate the effective special entry management measures
for foreign investment (negative list) and the target investment projects are genuine and in compliance with laws. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation on Foreign Debt</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A loan made by a foreign
entity as direct or indirect shareholder in a FIE is considered to be foreign debt in China and is regulated by various laws and regulations,
including the Regulation of the People&rsquo;s Republic of China on Foreign Exchange Administration, the Interim Provisions on the Management
of Foreign Debts, the Statistical Monitoring of Foreign Debts Tentative Provisions, the Detailed Rules for the Implementation of Provisional
Regulations on Statistics and Supervision of External Debt, and the Administrative Measures for Registration of Foreign Debts. Under
these rules and regulations, a shareholder loan in the form of foreign debt made to a PRC entity does not require the prior approval
of SAFE. However, such foreign debt must be registered with and recorded by SAFE or its local branches within fifteen (15) business days
after entering into the foreign debt contract. Pursuant to these rules and regulations, the maximum amount of the aggregate of (i) the
outstanding balance of foreign debts with a term not longer than one year, and (ii) the accumulated amount of foreign debts with a term
longer than one year, of a FIE shall not exceed the difference between its registered total investment and its registered capital, or
Total Investment and Registered Capital Balance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 12, 2017, the
People&rsquo;s Bank of China, or PBOC, promulgated the Notice of the People&rsquo;s Bank of China on Matters concerning the Macro-Prudential
Management of Full-Covered Cross-Border Financing, or PBOC Circular 9, which sets forth an upper limit for PRC entities, including FIEs
and domestic enterprises, regarding their foreign debts. Pursuant to PBOC Circular 9, the outstanding cross-border financing of an enterprise
(the outstanding balance drawn, here and below) shall be calculated using a risk-weighted approach, or Risk-Weighted Approach, and shall
not exceed the specified upper limit, namely: risk-weighted outstanding cross-border financing &pound; the upper limit of risk-weighted
outstanding cross-border financing. Risk-weighted outstanding cross-border financing =&sum; outstanding amount of RMB and foreign currency
denominated cross-border financing * maturity risk conversion factor * type risk conversion factor +&sum; outstanding foreign currency
denominated cross-border financing * exchange rate risk conversion factor. Maturity risk conversion factor shall be 1 for medium- and
long-term cross-border financing with a term of more than one year and 1.5 for short-term cross-border financing with a term of one year
or less than one year. Type risk conversion factor shall be 1 for on-balance-sheet financing and 1 for off-balance-sheet financing (contingent
liabilities) for the time being. Exchange rate risk conversion factor shall be 0.5. The PBOC Circular 9 further provides that the upper
limit of risk-weighted outstanding cross-border financing for enterprises, or Net Asset Limits, shall be 200% of its net assets. The
PBOC Circular 9 does not supersede the Interim Provisions on the Management of Foreign Debts, but rather serves as a supplement to it.
PBOC Circular 9 provided for a one-year transitional period, or the Transitional Period, from its promulgation date for FIEs, during
which period FIEs could choose to calculate their maximum amount of foreign debt based on either (i) the Total Investment and Registered
Capital Balance, or (ii) the Risk-Weighted Approach and the Net Asset Limits. Under the PBOC Circular 9, after the Transitional Period
ends on January 11, 2018, the PBOC and SAFE will determine the cross-border financing administration mechanism for the foreign-invested
enterprises after evaluating the overall implementation of PBOC Circular 9. In addition, according to PBOC Circular 9, a foreign loan
must be filed with SAFE through the online filing system of SAFE after the loan agreement is signed and at least three business days
prior to the borrower withdraws any amount from such foreign loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Dividend Distributions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the PRC
Company Law and Foreign Investment Law, each of our Shanghai subsidiary, as a foreign invested enterprise, or FIE, is required to
draw 10% of its after-tax profits each year, if any, to fund a common reserve, which may stop drawing its after-tax profits if
the aggregate balance of the common reserve has already accounted for over 50% of its registered capital. These reserves are not
distributable as cash dividends. Furthermore, under the EIT Law, which became effective in January 2008, the maximum tax rate for
the withholding tax imposed on dividend payments from PRC foreign invested companies to their overseas investors that are not regarded
as &ldquo;resident&rdquo; for tax purposes is 20%. The rate was reduced to 10% under the Implementing Regulations for the EIT Law
issued by the State Council. However, a lower withholding tax rate might be applied if there is a tax treaty between China and
the jurisdiction of the foreign holding companies, such as tax rate of 5% in the case of Hong Kong companies that holds at least
25% of the equity interests in the foreign-invested enterprise, and certain requirements specified by PRC tax authorities are satisfied.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations Relating to Employment, Social
Insurance and housing fund</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Labor Law and The Labor
Contract Law provide requirements concerning employment contracts between an employer and its employees. If an employer fails to enter
into a written employment contract with an employee within one year from the date on which the employment relationship is established,
the employer must rectify the situation by entering into a written employment contract with the employee and pay the employee twice the
employee&rsquo;s salary for the period from the day following the lapse of one month from the date of establishment of the employment
relationship to the day prior to the execution of the written employment contract. All employers must comply with local minimum wage
standards. The Labor Contract Law and its implementation rules also require compensation to be paid upon certain terminations, which
significantly affects the cost of reducing workforce for employers. In addition, if an employer intends to enforce a non-compete provision
with an employee in an employment contract or non-competition agreement, it has to compensate the employee on a monthly basis during
the term of the restriction period after the termination or ending of the labor contract. Employers in most cases are also required to
provide a severance payment to their employees after their employment relationship are terminated. Violations of the PRC Labor Contract
Law and the PRC Labor Law may result in the imposition of fines and other administrative and criminal liability in the case of serious
violations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Enterprises in China are
required by PRC laws and regulations to participate in certain employee benefit plans, including social insurance funds, namely a pension
plan, a medical insurance plan, an unemployment insurance plan, a work-related injury insurance plan and a maternity insurance plan,
and a housing provident fund, and contribute to the plans or funds in amounts equal to certain percentages of salaries, including bonuses
and allowances, of the employees as specified by the local government from time to time at locations where they operate their businesses
or where they are located. According to the Social Insurance Law, an employer that fails to make social insurance contributions may be
ordered to pay the required contributions within a stipulated deadline and be subject to a late fee. If the employer still fails to rectify
the failure to make social insurance contributions within the stipulated deadline, it may be subject to a fine ranging from one to three
times the amount overdue. According to the Regulations on Management of Housing Fund, an enterprise that fails to make housing fund contributions
may be ordered to rectify the noncompliance and pay the required contributions within a stipulated deadline; otherwise, an application
may be made to a local court for compulsory enforcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulations on Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Enterprise Income Tax</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Enterprise Income
Tax Law of the PRC, or the EIT Law, which became effective on January 1, 2008 and was subsequently amended on February 24, 2017 and December
29, 2018, and its implementing rules, enterprises are classified as resident enterprises and non-resident enterprises. PRC resident enterprises
typically pay an enterprise income tax at the rate of 25% while non-PRC resident enterprises without any branches in the PRC should pay
an enterprise income tax in connection with their income from the PRC at the tax rate of 10%. An enterprise established outside of the
PRC with its &ldquo;de facto management bodies&rdquo; located within the PRC is considered a &ldquo;resident enterprise,&rdquo; meaning
that it can be treated in a manner similar to a PRC domestic enterprise for enterprise income tax purposes. The implementing rules of
the EIT Law define a de facto management body as a managing body that in practice exercises &ldquo;substantial and overall management
and control over the production and operations, personnel, accounting, and properties&rdquo; of the enterprise. Enterprises qualified
as &ldquo;High and New Technology Enterprises&rdquo; are entitled to a 15% enterprise income tax rate rather than the 25% uniform statutory
tax rate. The preferential tax treatment continues as long as an enterprise can retain its &ldquo;High and New Technology Enterprise&rdquo;
status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EIT Law and the implementation
rules provide that an income tax rate of 10% should normally be applicable to dividends payable to investors that are &ldquo;non-resident
enterprises,&rdquo; and gains derived by such investors, which (a) do not have an establishment or place of business in the PRC or (b)
have an establishment or place of business in the PRC, but the relevant income is not effectively connected with the establishment or
place of business to the extent such dividends and gains are derived from sources within the PRC. Such income tax on the dividends may
be reduced pursuant to a tax treaty between China and other jurisdictions. Pursuant to the Arrangement Between the Mainland of China
and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation on Income, or the Double Tax Avoidance Arrangement,
and other applicable PRC laws, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied
the relevant conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax
on the dividends the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5% upon receiving approval
from in-charge tax authority. However, based on the Notice on Certain Issues with Respect to the Enforcement of Dividend Provisions in
Tax Treaties issued on February 20, 2009 by the SAT, if the relevant PRC tax authorities determine, in their discretion, that a company
benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may
adjust the preferential tax treatment; and based on the Announcement on Relevant Issues Concerning the &ldquo;Beneficial Owners&rdquo;
in Tax Treaties issued on February 3, 2018 by the SAT and effective from April 1, 2018, which replaces the Notice on the Interpretation
and Recognition of Beneficial Owners in Tax Treaties and the Announcement on the Recognition of Beneficial Owners in Tax Treaties by
the SAT, comprehensive analysis based on the stipulated factor therein and actual circumstances shall be adopted when recognizing the
&ldquo;beneficial owner&rdquo; and agents and designated wire beneficiaries are specifically excluded from being recognized as &ldquo;beneficial
owners.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 17, 2019, the State Taxation Administration issued the notice
on the scope of small-scale and low-profit corporate income tax preferential policies of the Ministry of Finance and the State Administration
of Taxation (&ldquo;MOF and SAT&rdquo;), [2019] No. 13 for small-scale and low-profit enterprises whose annual taxable income is less
than RMB1,000,000 (including RMB1,000,000), approximately $142,209, their income is reduced by 25% to the taxable income, and enterprise
income tax is paid at 20% tax rate, which is essentially resulting in a favorable income tax rate of 5%. While for the portion of annual
taxable income exceeding RMB1,000,000, approximately $142,209, but not more than RMB3,000,000, approximately $426,627, the income is reduced
by 50% to the taxable income, and enterprise income tax is paid at 20% tax rate, which is essentially resulting in a favorable income
tax rate of 10%. On April 9, 2021, MOF and SAT issued [2021] No.12 which provides an enterprise income tax rate of 2.5% on a small-scale
and low-profit enterprises whose annual taxable income less than RMB1,000,000, approximately $142,209, from January 1, 2021 to December
31, 2022. MOF and SAT [2022] No.13, issued on May 29, 2023, also provides an enterprise income tax rate of 5% on a small-scale and low-profit
enterprises whose annual taxable income more than RMB1,000,000, approximately $142,209, but not more than RMB3,000,000, approximately
$426,627, from January 1, 2022 to December 31, 2024. The qualifications of small-scale and low-profit enterprises were examined annually
by the Tax Bureau. All of the Company&rsquo;s Shanghai subsidiary met the criteria of small-scale and low-profit enterprises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Value-added Tax</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to applicable PRC
tax regulations, any entity or individual conducting business in the service industry used to be generally required to pay a business
tax at the rate of 5% on the revenues generated from providing such services. However, if the services provided are related to technology
development and transfer, such business tax may be exempted subject to approval by the relevant tax authorities. Whereas, pursuant to
the Provisional Regulations on Value-Added Tax of the PRC and its implementation regulations, unless otherwise specified by relevant
laws and regulations, any entity or individual engaged in the sales of goods, provision of processing, repairs and replacement services
and importation of goods into China is generally required to pay a value-added tax, or VAT, for revenues generated from sales of products,
while qualified input VAT paid on taxable purchase can be offset against such output VAT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2011, the Ministry
of Finance and the State Administration of Taxation promulgated the Pilot Plan for Imposition of Value-Added Tax to Replace Business
Tax. In March 2016, the Ministry of Finance and the State Administration of Taxation further promulgated the Notice on Fully Promoting
the Pilot Plan for Replacing Business Tax by Value-Added Tax, which became effective on May 1, 2016. Pursuant to the pilot plan and relevant
notices, VAT is generally imposed in lieu of business tax in the modern service industries, including the VATS, on a nationwide basis.
VAT of a rate of 6% applies to revenue derived from the provision of some modern services. Certain small taxpayers under PRC law are
subject to reduced value-added tax at a rate of 3%. Unlike business tax, a taxpayer is allowed to offset the qualified input VAT paid
on taxable purchases against the output VAT chargeable on the modern services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2018, the Ministry
of Finance and the State Administration of Taxation issued the Notice on Adjustment of VAT Rates, which came into effect on May 1, 2018.
According to the abovementioned notice, the taxable goods previously subject to VAT rates of 17% and 11%, respectively, become subject
to lower VAT rates of 16% and 10%, respectively, starting from May 1, 2018. Furthermore, according to the Announcement on Relevant Policies
for Deepening Value-added Tax Reform jointly promulgated by the Ministry of Finance, the State Administration of Taxation and the General
Administration of Customs, which became effective on April 1, 2019, the taxable goods previously subject to VAT rates of 16% and 10%,
respectively, become subject to lower VAT rates of 13% and 9%, respectively, starting from April 1, 2019. Under Provisional Regulations
of the People&rsquo;s Republic of China on Value-added Tax, amended and effective on November 19, 2017, for entities that are VAT small
taxpayers, VAT is levied at a levy rate of 3%. On February 29, 2020, the State Administration of Taxation issued the Announcement on
Taxation Matters to Support Individual Businesses in Resumption of Business, during the COVID-19, the small taxpayers are allowed to
enjoy the preferred tax policy, tax rate from 3% to 1% for the period from March 1, 2020 to December 31, 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth information regarding our executive officers and directors as of the date of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 62%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Position with the Company</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Yi Lu, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">59</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chairman of the Board and Chief Executive Officer </FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">51</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Mingze Yin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">35</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Steven I-Fang Cheng, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">44</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Technology Officer and Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Jing Zhang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">46</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Independent Director Nominee and Chair of the Audit Committee</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Cheang I Kei</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">29</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Independent Director Nominee and Chair of the Compensation Committee</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Mingyue Cai</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Independent Director Nominee and Chair of the Nominating and Corporate Governance Committee</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Dr. Yi Lu </I></B>has served
as our Chairman of the Board since November 2022 and as our Chief Executive Officer since March 2024. He has been the Chairman and Chief
Science Officer of Advanced Biomed Taiwan since June 2014. He was the Chairman of HFC Semiconductor from January 2020 to October 2022
and was responsible for the company&rsquo;s strategic development. Dr.&nbsp;Lu previously served as Chairman of Nextchip Semiconductor
Corporation, a semiconductor foundry specializing in integrated circuit production, from February 2016 to December 2019 and led the company
to launch the first 12-inch integrated circuit production line in Anhui Province with an investment of RMB20 billion. From January 2004
to December 2007, he was the senior executive of Cypress Semiconductor, overseeing the company&rsquo;s business operation. From May 2001
to January 2004, he was the founder, Chairman and CEO of Cascade Semiconductor, which was acquired by Cypress Semiconductor Corporation
(Nasdaq: CY), and managed the overall operations of the company. Dr.&nbsp;Lu received a Doctor of Philosophy from the University of Florida
in 1994. Dr. Lu has a wealth of experience in successful entrepreneurship and has extensive experience in the fields of technology management,
market management, and operations. He has a clear strategic orientation and has established a clear strategic plan for us. We believe
Dr.&nbsp;Lu&rsquo;s significant experience in the United States and China qualifies him to serve as a member of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Dr. Hung To</I></B>
Pau has served as our director since November 2022. He also served as our Chief Executive Officer from November 2022 to March 2024.
He has been the Chairman of Shanghai Sglcell Biotech Co., Ltd. since November 2019 and oversees business operations and strategic
development. From January 2017 to October 2019, Dr. Pau held positions as chairman of Take Chance HK Development Ltd., where he led
the senior executives to expand the company&rsquo;s business operations. From January 2017 to date, He was also a director at Well
Fancy Development Ltd. and worked on areas such as corporate governance and strategic development. From 1994 to 2008, Dr. Pau worked
at Shanghai Changzheng Hospital and managed its R&amp;D department. He graduated from the Second Military Medical University with a
Ph.D. in Immunology in 2008. He also obtained EMBA from Shanghai Jiaotong University in 2011. Dr. Pau has solid medical research and
development experience as well as sufficient practical experience in managing a company&rsquo;s overall and long-term development
and its core competitiveness. We believe he will play a pivotal role in steering our long-term development and achieving future
business goals.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Mr.
Mingze Yin </I></B>has served as our Chief Financial Officer since November 2022. He has over 11 years of experience in the financial
and investment banking industry. He has been the Chief Financial Officer of Shanghai Sglcell Biotech Co., Ltd. since January 2021 and
oversees its finance department. From March 2017 to December 2021, Mr. Yin was Director of Shanghai Guangdian Asset Management Co., Ltd.,
where he participated in all major corporate decisions and financial compliance matters. From February 2020 to November 2020, he was
an independent director of TMSR Holding Company Limited (Nasdaq: TMSR) and a member of its Audit Committee, Nominating and Governance
Committee, and Compensation Committee. From February 2018 to November 2018, Mr. Yin was the investors relations manager of Planet Green
Holdings Corp. (NYSE: PLAG). From November 2015 to February 2017, Mr. Yin was a senior manager of the Investment Banking Department of
Zhongshan Securities Co., Ltd. From October 2012 to October 2015, he was the senior audit manager of BDO China Shu Lun Pan Certified
Public Accountants LLP. Mr. Yin is a certified internal auditor and obtained his Bachelor of Management from Jiangsu Haiyang University
in 2011.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dr.
Steven I-Fang Cheng</I></B> has served as our director since August 2024 and as our Chief Technology Officer since November 2022. Since
2014, Dr. Cheng joined Advanced Biomed Taiwan. as a co-founder and CTO. Since 2013, he was an associate research fellow (Principal Investigator)
in TSRI. His professional research expertise includes biomicrofluidics, biosensors, cancer diagnosis and infectious detection, micro/nano
fabrication technology, on-chip drug screening, electrokinetics/electrical analysis and their biomedical applications, patent design
and implantation. He received his Master of Science degree from Department of Biomedical Engineering of National Cheng Kung University
in Taiwan in 2007 and received his Ph.D. degree from Institute of Nanotechnology &amp; Microsystems Engineering at National Cheng Kung
University in 2010. He has great experience in cross-disciplinary integration development and novel techniques/products creation on biomedical
research. He also has great professional capability and personality characteristic to lead and co-operate with our top researchers from
many different fields.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Jing Zhang </I></B>will
serve as our independent director and the Chair of the Audit Committee immediately upon the effectiveness of our registration statement
on Form S-1, of which this prospectus is a part. Ms. Zhang has more than 25 years of working experience in financial management. Since
July 2013, Ms. Zhang has been the Chief Financial Officer of Shanghai Xun Yang Network Technology Co., Ltd. From September 2022 to February
2023, Ms. Zhang served as an independent director and the chair of the audit committee of Code Chain New Continent Limited Co., Ltd. (NASDAQ:
CCNC). From March 2009 to July 2013, Ms. Zhang served as the financial manager of Shanghai Branch of Jiangsu Zi Guang Intelligence Co.,
Ltd. From March 1999 to February 2009, Ms. Zhang served as the accountant and financial director of the Finance Department of the Eight
Five Hospital. Ms. Zhang graduated from Zaozhuang University in 1999.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Cheang I Kei</I></B> will
serve as our independent director and the Chair of the Compensation Committee immediately upon the effectiveness of our registration statement
on Form S-1, of which this prospectus is a part. Ms. Cheang has been the legal senior manager at Luso International Banking Ltd. since
October 2022. She served as the legal manager at Bank of China (Macau) from May 2019 to October 2022. She was the legal assistant at Luso
International Banking Ltd. between August 2016 and May 2019. Ms. Cheang is experienced in corporate governance matters and day to day
administrative affairs, which we believe makes her a suitable member to our Board. Ms. Cheang received her bachelor&rsquo;s degree in
Chinese-English translation and interpretation from Macau Polytechnic University in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Mingyue Cai</I></B> will
serve as our independent director and the Chair of the Nominating and Corporate Governance Committee immediately upon the effectiveness
of our registration statement on Form S-1, of which this prospectus is a part. Mr. Cai has been the Vice President at Yitu Safety Technology
(Shenzhen) Co., Ltd., a PRC company engages in artificial intelligence development and application. From February 2020 to April 2024,
Mr. Cai worked as an independent director and the chair of compensation committee of GD Culture Group Limited (NASDAQ: GDC). From November
2009 to August 2017, he was an administrative director at Rugao Port Group Co., Ltd., a PRC company that focuses on port logistics, industrial
park construction and timber, coal and ore trade. From June 2004 to October 2009, Mr. Cai worked as a manager at Shanghai Rishan Environmental
Protection Technology Co., Ltd., a PRC company that distribute and retail environmentally friendly cleaning products. Mr. Cai graduated
from China Central Radio &amp; TV University in 2015 with a major in administration.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships,
or other arrangements or understandings between or among any of the directors or executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All directors hold office
until the next annual meeting of stockholders and until their successors have been duly elected and qualified. Directors are elected at
the annual meetings to serve for one-year terms. Officers are elected by, and serve at the discretion of, the board of directors. Our
board of directors shall hold meetings on at least a quarterly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors has
determined to comply with the Nasdaq Listing Rules with respect to certain corporate governance matters. We also intend to comply with
the requirements of Rule 10A-3 under the Securities Exchange Act of 1934 within the applicable time frame.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors has reviewed the independence of our directors,
applying the Nasdaq independence standards. Based on this review, the board of directors determined that Jing Zhang, Cheang I Kei, and
Mingyue Cai are independent within the meaning of the Nasdaq rules. In making this determination, our board of directors considered the
relationships that each of these non-employee directors has with us and all other facts and circumstances our board of directors deemed
relevant in determining their independence. As required under applicable Nasdaq rules, we anticipate that our independent directors will
meet on a regular basis as often as necessary to fulfil their responsibilities, including at least annually in executive session without
the presence of non-independent directors and management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon effectiveness of the
registration statement, our board of directors will establish standing committees in connection with the discharge of its responsibilities.
These committees include an Audit Committee, a Compensation Committee and a Corporate Governance and Nominating Committee. Our board of
directors will adopt written charters for each of these committees. Our board of directors may establish other committees as it deems
necessary or appropriate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon effectiveness of the registration statement, we will establish an
audit committee which will be composed of three of our independent directors: Jing Zhang (Chair), Cheang I Kei and Mingyue Cai. It is
anticipated that the Board will determine that Alfred Lee Ming Sung qualifies as the Audit Committee financial expert as defined in Item
407(d)(5) of Regulation S-K promulgated under the Securities Act.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to its charter,
the Audit Committee consists of at least three members, each of whom shall be a non-employee director who has been determined by the Board
to meet the independence requirements of Nasdaq, and also Rule 10A-3(b)(1) of the SEC, subject to the exemptions provided in Rule 10A-3(c).
The Audit Committee Charter describes the primary functions of the Audit Committee, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Oversee the Company&rsquo;s accounting and the financial reporting processes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Oversee audits of the Company&rsquo;s financial statements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Review and discuss with management the Company&rsquo;s audited financial statements and review with management
and the Company&rsquo;s independent registered public accounting firm the Company&rsquo;s financial statements prior to the filing with
the SEC of any report containing such financial statements;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Discuss policies with respect to risk assessment and risk management, and discuss the Company&rsquo;s
major financial risk exposures and the steps management has taken to monitor and control such exposures;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Review major changes to the Company&rsquo;s auditing and accounting principles and practices as suggested
by the Company&rsquo;s independent registered public accounting firm, internal auditors or management; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Take, or recommend that the board take, appropriate action to oversee and ensure the independence of the
Company&rsquo;s independent registered public accounting firm.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon effectiveness of the registration statement, we will establish a compensation
committee, which will be composed of three of our independent directors: Cheang I Kei (Chair), Jing Zhang, and Mingyue Cai. The Compensation
Committee will be responsible for, among other matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reviewing and approving employment agreements and other similar arrangements between us and our executive
officers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reviewing and approving, or recommending to the board of directors to approve the compensation of our
CEO and other executive officers and directors reviewing key employee compensation goals, policies, plans and programs; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">appointing and overseeing any compensation consultants or advisors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Governance and Nominating Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon effectiveness of the registration statement, we will establish a corporate
governance and nominating committee, which will be composed of three of our independent directors: Mingyue Cai (Chair), Jing Zhang, and
Cheang I Kei. The Corporate Governance and Nominating Committee will be responsible for, among other matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reviewing and making recommendations regarding the structure and composition of our board and the board
committees;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">evaluating the independence of directors and director nominees;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developing and recommending to the board corporate governance principles and practices;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reviewing and monitoring the Company&rsquo;s code of business conduct; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">overseeing the evaluation of the Company&rsquo;s management.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have adopted our code of business
conduct (the &ldquo;code of business conduct&rdquo;) that applies to all directors, executive officers and employees, which will become
effective upon the effectiveness of the registration statement of which this prospectus forms a part and available on our website. Our
code of business conduct is a &ldquo;code of ethics,&rdquo; as defined in Item 406(b) of Regulation&nbsp;S-K.&nbsp;Copies of the code
of business conduct and charters for each of our board committees will be provided without charge upon request from us and will be posted
on our company website. We will make any legally required disclosures regarding amendments to, or waivers of, provisions of our code of
ethics on our Internet website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recovery of Erroneously Awarded Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have adopted an executive incentive
compensation recovery policy pursuant to Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act (&ldquo;Rule 10D-1&rdquo;),
and Listing Rule 5608 adopted by Nasdaq (the &ldquo;Listing Standards&rdquo;) to provide for the recovery of certain incentive-based compensation
in the event of an accounting restatement. The policy will become effective upon the effectiveness of the registration statement of which
this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, there are
no material proceedings to which any of our directors, officers or affiliates of the Company is a party adverse to the Company or has
a material interest adverse to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Equity Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no outstanding
equity awards as of September 30, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective March 30, 2023, our Stock Incentive Plan (the &ldquo;2023 Plan&rdquo;)
was approved by our Board of Directors. Under the 2023 Plan, the Board of Directors may grant options or purchase rights to purchase Common
Stock to officers, employees, and other persons who provide services to us or any related company. The participants to whom awards are
granted, the type of awards granted, the number of shares covered for each award, and the purchase or exercise price, conditions and other
terms of each award are determined by the Board of Directors, except that the term of the options shall not exceed 10 years. A total of
15 million shares of our Common Stock are subject to the 2023 Plan and maybe either a qualified or non-qualified stock option. The shares
issued for the 2023 Plan may be either treasury or authorized and unissued shares. As of the date of this prospectus, we have granted
no stock options to purchase any shares of our Common Stock under the 2023 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation of Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No directors&rsquo; or executive
officers&rsquo; compensation was paid during the year ended June 30, 2021. Other than our CFO, no directors&rsquo; or executive officers&rsquo;
compensation was paid during the year ended June 30, 2022. For the year ended June 30, 2022, we paid $20,000 to our CFO. Other than our
CFO, no directors&rsquo; or executive officers&rsquo; compensation was paid during the year ended June 30, 2023. For the year ended June
30, 2023, we paid $40,000 to our CFO. No directors&rsquo; or officers&rsquo; compensation was paid during the year ended June 30, 2024
and three-month period ended September 30, 2024.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><B>CERTAIN RELATIONSHIPS AND
RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since July 1, 2019, there has
not been any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded,
or will exceed, the lesser of (i) $120,000 or (ii) one percent of the average of our total assets for the last two completed fiscal years,
and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate
family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest except
for the followings:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Related Party</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 70%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Relationship to Us</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Yi Lu, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chairman of the Board and Chief Executive Officer of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Steven I-Fang Cheng, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Technology Officer and Director of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Chen-Yi Lee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. </FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Advance On Ventures Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Well Fancy Development Ltd</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau is the director and shareholder of the entity</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau is the legal person and shareholder of the entity</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2021, the Company
issued 8,000,000 shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd.,
an exempted company incorporated under the law of Cayman Islands, the sole shareholder of which is Dr. Hung To Pau for a total consideration
of $8,000. On June 8, 2022, Sglcell Ltd. transferred all of its 8,000,000 shares to Dr. Yi Lu for a total consideration of $8,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Shares Issued to Advanced Biomed Taiwan Holders/Employees</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 12, 2022, we issued
additional 385,000 shares to Dr. Yi Lu, and 257 shares to Chen-Yi Lee while Dr. Yi Lu and Chen-Yi Lee transferred 2,998,000 shares and
2,000 shares owned by them respectively in Advanced Biomed Taiwan, representing in aggregate 100% of the issued share capital of Advanced
Biomed Taiwan, to the Company pursuant to the share exchange agreement the Company entered into with Dr. Yi Lu and Chen-Yi Lee.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 24, 2022, we issued
365,352 shares for no consideration to Chen-Yi Lee, who is an employee of Advanced Biomed Taiwan, for past services to Advanced Biomed
Taiwan. On October 24, 2022, we also issued 2,730,000 shares for no consideration to Advance On Ventures Limited, a company incorporated
under the law of British Virgin Islands (the &ldquo;Ventures Limited&rdquo;), the beneficial owners of which are employees of Advanced
Biomed Taiwan for past services to Advanced Biomed Taiwan. We issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares,
1,243,750 shares, 1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant
to the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt
of a total amount of NTD 174,020,033 and RMB22,200,000 (approximately $9.04 million).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
business, during three-month period ended September 2024 and the&nbsp;fiscal years ended June&nbsp;30, 2024 and 2023, the Company was
involved in certain transactions, either at cost or current market prices, and on the normal commercial terms with related parties. The
following table provides the transactions with these parties for the&nbsp;years as presented (for the portion of such period that they
were considered related):</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30,<BR>

2024</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30,<BR>
 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,<BR>
 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">US$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">US$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">US$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Amount due to related parties &ndash; major stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Name of related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Hung To Pau, Ph.D. <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">200,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">933,471</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Yi Lu, Ph.D. <SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,907</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Chen-Yi Lee <SUP>(3)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,721</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,544</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">317,777</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">113,812</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,052,677</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Amount due to related parties &ndash; related corporations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt">Name of related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Well Fancy Development Ltd <SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">181,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">396,905</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <SUP>(5)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">698,244</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">674,262</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">206,897</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">879,622</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">674,262</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">603,802</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">For the</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">three-month</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">period ended</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">September 30,</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the years ended <BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2024</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2023</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">US$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">US$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">US$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Waiver of amount due to related parties &ndash;Hung To Pau, Ph.D.&nbsp;&nbsp;<SUP>(6)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,233,764</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Waiver of amount due to related parties &ndash; Well Fancy Development Ltd.(7)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,586,860</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; font-size: 10pt"></TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed Inc.(HK) entered into one unsecured,
    interest-free loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024. As of September 30, 2024, the
    loan balance due to Hung To Pau, Ph.D. totally amounted to US$200,000 for general working capital.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended June 30, 2024 and 2023, it
    was related to payments of initial public offering costs paid on behalf of Advanced Biomed Inc. As of June 30, 2024, the amount due to
    Hung To Pau, Ph.D. of US$1,233,764 has been waived off by Hung To Pau, Ph.D.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; font-size: 10pt"></TD>
    <TD STYLE="width: 19px; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$110,268) for general working capital in January 2023. As of September 30, 2024, June 30, 2024 and 2023, the loan balance due to Yi Lu amounted to US$113,056, US$110,268 and US$114,907, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; font-size: 10pt"></TD>
    <TD STYLE="width: 19px; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; font-size: 10pt"></TD>
    <TD STYLE="width: 19px; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed Inc.(HK) entered into one unsecured,
    interest-free loan to Well Fancy Development Ltd amounting to US$181,378 for general working capital in July 2024. As of September 30,
    2024, the loan balance due to Well Fancy Development Ltd totally amounted to US$181,378 for general working capital.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed Inc.(Taiwan) entered into ten
    unsecured, interest-free loans to Well Fancy Development Ltd amounting to NTD 2,967,700 (approximately US$91,455), NTD2,989,873 (approximately
    US$92,138), NTD4,270,200 (approximately US$131,593), NTD1,945,000 (approximately US$59,938), NTD1,858,120 (approximately US$57,261), NTD2,912,200
    (approximately US$89,744), NTD2,890,065 (approximately US$89,062), NTD5,857,750 (approximately US$180,516), NTD4,356,145 (approximately
    US$134,242) and NTD3,732,100 (approximately US$115,011) for general working capital in August 2022, April 2023, May 2023, June 2023, July
    2023, August 2023, October 2023, December 2023, February 2024 and April 2024, respectively. As of June 30, 2024, the loan balance due
    to Well Fancy Development Ltd totally amounted to US$1,040,960 and amounted to US$545,900 for general working capital. And the total amount
    due to Well Fancy Development Ltd of NTD33,779,153 and US$545,900 have been waived off by Well Fancy Development Ltd. As of June 30, 2023,
    the loan balance due to Well Fancy Development Ltd totally amounted to US$396,905.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 19px"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shanghai Sglcell Biotech Co., Ltd entered into
    four unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$68,802)
    in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$96,323), RMB1,500,000 (approximately
    US$206,407) and RMB700,000 (approximately US$96,323) in January 2024, March 2024 and June 2024, respectively, for general working capital.
    As of September 30, 2024, June 30, 2024 and June 30, 2023, the loan balance due to Shanghai Sglcell Biotech Co., Ltd totally amounted
    to US$ 698,244, US$674,262 and US$206,897, respectively.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As of June 30, 2024, the amount due to Hung To Pau, Ph.D. of US$1,233,764 has been waived off by Hung To Pau, Ph.D.&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As of June 30, 2024, the total amount due to Well Fancy Development Ltd of US$1,586,860 has been waived off by Well Fancy Development Ltd.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus, there are 20,000,000 shares of Common
Stock outstanding. The following table sets forth certain information known to us with respect to the beneficial ownership of Common Stock
as of that date by (i) each of our directors, (ii) each of our executive officers, (iii) all of our directors and executive officers as
a group, and (iv) each person, or group of affiliated persons, whom we know to beneficially own more than 5% of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined beneficial ownership in accordance with the rules of
the SEC, which generally define beneficial ownership to include any shares over which a person exercises sole or shared voting or investment
power. Such determination is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated, we
believe, based on the information furnished to us, that all persons named in the table have sole voting and investment power with respect
to all shares beneficially owned by them. None of the stockholders listed in the table are a broker-dealer or an affiliate of a broker
dealer. Applicable percentage ownership prior to the offering is based on 20,000,000 shares of Common Stock outstanding as of the date
of this prospectus. The table also lists the percentage ownership after this offering based on 21,875,000 shares of Common Stock outstanding
immediately after the completion of this offering, assuming no exercise of the underwriters&rsquo; over-allotment option to purchase additional
shares of Common Stock from us in this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Prior to Offering</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">After Offering</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name and Address of Beneficial Owner<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount and</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nature of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Beneficial</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ownership</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Approximate</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Percentage of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Outstanding</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares<SUP>(2)</SUP></B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount and</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nature of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Beneficial</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ownership</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Approximate</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Percentage of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Outstanding</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares<SUP>(3)</SUP></B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Directors and Officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left">Yi Lu</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,708,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">33.54</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,708,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">30.67</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Hung To Pau</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,524,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.62</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,524,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.11</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Mingze Yin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Steven I-Fang Cheng<B><SUP>(4)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">742,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.71</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">742,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.39</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jing Zhang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cheang I Kei</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Mingyue Cai</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">All officers and directors as a group (four persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,975,060</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54.88</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,975,060</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50.17</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>5% Stockholders</B></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Advance On Ventures Limited<B><SUP>(5)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,184,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.92</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,184,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.98</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Yimin Jin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,755,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.78</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,755,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.02</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Xiaoyuan Luo</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,648,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.24</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,648,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.53</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Nanzhen Shen</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,209,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.05</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,209,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.53</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Unless otherwise indicated, the business address of each of the individuals is 689-85 Xiaodong Road, Yongkang District, Tainan, Taiwan. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Based on 20,000,000 shares issued and outstanding as of the date of this prospectus. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Based on 21,875,000 shares issued and outstanding immediately after this offering.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents 3,712,800 shares beneficially owned by Mr. Steven I-Fang Cheng through Advance On Ventures Limited, a company incorporated in the British Virgin Islands, in which Mr. Cheng owns 34% equity interests. The registered address of Advance on Ventures Limited is Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chen-Yi Lee is the sole director and a 25% shareholder of Advance On Ventures Limited. Ms. Lee is the controlling person and has sole voting and dispositive power over shares beneficially owned by Advance on Ventures Limited.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 6, 2022, we
entered into an investment agreement with Hanyu Assets Co., Ltd. (&ldquo;Hanyu&rdquo;). Under this agreement, Hanyu will invest
US$2.5 million in the Company to acquire a 2.5% equity interest in the Company after the transaction, and Hanyu must pay US$2.5
million before June 30, 2022 to the Company&rsquo;s designated bank account. Hanyu transferred US$2.5 million to us on June 29,
2023. This agreement can only be terminated by mutual agreement in writing. The formation, validity, interpretation, performance,
and settlement of disputes arising from this agreement will be governed by the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 6, 2022, we entered
into an investment agreement with Newlink Technology Inc. (&ldquo;Newlink&rdquo;). Under this agreement, Newlink will invest
HK$8,000,000 to acquire a 1% equity interest in the Company after the transaction, and Newlink must pay HK$8,000,000 before
September 10, 2022, to the Company&rsquo;s designated bank account. We received the payment from Newlink on September 13, 2022. This
agreement can only be terminated by mutual agreement in writing. The formation, validity, interpretation, performance, and
settlement of disputes arising from this agreement will be governed by the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After receiving the fund from
Newlink and Hanyu, we issued 625,000 shares to Hanyu Assets Co. Ltd. and 250,000 shares to Newlink Technology Inc. on October 25, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 30, 2022, we entered into a Debt-for-Equity Exchange Agreement
with Pau Hung To, Jin Yimin, Luo Xiaoyuan, Shen Nanzhen, Wang Jian, and Chen Qiang (collectively, the &ldquo;Creditors&rdquo;) to settle
certain debts owed to the Creditors. Pursuant to the agreement, we issued 12,644,375 Common Stock to the Creditors to completely settle
the debt between the Creditors and us. Any disputes arising from this agreement must be submitted to China International Economic and
Trade Arbitration Commission&rsquo;s Shanghai Office for arbitration. The agreement cannot be amended unless all parties agree in writing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following description summarizes important
terms of our securities. For a complete description, you should refer to our certificate of incorporation and bylaws, forms of which
are incorporated by reference to the exhibits to the registration statement of which this prospectus is a part, as well as the relevant
portions of the Nevada law. References to our certificate of incorporation and bylaws are to our certificate of incorporation and our
bylaws, respectively, each of which will become effective upon completion of this offering.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are authorized to issue 400,000,000
shares of common stock, par value $0.001 per share. On May 16, 2023, we effected a forward stock split of all issued and outstanding shares
of 25,000,000 shares at a ratio of 1-to-4. We had 100,000,000 shares of common stock issued and outstanding after the forward stock split.
On October 15, 2024, we effected a 5 for 1 reverse share split. As of the date of this prospectus, we have 20,000,000 shares of common
stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of our Common Stock is entitled to one vote on all matters submitted
to a vote of the stockholders, including the election of directors. Except as otherwise required by law, the holders of Common Stock will
possess all voting power. Generally, all matters to be voted on by stockholders must be approved by a majority of the votes entitled to
be cast by all shares of Common Stock that are present in person or represented by proxy. Holders of Common Stock representing a majority
of our capital stock issued, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum
at any meeting of our stockholders. Our Articles of Incorporation do not provide for cumulative voting in the election of directors. Holders
of Common Stock have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Non-cumulative Voting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of shares of our Common Stock do not have cumulative voting rights;
meaning that the holders of 50.1% of the outstanding shares, voting for the election of directors, can elect all of the directors to be
elected, and, in such event, the holders of the remaining shares will not be able to elect any of our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
we have not paid any cash dividends to stockholders. The declaration of any future cash dividend will be at the discretion of our Board
and will depend upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other
pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings,
if any, in our business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exchange Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have applied to list our Common Stock on the Nasdaq Capital Market under
the trading symbol &ldquo;ADVB.&rdquo; This offering will occur only if our listing application is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar for our Common Stock is Transhare Corporation,
with an address at Bayside Center 1, 17755 North US Highway 19, Suite 140, Clearwater, FL 33764, telephone number is (303) 662-1112.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification of Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Articles
of Incorporation as amended, and Bylaws, we may indemnify an officer or director who is made a party to any proceeding, including a lawsuit,
because of his position, if he acted in good faith and in a manner he reasonably believed to be in or not opposed to our best interest,
provided, however, that (i) we will not indemnify such person against expenses incurred in connection with an action if he is threatened
but does not become a party unless the incurring of such expenses was authorized by the board of directors and (ii) we will not indemnify
against any amount paid in settlement unless our board of directors has consented to such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An officer or director is
not entitled to indemnification against costs or expenses incurred in connection with any action, commenced by such person against us
or any person who is or was a director, officer, fiduciary, employee or agent of our company unless and to the extent that the officer
or directors is successful on the merits in any such proceeding as to which such person is to be indemnified, we must indemnify him against
all expenses incurred, including attorney&rsquo;s fees. With respect to a derivative action, indemnity may be made only for expenses
actually and reasonably incurred in defending the proceeding, and if the officer or directors is judged liable, only by a court order.
The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted for directors, executive officers, or persons controlling us, we have
been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>SHARES ELIGIBLE FOR FUTURE
SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Before the closing of this offering,
there has been no public market for our Common Stock. We have applied to list our Common Stock on the Nasdaq Capital Market under the
trading symbol &ldquo;ADVB.&rdquo; We make no prediction as to the effect, if any, that market sales of our Common Stock or the availability
of our Common Stock for sale will have on the market price of Common Stock prevailing from time to time. Nevertheless, sales of substantial
amounts of our Common Stock in the public market, or the perception that such sales could occur, could adversely affect the market price
of our Common Stock and could impair our future ability to raise capital through the sale of equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon the completion of this offering,
we will have an aggregate of 21,875,000 shares of Common Stock outstanding, assuming the underwriters do not exercise their over-allotment
option. Of the outstanding Common Stock, all of the shares of Common Stock sold in this offering will be freely tradable, except that
any Common Stock purchased by &ldquo;affiliates&rdquo; (as that term is defined in Rule 144 under the Securities Act), may only be sold
in compliance with the limitations described below. After this offering, 20,000,000 shares of Common Stock will be deemed &ldquo;restricted
securities&rdquo; as defined in Rule 144. Restricted securities may be sold in the public market only if registered or if they qualify
for an exemption from registration under Rule 144 or Rule 701, promulgated under the Securities Act, which rules are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the contractual
restrictions described below and the provisions of Rule 144 and Rule 701, the restricted shares will be available for sale in the public
market as follows: shares of Common Stock will be eligible for sale upon the expiration of the lock-up agreements, described below, beginning
180 days after the completion of the offering subject to extension in certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule 144
as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is not
deemed to have been one of our affiliates for purposes of the Securities Act at any time during 90 days preceding a sale and who has
beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than
our affiliates, is entitled to sell such shares without complying with the manner of sale, volume limitation or notice provisions of
Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares
proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person
is entitled to sell such shares without complying with any of the requirements of Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule 144,
as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon expiration of
the lock-up agreements described above, within any three-month period beginning 90 days after the date of this prospectus, a number of
shares that does not exceed the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1% of the number of shares of Common Stock then outstanding, which will
equal approximately shares immediately after this offering; or</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">the average weekly trading volume of our Common Stock during the four calendar
weeks preceding the filing of a notice on Form 144 with respect to such sale.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales under Rule 144 by our affiliates or persons
selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability
of current public information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule 701,
any of our employees, directors, officers, consultants or advisors who purchase shares from us in connection with a compensatory stock
or option plan or other written agreement before the effective date of this offering are entitled to resell such shares 90 days after
the effective date of this offering in reliance on Rule 144, without having to comply with the holding period requirements or other restrictions
contained in Rule 701.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC has indicated that
Rule 701 will apply to typical stock options granted by an issuer before it becomes subject to the reporting requirements of the Exchange
Act, along with the shares acquired upon exercise of such options, including exercises after the date of this prospectus. Securities
issued in reliance on Rule 701 are restricted securities and, subject to the contractual restrictions described above, beginning 90 days
after the date of this prospectus, may be sold by persons other than affiliates, subject only to the manner of sale provisions of Rule
144 and by affiliates under Rule 144 without compliance with its one-year minimum holding period requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &ldquo;Underwriting&mdash;Lock-up
Agreements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TAX<FONT STYLE="font-family: Times New Roman, Times, Serif">ATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The following discussion of material Taiwan, PRC and United States federal
income tax consequences of an investment in our Common Stock is based upon laws and relevant interpretations thereof in effect as of the
date of this prospectus, all of which are subject to change. This discussion does not deal with all possible tax consequences relating
to an investment in our Common Stock, such as the tax consequences under state, local and other tax laws. To the extent that the discussion
relates to matters of Taiwan tax law, it represents the opinion of Wiseteam Law Firm, our Taiwan counsel. To the extent that the discussion
relates to matters of PRC tax law, it represents the opinion of AllBright, our PRC counsel.</I>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Taiwan
Taxation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a general summary of the principal Taiwan tax consequences
of the ownership and disposition of our Common Stock by and to a non-resident individual or non-resident entity holder (referred to herein
as a &ldquo;Non-Taiwan Holder&rdquo;). As used in the preceding sentence, a &ldquo;non-resident individual&rdquo; is generally a foreign
national who owns our Common Stock and is not physically present in Taiwan for 183 days or more during any calendar year, and a &ldquo;non-resident
entity&rdquo; is a corporation or a non-corporate body that owns our Common Stock and is organized under the laws of a jurisdiction other
than Taiwan. Holders should consult their tax advisors concerning the Taiwan tax consequences of holding our Common Stock and the laws
of any relevant taxing jurisdiction to which they are subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Capital gains from the sale or disposal of our
Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sale or disposal of the Common
Stock of a Nevada company is generally not regarded as the sale of Taiwan securities; thus, any gains generated therefrom by Non-Taiwan
Holders are not subject to Taiwan income tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Securities Transaction Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">Sale of the Common Stock of a Nevada company by Non-Taiwan Holders is generally
not subject to Taiwan securities transaction tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>People&rsquo;s Republic of China Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Enterprise Income Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Enterprise Income
Tax Law of the PRC, or the EIT Law, which became effective on January 1, 2008 and was subsequently amended on February 24, 2017 and December
29, 2018, and its implementing rules, enterprises are classified as resident enterprises and non-resident enterprises. PRC resident enterprises
typically pay an enterprise income tax at the rate of 25% while non-PRC resident enterprises without any branches in the PRC should pay
an enterprise income tax in connection with their income from the PRC at the tax rate of 10%. An enterprise established outside of the
PRC with its &ldquo;de facto management bodies&rdquo; located within the PRC is considered a &ldquo;resident enterprise,&rdquo; meaning
that it can be treated in a manner similar to a PRC domestic enterprise for enterprise income tax purposes. The implementing rules of
the EIT Law define a de facto management body as a managing body that in practice exercises &ldquo;substantial and overall management
and control over the production and operations, personnel, accounting, and properties&rdquo; of the enterprise. Enterprises qualified
as &ldquo;High and New Technology Enterprises&rdquo; are entitled to a 15% enterprise income tax rate rather than the 25% uniform statutory
tax rate. The preferential tax treatment continues as long as an enterprise can retain its &ldquo;High and New Technology Enterprise&rdquo;
status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EIT Law and the implementation
rules provide that an income tax rate of 10% should normally be applicable to dividends payable to investors that are &ldquo;non-resident
enterprises,&rdquo; and gains derived by such investors, which (a) do not have an establishment or place of business in the PRC or (b)
have an establishment or place of business in the PRC, but the relevant income is not effectively connected with the establishment or
place of business to the extent such dividends and gains are derived from sources within the PRC. Such income tax on the dividends may
be reduced pursuant to a tax treaty between China and other jurisdictions. Pursuant to the Arrangement Between the Mainland of China and
the Hong Kong Special Administrative Region for the Avoidance of Double Taxation on Income, or the Double Tax Avoidance Arrangement, and
other applicable PRC laws, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied the relevant
conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax on the dividends
the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5% upon receiving approval from in-charge
tax authority. However, based on the Notice on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties issued
on February 20, 2009 by the SAT, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such
reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential
tax treatment; and based on the Announcement on Relevant Issues Concerning the &ldquo;Beneficial Owners&rdquo; in Tax Treaties issued
on February 3, 2018 by the SAT and effective from April 1, 2018, which replaces the Notice on the Interpretation and Recognition of Beneficial
Owners in Tax Treaties and the Announcement on the Recognition of Beneficial Owners in Tax Treaties by the SAT, comprehensive analysis
based on the stipulated factor therein and actual circumstances shall be adopted when recognizing the &ldquo;beneficial owner&rdquo; and
agents and designated wire beneficiaries are specifically excluded from being recognized as &ldquo;beneficial owners.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On January 17, 2019, the State Taxation Administration
issued the notice on the scope of small-scale and low-profit corporate income tax preferential policies of the Ministry of Finance and
the State Administration of Taxation (&ldquo;MOF and SAT&rdquo;), [2019] No. 13 for small-scale and low-profit enterprises whose annual
taxable income is less than RMB1,000,000 (including RMB1,000,000), approximately $142,209, their income is reduced by 25% to the taxable
income, and enterprise income tax is paid at 20% tax rate, which is essentially resulting in a favorable income tax rate of 5%. While
for the portion of annual taxable income exceeding RMB1,000,000, approximately $142,209, but not more than RMB3,000,000, approximately
$426,627, the income is reduced by 50% to the taxable income, and enterprise income tax is paid at 20% tax rate, which is essentially
resulting in a favorable income tax rate of 10%. MOF and SAT [2021] No.12 provides an enterprise income tax rate of 2.5% on a small-scale
and low-profit enterprises whose annual taxable income less than RMB1,000,000, approximately $142,209, from January 1, 2021 to December
31, 2022. MOF and SAT [2022] No.13 also provides an enterprise income tax rate of 5% on a small-scale and low-profit enterprises whose
annual taxable income more than RMB1,000,000, approximately $142,209, but not more than RMB3,000,000, approximately $426,627, from January
1, 2022 to December 31, 2024. The qualifications of small-scale and low-profit enterprises were examined annually by the Tax Bureau. All
of the Company&rsquo;s Shanghai subsidiary met the criteria of small-scale and low-profit enterprises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Value-added Tax</I> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to applicable PRC
tax regulations, any entity or individual conducting business in the service industry used to be generally required to pay a business
tax at the rate of 5% on the revenues generated from providing such services. However, if the services provided are related to technology
development and transfer, such business tax may be exempted subject to approval by the relevant tax authorities. Whereas, pursuant to
the Provisional Regulations on Value-Added Tax of the PRC and its implementation regulations, unless otherwise specified by relevant laws
and regulations, any entity or individual engaged in the sales of goods, provision of processing, repairs and replacement services and
importation of goods into China is generally required to pay a value-added tax, or VAT, for revenues generated from sales of products,
while qualified input VAT paid on taxable purchase can be offset against such output VAT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2011, the Ministry
of Finance and the State Administration of Taxation promulgated the Pilot Plan for Imposition of Value-Added Tax to Replace Business Tax.
In March 2016, the Ministry of Finance and the State Administration of Taxation further promulgated the Notice on Fully Promoting the
Pilot Plan for Replacing Business Tax by Value-Added Tax, which became effective on May 1, 2016. Pursuant to the pilot plan and relevant
notices, VAT is generally imposed in lieu of business tax in the modern service industries, including the VATS, on a nationwide basis.
VAT of a rate of 6% applies to revenue derived from the provision of some modern services. Certain small taxpayers under PRC law are subject
to reduced value-added tax at a rate of 3%. Unlike business tax, a taxpayer is allowed to offset the qualified input VAT paid on taxable
purchases against the output VAT chargeable on the modern services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 4, 2018, the Ministry of Finance and
the State Administration of Taxation issued the Notice on Adjustment of VAT Rates, which came into effect on May 1, 2018. According to
the abovementioned notice, the taxable goods previously subject to VAT rates of 17% and 11%, respectively, become subject to lower VAT
rates of 16% and 10%, respectively, starting from May 1, 2018. Furthermore, according to the Announcement on Relevant Policies for Deepening
Value-added Tax Reform jointly promulgated by the Ministry of Finance, the State Administration of Taxation and the General Administration
of Customs, which became effective on April 1, 2019, the taxable goods previously subject to VAT rates of 16% and 10%, respectively, become
subject to lower VAT rates of 13% and 9%, respectively, starting from April 1, 2019. Under Provisional Regulations of the People&rsquo;s
Republic of China on Value-added Tax, amended and effective on November 19, 2017, for entities that are VAT small taxpayers, VAT is levied
at a levy rate of 3%. On February 29, 2020, the State Administration of Taxation issued the Announcement on Taxation Matters to Support
Individual Businesses in Resumption of Business, during the COVID-19, the small taxpayers are allowed to enjoy the preferred tax policy,
tax rate from 3% to 1% for the period from March 1, 2020 to December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>United States Federal Income Tax Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a discussion of United States federal income tax considerations
relating to the acquisition, ownership, and disposition of our Common Stock by a U.S. Holder, as defined below, that acquires our Common
Stock in this offering and holds our Common Stock as &ldquo;capital assets&rdquo; (generally, property held for investment) under the
United States Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;). This discussion is based upon existing United States
federal income tax law, which is subject to differing interpretations or change, possibly with retroactive effect. No ruling has been
sought from the Internal Revenue Service (the &ldquo;IRS&rdquo;) with respect to any United States federal income tax consequences described
below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion does not address all aspects
of United States federal income taxation that may be important to particular investors in light of their individual circumstances, including
investors subject to special tax rules&nbsp;(such as, for example, certain financial institutions, insurance companies, regulated investment
companies, real estate investment trusts, broker-dealers, traders in securities that elect mark-to-market treatment, partnerships and
their partners, tax-exempt organizations (including private foundations)), investors who are not U.S. Holders, investors that own (directly,
indirectly, or constructively) 10% or more of our voting shares, investors that hold their Common Stock as part of a straddle, hedge,
conversion, constructive sale or other integrated transaction), or investors that have a functional currency other than the U.S. dollar,
all of whom may be subject to tax rules&nbsp;that differ significantly from those summarized below. In addition, this discussion does
not address any tax laws other than the United States federal income tax laws, including any state, local, alternative minimum tax or
non-United States tax considerations, or the Medicare tax. Each potential investor is urged to consult its tax advisor regarding the United
States federal, state, local and non-United States income and other tax considerations of an investment in our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of this discussion,
a &ldquo;U.S. Holder&rdquo; is a beneficial owner of our Common Stock that is, for United States federal income tax purposes, (i)&nbsp;an
individual who is a citizen or treated as a tax resident of the United States, (ii)&nbsp;a corporation (or other entity treated as a corporation
for United States federal income tax purposes) created in, or organized under the laws of, the United States or any state thereof or the
District of Columbia, (iii)&nbsp;an estate the income of which is includible in gross income for United States federal income tax purposes
regardless of its source, or (iv)&nbsp;a trust (A)&nbsp;the administration of which is subject to the primary supervision of a United
States court and which has one or more United States persons who have the authority to control all substantial decisions of the trust
or (B)&nbsp;that has otherwise elected to be treated as a United States person under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If a partnership (or other entity
treated as a partnership for United States federal income tax purposes) is a beneficial owner of our Common Stock, the tax treatment of
a partner in the partnership will depend upon the status of the partner and the activities of the partnership. Partnerships and partners
of a partnership holding our Common Stock are urged to consult their tax advisors regarding an investment in our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The discussion set forth below
is addressed only to U.S. Holders that purchase Common Stock in this offering. Prospective purchasers are urged to consult their own tax
advisors about the application of the U.S. federal income tax rules&nbsp;to their particular circumstances as well as the state, local,
foreign and other tax consequences to them of the purchase, ownership and disposition of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Taxation of Dividends and Other Distributions
on our Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to the passive foreign
investment company rules&nbsp;discussed below, the gross amount of distributions made by us to you with respect to the Common Stock (including
the amount of any taxes withheld therefrom) will generally be includable in your gross income as dividend income on the date of receipt
by you, but only to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under
U.S. federal income tax principles). With respect to corporate U.S. Holders, the dividends will not be eligible for the dividends-received
deduction allowed to corporations in respect of dividends received from other U.S. corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With respect to non-corporate
U.S. Holders, including individual U.S. Holders, dividends will be taxed at the lower capital gains rate applicable to qualified dividend
income, provided that (1)&nbsp;the Common Stock are readily tradable on an established securities market in the United States, or we are
eligible for the benefits of an approved qualifying income tax treaty with the United States that includes an exchange of information
program, (2)&nbsp;we are not a passive foreign investment company (as discussed below) for either our taxable year in which the dividend
is paid or the preceding taxable year, and (3)&nbsp;certain holding period requirements are met. Under U.S. Internal Revenue Service authority,
Common Stock are considered for purpose of clause (1)&nbsp;above to be readily tradable on an established securities market in the United
States if they are listed on Nasdaq. You are urged to consult your tax advisors regarding the availability of the lower rate for dividends
paid with respect to our Common Stock, including the effects of any change in law after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">To the extent that the amount of the distribution exceeds our current and
accumulated earnings and profits (as determined under U.S. federal income tax principles), it will be treated first as a tax-free return
of your tax basis in your Common Stock, and to the extent the amount of the distribution exceeds your tax basis, the excess will be taxed
as capital gain. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder
should expect that a distribution will be treated as a dividend even if that distribution would otherwise be treated as a non-taxable
return of capital or as capital gain under the rules&nbsp;described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Taxation of Dispositions of Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will recognize taxable gain or loss on any sale, exchange or other
taxable disposition of a share equal to the difference between the amount realized (in U.S. dollars) for the share and your tax basis
(in U.S. dollars) in the Common Stock. The gain or loss will be capital gain or loss. If you are a non-corporate U.S. Holder, including
an individual U.S. Holder, who has held the Common Stock for more than one year, you may be eligible for reduced tax rates on any such
capital gains. The deductibility of capital losses is subject to limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Information Reporting and Backup Withholding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividend payments with respect
to our Common Stock and proceeds from the sale, exchange or redemption of our may be subject to information reporting to the U.S. Internal
Revenue Service and possible U.S. backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct
taxpayer identification number and makes any other required certification on U.S. Internal Revenue Service Form&nbsp;W-9 or who is otherwise
exempt from backup withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification
on U.S. Internal Revenue Service Form&nbsp;W-9. U.S. Holders are urged to consult their tax advisors regarding the application of the
U.S. information reporting and backup withholding rules.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal income tax liability, and you may
obtain a refund of any excess amounts withheld under the backup withholding rules&nbsp;by filing the appropriate claim for refund with
the U.S. Internal Revenue Service and furnishing any required information. We do not intend to withhold taxes for individual stockholders.
However, transactions effected through certain brokers or other intermediaries may be subject to withholding taxes (including backup withholding),
and such brokers or intermediaries may be required by law to withhold such taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>UNDERWRITING&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with this offering, we will enter into an underwriting agreement
with Craft Capital Management LLC, as representative (the &ldquo;Representative&rdquo;) of the underwriters named below. The Representative
may retain other brokers or dealers to act as sub-agents or selected dealers on their behalf in connection with this offering. Subject
to the terms and conditions of the underwriting agreement, each underwriter will agree to purchase from us, on a firm commitment basis,
the number of shares of Common Stock set forth opposite its name below, at the offering price less the underwriting discounts set forth
on the cover page of this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Underwriter</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common stock</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 84%"><FONT STYLE="font-size: 10pt">Craft Capital Management LLC</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;[&bull;]</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>1,875,000</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The underwriters are committed
to purchase all the shares of Common Stock offered by this prospectus if they purchase any shares pursuant to the underwriting agreement.
The underwriters are not obligated to purchase the shares covered by the underwriter&rsquo;s over-allotment option as described below.
The underwriting agreement provides that the obligation of the underwriters to purchase all of the shares of Common Stock being offered
to the public is subject to specific conditions, including the absence of any material adverse change in our business or in the financial
markets and the receipt of certain legal opinions, certificates and letters from us, our counsel and the independent auditors. The underwriters
reserve the right to withdraw, cancel, or modify offers to the public and to reject orders in whole or in part. In connection with this
offering, certain of the underwriters or securities dealers may distribute prospectuses electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Representative has advised
us that it proposes to offer the Common Stock to the public at the Primary Offering price set forth on the cover page of this prospectus
and to certain dealers at that Primary Offering price less a selling concession not in excess of $[&bull;] per share. After this offering,
the Primary Offering price, concession and reallowance to dealers may be reduced by the Representative. No such reduction shall change
the amount of proceeds to be received by us as set forth on the cover page of this prospectus. The securities are offered by the underwriters
as stated herein, subject to receipt and acceptance by them and subject to their right to reject any order in whole or in part. The underwriters
have informed us that they do not intend to confirm sales to any accounts over which they exercise discretionary authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify the
underwriters against specified liabilities, including liabilities under the Securities Act, and liabilities arising from breaches of representations
and warranties contained in the underwriting agreement, or to contribute to payments the underwriters may be required to make in respect
thereof.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Underwriting Commissions and Discounts and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriting discounts
for the shares of Common Stock to be sold in this offering are seven and one half percent (7.5%) of the Primary Offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table shows
the price per share and total Primary Offering price, underwriting discounts, and proceeds before expenses to us, assuming a $4.00 per
share offering price, which is the lower end of the price range set forth on the cover page of this prospectus. The total amounts are
shown assuming both no exercise and full exercise of the over-allotment option.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Per</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Share</B></P></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Without</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Over-Allotment</B></P></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>With</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Over-Allotment</B></P></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 49%"><FONT STYLE="font-size: 10pt"><B>Primary Offering price</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">4.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">7,500,000&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-size: 10pt">8,625,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>Underwriting discounts and commissions (7.5%)<SUP>(1)</SUP></B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">562,500</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">646,875</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Proceeds, before expenses, to us</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.70</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,937,500</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7,978,125</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt; text-align: left; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The fees do not include the representative&rsquo;s warrants or
expense reimbursement provisions described below.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to pay all
expenses relating to the offering, including, without limitation: (a) all filing fees and communication expenses relating to the registration
of the securities (including the over-allotment shares and the shares of Common Stock underlying the representative&rsquo;s warrants)
of the Company with the SEC; (b) all fees and expenses relating to the listing of the Common Stock on Nasdaq Capital Market; (c) all fees
associated with the review of the offering by FINRA; (d) all fees, expenses and disbursements relating to background checks of the Company's
officers and directors; (e) the registration, qualification or exemption of shares offered under &ldquo;blue sky&rdquo; securities laws
or the securities laws of other jurisdictions designated by the Representative; (f) all fees, expenses and disbursements relating to the
registration, qualification or exemption of the securities of the Company under the securities laws of such foreign jurisdictions; (g)
the costs of mailing and printing the offering materials; (h) the costs of preparing, printing and delivering certificates representing
the shares offered in the offering; (i) fees and expenses of the transfer agent for such shares; (j) stock transfer and/or stamp taxes,
if any, payable upon our transfer of the securities to the Representative; (k) the fees and expenses of our accountants; (l) the fees
and expenses of the Company&rsquo;s legal counsel and other agents and representatives; (m) the fees and expenses of the Representative&rsquo;s
legal counsel; (n) the costs associated with bound volumes of the Primary Offering materials as well as commemorative mementos and lucite
tombstones, each of which the Company or its designee will provide within a reasonable time after the closing of our Primary Offering
in such quantities as Craft Capital may reasonably requests; and (o) the reasonable cost of the Company for roadshow meetings and the
preparation of a power point presentation.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company will pay the reasonable and documented out-of-pocket expenses of the Representative actually incurred (including, but not limited
to reasonable and documented fees and expenses of due diligence and its legal counsel; all fees, expenses and disbursements relating to
background checks of the Company&rsquo;s officers and directors; and the reasonable cost for roadshow meetings) up to $200,000. The Company
shall pay the Representative a $50,000 advance toward Primary Offering expenses due and payable immediately upon signing the engagement
letter with the Representative, and an additional $50,000 payable to the Representative upon the receipt of the ''No Objection Letter&quot;
for the Primary Offering from FINRA. As of the date of this prospectus, we paid advance expenses to the Representative equal to US$50,000
upon executing the engagement letter. &nbsp;</FONT>&nbsp;<FONT STYLE="font-size: 10pt">The advance expense will be returned to us to the
extent such out-of-pocket accountable expenses are not actually incurred in accordance with FINRA Rule 5110(g)(4)(A). In addition, we
also agreed to pay a non-accountable expense allowance to the Representative equal to 1.0% of the gross proceeds received at the completion
of the offering.<B>&nbsp;</B></FONT></P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Representative&rsquo;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon completion of this offering,
we have agreed to issue warrants to the Representative or its designees to purchase 112,500 shares of Common Stock (or 129,375 shares
of Common Stock if the Representative exercises its over-allotment option in full) equal to 6% of the total number of shares of Common
Stock sold in this offering (including any shares sold in the offering to cover over-allotments) at an exercise price equal to 125% of
the offering price of the Common Stock sold in this offering. The underwriter warrants are exercisable at any time and from time to time,
in whole or in part,&nbsp;during the four and a half year period commencing six months following the date of commencement of sales of
the securities issued in this offering. The warrants are not redeemable by us. The Representative&rsquo;s warrants and the shares underlying
the warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e)(2)(B)(i).
The Representative (or permitted assignees under the FINRA Rule 5110(e)) may not sell, transfer, assign, pledge, or hypothecate the Representative&rsquo;s
warrants or the shares underlying the Representative&rsquo;s warrants, nor will they engage in any hedging, short sale, derivative, put,
or call transaction that would result in the effective economic disposition of the Representative&rsquo;s warrants or the underlying shares
for a period of six (6) months following the date of commencement of sales of the securities issued in this offering except as permitted
by FINRA Rule 5110(e)(2). The Representative or its designees will also be entitled to one-time demand registration and unlimited piggyback
rights of the sale of the shares underlying the Representative&rsquo;s warrants at our expense with a duration of no more than five (5)
years following the commencement of sales of securities issued in this offering as permitted by FINRA Rule 5110(g)(8)(C), and unlimited
&ldquo;piggyback&rdquo; registration rights with a duration of no more than seven (7) years following the commencement of sales of securities
issued in this offering as permitted by FINRA Rule 5110(g)(8)(D). The Representative&rsquo;s warrants will provide for adjustment in the
number and price of such warrants and the shares underlying such warrants in the event of recapitalization, merger, or other structural
transaction to prevent mechanical dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Over-Allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have granted to the Representative
an option, exercisable not later than 45 days after the closing date of this offering, to purchase up to 281,250 additional shares of
Common Stock equal to 15% of the number of shares of Common Stock sold in this offering at a price per share equal to the Primary Offering
price, less the underwriting discount. The Representative may exercise the option solely to cover over-allotments, if any, made in connection
with this offering. If any additional shares of Common Stock are purchased pursuant to the over-allotment option, the underwriters will
offer these shares of Common Stock on the same terms as those on which the other securities are being offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Right of First Refusal </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Provided that this offering is
completed, we have agreed to grant the Representative, for a period of twelve (12) months from the closing of this offering, a right of
first refusal to provide investment banking services to us on an exclusive basis in all matters for which investment banking services
are sought by the Company, including, without limitation to act as (a) exclusive financial advisor, sole investment banker, sole book-runner
and/or sole placement agent, for any underwritten public offering; (b) exclusive financial advisor, sole investment banker, sole book-runner
and/or sole placement agent in connection with any private offering of securities of the Company; (c) sole investment banker, sole book-runner,
sole placement agent and/or sole advisor, at the Representative's sole discretion with respect to financing or refinancing any indebtedness
using a manager or agent; and (d) financial advisor in connection with any sale or other transfer by the Company, directly or indirectly,
of a majority or controlling portion of its capital stock or assets to another entity, any purchase or other transfer by another entity,
directly or indirectly, of a majority or controlling portion of the capital stock or assets of the Company, and any merger or consolidation
of the Company with another entity, provided, however, that such right shall be&nbsp;subject to FINRA Rule 5110(g). Any decision by the
Representative to act in any such capacity shall be contained in separate agreements, which agreements would contain, among other matters,
provisions for customary fees for transactions of similar size and nature, as may be mutually agreed upon, and indemnification of the
Representative and shall be subject to general market conditions. In accordance with FINRA Rule 5110(g)(6)(A), such right of first refusal
shall not have a duration of more than three years from the date of commencement of sales of the securities issued in this offering or
the termination date of the engagement between us and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have agreed that, without the
prior written consent of the Representative, subject to certain exceptions, we will not, for a period of 180 days after the date of the
prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
    <TD STYLE="width: 20pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">issue, offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose
of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock;</P></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">file or caused to be filed any registration statement with the SEC relating
to the offering of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock,</P></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">complete any offering of debt securities of the
    Company, other than entering into a line of credit with a traditional bank or,</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of the shares of Common Stock,</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">whether any such transaction described
above is to be settled by delivery of shares of Common Stock or such other securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, for a period
of six months after the date of the prospectus, our directors, executive officers, and certain holders of 5% or more of the outstanding
shares of Common Stock as of the effective date of the registration statement of which this prospectus is a part and certain other stockholders,
without the prior written consent of the Representative, subject to limited exceptions, not to (i) offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend
or otherwise transfer or dispose of, directly or indirectly, any Common Stock or any securities convertible into or exercisable or exchangeable
for Common Stock, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, the Resale Shares
are not subject to the lock-up agreement inclusive of the Selling Stockholders holding more than 5% of our Common Stock. Moreover, the
lock-up restrictions will not apply to certain transactions, including without limitation (a) certain exercise of options or warrants
pursuant to any share incentive or award plan or share purchase plan of the Company, (b) certain qualified Rule 10b5-1 plans, (c) certain
transactions made in open market following the closing of the Offering, (d) as the results of certain qualified termination of employment,
(e) qualified conversion of outstanding security of the Company into Common Stock, and (f) pursuant to a bona fide third-party tender
offer for securities of the Company, merger, consolidation or other similar transaction that is approved by the board of directors of
the Company, made to all holders of Common Stock involving a change of control. For a complete description of the terms of the lock-up
agreement and the exceptions, refer to the form of lock-up agreement included in the Exhibit 1.1 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Representative has no present
intention to waive or shorten the lock-up&nbsp;period; however, the terms of the lock-up&nbsp;agreement may be waived at its discretion.
In determining whether to waive the terms of the lock-up&nbsp;agreements, the Representative may base its decision on its assessment of
the relative strengths of the securities markets and companies similar to ours in general, and the trading pattern of, and demand for,
our securities in general.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify the
underwriters against certain liabilities, including liabilities under the Securities Act and liabilities arising from breaches of representations
and warranties contained in the underwriting agreement, or to contribute to payments that the underwriters may be required to make in
respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Electronic Offer, Sale and Distribution of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;A prospectus in electronic
format may be made available on the Internet sites or through other online services maintained by one or more underwriters participating
in this offering, or by their affiliates. In those cases, prospective investors may view offering terms online and, depending upon the
particular underwriter, prospective investors may be allowed to place orders online. The underwriters may agree with us to allocate a
specific number of shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the
underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on, or that can be
accessed through, any underwriter&rsquo;s website and any information contained in any other website maintained by an underwriter is not
part of, and is not incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part,
has not been approved and/or endorsed by us or the underwriters, and it should not be relied upon by investors.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any underwriter who is a qualified
market maker on Nasdaq Capital Market may engage in passive market making transactions on Nasdaq Capital Market in accordance with Rule&nbsp;103
of Regulation&nbsp;M, during the business&nbsp;day prior to the pricing of the offering, before the commencement of offers or sales. Passive
market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a
passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent
bids are lowered below the passive market maker&rsquo;s bid, however, the passive market maker&rsquo;s bid must then be lowered when certain
purchase limits are exceeded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Pricing of this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have applied to list the Common
Stock on the Nasdaq Capital Market under the symbol &ldquo;ADVB.&rdquo; We believe that upon the completion of the offering contemplated
by this prospectus, we will meet the standards for listing on the Nasdaq Capital Market or other national exchange. However, there can
be no assurance that the Common Stock will be approved for listing on the Nasdaq Capital Market. We will not consummate and close this
offering without obtaining the approval from Nasdaq Capital Market. We do not intend to apply to list the Representative&rsquo;s warrants
on any security exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Primary Offering price
for the Common Stock will be determined through negotiations between us and the Representative. Among the factors to be considered in
these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the
Representative believe to be comparable to us, estimate of our business potential and earning prospects, the present state of our development,
and other factors deemed relevant. The offering price stated on the cover page of this prospectus should not be considered an indication
of the actual value of the shares of Common Stock sold in the Primary Offering. The values of such shares of Common Stock are subject
to change as a result of market conditions and other factors. We offer no assurances that the offering price will correspond to the price
at which our shares of Common Stock will trade in the public market subsequent to this offering or that an active trading market for our
shares will develop and continue after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Prior Public Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this offering, there
has been no public market for our securities and the Primary Offering price for our shares of Common Stock will be determined through
negotiations between us and the Representative. Among the factors to be considered in these negotiations will be prevailing market conditions,
our financial information, market valuations of other companies that we and the Representative believe to be comparable to our estimates
of our business potential, the present state of our development and other factors deemed relevant. The offering price for our shares of
Common Stock in this offering has been arbitrarily determined by the Company in its negotiations with the underwriters and does not necessarily
bear any direct relationship to the assets, operations, book or other established criteria of value of the Company. The offering price
stated on the cover page of this prospectus should not be considered an indication of the actual value of shares of our Common Stock sold
in the Primary Offering. The values of such shares are subject to change as a result of market conditions and other factors. We offer
no assurances that the offering price will correspond to the price at which our shares of Common Stock will trade in the public market
subsequent to this offering or that an active trading market for our shares of Common Stock will develop and continue after this offering.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Price Stabilization, Short Positions and Penalty
Bids</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with this offering,
the underwriters may engage in activities that stabilize, maintain or otherwise affect the price of shares of Common Stock during and
after this offering, including:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">stabilizing transactions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">short sales;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases to cover positions created by short sales;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">imposition of penalty bids; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 20pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">syndicate covering transactions.</P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stabilizing transactions consist
of bids or purchases made for the purpose of preventing or retarding a decline in the market price of shares of Common Stock while this
offering is in progress. Stabilization transactions permit bids to purchase the underlying security so long as the stabilizing bids do
not exceed a specified maximum. These transactions may also include making short sales of the Common Stock, which involve the sale by
the underwriters of a greater number of shares of Common Stock than they are required to purchase in this offering and purchasing shares
of Common Stock on the open market to cover short positions created by short sales. Short sales may be &ldquo;covered short sales,&rdquo;
which are short positions in an amount not greater than the underwriters&rsquo; option to purchase additional shares referred to above,
or may be &ldquo;naked short sales,&rdquo; which are short positions in excess of that amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The underwriters may close out
any covered short position by either exercising their option, in whole or in part, or by purchasing shares in the open market. In making
this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market
as compared to the price at which they may purchase shares through the over-allotment&nbsp;option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Naked short sales are short sales
made in excess of the over-allotment&nbsp;option. The underwriters must close out any naked short position by purchasing shares in the
open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure
on the price of the shares of Common Stock in the open market that could adversely affect investors who purchased in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The underwriters also may impose
a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by
it because the Representative has repurchased shares sold by or for the account of that underwriter in stabilizing or short covering transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These stabilizing transactions,
short sales, purchases to cover positions created by short sales, the imposition of penalty bids and syndicate covering transactions may
have the effect of raising or maintaining the market price of shares of Common Stock or preventing or retarding a decline in the market
price of our shares of Common Stock. As a result of these activities, the price of our shares of Common Stock may be higher than the price
that otherwise might exist in the open market. The underwriters may carry out these transactions on the Nasdaq Capital Market, in the
over-the-counter&nbsp;market or otherwise. Neither we nor the underwriters make any representation or prediction as to the effect that
the transactions described above may have on the price of the shares. Neither we, nor any of the underwriters make any representation
that the underwriters will engage in these stabilization transactions or that any transaction, once commenced, will not be discontinued
without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The underwriters and their respective
affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and
investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage
activities. The underwriters and their affiliates may, from time to time, engage in transactions with and perform services for us in the
ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary course of their
various business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt
and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own accounts and for
the accounts of their customers, and such investment and securities activities may involve securities and/or instruments of our Company.
The underwriters and their respective affiliates may also make investment recommendations and/or publish or express independent research
views in respect to such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short
positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Offer restrictions outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other than in the United States,
no action has been taken by us or the underwriter that would permit a public offering of the securities offered by this prospectus in
any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly
or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such
securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable
rules and regulations of that jurisdiction. Persons who come into possession of this prospectus are advised to inform themselves about
and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute
an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer
or a solicitation is unlawful.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin: 0pt 0; text-align: justify"><B><I>Australia</I></B>. This document has not
been lodged with the Australian Securities &amp; Investments Commission and is only directed to certain categories of exempt persons.
Accordingly, if you receive this document in Australia:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) you confirm and warrant
that you are either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i) &ldquo;sophisticated investor&rdquo;
under section 708(8)(a) or (b) of the Corporations Act 2001 (Cth) of Australia, or the Corporations Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) &ldquo;sophisticated investor&rdquo;
under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant&rsquo;s certificate to the company which
complies with the requirements of section 708(8)(c)(i) or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii) of the Corporations Act and related
regulations before the offer has been made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii) person associated with the company
under section 708(12) of the Corporations Act; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iv) &ldquo;professional investor&rdquo;
within the meaning of section 708(11)(a) or (b) of the Corporations Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and to the extent that you are unable
to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations
Act, any offer made to you under this document is void and incapable of acceptance; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) you warrant and agree that
you will not offer any of the Common Stock issued to you pursuant to this document for resale in Australia within 12 months of those Common
Stock being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the
Corporations Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Canada. </I></B>The Common
Stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument 45-106 <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted
customers, as defined in National Instrument 31-103 <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any
resale of the Common Stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities legislation in certain provinces or territories
of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains
a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser should refer to any applicable provisions
of the securities legislation of the purchaser&rsquo;s province or territory for particulars of these rights or consult with a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to section 3A.3 (or, in the case of securities
issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105 <I>Underwriting Conflicts</I>
(&ldquo;NI 33-105&rdquo;), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter
conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Cayman Islands. </I></B>This
prospectus does not constitute an invitation or offer to the public in the Cayman Islands of the Common Stock, whether by way of sale
or subscription. The underwriters have not offered or sold, and will not offer or sell, directly or indirectly, any Common Stock in the
Cayman Islands.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><B><I>European Economic Area.</I></B> In relation
to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &ldquo;Relevant Member State&rdquo;)
an offer to the public of any shares which are the subject of the offering contemplated by this prospectus may not be made in that Relevant
Member State unless the prospectus has been approved by the competent authority in such Relevant Member State or, where appropriate,
approved in another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with
the Prospectus Directive, except that an offer to the public in that Relevant Member State of any shares may be made at any time under
the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">to legal entities which are authorized or regulated to operate in the
    financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">to any legal entity which has two or more of (i) an average of at least
    250 employees during the last financial year; (ii) a total balance sheet of more than &euro;43,000,000 and (iii) an annual net turnover
    of more than &euro;50,000,000, as shown in its last annual or consolidated accounts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">by the underwriters to fewer than 100 or, if the Relevant Member State
    has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than &ldquo;qualified
    investors&rdquo; as defined in the Prospectus Directive) subject to obtaining the prior consent of the representatives for any such
    offer; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">in any other circumstances falling within Article 3(2) of the Prospectus
    Directive; provided that no such offer of shares shall result in a requirement for the publication by us or any representative of
    a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus
    Directive.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Any person making or intending to make any offer
of shares within the EEA should only do so in circumstances in which no obligation arises for us or the underwriters to produce a prospectus
for such offer. Neither we nor the underwriters have authorized, nor do they authorize, the making of any offer of shares through any
financial intermediary, other than offers made by the underwriters which constitute the final offering of shares contemplated in this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">For the purposes of this provision, and your
representation below, the expression an &ldquo;offer to the public&rdquo; in relation to any shares in any Relevant Member State means
the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as
to enable an investor to decide to purchase any shares, as the same may be varied in that Relevant Member State by any measure implementing
the Prospectus Directive in that Relevant Member State and the expression &ldquo;Prospectus Directive&rdquo; means Directive 2003/71/EC
(including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State) and includes any relevant implementing
measure in each Relevant Member State and the expression &ldquo;2010 PD Amending Directive&rdquo; means Directive 2010/73/EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Each person in a Relevant Member State who receives
any communication in respect of, or who acquires any shares under, the offer of shares contemplated by this prospectus will be deemed
to have represented, warranted and agreed to and with us and the underwriters that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">it is a &ldquo;qualified investor&rdquo; within the meaning of the law
    in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in the case of any shares acquired by it as a financial intermediary,
    as that term is used in Article 3(2) of the Prospectus Directive, (i) the shares acquired by it in the offering have not been acquired
    on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member State other than
    &ldquo;qualified investors&rdquo; (as defined in the Prospectus Directive), or in circumstances in which the prior consent of the
    representatives has been given to the offer or resale; or (ii) where shares have been acquired by it on behalf of persons in any
    Relevant Member State other than qualified investors, the offer of those shares to it is not treated under the Prospectus Directive
    as having been made to such persons.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, in the United Kingdom,
this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who
are &ldquo;qualified investors&rdquo; (as defined in the Prospectus Directive) (i) who have professional experience in matters relating
to investments falling within Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended,
or the Order, and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within
Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &ldquo;relevant persons&rdquo;). This document must
not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment
activity to which this document relates is only available to, and will be engaged in with, relevant persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<B><I>France.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;This
document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in
France within the meaning of Article L.411-1&nbsp;of the French Monetary and Financial Code (Code Mon&eacute;taire et Financier) and Articles
211-1&nbsp;et seq. of the General Regulation of the French Autorit&eacute; des March&eacute;s Financiers (&ldquo;AMF&rdquo;). The securities
have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This document and any other offering
material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may
not be distributed or caused to distributed, directly or indirectly, to the public in France.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Such offers, sales and distributions
have been and shall only be made in France to (i) qualified investors (investisseurs qualifi&eacute;s) acting for their own account, as
defined in and in accordance with Articles L.411-2-II-2&deg; and D.411-1&nbsp;to D.411-3, D. 744-1, D.754-1&nbsp;and D.764-1&nbsp;of the
French Monetary and Financial Code and any implementing regulation; and/or (ii) a restricted number of non-qualified&nbsp;investors (cercle
restreint d&rsquo;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&nbsp;and D.411-4,
D.744-1, D.754-1&nbsp;and D.764-1&nbsp;of the French Monetary and Financial Code and any implementing regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to Article 211-3&nbsp;of
the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly)
to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1&nbsp;and L.621-8&nbsp;to L.621-8-3&nbsp;of
the French Monetary and Financial Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Hong Kong</I></B>. The Common
Stock may not be offered or sold in Hong Kong by means of any document other than (i) in circumstances which do not constitute an offer
to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32, Laws of Hong Kong), or
(ii) to &ldquo;professional investors&rdquo; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and
any rules made thereunder, or (iii) in other circumstances which do not result in the document being a &ldquo;prospectus&rdquo; within
the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation
or document relating to the Common Stock may be issued or may be in the possession of any person for the purpose of issue (in each case
whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in
Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to Common Stock which are or are intended
to be disposed of only to persons outside Hong Kong or only to &ldquo;professional investors&rdquo; within the meaning of the Securities
and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Malaysia</I></B>. The shares
have not been and may not be approved by the securities commission Malaysia, or SC, and this document has not been and will not be registered
as a prospectus with the SC under the Malaysian capital markets and services act of 2007, or CMSA. Accordingly, no securities or offer
for subscription or purchase of securities or invitation to subscribe for or purchase securities are being made to any person in or from
within Malaysia under this document except to persons falling within any of paragraphs 2(g)(i) to (xi) of schedule 5 of the CMSA and distributed
only by a holder of a capital markets services license who carries on the business of dealing in securities and subject to the issuer
having lodged this prospectus with the SC within seven days from the date of the distribution of this prospectus in Malaysia. The distribution
in Malaysia of this document is subject to Malaysian laws. Save as aforementioned, no action has been taken in Malaysia under its securities
laws in respect of this document. This document does not constitute and may not be used for the purpose of a public offering or an issue,
offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the approval of the SC or the registration
of a prospectus with the SC under the CMSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<B><I>Ireland.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The
information in this document does not constitute a prospectus under any Irish laws or regulations, and this document has not been filed
with or approved by any Irish regulatory authority, as the information has not been prepared in the context of a public offering of securities
in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &ldquo;Prospectus Regulations&rdquo;).
The shares of Common Stock have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland
by way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations; and (ii) fewer
than 100 natural or legal persons who are not qualified investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Japan</I></B>. The Common
Stock have not been and will not be registered under the Financial Instruments and Exchange Law of Japan, and Common Stock will not be
offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means
any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering
or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to any exemption from the registration requirements
of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial
guidelines of Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Malaysia.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>The
shares of Common Stock have not been and may not be approved by the securities commission Malaysia, or SC, and this document has not been
and will not be registered as a prospectus with the SC under the Malaysian capital markets and services act of 2007, or CMSA.&nbsp;Accordingly,
no securities or offer for subscription or purchase of securities or invitation to subscribe for or purchase securities are being made
to any person in or from within Malaysia under this document except to persons falling within any of paragraphs 2(g)(i)&nbsp;to (xi)&nbsp;of
schedule 5 of the CMSA and distributed only by a holder of a capital markets services license who carries on the business of dealing in
securities and subject to the issuer having lodged this prospectus with the SC within seven&nbsp;days from the date of the distribution
of this prospectus in Malaysia. The distribution in Malaysia of this document is subject to Malaysian laws. Save as aforementioned, no
action has been taken in Malaysia under its securities laws in respect of this document. This document does not constitute and may not
be used for the purpose of a public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase
any securities requiring the approval of the SC or the registration of a prospectus with the SC under the CMSA.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>People&rsquo;s Republic
of China</I></B>. This prospectus has not been and will not be circulated or distributed in the PRC, and Common Stock may not be offered
or sold, and will not be offered or sold to any person for re-offering or resale, directly or indirectly, to any resident of the PRC except
pursuant to applicable laws and regulations of the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Singapore</I></B>. This
prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of our Common Stock may not be
circulated or distributed, nor may our Common Stock be offered or sold, or be made the subject of an invitation for subscription or purchase,
whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities
and Futures Act, Chapter 289 of Singapore, or SFA, (ii) to a relevant person or any person pursuant to Section 275(1A), and in accordance
with the conditions specified in Section 275 of the SFA, and in accordance with the conditions specified in Section 275 of the SFA or
(iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject
to compliance with conditions set forth in the SFA.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Where our Common Stock are subscribed
or purchased under Section 275 by a relevant person which is: (a) a corporation (which is not an accredited investor as defined in Section
4A of the SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold
investments and each beneficiary of the trust is an individual who is an accredited investor; shares, debentures and units of shares and
debentures of that corporation or the beneficiaries&rsquo; rights and interest (howsoever described) in that trust shall not be transferred
within six months after that corporation or that trust has acquired the Common Stock under Section 275 of the SFA, except: (1) to an institutional
investor (for corporations under Section 274 of the SFA) or to a relevant person defined in Section 275(2) of the SFA, or to any person
pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such
rights and interest in that trust are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency)
for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations,
in accordance with the conditions, specified in Section 275 of the SFA; (2) where no consideration is or will be given for the transfer;
or (3) where the transfer is by operation of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Switzerland.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The
shares of Common Stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&ldquo;SIX&rdquo;)
or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure
standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility
in Switzerland. Neither this document nor any other offering material relating to the shares of Common Stock may be publicly distributed
or otherwise made publicly available in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Taiwan </I></B>The Common
Stock have not been and will not be registered or filed with, or approved by, the Financial Supervisory Commission of Taiwan pursuant
to relevant securities laws and regulations and may not be offered or sold in Taiwan through a public offering or in circumstances which
constitute an offer within the meaning of the Securities and Exchange Act of Taiwan or relevant laws and regulations that require a registration,
filing, or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer or sell
the Common Stock in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><I>Thailand.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>This
prospectus does not, and is not intended to, constitute a public offering in Thailand. The shares of Common Stock may not be offered or
sold to persons in Thailand, unless such offering is made under the exemptions from approval and filing requirements under applicable
laws, or under circumstances which do not constitute an offer for sale of the shares of Common Stock to the public for the purposes of
the Securities and Exchange Act of 1992 of Thailand, nor require approval from the Office of the Securities and Exchange Commission of
Thailand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>United
Kingdom</I></B><I>.</I> An offer of the Common Stock may not be made to the public in the United Kingdom within the meaning of Section
102B of the Financial Services and Markets Act 2000, as amended, or the FSMA, except to legal entities that are authorized or regulated
to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities or
otherwise in circumstances that do not require the publication by the company of a prospectus pursuant to the Prospectus Rules of the
Financial Services Authority, or the FSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B><I>Vietnam.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;This
offering of shares of Common Stock has not been and will not be registered with the State Securities Commission of Vietnam under the Law
on Securities of Vietnam and its guiding decrees and circulars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An invitation or inducement to
engage in investment activity (within the meaning of Section 21 of FSMA) may only be communicated to persons who have professional experience
in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order
2005 or in circumstances in which Section 21 of FSMA does not apply to the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All applicable provisions of the
FSMA with respect to anything done by the underwriters in relation to the shares must be complied with in, from or otherwise involving
the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are represented by VCL Law
LLP with respect to U.S. federal and New York State law in connection with this offering. Ortoli Rosenstadt LLP has acted as counsel to
the Representative. The validity of the Common Stock offered in this offering and legal matters as to Nevada law will be passed upon for
us by Fennemore Craig, P.C. Certain legal matters as to Taiwan law will be passed upon for us by Wiseteam Law Firm. Certain legal matters
as to PRC law will be passed upon for us by AllBright Law Offices. VCL Law LLP may rely upon Wiseteam Law Firm with respect to matters
governed by Taiwan law and upon AllBright Law Offices with respect to matters governed by PRC law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements
for the fiscal years ended June 30, 2024 and 2023, included in this prospectus have been so included in reliance on the report of WWC,
P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The
office of WWC, P.C. is located at 2010 Pioneer Ct, San Mateo, CA 94403.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c_001"></A>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are organized under the
laws of the state of Nevada. Substantially all of our assets are located outside the United States. In addition, most of our officers
and directors, including director nominees, are nationals or residents of jurisdictions other than the United States, and all or a substantial
portion of their assets are located outside the United States. Specifically, our Chairman of the Board and Chief Executive Officer, is
a U.S. citizen and lives in Taiwan; Our CTO, CFO, and the other director of the Board live in and are residents of Taiwan, Mainland China,
and Hong Kong, respectively. Furthermore, none of our three independent director nominees are residents of the United States. Specifically,
Jing Zhang and Mingyue Cai are Chinese citizens residing in China, and Cheang I Kei is a resident of Macau.&nbsp; As a result, it may
be difficult for investors to effect service of process within the United States upon us or these persons, or to enforce judgments obtained
in U.S. courts against us or them, including judgments predicated upon the civil liability provisions of the securities laws of the United
States or any state in the United States. It may also be difficult for you to enforce judgments obtained in U.S. courts based on the civil
liability provisions of the U.S. federal securities laws against us and our officers and directors.</P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have appointed Cogency Global Inc. as our
agent to receive service of process in any action against us in any U.S. federal or state court arising out of this offering or any purchase
or sale of securities in connection with this offering. The address of our agent is 122 East 42nd Street, 18th Floor, New York, NY 10168.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Hong Kong, foreign judgments
can be enforced under statute under the Foreign Judgments (Reciprocal Enforcement) Ordinance or under common law. The Foreign Judgments
(Reciprocal Enforcement) Ordinance is a registration scheme for the recognition and enforcement of foreign judgments based on reciprocity
but the United States is not a designated country under the Foreign Judgments (Reciprocal Enforcement) Ordinance. As a result, a judgment
rendered by a court in the United States, including as a result of administrative actions brought by regulatory authorities, such as the
SEC, and other actions, will not be enforced by the Hong Kong courts under the statutory regime. However, the common law permits an action
to be brought upon a foreign judgment. That is to say, a foreign judgment itself may form the basis of a cause of action since the judgment
may be regarded as creating a debt between the parties to it. In a common law action for enforcement of a foreign judgment in Hong Kong,
the enforcement is subject to various conditions, including but not limited to, that the foreign judgment is a final judgment conclusive
upon the merits of the claim, the judgment is for a liquidated amount in a civil matter and not in respect of taxes, fines, penalties,
or similar charges, the proceedings in which the judgment was obtained were not contrary to natural justice, and the enforcement of the
judgment is not contrary to public policy of Hong Kong. Such a judgment must be for a fixed sum and must also come from a &ldquo;competent&rdquo;
court as determined by the private international law rules applied by the Hong Kong courts. The defenses that are available to a defendant
in a common law action brought on the basis of a foreign judgment include lack of jurisdiction, breach of natural justice, fraud, and
contrary to public policy. However, a separate legal action for debt must be commenced in Hong Kong in order to recover such debt from
the judgment debtor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AllBright Law Offices,
our counsel as to Chinese law, has advised us that there is uncertainty as to whether Chinese courts would (1) recognize or enforce
judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of
the securities laws of the United States or any state in the United States, or (2) entertain original actions brought in China
against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States.
Furthermore, AllBright Law Offices have advised us that, as of the date of this prospectus, no treaty or other form of reciprocity
exists between the United States and China governing the recognition and enforcement of judgments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AllBright Law Offices
has advised us that the recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedure Law. Chinese
courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedure Law based either
on treaties between China and the country where the judgment is made or on principles of reciprocity between jurisdictions.
AllBright Law Offices has advised us further that under Chinese law, courts in China will not recognize or enforce a foreign
judgment against us or our directors and officers if they decide that the judgment violates the basic principles of Chinese law or
national sovereignty, security or social public interest. As there exists no treaty or other form of reciprocity between China and
the United States governing the recognition and enforcement of judgments as of the date of this prospectus, including those
predicated upon the liability provisions of the United States federal securities laws, there is uncertainty whether and on what
basis a Chinese court would enforce judgments rendered by United States courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Wiseteam Law Firm, our counsel as to Taiwan law, has informed us that any final judgment obtained against us, our directors or executive officers,
or our Taiwan subsidiary in any court other than the courts of Taiwan in respect of any legal suit or proceeding will be enforced by the
courts of Taiwan without further review of the merits only if the court of Taiwan in which enforcement is sought is satisfied that: (i)&nbsp;the
court rendering the judgment had jurisdiction over the subject matter according to the laws of Taiwan; (ii)&nbsp;the judgment and the
legal procedures resulting in the judgment were not contrary to the public order or good morals of Taiwan; (iii)&nbsp;if the judgment
was rendered by default by the court rendering the judgment, (a)&nbsp;we or such persons were duly served within a reasonable time in
the jurisdiction of such court in accordance with the laws and regulations of such jurisdiction or (b)&nbsp;process was served on us or
such persons with judicial assistance of Taiwan; and (iv)&nbsp;judgments of the courts of Taiwan would be recognized and enforceable in
the jurisdiction of the court rendering the judgment on a reciprocal basis. Moreover, Wiseteam Law Firm has advised us that a party seeking
to remit money in the process of enforcing a foreign judgment in Taiwan would, except under limited circumstances, be required to obtain
foreign exchange approval from the Central Bank of the Republic of China (Taiwan) for the remittance out of Taiwan of any amounts recovered
in respect of such judgment denominated in a currency other than New Taiwan Dollars.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>WHERE YOU CAN FIND MORE
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC a registration statement on Form S-1 (including
the exhibits, schedules and amendments to the registration statement) under the Securities Act with respect to the shares of our Common
Stock offered by this prospectus. This prospectus does not contain all the information set forth in the registration statement. For further
information with respect to us and the shares of our Common Stock to be sold in this offering, we refer you to the registration statement.
Statements contained in this prospectus as to the contents of any contract, agreement or other documents to which we make reference are
not necessarily complete. In each instance, we refer you to the copy of such contract, agreement or other document filed as an exhibit
to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual, quarterly
and current reports, and other information with the SEC. Our filings with the SEC are available to the public on the SEC&rsquo;s website
at http://www.sec.gov. The information we file with the SEC or contained on or accessible through our corporate web site or any other
web site that we may maintain is not part of this prospectus or the registration statement of which this prospectus is a part. You may
read and copy this information at the Public Reference Room of the SEC located at 100 F Street, N.E., Washington, D.C. 20549. Please
call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. The SEC maintains an internet site
that contains periodic and current reports, information statements and other information regarding issuers that file electronically with
the SEC. The address of the SEC&rsquo;s website is <U>http://www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
                                            dealer, salesperson or any other person is authorized to give any information or make any
                                            representations in connection with this offering other than those contained in this prospectus
                                            and, if given or made, the information or representations must not be relied upon as having
                                            been authorized by us. This prospectus does not constitute an offer to sell or a solicitation
                                            of an offer to buy any security other than the securities offered by this prospectus, or
                                            an offer to sell or a solicitation of an offer to buy any securities by anyone in any jurisdiction
                                            in which the offer or solicitation is not authorized or is unlawful.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until,
all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a
prospectus. This is in an addition to the dealers obligation to deliver a prospectus when acting as underwriters and with respect to
their unsold allotments or subscriptions.&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="index"></A>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 90%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><A HREF="#fin_001"><FONT STYLE="font-size: 10pt">Report of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#fin_001"><FONT STYLE="font-size: 10pt">&nbsp;F-2&nbsp;</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#fin_002"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Balance Sheets as of September 30, 2024 and June 30, 202</FONT><FONT STYLE="font-size: 10pt"><U>4</U></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#fin_002"><FONT STYLE="font-size: 10pt">F-3</FONT></A></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-left: 14.2pt; text-indent: -14.2pt"><A HREF="#fin_003"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three-month Periods Ended September 30, 2024 and 202</FONT><FONT STYLE="font-size: 10pt"><U>3</U></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#fin_003"><FONT STYLE="font-size: 10pt">&nbsp;F-4</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-left: 14.2pt; text-align: justify; text-indent: -14.2pt"><A HREF="#fin_004"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Statements of Stockholders&rsquo; Equity for the Three-month Periods Ended September 30, 2024 and 202</FONT><FONT STYLE="font-size: 10pt"><U>3</U></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#fin_004"><FONT STYLE="font-size: 10pt">&nbsp;F-5</FONT></A></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-left: 14.2pt; text-indent: -14.2pt"><A HREF="#fin_005"><FONT STYLE="font-size: 10pt">Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Three-month Periods Ended September 30, 2024 and 202</FONT><FONT STYLE="font-size: 10pt"><U>3</U></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#fin_005"><FONT STYLE="font-size: 10pt">&nbsp;F-6</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#fin_006"><FONT STYLE="font-size: 10pt">Notes to Unaudited Interim Condensed Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#fin_006"><FONT STYLE="font-size: 10pt">&nbsp;F-7</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 90%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#reportofinde"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#reportofinde"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-24</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><A HREF="#a_112"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets
    as of June 30, 2024 and 2023</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_112"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-25</FONT></A></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><A HREF="#a_113"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations and Comprehensive Income (Loss) for the Financial Years Ended June 30, 2024 and 2023</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_113"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-26</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-left: 21.3pt; text-indent: -21.3pt"><A HREF="#a_114"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Changes in Stockholders&rsquo; Equity for the Financial Years Ended June 30, 2024 and 2023&nbsp;</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_114"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-27</FONT></A></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#a_115"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Cash Flows for the Financial Years Ended June 30, 2024 and 2023</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_115"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-28</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><A HREF="#a_116"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial
    Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><A HREF="#a_116"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-29</FONT></A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 125; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc051_img16.jpg" ALT=""><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fin_001"></A><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-size: 10pt">To:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">The Board of Directors and Stockholders of</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have reviewed the accompanying unaudited interim
condensed consolidated balance sheet of Advanced Biomed Inc. and its subsidiaries (collectively the &ldquo;Company&rdquo;) as of September
30, 2024, and the related unaudited interim condensed consolidated statements of operations and comprehensive loss, stockholders&rsquo;
equity, and cash flows for the three-month periods ended September 30, 2024 and 2023, and the related notes (collectively referred to
as the &ldquo;unaudited interim condensed consolidated financial statements&rdquo;). Based on our reviews, we are not aware of any material
modifications that should be made to the accompanying interim financial statements for them to be in conformity with accounting principles
generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have previously audited, in accordance with
the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company
as of June 30, 2024, and the related statements of operations and comprehensive loss, stockholders&rsquo; equity and cash flows for the
year then ended (not presented herein); and in our report dated October 28, 2024, we expressed an unqualified opinion with a paragraph
indicating that there was substantial doubt regarding the Company&rsquo;s ability to continue as a going concern. In our opinion, the
information set forth in the accompanying consolidated balance sheet as of June 30, 2024, is fairly stated, in all material respects,
in relation to the consolidated balance sheet from which it has been derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Explanatory Paragraph &mdash; Substantial Doubt
about the Company&rsquo;s Ability to Continue as a Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As described in Note 2, the Company has a significant working
capital deficiency, has significant net cash outflows from operating activities and needs to raise additional funds to meet its obligations
and sustain its operations. These conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.
Management&rsquo;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis for Review Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These interim consolidated financial statements
are the responsibility of the Company&rsquo;s management. We conducted our review in accordance with the standards of the PCAOB. A review
of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for
financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with standards of the PCAOB,
the objective of which is the expression of an opinion regarding the consolidated financial statements taken as a whole. Accordingly,
we do not express such an opinion. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WWC, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCAOB ID No. 1171</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Mateo, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 7, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc051_img17.jpg" ALT=""><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_002"></A>ADVANCED BIOMED INC.AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE
SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As of </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30,</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: justify; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,646,992</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,607,973</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Prepaid expenses and other current assets, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">485,744</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">443,137</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,132,736</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,051,110</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">477,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">524,528</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Right-of-use assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,078</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,740</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,070</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">118,998</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify; padding-left: 10pt">Deferred initial public offering (&ldquo;IPO&rdquo;) costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">655,671</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">638,871</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total non-current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,341,035</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,409,137</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,473,771</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,460,247</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Accounts payable, accruals, and other current liabilities (including amount due to related parties &ndash; major stockholders and related corporations of $317,777 and $879,622 respectively, as of September 30, 2024 and $113,812&nbsp;and $674,262, respectively, as of June 30, 2024 <SUP>(1)</SUP>)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,253,327</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,670,249</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Lease payable - current</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56,045</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62,211</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,309,372</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,732,460</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 9pt">Lease payable &ndash; non-current</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64,529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64,529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,379,941</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,796,989</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Commitments and contingencies</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Common stock $0.001 par value per share; as of September 30, 2024 and June 30, 2024; 400,000,000 and 400,000,000 shares authorized; 20,000,000 and 20,000,000 shares issued and outstanding, respectively*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,493,989</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,493,989</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -7.1pt; padding-left: 14.2pt">&nbsp;Accumulated deficits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,239,655</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,974,075</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Accumulated other comprehensive income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">819,496</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,123,344</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,093,830</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,663,258</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,473,771</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,460,247</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Giving retroactive effect to the 4 for 1 share
split effected on May 16, 2023 and 5 for 1 reverse share split effected on October 15, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px"><FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">See Note 12 for disclosure of related parties amounts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
these unaudited interim condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_003"></A>ADVANCED BIOMED INC.AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS AND COMPREHENSIVE INCOME(LOSS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the three-month periods </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ended September 30,</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(181,703</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(169,185</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(338,324</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(271,060</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(520,027</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(440,245</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">254,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(331,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">254,447</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(331,071</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss before tax expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(265,580</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(771,316</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(265,580</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(771,316</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Foreign currency translation (loss) gain, net of taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(303,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">270,872</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(569,428</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(500,444</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">basic and diluted*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.04</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Weighted average number of shares of common stock in computing net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">basic and diluted*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Giving retroactive effect to the 4 for 1 share
split effected on May 16, 2023 and 5 for 1 reverse share split effected on October 15, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
these unaudited interim condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B><A NAME="fin_004"></A>ADVANCED BIOMED INC.AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS
OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>No. of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>shares*</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount*</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Additional </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>paid-</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>in capital*</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Accumulated</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>other</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>comprehensive</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>income</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Accumulated</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>deficit</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%">Balance as of July 1, 2023</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">20,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">20,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">13,673,365</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">804,020</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(13,191,797</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">1,305,588</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(771,316</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(771,316</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">270,872</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">270,872</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of September 30, 2023</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,000,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">13,673,365</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,074,892</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(13,963,113</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">805,144</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance as of July 1, 2024</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">20,000,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">20,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">16,493,989</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,123,344</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(15,974,075</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,663,258</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(265,580</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(265,580</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(303,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(303,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of September 30, 2024</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,000,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16,493,989</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">819,496</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(16,239,655</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,093,830</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Giving retroactive effect to the 4 for 1 share split effected on
May 16, 2023 and 5 for 1 reverse share split effected on October 15, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fin_005"></A><B>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the three-month periods ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30,</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(265,580</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(771,316</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Adjustment:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,218</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,309</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Changes in operating assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42,607</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,379</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable, accruals and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">173,753</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Lease obligations, net cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,536</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other non-current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,915</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest received</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,680</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(619,138</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Purchase of equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,978</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,978</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Payment of deferred initial public offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,800</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amount due to related parties &ndash; major stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Amount due to related parties &ndash; related corporations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">205,360</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">313,206</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">392,525</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">313,206</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Foreign currency effect</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(303,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">270,871</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net change in cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,019</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash at beginning of the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,607,973</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,622,279</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash at year end</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,646,992</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,587,218</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net decrease in cash</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,019</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplementary Cash Flow Information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash paid for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid for taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited interim condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fin_006"></A><B>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. ORGANIZATION AND PRINCIPAL ACTIVITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, Advanced Biomed Inc. (the &ldquo;Company&rdquo;)
was incorporated in the State of Nevada, as an investment holding company. The Company&rsquo;s principal executive offices are located
in Tainan City, Taiwan. The Company has no substantive operations and assets. It is holding Company that holds all of the issued and outstanding
shares of Advanced Biomed HK Limited and Advanced Biomed Inc. (Taiwan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><I>(1)</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Establishment of Advanced Biomed HK Limited </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2021, the Company incorporated a
wholly owned subsidiary, Advanced Biomed HK Limited, in Hong Kong to facilitate market development and commercialization of the Company&rsquo;s
oncology products for sale and distribution in the People&rsquo;s Republic of China (the &ldquo;PRC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><I>(2)</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Acquisition of Shanghai Sglcell Biotech Co., Ltd. and its subsidiaries</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2022, Advanced Biomed HK Limited
acquired 100% equity interest of Shanghai Sglcell Biotech Co., Ltd. Shanghai Sglcell Biotech Co., Ltd. was established in the PRC on April
12, 2019. It is engaged in the establishment and operation of medical clinics in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shanghai Sglcell Biotech Co., Ltd. owns 100% equity
interest of two subsidiaries namely 1.) Shandong Sglcell Medical Devices Co., Ltd. and 2.) Nanjing Yitian Biotech Co., Ltd. Shandong Sglcell
Medical Devices Co., Ltd. was incorporated in the PRC on July 8, 2021 to carry out the establishment of medical clinics, and the supply
of medical products and services to clinics in the PRC. Nanjing Yitian Biotech Co., Ltd. was established in the PRC on January 6, 2017.
Nanjing Yitian Biotech Co., Ltd. wholly owns a subsidiary, Beijing Yitan Jiarui Technology Co. Ltd., which was established in the PRC
on October 20, 2017. Both were established to carry out marketing and clinical services in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 8, 2023, Shanghai Sglcell Biotech Co.,
Ltd. transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co.,
Ltd., to independent third-party individuals at aggregate consideration of CNY500,000 (approximately US$71,942) without any other obligations
arising from the transfer. Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd. have not commenced
business activity since it was acquired on January 1, 2022 and the Company believed the transfer will improve in operational efficiency.
The consideration is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal
company on May 31, 2023, as of the date of May 31, 2023, the net assets value of Nanjing Yitian Biotech Co., Ltd. and its subsidiary,
Beijing Yitan Jiarui Technology Co., Ltd., was CNY498,587 (approximately US$71,739).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 9, 2023, Shandong Sglcell Biotech Co.,
Ltd., the wholly owned subsidiary of Shanghai Sglcell Biotech Co., Ltd., was transferred to independent third-party individuals at zero
consideration without any other obligations arising from the transfer. Shandong Sglcell Biotech Co., Ltd. has been inactive since it was
incorporated on July 8, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration is determined
by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May 31, 2023, as
of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><I>(3)</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Subsidiary established under Advanced Biomed HK Limited</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed HK Limited incorporated a wholly
owned subsidiary, Sglcell (Huangshan) Biotech Co., Ltd., in the PRC on March 4, 2022; it was established for the expected future manufacturing
of medical devices in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2023, Sglcell (Huangshan) Biotech
Co., Ltd., the wholly owned subsidiary of Advanced Biomed HK Limited, was transferred to an independent third-party corporation at zero
consideration without any other obligations arising from the transfers. Sglcell (Huangshan) Biotech Co., Ltd. has been dormant since its
incorporation date from March 4, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration
is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May
31, 2023, as of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><I>(4)</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Reorganization of Advanced Biomed Inc. (Taiwan) </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed Inc. (Taiwan) was established
in Taiwan on September 1, 2014. It is primarily focused on mainly operates as a research and development of new center for technologies
in the field of oncology to help efficiently and cost-effectively identify and diagnose cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On date of incorporation, July 16, 2021, the Company
issued 8,000,000 shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd,
an exempted company incorporated under the law of Cayman Islands, the sole shareholder of which is Dr. Hung To Pau for a total consideration
of $8,000. The Company was dormant and has no substantive assets. On June 8, 2022, Sglcell Ltd transferred all of its 8,000,000 shares
to Dr. Yi Lu for a total consideration of $8,000. In July 2022, the Company consummated a reorganization of Advanced Biomed Inc. (Taiwan)
under share exchange arrangement of its then existing stockholders, who collectively owned all the equity interests of Advanced Biomed
Inc. (Taiwan) prior to the reorganization, transferred their respective shares in Advanced Biomed Inc. (Taiwan) to the Company. Prior
to the re-organization, Advanced Biomed Inc. (Taiwan) was directly owned and controlled by Dr. Yi Lu and Chen-Yi Lee with 99.93% and 0.07%
beneficial ownership interest, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>The Share Exchange</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a share exchange agreement (the &ldquo;Agreement&rdquo;)
dated July 11, 2022, Dr. Yi Lu and Chen-Yi Lee transferred their respective shares in Advanced Biomed Inc. (Taiwan) at the time of the
Agreement, representing in aggregate 100% of the issued share capital of Advanced Biomed Inc. (Taiwan), to the Company. The consideration
for the share transfers was satisfied by the allotment and issuance of an aggregate of 385,257 fully paid up shares of common stock to
Dr. Yi Lu and Chen-Yi Lee. Following the completion of the share exchange and related issuances by and among the Company, Dr. Yi Lu and
Chen-Yi Lee, Advanced Biomed Inc. (Taiwan) ultimately became a wholly-owned subsidiary of the Company, and Dr. Yi Lu and Chen-Yi Lee became
the beneficial owners of the Company with percentage ownerships of 99.99% and 0.01% as of August 12, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequently, on October 24, 2022, the Company
issued 365,368 shares to Chen-Yi Lee, and on October 24, 2022, the Company also issued 2,730,000 shares to Advance On Ventures Limited,
a company incorporated under the law of British Virgin Islands (the &ldquo;Ventures Limited&rdquo;), the beneficial owners of which are
employees of Advanced Biomed Taiwan. The Company issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares, 1,243,750
shares, 1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant to
the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt of
a total amount of NTD 174,020,033 and RMB22,200,000 (approximately $9.04 million). On October 25, 2022, the Company issued 625,000 shares
to Hanyu Assets Co. Ltd. pursuant to the Investment Agreement the Company entered into with Hanyu Assets Co. Ltd. on June 6, 2022, and
the Company issued 250,000 shares to Newlink Technology Inc. pursuant to the Investment Agreement the Company entered into with Newlink
Technology Inc. on June 6, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of the reorganization, Dr. Yi
Lu&rsquo;s percentage of ownerships of the Company became 33.54% as of October 25, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 7, 2022, the Company obtained the
approval of the Investment Commission of the Ministry of Economic Affairs (&ldquo;Taiwan Investment Commission&rdquo;) for the reorganization,
and the issuance number of which is &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#32147;&#23529;&#19968;&#23383;&#31532;</FONT>11100116890<FONT STYLE="font-family: Times New Roman, Times, Serif">&#34399;</FONT>&rdquo;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to this reorganization, the Company determined
that Advanced Biomed Inc. (Taiwan) is the predecessor entity as the Company is an investment holding company with no business activities
carried out and all of the business of Advanced Biomed Inc. (Taiwan) acquired formed substantially all of the business of the Company
under Rule 405 of Regulation C. To reflect the real economic substance of the Company&rsquo;s business under the reorganization, the accompanying
unaudited interim consolidated financial statements were prepared assuming that the share exchange transaction, as disclosed above has
been completed, and the Company exercises control of Advanced Biomed Inc. (Taiwan). The transaction detailed above has been accounted
for as reverse takeover and recapitalization of the Company; whereby the Company (the legal acquirer) is considered the accounting acquiree,
and Advanced Biomed Inc. (Taiwan)(the legal acquiree) is considered as the accounting acquirer. This transaction is deemed to be a continuation
of the business of Advanced Biomed Inc. (Taiwan); therefore, no goodwill has been recorded for this transaction, and the Company&rsquo;s
historical financial information prior to the date of the recapitalization transaction is that of Advanced Biomed Inc. (Taiwan) and historical
changes in stockholders&rsquo; deficit and its results of operations have been presented from the beginning of the first period presented.
The above-mentioned equity is before the stock split on May 16, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and its subsidiaries are in the table
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="15" STYLE="text-align: center; border-bottom: Black 1pt solid">Percentage of effective ownership</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="15">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Date of <BR> Incorporation</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR>
 2024</TD><TD STYLE="text-align: left; padding-bottom: 1pt; font-weight: bold; vertical-align: top">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,<BR>
 2024</TD><TD STYLE="text-align: left; padding-bottom: 1pt; font-weight: bold; vertical-align: top">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Place of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>incorporation</B></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Principal <BR> Activities</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Advanced Biomed Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">July 16, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Nevada</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Investment holding</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; width: 30%; text-align: left">Advanced Biomed Inc. (Taiwan)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 11%; text-align: center">September 1, 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; width: 9%; text-align: right">100</TD><TD STYLE="vertical-align: top; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; width: 9%; text-align: right">100</TD><TD STYLE="vertical-align: top; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 11%; text-align: center">Taiwan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 21%; text-align: left">Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Advanced Biomed HK Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">August 10, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">100</TD><TD STYLE="vertical-align: top; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">100</TD><TD STYLE="vertical-align: top; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Hong Kong</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Market development</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Shanghai Sglcell Biotech Co., Ltd.</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">April 12, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">100</TD><TD STYLE="vertical-align: top; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">100</TD><TD STYLE="vertical-align: top; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">People&rsquo;s Republic of China</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Clinical-related business</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited interim condensed consolidated
financial statements are presented assuming that the Company was in existence at the beginning of the first period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. LIQUIDITY AND GOING CONCERN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited interim condensed consolidated
financial statements have been prepared in conformity with U.S. GAAP which contemplates continuation of the Company on a going concern
basis. The going concern basis assumes that assets are realized, and liabilities are settled in the ordinary course of business at amounts
disclosed in the consolidated financial statements. The Company&rsquo;s ability to continue as a going concern depends upon its ability
to develop, register and obtain regulatory approval for commercial sell of its products to generate positive operating cash flows. For
the three-month period ended September 30, 2024, the Company reported net loss of $265,580. In addition, the Company had net cash outflows
of $29,680 from operating activities for the three-month period ended September 30, 2024 and net current liabilities of $176,636
as of September 30, 2024. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going
concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To sustain its ability to support the Company&rsquo;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">cash generated from upcoming operations; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">financial support from the Company&rsquo;s related party and stockholders as well as third parties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has commenced a strategy to raise debt
and equity and certain related parties have waived off the amount due to them as of June 30, 2024 amounted to $2,820,624 in order to improve
the Company&rsquo;s working capital. However, there can be no certainty that these additional financings will be available on acceptable
terms or at all. If management is unable to execute this plan, there would likely be a material adverse effect on the Company&rsquo;s
business. All of these factors raise substantial doubt about the ability of the Company to continue as a going concern. The unaudited
interim condensed consolidated financial statements for the three-month periods ended September 30, 2024 and 2023 have been prepared on
a going concern basis and do not include any adjustments to reflect the possible future effects on the recoverability and classifications
of assets or the amounts and classifications of liabilities that may result from the inability of the Company to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(a) Basis of presentation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited interim condensed consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;US
GAAP&rdquo;) and pursuant to the regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(b) Consolidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited interim condensed consolidated financial
statements include the financial statements of the Company and its subsidiaries. All inter-company transactions, if any, and balances
due to, due from, long-term investment subsidiary, and registered paid in capital have been eliminated upon consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business combinations are accounted for using
the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective
fair values as of the acquisition date in the Company&rsquo;s consolidated financial statements. Any excess fair value of consideration
transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection
with the business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent
reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in the consolidated statements
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the Company determines that assets acquired
do not meet the definition of a business under the acquisition method of accounting, acquired assets is expensed, no goodwill is recorded,
and any contingent consideration is recognized only when it becomes payable or is paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(c) Use of estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to useful lives for property,
plant and equipment and intangible assets, fair value of financial instruments, assumptions used in assessing right of use assets, impairment
of long-lived assets, property, plant and equipment, intangible assets and uncertain tax position. Actual results could vary from the
estimates and assumptions that were used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(d) Stock split</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split. The shares of common stock retain a par value of $0.001 per share. Accordingly, an amount equal to the par value
of the increased shares resulting from the share split was reclassified from &ldquo;Additional paid-in capital&rdquo; to &ldquo;Common
stock&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(e) Risks and uncertainties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operations of the Company are located
in Taiwan and mainland China. Accordingly, the Company&rsquo;s business, financial condition, and results of operations may be influenced
by political, economic, and legal environments in Taiwan and mainland China, as well as by the general state of the economy in these two
countries. The Company&rsquo;s results may be adversely affected by changes in the political, regulatory and social conditions in these
two countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company continues to face relative uncertainty
as to the remaining intensity and duration of and the nature and timeline for recovery from the COVID-19 pandemic going forward and how
all of that impacts the Company, including the extent to which potentially permanent changes clinical trial operations have been caused
by the pandemic. The Company has taken the approach of managing the pandemic (to the extent that it continues to remain a significant
factor) via strengthening its balance sheet and cash assets and avoiding debt while focusing on cost controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(f) Foreign currency translation and transaction
and convenience translation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited interim condensed consolidated
financial statements are presented in the US Dollar (&ldquo;US$&rdquo;), which is the reporting currency of the Company. The functional
currency of the Company is the US$. Advanced Biomed Inc. (Taiwan) use New Taiwan dollar (&ldquo;NT$&rdquo;) as its functional currency.
Advanced Biomed HK Limited uses Hong Kong dollars (&ldquo;HKD&rdquo;) and Shanghai Sglcell Biotech Co., Ltd., Nanjing Yitian Biotech Co.,
Ltd., Beijing Yitan Jiarui Technology Co., Ltd., Shandong Sglcell Medical Devices Co., Ltd., Sglcell (Huangshan) Biotech Co., Ltd use
Chinese Yuan Renminbi (&ldquo;CNY&rdquo;) as their functional currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities denominated in currencies
other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the balance sheet
date. Translation gains and losses are recognized in the consolidated statements of income and comprehensive income as other comprehensive
income or loss. Transactions in currencies other than the reporting currency are measured and recorded in the reporting currency at the
exchange rate prevailing on the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the unaudited
interim condensed consolidated statements of income and comprehensive income as other income (other expense).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of foreign currencies including, the
NT$, CNY and HKD, may fluctuate against the US Dollar. Any significant variations of the aforementioned currencies relative to the US
Dollar may materially affect the Company&rsquo;s financial condition in terms of reporting in US Dollar. The following table outlines
the currency exchange rates that were used in preparing the accompanying unaudited interim condensed consolidated financial statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June 30,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: justify">US$ to NT$ fiscal year end</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">31.65</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">32.45</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">US$ to NT$ average rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31.83</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">US$ to CNY fiscal year end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">US$ to CNY average rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">US$ to HKD fiscal year end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.77</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">US$ to HKD average rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(g) Fair value measurement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded
at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions
that market participants would use when pricing the asset or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
A financial instrument&rsquo;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. Accounting guidance establishes three levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices, in active markets for identical assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical asset or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 3 applies to asset or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash, other current assets, leases payable, accounts
payables, accruals and other current liabilities are financial assets and liabilities. Cash, other current assets, accounts payable, accruals
and other current liabilities are subject to fair value measurement; however, because of their being short term in nature management believes
their carrying values approximate their fair value. Financial instruments are fair value financial assets that are marked to fair value
and are accounted for under as Level 3 under the above hierarchy. The Company accounts for bank loans and lease payables at amortized
cost and has elected NOT to account for them under the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(h) Related parties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted ASC 850, Related Party Disclosures,
for the identification of related parties and disclosure of related party transactions for the three-month periods ended September 30,
2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(i) Cash </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash consists of cash on hand, the Company&rsquo;s
demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal
and use. Deposits are held at highly liquid and well capitalized financial institutions. Risk of loss is not expected by management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(j) Intangible assets, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Software</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">Patents</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 68%"><FONT STYLE="font-size: 10pt">6 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Software represents purchased software and is
amortized straight-line over the Company&rsquo;s estimates to generate economic benefits from such software, generally three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents represent the estimated fair value assigned
to finite-lived intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination
are initially recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets
acquired is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over
the estimated useful lives of the respective finite-lived intangible assets, generally six years. Intangible assets are reviewed for impairment
at least annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for
impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might
not be recoverable. If the carrying value of an finite-lived intangible asset exceeds its fair value, then it is written down to its adjusted
fair value. As of September 30, 2024 and June 30, 2024, the Company had finite-lived intangible assets of US$1.6 million of purchased
patents from the acquisition of Shanghai Sglcell Biotech Co., Ltd. The accumulated impairment allowance recognised was approximately US$1.6
million as of September 30, 2024 and June 30, 2024, respectively, as management assessed that there were changes in circumstances indicate
that the carrying value of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(k) Equipment, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net are stated at cost less accumulated
depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the assets. Cost represents
the purchase price of the asset and other costs incurred to bring the asset into its intended use. Estimated useful lives are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 68%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Lab equipment</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Computer equipment</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Furniture and fixtures</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Leasehold improvements</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditure for repair and maintenance costs,
which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for major
renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the related
assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment with any
resulting gain or loss recognized in the consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(l) Deferred Initial Public Offering (&ldquo;IPO&rdquo;) costs&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&ldquo;SAB&rdquo;) Topic 5A &mdash; &ldquo;Expenses of Offering&rdquo;. Initial public
offering expense directly attributable to offering of securities are deferred and would be charged against the gross proceeds of the offering,
as a reduction in share capital. These deferred expenses mainly consist of underwriting, legal and other expenses incurred through the
balance sheet date that are directly related to the intended IPO. Should the IPO prove to be unsuccessful, these deferred initial public
offering costs, as well as additional expenses to be incurred, will be charged to operations. As of September 30, 2024 and June 30, 2024,
the Company capitalized US$655,671 and US$638,871 of deferred initial public offering costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(m) Impairment of long-lived assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews its long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When
these events occur, the Company measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted
future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted
cash flow is less than the carrying amount of the assets, the Company would recognize an impairment loss, which is the excess of carrying
amount over the fair value of the assets, using the expected future discounted cash flows. As of September 30, 2024 and June 30, 2024,
the Company had finite-lived intangible assets of US$1.6 million of purchased patents from the acquisition of Shanghai Sglcell Biotech
Co., Ltd. The accumulated impairment allowance recognised was approximately US$1.6 million as of September 30, 2024 and June 30, 2024,
respectively, as management assessed that there were changes in circumstances indicate that the carrying value of the assets might not
be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(n) Commitments and contingencies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
is subject to commitments and contingencies, including operating lease commitments, legal proceedings and claims arising out of its business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such
contingency if it determines it is probable that a loss will occur, and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments on liability for contingencies, including historical and the specific facts and circumstances
of each matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(o) Research and development expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs
directly attributable to the conduct of research and development programs, including licensing fees, cost of salaries, payroll taxes and
other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing
costs and professional services. All costs associated with research and developments are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has already started the registration
process and plans to start the clinical research by the end of June 2025, which are expected to end in April 2026, and we expect to obtain
the required registration certificate by October 2027. As of September 30, 2024, the Company has not commenced sales of the products nor
have any revenue-generating products and do not expect sales of revenue-generating product candidates until the Company has completed
clinical development, submitted regulatory filings, and received applicable regulatory approvals for candidate products.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hence, the Company incurred its research and development
cost during the three-month periods ended September 30, 2024 and 2023, which is in compliance under ASC 730-10-25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(p) General and administrative expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses mainly consist
of staff cost, depreciation, office supplies and upkeep expenses, travelling and entertainment, legal and professional fees, property
and related expenses, other miscellaneous administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(q) Operating leases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Prior to the adoption of ASC 842 on January
1, 2019:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases, mainly leases of factory buildings, offices
and employee dormitories, where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for
as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The
Company had no finance leases for any of the periods stated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Upon and hereafter the adoption of ASC 842
on January 1, 2019:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if an arrangement is a
lease at inception. Operating leases are included in operating lease right-of-use (&ldquo;ROU&rdquo;) assets, operating lease liability,
and operating lease liability, non-current in the Company&rsquo;s consolidated balance sheets. ROU assets represent the Company&rsquo;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&rsquo;s obligation to make lease payments
arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is
reasonably certain that it will exercise that option, if any. As the Company&rsquo;s leases do not provide an implicit rate, the Company
used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.
The Company has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) for leases that have
lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Company elected not
to apply ASC 842 recognition requirements; and (ii) the Company elected to apply the package of practical expedients for existing arrangements
entered into prior to January 1, 2019 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification
applied to existing leases, and (c) initial direct costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<I>(r) Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not
that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical
merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount
of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50
percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition
threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that
no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the
threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense
in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three-month periods ended
September 30, 2024 and 2023. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim
periods, disclosures and transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Valuation of Deferred Tax Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&rsquo;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&rsquo;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(s) Loss per share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share is computed by dividing net loss
attributable to common stockholders &nbsp;by the weighted average number of common stock outstanding during the year. Diluted earnings
per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted
into common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(t) Recent accounting pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, the FASB issued ASU 2021-10,
Codification Improvements. The amendments in this Update represent changes to clarify the Codification or correct unintended application
of guidance that are not expected to have a significant effect on current accounting practice or create a significant administrative cost
to most entities. The amendments in this Update affect a wide variety of Topics in the Codification and apply to all reporting entities
within the scope of the affected accounting guidance. ASU 2021-10 is effective for annual periods beginning after December 15, 2021 for
public business entities. Early application is permitted. The amendments in this Update should be applied retrospectively. The Company
does not expect the adoption of this standard to have a material impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2023, the FASB issued ASU 2023-06,
&ldquo;Disclosure Improvements: Codification Amendments in Response to the SEC&rsquo;s Disclosure Update and Simplification Initiative.&rdquo;
This amendment incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards
Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification
Topics, allow users to more easily compare entities subject to the SEC&rsquo;s existing disclosures with those entities that were not
previously subject to the requirements, and align the requirements in the Codification with the SEC&rsquo;s regulations. For entities
subject to the SEC&rsquo;s existing disclosure requirements and for entities required to file or furnish financial statements with or
to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer,
the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other
entities, the amendments will be effective two years later. However, if by June 30, 2027, the SEC has not removed the related disclosure
from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not
expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280)&nbsp;&mdash;&nbsp;Improvements to Reportable Segment Disclosures. The amendment requires entities to report
a measure of segment profit or loss that the chief operating decision maker uses to assess segment performance and make decisions about
allocating resources. The amendment also requires other specified segment items and amounts, such as depreciation, amortization, and depletion
expense, to be disclosure under certain circumstances. The amendment does not change or remove those disclosure requirements and also
does not change how an entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds
to determine its reportable segments. This amendment is effective for the Group&rsquo;s consolidated financial statements issued for annual
periods beginning after December 15, 2023. Early adoption is permitted. The Group is currently evaluating the impact of adopting this
amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740)&nbsp;&mdash;&nbsp;Improvements to income Tax Disclosures. The amendment in this update are effective for annual
periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods
beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available
for issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2024, the FASB issued ASU 2024-01, Compensation
&mdash; Stock Compensation (Topic 718)&nbsp;&mdash;&nbsp;Scope Application of Profits Interest and Similar Award. For public business
entities, the amendments in this Update are effective for annual periods beginning after December 15, 2024, and interim periods within
those annual periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim
periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been
issued or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning
of the annual period that includes that interim period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as mentioned above, the Company does not
believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&rsquo;s
consolidated balance sheets, statements of operations and comprehensive loss and statements of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4. PREPAID EXPENSES AND OTHER CURRENT ASSETS,
NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Tax refundable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">195,368</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">161,142</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,588</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,035</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Prepayment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">234,788</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">237,960</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">485,744</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">443,137</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: allowance for credit losses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">485,744</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">443,137</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5. EQUIPMENT, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net, consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Lab equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,533,588</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,486,392</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Computer equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,833</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,746</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Furniture and fixtures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,518</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,332</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">208,683</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">201,516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,811,622</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,754,985</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,334,406</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,230,457</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Equipment, net</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">477,216</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">524,528</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses were approximately
US$67,290 and US$38,789 for the three-month periods ended September 30, 2024 and 2023, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6. INTANGIBLE ASSETS, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the carrying amount
of the Company&rsquo;s finite-lived intangible assets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Acquired technology</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">379,940</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">391,016</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(295,870</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(272,018</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">84,070</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">118,998</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finite-lived intangible assets are carried at
cost less accumulated amortization. Amortization expense was approximately US$34,928 and US$34,295 for the three-month periods ended September
30, 2024 and 2023, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Acquired patents through acquisition</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,617,974</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,617,974</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: impairment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024 and June 30, 2024, the
Company had finite-lived intangible assets of US$1.6 million of purchased patents from the acquisition of Shanghai Sglcell Biotech Co.,
Ltd. The accumulated impairment allowance recognized was US$1,617,974 as of September 30, 2024 and June 30, 2024, respectively, as management
assessed that there were changes in circumstances indicate that the carrying value of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT
LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Payable, accrued expenses and other liabilities
consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Accounts Payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">641,955</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">620,476</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payroll payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,887</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,113</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amount due to related parties &ndash; major stockholders *</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">317,777</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,812</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amount due to related parties &ndash; related corporations**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">879,622</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">674,262</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other payable#</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,337,086</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,184,586</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,253,327</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,670,249</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* The amount due to the Company&rsquo;s major
stockholders as of September 30, 2024 and June 30, 2024 are non-trade, unsecured, interest-free and repayable on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">** The amount due to related corporations, which
the Company&rsquo;s major stockholders have controlling equity interest in, as of September 30, 2024 and June 30, 2024 are non-trade,
unsecured, interest-free and repayable on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"># The amount consists of payables owed to third
party creditors, which are unsecured, interest-free and repayable on demand, and other payables due to operational use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8. OTHER INCOME (EXPENSE), NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three-month periods ended <BR> September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">US$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">US$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(unaudited)</P></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,341</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">604</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Foreign exchange gain (loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">252,096</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(331,689</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Other income (expense), net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">254,437</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(331,085</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9. EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the sake of undertaking a public offering
of the Company&rsquo;s common stock, the Company has performed a series of re-organizing transactions resulting in 25,000,000 of common
stock and 25,000,000 of common stock outstanding as of September 30, 2024 and June 30, 2024. The Company has accounted for these shares
had they been issued and outstanding at the beginning of the first period presented. The Company only has one single class of common stock
that is accounted for as permanent equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above mentioned re-organizing transactions
and equity is before the share split on May 16, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split. The shares of common stock retain a par value of $0.001&nbsp;per share. Accordingly, an amount equal to the par
value of the increased shares resulting from the stock split was reclassified from &ldquo;Additional paid-in capital&rdquo; to &ldquo;Common
stock&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock&nbsp;in this report has been retrospectively adjusted for the reverse share split, as if such reverse share
split occurred on the first day of the years presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10. INCOME TAXES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is not an operating company but a
holding company incorporated in the State of Nevada and is considered U.S. tax resident under U.S. tax laws; accordingly, it is subject
to U.S. tax laws at a statutory tax rate of 21%. The Company is subject to the State of Nevada tax laws at a tax rate of&nbsp;0%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s net deferred income tax assets
as of September 30, 2024 and June 30, 2024 consist of net operating loss carry forwards. The net operating loss carry forwards for U.S.
federal tax and Taiwan, China, Hong Kong tax purposes are available for carry forward indefinitely for use in offsetting taxable income.
The U.S. federal net operating loss carry forward offset is limited to up to 80% of the taxable income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024 and June 30, 2024, the
Company had total net operating loss carry forwards of approximately $10,124,561 and $8,767,393, which consists of China net operating
loss carry forwards of $4,246,746 and $3,817,009, Taiwan net operating losses of $4,554,324 and $4,200,888&nbsp;, Hong Kong net operating
loss carry forwards of $5,539 and $5,014 , and US net operating loss carry forwards of $1,317,952 and $744,480.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Taiwan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company&rsquo;s operating
subsidiary, Advanced Biomed Inc. (Taiwan) is considered Taiwan tax resident enterprises under Taiwan tax laws; accordingly, it is subject
to enterprise income tax on its taxable income as determined under Taiwan tax laws at a statutory tax rate of 20%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>China</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company&rsquo;s operating
subsidiary, Shanghai Sglcell Biotech Co., Ltd. is considered PRC resident enterprises under Enterprise Income Tax Law of the PRC; accordingly,
it is subject to enterprise income tax on their taxable income as determined under Enterprise Income Tax Law of the PRC at a statutory
tax rate of 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Hong Kong</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Under the current Hong&nbsp;Kong
Inland Revenue Ordinance, a two-tier&nbsp;corporate income tax system was implemented in Hong&nbsp;Kong, which is 8.25% for the first
HK$2.0&nbsp;million taxable income, and 16.5% for the subsequent taxable income generated from operations in Hong&nbsp;Kong. The Company&rsquo;s
subsidiary, Advanced Biomed HK Limited is considered Hong Kong tax resident under Hong Kong Tax Law; accordingly, it is subject to corporate
income tax on its taxable income at 8.25% with nil and nil for the three-months periods ended September 30, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision consists of the following
component:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the three-month <BR> periods ended</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30,</B></P>

</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(unaudited)</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(unaudited)</P>

</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 2.5pt">Income tax expense</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following table reconciles the operating
profit to the Company&rsquo;s effective tax rate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the three-month </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>periods ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30,</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Loss before tax</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(265,577</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(771,316</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Statutory income tax rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income tax expense calculated at the statutory tax rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of tax losses carry forwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,974,754</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,448,110</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Effect of subsidiaries foreign income (loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,974,754</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,448,110</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Income tax expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Effective tax rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-%</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The component of deferred tax assets are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,<BR> 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Net operating losses carry forward</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,974,754</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,019,708</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,974,754</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,019,708</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In assessing
the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred
tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those temporary differences become deductible. Management considers the cumulative earnings and projected
future taxable income in making this assessment. Recovery of substantially all of the Company&rsquo;s deferred tax assets is dependent
upon the generation of future income, exclusive of reversing taxable temporary differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>11. STOCK OPTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective from March 30, 2023, the Stock Incentive
Plan (the &ldquo;2023 Plan&rdquo;) was approved by the Company's Board of Directors. Under the 2023 Plan, the Board of Directors may grant
options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to the Company or any
related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award,
and the purchase or exercise price, conditions and other terms of each award are determined by the Board of Directors, except that the
term of the options shall not exceed 10 years. A total of 15 million shares of our common stock are subject to the 2023 Plan and maybe
either a qualified or non-qualified stock option. The shares issued for the 2023 Plan may be either treasury or authorized and unissued
shares. As of the date of this prospectus, the Company has granted no stock options to purchase any shares of the common stock under the
2023 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12. RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These related parties of the Company with whom
transactions are reported in these financial statements are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Related Party</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 65%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Relationship to Us</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Yi Lu, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chairman of the Board and Chief Executive Officer of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director, Secretary and Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Steven I-Fang Cheng, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Technology Officer of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Chen-Yi Lee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Chen-Yi Lee is also the Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Advance On Ventures Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Well Fancy Development Ltd</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau is the director and shareholder of the entity</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau is the legal person and shareholder of the entity</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of business, during the&nbsp;three-month
periods ended September&nbsp;30, 2024 and 2023, the Company was involved in certain transactions, either at cost or current market prices,
and on the normal commercial terms with related parties. The following table provides the transactions with these parties for the&nbsp;years
as presented (for the portion of such period that they were considered related):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-style: normal; font-weight: normal">(unaudited)&nbsp;</FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Amount due to related parties &ndash; major stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">&nbsp;</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left"><FONT STYLE="font-size: 10pt">Yi Lu, Ph.D. <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">113,056</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">110,268</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chen-Yi Lee <SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,721</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,544</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Hung To Pau, Ph.D. <SUP>(3)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">200,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">317,777</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">113,812</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Amount due to related parties &ndash; related corporations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Well Fancy Development Ltd <SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">181,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <SUP>(5)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">698,244</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">674,262</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">879,622</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">674,262</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered
into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$110,268) for general working capital in January
2023. As of September 30, 2024 and June 30, 2024, the loan balance due to Yi Lu amounted to US$113,056 and US$110,268, respectively.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Payments of expenses on behalf of
Advanced Biomed Inc. (Taiwan).</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">3.</TD><TD STYLE="text-align: justify">Advanced Biomed Inc.(HK) entered into one unsecured, interest-free
loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024. As of September 30, 2024, the loan balance
due to Hung To Pau, Ph.D. totally amounted to US$200,000 for general working capital.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt; font-size: 10pt"></TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Advanced Biomed Inc.(HK) entered into one
unsecured, interest-free loan to Well Fancy Development Ltd amounting to US$181,378 for general working capital in July 2024. As of September
30, 2024, the loan balance due to Well Fancy Development Ltd totally amounted to US$181,378 for general working capital.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">In 2024, Advanced Biomed Inc.(Taiwan) entered into ten unsecured, interest-free
    loans to Well Fancy Development Ltd amounting to NTD 2,967,700 (approximately US$91,455), NTD2,989,873 (approximately US$92,138), NTD4,270,200
    (approximately US$131,593), NTD1,945,000 (approximately US$59,938), NTD1,858,120 (approximately US$57,261), NTD2,912,200 (approximately
    US$89,744), NTD2,890,065 (approximately US$89,062), NTD5,857,750 (approximately US$180,516), NTD4,356,145 (approximately US$134,242) and
    NTD3,732,100 (approximately US$115,011) for general working capital in August 2022, April 2023, May 2023, June 2023, July 2023, August
    2023, October 2023, December 2023, February 2024 and April 2024, respectively. As of June 30, 2024, the loan balance due to Well Fancy
    Development Ltd totally amounted to US$1,040,960 and amounted to US$545,900 for general working capital. And the total amount due to Well
    Fancy Development Ltd of NTD33,779,153 and US$545,900, totalling US$1,586,860, have been waived off by Well Fancy Development Ltd as of
    June 30, 2024.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd
entered into four unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately
US$71,249) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$99,749), RMB1,500,000
(approximately US$213,748) and RMB700,000 (approximately US$99,749) in January 2024, March 2024 and June 2024, respectively, for general
working capital. As of September 30, 2024 and June 30, 2024, the loan balance due to Shanghai Sglcell Biotech Co., Ltd totally amounted
to US$ 698,244 and US$674,262, respectively.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>13. CONCENTRATIONS AND RISKS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Credit Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk is the potential financial loss to
the Company resulting from the failure of a customer or a counterparty to settle its financial and contractual obligations to the Company,
as and when they fall due. As the Company does not hold any collateral, the maximum exposure to credit risk is the carrying amounts of
other receivables (exclude prepayments) and cash and bank deposits presented on the consolidated balance sheets. The Company has no other
financial assets which carry significant exposure to credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidity Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk is the risk that the Company will
encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another
financial asset. The Company&rsquo;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking
damage to the Company&rsquo;s reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Typically, the Company ensures that it has sufficient
cash on demand to meet expected operational expenses for a period of 60 days, including the servicing of financial obligations; this excludes
the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Foreign currency risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency risk is the risk that the fair
value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The company&rsquo;s exposure to
the risk of changes in foreign exchange rates relates primarily to the Company&rsquo;s operating activities (when expense is denominated
in a foreign currency) and the Company&rsquo;s net investments in foreign subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Impact of Inflation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation in Taiwan and PRC has not materially
affected the Company&rsquo;s profitability and operating results. However, the Company can provide no assurance that we will be unaffected
by higher inflation rates in Taiwan and PRC or globally in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>14. COMMITMENTS AND CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of business, the
Company may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The
Company records contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the
loss is reasonably estimable. In the opinion of management, there were no pending or threatened claims and litigation as of
September 30, 2024 and up through January 7, 2025, the issuance date of these consolidated financial statements were available to be
issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Lease commitment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if a contract contains
a lease at inception. US GAAP requires that the Company&rsquo;s leases be evaluated and classified as operating or finance leases for
financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation
includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods
when the exercise of the renewal option is reasonably certain and failure to exercise such option which results in an economic penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use assets relate to leases of office
premises and a dormitory for employees in the PRC and the laboratory in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recognized operating lease ROU assets and
lease liabilities as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September,&nbsp;2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-style: normal; font-weight: normal; text-align: center"><P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">(unaudited)</P></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Operating lease ROU asset</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">124,078</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">126,740</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Current portion</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">56,045</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">62,211</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Non-current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64,529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">126,614</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">126,740</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, future minimum lease
payments under the non-cancellable operating leases are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Future payment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">2025</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">60,104</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,592</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2029</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total future lease payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,427</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: imputed interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,812</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">126,614</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease liabilities, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,045</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liabilities, non-current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,569</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes other supplemental information
about the Company&rsquo;s operating lease as of September 30, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Weighted average discount rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.56</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted average remaining lease term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>15. SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has assessed all events from
September 30, 2024 through January 7, 2025, which is the date that these consolidated financial statements are available to
be issued, unless as disclosed below, there are not any material subsequent events that require disclosure in these consolidated
financial statements other than events detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common shares issued and outstanding as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="vc051_img16.jpg" ALT=""></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="reportofinde"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors and
    Stockholders of</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Advanced
Biomed Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Advanced Biomed Inc. and its subsidiaries (collectively the &ldquo;Company&rdquo;) as of June 30, 2024 and 2023, and
the related consolidated statements of operations and comprehensive income (loss), changes in stockholders&rsquo; equity, and cash flows
in each of the years for the two-year period ended June 30, 2024, and the related notes (collectively referred to as the financial statements).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30,
2024, and 2023, and the results of its operations and its cash flows in each of the years for the two-year period ended June 30, 2024,
in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Explanatory Paragraph &mdash; Substantial Doubt
about the Company&rsquo;s Ability to Continue as a Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As described in Note 2, the Company has a significant working
capital deficiency, has significant net cash outflows from operating activities and needs to raise additional funds to meet its obligations
and sustain its operations. These conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.
Management&rsquo;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WWC, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCAOB ID No. 1171</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Mateo, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 28, 2024</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="vc051_img17.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><A NAME="a_112"></A><B>ADVANCED
BIOMED INC.AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of June 30,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Current assets:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,607,973</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,622,279</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Prepaid expenses and other current assets, net</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">443,137</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">163,709</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total current assets</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3,051,110</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,785,988</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Equipment, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">524,528</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">718,697</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Right-of-use assets, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">126,740</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">235,373</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Intangible assets, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">118,998</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">250,321</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Deferred initial public offering (&ldquo;IPO&rdquo;) costs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">638,871</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">553,471</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Other non-current assets</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">56,127</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total non-current assets</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,409,137</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,813,989</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>TOTAL ASSETS</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,460,247</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,599,977</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Liabilities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Current liabilities:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Accounts payable, accruals, and other current liabilities (including amount due to related parties &ndash; major stockholders and related corporations of $113,812 and $674,262, respectively, as of June 30, 2024 and $1,052,677&nbsp;and $603,802, respectively, as of June 30, 2023 <SUP>(1)</SUP>)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,670,249</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,059,016</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Lease payable - current</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">62,211</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">216,567</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total current liabilities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,732,460</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3,275,583</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Lease payable &ndash; non-current</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">64,529</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">18,806</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total non-current liabilities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">64,529</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">18,806</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>TOTAL LIABILITIES</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,796,989</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">3,294,389</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Commitments and contingencies</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Stockholders&rsquo; equity</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Common stock $0.001 par value per share; as of June 30, 2024 and 2023; 400,000,000 and 400,000,000 shares authorized; 20,000,000 and 20,000,000 shares issued and outstanding, respectively*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16,493,989</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,673,365</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 14.2pt; text-align: justify; text-indent: -7.1pt"><FONT STYLE="font-size: 10pt">&nbsp;Accumulated deficits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(15,974,075</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(13,191,797</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Accumulated other comprehensive income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,123,344</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">804,020</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total stockholders&rsquo; equity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,663,258</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,305,588</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,460,247</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,599,977</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Giving retroactive effect to the 4 for 1 share
split effected on May 16, 2023 and 5 for 1 reverse share split effected on October 15, 2024.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">See Note 13 for disclosure of related parties amounts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_113"></A>ADVANCED BIOMED INC.AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
INCOME(LOSS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the years ended June 30,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Operating expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 74%; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Research and development expenses</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(880,193</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(1,383,181</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">General and administrative expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,661,379</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,688,042</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,541,572</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(3,071,223</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Other income (expense):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Interest income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">53,495</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21,402</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt">Other expense, net</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(294,201)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(682,956</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt">Total other expense, net</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(240,706)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(661,554</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Loss before tax expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,782,278</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,732,777</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Income tax expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>Net Loss</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,782,278</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(3,732,777</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>Other comprehensive income</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Foreign currency translation gain, net of taxes</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">319,324</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">535,161</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>Total comprehensive income (loss)</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,462,954)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(3,197,616</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>Loss per share:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">basic and diluted*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(0.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(0.19</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>Weighted average number of shares of common stock in computing net loss per share</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">basic and diluted*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19,935,890</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">* Giving retroactive effect
to the 4 for 1 share split effected on May 16, 2023 and 5 for 1 reverse share split effected on October 15, 2024.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_114"></A>&nbsp;<B>ADVANCED BIOMED INC.AND
ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&rsquo;
EQUITY</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>No. of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>shares*</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount*</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Additional </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>paid-</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>in capital*</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Accumulated</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>other</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>comprehensive</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>income</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Accumulated</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>deficit</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">US$</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 22%">Balance as of July 1, 2022</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">19,800,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">19,800</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">12,661,957</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">268,859</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">(9,459,020</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">3,491,596</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,732,777</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,732,777</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">535,161</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">535,161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Issuance of shares for cash</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">200,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,011,408</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,011,608</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of June 30, 2023</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,000,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">13,673,365</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">804,020</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(13,191,797</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,305,588</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Balance as of July 1, 2023</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">20,000,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">20,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">13,673,365</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">804,020</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(13,191,797</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,305,588</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Waiver of amount due to related parties &ndash; major stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,233,764</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,233,764</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Waiver of amount due to related parties &ndash; related corporations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,586,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,586,860</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,782,278</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,782,278</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">319,324</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">319,324</P>
</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of June 30, 2024</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,000,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">20,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">16,493,989</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,123,344</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(15,974,075</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,663,258</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Giving retroactive effect to the 4 for 1 share split effected on
May 16, 2023 and 5 for 1 reverse share split effected on October 15, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of these consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_115"></A><B>ADVAN<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CED
BIOMED INC. AND ITS SUBSIDIARIES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the years ended June 30,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(2,782,278</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(3,732,777</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Adjustment:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Depreciation and amortization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">399,602</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">365,231</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Loss from disposal of subsidiaries</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">150,207</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Interest Income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(53,495</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(21,402</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Changes in operating assets:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Prepaid expenses and other current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(279,425</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(116,460</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Accounts payable, accruals and other current liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">479,634</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">381,253</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Lease obligations, net cash</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(25,973</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Other non-current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">56,127</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14,894</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Interest received</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">53,495</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">21,402</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Cash used in operating activities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(2,126,340</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(2,963,625</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Purchase of intangible assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,640</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Purchase of equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(74,110</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(210,883</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Disposal of subsidiaries (Note 7)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(50,486</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Cash used in investing activities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(74,110</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(263,009</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Payment of deferred initial public offering costs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(85,400</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(553,471</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Proceeds from issuance of shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,011,608</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Expenses paid on behalf by related parties &ndash; major stockholders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">294,900</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Drawdown of loans from related parties &ndash; related corporations</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,657,320</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Cash provided by financing activities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>1,866,820</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>458,137</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Foreign currency effect</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">319,324</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">606,912</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Net change in cash and cash equivalents</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(14,306</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>(2,161,585</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Cash at beginning of the year</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,622,279</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,783,864</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Cash at year end</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,607,973</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,622,279</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Net decrease in cash</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(14,306</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,161,585</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Supplementary Cash Flow Information:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Cash paid for interest</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Cash paid for taxes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>NON-CASH INVESTING AND FINANCING ACTIVITIES:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Disposal of Nanjing Yitian Biotech Co., Ltd. and its subsidiary with proceeds from disposal receivables</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">71,942</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
consolidated financial statements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_116"></A>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
ORGANIZATION AND PRINCIPAL ACTIVITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 16, 2021, Advanced Biomed Inc. (the &ldquo;Company&rdquo;) was incorporated in the State of Nevada, as an investment holding company.
The Company&rsquo;s principal executive offices are located in Tainan City, Taiwan. The Company has no substantive operations and assets.
It is holding Company that holds all of the issued and outstanding shares of Advanced Biomed HK Limited and Advanced Biomed Inc. (Taiwan).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(1)</I></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Establishment
    of Advanced Biomed HK Limited </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 10, 2021, the Company incorporated a wholly owned subsidiary, Advanced Biomed HK Limited, in Hong Kong to facilitate market development
and commercialization of the Company&rsquo;s oncology products for sale and distribution in the People&rsquo;s Republic of China (the
&ldquo;PRC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(2)</I></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Acquisition
    of Shanghai Sglcell Biotech Co., Ltd. and its subsidiaries</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 202</FONT>2, Advanced Biomed HK Limited acquired 100% equity interest of Shanghai Sglcell Biotech Co., Ltd. Shanghai Sglcell
Biotech Co., Ltd. was established in the PRC on April 12, 2019. It is engaged in the establishment and operation of medical clinics in
the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shanghai Sglcell Biotech Co., Ltd. owns 100% equity
interest of two subsidiaries namely 1.) Shandong Sglcell Medical Devices Co., Ltd. and 2.) Nanjing Yitian Biotech Co., Ltd. Shandong Sglcell
Medical Devices Co., Ltd. was incorporated in the PRC on July 8, 2021 to carry out the establishment of medical clinics, and the supply
of medical products and services to clinics in the PRC. Nanjing Yitian Biotech Co., Ltd. was established in the PRC on January 6, 2017.
Nanjing Yitian Biotech Co., Ltd. wholly owns a subsidiary, Beijing Yitan Jiarui Technology Co. Ltd., which was established in the PRC
on October 20, 2017. Both were established to carry out marketing and clinical services in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 8, 2023, Shanghai Sglcell Biotech Co.,
Ltd. transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co.,
Ltd., to independent third-party individuals at aggregate consideration of CNY500,000 (approximately US$71,942) without any other obligations
arising from the transfer. Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd. have not commenced
business activity since it was acquired on January 1, 2022 and the Company believed the transfer will improve in operational efficiency.
The consideration is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal
company on May 31, 2023, as of the date of May 31, 2023, the net assets value of Nanjing Yitian Biotech Co., Ltd. and its subsidiary,
Beijing Yitan Jiarui Technology Co., Ltd., was CNY498,587 (approximately US$71,739).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 9, 2023, Shandong Sglcell Biotech Co.,
Ltd., the wholly owned subsidiary of Shanghai Sglcell Biotech Co., Ltd., was transferred to independent third-party individuals at zero
consideration without any other obligations arising from the transfer. Shandong Sglcell Biotech Co., Ltd. has been inactive since it was
incorporated on July 8, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration is determined
by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May 31, 2023, as
of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>(3)</I></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Subsidiary established under Advanced Biomed HK Limited</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed HK Limited incorporated a wholly
owned subsidiary, Sglcell (Huangshan) Biotech Co., Ltd., in the PRC on March 4, 2022; it was established for the expected future manufacturing
of medical devices in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2023, Sglcell (Huangshan) Biotech
Co., Ltd., the wholly owned subsidiary of Advanced Biomed HK Limited, was transferred to an independent third-party corporation at zero
consideration without any other obligations arising from the transfers. Sglcell (Huangshan) Biotech Co., Ltd. has been dormant since its
incorporation date from March 4, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration
is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May
31, 2023, as of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>(4)</I></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Reorganization of Advanced Biomed Inc. (Taiwan) </I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed Inc. (Taiwan) was established
in Taiwan on September 1, 2014. It is primarily focused on mainly operates as a research and development of new center for technologies
in the field of oncology to help efficiently and cost-effectively identify and diagnose cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On date of incorporation, July 16, 2021, the Company
issued 8,000,000 shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd,
an exempted company incorporated under the law of Cayman Islands, the sole shareholder of which is Dr. Hung To Pau for a total consideration
of $8,000. The Company was dormant and has no substantive assets. On June 8, 2022, Sglcell Ltd transferred all of its 8,000,000 shares
to Dr. Yi Lu for a total consideration of $8,000. In July 2022, the Company consummated a reorganization of Advanced Biomed Inc. (Taiwan)
under share exchange arrangement of its then existing stockholders, who collectively owned all the equity interests of Advanced Biomed
Inc. (Taiwan) prior to the reorganization, transferred their respective shares in Advanced Biomed Inc. (Taiwan) to the Company. Prior
to the re-organization, Advanced Biomed Inc. (Taiwan) was directly owned and controlled by Dr. Yi Lu and Chen-Yi Lee with 99.93% and 0.07%
beneficial ownership interest, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>The Share Exchange</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a share exchange agreement (the &ldquo;Agreement&rdquo;)
dated July 11, 2022, Dr. Yi Lu and Chen-Yi Lee transferred their respective shares in Advanced Biomed Inc. (Taiwan) at the time of the
Agreement, representing in aggregate 100% of the issued share capital of Advanced Biomed Inc. (Taiwan), to the Company. The consideration
for the share transfers was satisfied by the allotment and issuance of an aggregate of 385,257 fully paid up shares of common stock to
Dr. Yi Lu and Chen-Yi Lee. Following the completion of the share exchange and related issuances by and among the Company, Dr. Yi Lu and
Chen-Yi Lee, Advanced Biomed Inc. (Taiwan) ultimately became a wholly-owned subsidiary of the Company, and Dr. Yi Lu and Chen-Yi Lee became
the beneficial owners of the Company with percentage ownerships of 99.99% and 0.01% as of August 12, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequently, on October 24, 2022, the Company
issued 365,368 shares to Chen-Yi Lee, and on October 24, 2022, the Company also issued 2,730,000 shares to Advance On Ventures Limited,
a company incorporated under the law of British Virgin Islands (the &ldquo;Ventures Limited&rdquo;), the beneficial owners of which are
employees of Advanced Biomed Taiwan. The Company issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares, 1,243,750
shares, 1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant to
the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt of
a total amount of NTD 174,020,033 and RMB22,200,000 (approximately $9.04 million). On October 25, 2022, the Company issued 625,000 shares
to Hanyu Assets Co. Ltd. pursuant to the Investment Agreement the Company entered into with Hanyu Assets Co. Ltd. on June 6, 2022, and
the Company issued 250,000 shares to Newlink Technology Inc. pursuant to the Investment Agreement the Company entered into with Newlink
Technology Inc. on June 6, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of the reorganization, Dr. Yi
Lu&rsquo;s percentage of ownerships of the Company became 33.54% as of October 25, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 7, 2022, the Company obtained the
approval of the Investment Commission of the Ministry of Economic Affairs (&ldquo;Taiwan Investment Commission&rdquo;) for the reorganization,
and the issuance number of which is &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#32147;&#23529;&#19968;&#23383;&#31532;</FONT>11100116890<FONT STYLE="font-family: Times New Roman, Times, Serif">&#34399;</FONT>&rdquo;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to this reorganization, the Company
determined that Advanced Biomed Inc. (Taiwan) is the predecessor entity as the Company is an investment holding company with no business
activities carried out and all of the business of Advanced Biomed Inc. (Taiwan) acquired formed substantially all of the business of
the Company under Rule 405 of Regulation C. To reflect the real economic substance of the Company&rsquo;s business under the reorganization,
the accompanying unaudited interim consolidated financial statements were prepared assuming that the share exchange transaction, as disclosed
above has been completed, and the Company exercises control of Advanced Biomed Inc. (Taiwan). The transaction detailed above has been
accounted for as reverse takeover and recapitalization of the Company; whereby the Company (the legal acquirer) is considered the accounting
acquiree, and Advanced Biomed Inc. (Taiwan)(the legal acquiree) is considered as the accounting acquirer. This transaction is deemed
to be a continuation of the business of Advanced Biomed Inc. (Taiwan); therefore, no goodwill has been recorded for this transaction,
and the Company&rsquo;s historical financial information prior to the date of the recapitalization transaction is that of Advanced Biomed
Inc. (Taiwan) and historical changes in stockholders&rsquo; deficit and its results of operations have been presented from the beginning
of the first period presented. The above-mentioned equity is before the stock split on May 16, 2023.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and its subsidiaries are in the table
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="19" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Percentage of effective ownership</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="19">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date of <BR>
Incorporation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30,<BR>
 2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30,<BR>
 2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Place of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>incorporation</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt"><B>Principal <BR>
Activities</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Advanced Biomed Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">July 16, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Nevada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Investment holding</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left; width: 21%; vertical-align: top"><FONT STYLE="font-size: 10pt">Advanced Biomed Inc. (Taiwan)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt">September 1, 2014&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; text-align: center"><FONT STYLE="font-size: 10pt">Taiwan</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 20%; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Advanced Biomed HK Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">August 10, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Hong Kong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Market development</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">April 12, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Clinical-related business</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are presented assuming that the Company was in existence at the beginning of the first period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. LIQUIDITY AND GOING CONCERN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared in
conformity with U.S. GAAP which contemplates continuation of the Company on a going concern basis. The going concern basis assumes that
assets are realized, and liabilities are settled in the ordinary course of business at amounts disclosed in the consolidated financial
statements. The Company&rsquo;s ability to continue as a going concern depends upon its ability to develop, register and obtain regulatory
approval for commercial sell of its products to generate positive operating cash flows. For the financial year ended June 30, 2024, the
Company reported net loss of $2,782,278. In addition, the Company had net cash outflows of $2,126,340 from operating activities for the
financial year ended June 30, 2024. These conditions give rise to substantial doubt as to whether the Company will be able to continue
as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To sustain its ability to support the Company&rsquo;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">cash generated from upcoming operations; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">financial support from the Company&rsquo;s related party and stockholders as well as third parties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has commenced a strategy to raise debt
and equity and certain related parties have waived off the amount due to them as of June 30, 2024 amounted to $2,820,624 in order to improve
the Company&rsquo;s working capital. However, there can be no certainty that these additional financings will be available on acceptable
terms or at all. If management is unable to execute this plan, there would likely be a material adverse effect on the Company&rsquo;s
business. All of these factors raise substantial doubt about the ability of the Company to continue as a going concern. The consolidated
financial statements for the financial years ended June 30, 2024 and 2023 have been prepared on a going concern basis and do not include
any adjustments to reflect the possible future effects on the recoverability and classifications of assets or the amounts and classifications
of liabilities that may result from the inability of the Company to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(a) Basis of presentation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;US GAAP&rdquo;)
and pursuant to the regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(b) Consolidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the financial statements of the Company and its subsidiaries. All inter-company transactions, if any, and balances due to, due from, long-term
investment subsidiary, and registered paid in capital have been eliminated upon consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business combinations are accounted for using
the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective
fair values as of the acquisition date in the Company&rsquo;s consolidated financial statements. Any excess fair value of consideration
transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection
with the business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent
reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in the consolidated statements
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the Company determines that assets acquired
do not meet the definition of a business under the acquisition method of accounting, acquired assets is expensed, no goodwill is recorded,
and any contingent consideration is recognized only when it becomes payable or is paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(c) Use of estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to useful lives for property,
plant and equipment and intangible assets, fair value of financial instruments, assumptions used in assessing right of use assets, impairment
of long-lived assets, property, plant and equipment, intangible assets and uncertain tax position. Actual results could vary from the
estimates and assumptions that were used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(d) Stock split</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward share split of all issued
and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company now have 100,000,000 common
stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the above transactions on a retroactive
basis similar to share split or dividend pursuant to ASC 260. All references made to share or per share amounts in the accompanying consolidated
financial statements and applicable disclosures have been retroactively adjusted to reflect the 4 for 1 share split. The shares of common
stock retain a par value of $0.001 per share. Accordingly, an amount equal to the par value of the increased shares resulting from the
share split was reclassified from &ldquo;Additional paid-in capital&rdquo; to &ldquo;Common stock&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(e) Risks and uncertainties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operations of the Company are located
in Taiwan and mainland China. Accordingly, the Company&rsquo;s business, financial condition, and results of operations may be influenced
by political, economic, and legal environments in Taiwan and mainland China, as well as by the general state of the economy in these two
countries. The Company&rsquo;s results may be adversely affected by changes in the political, regulatory and social conditions in these
two countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company continues to face relative uncertainty as to the remaining
intensity and duration of and the nature and timeline for recovery from the COVID-19 pandemic going forward and how all of that impacts
the Company, including the extent to which potentially permanent changes clinical trial operations have been caused by the pandemic. The
Company has taken the approach of managing the pandemic (to the extent that it continues to remain a significant factor) via strengthening
its balance sheet and cash assets and avoiding debt while focusing on cost controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(f) Foreign currency translation and transaction
and convenience translation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are presented in the US Dollar (&ldquo;US$&rdquo;), which is the reporting currency of the Company. The functional currency of the Company
is the US$. Advanced Biomed Inc. (Taiwan) use New Taiwan dollar (&ldquo;NT$&rdquo;) as its functional currency. Advanced Biomed HK Limited
uses Hong Kong dollars (&ldquo;HKD&rdquo;) and Shanghai Sglcell Biotech Co., Ltd., Nanjing Yitian Biotech Co., Ltd., Beijing Yitan Jiarui
Technology Co., Ltd., Shandong Sglcell Medical Devices Co., Ltd., Sglcell (Huangshan) Biotech Co., Ltd use Chinese Yuan Renminbi (&ldquo;CNY&rdquo;)
as their functional currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities denominated in currencies other than the reporting currency are translated into the reporting currency at the rates of
exchange prevailing at the balance sheet date. Translation gains and losses are recognized in the consolidated statements of income and
comprehensive income as other comprehensive income or loss. Transactions in currencies other than the reporting currency are measured
and recorded in the reporting currency at the exchange rate prevailing on the transaction date. The cumulative gain or loss from foreign
currency transactions is reflected in the consolidated statements of income and comprehensive income as other income (other expense).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of foreign currencies including, the NT$, CNY and HKD, may fluctuate against the US Dollar. Any significant variations of the aforementioned
currencies relative to the US Dollar may materially affect the Company&rsquo;s financial condition in terms of reporting in US Dollar.
The following table outlines the currency exchange rates that were used in preparing the accompanying consolidated financial statements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June
                                            30,</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2024</B></FONT></P></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June
                                            30,</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 75%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$ to NT$
    fiscal year end</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.45</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.14</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$ to NT$ average rate</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.83</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.71</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$ to CNY fiscal year
    end</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.27</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.25</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$ to CNY average rate</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.95</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$ to HKD fiscal year
    end</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.81</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.84</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$ to HKD average rate</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.82</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.84</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(g)
Fair value measurement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account</FONT>ing
guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required
or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact,
and it considers assumptions that market participants would use when pricing the asset or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
A financial instrument&rsquo;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. Accounting guidance establishes three levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices, in active markets for identical assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical asset or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 3 applies to asset or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash, other current assets, leases payable, accounts
payables, accruals and other current liabilities are financial assets and liabilities. Cash, other current assets, accounts payable, accruals
and other current liabilities are subject to fair value measurement; however, because of their being short term in nature management believes
their carrying values approximate their fair value. Financial instruments are fair value financial assets that are marked to fair value
and are accounted for under as Level 3 under the above hierarchy. The Company accounts for bank loans and lease payables at amortized
cost and has elected NOT to account for them under the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(h) Related parties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted ASC 850, Related Party Disclosures,
for the identification of related parties and disclosure of related party transactions for the years ended June 30, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(i) Cash </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash consists of cash on hand, the Company&rsquo;s
demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal
and use. Deposits are held at highly liquid and well capitalized financial institutions. Risk of loss is not expected by management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(j) Intangible assets, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Software</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt">Patents</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 66%"><FONT STYLE="font-size: 10pt">6 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Software represents purchased software and is
amortized straight-line over the Company&rsquo;s estimates to generate economic benefits from such software, generally three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents represent the estimated fair value assigned
to finite-lived intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination
are initially recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets
acquired is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over
the estimated useful lives of the respective finite-lived intangible assets, generally six years. Intangible assets are reviewed for impairment
at least annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for
impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might
not be recoverable. If the carrying value of an finite-lived intangible asset exceeds its fair value, then it is written down to its adjusted
fair value. As of June 30, 2024 and 2023, the Company had finite-lived intangible assets of US$1.6 million of purchased patents from the
acquisition of Shanghai Sglcell Biotech Co., Ltd. The accumulated impairment allowance recognised was approximately US$1.6 million as
of June 30, 2024 and 2023, respectively, as management assessed that there were changes in circumstances indicate that the carrying value
of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(k) Equipment, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net are stated at cost less accumulated
depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the assets. Cost represents
the purchase price of the asset and other costs incurred to bring the asset into its intended use. Estimated useful lives are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Category</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 66%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Estimated useful lives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Lab equipment</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Computer equipment</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Furniture and fixtures</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 to 5 years</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Leasehold improvements</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3 years</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditure for repair and maintenance costs,
which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for major
renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the related
assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment with any
resulting gain or loss recognized in the consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(l)
Deferred Initial Public Offering (&ldquo;IPO&rdquo;) costs&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirement of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&ldquo;SAB&rdquo;) Topic 5A &mdash;
&ldquo;Expenses of Offering&rdquo;. Initial public offering expense directly attributable to offering of securities are deferred and
would be charged against the gross proceeds of the offering, as a reduction in share capital. These deferred expenses mainly consist
of underwriting, legal and other expenses incurred through the balance sheet date that are directly related to the intended IPO. Should
the IPO prove to be unsuccessful, these deferred initial public offering costs, as well as additional expenses to be incurred, will be
charged to operations. As of June 30, 2024 and June 30, 2023, the Company capitalized US$638,871 and US$553,471 of deferred initial public
offering costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(m)
Impairment of long-lived assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of
an asset may no longer be recoverable. When these events occur, the Company measures impairment by comparing the carrying value of the
long-lived assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition.
If the sum of the expected undiscounted cash flow is less than the carrying amount of the assets, the Company would recognize an impairment
loss, which is the excess of carrying amount over the fair value of the assets, using the expected future discounted cash flows. As of
June 30, 2024 and 2023, the Company had finite-lived intangible assets of US$1.6 million of purchased patents from the acquisition of
Shanghai Sglcell Biotech Co., Ltd. The accumulated impairment allowance recognised was approximately US$1.6 million as of June 30, 2024
and 2023, respectively, as management assessed that there were changes in circumstances indicate that the carrying value of the assets
might not be recoverable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(n)
Commitments and contingencies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the normal course of business, the Company is subject to commitments and contingencies, including operating lease commitments, legal
proceedings and claims arising out of its business that relate to a wide range of matters, such as government investigations and tax
matters. The Company recognizes a liability for such contingency if it determines it is probable that a loss will occur, and a reasonable
estimate of the loss can be made. The Company may consider many factors in making these assessments on liability for contingencies, including
historical and the specific facts and circumstances of each matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(o) Research and development expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs
directly attributable to the conduct of research and development programs, including licensing fees, cost of salaries, payroll taxes and
other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing
costs and professional services. All costs associated with research and developments are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has already started the registration
process and plans to start the clinical research by the end of June 2025, which are expected to end in April 2026, and we expect to obtain
the required registration certificate by the October 2027. As of June 30, 2024, the Company has not commenced sales of the products nor
have any revenue-generating products and do not expect sales of revenue-generating product candidates until the Company has completed
clinical development, submitted regulatory filings, and received applicable regulatory approvals for candidate products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hence, the Company incurred its research and development
cost during the years ended June 30, 2024 and 2023, which is in compliance under ASC 730-10-25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(p) General and administrative expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses mainly consist
of staff cost, depreciation, office supplies and upkeep expenses, travelling and entertainment, legal and professional fees, property
and related expenses, other miscellaneous administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(q)
Operating leases</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Prior
to the adoption of ASC 842 on January 1, 2019:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases,
mainly leases of factory buildings, offices and employee dormitories, where substantially all the rewards and risks of ownership of assets
remain with the lessor are accounted for as operating leases. Payments made under operating leases are recognized as an expense on a
straight-line basis over the lease term. The Company had no finance leases for any of the periods stated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Upon
and hereafter the adoption of ASC 842 on January 1, 2019:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&ldquo;ROU&rdquo;)
assets, operating lease liability, and operating lease liability, non-current in the Company&rsquo;s consolidated balance sheets. ROU
assets represent the Company&rsquo;s right to use an underlying asset for the lease term and lease liabilities represent the Company&rsquo;s
obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date
based on the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend
or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Company&rsquo;s leases do not
provide an implicit rate, the Company used an incremental borrowing rate based on the information available at commencement date in determining
the present value of lease payments. The Company has elected to adopt the following lease policies in conjunction with the adoption of
ASU 2016-02: (i) for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain
to exercise, the Company elected not to apply ASC 842 recognition requirements; and (ii) the Company elected to apply the package of
practical expedients for existing arrangements entered into prior to January 1, 2019 to not reassess (a) whether an arrangement is or
contains a lease, (b) the lease classification applied to existing leases, and (c) initial direct costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<I>(r)
Income Taxes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax
assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred
taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more
likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first
step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution
of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that
meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is
measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions
that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in
which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized
in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related
to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating
to income taxes has been incurred for the years ended June 30, 2024 and 2023. GAAP also provides guidance on de-recognition, classification,
interest and penalties, accounting in interim periods, disclosures and transition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Valuation
of Deferred Tax Assets</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
valuation allowance is recorded to reduce the Company&rsquo;s deferred tax assets to the amount that is more likely than not to be realized.
In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and
ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will
consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording
a valuation allowance, the Company&rsquo;s projections of future taxable income and other positive evidence considered in evaluating
the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support
the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse
impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that
sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all
of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable
impact on its effective income tax rate and results in the period such determination was made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(s)
Loss per share</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Loss per share is computed by dividing
net loss attributable to common stockholders </FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">by the weighted
average number of common stock outstanding during the year. Diluted earnings per share reflect the potential dilution that could occur
if securities or other contracts to issue common stock were exercised or converted into common stock.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(t)
Recent accounting pronouncements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the FASB issued ASU 2021-10, Codification Improvements. The amendments in this Update represent changes to clarify the
Codification or correct unintended application of guidance that are not expected to have a significant effect on current accounting practice
or create a significant administrative cost to most entities. The amendments in this Update affect a wide variety of Topics in the Codification
and apply to all reporting entities within the scope of the affected accounting guidance. ASU 2021-10 is effective for annual periods
beginning after December 15, 2021 for public business entities. Early application is permitted. The amendments in this Update should
be applied retrospectively. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the FASB issued ASU 2023-06, &ldquo;Disclosure Improvements: Codification Amendments in Response to the SEC&rsquo;s Disclosure
Update and Simplification Initiative.&rdquo; This amendment incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure
requirements into the FASB Accounting Standards Codification. The amendments in the ASU are expected to clarify or improve disclosure
and presentation requirements of a variety of Codification Topics, allow users to more easily compare entities subject to the SEC&rsquo;s
existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification
with the SEC&rsquo;s regulations. For entities subject to the SEC&rsquo;s existing disclosure requirements and for entities required
to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that
are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC removes
that related disclosure from its rules. For all other entities, the amendments will be effective two years later. However, if by June
30, 2027, the SEC has not removed the related disclosure from its regulations, the amendments will be removed from the Codification and
not become effective for any entity. The Company does not expect the adoption of ASU 2023-06 to have a material impact on its consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280)&nbsp;&mdash;&nbsp;Improvements to Reportable Segment Disclosures.
The amendment requires entities to report a measure of segment profit or loss that the chief operating decision maker uses to assess
segment performance and make decisions about allocating resources. The amendment also requires other specified segment items and amounts,
such as depreciation, amortization, and depletion expense, to be disclosure under certain circumstances. The amendment does not change
or remove those disclosure requirements and also does not change how an entity identifies its operating segments, aggregates those operating
segments, or applies the quantitative thresholds to determine its reportable segments. This amendment is effective for the Group&rsquo;s
consolidated financial statements issued for annual periods beginning after December 15, 2023. Early adoption is permitted. The Group
is currently evaluating the impact of adopting this amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740)&nbsp;&mdash;&nbsp;Improvements to income Tax Disclosures. The amendment in this update are effective for annual
periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods
beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available
for issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2024, the FASB issued ASU 2024-01, Compensation
&mdash; Stock Compensation (Topic 718)&nbsp;&mdash;&nbsp;Scope Application of Profits Interest and Similar Award. For public business
entities, the amendments in this Update are effective for annual periods beginning after December 15, 2024, and interim periods within
those annual periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim
periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been
issued or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning
of the annual period that includes that interim period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as mentioned above, the Company does not
believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&rsquo;s
consolidated balance sheets, statements of operations and comprehensive loss and statements of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4. PREPAID EXPENSES AND OTHER CURRENT ASSETS,
NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Tax refundable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">161,142</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">146,625</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,035</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,325</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Prepayment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">237,960</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,759</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">443,137</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,709</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: allowance for credit losses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">443,137</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">163,709</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5. EQUIPMENT, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net, consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Lab equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,486,392</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,446,527</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Computer equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,135</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Furniture and fixtures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,412</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">201,516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">201,994</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,754,985</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,715,068</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,230,457</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(996,371</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Equipment, net</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">524,528</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">718,697</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses were approximately US$268,279
and US$228,807 for the years ended June 30, 2024 and 2023, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
DISPOSAL OF SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 8, 2023, Shanghai Sglcell Biotech Co., Ltd. transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary,
Beijing Yitan Jiarui Technology Co., Ltd., to independent third-party individuals at aggregate consideration of CNY500,000 (approximately
US$71,942). Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd. have not commenced its business
activity since it was acquired on January 1, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration
is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May
31, 2023, as of the date of May 31, 2023, the net assets value of Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan
Jiarui Technology Co., Ltd., was CNY498,587 (approximately US$71,739).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 9, 2023, Shandong Sglcell Biotech Co., Ltd., the wholly owned subsidiary of Shanghai Sglcell Biotech Co., Ltd., was transferred
to independent third-party individuals at zero consideration without any other obligations arising from the transfer. Shandong Sglcell
Biotech Co., Ltd. has been inactive since it was incorporated on July 8, 2021 and the Company believed the transfer will improve in operational
efficiency. The consideration is determined by the Company according to the net assets appraisal report issued by an independent third-party
appraisal company on May 31, 2023, as of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd.,
was zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, Sglcell (Huangshan) Biotech Co., Ltd., the wholly owned subsidiary of Advanced Biomed HK Limited, was transferred to an
independent third-party corporation at zero consideration without any other obligations arising from the transfers. Sglcell (Huangshan)
Biotech Co., Ltd. has been dormant since its incorporation date from March 4, 2022 and the Company believed the transfer will improve
in operational efficiency. The consideration is determined by the Company according to the net assets appraisal report issued by an independent
third-party appraisal company on May 31, 2023, as of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices
Co., Ltd., was zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
of disposal subsidiaries on the financial position of the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 87%"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">50,486</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Prepaid expenses and other current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">246,540</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">395</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Accounts payable, accruals and other current liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(75,272</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Net assets</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>222,149</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Consideration *</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">71,942</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Loss on disposal of subsidiaries</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">150,207</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Debt forgiving as consideration based on the
settlement agreement on June 10, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. INTANGIBLE ASSETS, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the carrying amount
of the Company&rsquo;s finite-lived intangible assets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2023</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Acquired technology</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">391,016</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">391,943</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(272,018</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(141,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">118,998</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">250,321</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finite-lived intangible assets are carried at
cost less accumulated amortization. Amortization expense was approximately US$131,323 and US$136,424 for the years ended June 30, 2024
and 2023, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2023</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Acquired patents through acquisition</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,617,974</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,617,974</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: impairment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,617,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024 and 2023, the Company had
finite-lived intangible assets of US$1.6 million of purchased patents from the acquisition of Shanghai Sglcell Biotech Co., Ltd. The accumulated
impairment allowance recognized was US$1,617,974 as of June 30, 2024 and 2023, respectively, as management assessed that there were changes
in circumstances indicate that the carrying value of the assets might not be recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8. ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT
LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Payable, accrued expenses and other liabilities
consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2023</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Accounts Payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">620,476</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">632,820</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payroll payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,113</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,561</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amount due to related parties &ndash; major stockholders *</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,812</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,052,677</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amount due to related parties &ndash; related corporations**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">674,262</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">603,802</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other payable#</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,184,586</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">684,156</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,670,249</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,059,016</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* The amount due to the Company&rsquo;s major
stockholders as of June 30, 2024 and 2023 is non-trade, unsecured, interest-free and repayable on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">** The amount due to related corporations, which
the Company&rsquo;s major stockholders have controlling equity interest in, as of June 30, 2024 and 2023 are non-trade, unsecured, interest-free
and repayable on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"># The amount consists of payables owed to third
party creditors, which are unsecured, interest-free and repayable on demand, and other payables due to operational use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9. OTHER EXPENSE, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the years ended <BR>
June 30,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 74%"><FONT STYLE="font-size: 10pt">Loss from disposal of subsidiaries</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">(150,207</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Other income (expense), net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">486</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(21,111</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Foreign exchange loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(294,687</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(511,638</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Other expense, net</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(294,201)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(682,956</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the sake of undertaking a public offering
of the Company&rsquo;s common stock, the Company has performed a series of re-organizing transactions resulting in 25,000,000 of common
stock and 24,750,000 of common stock outstanding as of June 30, 2024 and June 30, 2023. The Company has accounted for these shares had
they been issued and outstanding at the beginning of the first period presented. The Company only has one single class of common stock
that is accounted for as permanent equity.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above mentioned re-organizing transactions and equity is before the share split on May 16, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2023, the Company effected a forward share split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4.
As a result of the forward split, the Company now have 100,000,000 common stock issued and outstanding as of the date hereof. The Company
believed it is appropriate to reflect the above transactions on a retroactive basis similar to share split or dividend pursuant to ASC
260. All references made to share or per share amounts in the accompanying consolidated financial statements and applicable disclosures
have been retroactively adjusted to reflect the 4 for 1 share split. The shares of common stock retain a par value of $0.001&nbsp;per
share. Accordingly, an amount equal to the par value of the increased shares resulting from the stock split was reclassified from &ldquo;Additional
paid-in capital&rdquo; to &ldquo;Common stock&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock&nbsp;in this report has been retrospectively adjusted for the reverse share split, as if such reverse share
split occurred on the first day of the years presented.</P>
<P STYLE="margin: 0; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
INCOME TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is not an operating company but a
holding company incorporated in the State of Nevada and is considered U.S. tax resident under U.S. tax laws; accordingly, it is subject
to U.S. tax laws at a statutory tax rate of 21%. The Company is subject to the State of Nevada tax laws at a tax rate of&nbsp;0%.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company&rsquo;s net deferred
income tax assets as of June 30, 2024 and 2023 consist of net operating loss carry forwards. The net operating loss carry forwards for
U.S. federal tax and Taiwan, China, Hong Kong tax purposes are available for carry forward indefinitely for use in offsetting taxable
income. The U.S. federal net operating loss carry forward offset is limited to up to 80% of the taxable income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024 and 2023, the Company had
total net operating loss carry forwards of approximately $8,767,393 and $5,507,673, which consists of China net operating loss carry forwards
of $3,817,009&nbsp;and $1,821,045, Taiwan net operating losses of $4,200,888&nbsp;and $3,290,193, Hong Kong net operating loss carry forwards
of $5,014 and $3,994, and US net operating loss carry forwards of $744,480 and $392,441.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Taiwan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s operating subsidiary, Advanced Biomed Inc. (Taiwan) is considered Taiwan tax resident enterprises under Taiwan tax laws;
accordingly, it is subject to enterprise income tax on its taxable income as determined under Taiwan tax laws at a statutory tax rate
of 20%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>China</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s operating subsidiary, Shanghai Sglcell Biotech Co., Ltd. is considered PRC resident enterprises under Enterprise Income
Tax Law of the PRC; accordingly, it is subject to enterprise income tax on their taxable income as determined under Enterprise Income
Tax Law of the PRC at a statutory tax rate of 25%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Hong
Kong</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Under the current Hong&nbsp;Kong
Inland Revenue Ordinance, a two-tier&nbsp;corporate income tax system was implemented in Hong&nbsp;Kong, which is 8.25% for the first
HK$2.0&nbsp;million taxable income, and 16.5% for the subsequent taxable income generated from operations in Hong&nbsp;Kong. The Company&rsquo;s
subsidiary, Advanced Biomed HK Limited is considered Hong Kong tax resident under Hong Kong Tax Law; accordingly, it is subject to corporate
income tax on its taxable income at 8.25% with nil and nil for the years ended June 30, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision consists of the following component:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the years ended</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June 30,</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Income tax expense</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following table reconciles the operating
profit to the Company&rsquo;s effective tax rate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the years ended</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June 30,</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Loss before tax</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(2,782,278)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(3,732,777</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Statutory income tax rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Income tax expense calculated at the statutory tax rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Effect of tax losses carry forwards</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2,019,708</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,208,322</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Effect of subsidiaries foreign income (loss)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,019,708</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,208,322</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Income tax expense</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Effective tax rate</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-%</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The component of deferred tax assets are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June 30,</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>June 30,<BR>
2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Net operating losses carry forward</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">2,019,708</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,208,322</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,019,708</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(1,208,322</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Deferred tax assets, net</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In assessing
the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred
tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those temporary differences become deductible. Management considers the cumulative earnings and projected
future taxable income in making this assessment. Recovery of substantially all of the Company&rsquo;s deferred tax assets is dependent
upon the generation of future income, exclusive of reversing taxable temporary differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>12. STOCK OPTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective from March 30, 2023, the Stock Incentive
Plan (the &ldquo;2023 Plan&rdquo;) was approved by the Company's Board of Directors. Under the 2023 Plan, the Board of Directors may grant
options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to the Company or any
related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award,
and the purchase or exercise price, conditions and other terms of each award are determined by the Board of Directors, except that the
term of the options shall not exceed 10 years. A total of 15 million shares of our common stock are subject to the 2023 Plan and maybe
either a qualified or non-qualified stock option. The shares issued for the 2023 Plan may be either treasury or authorized and unissued
shares. As of the date of this prospectus, the Company has granted no stock options to purchase any shares of the common stock under the
2023 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>13. RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These related parties of the Company with whom
transactions are reported in these financial statements are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Related Party</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 64%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Relationship to Us</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Yi Lu, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chairman of the Board and Chief Executive Officer of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director, Secretary and Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Steven I-Fang Cheng, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Technology Officer of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Chen-Yi Lee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Chen-Yi Lee is also the Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Advance On Ventures Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Well Fancy Development Ltd</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau is the director and shareholder of the entity</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Hung To Pau is the legal person and shareholder of the entity</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of business, during the&nbsp;fiscal
years ended June&nbsp;30, 2024 and 2023, the Company was involved in certain transactions, either at cost or current market prices, and
on the normal commercial terms with related parties. The following table provides the transactions with these parties for the&nbsp;years
as presented (for the portion of such period that they were considered related):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2024</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2023</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Amount due to related parties &ndash; major stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left"><FONT STYLE="font-size: 10pt">Hung To Pau, Ph.D. <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">933,471</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Yi Lu, Ph.D. <SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,907</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Chen-Yi Lee <SUP>(3)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,544</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">113,812</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,052,677</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Amount due to related parties &ndash; related corporations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Well Fancy Development Ltd <SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">396,905</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <SUP>(5)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">674,262</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">206,897</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">674,262</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">603,802</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the years ended <BR>
June 30,</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Additional paid-in capital</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;US$</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>US$</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Waiver of amount due to related parties &ndash;Hung To Pau, Ph.D.&nbsp;&nbsp;<SUP>(6)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,233,764</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Waiver of amount due to related parties &ndash; Well Fancy Development Ltd.<SUP>(7)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,586,860</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 19px"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Payments of IPO costs paid on behalf of Advanced Biomed Inc. As of June 30, 2024, the amount due to Hung To Pau, Ph.D. of US$1,233,764 has been waived off by Hung To Pau, Ph.D.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 19px"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$110,268) for general working capital in January 2023. As of June 30, 2024 and 2023, the loan balance due to Yi Lu amounted to US$110,268 and US$114,907, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 19px"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 19px"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into ten unsecured, interest-free loans to Well Fancy Development Ltd amounting to NTD 2,967,700 (approximately US$91,455), NTD2,989,873 (approximately US$92,138), NTD4,270,200 (approximately US$131,593), NTD1,945,000 (approximately US$59,938), NTD1,858,120 (approximately US$57,261), NTD2,912,200 (approximately US$89,744), NTD2,890,065 (approximately US$89,062), NTD5,857,750 (approximately US$180,516), NTD4,356,145 (approximately US$134,242) and NTD3,732,100 (approximately US$115,011) for general working capital in August 2022, April 2023, May 2023, June 2023, July 2023, August 2023, October 2023, December 2023, February 2024 and April 2024, respectively. As of June 30, 2024, the loan balance due to Well Fancy Development Ltd totally amounted to US$1,040,960 and amounted to US$545,900 for general working capital. And the total amount due to Well Fancy Development Ltd of NTD33,779,153 and US$545,900 have been waived off by Well Fancy Development Ltd. As of June 30, 2023, the loan balance due to Well Fancy Development Ltd totally amounted to US$396,905.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 19px"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd entered into four unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$68,802) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$96,323), RMB1,500,000 (approximately US$206,407) and RMB700,000 (approximately US$96,323) in January 2024, March 2024 and June 2024, respectively, for general working capital. As of June 30, 2024 and June 30, 2023, the loan balance due to Shanghai Sglcell Biotech Co., Ltd totally amounted to US$674,262 and US$206,897, respectively.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As of June 30, 2024, the amount due to Hung To Pau, Ph.D. of US$1,233,764 has been waived off by Hung To Pau, Ph.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As of June 30, 2024, the total amount due to Well Fancy Development Ltd of US$1,586,860 has been waived off by Well Fancy Development Ltd.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>14. CONCENTRATIONS AND RISKS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Credit Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk is the potential financial loss to
the Company resulting from the failure of a customer or a counterparty to settle its financial and contractual obligations to the Company,
as and when they fall due. As the Company does not hold any collateral, the maximum exposure to credit risk is the carrying amounts of
other receivables (exclude prepayments) and cash and bank deposits presented on the consolidated balance sheets. The Company has no other
financial assets which carry significant exposure to credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidity Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk is the risk that the Company will
encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another
financial asset. The Company&rsquo;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking
damage to the Company&rsquo;s reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Typically, the Company ensures that it has sufficient
cash on demand to meet expected operational expenses for a period of 60 days, including the servicing of financial obligations; this excludes
the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Foreign currency risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency risk is the risk that the fair
value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The company&rsquo;s exposure to
the risk of changes in foreign exchange rates relates primarily to the Company&rsquo;s operating activities (when expense is denominated
in a foreign currency) and the Company&rsquo;s net investments in foreign subsidiaries.</P>
<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Impact of Inflation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation in Taiwan and PRC has not materially
affected the Company&rsquo;s profitability and operating results. However, the Company can provide no assurance that we will be unaffected
by higher inflation rates in Taiwan and PRC or globally in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>15. COMMITMENTS AND CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of June 30, 2024 and up through October 28,
2024, the issuance date of these consolidated financial statements were available to be issued.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Lease commitment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if a contract contains
a lease at inception. US GAAP requires that the Company&rsquo;s leases be evaluated and classified as operating or finance leases for
financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation
includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods
when the exercise of the renewal option is reasonably certain and failure to exercise such option which results in an economic penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use assets relate to leases of office
premises and a dormitory for employees in the PRC and the laboratory in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recognized operating lease ROU assets and
lease liabilities as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2023</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease ROU asset</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">126,740</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">235,373</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2023</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Current portion</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">62,211</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">216,567</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Non-current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">64,529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,806</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">126,740</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">235,373</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2024, future minimum lease payments
under the non-cancellable operating leases are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">Future payment</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">2025</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">66,074</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,282</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,282</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2029</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total future lease payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,638</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: imputed interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,898</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">126,740</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease liabilities, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,211</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liabilities, non-current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,529</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes other supplemental information
about the Company&rsquo;s operating lease as of June 30, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 87%"><FONT STYLE="font-size: 10pt">Weighted average discount rate</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">4.23</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Weighted average remaining lease term (years)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.40</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16. SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has assessed all events from June
30, 2024 through October 28, 2024, which is the date that these consolidated financial statements are available to be issued, unless as
disclosed below, there are not any material subsequent events that require disclosure in these consolidated financial statements other
than events detailed below.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common shares issued and outstanding as of the date hereof.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>25,000,000 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 170 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>The information in this preliminary prospectus is not complete and may
be changed. We may not sell these securities until the registration statement filed with the United States Securities and Exchange Commission
is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted.</B></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">RESALE PROSPECTUS &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DATED
JANUARY 7, 2025</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Advanced Biomed Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc051_img06.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1,875,000 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the resale of 1,875,000 shares of common stock, par value $0.001 per share, of Advanced Biomed Inc. (the &ldquo;Common Stock&rdquo;),
by each Selling Stockholder named in this prospectus. We will not receive any of the proceeds from the
sale of the Common Stock by the Selling Stockholders. We have applied to list our Common Stock on the Nasdaq Capital Market under the
symbol &ldquo;ADVB.&rdquo; We cannot guarantee that we will be successful in listing our Common Stock on the Nasdaq Capital Market; however,
we will not complete this offering unless we are so listed on the Nasdaq Capital Market.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No sales of the Common
Stock covered by this prospectus shall occur until the closing of our Primary Offering. The Selling Stockholders may sell all or a
portion of the Common Stock beneficially owned by them and offered hereby from time to time directly or through one or more
transactions that may take place in ordinary brokers&rsquo; transactions, privately negotiated transactions or through sales to one
or more dealers for resale of such securities as principals. Usual and customary or specifically negotiated brokerage fees or
commissions may be paid by the Selling Stockholders. The offering by the Selling Stockholders will remain open for 180 days
following the date of this prospectus, and following the expiration of such 180 days period, we no longer intend to keep this
registration statement effective. See &ldquo;Selling Stockholders Plan of Distribution.&rdquo; We expect the initial offering price
of the Resale Shares will be between $4.00 and $6.00 per Resale Share until our Common Stock is listed on the Nasdaq Capital Market
and there is an established market for the Resale Shares. There are risks associated with having two offerings. See &ldquo;Risk
Factors &mdash; Risks Related to this Offering.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Advanced Biomed Inc. (&ldquo;Advanced
Biomed&rdquo;) is not an operating company but a holding company incorporated in the State of Nevada. Substantially all of the business
operations are conducted in Taiwan by our Taiwan subsidiary. And we also have a subsidiary in Hong Kong and a Shanghai subsidiary in Mainland
China.&nbsp;<B>Shares of common stock offered in this offering are shares of a U.S. holding company</B>,&nbsp;<B>which does not conduct
operations</B>. As used in this prospectus, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company&rdquo; refers
to Advanced Biomed, the U.S. holding company. While our subsidiaries in Mainland China and Hong Kong do not operate with a variable interest
entity (&ldquo;VIE&rdquo;) structure, the Chinese regulatory authorities could disallow our current operating structure, which would likely
result in a material change in our operations and/or a material change in the value of the securities we are registering for sale, including
that it could cause the value of such securities to significantly decline or become worthless. See &ldquo;Risk Factors &mdash; Changes
in the policies, regulations, rules, and the enforcement of laws of the PRC government may be quick with little advance notice and could
have a significant impact upon our ability to operate profitably in the PRC.&rdquo;; and &ldquo;Risk Factors &mdash; The Chinese government
may intervene in or influence our operations in the Mainland China and Hong Kong at any time or may exert more control over offerings
conducted overseas and/or foreign investment in us, which could result in a material change in our operations and and/or the value of
the securities we are registering for sale.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I></I></P>

<!-- Field: Page; Sequence: 171 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Although the majority of
our operations are not conducted in Mainland China, we face various legal and operational risks and uncertainties relating to our Shanghai
subsidiary, Shanghai Sglcell Biotech Co., Ltd., and such legal and operational risks and uncertainties also apply to our holding company,
Advanced Biomed HK Limited (&ldquo;Advanced Biomed HK&rdquo;), in Hong Kong. The Chinese government may intervene or influence the operation
of our Shanghai subsidiary and Advanced Biomed HK and exercise significant oversight and control over the conduct of their business and
may intervene in or influence their operations at any time, or may exert more control over securities offerings conducted overseas and/or
foreign investment in us, which could result in a material change in our operations and/or the value of our common stock. Further, any
actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment
in us could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value
of such securities to significantly decline or be worthless.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Recently, the PRC government
initiated a series of regulatory actions and statements to regulate business operations in China with little advance notice, including
cracking down on illegal activities in the securities market, adopting new measures to extend the scope of cybersecurity reviews, and
expanding the efforts in&nbsp;anti-monopoly&nbsp;enforcement. As advised by our PRC counsel, AllBright Law Offices (&ldquo;AllBright&rdquo;),
we do not believe that we are directly subject to these regulatory actions or statements, as our Shanghai subsidiary does not have a
VIE structure and their operations are not subject to cybersecurity review requirements, or involve any type of foreign investment restricted
industry. Because these statements and regulatory actions are new, it is highly uncertain how soon legislative or administrative rule
making bodies in China will respond to them, or what existing or new laws or regulations will be modified or promulgated, if any, or
the potential impact such modified or new laws and regulations will have on our subsidiaries&rsquo; daily business operations or ability
to accept foreign investments and list on an U.S. exchange. In July 2021, the Cyberspace Administration of China (&ldquo;CAC&rdquo;)
opened cybersecurity probes into several U.S.-listed technology companies focusing on anti-monopoly regulation, and how companies collect,
store, process and transfer data, among other things. On October 23, 2021, the Standing Committee of the National People&rsquo;s Congress
issued a discussion draft of the amended Anti-Monopoly Law, which proposes to increase the fines for illegal concentration of business
operators to &ldquo;no more than ten percent of its last year&rsquo;s sales revenue if the concentration of business operator has or
may have an effect of excluding or limiting competition; or a fine of up to RMB5 million if the concentration of business operator does
not have an effect of excluding or limiting competition.&rdquo; On December 24, 2021, nine government agencies jointly issued the Opinions
on Promoting the Healthy and Sustainable Development of Platform Economy, which provides that, among others, monopolistic agreements,
abuse of dominant market position and illegal concentration of business operators in the field of platform economy will be strictly investigated
and punished in accordance with the relevant laws. We do not hold a dominant market position in our product markets and we have not entered
into any monopolistic agreement. We have not received any inquiry from the relevant governmental authorities. On July 10, 2021, the CAC
published a revised draft revision to the Cybersecurity Review Measures for public comment, or the Draft Cybersecurity Measures, and
together with 12 other Chinese regulatory authorities, released the final version of the Revised Measures for Cybersecurity Review, or
the Revised Cybersecurity Measures, in December 2021, which took effect on February 15, 2022. Pursuant to the Revised Cybersecurity Measures,
critical information infrastructure operators procuring network products and services and online platform operators carrying out data
processing activities, which affect or may affect national security, shall conduct a cybersecurity review pursuant to the provisions
therein. In addition, online platform operators possessing personal information of more than one million users seeking to be listed on
foreign stock markets must apply for a cybersecurity review. Further, an expert interpretation of the Revised Cybersecurity Measures
published at the CAC&rsquo;s website on February 17, 2022 indicated no application review is required for operators that have been listed
abroad before the implementation of the Revised Cybersecurity Measures. The Revised Cybersecurity Measures apply to companies going abroad
for secondary listing, dual primary listing and other new foreign listings and subject to the reporting requirements. As advised by AllBright,
we do not believe that we are an &ldquo;online platform operator&rdquo; within the meaning of the Revised Cybersecurity Measures, and,
we currently do not have over one million users&rsquo; personal information and do not anticipate that we will be collecting over one
million users&rsquo; personal information in the foreseeable future. The Regulation on Network Data Security Management (the &ldquo;Network
Data Regulation&rdquo;) was promulgated by the State Council on September 24, 2024, and will become effective as of January 1, 2025.
The Network Data Regulation restates and further specifies the legal requirements for personal information, important data, cross-border
data transfer, network platform services, and data security. Among others, if the network data processing activities have or may have
impacts on national security, such activities shall be subject to national security review in accordance with relevant laws and regulations.
Any failure to comply with such requirements may subject us to, among others, suspension of services, fines, revoking relevant business
permits or business licenses and penalties. We are also not subject to Network Data Regulation, since we currently do not collect data
that affects or may affect national security and we do not anticipate that we will be collecting data that affects or may affect national
security in the foreseeable future.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 172 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>On December&nbsp;24, 2021,&nbsp;China Securities Regulatory Commission
(the&nbsp;&ldquo;CSRC&rdquo;)&nbsp;issued the Administrative Provisions of the State Council Regarding the Overseas Issuance and Listing
of Securities by Domestic Enterprises (the &ldquo;Draft Administrative Provisions&rdquo;) and the Measures for the Overseas Issuance of
Securities and Listing Record-Filings&nbsp;by Domestic Enterprises (Draft for Comments) (the &ldquo;Draft Filing Measures&rdquo;), collectively,
the Draft Overseas Listing Rules. On February 17, 2023, the CSRC&nbsp;released Trial Administrative Measures of Overseas Securities Offering
and Listing by Domestic Companies with five interpretive guidelines (the &ldquo;Trial Measures&rdquo;) which came into effect on March
31, 2023. Pursuant to the Trial Measures, a PRC domestic company that seeks to offer and list securities in overseas markets, either in
direct or indirect overseas offering, shall fulfill the filing procedure with the CSRC per requirement of the Trial Measures, submit relevant
materials that contain a filing report and a legal opinion, and provide truthful, accurate and complete information on the shareholder
and etc. Direct overseas offering and listing by domestic companies refers to such overseas offering and listing by a joint-stock company
incorporated domestically. Any overseas offering and listing made by an issuer that meets both the following conditions will be determined
as indirect offering and listing in overseas market and, therefore, be subject to filing requirement: (i) 50% or more of the issuer&rsquo;s
operating revenue, total profit, total assets or net assets as documented in its audited consolidated financial statements for the most
recent accounting year is accounted for by domestic companies; and (ii) the main parts of the issuer&rsquo;s business activities are conducted
in the Mainland China, or its main places of business are located in the Mainland China, or the senior managers in charge of its business
operation and management are mostly Chinese citizens or domiciled in the Mainland China. The determination as to whether or not an overseas
offering and listing by domestic companies is indirect, shall be made on substance over form basis. As of the date of this prospectus,
as advised by AllBright, we are not required to obtain the approval from or complete the filing with the CSRC for this offering and thus
we have not submitted an application for approval for this offering with the CSRC pursuant to the Trial Measures based on the facts that
(i) we are a holding company incorporated in the State of Nevada, not a company incorporated under the PRC law; (ii) based on the report
on the Shanghai subsidiary from a third party accounting firm in China, the Shanghai subsidiary contributed less than 50% to our operating
revenue, total profit, total assets or net assets as documented in the audited consolidated financial statements for the fiscal year ended
June 30, 2024; (iii) the business activities are primarily conducted in Taiwan, with minimal operation in Mainland China, and (iv) most
of our officers and directors are non-Chinese citizens or domiciled outside Mainland China. Thus, we do not meet the explicit conditions
set out in the Trial Measures to determine whether an overseas offering shall be deemed as a direct or an indirect overseas offering and
listing by a domestic company. However, as the Trial Measures was newly published and the determination as to whether or not an overseas
offering and listing by domestic companies is indirect, shall be made on a substance over form basis, there are substantial uncertainties
as to the implementation and interpretation, and the CSRC may take a view that is contrary to our understanding of the Trial Measures.
If we are required by the CSRC to submit and complete the filing procedures of this offering and listing, we cannot assure you that we
will be able to complete such filings in a timely manner, or even at all. Any failure by us to comply with such filing requirements under
the Trial Measures may result in rectification, warnings, and a fine between RMB1 million and RMB10 million on our Shanghai subsidiary,&nbsp;which
could adversely and materially affect our business operations and financial outlook, and significantly limit or completely hinder our
ability to offer or continue to offer our common stock to investors and could cause the value of our common stock to significantly decline
or such shares to become worthless.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>As of the date of this
prospectus, we and our only subsidiaries in the Mainland China and Hong Kong (1) are not required to obtain permissions from any PRC authorities
to operate or issue our common stock to foreign investors, (2) are not subject to permission requirements from the CSRC, CAC or any other
entity that is required to approve of our PRC subsidiary&rsquo;s operations, and (3) have not received or were denied such permissions
by any PRC authorities. As of the date of this prospectus, these new laws and guidelines have not impacted our ability to conduct our
business, accept foreign investments, or continue to list on a U.S. or other foreign exchange; however, if (i) we inadvertently conclude
that permissions or approvals are not required from applicable PRC authorities, (ii) applicable laws, regulations, or interpretations
change, and we are required to obtain such permissions or approvals in the future, or (iii) we fail to file or were denied any required
permission from the PRC authorities to this offering, any follow-up offerings or transactions, our ability to conduct our business may
be materially impacted, and we will not be able to continue listing on any U.S. exchange, continue to offer securities to investors, the
interest of the investors may be materially and adversely affected and our common stock may significantly decrease in value or become
worthless. To date, there are uncertainties in the interpretation and enforcement of these new laws and guidelines, which could materially
and adversely impact our business and financial outlook and may impact our ability to accept foreign investments, or continue to list
on a U.S. or other foreign exchange. See &ldquo;Risk Factors &mdash; The Chinese government may intervene in or influence our operations
in the Mainland China or Hong Kong at any time or may exert more control over offerings conducted overseas and/or foreign investment in
us, which could result in a material change in our operations and and/or the value of the securities we are registering for sale;&rdquo;
&ldquo;Risk Factors &mdash; If the Chinese government were to exert more oversight and control over or impose new requirements for approval
from the PRC authorities to issue our common stock to foreign investors or list on a foreign exchange, such action could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to
significantly decline or be worthless;&rdquo; &ldquo;Risk Factors &mdash; If the Chinese government chooses to exert more oversight and
control over offerings that are conducted overseas and/or foreign investment in China-based issuers, such action could significantly limit
or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly
decline or be worthless;&rdquo; and &ldquo;Risk Factors &mdash; The M&amp;A Rules and certain PRC regulations may make it more difficult
for us to pursue growth through acquisitions.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 173 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Cash may be transferred
within our organization in the following manners: (i) Advanced Biomed may transfer funds to our subsidiaries, including our Shanghai subsidiary,
by way of capital contributions or loans, through intermediate holding subsidiaries or otherwise; (ii) we and our intermediate holding
subsidiaries may provide loans to our operating subsidiaries and vice versa; and (iii) our subsidiaries, including our Shanghai subsidiary,
may make dividends or other distributions to us through intermediate holding companies or otherwise. As of the date of this prospectus,
Advanced Biomed made nine capital contributions to Advanced Biomed Inc. (Taiwan) (&ldquo;Advanced Biomed Taiwan&rdquo;) and Advanced Biomed
HK to support their research and development.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><I>Date</I></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><I>Receiving Entity</I></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><I>Amount (US$)</I></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">June 29, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2,500,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 11, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">86,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">100,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 26, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">500,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">November 7, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">122,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 2, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">110,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 14, 2022</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed Taiwan</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">85,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">October 10, 2023</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">70,000</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 5, 2023</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">300,000</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 9, 2024</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Advanced Biomed HK</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">150,000</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Other than the transfers in the table above, we have not made any distribution
of dividends or assets, cash transfers, capital contributions or loans among the holding company or any of our subsidiaries. Any loans
from us or our holding subsidiaries outside of Mainland China to our Shanghai subsidiary, which is treated as a foreign-invested enterprise
(&ldquo;FIE&rdquo;) under PRC law, are subject to PRC regulations and foreign exchange loan registrations. Such loans to our FIE subsidiary
to finance its activities must be registered with the State Administration of Foreign Exchange (&ldquo;SAFE&rdquo;) or its local counterparts.
As advised by AllBright, our PRC counsel, PRC laws, regulations and judicial interpretations thereof do not prohibit using cash generated
from one subsidiary to fund another subsidiary&rsquo;s operations by way of short term interest free loans as long as they comply with relevant laws
and procedures. In the future, cash proceeds raised from overseas financing activities, including this offering, may be transferred
by us to our Taiwan and Hong Kong subsidiaries and Shanghai subsidiary via capital contributions or shareholder loans. As of the date
of this prospectus, Advanced Biomed has not made dividend or other distributions to our stockholders. Advanced Biomed may pay dividends
to our stockholders subject to our ability to service our debts as they become due and provided that our assets will exceed our liabilities
after the payment of such dividends. As a holding company, Advanced Biomed may rely on dividends and other distributions on equity paid
by our subsidiaries for our cash and liquidity requirements, including payment of any debt we may incur outside of China and our expenses.
If any of our subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may restrict their ability
to pay dividends to us. To the extent cash or assets in the business is in the PRC or a PRC subsidiary, the cash or assets may not be
available to fund operations or for other use outside of the PRC due to interventions in or the imposition of restrictions and limitations
on our or our subsidiaries&rsquo; ability by the PRC government to transfer cash or assets or distribute earnings within our group or
to U.S. investors. PRC laws and regulations applicable to our Shanghai subsidiary permit payments of dividends only out of their retained
earnings, if any, determined in accordance with applicable accounting standards and regulations. Our Shanghai subsidiary may pay dividends
only out of their respective accumulated after-tax profits as determined in accordance with PRC accounting standards and regulations.
In addition, our subsidiaries are required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund certain
statutory reserve funds, until the aggregate amount of such funds reaches 50% of its registered capital. At its discretion, a wholly foreign-owned
enterprise may allocate a portion of its after-tax profits to discretionary funds. These reserve funds and discretionary funds are not
distributable as cash dividends. Furthermore, dividends paid by our Shanghai subsidiary to its parent companies will be subject to a 10%
withholding tax, which can be reduced to 5% if certain requirements are met. The PRC government also imposes restrictions on the conversion
of RMB into foreign currencies and the remittance of currencies out of the PRC. As such, we may experience difficulties in completing
the administrative procedures necessary to obtain and remit foreign currency for the payment of dividends from our profits, if any, or
transfer cash within our group, across border, or to U.S. investors. Additionally, current Taiwan regulations only permit our Taiwan subsidiary
to pay dividends to its stockholders out of its accumulated profits, and Advanced Biomed Taiwan must set aside at least 10% of its accumulated
profits each year and use it to make up previous losses, if any. The statutory reserve cannot be distributed as cash dividends. As of
the date of this prospectus, no dividends, transfers, or distributions have been made within our group or to stockholders. We presently
intend to retain all earnings to fund our operations and business expansions and have no plan to distribute earnings to stockholders.
We do not anticipate paying dividends or other distributions to our stockholders, including U.S. investors, in the foreseeable future.
See the relevant discussions in &ldquo;Risk Factors &mdash; Risks Related to Doing Business in China&rdquo; on page 31; &ldquo;Risk Factors
&mdash; PRC regulation on loans to, and direct investment in, PRC entities by offshore holding companies and governmental control in currency
conversion may delay or prevent us from making loans to or making additional capital contributions to our Shanghai subsidiary&rdquo; on
page 35; &ldquo;Risk Factors &mdash; Our Shanghai subsidiary is subject to restrictions on paying dividends or making other payments to
us, which may restrict our ability to satisfy our liquidity requirements in the future&rdquo; on page 35; &ldquo;Risk Factors &mdash;
Payment of dividends is subject to restrictions under PRC laws&rdquo; on page 39; and &ldquo;Risk Factors &mdash; Advanced Biomed Taiwan
is subject to restrictions on paying dividend or making other payments to us, which may restrict our ability to satisfy its liquidity
requirements&rdquo; on page 29.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 174 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Our Common Stock may be
prohibited from trading on a national exchange or &ldquo;over-the-counter&rdquo; markets under the Holding Foreign Companies Accountable
Act (the &ldquo;HFCAA&rdquo;) if the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) determines it is unable to inspect
or investigate completely our auditors for three consecutive years beginning in 2021. Further, on June 22, 2021, the U.S. Senate passed
the Accelerating Holding Foreign Companies Accountable Act (&ldquo;AHFCAA&rdquo;). If the AHFCAA is enacted into law, it would amend the
HFCAA and require the SEC to prohibit an issuer&rsquo;s securities from trading on any U.S. stock exchanges if its auditor is not subject
to PCAOB inspections or complete investigations for two consecutive years instead of three. On December 29, 2022, a legislation entitled
&ldquo;Consolidated Appropriations Act, 2023&rdquo; (the &ldquo;Consolidated Appropriations Act&rdquo;), was signed into law by President
Biden. The Consolidated Appropriations Act contained, among other things, an identical provision to HFCAA, which reduces the number of
consecutive non-inspection years required for triggering the prohibitions under the HFCAA from three years to two. Pursuant to the HFCAA,
the PCAOB issued a Determination Report on December 16, 2021, which found that the PCAOB is unable to inspect or investigate completely
registered public accounting firms headquartered in Mainland China and Hong Kong because of positions taken by the authorities in those
jurisdictions. In addition, the PCAOB&rsquo;s report identified the specific registered public accounting firms which are subject to these
determinations. On August 26, 2022, the PCAOB signed a Statement of Protocol Agreement with the CSRC and the Ministry of Finance (the
&ldquo;MOF&rdquo;) of the PRC governing inspections and investigations of audit firms based in China or Hong Kong. On December 15, 2022,
the PCAOB announced in the 2022 Determination its determination that the PCAOB was able to secure complete access to inspect and investigate
accounting firms headquartered in Mainland China and Hong Kong, and the PCAOB Board voted to vacate previous determinations to the contrary.
Should the PCAOB again encounter impediments to inspections and investigations in Mainland China or Hong Kong as a result of positions
taken by any authority in either jurisdiction, including by the CSRC or the MOF, the PCAOB will make determinations under the HFCAA as
and when appropriate. Our auditor, WWC, P.C., is headquartered in California and, as a PCAOB-registered public accounting firm, is required
to undergo regular inspections by the PCAOB to assess its compliance with the laws of the U.S. and professional standards. WWC, P.C. has
been subject to PCAOB inspections and is not among the PCAOB-registered public accounting firms headquartered in the PRC or Hong Kong
that are subject to PCAOB&rsquo;s determination of having been unable to inspect or investigate completely. Notwithstanding the foregoing,
if it is later determined that the PCAOB is unable to inspect or investigate our auditor completely, if there is any regulatory change
or step taken by PRC regulators that does not permit WWC, P.C. to provide audit documentations located in China or Hong Kong to the PCAOB
for inspection or investigation, or the PCAOB expands the scope of the Determination so that we are subject to the HFCAA, as the same
may be amended, you may be deprived of the benefits of such inspection. Any audit reports not issued by auditors that are completely inspected
or investigated by the PCAOB, or a lack of PCAOB inspections of audit work undertaken in China that prevents the PCAOB from regularly
evaluating our auditors&rsquo; audits and their quality control procedures, could result in a lack of assurance that our financial statements
and disclosures are adequate and accurate, which could result in limitation or restriction to our access to the U.S. capital markets,
and trading of our securities, including trading on the national exchange and trading on &ldquo;over-the-counter&rdquo; markets, may be
prohibited under the HFCAA and our securities may be delisted by an exchange. See &ldquo;Risk Factors &mdash; Recent joint statement by
the SEC and the PCAOB, rule changes by Nasdaq, and the Holding Foreign Companies Accountable Act all call for additional and more stringent
criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors
who are not inspected by the PCAOB. These developments could add uncertainties to our continued listing or future offerings of our securities
in the U.S.&rdquo;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 175 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Although our Hong Kong
subsidiary is a holding company with no operations, it may be subject to similar risks faced by our Shanghai subsidiary if the Chinese
government exert more control over or impose new laws or regulations on business activities in Hong Kong. See &ldquo;Risk Factors &mdash;
Chinese government may exert more control over Hong Kong business or impose new laws or regulations on business activities in Hong Kong.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company&rdquo; under applicable U.S. federal securities laws and are eligible for reduced public company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 15.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 176 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 10%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Page</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">15</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">46</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_034"><FONT STYLE="font-size: 10pt">Selling Stockholders</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_034"><FONT STYLE="font-size: 10pt">Alt- 2</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_036"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_036"><FONT STYLE="font-size: 10pt">Alt- 5</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">48</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">49</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_017"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">50</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_001"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Conditions and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#b_001"><FONT STYLE="font-size: 10pt">51</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#v_001"><FONT STYLE="font-size: 10pt">Our Industry</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#v_001"><FONT STYLE="font-size: 10pt">60</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#za_001"><FONT STYLE="font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#za_001"><FONT STYLE="font-size: 10pt">62</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Management</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">95</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">100</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Description of Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">101</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Shares Eligible for Future Sale</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">102</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_035"><FONT STYLE="font-size: 10pt">Selling Stockholders Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_035"><FONT STYLE="font-size: 10pt">Alt- 3</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_037"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_037"><FONT STYLE="font-size: 10pt">Alt-5</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">114</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#c_001"><FONT STYLE="font-size: 10pt">Enforceability of Civil Liabilities</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#c_001"><FONT STYLE="font-size: 10pt">114</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">115</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#index"><FONT STYLE="font-size: 10pt">Index to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><A HREF="#index"><FONT STYLE="font-size: 10pt">F-1</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 177 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information contained in this prospectus or
in any related free writing prospectus. We have not authorized anyone to provide you with information different from that contained in
this prospectus or any free writing prospectus. We are offering to sell, and seeking offers to buy, the Common Stock only in jurisdictions
where offers and sales are permitted. The information contained in this prospectus is current only as of the date of this prospectus,
regardless of the time of delivery of this prospectus or of any sale of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RESALE PROSPECTUS ALTERNATE PAGE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">Securities being offered: </FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 75%; text-align: justify"><FONT STYLE="font-size: 10pt">Up to 1,875,000 Common Stock</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Offering price: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No sales of the Resale Shares shall occur until the closing of our
Primary Offering. We expect the initial offering price of the Resale Shares will be between $4.00 and $6.00 per Resale Share until our Common Stock is listed on the Nasdaq Capital
Market and there is an established market for the Resale Shares. Once, and if, our Common Stock is listed on the Nasdaq Capital Market
and there is an established market for these resale shares, the Selling Stockholders may sell the Resale Shares from time to time at the
market price prevailing on the Nasdaq Capital Market at the time of offer and sale, or at prices related to such prevailing market prices
or in negotiated transactions or a combination of such methods of sale directly or through brokers.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Use of proceeds: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We are not selling any Common Stock covered by this prospectus. As such, we will not receive any of the proceeds from the sale of the Common Stock by the Selling Stockholders named in this prospectus.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Nasdaq Symbol:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ADVB</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Risk factors:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Investing in our Common Stock involves a high degree of risk. As an investor you should not buy our Common Stock unless you are able to bear a complete loss of your investment. You should carefully consider the information set forth in the &ldquo;Risk Factors&rdquo; section beginning on page 15.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 178; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Alt - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_034"></A>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering an aggregate
of 1,875,000 Common Stock to be offered by the Selling Stockholders. See &ldquo;Selling Stockholders Plan of Distribution.&rdquo; The
following table sets forth the name of the Selling Stockholders, the number of Common Stock owned by the Selling Stockholders immediately
prior to the date of this prospectus and the number of Common Stock to be offered by the Selling Stockholders pursuant to this Resale
Prospectus. The table also provides information regarding the beneficial ownership of our Common Stock by the Selling Stockholders to
reflect the sale of all of the shares offered under this Resale Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership is based
on information furnished by the Selling Stockholders. Unless otherwise indicated and subject to community property laws where applicable,
the Selling Stockholders named in the following table have, to our knowledge, sole voting and investment power with respect to the shares
beneficially they own.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders have
not had any position, office or other material relationship within past three&nbsp;years with the Company. The Selling Stockholders are
not broker dealers or affiliates of a broker dealer. The Selling Stockholders do not have any agreement or understanding to distribute
any of the Common Stock being registered. The Selling Stockholders are offering to sell all their Common Stock from time to time after
the closing of the Primary Offering by the Company. None of the Selling Stockholders or the natural controlling persons of the Selling
Stockholders are in the business of underwriting securities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">Name of the <BR> Selling <BR> Stockholders</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common<BR> Stock<BR> Beneficially <BR> Owned Prior to<BR> Offering</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> Common<BR> Stock to be<BR> Sold</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Common<BR> Stock<BR> owned<BR> After<BR> Offering</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Percentage <BR> Ownership<BR> After <BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left"><FONT STYLE="font-size: 10pt">Yimin Jin <SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,755,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,755,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Nanzhen Shen <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,209,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,089,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.98</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">assuming the underwriter does not exercise its over-allotment option</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company issued shares to Yimin Jin pursuant to the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt as mentioned in this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Company issued shares to Nanzhen Shen pursuant to the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt as mentioned in this offering. </FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Alt - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_035"></A>SELLING STOCKHOLDERS PLAN
OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering the Common Stock of the Selling
Stockholders to permit the resale of Common Stock by the Selling Stockholders from time to time after the date of this prospectus. We
will not receive any of the proceeds from the sale of Common Stock by the Selling Stockholders. We will bear all fees and expenses incident
to the registration of the Common Stock by the Selling Stockholders in the registration statement of which this prospectus forms a part.
The Common Stock being offered by the Selling Stockholders will not be sold by or through Craft Capital Management LLC in this offering.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may sell all or a portion
of the Common Stock beneficially owned by them and offered hereby from time to time directly or through one or more broker-dealers or
agents at market prices prevailing at the time of sale. If the Common Stock are sold through broker-dealers, the Selling Stockholders
will be responsible for any commissions or agent&rsquo;s commissions. The Common Stock may be sold by Selling Stockholders in one or more
transactions at prevailing market prices at the time of the sale. However, the Selling Stockholders will not sell any Common Stock until
after the closing of the underwritten primary offering. The offering by the Selling Stockholders will remain open for 180 days following
the date of this prospectus. Following the expiration of such 180 days period, we no longer intend to keep this registration statement
effective. We do not have any contractual agreements with the Selling Stockholders requiring registration of their shares or otherwise.
Instead, the Company has decided to register their shares for resale as a method for providing some liquidity to its prior private investors.
These sales may be effected in transactions, which may involve crosses or block transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">short sales;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a combination of any such methods of sale; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Alt - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may also sell securities
under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus. However,
the Selling Stockholders will not sell any Common Stock until after the closing of the Primary Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under applicable rules and regulations under the
Securities Exchange Act, as amended (the &ldquo;Exchange Act&rdquo;), any person engaged in the distribution of the shares of Common Stock
may not simultaneously engage in market making activities with respect to the shares of Common Stock for the applicable restricted period,
as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable
provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases
and sales of shares of Common Stock by the Selling Stockholders or any other person. We will make copies of this prospectus available
to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus at or prior to the time of the sale
(including by compliance with Rule 172 under the Securities Act, as amended).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Selling Stockholders effect such transactions
to or through broker-dealers or agents, such broker-dealers or agents may receive commissions in the form of discounts, concessions or
commissions from the Selling Stockholders or commissions from purchasers of Common Stock from the Selling Stockholders for whom they may
act as agent or to whom they may sell as principal (which discounts, concessions or commissions as to particular broker-dealers or agents
may be in excess of those customary in the types of transactions involved). In connection with sales of Common Stock by the Selling Stockholders
or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales
of Common Stock by the Selling Stockholders in the course of hedging in positions they assume. The Selling Stockholders may also sell
Common Stock short and deliver Common Stock covered by this prospectus to close out short positions and to return borrowed shares in connection
with such short sales. The Selling Stockholders may also loan or pledge Common Stock to broker-dealers that in turn may sell such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may pledge or grant a
security interest in some or all of the Common Stock owned by them and, if they default in the performance of their secured obligations,
the pledgees or secured parties may offer and sell Common Stock from time to time pursuant to an amendment to this prospectus under applicable
provision of the Securities Act, amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other
successors in interest as Selling Stockholders under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders and any broker-dealer
participating in the distribution of Common Stock may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities
Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions
or discounts under the Securities Act. At the time a particular offering of Common Stock by the Selling Stockholders is made, a prospectus
supplement, if required, will be distributed which will set forth the aggregate amount of Common Stock being offered and the terms of
the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation
from the Selling Stockholders and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the securities laws of some states, Common
Stock may be sold by the Selling Stockholders in such states only through registered or licensed brokers or dealers. In addition, in some
states the Selling Stockholders may not sell Common Stock unless such shares have been registered or qualified for sale in such state
or an exemption from registration or qualification is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that any Selling Shareholder
will sell any or all of their Common Stock registered pursuant to the registration statement, of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders and any other person
participating in such distribution will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder,
including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any Common Stock
by the Selling Stockholders and any other participating person. Regulation M may also restrict the ability of any person engaged in the
distribution of Common Stock to engage in market-making activities with respect to such Common Stock. All of the foregoing may affect
the marketability of the Common Stock and the ability of any person or entity to engage in market-making activities with respect to the
Common Stock by Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Alt - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once sold under the registration statement, of
which this prospectus forms a part, the Selling Stockholders&rsquo; Common Stock will be freely tradeable in the hands of persons other
than our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_036"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not receive any of the proceeds from the
sale of our Common Stock by the Selling Stockholders. In addition, the underwriters of our Primary Offering will not receive any compensation
from the sale of the Common Stock by the Selling Stockholders. The Selling Stockholders will receive all of the net proceeds from the
sales of Common Stock offered by it under this prospectus. We have agreed to bear the expenses relating to the registration of the Common
Stock for the Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_037"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the Common Stock offered by this
prospectus and legal matters as to Nevada law will be passed upon for us by Fennemore Craig, P.C.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 182; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Alt - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>RELIMINARY PROSPECTUS</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Up to 1,875,000 Common Stock to be Offered
by the Selling Stockholders</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I></I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[&nbsp;&nbsp; ], 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through and including [&nbsp; ], 2025 (the 25th day
after the date of this prospectus), all dealers effecting transactions in the Common Stock, whether or not participating in this offering,
may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&rsquo;s obligation to deliver a prospectus
when acting as an underwriter and with respect to an unsold allotment or subscription.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 183 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13. Other Expenses of Issuance and Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the costs and
expenses, other than underwriting commissions and the underwriter&rsquo;s unaccountable expense allowance, to be paid in connection with
the sale of the shares of common stock being registered, all of which we will pay. All amounts, other than the SEC registration fee,
and the FINRA filing fee are estimates.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">16,722</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printing/EDGAR expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23,261</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Nasdaq entry and listing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">550,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">760,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Miscellaneous</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">220,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,670,183</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Indemnification of Directors and Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nevada
Law</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.7502 of the Nevada Revised Statutes provides that a Nevada corporation may indemnify any person who was or is a party or is threatened
to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative,
except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses, including attorneys&rsquo; fees, judgments, fines and amounts
paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he is not liable under
Section 78.138 of the Nevada Revised Statutes for breach of his or her fiduciary duties to the corporation or he acted in good faith
and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any
criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.7502 further provides a Nevada corporation may indemnify any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of
the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses,
including amounts paid in settlement and attorneys&rsquo; fees actually and reasonably incurred by him in connection with the defense
or settlement of the action or suit if he is not liable under Section 78.138 of the Nevada Revised Statutes for breach of his or her
fiduciary duties to the corporation or he acted in good faith and in a manner which he reasonably believed to be in or not opposed to
the best interests of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after
exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and
only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application
that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the
court deems proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of
any non-derivative proceeding or any derivative proceeding, or in defense of any claim, issue or matter therein, the corporation shall
indemnify him or her against expenses, including attorneys&rsquo; fees, actually and reasonably incurred in connection with the defense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 184; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Nevada law permits a Nevada corporation to purchase and maintain insurance or to make other financial arrangements on behalf of any person
who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise for any liability
asserted against him or her and liability and expenses incurred by him or her in his or her capacity as a director, officer, employee
or agent, or arising out of his or her status as such, whether or not the corporation has the authority to indemnify him or her against
such liability and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Charter
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Articles of Incorporation and Bylaws, we may indemnify an officer or director who is made a party to any proceeding, including
a lawsuit, because of his position, if he acted in good faith and in a manner he reasonably believed to be in or not opposed to our best
interest, provided, however, that (i) we will not indemnify such person against expenses incurred in connection with an action if he
is threatened but does not become a party unless the incurring of such expenses was authorized by the board of directors and (ii) we
will not indemnify against any amount paid in settlement unless our board of directors has consented to such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
officer or director is not entitled to indemnification against costs or expenses incurred in connection with any action, commenced by
such person against us or any person who is or was a director, officer, fiduciary, employee or agent of our company unless and to the
extent that the officer or directors is successful on the merits in any such proceeding as to which such person is to be indemnified,
we must indemnify him against all expenses incurred, including attorney&rsquo;s fees. With respect to a derivative action, indemnity
may be made only for expenses actually and reasonably incurred in defending the proceeding, and if the officer or directors is judged
liable, only by a court order. The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Recent Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the past three years, we have issued the following securities which were not registered under the Securities Act. We believe that each
of the following issuance was exempt from registration under the Securities Act in reliance on Regulation S under the Securities Act
regarding sales by an issuer in offshore transactions. No underwriters were involved in these issuances of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 16, 2021, we issued 8,000,000 shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares
to Sglcell Ltd, an exempted company incorporated under the law of Cayman Islands, the sole shareholder of which is Dr. Hung To Pau for
a total consideration of $8,000. On June 8, 2022, Sglcell Ltd transferred all of its 8,000,000 shares to Dr. Yi Lu for a total consideration
of $8,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Shares
Issued to Advanced Biomed Taiwan Holders/Employees</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2022, we issued additional 385,000
shares to Dr. Yi Lu, and 257 shares to Chen-Yi Lee as a consideration of Dr. Yi Lu and Chen-Yi Lee transferred 2,998,000 shares and 2,000
shares owned by them respectively in Advanced Biomed Taiwan, representing in aggregate 100% of the issued share capital of Advanced Biomed
Taiwan, to the Company pursuant to the share exchange agreement the Company entered into with Dr. Yi Lu and Chen-Yi Lee.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 24, 2022, we issued 365,352 shares
at nil consideration to Chen-Yi Lee , who is an employee of Advanced Biomed Taiwan, for consideration of past services to Advanced Biomed
Taiwan. On October 24, 2022, we also issued 2,730,000 shares at nil consideration to Advance On Ventures Limited, a company incorporated
under the law of British Virgin Islands (the &ldquo;Ventures Limited&rdquo;), the beneficial owners of which are employees of Advanced
Biomed Taiwan for past services to Advanced Biomed Taiwan. We issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares,
1,243,750 shares, 1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant
to the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt
of a total amount of NTD 174,020,033 and RMB22,200,000 (approximately $9.04 million).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Shares
Issued to Advanced Biomed Nevada Investors</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2022, we issued 625,000 shares to Hanyu Assets Co. Ltd. pursuant to the Investment Agreement the Company entered into with
Hanyu Assets Co. Ltd for a total consideration of $2,500,000. on June 6, 2022, and we issued 250,000 shares to Newlink Technology Inc.
pursuant to the Investment Agreement the Company entered into with Newlink Technology Inc. on June 6, 2022 for a total consideration
of $1,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our issued and outstanding securities after the
issuance of shares to Hanyu Assets Co., Ltd. were as follows:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchaser</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
    of <BR>
    Issuance</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">June 8, 2022 &amp; August 12,<BR>
    2022</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,385,000</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi
    Lee</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
                                            12, 2022 &amp;</FONT></P><FONT STYLE="font-size: 10pt">October 24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">365,625</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung
    To Pau</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,405,625</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced
    On Ventures Limited</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,730,000</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yimin
    Jin</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,193,750</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nanzhen
    Shen</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,511,250</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qiang
    Chen</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,230,000</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jian
    Wang</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,243,750</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hanyu
    Assets Co., ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    25, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">625,000</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newlink
    Technology Inc.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    25, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Xiaoyuan
    Luo</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    24, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,060,000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Forward and Reverse Share Splits in 2023 and
2024</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
stock split of all issued and outstanding shares of 25,000,000 Common Stock at a ratio of 1-to-4. As a result of the forward split, the
Company had 100,000,000 Common Stock issued and outstanding. On October 15, 2024, the Company effected a reverse share split of all issued
and outstanding shares of 100,000,000 Common Stock at a ratio of 5-to-1. As a result of the reverse share split, the Company now has 20,000,000
Common Stock issued and outstanding.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, our issued
and outstanding securities are as follows:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Purchaser</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date of <BR> Issuance</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 65%; text-align: left">Yi Lu</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">6,708,000</TD><TD STYLE="width: 1%; text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Chen-Yi Lee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">292,500</TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Hung To Pau</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,524,500</TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Advanced On Ventures Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,184,000</TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Yimin Jin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,755,000</TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Nanzhen Shen</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,209,000</TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Qiang Chen</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">984,000</TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jian Wang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995,000</TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Hanyu Assets Co., ltd.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Newlink Technology Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Xiaoyuan Luo</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">October 15, 2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,648,000</TD><TD STYLE="text-align: left">*</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Giving effect to the 4 for 1 share split effected on May 16, 2023
and 5 for 1 reverse share split effected on October 15, 2024.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 185; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. Exhibits Index</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 88%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc051_ex1-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex1-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting Agreement.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1**</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex3-1.htm" STYLE="-sec-extract: exhibit">Amended
    and Restated Articles of Incorporation of Advanced Biomed Inc.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex3-2.htm" STYLE="-sec-extract: exhibit">3.2**</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex3-2.htm" STYLE="-sec-extract: exhibit">Corporate
    Bylaws</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="vc051_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
        of Representative&rsquo;s Warrant</FONT></A></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">4.2**</FONT></FONT></A></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 88%"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Specimen
    Stock Certificate evidencing the shares of common stock</FONT></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="vc051_ex5-1.htm">Opinion of Fennemore Craig, P.C.</A></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="vc051_ex5-2.htm">5.2*</A></P></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="vc051_ex5-2.htm">Opinion of VCL Law LLP <FONT STYLE="background-color: #CCEEFF">a</FONT>s to the validity of the Representative&rsquo;s Warrants</A></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">Opinion of
    AllBright Law Offices regarding certain PRC tax matters (included in Exhibit 99.3)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001306/vc024_ex99-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001306/vc024_ex99-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
of Wiseteam Law Firm regarding certain Taiwan tax matters (included in Exhibit 99.4)</FONT> </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement with the Chief Financial Officer</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-2.htm" STYLE="-sec-extract: exhibit">10.2**</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-2.htm" STYLE="-sec-extract: exhibit">2023
    Equity Incentive Plan&nbsp;</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex10-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&dagger;*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex10-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisory
    Agreement between Advanced Biomed Inc. and Lin Chien Huang</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc051_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&dagger;*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisory
    Agreement between Advanced Biomed Inc. and Zhou Caicun</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex10-5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&dagger;*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex10-5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry-Academia
    Cooperation Agreement between National Taiwan University and Advanced Biomed Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc051_ex10-6.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&dagger;*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex10-6.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Disclosure
    Agreement between Advanced Biomed Inc. and Unimold Technology Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex10-7.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&dagger;*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex10-7.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industrial
    Cooperation Research Agreement between TSRI and Advanced Biomed Inc. </FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc051_ex10-8.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex10-8.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    Agreement between Advanced Biomed Inc. and Hanyu Assets Co., Ltd.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex10-9.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex10-9.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    Agreement between Advanced Biomed Inc. and Newlink Technology Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc051_ex10-10.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&dagger;*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex10-10.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt-for-Equity
    Swap Agreement</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-11.htm" STYLE="-sec-extract: exhibit">10.11**</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223000995/vc019_ex10-11.htm" STYLE="-sec-extract: exhibit">Written
    Consent of Directors to Approve the 2023 Equity Incentive Plan</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc051_ex10-12.htm">10.12&dagger;*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="vc051_ex10-12.htm">Renewed Industry-Academia Cooperation Agreement between National Taiwan
University and Advanced Biomed Inc.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex15-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex15-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter In Lieu of Consent
    for Review Report of WWC, P.C.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc051_ex21-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex21-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of Subsidiaries</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of WWC, P.C.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="vc051_ex5-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="vc051_ex5-1.htm">Consent of Fennemore Craig, P.C. (included in the opinion filed as
Exhibit 5.1)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">23.3**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Consent
    of AllBright Law Offices (included in the opinion filed as Exhibit 99.3)</FONT></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001306/vc024_ex99-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001306/vc024_ex99-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Wiseteam Law Firm (included in the opinion filed as Exhibit 99.4)</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="vc051_ex5-2.htm">23.5*</A></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="vc051_ex5-2.htm">Consent of VCL Law LLP (included in the opinion filed as Exhibit 5.2)</A></p></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#poa_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="#poa_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
    of Attorney (contained on signature page).</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001181/vc022_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1**</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001181/vc022_ex99-1.htm" STYLE="-sec-extract: exhibit">Code
    of Business Conduct and Ethics of the Registrant</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001306/vc024_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001306/vc024_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Grand View Research
    Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">99.3**</FONT></FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Opinion
    of AllBright Law Offices</FONT></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001306/vc024_ex99-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001306/vc024_ex99-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Wiseteam Law Firm</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587224001108/vc038_ex99-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">99.5**</FONT></FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587224001108/vc038_ex99-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Consent of Jing Zhang</FONT></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex99-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">99.6**</FONT></FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587223001368/vc025_ex99-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Consent
    of Cheang I Kei</FONT></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587224001108/vc038_ex99-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">99.7**</FONT></FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587224001108/vc038_ex99-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Consent of Mingyue Cai</FONT></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587224000031/vc034_ex99-8.htm">99.8**</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587224000031/vc034_ex99-8.htm">Policy For the Recovery of Erroneously Awarded Compensation</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587224001108/vc038_ex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107**</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1941029/000157587224001108/vc038_ex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Exhibit</FONT></A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed herewith</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Previously filed</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To be filed by amendment</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&dagger;</TD>
    <TD STYLE="text-align: justify">Portions of this exhibit (indicated by
asterisks) have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K. If requested by the Commission or its staff, the registrant will promptly provide on a supplemental basis an
unredacted copy of the exhibit and its materiality and privacy or confidentiality analyses.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. Undertakings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The undersigned registrant
hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement:</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">ii.</TD><TD STYLE="text-align: justify">To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) (&sect; 230.424(b) of this chapter) if, in the aggregate, the changes in volume and
price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Filing Fee Tables&rdquo;
or &ldquo;Calculation of Registration Fee&rdquo; table, as applicable, in the effective registration statement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">iii.</TD><TD STYLE="text-align: justify">To include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">That, for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned registrant undertakes that in a primary
offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications,
the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">Any preliminary prospectus or prospectus of the undersigned registrant
relating to the offering required to be filed pursuant to Rule 424;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">Any free writing prospectus relating to the offering prepared
by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">The portion of any other free writing prospectus relating to the
offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned
registrant; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">Any other communication that is an offer in the offering made
by the undersigned registrant to the purchaser.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions,
or otherwise, the undersigned registrant has been informed that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or person controlling the registrant in
the successful defense of any action, suit or proceeding) is asserted by such director, officer or person controlling the registrant in
connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned registrant hereby undertakes that:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">For purposes of determining any liability under the Securities
Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance on Rule 430A and contained
in a form of prospectus filed by the registrant under Rule 424(b)(1) or (4) or 497(h) under the Securities Act will be deemed to be part
of this registration statement as of the time it was declared effective.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">For the purpose of determining any liability under the Securities
Act, each post-effective amendment that contains a form of prospectus will be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time will be deemed to be the initial bona fide offering thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 187; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities Act of 1933, as amended,
the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in
Tainan, Taiwan, on January 7, 2025.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADVANCED BIOMED INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: white 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: white 1.5pt double"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Yi Lu</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Yi Lu</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><B><A NAME="poa_001"></A>POWERS OF ATTORNEY</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of
the undersigned officers and directors of Advanced Biomed Inc., a Nevada corporation, hereby constitutes and appoints Yi Lu and Mingze
Yin and each of them, severally, as his attorney-in-fact and agent, with full power of substitution and re-substitution, in his name and
on his behalf, to sign in any and all capacities this registration statement and any and all amendments (including post-effective amendments)
and exhibits to this registration statement and any and all applications and other documents relating thereto, with the Securities and
Exchange Commission, with full power and authority to perform and do any and all acts and things whatsoever which any such attorney or
substitute may deem necessary or advisable to be performed or done in connection with any or all of the above described matters, as fully
as each of the undersigned could do if personally present and acting, hereby ratifying and approving all acts of any such attorney or
substitute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in
the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 38%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 28%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Yi Lu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chairman of the Board and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">January 7, 2025</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Yi Lu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Mingze Yin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">January 7, 2025</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Mingze Yin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Steven I-Fang Cheng </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Technology Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">January 7, 2025</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Steven I-Fang Cheng</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Hung To Pau</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">January 7, 2025</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Hung To Pau</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 188; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>vc051_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ADVANCED BIOMED INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: right">[&#9679;], 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Craft Capital Management LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">377 Oak Street, Lower Concourse</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Garden City, NY 11530</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>As Representative of the Underwriters</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>named on Schedule A hereto</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, <B>Advanced Biomed Inc.</B>, a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this
&ldquo;<B>Agreement</B>&rdquo;) with several underwriters (such underwriters, including the Representative (as defined below), the &ldquo;<B>Underwriters</B>&rdquo;)
named on Schedule A hereto for which Craft Capital Management LLC shall act as the representative (in such capacity, the &ldquo;<B>Representative</B>&rdquo;)
to issue and sell an aggregate of [&#9679;] shares of common stock (the &ldquo;<B>Firm Shares</B>&rdquo;) of the Company, par value $0.001
(the &ldquo;<B>Common Stock</B>&rdquo;). The Company has also granted to the Representative an option to purchase up to [&#9679;]</FONT><SUP>1
</SUP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional shares of Common Stock, on the terms and for
the purposes set forth in <U>Section 2(c)</U> hereof (the &ldquo;<B>Additional Shares</B>&rdquo;). The Firm Shares and any Additional
Shares purchased pursuant to this Agreement are herein collectively referred to as the &ldquo;<B>Offered Securities</B>.&rdquo; The offering
and sale of the Offered Securities contemplated by this Agreement is referred to herein as the &ldquo;<B>Offering</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company confirms its agreement
with the Underwriters as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties of the Company.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company represents and warrants
to the Underwriters as follows with the understanding that the same may be relied upon by the Underwriters in this Offering, as of the
date hereof and as of the Closing Date (as defined below) and each applicable Option Closing Date (as defined below), if any:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filing
of the Registration Statement</U>. The Company has prepared and filed with the U.S. Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
a registration statement on Form S-1 (File No. 333-272110), which contains a form of prospectus to be used in connection with the public
offering and sale of the Offered Securities. Such registration statement, as amended, including the financial statements and the notes
thereto, exhibits and schedules contained in the registration statement at the time such registration statement became effective in the
form in which it was declared effective by the Commission under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;),
and the rules and regulations promulgated thereunder (the &ldquo;<B>Securities Act Regulations</B>&rdquo;), and including any required
information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A under the Securities Act, or pursuant to the
Securities Exchange Act of 1934, as amended (collectively being the &ldquo;<B>Exchange Act</B>&rdquo;) and the rules and regulations promulgated
thereunder (the &ldquo;<B>Exchange Act Regulations</B>&rdquo;), is called the &ldquo;<B>Registration Statement</B>.&rdquo; Any registration
statement filed by the Company pursuant to Rule 462(b) under the Securities Act is called the &ldquo;<B>Rule 462(b) Registration Statement,</B>&rdquo;
and from and after the date and time of filing of the Rule 462(b) Registration Statement, the term &ldquo;<B>Registration Statement</B>&rdquo;
shall include the Rule 462(b) Registration Statement. Such prospectus, in the form first filed pursuant to Rule 424(b) under the Securities
Act after the date and time that this Agreement is executed and delivered by the parties hereto, or, if no filing pursuant to Rule 424(b)
under the Securities Act is required, the form of final prospectus relating to the Offered Securities included in the Registration Statement
at the effective date of the Registration Statement (the &ldquo;<B>Effective Date</B>&rdquo;), is called the &ldquo;<B>Prospectus</B>.&rdquo;
All references in this Agreement to the Registration Statement, the Rule 462(b) Registration Statement, the preliminary prospectus included
in the Registration Statement (each, a &ldquo;<B>preliminary prospectus</B>&rdquo;), the Prospectus, or any amendments or supplements
to any of the foregoing, shall include any copy thereof filed with the Commission pursuant to the Commission&rsquo;s Electronic Data Gathering,
Analysis and Retrieval System (&ldquo;<B>EDGAR</B>&rdquo;). The preliminary prospectus included in the Registration Statement immediately
prior to the Applicable Time (as defined below) is hereinafter called the &ldquo;<B>Pricing Prospectus</B>.&rdquo; Any reference to the
&ldquo;most recent preliminary prospectus&rdquo; shall be deemed to refer to the latest preliminary prospectus included in the registration
statement. Any reference herein to any preliminary prospectus or the Prospectus or any supplement or amendment to either thereof shall
be deemed to refer to and include any documents incorporated by reference therein as of the date of such reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">15% of the shares of common stock being offered.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Applicable
Time</B>&rdquo; means 4:00pm, Eastern Time, on the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Registration Requirements</U>. The Registration Statement has been declared effective by the Commission under the Securities Act
and the Securities Act Regulations on [&#9679;], 2025. The Company has complied, to the Commission&rsquo;s satisfaction, with all requests
of the Commission for additional or supplemental information. No stop order preventing or suspending the effectiveness of the Registration
Statement, or any Rule 462(b) Registration Statement is in effect, and no proceedings for such purpose have been instituted or are pending
or, to the best knowledge of the Company, are contemplated or threatened by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each preliminary prospectus and the Prospectus when
filed complied or will comply in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR
(except as may be permitted by Regulation S-T under the Securities Act), was identical in content to the copy thereof delivered to the
Underwriters for use in connection with the Offering, other than with respect to any artwork and graphics that were not filed. Each of
the Registration Statement, any Rule 462(b) Registration Statement, and any post-effective amendment to either the Registration Statement
or the Rule 462(b) Registration Statement, at the time it became effective and at all subsequent times until the expiration of the prospectus
delivery period required under Section 4(3) of the Securities Act, complied and will comply in all material respects with the Securities
Act and the Securities Act Regulations and did not and will not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus, as amended or supplemented,
as of its date and at all subsequent times until the Underwriters have completed the Offering, did not and will not contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The representations and warranties set forth in the two immediately preceding sentences do
not apply to statements in or omissions from the Registration Statement or any Rule 462(b) Registration Statement, or any post-effective
amendment to either the Registration Statement or the Rule 462(b) Registration Statement, or in the Pricing Prospectus or the Prospectus,
or any amendment or supplement thereto, made in reliance upon and in conformity with information relating to the Underwriters furnished
to the Company in writing expressly for use therein, it being understood and agreed that the only such information furnished on behalf
of any of the Underwriters consists of (i) the name of the Underwriters contained on the cover page of the Pricing Prospectus and Prospectus
and (ii) the sub-sections titled &ldquo;Electronic Offer, Sale and Distribution of Securities&rdquo; &ldquo;Other Relationships&rdquo;
and &ldquo;Price Stabilization, Short Positions and Penalty Bids&rdquo; in each case under the caption &ldquo;Underwriting&rdquo; in the
Prospectus (the &ldquo;Underwriters Information&rdquo;).There are no contracts or other documents required to be described in the Pricing
Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement that have not been fairly and accurately described
in all material respects or filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
Package</U>. The term &ldquo;<B>Disclosure Package</B>&rdquo; shall mean (i) the Pricing Prospectus, as amended or supplemented, (ii)
each issuer free writing prospectus, as defined in Rule 433 under the Securities Act (each, an &ldquo;<B>Issuer Free Writing Prospectus</B>&rdquo;),
if any, identified in <U>Schedule B</U> hereto, (iii) the pricing terms set forth in <U>Schedule C</U> to this Agreement, and (iv) any
other free writing prospectus that the parties hereto shall hereafter expressly agree in writing to treat as part of the Disclosure Package.
As of the Applicable Time, the Disclosure Package did not contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The
preceding sentence does not apply to statements in or omissions from the Disclosure Package based upon and in conformity with the Underwriters
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Not Ineligible Issuer</U>. (i) At the time of filing the Registration Statement and (ii) as of the date of the execution and delivery
of this Agreement, the Company was not and is not an Ineligible Issuer (as defined in Rule 405 under the Securities Act), without taking
account any determination by the Commission pursuant to Rule 405 under the Securities Act that it is not necessary that the Company be
considered an Ineligible Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuer
Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus includes any information that conflicts with the information contained
in the Registration Statement, including any document incorporated by reference therein that has not been superseded or modified. The
foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with
the Underwriters Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Offering
Materials Furnished to the Underwriters</U>. The Company has delivered to the Underwriters a copy of the Registration Statement and of
each consent and certificate of experts filed as a part thereof, and each preliminary prospectus and the Prospectus, as amended or supplemented,
in such quantities and at such places as the Underwriters have reasonably requested in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Distribution
of Offering Material by the Company</U>. The Company has not distributed or authorized the distribution of, and will not distribute, prior
to the completion of the Underwriters&rsquo; purchase of the Offered Securities, any offering material in connection with the offering
and sale of the Offered Securities other than a preliminary prospectus, the Pricing Prospectus, the Prospectus, any Issuer Free Writing
Prospectus reviewed and consented to by the Underwriters, and the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriting
Agreement</U>. This Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company,
enforceable in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as
the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting
the rights and remedies of creditors or by general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization
of the Offered Securities and the Underwriter&rsquo;s Securities</U>. The Offered Securities to be sold by the Company through the Underwriters,
the Representative&rsquo;s Warrant (as defined below in Section 2(g)) and Common Stock underlying the Representative&rsquo;s Warrant (the
&ldquo;<B>Warrant Shares</B>&rdquo; and together with the Representative&rsquo;s Warrants, the &ldquo;<B>Underwriters&rsquo; Securities</B>&rdquo;)
have been duly and validly authorized by all required corporate action and have been reserved for issuance and sale pursuant to this Agreement
and, when so issued and delivered by the Company, will be validly issued, fully paid and non-assessable, free and clear of all Liens (as
defined in <U>Section1(r)</U>). The Company has sufficient Common Stock for the issuance of the maximum number of Offered Securities and
the Underwriters&rsquo; Securities issuable pursuant to the Offering as described in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Applicable Registration or Other Similar Rights</U>. Except as described in the Registration Statement, the Disclosure Package and the
final prospectus, there are no persons with registration or other similar rights to have any securities of the Company registered for
sale under the Registration Statement and included in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Adverse Change</U>. Except as otherwise disclosed in the Disclosure Package subsequent to the respective dates as of which information
is given in the Disclosure Package: (i) there has been no material adverse change, or any development that could reasonably be expected
to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business prospects or operations,
whether or not arising from transactions in the ordinary course of business, of the Company (any such change, a &ldquo;<B>Material Adverse
Change</B>&rdquo;; and any resulting effect, a &ldquo;<B>Material Adverse Effect</B>&rdquo;); (ii) the Company has not incurred any material
liability or obligation, indirect, direct or contingent, not in the ordinary course of business nor entered into any material transaction
or agreement not in the ordinary course of business; and (iii) there has been no dividend or distribution of any kind declared, paid or
made by the Company in respect of its shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Accountant</U>. To the Company&rsquo;s knowledge, WWC, P.C. (the &ldquo;<B>Accountant</B>&rdquo;), which has expressed its opinions with
respect to the audited financial statements (which term as used in this Agreement includes the related notes thereto) of the Company filed
with the Commission as a part of the Registration Statement and included in the Disclosure Package and the Prospectus, is an independent
registered public accounting firm as required by the Securities Act and the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Preparation
of the Financial Statements</U>. Each of the historical financial statements of the Company, respectively, filed with the Commission as
a part of the Registration Statement and included in the Disclosure Package and the Prospectus, presents fairly the information provided
as of and at the dates and for the periods indicated. Such financial statements comply as to form with the applicable accounting requirements
of the Securities Act and the Securities Act Regulations and have been prepared in conformity with generally accepted accounting principles
of the United States of America (&ldquo;<B>U.S. GAAP</B>&rdquo;) applied on a consistent basis throughout the periods involved, except
as may be expressly stated in the related notes thereto or in the case of unaudited interim financial statements, which are subject to
normal year-end audit adjustments that are not expected to be material. No other financial statements or supporting schedules are required
to be included or incorporated by reference in the Registration Statement. Each item of historical financial data relating to the operations,
assets or liabilities of the Company set forth in summary form in each of the preliminary prospectuses and the Prospectus fairly presents
such information on a basis consistent with that of the complete financial statements contained in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Incorporation
and Good Standing</U>. The Company has been duly incorporated or formed and is validly existing and in good standing as a corporation
under the laws of the jurisdiction of its formation and has corporate power and authority to own, lease and operate its properties and
to conduct its business as described in the Registration Statement, the Disclosure Package and the Prospectus and to enter into and perform
its obligations under this Agreement. As of the Closing Date, the Company does not own or control, directly or indirectly, any corporation,
association or other entity that is not otherwise disclosed in the Registration Statement, the Disclosure Package, or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization
and Other Capital Stock Matters</U>. The authorized, issued, and outstanding capital stock of the Company is as set forth in each of
the Disclosure Package and the Prospectus (other than for subsequent issuances, if any, pursuant to employee benefit plans described
in each of the Disclosure Package and the Prospectus or upon exercise of outstanding options or warrants described in the Disclosure
Package and Prospectus, as the case may be). The shares of Common Stock conform, and, when issued and delivered as provided in this Agreement,
the Offered Securities will conform, in all material respects, to the description thereof contained in each of the Disclosure Package
and Prospectus. All of the issued and outstanding shares of capital stock of the Company have been duly authorized and validly issued,
are fully paid and non-assessable, and have been issued in compliance with applicable laws. None of the outstanding shares of capital
stock of the Company were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe
for or purchase securities of the Company. The Depository Trust Company (the &ldquo;DTC&rdquo;) has authorized the Common Stock for delivery
through its full fast transfer facilities. There are no authorized or outstanding options, warrants, preemptive rights, rights of first
refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any shares of
the Company other than those described in the Disclosure Package and the Prospectus. The description of the Company&rsquo;s stock option
and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Disclosure Package and the
Prospectus accurately and fairly presents the information required to be shown with respect to such plans, arrangements, options, and
rights. No further approval from the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">Nasdaq
Stock Market (&ldquo;<B>Nasdaq</B>&rdquo;)</FONT> or authorization of any regulatory authority or governmental body, stockholder, the
Company&rsquo;s board of directors (the &ldquo;<B>Board of Directors</B>&rdquo;), or others, is required for the issuance and sale of
the Offered Securities and the Underwriters&rsquo; Securities. Except as set forth in the Registration Statement, the Disclosure Package
and the Prospectus, there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s
Common Stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Contravention
of Existing Instruments; No Further Authorizations or Approvals Required</U>. The Company is not in violation of its amended and restated
articles of incorporation or bylaws or in default (or, with the giving of notice or lapse of time, would be in default) (&ldquo;<B>Default&rdquo;</B>)
under any indenture, mortgage, loan or credit agreement, note, contract, franchise, lease or other instrument to which it is a party or
by which it may be bound (including, without limitation, any agreement or contract filed as an exhibit to the Registration Statement or
to which any of the property or assets of the Company are subject (each, an &ldquo;<B>Existing Instrument</B>&rdquo;)), except for such
Defaults as would not, individually or in the aggregate, result in a Material Adverse Change. The Company&rsquo;s execution, delivery
and performance of this Agreement and consummation of the transactions contemplated hereby and by the Disclosure Package and the Prospectus
(i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of its amended
and restated articles of incorporation or bylaws, (ii) will not conflict with or constitute a breach of, or Default under, or result in
the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to, or require the consent
of any other party to, any Existing Instrument and (iii) will not result in any violation of any law, administrative regulation, or administrative
or court decree applicable to the Company, except in the case of each of clauses (ii) and (iii), to the extent such conflict, breach,
Default or violation could not reasonably be expected to result in a Material Adverse Effect. No consent, approval, authorization or other
order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&rsquo;s
execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Disclosure Package
and the Prospectus, except the registration or qualification of the Offered Securities and the Underwriters&rsquo; Securities under the
Securities Act and applicable state securities or blue sky laws and from the Financial Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
Each of the Company&rsquo;s direct and indirect subsidiaries (each a &ldquo;<B>Subsidiary</B>&rdquo; and collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;)
has been identified on <U>Schedule E</U> hereto. Each of the Subsidiaries has been duly incorporated or organized, is validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, as the case may be, has full power and authority
(corporate or otherwise) to own its property and to conduct its business as described in the Registration Statement, the Disclosure Package,
and the Prospectus, and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its
business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified
or be in good standing would not result in a Material Adverse Change on the Company and its Subsidiaries, taken as a whole. All of the
equity interests of each Subsidiary have been duly and validly authorized and issued, are owned directly or indirectly by the Company,
are fully paid in accordance with their respective constitutive or organizational documents and non-assessable and are free and clear
of all liens, encumbrances, equities or claims (&ldquo;<B>Liens</B>&rdquo;). None of the outstanding capital stock or equity interest
in any Subsidiary was issued in violation of preemptive or similar rights of any security holder of such Subsidiary. All of the constitutive
or organizational documents of each of the Subsidiaries comply with the requirements of applicable laws of its jurisdiction of incorporation
or organization and are in full force and effect. Apart from the Subsidiaries, the Company has no direct or indirect subsidiaries or any
other company over which it has direct or indirect effective control. Other than the Subsidiaries, the Company does not directly or indirectly
control any entity through contractual arrangements or otherwise such that the entity would be deemed a consolidated affiliated entity
whose financial results would be consolidated under U.S. GAAP with the financial results of the Company on the consolidated financial
statements of the Company, regardless of whether the Company directly or indirectly owns less than a majority of the equity interests
of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Actions or Proceedings</U>. There are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations,
inquiries or proceedings (collectively, &ldquo;<B>Actions</B>&rdquo;) pending or, to the Company&rsquo;s knowledge, threatened (i) against
the Company or any of its Subsidiaries, (ii) which have as the subject thereof any officer or director (in such capacities) of, or property
owned or leased by, the Company or any of its Subsidiaries, where in any such case (A) there is a reasonable possibility that such Action
might be determined adversely to the Company or any of its Subsidiaries and (B) any such Action, if so determined adversely, would reasonably
be expected to result in a Material Adverse Change or adversely affect the consummation of the transactions contemplated by this Agreement.
No material labor disputes with the employees of the Company exists or, to the knowledge of the Company, is threatened or imminent. None
of the Company&rsquo;s or its Subsidiaries&rsquo; employees is a member of a union that relates to such employee&rsquo;s relationship
with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement,
and the Company and its Subsidiaries believe that their relationships with their employees are good. No executive officer, to the knowledge
of the Company, is in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information
agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and
the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with
respect to any of the foregoing matters. The Company and its Subsidiaries have been and are in compliance with all applicable laws and
regulations, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to result
in a Material Adverse Change. Neither the Company or any Subsidiary, nor any director or officer thereof, is or has within the last ten
years been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim
of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation
by the Commission involving the Company or any current or former director or officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property Rights</U>. Each of the Company and its Subsidiaries owns, possesses or has obtained valid and legally enforceable licenses for,
and otherwise has legally enforceable rights to use, all patents, patent applications, trademarks, trade names, copyrights, domain names,
licenses, approvals and trade secrets (collectively, &ldquo;<B>Intellectual Property Rights</B>&rdquo;) necessary to conduct its business
as now conducted or, otherwise, as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, except to the extent
such failure to own, possess or have other rights to use such Intellectual Property would not be expected to result in a Material Adverse
Change. (i) Neither the Company nor any Subsidiary has received any written notice of infringement or conflict with asserted Intellectual
Property Rights of others; (ii) the Company nor any Subsidiary is not a party to or bound by any options, licenses or agreements with
respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement,
Disclosure Package and the Prospectus and are not described in all material respects; (iii) none of the technology employed by the Company
or any Subsidiary has been obtained or is being used by the Company or such Subsidiary, as applicable, in violation of any contractual
obligation binding on the Company or such Subsidiary, as applicable, to the knowledge of the Company or such Subsidiary, as applicable,
in violation of the rights of any persons; and (iv) Neither the Company nor any Subsidiary is subject to any judgment, order, writ, injunction
or decree of any court or any governmental department, commission, board, bureau, agency or instrumentality, or any arbitrator, nor has
it entered into nor is it a party to any agreement made in settlement of any pending or threatened litigation, which materially restricts
or impairs its use of any Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>All
Necessary Permits, etc</U>. Each of the Company and its Subsidiaries possesses such valid and current certificates, authorizations or
permits issued by the applicable regulatory agencies or bodies necessary to conduct its business, and has made all declarations and filings
with, the appropriate national, regional, local or other governmental or regulatory authorities that are necessary for the ownership or
lease of their respective properties or assets or the conduct of their respective business as described in the Registration Statement,
the Disclosure Package and the Prospectus, except where lack of the licenses would not reasonably be expected to have, individually or
in aggregate, a Material Adverse Effect, and has not received any notice of proceedings relating to the revocation or modification of,
or non-compliance with, any such licenses and, to the knowledge of the Company, the Company has no reason to believe that such licenses
will not be renewed in the ordinary course of their respective business that, if determined adversely to the Company, would individually
or in the aggregate have a Material Adverse Effect. Such licenses are valid and in full force and effect and contain no materially burdensome
restrictions or conditions not described in the Registration Statement, the Disclosure Package, or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Properties</U>. Except as otherwise disclosed in the Disclosure Package and the Prospectus, the Company and its Subsidiaries have good
and marketable title to all the properties and assets reflected as owned by it in the financial statements referred to in <U>Section 1(n)</U>
above (or elsewhere in the Disclosure Package and the Prospectus), in each case free and clear of any security interest, mortgage, lien,
encumbrance, equity, adverse claim or other defect, except such as do not materially and adversely affect the value of such property and
do not materially interfere with the use made or proposed to be made of such property by the Company. The real property, improvements,
equipment, and personal property held under lease by the Company and its Subsidiaries are held under valid and enforceable leases, with
such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements,
equipment or personal property by the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Law Compliance</U>. (i) The Company and its Subsidiaries have each filed all necessary federal, state, local and foreign income tax returns
required to be filed as of the date of this Agreement or have timely and properly filed requested extensions thereof and have paid all
taxes required to be paid by them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them
in all material respects; (ii) No tax deficiency has been determined adversely to the Company or any of its Subsidiaries that has had
(nor does the Company nor any of its Subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected
to be determined adversely to the Company or its Subsidiaries and which could reasonably be expected to have) a Material Adverse Effect;
(iii) The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in <U>Section 1(n)</U>
above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company
has not been finally determined; and (iv) all governmental tax credit, exemptions, waivers, financial subsidies, and tax relief, concessions
and preferential Treatment enjoyed by the Company or any of the Subsidiaries as disclosed in the Registration Statement, the Disclosure
Package and the Prospectus and the Prospectus are valid, binding and enforceable and do not violate any laws, regulations, rules, orders,
decrees, guidelines, judicial interpretations, notices or other legislation of the applicable jurisdictions, including without limitation,
the Hong Kong Special Administrative Region (&ldquo;<B>Hong Kong</B>&rdquo;) of the People&rsquo;s Republic of China (the &ldquo;<B>PRC</B>&rdquo;),
and Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Not an &ldquo;Investment Company&rdquo;</U>. The Company is not, and after giving effect to payment for the Offered Securities and the
application of the proceeds as contemplated under the caption &ldquo;Use of Proceeds&rdquo; in each of the Disclosure Package and the
Prospectus will not be, required to register as an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of
1940, as amended (the &ldquo;<B>Investment Company Act</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Price Stabilization or Manipulation</U>. The Company has not taken and will not take, directly or indirectly, any action designed to,
or that might be reasonably expected to cause or result in, stabilization or manipulation of the price of any securities of the Company
to facilitate the sale or resale of the Offered Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Matters</U>. To the knowledge of the Company, no officer, director or any beneficial owner of ten percent (10%) or more of the Company&rsquo;s
unregistered securities has any direct or indirect affiliation or association with any Participating Member (as defined under FINRA rules).
The Company will advise the Representative and its counsel, Ortoli Rosenstadt LLP, if it learns that any officer, director, or owner of
ten percent (10%) or more of the Company&rsquo;s outstanding capital stock is or becomes an affiliate or registered person of a Participating
Member. All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers
and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with
the offering of the Offered Shares is true, complete, correct and compliant in all material respects with FINRA&rsquo;s rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Related Party Transactions</U>.
There are no business relationships or related-party transactions, directly or indirectly, involving the Company, its Subsidiaries, or
any other person, required to be described in the Registration Statement, or described in the Disclosure Package, or the Prospectus, that
have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure Controls
and Procedures</U>. To the extent required ,the Company has established and maintains disclosure controls and procedures (as such term
is defined in Rule 13a-15(e) of the Exchange Act Regulations) designed to ensure that information required to be disclosed by the Company
in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified
in the Commission&rsquo;s rules and forms. The Company is not aware of (a) any significant deficiency in the design or operation of internal
controls which could adversely affect the Company&rsquo;s ability to record, process, summarize and report financial data or any material
weaknesses in internal controls or (b) any fraud, whether or not material, that involves management or other employees who have a significant
role in the Company&rsquo;s internal controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company&rsquo;s Accounting
System</U>. The Company has established and maintains a system of accounting controls designed to provide reasonable assurances that (i)
transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with the applicable generally accepted accounting principles and to maintain
accountability for assets; (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization;
and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken
with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money Laundering Law
Compliance</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with all applicable
financial recordkeeping and reporting requirements, including those of the United States Bank Secrecy Act, as amended by Title III of
the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT
Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its Subsidiaries conduct business, and
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by
any competent governmental agency (collectively, the &ldquo;<B>Anti-Money Laundering Laws</B>&rdquo;), and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with
respect to any Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>OFAC</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Company nor any of its Subsidiaries, or, to the knowledge of the Company, any director, officer, employee, or affiliate of the Company,
of any other person authorized to act on behalf of the Company or any of its Subsidiaries, is an individual or entity of any kind (&ldquo;<B>Person</B>&rdquo;)
that is, or is owned or controlled by a Person that is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
subject of any sanctions administered or enforced by the U.S. Department of Treasury&rsquo;s Office of Foreign Assets Control (&ldquo;<B>OFAC</B>&rdquo;),
the United Nations Security Council (&ldquo;<B>UNSC</B>&rdquo;), the European Union (&ldquo;<B>EU</B>&rdquo;), His Majesty&rsquo;s Treasury
(&ldquo;<B>HMT</B>&rdquo;), or other relevant sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;), nor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;located,
organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Burma/Myanmar, Russia,
Crimea, Cuba, Iran, North Korea, Sudan, and Syria).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will not, directly or indirectly, use the proceeds of the Offering, or lend, contribute or otherwise make available such proceeds
to any Subsidiary or affiliated entity, joint venture partner or other Person:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or
facilitation, is the subject of Sanctions; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the Offering, whether
as underwriter, advisor, investor or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign Corrupt Practices
Act</U>. Neither the Company nor any of its Subsidiaries, or, to the knowledge of the Company, any director, officer, employee or affiliate
of the Company, any Subsidiary or any other person authorized to act on behalf of the Company has, directly or indirectly, taken any action
that (i) would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations
thereunder (the &ldquo;<B>FCPA</B>&rdquo;) or otherwise subject the Company or any of its Subsidiaries to any damage or penalty in any
civil, criminal or governmental litigation or proceeding; (ii) if done in the past, might reasonably be expected to have a Material Adverse
Effect or (iii) if continued in the future, might reasonably be expected to materially and adversely affect the assets, business, or operations
of the Company or any of its Subsidiaries. The foregoing includes, without limitation, giving or agreeing to give any money, gift or similar
benefit (other than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent
of a customer or supplier, or official or employee of any governmental agency or instrumentality of any government (domestic or foreign)
or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder
the business of the Company or any of its Subsidiaries (or assist it in connection with any actual or proposed transaction) that might
subject the Company or any of its Subsidiaries to any damage or penalty in any civil, criminal or governmental litigation or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Internal Control and
Compliance with Sarbanes-Oxley Act of 2002</U>. The Company is in full compliance with any provision applicable to it of the Sarbanes-Oxley
Act of 2002 (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;) and the rules and regulations promulgated in connection therewith, including,
without limitation, Section 402 related to loans and Sections 302 and 906 related to certifications of the Sarbanes-Oxley Act. and all
applicable rules of the listing exchanges. The Company maintains a system of internal controls, including, but not limited to, disclosure
controls and procedures, internal controls over accounting matters and financial reporting, an internal audit function and legal and regulatory
compliance controls that comply with all applicable laws and regulations including without limitation the Securities Act, the Exchange
Act, the Sarbanes-Oxley Act, the rules and regulations of the Commission, and the rules of the listing exchanges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange Act Filing</U>.
A registration statement in respect of the Common Stock has been filed on Form 8-A (the &ldquo;<B>Form 8-A Registration Statement</B>&rdquo;)
pursuant to Section 12(b) of the Exchange Act, which registration statement complies in all material respects with the Exchange Act. The
Form 8-A Registration Statement is effective and the Company has taken no action designed to, or which to its knowledge is likely to have
the effect of, terminating the registration of the Common Stock under the Exchange Act, nor has the Company received any notification
that the Commission is contemplating terminating such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Earning
Statements</U>. The Company will make generally available (which includes filings pursuant to the Exchange Act made publicly through the
EDGAR system) to its securityholders as soon as practicable, but in any event not later than sixteen (16) months after the end of the
Company&rsquo;s current fiscal year, an earnings statement (which needs not be audited) covering a twelve (12)-month period that shall
satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Periodic Reporting
Obligations</U>. During the Prospectus Delivery Period, the Company shall file, on a timely basis, with the Commission, all reports and
documents required to be filed under the Exchange Act. Additionally, the Company shall report the use of proceeds from the issuance of
the Firm Shares as may be required under Rule 463 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Valid Title</U>. The
Company or its Subsidiaries, as applicable, has legal and valid title to all of its properties and assets, free and clear of all liens,
charges, encumbrances, equities, claims, options and restrictions except such as do not materially and adversely affect the value of such
property and do not materially interfere with the use made or proposed to be made of such property by such entity; each lease agreement
to which it is a party is duly executed and legally binding; its leasehold interests are set forth in and governed by the terms of the
applicable lease agreements, and, to the knowledge of the Company, such agreements are valid, binding and enforceable in accordance with
their respective terms and the applicable law; and except as described in the Prospectus or the Disclosure Package, none of the Company
of any of its Subsidiaries owns, operates, manages or has any other right or interest in any other material real property of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign Tax Compliance</U>.
Except as otherwise disclosed in the Disclosure Package and the Final Prospectus, to the best of our knowledge, no transaction, stamp,
capital or other issuance, registration, transaction, transfer or withholding taxes or duties are payable in the PRC, Hong Kong, Taiwan
to any PRC, Hong Kong or Taiwanese taxing authority in connection with the issuance, sale and delivery of the Offered Securities, and
the delivery of the Offered Securities to or for the account of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with PRC
Overseas Investment and Listing Rules and Regulations</U>. Except as otherwise disclosed in Disclosure Package and the Prospectus, the
Company has complied with the filing procedures as set out in the relevant laws and regulations, including, among others, the Trial Administrative
Measures for Overseas Securities Offering and Listing by Domestic Companies, and has taken reasonable steps to cause the Company&rsquo;s
direct or indirect principal stockholders, directors and officers that are, or are directly or indirectly controlled by PRC residents
to comply with any applicable rules and regulations of relevant PRC government agencies (including but not limited to the Ministry of
Commerce, the National Development and Reform Commission, the China Securities Regulatory Commission (&ldquo;<B>CSRC</B>&rdquo;) , and
the State Administration of Foreign Exchange (&ldquo;<B>SAFE</B>&rdquo;) relating to overseas investment by PRC residents and citizens
(all of the foregoing laws, rules, and regulations, collectively, the &ldquo;<B>PRC Overseas Investment and Listing Rules and Regulations</B>&rdquo;),
including, without limitation, requiring each such person that is, or is directly or indirectly owned or controlled by, a PRC resident
or citizen to complete any registration, to timely report material changes, and other procedures required under any applicable PRC Overseas
Investment and Listing Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(nn)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>M&amp;A Rules</U>.
The Company is aware of and has been advised as to the content of the Rules on Mergers and Acquisitions of Domestic Enterprises by Foreign
Investors jointly promulgated by the Ministry of Commerce, the State Assets Supervision and Administration Commission, the State Tax Administration,
the State Administration of Industry and Commerce, the CSRC and SAFE on August 8, 2006 and amended on June 22, 2009 (the &ldquo;<B>M&amp;A
Rules</B>&rdquo;), in particular, the relevant provisions thereof that purport to require offshore special purpose vehicles formed for
the purpose of obtaining a stock exchange listing outside of the PRC and controlled directly or indirectly by companies or natural persons
of the PRC, to obtain the approval of the CSRC prior to the listing and trading of their securities on a stock exchange located outside
of the PRC; the Company has received legal advice specifically with respect to the M&amp;A Rules from its PRC counsel and based on such
legal advice, the Company confirms with the Underwriters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as disclosed in the Disclosure Materials, Registration Statement and the Prospectus, the issuance and sale of the Offered Securities,
the listing and trading of the Offered Securities and the consummation of the transactions contemplated by this Agreement are not and
will not be, as of the date hereof, at the Closing Date or applicable Option Closing Date, materially affected by the M&amp;A Rules or
any official clarifications, guidance, interpretations or implementation rules in connection with or related to the M&amp;A Rules as amended
as of the date hereof (collectively, the &ldquo;<B>M&amp;A Rules and Related Clarifications</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as disclosed in the Disclosure Materials, Registration Statement and the Prospectus, as of the date hereof, the M&amp;A Rules and Related
Classifications did not and do not require the Company to obtain the approval of the CSRC prior to the issuance and sale of the Offered
Securities on the Nasdaq Capital Market, the listing and trading of the Offered Securities or the consummation of the transactions contemplated
by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>D&amp;O
Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires (the &ldquo;<B>Questionnaires</B>&rdquo;)
completed by each of the Company&rsquo;s directors and officers prior to the Offering (the &ldquo;<B>Insiders</B>&rdquo;) as well as in
the Lock-Up Agreement in the form attached hereto as <U>Exhibit A</U> provided to the Representative is true and correct in all respects
and the Company has not become aware of any information which would cause the information disclosed in the Questionnaires completed by
each Insider to become inaccurate and incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Any certificate signed
by an officer of the Company and delivered to the Representative or to counsel for the Representative shall be deemed to be a representation
and warranty by the Company to the Underwriters as to the matters set forth therein. The Company acknowledges that the Underwriters and,
for purposes of the opinions to be delivered pursuant to <U>Section 5</U> hereof, counsel to the Company, will rely upon the accuracy
and truthfulness of the foregoing representations and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(pp)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>. Based
on the consolidated financial condition of the Company as of each Closing Date and any applicable Option Closing Date, after giving effect
to the receipt by the Company of the proceeds from the sale of the Offered Securities hereunder, the current cash flow of the Company,
together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated
uses of the cash, are sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The
Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts
of cash to be payable on or in respect of its debt). Except as set forth in the Registration Statement and the Prospectus, the Company
has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the
bankruptcy or reorganization laws of any jurisdiction within one year from each Closing Date. The Registration Statement and the Prospectus
set forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the
Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<B>Indebtedness</B>&rdquo; means (x)&nbsp;any liabilities
for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business),
(y)&nbsp;all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are
or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable
instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease
payments in excess of $50,000 due under leases required to be capitalized in accordance with U.S. GAAP. Except as set forth in the Registration
Statement and the Prospectus, neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(qq)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation M Compliance</U>.
Neither the Company nor any Subsidiary has, and, to its knowledge, no one authorized to act on their behalf has, (i) taken, directly or
indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any of the Offered Securities or the Underwriters&rsquo; Securities, (ii) sold, bid for, purchased,
or, paid any compensation for soliciting purchases of, any of the Offered Securities or the Underwriters&rsquo; Securities, or (iii) paid
or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in
the case of clauses (ii) and (iii), compensation paid to the Underwriters in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(rr)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>EGC Status and Testing-the-Waters
Communications</U>. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier,
the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters Communication)
through the date hereof, the Company has been and is an &ldquo;emerging growth company&rdquo;, as defined in Section 2(a) of the Securities
Act (&ldquo;<B>Emerging Growth Company</B>&rdquo;). &ldquo;<B>Testing-the-Waters Communication</B>&rdquo; means any oral or written communication
with potential investors undertaken in reliance on Section 5(d) of the Securities Act. Neither the Company nor any Subsidiary (a) has
alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent of the Representative
with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are
accredited investors within the meaning of Rule 501 under the Securities Act and (b) has authorized anyone other than the Underwriters
to engage in Testing-the-Waters Communications. The Company reconfirms that the Underwriters have been authorized to act on its behalf
in undertaking Testing-the-Waters Communications. The Company has not distributed any written Testing-the-Waters Communications other
than those listed on <U>Schedule F</U> hereto. &ldquo;Written Testing the Waters Communication&rdquo; means any Testing the Waters Communication
that is a written communication within the meaning of Rule 405 under the Securities Act. As of the time of each sale of the Offered Securities
in connection with the Offering when the Prospectus is not yet available to prospective purchasers, no individual Written Testing the
Waters Communications, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state
a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank Holding Company
Act</U>. Neither the Company nor any of its Subsidiaries is subject to the Bank Holding Company Act of 1956, as amended (the &ldquo;<B>BHCA</B>&rdquo;)
and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<B>Federal Reserve Board</B>&rdquo;). Neither the
Company nor any of its Subsidiaries owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any
class of voting securities or twenty-five percent (25%) or more of the total equity securities of a bank or any entity that is subject
to the BHCA and the regulations promulgated thereunder by the Federal Reserve Board. Neither the Company nor any Subsidiary controls (as
such term is defined under Section 2 of the BHCA) a bank or any entity that is subject to the BHCA and to regulation promulgated thereunder
by the Federal Reserve Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(tt)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S. Real Property
Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section
897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon the Underwriters&rsquo; request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(uu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Margin Securities</U>.
The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U promulgated by the Board of Governors of the
Federal Reserve System, and none of the proceeds of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying
any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin
security or for any other purpose which might cause any of the Offered Securities to be considered a &ldquo;purpose credit&rdquo; within
the meanings of Regulation T, U or X promulgated by the Federal Reserve System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(vv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>. Neither
the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated with prior
offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ww)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Accounting Issues</U>.
The Company has not received any notice, oral or written, from its Board of Directors or Audit Committee (as defined below) stating that
it is reviewing or investigating, and neither the Company&rsquo;s independent auditors nor its internal auditors have recommended that
the Board of Directors or Audit Committee review or investigate, (i) any matter that may add to, delete, change the application of, or
change the Company&rsquo;s disclosure with respect to, any of the Company&rsquo;s material accounting policies; or (ii) any matter which
could result in a restatement of the Company&rsquo;s financial statements for any annual or interim period during the current or prior
two (2) fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forward-looking
Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in the Registration Statement, the Disclosure Package, or the Prospectus, or shall be contain in any amendments and supplements
thereof, has been made or reaffirmed, or will be made, without a reasonable basis, or has been disclosed or will be disclosed other than
in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(yy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. The
Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which they are engaged the jurisdictions that the Company and each of
its Subsidiaries operate as required by the laws of such jurisdictions; neither the Company nor any of its Subsidiaries has been refused
any insurance coverage sought or applied for; and neither the Company nor any of its Subsidiaries has any reason to believe that it will
not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(zz)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Finder&rsquo;s Fee</U>.
There are no contracts, agreements, or understandings between the Company or its Subsidiaries and any other person that would give rise
to a valid claim against the Company or its Subsidiaries or any Underwriters for a brokerage commission, finder&rsquo;s fee or other like
payment in connection with this Offering, or any other arrangements, agreements, understandings, payments, or issuance with respect to
the Company, or its Subsidiaries, or any of their respective officers, directors, stockholders, partners, employees or related parties
that may affect the Underwriters&rsquo; compensation as determined by FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(aaa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Operating and Other
Data</U>. All operating and other data pertaining to the Disclosure Package and the Prospectus are true and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(bbb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-party Data</U>.
Any statistical, industry-related and market-related data included in the Disclosure Package and the Prospectus is based on or derived
from sources that the Company reasonably and in good faith believes to be reliable and accurate, and such data agrees with the sources
from which it is derived, and the Company has obtained the written consent for the use of such data from such sources to the extent required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ccc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Environmental
Laws</U>. The Company and its Subsidiaries are (a) in compliance with any and all applicable foreign, federal, state and local laws and
regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants (&ldquo;<B>Environmental Laws</B>&rdquo;), (b) have received and are in compliance with all permits, licenses or other
approvals required of them under applicable Environmental Laws to conduct their respective businesses, and (c) have not received notice
of any actual or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic substances
or wastes, pollutants or contaminants, except where such non-compliance with Environmental Laws, failure to receive required permits,
licenses or other approvals, or liability would not cause a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ddd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Law,
Constitutive Documents and Contracts</U>. Neither the Company nor any of the Subsidiaries is (a) in breach or violation of any provision
of applicable law (including, but not limited to, any applicable law concerning information collection and user privacy protection), or
(b) in breach or violation of its respective constitutive or foundational documents, or (c) in default under (nor has any event occurred
that, with notice, lapse of time or both, would result in any breach or violation of, constitute a default under or give the holder of
any indebtedness (or a person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all
or a part of such indebtedness under) any agreement or other instrument that is binding upon the Company or any of the Subsidiaries, or
any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any of the Subsidiaries,
except in the cases of (a) and (c) above, where any such breach, violation or default would not cause a Material Adverse Change</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(eee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Unlawful Influence</U>.
The Company has not offered, or caused the Underwriters to offer, Common Stock to any person or entity with the intention of unlawfully
influencing: (a) a customer or supplier of the Company or any affiliate of the Company to alter the customer&rsquo;s or supplier&rsquo;s
level or type of business with the Company or such affiliate, or (b) a journalist or publication to write or publish favorable information
about the Company or any such affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(fff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Scheme or Arrangement
with Stockholders</U>. Neither the Company nor any of its affiliate is a party to any scheme or arrangement through which stockholders
or potential stockholders are being loaned, given or otherwise having money made available for the purchase of shares whether before,
in or after the Offering. Neither the Company nor any of its affiliates is aware of any such scheme or arrangement, regardless of whether
it is a party to a formal agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ggg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reliance on Representations</U>.
Any certificate signed by an officer of the Company and delivered to the Representative or to counsel for the Representative shall be
deemed to be a representation and warranty by the Company to the Underwriters as to the matters set forth therein. The Company acknowledges
that the Underwriters and counsel to the Representative and, for purposes of the opinions to be delivered pursuant to <U>Section 5</U>
hereof, counsel to the Company, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such
reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><B>Section 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"><U>Firm
Shares; Additional Shares; Representative&rsquo;s Warrants</U></FONT>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase
of Firm Shares. </U>On the basis of the representations and warranties herein contained, and subject to the terms and conditions herein
set forth, the Company agrees to issue and sell to the Underwriters, and the Underwriters agree to purchase from the Company, the Firm
Shares at the purchase price (net of discounts) of $[</FONT>&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">]</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT><U>
</U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">per share. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of and Payment for Firm Shares. </U>Delivery of and payment for the Firm Shares shall be made at 10:00 A.M., Eastern time, on the second
(2</FONT><SUP>nd</SUP><FONT STYLE="vertical-align: baseline">) business day following the Applicable Time, or at such time as shall be
agreed upon by the Underwriters and the Company, at the offices of the Underwriters&rsquo; counsel or at such other place as shall be
agreed upon by the Underwriters and the Company. The hour and date of delivery of and payment for the Firm Shares is called the &ldquo;<B>Closing
Date</B>.&rdquo; The closing of the payment of the purchase price for is referred to herein as the &ldquo;<B>Closing</B>.&rdquo; Payment
for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds upon delivery to the Underwriters
of certificates (in form and substance reasonably satisfactory to the Underwriters) representing the Firm Shares (or if uncertificated
through the full fast transfer facilities of the Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;)) for the account of the Underwriters.
The Firm Shares shall be registered in such names and in such denominations as the Underwriters may request in writing at least two (2)
business days prior to the Closing Date. If certificated, the Company will permit the Underwriters to examine and package the Firm Shares
for delivery at least one (1) full business day prior to the Closing Date. The Company shall not be obligated to sell or deliver the
Firm Shares except upon tender of payment by the Underwriters for all the Firm Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>2</SUP></TD><TD STYLE="text-align: justify">7.5%</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Shares. </U>The Company hereby grants to the Underwriters an option (the <B>&ldquo;Over-allotment Option</B>&rdquo;), exercisable for
45 days after the Closing, to purchase up to an additional [</FONT>&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">]</FONT><SUP>3
</SUP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">shares of Common Stock, in
each case solely for the purpose of covering over-allotments of such securities, if any. The Over-allotment Option is, at the Representative&rsquo;s
sole discretion, for Additional Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Exercise
of Over-allotment Option. </U>The Over-allotment Option granted pursuant to <U>Section 2(c)</U> hereof may be exercised by the Representative
within 45 days of the Closing Date. The purchase price to be paid per Additional Shares shall be equal to the price per Firm Share in
<U>Section 2(a)</U>. The Underwriters shall not be under any obligation to purchase any Additional Shares prior to the exercise of the
Over-allotment Option. The Over-allotment Option granted hereby may be exercised by the giving of oral notice to the Company from the
Representative, which shall be confirmed in writing via overnight mail or facsimile or other electronic transmission, setting forth the
number of Additional Shares to be purchased and the date and time for delivery of and payment for the Additional Shares (the &ldquo;<B>Option
Closing Date</B>&rdquo;), which shall not be later than five (5) full Business Days after the date of the notice or such other time as
shall be agreed upon by the Company and the Representative, at the offices of the Representative&rsquo;s counsel or at such other place
(including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the Representative. If
such delivery and payment for the Additional Shares does not occur on the Closing Date, the Option Closing Date will be as set forth
in the notice. Upon exercise of the Over-allotment Option with respect to all or any portion of the Additional Shares, subject to the
terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of Additional Shares
specified in such notice and (ii) the Underwriters shall purchase that portion of the total number of Additional Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
and Payment of Additional Shares. </U>Payment for the Additional Shares shall be made on the Option Closing Date by wire transfer in
Federal (same day) funds, upon delivery to the Representative of certificates (in form and substance satisfactory to the Representative)
representing the Additional Shares (or through the facilities of DTC) for the account of the Underwriters. The Additional Shares shall
be registered in such name or names and in such authorized denominations as the Representative may request in writing at least two (2)
full Business Days prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the Additional Shares except
upon tender of payment by the Underwriters for applicable Additional Shares. The Option Closing Date may be simultaneous with, but not
earlier than, the Closing Date; and in the event that such time and date are simultaneous with the Closing Date, the term &ldquo;Closing
Date&rdquo; shall refer to the time and date of delivery of the Firm Shares and Additional Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriting
Discount. </U>In consideration of the services to be provided for hereunder, the Company shall pay to the Underwriters, with respect
to any Offered Securities sold to investors in this Offering, a seven and a half percent (7.5%) underwriting discount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representative&rsquo;s
Warrants. </U>The Company hereby agrees to issue to the Representative (and/or its designees) on the applicable Closing Date and applicable
Option Closing Date, Representative&rsquo;s Warrants to purchase such number of Common Stock, representing six percent (6%) of the total
number of Offered Securities. The agreement(s) representing the Representative&rsquo;s Warrants, in the form attached hereto as <U>Exhibit
B</U> (the &ldquo;<B>Representative&rsquo;s Warrant Agreement</B>&rdquo;), shall be exercisable at any time, and from time to time, in
whole or in part, during the four and half year period commencing six months from the commencement of sales of the Offering, at an initial
exercise price of $[</FONT>&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">]
per share of Common Stock, which is equal to one hundred and twenty-five percent (125%) of the initial public offering price of the Firm
Shares. During such time as the Representative's Warrants are outstanding, the Company agrees not to merge, reorganize, or take any action
which would terminate the Representative&rsquo;s Warrants without first making adequate provisions for the Representative&rsquo;s Warrants.
The Representative&rsquo;s Warrant Agreement and the Warrant Shares issuable upon exercise thereof. The Representative understands and
agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative&rsquo;s Warrants and
the Warrant Shares during the one hundred eighty (180) days beginning on the date of commencement of sales of the Offering and by its
acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative&rsquo;s Warrants, or
any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective
economic disposition of such securities for a period of one hundred eighty (180) days beginning on the date of commencement of sales
of the Offering to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer
or partner of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing
lock-up restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>3</SUP></TD><TD STYLE="text-align: justify">15% of the Firm Shares</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of the Representative&rsquo;s Warrants. </U>Delivery of the Representative&rsquo;s Warrants shall be made on the Closing Date and each
Closing Date and shall be issued in the name or names and in such authorized denominations as the Representative may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Covenants of the Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="vertical-align: baseline">The
Company covenants and agrees with the Underwriters as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriters&rsquo;
Review of Proposed Amendments and Supplements. </U>During the period beginning at the Applicable Time and ending on the later of the
Closing Date or such date as, in the opinion of the Representative&rsquo;s counsel, the Prospectus is no longer required by law to be
delivered in connection with sales by the Underwriters or selected dealers, including under circumstances where such requirement may
be satisfied pursuant to Rule 172 under the Securities Act (the &ldquo;<B>Prospectus Delivery Period</B>&rdquo;), prior to amending or
supplementing the Registration Statement or the Prospectus, including any amendment or supplement through incorporation by reference
of any report filed under the Exchange Act, the Company shall furnish to the Underwriters for review a copy of each such proposed amendment
or supplement, and the Company shall not file any such proposed amendment or supplement to which the Underwriters reasonably objects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline"></FONT><U>Securities
Act Compliance. </U>After the date of this Agreement, during the Prospectus Delivery Period, the Company shall promptly advise the Underwriters
in writing (i) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission, (ii) of
the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to the Pricing
Prospectus or the Prospectus, (iii) of the time and date that any post-effective amendment to the Registration Statement becomes effective
and (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment thereto or of any order or notice preventing or suspending the use of the Registration Statement, the Pricing Prospectus or
the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Offered Securities from any securities
exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings
for any of such purposes. If the Commission shall enter any such stop order or order or notice of prevention or suspension at any time,
the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment or will file a new registration
statement and use its best efforts to have such new registration statement declared effective as soon as practicable. Additionally, the
Company agrees that it shall comply with the provisions of Rules 424(b) and 430A, as applicable, under the Securities Act, including
with respect to the timely filing of documents thereunder and will confirm that any filings made by the Company under such Rule 424(b)
were received in a timely manner by the Commission.

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Act Compliance</U>. During the Prospectus Delivery Period, to the extent the Company becomes subject to reporting obligation under the
Exchange Act, the Company will file all documents required to be filed with the Commission pursuant to Sections 13, 14 or 15 of the Exchange
Act in the manner and within the time periods required by the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments
and Supplements to the Registration Statement, Prospectus and Other Securities Act Matters</U>. If, during the Prospectus Delivery Period,
any event or development shall occur or condition exist as a result of which the Disclosure Package or the Prospectus as then amended
or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements therein in light of the circumstances under which they were made, as the case may be, not misleading, or if it shall be necessary
to amend or supplement the Disclosure Package or the Prospectus, in order to make the statements therein, in light of the circumstances
under which they were made, as the case may be, not misleading, or if in the opinion of the Underwriters it is otherwise necessary to
amend or supplement the Registration Statement, the Disclosure Package or the Prospectus, or to file a new registration statement containing
the Prospectus, in order to comply with law, including in connection with the delivery of the Prospectus, the Company agrees to (i) notify
the Underwriters of any such event or condition (unless such event or condition was previously brought to the Company&rsquo;s attention
by the Underwriters during the Prospectus Delivery Period) and (ii) promptly prepare (subject to <U>Section 3(a)</U> and <U>Section 3(f)</U>
hereof), file with the Commission (and use its best efforts to have any amendment to the Registration Statement or any new registration
statement to be declared effective) and furnish at its own expense to the Underwriters and to dealers, amendments or supplements to the
Registration Statement, the Disclosure Package or the Prospectus, or any new registration statement, necessary in order to make the statements
in the Disclosure Package or the Prospectus as so amended or supplemented, in the of the circumstances under which they were made, as
the case may be, not misleading or so that the Registration Statement, the Disclosure Package or the Prospectus, as amended or supplemented,
will comply with law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted
Free Writing Prospectuses</U>. The Company represents that it has not made, and agrees that, unless it obtains the prior written consent
of the Underwriters, it will not make, any offer relating to the Offered Securities that would constitute an Issuer Free Writing Prospectus
or that would otherwise constitute a &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 under the Securities Act) required
to be filed by the Company with the Commission or retained by the Company under Rule 433 under the Securities Act; provided that the prior
written consent of the Underwriters hereto shall be deemed to have been given in respect of each free writing prospectuses listed on <U>Schedule
B</U> hereto. Any such free writing prospectus consented to by the Underwriters is hereinafter referred to as a &ldquo;<B>Permitted Free
Writing Prospectus</B>.&rdquo; The Company agrees that (i) it has treated and will treat, as the case may be, each Permitted Free Writing
Prospectus as an Issuer Free Writing Prospectus, and (ii) has complied and will comply, as the case may be, with the requirements of Rules
164 and 433 under the Securities Act applicable to any Permitted Free Writing Prospectus, including in respect of timely filing with the
Commission, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Copies
of any Amendments and Supplements to the Prospectus</U>. The Company agrees to furnish the Underwriters, without charge, during the Prospectus
Delivery Period, as many copies of each of the preliminary prospectuses, the Prospectus and the Disclosure Package and any amendments
and supplements thereto (including any documents incorporated or deemed incorporated by reference therein) as the Underwriters may reasonably
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company shall apply the net proceeds from the sale of the Offered Securities sold by it in the manner described under
the caption &ldquo;Use of Proceeds&rdquo; in the Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
Agent</U>. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Offered Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Internal
Controls</U>. The Company will maintain a system of internal accounting controls designed to provide reasonable assurances that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded as necessary in order
to permit preparation of financial statements in accordance with U.S. GAAP and to maintain accountability for assets; (iii) access to
assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The
internal controls, upon consummation of the Offering, will be overseen by the Audit Committee of the Board of Directors (the &ldquo;<B>Audit
Committee</B>&rdquo;) in accordance with the rules of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Listing</U>. The shares of Common Stock have been duly authorized for listing on the Nasdaq Capital Market, subject to official notice
of issuance. The Company is in material compliance with the provisions of the rules and regulations promulgated by Nasdaq and has no reason
to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements
(to the extent applicable to the Company as of the date hereof or the Closing Date or the applicable Option Closing Date; and subject
to all exemptions and exceptions from the requirements thereof as are set forth therein, to the extent applicable to the Company). Without
limiting the generality of the foregoing and subject to the qualifications above: (i) all members of the Company&rsquo;s Board of Directors
who are required to be &ldquo;independent&rdquo; (as that term is defined under applicable laws, rules and regulations), including, without
limitation, all members of each of the Audit Committee of the Board of Directors, compensation committee and nominating and corporate
governance committee of the Company&rsquo;s Board of Directors, meet the qualifications of independence as set forth under such laws,
rules and regulations, (ii) the Audit Committee of the Board of Directors has at least one (1) member who is an &ldquo;audit committee
financial expert&rdquo; (as that term is defined under such laws, rules and regulations), and (iii) that, based on discussions with Nasdaq,
the Company meets all requirements for listing on the Nasdaq Capital Market. The Company shall use its best efforts to maintain the effectiveness
of the registration statement and a current prospectus relating to the registration of the Warrant Shares until (i) all Warrant Shares
have been disposed of pursuant to such effective registration statement, (ii) all Warrant Shares are sold under circumstances in which
all of the applicable conditions of Rule 144 under the Securities Act are met, or (iii) all Warrant Shares become and remain eligible
for sale pursuant to Rule 144 without volume or manner-of-sale restrictions and without the requirement for the Company to be in compliance
with the current public information requirement under Rule 144(c)(1). During any period when the Company fails to have maintained an effective
Registration Statement or a current Prospectus relating thereto and a holder of the Representative&rsquo;s Warrant desires to exercise
such warrant and, in the opinion of counsel to the Holder, Rule 144 is not available as an exemption from registration for the resale
of the Warrant Shares, the Company shall promptly file a registration statement registering the resale of such Warrant Shares and use
its reasonable best efforts to have it declared effective by the Commission within thirty (30) days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Future
Reports to the Underwriters</U>. For one (1) year after the date of this Agreement, the Company will furnish, if not otherwise available
on EDGAR, to the Representative at 377 Oak Street, Lower Concourse, Garden City, NY 11530, Attention: Stephen Kiront, Chief Operating
Officer: (i) as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance
sheet of the Company as of the close of such fiscal year and statements of income, stockholders&rsquo; equity and cash flows for the year
then ended and the opinion thereon of the Company&rsquo;s independent public or certified public accountants; (ii) as soon as practicable
after the filing thereof, copies of each proxy statement, Annual Report on Form 10-K, quarterly financial statements using a Form 8-K
or other report filed by the Company with the Commission; and (iii) as soon as available, copies of any report or communication of the
Company mailed generally to holders of its shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Manipulation of Price</U>. The Company will not take, directly or indirectly, any action designed to cause or result in, or that has constituted
or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Existing
Lock-Up Agreements</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, there are no existing
agreements between the Company and its securityholders that prohibit the sale, transfer, assignment, pledge or hypothecation of any of
the Company&rsquo;s securities. The Company will direct the transfer agent to place stop transfer restrictions upon the securities of
the Company that are bound by such &ldquo;lock-up&rdquo; agreements for the duration of the periods contemplated therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Lock-Up</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; vertical-align: baseline">The
Company on behalf of itself and any successor entity agrees that it will not, without the prior written consent of the Representative,
for a period</FONT> of one hundred eighty (180) days following the Effective Date (the &ldquo;<B>Lock-Up Period</B>&rdquo;), (i) issue,
offer, pledge, announce the intention to sell, contract to sell, or sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, or file with the
Commission a registration statement under the Securities Act relating to, any shares of Common Stock or any securities convertible into
or exercisable or exchangeable for shares of Common Stock, or (ii) enter into any swap or other agreement that transfers, in whole or
in part, any of the economic consequences of ownership of the shares of Common Stock or any such other securities including but not limited
to a direct or indirect &ldquo;at-the-market&rdquo; or continuous equity transaction, whether any such transaction described in clause
(i) or (ii) above is to be settled by delivery of shares of Common Stock or such other securities, in cash or otherwise, except to the
Underwriters pursuant to this Agreement. The Company agrees not to accelerate the vesting of any option or warrant or the lapse of any
repurchase right prior to the expiration of the Lock-Up Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictions
contained in <U>Section 3(n)(i) </U>hereof shall not apply to: (A) the Offered Securities, the Underlying Shares, (B) any shares of Common
Stock issued (i) under any Company stock inventive plans, dividend reinvestment plan, or stock purchase plans, or (ii) pursuant to the
conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options issued by the Company, as applicable,
and in each case outstanding as of the Applicable Time and as described in the Registration Statement, the Disclosure Package or the Prospectus,
(C) any options to purchase any shares of Common Stock and other awards granted under any share plan of the Company or shares of Common
Stock issued pursuant to an employee share purchase plan, as applicable, and in each case, as described in the Registration Statement,
the Disclosure Package or the Prospectus, or (D) shares of Common Stock or other securities issued in connection with a transaction with
an unaffiliated third party that includes a bona fide commercial relationship (including joint ventures, marketing or distribution arrangements,
collaboration agreements or intellectual property license agreements) or any acquisition of assets or acquisition of not less than a majority
or controlling portion of the equity of another entity; provided that (x) the aggregate number of shares of Common Stock issued pursuant
to clause (D) shall not exceed five percent (5%) of the total number of outstanding shares of Common Stock immediately following the issuance
and sale of the Offered Securities pursuant hereto and (y) the recipient of any such shares of Common Stock or other securities issued
or granted pursuant to clause (D) during the Lock-Up Period shall enter into an agreement substantially in the form of <U>Exhibit A</U>
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Right
of First Refusal</U>. The Company and the Representative agree that for a period of twelve (12) months from the Closing Date, whether
or not the engagement contemplated under this Agreement is terminated (other than termination for Cause, as defined below), the Company
grants the Representative the right (provided that the Offering is completed) to act as sole investment banker, sole book-runner, sole
placement agent and/or sole advisor, at the representative&rsquo;s sole discretion, with respect to such financing or refinancing; or
(ii) decides to raise funds by means of an equity offering or a private placement of equity or debt securities using an underwriter or
placement agent, the representative (or any affiliate designated by the Representative) shall have the right to act as exclusive financial
advisor, sole investment banker, sole book-runner and/or sole placement agent, at the Representative&rsquo;s sole discretion, for such
financing (the &ldquo;<B>Right of First Refusal</B>&rdquo;). The Right of First Refusal shall be subject to FINRA Rule 5110(g)(5), including
that it may be terminated by the Company for Cause, which shall mean a material breach by the Representative of this Agreement. The Representative
shall notify the Company of its intention to exercise the Right of First Refusal within fifteen (15) business days following notice in
writing by the Company. Any decision by the Representative to act in any such capacity shall be contained in separate agreements, which
agreements would contain, among other matters, provisions for customary fees for transactions of similar size and nature, as may be mutually
agreed upon, and indemnification of the Representative and shall be subject to general market conditions. If the Representative declines
to exercise the Right of First Refusal, the Company shall have the right to retain any other person or persons to provide such services
on terms and conditions which are not more favorable to such other person or persons than the terms declined by the Representative. The
services provided by the Representative is solely for the benefit of the Company and are not intended to confer any rights upon any persons
or entities not a party hereto (including without limitation, securityholders, employees or creditors of the Company) as against the Representative
or its directors, officers, agents, and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Tail
Period</I>. The Representative shall be entitled to receive from the Company a cash placement fee equal to 7.5% of the aggregate purchase
price paid by each purchaser of securities of the Company, with respect to any public or private offering or other financing or capital-raising
transaction of any kind (the &ldquo;<B>Tail Financing</B>&rdquo;) to the extent that such financing or capital is provided to the Company
by investors whom the Representative has directly introduced, by way of at least one meeting in person or telephonically, to the Company
during the Engagement Period (as defined below), if such Tail Financing is consummated at any time during the Engagement Period or within
twelve (12) months following the expiration of the Engagement Period or termination of that certain engagement letter agreement by and
between the Company and the Representative, dated as of July 30, 2024, as amended (the &ldquo;<B>Engagement Agreement</B>&rdquo;). The
Representative will provide a list of investors at the conclusion of the Engagement Period that were introduced to the Company during
the Engagement Period and only these investors will be eligible for the fees specified in this section. &ldquo;<B>Engagement Period</B>&rdquo;
shall mean the period beginning on July 30, 2024, and ending on the earliest of (i) July 30, 2025, (ii) the date the Offering is completed,
or (iii) the date that either the Company or the Representative terminates the Engagement Agreement pursuant to the terms therein. In
compliance with FINRA Rule 5110(g)(5)(B), the right granted to the Representative under this Section 3(r) shall be terminated upon termination
by the Company of this Agreement for cause and the Company shall not be responsible for paying for the fee set forth in this Section 3(q)
unless a Tail Financing is consummated within the Engagement Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence
of Further Requirements</U>. No consent, approval, authorization, or order of, or filing or registration with, any person (including any
governmental or regulatory agency or body or any court) is required to be obtained or made by the Company for the consummation of the
transactions contemplated by this Agreement, and issuance and sale of the Offered Securities, except for such as have been obtained, or
made on or prior to the Closing Date, and are, or on the Closing Date or any applicable Option Closing Date will be, in full force and
effect. No authorization, consent, approval, license, qualification or order of, or filing or registration with any person (including
any governmental agency or body or any court) in any foreign jurisdiction is required for the consummation of the transactions contemplated
by this Agreement in connection with the Offering, issuance and sale of the Offered Securities under the laws and regulations of such
jurisdiction, except for such as have been obtained or made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of Fees and Expenses.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">The
Company covenants and agrees with Representative that the Company will pay or cause to be paid the following: (i) the fees, disbursements
and expenses of the Company&rsquo;s counsel and accountants in connection with the registration of the Offered Securities and the Underwriters&rsquo;
Securities under the Securities Act and all other expenses in connection with the preparation, printing, reproduction and filing of the
Registration Statement, any preliminary prospectus, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements
thereto and the mailing and delivering of copies thereof to the Underwriters and dealers; (ii) the cost of printing or producing this
Agreement, closing documents (including any compilations thereof) and any other documents in connection with the offering, purchase, sale
and delivery of the Offered Securities and the Underwriters&rsquo; Securities; (iii) all expenses in connection with the qualification
of the Offered Securities and the Underwriters&rsquo; Securities for offering and sale under state securities laws, including the reasonable
fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky survey
if any; (iv) all fees and expenses in connection with listing the Offered Securities on Nasdaq; (v) the filing fees incident to, and the
reasonable fees and disbursements of counsel for the Underwriters in connection with, any required review by FINRA of the terms of the
sale of the Offered Securities and the Underwriters&rsquo; Securities; provided, that the reasonable fees and disbursements of counsel
to the Underwriters; (vi) the cost of preparing stock certificates, if applicable; (vii) the cost and charges of any transfer agent or
registrar; (viii) the costs and expenses of the Company relating to investor presentations on any &ldquo;road show&rdquo; undertaken in
connection with the marketing of the Offered Securities, including without limitation, expenses associated with the production of road
show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval
of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants if any incurred;
and (ix) all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided
for in this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">The
Company also agrees to pay to the Representative a non-accountable expense allowance of one percent (1.0%) of the gross proceeds of the
Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">The
Company will also reimburse the Representative up to a maximum of $200,000 for out-of-pocket accountable expenses, including, but not
limited to: (i) background check on the Company&rsquo;s principal stockholders, directors and officers; (ii) all due diligence expenses;
and (iii) legal counsel fees. The Company has paid an advance of $[&bull;] to the Representative for its anticipated out-of-pocket expenses;
any advance will be returned to the Company to the extent the Representative&rsquo;s out-of-pocket accountable expenses are not actually
incurred in accordance with FINRA Rule 5110(g)(4)(A). It is understood and agreed that the Company shall be responsible for the Representative&rsquo;s
external counsel legal costs, any due diligence costs and any other accountable out-of-pocket fees and expenses in connection with the
Offering irrespective of whether the Offering is consummated or not, subject to a maximum of $50,000 in the event that there is not a
Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions of the Obligations of the Underwriters. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">The
obligations of the Underwriters to purchase the Offered Securities as provided herein on the Closing Date or the applicable Option
Closing Date shall be subject to (i) the accuracy of the representations and warranties on the part of the Company set forth in <U>Section
1</U> hereof as of the date hereof and as of the Closing Date or the applicable Option Closing Date as though then made; (ii) the
timely performance by the Company of its covenants and other obligations hereunder; (iii) no objections from FINRA as to the amount
of compensation allowable or payable to the Underwriters as described in the Registration Statement; and (iv) each of the following
additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accountant&rsquo;s
Comfort Letter</U>. On the date hereof, the Representative shall have received from the Accountant, a letter dated the date hereof addressed
to the Representative, in form and substance satisfactory to the Representative, containing statements and information of the type ordinarily
included in accountants&rsquo; &ldquo;comfort letters&rdquo; to Representative, delivered according to Statement of Auditing Standards
No. 72 (or any successor bulletin), with respect to the audited and unaudited financial statements and certain financial information
contained in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness
of Registration Statement; Compliance with Registration Requirements; No Stop Order.</U> During the period from and after the execution
of this Agreement to and including the Closing Date and each Option Closing Date, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 76.5pt"><FONT STYLE="vertical-align: baseline">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company shall have filed the Prospectus with the Commission (including the information required by Rule 430A under the Securities Act)
in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post-effective
amendment to the Registration Statement containing the information required by such Rule 430A, and such post-effective amendment shall
have become effective; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 76.5pt"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 76.5pt"><FONT STYLE="vertical-align: baseline">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no
stop order suspending the effectiveness of the Registration Statement, or any post-effective amendment to the Registration Statement,
shall be in effect and no proceedings for such purpose shall have been instituted or threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 76.5pt"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Adverse Change</U>. For the period from and after the date of this Agreement to and including the Closing Date and/or each Option
Closing Date, as applicable, in the reasonable judgment of the Representative there shall not have occurred any Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>CFO
Certificate</U>. On the Closing Date and on each Option Closing Date, as applicable, the Representative shall have received a written
certificate executed by the Chief Financial Officer of the Company, dated as of such date, on behalf of the Company, with respect to certain
financial data contained in the Registration Statement, Disclosure Package and the Prospectus, providing &ldquo;management comfort&rdquo;
with respect to such information, in form and substance reasonably satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. On the Closing Date and on each Option Closing Date, as applicable, the Representative shall have received a written
certificate executed by the Chief Executive Officer and the Chief Financial Officer of the Company, dated as of such date, to the effect
that the signers of such certificate have reviewed the Registration Statement, the Disclosure Package and the Prospectus and any amendment
or supplement thereto, each Issuer Free Writing Prospectus and this Agreement, to the effect that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
representations and warranties of the Company in this Agreement are true and correct, as if made on and as of such Closing Date and on
each Option Closing Date, as applicable, and the Company has complied with all the agreements and satisfied all the conditions on its
part to be performed or satisfied at or prior to such Closing Date or Option Closing Date, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
stop order suspending the effectiveness of the Registration Statement or the use of the Prospectus has been issued and no proceedings
for that purpose have been instituted or are pending or, to the Company&rsquo;s knowledge, threatened under the Securities Act; no order
having the effect of ceasing or suspending the distribution of the Offered Securities or any other securities of the Company has been
issued by any securities commission, securities regulatory authority or stock exchange in the United States and no proceedings for that
purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission, securities
regulatory authority or stock exchange in the United States; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
to the respective dates as of which information is given in the Registration Statement and the Prospectus, there has not been: (a) any
Material Adverse Change; (b) any transaction that is material to the Company and the Subsidiaries taken as a whole, except transactions
entered into in the ordinary course of business; (c) any obligation, direct or contingent, that is material to the Company and the Subsidiaries
taken as a whole, incurred by the Company or any Subsidiary, except obligations incurred in the ordinary course of business; (d) any material
change in the capital stock (except changes thereto resulting from the exercise of outstanding options or warrants or conversion of outstanding
indebtedness into Common Stock of the Company) or outstanding indebtedness of the Company or any Subsidiary (except for the conversion
of such indebtedness into Common Stock of the Company); (e) any dividend or distribution of any kind declared, paid or made on Common
Stock of the Company; or (f) any loss or damage (whether or not insured) to the property of the Company or any Subsidiary which has been
sustained or will have been sustained which has a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary&rsquo;s
Certificate</U>. On the Closing Date and on each Option Closing Date, as applicable, the Representative shall have received a certificate
of the Company signed by the Secretary or the Chief Financial Officer of the Company, dated such Closing Date or Option Closing Date,
as applicable, certifying: (i) that each of the Company&rsquo;s amended and restated articles of incorporation and bylaws is, attached
to such articles is true and complete, has not been modified, and is in full force and effect; (ii) that each of the Subsidiaries&rsquo;
constitutive and organizational documents attached to such certificate is true and complete, has not been modified, and is in full force
and effect; (iii) that the resolutions of the Board of Directors relating to the Offering attached to such certificate are in full force
and effect and have not been modified; and (iv) the good standing of the Company and each of the Subsidiaries (except in such jurisdictions
where the concept of good standing is not applicable). The documents referred to in such certificate shall be attached to such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bring-down
Comfort Letter</U>. On the Closing Date and on each Option Closing Date, as applicable, the Representative shall have received from the
Accountant, a letter dated such date, in form and substance satisfactory to the Representative, to the effect that the Accountant reaffirms
the statements made in the letter furnished by it pursuant to <U>Section 5(a)</U>, except that the specified date referred to therein
for the carrying out of procedures shall be no more than two (2) business days prior to the Closing Date or applicable Option Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lock-Up
Agreement from Certain Securityholders of the Company</U>. On or prior to the date hereof, the Company shall have furnished to the Representative
an agreement substantially in the form of <U>Exhibit A</U> hereto from each of the Company&rsquo;s officers, directors, securityholders
of five percent (5%) or more of the Common Stock or securities convertible into or exercisable for shares of Common Stock listed on <U>Schedule
D</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Listing</U>. The Offered Securities to be delivered on the Closing Date and the applicable Option Closing Date shall have been approved
for listing on the Nasdaq Capital Market, subject to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Counsel Opinions</U>. On the Closing Date and the applicable Option Closing Date, the Representative shall have received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
favorable opinion of VCL Law LLP, U.S. securities and New York counsel to the Company, dated as of such date, addressed to the Representative,
including a negative assurance letter, in form and substance reasonably satisfactory to the Representative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
favorable opinion of AllBright Law Offices, PRC counsel to the Company, in form and substance reasonably satisfactory to the Representative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
favorable opinion of Wiseteam Law Firm, Taiwanese counsel to the Company, in form and substance reasonably satisfactory to the Representative;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
favorable opinion of Fennemore Craig, P.C., Nevada counsel to the Company, in form and substance reasonably satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Underwriters shall rely on
the opinions of (i) the Company&rsquo;s Nevada counsel, Fennemore Craig, P.C., filed as Exhibit 5.1 to the Registration Statement, as
to the due incorporation, validity of the Offered Securities, and due authorization, execution and delivery of the Agreement, (ii) the
Company&rsquo;s U.S. securities and New York counsel, VCL Law LLP, filed as Exhibit 5.2 to the Registration Statement, as to the validity
of the Underwriters&rsquo; Securities, (iii) the Company&rsquo;s PRC counsel, AllBright Law Offices, filed as Exhibit 8.1 to the Registration
Statement, and (iv) the Company&rsquo;s Taiwanese counsel, Wiseteam Law Firm, filed as Exhibit 8.2 to the Registration Statement .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Documents</U>. On or before the Closing Date or applicable Option Closing Date, the Representative and counsel for the Representative
shall have received such information, documents and opinions as they may reasonably require for the purposes of enabling them to pass
upon the issuance and sale of the Offered Securities as contemplated herein, or in order to evidence the accuracy of any of the representations
and warranties, or the satisfaction of any of the conditions or agreements, herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If any condition specified in
this <U>Section 5</U> is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representative by
written notice to the Company at any time on or prior to the Closing Date, or applicable Option Closing Date which termination shall be
without liability on the part of any party to any other party, except that <U>Section 4</U> (with respect to the reimbursement of out-of-pocket
accountable, bona fide expenses actually incurred by the Representative) and <U>Section 7</U> (with respect to indemnification and contribution
obligations) shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effectiveness of this Agreement.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">This
Agreement shall not become effective until the later of (i) the execution of this Agreement by the parties hereto and (ii) notification
(including by way of oral notification from the reviewer at the Commission) by the Commission to the Company of the effectiveness of the
Registration Statement under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
by the Company.</U> The Company shall indemnify and hold harmless the Underwriters, their respective affiliates and each of their respective
directors, officers, members, employees and agents and each person, if any, who controls such Underwriters within the meaning of Section
15 of the Securities Act of or Section 20 of the Exchange Act (collectively the &ldquo;Underwriter Indemnified Parties,&rdquo; and each
a &ldquo;Underwriter Indemnified Party&rdquo;) from and against any losses, claims, fines (which may be imposed by any governmental authority,
including if applicable, the CSRC), damages or liabilities (including in settlement of any litigation if such settlement is effected with
the prior written consent of the Company) arising out of (i) an untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement, including the information deemed to be a part of the Registration Statement at the time of effectiveness
and at any subsequent time pursuant to Rules 430A and 430B of the Securities Act Regulations, or arise out of or are based upon the omission
from the Registration Statement, or alleged omission to state therein, a material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading&#894; or (ii) an untrue statement
or alleged untrue statement of a material fact contained in the Prospectus, or any amendment or supplement thereto, or in any other materials
used in connection with the Offering, or arise out of or are based upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading, and shall reimburse such Underwriter Indemnified Party for any legal or other expenses reasonably incurred by it in connection
with evaluating, investigating or defending against such loss, claim, fine, damage, liability or action; provided, however, that the Company
shall not be liable in any such case to the extent that any such loss, claim, fine, damage, expense or liability arises out of or is based
upon an untrue statement in, or omission from any preliminary prospectus, any Registration Statement or the Prospectus, or any such amendment
or supplement thereto, or any Issuer Free Writing Prospectus or in any other materials used in connection with the Offering made in reliance
upon and in conformity with the Underwriter Information. The indemnification obligations under this Section 7(a) are not exclusive and
will be in addition to any liability, which the Underwriters might otherwise have and shall not limit any rights or remedies which may
otherwise be available at law or in equity to each Underwriter Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
by the Underwriters.</U> The Underwriters shall indemnify and hold harmless the Company and the Company&rsquo;s affiliates and each of
their respective directors, officers, employees, agents and each person, if any, who controls the Company within the meaning of Section
15 of the Securities Act or Section 20 of the Exchange Act (collectively the &ldquo;Company Indemnified Parties&rdquo; and each a &ldquo;Company
Indemnified Party&rdquo;) from and against any losses, claims, damages or liabilities (including in settlement of any litigation if such
settlement is effected with the prior written consent of the Underwriters) arising out (i) any untrue statement of a material fact contained
in any preliminary prospectus, any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo; filed or required to be filed
pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement or the Prospectus, or in any amendment or supplement
thereto, or (ii) the omission to state in any preliminary prospectus, any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo;
filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement or the Prospectus,
or in any amendment or supplement thereto, a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading, but in each case only to the extent that the untrue statement
or omission was made in reliance upon and in conformity with the Underwriters Information and shall reimburse the Company for any legal
or other expenses reasonably incurred by such party in connection with investigating or preparing to defend or defending against or appearing
as third party witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding, as such fees
and expenses are incurred. Notwithstanding the provisions of this <U>Section 7(b)</U>, in no event shall any indemnity by the Underwriters
under this <U>Section 7(b)</U> exceed the total discounts received by the Underwriters in connection with the Offering. The indemnification
obligations under this <U>Section 7(b)</U> are not exclusive and will be in addition to any liability, which the Company might otherwise
have and shall not limit any rights or remedies which may otherwise be available at law or in equity to each Company Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure.
</U>Promptly after receipt by an indemnified party under this <U>Section 7</U> of notice of the commencement of any action, the indemnified
party shall, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section 7,</U> notify such indemnifying
party in writing of the commencement of that action; provided, however, that the failure to notify the indemnifying party shall not relieve
it from any liability which it may have under this <U>Section 7</U> except to the extent it has been materially adversely prejudiced
by such failure; and, provided, further, that the failure to notify an indemnifying party shall not relieve it from any liability which
it may have to an indemnified party otherwise than under this <U>Section 7</U>. If any such action shall be brought against an indemnified
party, and it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the
extent that it wishes, jointly with any other similarly notified indemnifying party, to assume the defense of such action with counsel
reasonably satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified party,
be counsel to the indemnifying party). After notice from the indemnifying party to the indemnified party of its election to assume the
defense of such action, except as provided herein, the indemnifying party shall not be liable to the indemnified party under <U>Section
7(a)</U> or <U>7(b),</U> as applicable, for any legal or other expenses subsequently incurred by the indemnified party in connection
with the defense of such action other than reasonable costs of investigation; provided, however, that any indemnified party shall have
the right to employ separate counsel in any such action and to participate in the defense of such action but the fees and expenses of
such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified party unless (i) the employment
thereof has been specifically authorized in writing by the Company in the case of a claim for indemnification under <U>Section 7(a),
</U>(ii) such indemnified party shall have been advised by its counsel that there may be one or more legal defenses available to it which
are different from or additional to those available to the indemnifying party, or (iii) the indemnifying party has failed to assume the
defense of such action and employ counsel reasonably satisfactory to the indemnified party within a reasonable period of time after notice
of the commencement of the action or the indemnifying party does not diligently defend the action after assumption of the defense, in
which case, if such indemnified party notifies the indemnifying party in writing that it elects to employ separate counsel at the expense
of the indemnifying party, the indemnifying party shall not have the right to assume the defense of (or, in the case of a failure to
diligently defend the action after assumption of the defense, to continue to defend) such action on behalf of such indemnified party
and the indemnifying party shall be responsible for legal or other expenses subsequently incurred by such indemnified party in connection
with the defense of such action; provided, however, that the indemnifying party shall not, in connection with any one such action or
separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances,
be liable for the reasonable fees and expenses of more than one separate firm of attorneys at any time any such indemnified party (in
addition to any local counsel), which firm shall be designated in writing by the Underwriters if the indemnified party under this <U>Section
7</U> is an Underwriter Indemnified Party or by the Company if an indemnified party under this <U>Section 7</U> is a Company Indemnified
Party. Subject to this <U>Section 7(c),</U> the amount payable by an indemnifying party under <U>Section 7</U> shall include, but not
be limited to, (x) reasonable legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or
preparing to defend or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with,
any action, investigation, proceeding or claim, and (y) all amounts paid in settlement of any of the foregoing. No indemnifying party
shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of judgment with respect
to any pending or threatened action or any claim whatsoever, in respect of which indemnification or contribution could be sought under
this <U>Section 7</U> (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise
or consent (i) includes an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified
party from all liability arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability
or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the following sentence, no indemnifying party
shall be liable for settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent
(which consent shall not be unreasonably withheld or delayed), but if settled with its written consent, if its consent has been unreasonably
withheld or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold
harmless any indemnified party from and against any loss or liability by reason of such settlement or judgment. In addition, if at any
time an indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel,
such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated herein effected without its written
consent if (i) such settlement is entered into more than forty-five (45) days after receipt by such indemnifying party of the request
for reimbursement, (ii) such indemnifying party shall have received notice of the terms of such settlement at least thirty (30) days
prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance
with such request prior to the date of such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution.
</U>If the indemnification provided for in this <U>Section 7</U> is unavailable or insufficient to hold harmless an indemnified party
under <U>Section 7(a)</U> or <U>Section 7(b),</U> then each indemnifying party shall, in lieu of indemnifying such indemnified party,
contribute to the amount paid, payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage, expense
or liability (or any action, investigation or proceeding in respect thereof), as incurred, (i) in such proportion as shall be appropriate
to reflect the relative benefits received by the indemnifying party or parties on the one hand and the indemnified parry or parties on
the other hand from the Offering, or (ii) if the allocation provided by clause (i) of this <U>Section 7(d)</U> is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) of this <U>Section 7(d)
</U>but also the relative fault of the indemnifying party or parties on the one hand and the indemnified party or parties on the other
with respect to the statements, omissions, acts or failures to act which resulted in such loss, claim, damage, expense or liability (or
any action, investigation or proceeding in respect thereof) as well as any other relevant equitable considerations. The relative benefits
received by the Company on the one hand and the Underwriters on the other with respect to such offering shall be deemed to be in the
same proportion as the total proceeds from the Offering purchased by investors as contemplated by this Agreement (before deducting expenses)
received by the Company bear to the total underwriting discounts received by the Underwriters in connection with the Offering, in each
case as set forth in the table on the cover page of the Prospectus. The relative fault of the Company on the one hand and the Underwriters
on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Underwriters
on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such
untrue statement, omission, act or failure to act; provided that the parties hereto agree that the written information furnished to the
Company by the Underwriters for use in any preliminary prospectus, any Registration Statement or the Prospectus, or in any amendment
or supplement thereto, consists solely of the Underwriters&rsquo; Information. The Company and the Underwriters agree that it would not
be just and equitable if contributions pursuant to this <U>Section 7(d)</U> be determined by pro rata allocation or by any other method
of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified
party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to above in this <U>Section
7(d)</U> shall be deemed to include, for purposes of this <U>Section 7(d),</U> any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating, preparing to defend or defending against or appearing as a third party witness in
respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding.
Notwithstanding the provisions of this <U>Section 7(d),</U> an underwriter shall not be required to contribute any amount in excess of
the total discounts received in cash by such underwriter in connection with the Offering less the amount of any damages that such underwriter
has otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission, act or
alleged act or failure to act or alleged failure to act by such underwriter. No person guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><B>Section 8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination
of this Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">Prior
to the Closing Date, whether before or after notification by the Commission to the Company of the effectiveness of the Registration Statement
under the Securities Act, this Agreement may be terminated by the Underwriters by written notice given to the Company if at any time
(i) trading or quotation in any of the Company&rsquo;s securities shall have been suspended or limited by the Commission or by Nasdaq;
(ii) a general banking moratorium shall have been declared by any U.S. federal authorities; (iii) there shall have occurred any outbreak
or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international
financial markets, or any substantial change or development involving a prospective substantial change in United States&rsquo; or international
political, financial or economic conditions that, in the reasonable judgment of the Underwriters, is material and adverse and makes it
impracticable to market the Offered Securities or Underwriters&rsquo; Securities in the manner and on the terms described in the Prospectus
or to enforce contracts for the sale of securities; (iv) if the Company shall have sustained a material loss by fire, flood, accident,
hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will,
in the Representative&rsquo;s opinion, make it inadvisable to proceed with the delivery of the Offered Securities, (v) if the Company
is in material breach of any of its representations, warranties or covenants hereunder, (vi) if the Representative shall have become
aware after the date hereof of such a material adverse change in the conditions or prospects of the Company, or such adverse material
change in general market conditions as in the Representative&rsquo;s reasonable judgment would make it impracticable to proceed with
the offering, sale and/or delivery of the Offered Securities or to enforce contracts made by the Underwriters </FONT>for the sale of
the Offered Securities, or (vii) regulatory approval (including but not limited to Nasdaq approval) for the Offering is denied, conditioned
or modified and as a result it makes it impracticable for the Representative to proceed with the Offering, sale and/or delivery of the
Offered Securities or to enforce contracts <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">for
the sale of the Offered Securities. Any termination pursuant to this <U>Section 8</U> shall be without liability on the part of (a) the
Company to any of the Underwriters, except that the Company shall be, subject to demand by the Underwriters, obligated to reimburse the
Representative for only those out-of-pocket expenses (including the reasonable fees and expenses of their counsel, and expenses associated
with a due diligence report), actually incurred by the Representative in connection herewith as allowed under FINRA Rule 5110, less any
amounts previously paid by the Company; <U>provided, however,</U> that all such expenses shall not exceed $20</FONT>0,000 in the aggregate,
subject to <U>Section 4</U> of this Agreement, (b) the Underwriters to the Company, or (c) any party hereto to any other party except
that the provisions of <U>Section 4</U> (with respect to the reimbursement of out-of-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">pocket
accountable, bona fide expenses actually incurred by the Representative) and <U>Section 7</U> (with respect to indemnification and contribution
obligations) shall at all times be effective and shall survive such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><B>Section 9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Advisory
or Fiduciary Responsibility.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">The
Company hereby acknowledges that the Underwriters are acting solely as underwriters in connection with the Offering. The Company further
acknowledges that the Underwriters are acting pursuant to a contractual relationship created solely by this Agreement entered into on
an arm&rsquo;s-length basis and in no event do the parties intend that the Underwriters act or be responsible as a fiduciary to the Company,
its management, stockholders, creditors or any other person in connection with any activity that the Underwriters may undertake or have
undertaken in furtherance of the Offering, either before or after the date hereof. The Underwriters hereby expressly disclaim any fiduciary
or similar obligations to the Company, either in connection with the transactions contemplated by this Agreement or any matters leading
up to such transactions, and the Company hereby confirms its understanding and agreement to that effect. The Company hereby further confirms
its understanding that no Underwriters has assumed an advisory or fiduciary responsibility in favor of the Company with respect to the
Offering contemplated hereby or the process leading thereto, including, without limitation, any negotiation related to the pricing of
the Offered Securities; and the Company has consulted its own legal and financial advisors to the extent it has deemed appropriate in
connection with this Agreement and the Offering. The Company and the Underwriters agree that they are each responsible for making their
own independent judgments with respect to any such transactions, and that any opinions or views expressed by the Underwriters to the Company
regarding such transactions, including but not limited to any opinions or views with respect to the price or market for the Company&rsquo;s
securities, do not constitute advice or recommendations to the Company. The Company hereby waives and releases, to the fullest extent
permitted by law, any claims that the Company may have against the Underwriters with respect to any breach or alleged breach of any fiduciary
or similar duty to the Company in connection with the transactions contemplated by this Agreement or any matters leading up to such transactions.
Notwithstanding anything in this Agreement to the contrary, the Company acknowledges that the Underwriters may have financial interests
in the success of the Offering that are not limited to the difference between the price to the public and the purchase price paid to the
Company by the Underwriters for the Offered Securities, the Underwriters&rsquo; Securities, and the Underwriters have no obligation to
disclose, or account to the Company for, any of such additional financial interests. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><B>Section 10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations
and Indemnities to Survive Delivery.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">The
respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers, and of the Underwriters
set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf
of the Underwriters or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be,
and will survive delivery of and payment for the Offered Securities sold hereunder and any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><B>Section 11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any sum payable by the Company under this Agreement is subject to tax in the hands of an Underwriter or Representative (each a &ldquo;Taxable
Entity&rdquo;) or taken into account as a receipt in computing the taxable income of that Taxable Entity (excluding net income taxes on
underwriting commissions payable hereunder), the Company shall pay such additional amount as will ensure that the Taxable Entities shall
be left with the sum it would have had in the absence of such tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
sums payable by the Company under this Agreement shall be paid free and clear of and without deductions or withholdings of any present
or future taxes or duties, unless the deduction or withholding is required by law, in which case the Company shall pay such additional
amount as will result in the receipt by each Taxable Entity of the full amount that would have been received had no deduction or withholding
been made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
sums payable to a Taxable Entity shall be considered exclusive of any value added or similar taxes. Where the Company is obliged to pay
value added or similar tax on any amount payable hereunder to a Taxable Entity, the Company shall in addition to the sum payable hereunder
pay an amount equal to any applicable value added or similar tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
prejudice to the generality of the foregoing, if a Taxable Entity is required by any relevant foreign government authority to pay any
taxes imposed by the Hong Kong, PRC or Taiwanese governments or any administrative subdivision or taxing authority thereof or therein
(&ldquo;<B>Foreign Taxes</B>&rdquo;) as a result of this Agreement, the Company will pay an additional amount to</FONT> such <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">Taxable
Entity so that the full amount of such payments as agreed herein to be paid to the such Taxable Entity is received by the such Taxable
Entity and will further, if requested by such Taxable Entity, use commercially reasonable efforts to give such assistance as such Taxable
Entity may reasonably request to assist such Taxable Entity in discharging its obligations in respect of such Foreign Taxes, including
by making filings and submissions on such basis and such terms as such Taxable Entity may reasonably request, promptly making available
to such Taxable Entity notices received from any Hong Kong governmental authority and, subject to the receipt of funds from such Taxable
Entity, by making payment of such funds on behalf of such Taxable Entity to the relevant foreign government authority in settlement of
such Foreign Taxes. In the event the Company must pay any such Foreign Taxes to a relevant taxing authority, the Company shall forward
to such Taxable Entity an official receipt or a copy of the official receipt issued by the taxing authority or other document evidencing
such payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">All
communications hereunder shall be in writing and shall be mailed, hand delivered, or emailed to the parties hereto as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the Underwriters at:</FONT></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Craft Capital Management LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">377 Oak Street, Lower Concourse</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Garden City, NY 11530</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attn: Stephen Kiront, COO</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Email: skiront@craftcm.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With a copy (which shall not constitute notice) to</I>:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ortoli Rosenstadt LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">366 Madison Avenue, 3rd Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, NY 10017</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attn: William S. Rosenstadt, Esq.; Mengyi &ldquo;Jason&rdquo; Ye, Esq. Email: wsr@orllp.legal; jye@orllp.legal</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the Company at:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">689-85 Xiaodong Road, Yongkang District</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tainan, Taiwan</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tel: 886-6-3121716</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attn: Yi Lu</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Email: [&#9679;]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With a copy (which shall not constitute notice) to</I>:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">VCL Law LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1945 Old Gallows Road</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Suite 260</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Vienna, VA 22182</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attn: Fang Liu, Esq.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Email: fliu@vcllegal.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">Any
party hereto may change the address for receipt of communications by giving written notice to the others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successors.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">This
Agreement will inure to the benefit of and be binding upon the parties hereto and to the benefit of the employees, officers and directors
and controlling persons referred to in <U>Section 7,</U> and in each case their respective successors, and no other person will have
any right or obligation hereunder. The term &ldquo;successors&rdquo; shall not include any purchaser of the Offered Securities as such
merely by reason of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Partial Unenforceability.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">The
invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability
of any other Section, paragraph, or provision hereof. If any Section, paragraph, or provision of this Agreement is for any reason determined
to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to
make it valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law Provisions. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">This
Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, without giving effect to conflict
of laws principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consent to Jurisdiction.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">No
legal suit, action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby (each, a &ldquo;<B>Related
Proceeding</B>&rdquo;) may be commenced, prosecuted or continued in any court other than the courts of the State of New York located in
the City and County of New York or in the United States District Court for the Southern District of New York, which courts (collectively,
the &ldquo;<B>Specified Courts</B>&rdquo;) shall have jurisdiction over the adjudication of any Related Proceeding, and the parties to
this Agreement hereby irrevocably consent to the exclusive jurisdiction the Specified Courts and personal service of process with respect
thereto. The parties to this Agreement hereby irrevocably waive any objection to the laying of venue of any Related Proceeding in the
Specified Courts and irrevocably waive and agree not to plead or claim in any Specified Court that any Related Proceeding brought in any
Specified Court has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="vertical-align: baseline"><B>Section
17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Provisions. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">This
Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous
oral agreements, understandings and negotiations with respect to the Offering, except for those specific provisions of the Engagement
Letter between the Company and the Representative, dated as of July 30, 2024, that are not related to the Offering, each of which provisions
shall remain in full force and effect for the term of the Engagement Letter. This Agreement may be executed in two or more counterparts,
each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This
Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied)
may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience
of the parties only and shall not affect the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">Each
of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations
regarding the provisions hereof, including, without limitation, the indemnification and contribution provisions of <U>Section 7,</U>
and is fully informed regarding said provisions. Each of the parties hereto further acknowledges that the provisions of <U>Section 7
</U>hereto fairly allocate the risks in the light of the ability of the parties to investigate the Company, its affairs and its business
in order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus and the Prospectus
(and any amendments and supplements thereto), as required by the Securities Act and the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">The
respective indemnities, contribution agreements, representations, warranties and other statements of the Company and the Underwriters
set forth in or made pursuant to this Agreement shall remain operative and in full force and effect, regardless of (i) any investigation,
or statement as to the results thereof, made by or on behalf of the Underwriters, the officers or employees of the Underwriters, any person
controlling any of the Underwriters, the Company, the officers or employees of the Company, or any person controlling the Company, (ii)
acceptance of the Offered Securities and payment for them as contemplated hereby and (iii) termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="vertical-align: baseline"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">Except
as otherwise provided, this Agreement has been and is made solely for the benefit of and shall be binding upon the Company, the Underwriters,
the Underwriters&rsquo; officers and employees, any controlling persons referred to herein, the Company&rsquo;s directors and the Company&rsquo;s
officers who sign the Registration Statement and their respective successors and assigns, all as and to the extent provided in this Agreement,
and no other person shall acquire or have any right under o</FONT>r by virtue of this Agreement. The term &ldquo;successors and assigns&rdquo;
shall not include a purchaser of any of the Offered Securities from the Underwriters merely because of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase">[<I>signature
page follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance
with your understanding of the Agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument,
along with all counterparts hereof, shall become a binding agreement in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADVANCED BIOMED INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The foregoing Agreement is hereby confirmed and accepted
by the Underwriters as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For itself and on behalf of the several</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Underwriters listed on Schedule A hereto</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CRAFT CAPITAL MANAGEMENT LLC </B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen Kiront</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Underwriter</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%"></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Firm Shares</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%"></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craft Capital Management LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Issuer Free Writing Prospectus(es)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE C</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pricing Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Number of Firm Shares: [&#9679;] shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Number of Additional Shares: [&#9679;] shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Public Offering Price per Firm Share: $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Public Offering Price per Additional Share: $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Underwriting Discount per Firm Share: $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Underwriting Discount per Additional Share: $[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proceeds to Company per Firm Share (before expenses):
$[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proceeds to Company per Additional Share (before expenses):
$[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE D</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Name</B></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up Period</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu, Ph.D.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau, Ph.D.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mingze Yin</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven I-Fang Cheng, Ph.D.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jing Zhang</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cheang I Kei</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mingyue Cai</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance On Ventures Limited</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yimin Jin*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Xiaoyuan Luo</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nanzhen Shen*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">six (6) months</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>*</SUP></TD><TD STYLE="text-align: justify">Except for 1,875,000&nbsp;shares of Common Stock beneficially owned by the selling stockholders,
                                                                              including Yimin Jin with respect to 1,755,000 shares of Common Stock, and Nanzhen Shen with respect to 120,000 shares of Common
                                                                              Stock.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE E</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Subsidiary</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction of Incorporation or<BR>
Organization</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed Inc. (Taiwan)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed (HK) Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">People&rsquo;s Republic of China</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE F</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Written Testing the Waters Communications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>EXHIBIT A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form of Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form of Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5in; text-align: center; text-indent: 0.5in">_______________, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Craft Capital Management LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>377 Oak St, Lower Concourse</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Garden City, New York 11530</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Re: Advanced Biomed Inc. &mdash; Initial Public Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned (the &ldquo;<B>Undersigned</B>&rdquo;),
being an officer, director, and/or holder of Common Stock, par value $0.001, or rights to acquire shares of Common Stock (such rights,
together with the shares of Common Stock, collectively, the &ldquo;<B>Shares</B>&rdquo;) of Advanced Biomed Inc. (the &ldquo;<B>Company</B>&rdquo;),
understands that you are the representative (the &ldquo;<B>Representative</B>&rdquo;) of several underwriters (collectively, the &ldquo;<B>Underwriters</B>&rdquo;),
named or to be named in <U>Schedule&nbsp;A</U> to the underwriting agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) entered
or to be entered into among the Underwriters and the Company, providing for the Offering of securities of the Company pursuant to a Registration
Statement. Capitalized terms not defined herein shall have the meaning ascribed to them in the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In consideration of the Underwriters&rsquo;
agreement to enter into the Underwriting Agreement and to proceed with the Offering of the securities of the Company, and for other good
and valuable consideration, receipt of which is hereby acknowledged, the Undersigned hereby agrees, for the benefit of the Company, the
Representative and the other Underwriters that, without the prior written consent of the Representative, the Undersigned will not, during
the period commencing on the date of this Lock-up Agreement and continuing to and including the date that is one-hundred and eighty (180)
days after the Effective Date (the &ldquo;<B>Lock-Up Period</B>&rdquo;), unless otherwise provided herein, directly or indirectly (a)
offer, sell, agree to offer or sell, solicit offers to purchase, grant any call option or purchase any put option with respect to, pledge,
encumber, assign, borrow or otherwise dispose of (each, a &ldquo;<B>Transfer</B>&rdquo;) any Relevant Security (as defined below) or otherwise
publicly disclose the intention to do so, or (b) establish or increase any &ldquo;put equivalent position&rdquo; or liquidate or decrease
any &ldquo;call equivalent position&rdquo; with respect to any Relevant Security (in each case within the meaning of Section 16 of the
Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), and the rules and regulations promulgated thereunder)
with respect to any Relevant Security or otherwise enter into any swap, derivative or other transaction or arrangement that Transfers
to another, in whole or in part, any economic consequence of ownership of a Relevant Security, whether or not such transaction is to be
settled by the delivery of Relevant Securities, other securities, cash or other consideration, or otherwise publicly disclose the intention
to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As used herein, the term &ldquo;<B>Relevant
Security</B>&rdquo; or &ldquo;<B>Relevant Securities</B>&rdquo; means any Share, any warrant to purchase Shares, or any other security
of the Company or any other entity that is convertible into, or exercisable or exchangeable for, Shares or any other equity security of
the Company, in each case owned beneficially or otherwise by the Undersigned on the date of closing of the Offering or acquired by the
Undersigned during the Lock-Up Period. For avoidance of doubt, a &ldquo;Relevant Security&rdquo; shall not include such Shares registered
for resale, if any, by the Undersigned, in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The restrictions in the foregoing
paragraph shall not apply to (a) any exercise (including a cashless exercise or broker-assisted exercise and payment of tax obligations),
vesting, or settlement, as applicable, by the Undersigned of options or warrants to purchase Shares or other equity awards pursuant to
any share incentive or award plan or share purchase plan of the Company; <I>provided</I> that any Shares received by the Undersigned upon
such exercise, conversion, or exchange will be subject to the Lock-Up Period, (b) any establishment of a trading plan pursuant to Rule
10b5-1 under the Exchange Act for the Transfer of Shares (such, a &ldquo;<B>Trading Plan</B>&rdquo;); <I>provided</I> that (i) the Trading
Plan shall not provide for or permit any Transfers, sales or other dispositions of Shares during the Lock-Up Period and (ii) the Trading
Plan would not require any filing under Section 16(a) of the Exchange Act and no such filing is voluntarily made, (c) any Transfer of
Shares acquired in open market transactions following the closing of the Offering, <I>provided</I> the Transfer would not require any
filing under Section 16(a) of the Exchange Act and no such filing is voluntarily made, (d) any Transfer of the Undersigned&rsquo;s Shares
or any other security convertible into or exercisable or exchangeable for Common Stock to the Company in connection with the termination
of the Undersigned&rsquo;s employment with the Company or pursuant to any contractual arrangement under which the Company has the option
to repurchase such Shares; <I>provided</I> that no filing by any party under the Exchange Act shall be required or shall be made voluntarily
within forty-five (45) days after the date the Undersigned ceases to provide services to the Company, and after such forty-fifth (45<SUP>th</SUP>)
day, if the Undersigned is required make any filing under the Exchange Act to report a reduction in beneficial ownership of Common Stock
during the Lock-Up Period, the Undersigned shall clearly indicate in the footnotes thereto that such filing and the reduction in beneficial
ownership in connection therewith relates to the termination of the Undersigned&rsquo;s employment, and no other public announcement shall
be made voluntarily in connection with such Transfer (other than the filing on a Form 5 made after the expiration of the Lock-Up Period),
(e) any conversion of any outstanding security of the Company into Shares; <I>provided</I> that any such Shares received upon such conversion
shall be subject to the restrictions on the Transfer of Relevant Securities set forth in this Lock-Up Agreement, or (f) any Transfer of
Shares or any other security convertible into or exercisable or exchangeable for Shares pursuant to a bona fide third-party tender offer
for securities of the Company, merger, consolidation or other similar transaction that is approved by the board of directors of the Company,
made to all holders of Common Stock involving a change of control (as defined below); <I>provided</I> that all of the Undersigned&rsquo;s
Relevant Securities subject to this Lock-Up Agreement shall remain subject to the restrictions described herein. For purposes of this
Lock-Up Agreement, &ldquo;change of control&rdquo; means any bona fide third party tender offer, merger, consolidation, or other similar
transaction, in one transaction or a series of related transactions, the result of which is that any &ldquo;person&rdquo; (as defined
in Section 13(d)(3) of the Exchange Act), or group of affiliated persons, other than the Company, becomes the beneficial owner (as defined
in Rules 13d-3 and 13d-5 of the Exchange Act) of 50% or more of the total voting power of the voting securities of the Company (or any
surviving entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the Undersigned further
agrees that, except for the Registration Statement or any registration statement on Form S-8, during the Lock-Up Period, the Undersigned
will not, without the prior written consent of the Representative: (a) file or participate in the filing with the Commission any registration
statement or circulate or participate in the circulation of any preliminary or final prospectus or other disclosure documents, in each
case with respect to any proposed offer or sale of any Relevant Security beneficially owned by the Undersigned, or (b) exercise any rights
the Undersigned may have to require registration with the Commission of any proposed offeror sale of any Relevant Security beneficially
owned by the Undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In furtherance of the Undersigned&rsquo;s
obligations hereunder, the Undersigned hereby authorizes the Company during the Lock-Up Period to cause the transfer agent for the Relevant
Securities to decline to Transfer, and to note stop transfer restrictions on the shareholder register and any other record relating to,
Relevant Securities, for which the Undersigned is the record owner and the Transfer of which would be a violation of this Lock-Up Agreement.
In the case of any Relevant Securities for which the Undersigned is the beneficial owner but not the record owner, the Undersigned agrees
that during the Lock-Up Period it will use its best efforts to cause the record owner to authorize the Company to cause the relevant transfer
agent to decline to transfer and to note stop transfer restrictions on the shareholder register or any other records relating to such
Relevant Securities to the extent such Transfer would be a violation of this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing
or anything contained herein to the contrary, the Undersigned may Transfer the Undersigned&rsquo;s Relevant Securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">as a <I>bona fide</I> gift or gifts;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">to any immediate family member of the Undersigned, or to any trust,
partnership, limited liability company, or other legal entity commonly used for estate planning purposes which are established for the
direct or indirect benefit of the Undersigned or a member or members of the immediate family of the Undersigned;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">if the Undersigned is a corporation, partnership, limited liability
company, trust or other business entity, (1) to another corporation, partnership, limited liability company, trust, or other business
entity that is a direct or indirect Affiliate (as defined in Rule 405 under the Securities Act of 1933, as amended) of the Undersigned,
(2) to partners, limited liability company members, stockholders or stockholders of the Undersigned or holders of similar equity interests
in the Undersigned, or (3) in connection with a sale, merger or transfer of all or substantially all of the assets of the Undersigned
or any other change of control of the Undersigned, not undertaken for the purpose of avoiding the restrictions imposed by this Lock-Up
Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">if the Undersigned is a trust, to the trustee or beneficiary of
such trust or to the estate of a beneficiary of such trust;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">by testate or intestate succession;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">by operation of law, such as pursuant to a qualified domestic
order or in connection with a divorce settlement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(vii)</TD><TD STYLE="text-align: justify">as permitted under the Underwriting Agreement; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(viii)</TD><TD STYLE="text-align: justify">the withholder of Shares by, or surrender of Shares to, the Company
pursuant to a &ldquo;net&rdquo; or &ldquo;cashless&rdquo; exercise or settlement feature to cover taxes due upon or the consideration
required in connection with the exercise of securities issued under an equity incentive plan or share purchase plan of the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>provided, </I>in the case of clauses (i)-(vi),
that (A) such Transfer shall not involve a disposition for value, (B) the transferee agrees in writing with the Underwriters and the Company
to be bound by the terms of this Lock-Up Agreement, and (C) such Transfer would not require any filing under Section 16(a) of the Exchange
Act and no such filing is voluntarily made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of this Lock-Up Agreement,
&ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage, or adoption, not more remote than the first cousin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
Undersigned agrees that, prior to engaging in any transaction or taking any other action that is subject to the terms of this Lock-Up
Agreement (for the avoidance of doubt, excluding any transaction or other action in connection with a Transfer permitted hereunder) during
the period from the date hereof to and including the 15 days following the expiration of the Lock-Up Period, the undersigned will give
notice thereof to the Company and will not consummate any such transaction or take any such action unless it has received written confirmation
from the Company that the Lock-Up Period has expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Undersigned agrees that the
foregoing restrictions shall be equally applicable to any issuer-directed or &ldquo;friends and family&rdquo; Common Stock that the Undersigned
may purchase in the Offering. If the Undersigned is an officer or director of the Company, (i) the Representative shall notify the Company
of the impending release or waiver substantially in the form of <U>Exhibit A</U> at least three (3) business days before the effective
date of any release or waiver of the foregoing restrictions in connection with a Transfer of Shares, the Representative will notify the
Company of the impending release or waiver, and (ii) the Company shall announce the impending release or waiver by issuing a press release
substantially in the form of <U>Exhibit B</U> hereto through a major news service at least two (2) business days before the effective
date of such release or waiver. Any release or waiver granted by the Representative hereunder to any such officer or director shall only
be effective two (2) business days after the publication date of such press release. The provisions of this paragraph will not apply if
(a) the release or waiver is effected solely to permit a Transfer not for consideration, and (b) the transferee has agreed in writing
to be bound by the same terms described in this Lock-Up Agreement to the extent and for the duration that such terms remain in effect
at the time of the Transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Undersigned, whether or not
participating in the Offering, understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the
Offering in reliance upon this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Undersigned hereby represents
and warrants that the Undersigned has full power and authority to enter into this Lock-Up Agreement and that this Lock-Up Agreement has
been duly authorized (if the Undersigned is not a natural person) and constitutes the legal, valid, and binding obligation of the Undersigned,
enforceable in accordance with its terms. Upon request, the Undersigned will execute any additional documents that the Underwriters deem
necessary in connection with the enforcement hereof. Any obligations of the Undersigned shall be binding upon the successors and assigns
of the Undersigned from the date of this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Lock-Up Agreement shall be
delivered to the Representative prior to the execution of the Underwriting Agreement and shall automatically terminate upon the earliest
to occur, if any, of (1) either the Representative, on the one hand, or the Company, on the other hand, advising the other in writing,
they have determined not to proceed with the Offering, (2) termination of the Underwriting Agreement before the sale of Common Stock,
(3) the withdrawal of the Registration Statement, or (4) the termination of the Offering prior to the sale of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Lock-Up Agreement shall be
governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.
No legal suit, action or proceeding arising out of or relating to this Lock-Up Agreement or the transactions contemplated hereby (each,
a &ldquo;<B>Related Proceeding</B>&rdquo;) may be commenced, prosecuted or continued in any court other than the courts of the State of
New York located in the City and County of New York or in the United States District Court for the Southern District of New York, which
courts (collectively, the &ldquo;<B>Specified Courts</B>&rdquo;) shall have jurisdiction over the adjudication of any Related Proceeding,
and the Undersigned hereby irrevocably consent to the exclusive jurisdiction the Specified Courts and personal service of process with
respect thereto. The Undersigned hereby irrevocably waive any objection to the laying of venue of any Related Proceeding in the Specified
Courts and irrevocably waive and agree not to plead or claim in any Specified Court that any Related Proceeding brought in any Specified
Court has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Delivery of a signed copy of this
Lock-Up Agreement by facsimile or e-mail/.pdf transmission shall be effective as the delivery of the original hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours, </FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature:</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Name (printed):</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Title (if applicable):</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Entity (if applicable): </I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM OF WAIVER OF&nbsp;LOCK-UP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.75in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">[Name and Address of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Officer or Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Requesting Waiver]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dear Mr./Ms.&nbsp;[Name]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">This letter is being delivered
to you in connection with the offering by Advanced Biomed Inc. (the &ldquo;<B>Company</B>&rdquo;) of [&#9679;] Common Stock, and the&nbsp;lock-up&nbsp;agreement
dated&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2025 (the &ldquo;<B>Lock-up&nbsp;Agreement</B>&rdquo;), executed by you in connection
with such offering, and your request for a [waiver] [release] dated&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
20[&#9679;], with respect to [&#9679;] shares of Common Stock (the &ldquo;<B>Shares</B>&rdquo;). Capitalized terms used herein but not
otherwise defined has the meaning given to such terms in the Lock-up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">The undersigned hereby agree
to [waive] [release] the transfer restrictions set forth in the&nbsp;Lock-up&nbsp;Agreement, but only with respect to the Shares, effective&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
20[&#9679;]; provided, however, that such [waiver] [release] is conditioned on the Company announcing the impending [waiver] [release]
by press release through a major news service at least two business days before effectiveness of such [waiver] [release]. This letter
will serve as notice to the Company of the impending [waiver] [release].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">Except as expressly [waived]
[released] hereby, the&nbsp;Lock-up&nbsp;Agreement shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acting severally on behalf of themselves and the several Underwriters named in Schedule A of the Underwriting Agreement </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRAFT CAPITAL MANAGEMENT LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">cc: Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form of Press Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Advanced Biomed Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[&#9679;], 202[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advanced Biomed Inc. (the &ldquo;Company&rdquo;) announced
today that CRAFT CAPITAL MANAGEMENT LLC, acting as representative for the underwriters in the Company&rsquo;s recent Offering of [&#9679;]
of the Company&rsquo;s Common Stock, is [waiving] [releasing] a lock-up restriction with respect to [&#9679;] Common Stock held by [certain
officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on [&#9679;], 20[&#9679;], and
the securities may be sold on or after such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>This press release is not an offer or sale of the
securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not be offered
or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>EXHIBIT B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form of Representative&rsquo;s Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 45; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>vc051_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THE SECURITIES UNDERLYING THIS REPRESENTATIVE&rsquo;S
WARRANT ARE SUBJECT TO A LOCK-UP PERIOD OF ONE HUNDRED AND EIGHTY (180) DAYS BEGINNING ON THE DATE OF COMMENCEMENT OF SALES OF THE OFFERING
PURSUANT TO THE REGISTRATION STATEMENT OF THE COMPANY (FILE NO. 333-272110). THE REGISTERED HOLDER OF THIS REPRESENTATIVE&rsquo;S WARRANT
BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS REPRESENTATIVE&rsquo;S WARRANT EXCEPT AS HEREIN PROVIDED
AND THE REGISTERED HOLDER OF THIS REPRESENTATIVE&rsquo;S WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE
THIS REPRESENTATIVE&rsquo;S WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS FOLLOWING THE COMMENCEMENT OF THE SALE OF THE COMPANY&rsquo;S
COMMON STOCK, PAR VALUE $0.001 PER SHARE, PURSUANT TO THE REGISTRATION STATEMENT OF THE COMPANY&rsquo;S SECURITIES (FILE NO. 333-272110)
TO ANYONE OTHER THAN (I) CRAFT CAPITAL MANAGEMENT LLC, OR A REPRESENTATIVE OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II)
A BONA FIDE OFFICER OR PARTNER OF CRAFT CAPITAL MANAGEMENT LLC, OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER AND IN ACCORDANCE WITH FINRA
RULE 5110(E)(2).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>THIS REPRESENTATIVE&rsquo;SWARRANT IS NOT EXERCISABLE
PRIOR TO [&#9679;], 2025. VOID AFTER 5:00 P.M., EASTERN TIME, [&#9679;], 2030.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM OF REPRESENTATIVE&rsquo;S&nbsp;WARRANT<BR>
FOR THE PURCHASE OF [&#9679;] SHARES OF COMMON STOCK<BR>
OF<BR>
ADVANCED BIOMED INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representative&rsquo;s
Warrant</U>. THIS CERTIFIES THAT, pursuant to that certain Underwriting Agreement by and between ADVANCED BIOMED INC., a Nevada corporation
(the &ldquo;<B>Company</B>&rdquo;) and CRAFT CAPITAL MANAGEMENT LLC (the &ldquo;<B>Holder</B>&rdquo;), dated as of [&#9679;], 2025 (the
&ldquo;<B>Underwriting Agreement</B>&rdquo;), the Holder, as registered owner of this Purchase Warrant, is entitled, at any time and from
time to time, during the four and half year period commencing six months from the commencement of sales of the Offering, <I>i.e.,</I>
from [&#9679;], 2025 (the &ldquo;<B>Exercise Date</B>&rdquo;), to [&#9679;], 2030 (the &ldquo;<B>Expiration Date</B>&rdquo;), at or before
5:00 p.m., Eastern time, but not thereafter, to subscribe for, purchase, and receive, in whole or in part, up to such number of Common
Stock representing six percent (6%) of the aggregate number of shares of Common Stock sold in the Offering, including any Additional Shares
sold upon exercise of the Over-allotment Option, subject to adjustment as provided in <U>Section 6</U> hereof. If the Expiration Date
is a day on which banking institutions are authorized by law or executive order to close, then this Representative&rsquo;s Warrant may
be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period commencing on the
date hereof and ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This
Representative&rsquo;s Warrant is initially exercisable at $[&#9679;] per share of Common Stock (which is equal to one hundred and twenty
five percent (125%) of the price of the shares of Common Stock sold in the Offering); <I>provided, however,</I> that upon the occurrence
of any of the events specified in <U>Section 6</U> hereof, the rights granted by this Representative&rsquo;s Warrant, including the exercise
price per share of Common Stock and the number of Common Stock to be received upon such exercise, shall be adjusted as therein specified.
The term &ldquo;<B>Exercise Price</B>&rdquo; shall mean the initial exercise price as set forth above or the adjusted exercise price as
a result of the events set forth in <U>Section 6</U> below, depending on the context. Capitalized terms not defined herein shall have
the meaning ascribed to them in the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD><U>Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Form</U>. In order to exercise this Representative&rsquo;s Warrant, the exercise form attached hereto as <U>Exhibit A</U> must be duly
executed and completed and delivered to the Company, together with this Representative&rsquo;s Warrant and payment of the Exercise Price
for the Common Stock being purchased payable in cash by wire transfer of immediately available funds to an account designated by the Company
or by certified check or official bank check to the order of the Company. If the subscription rights represented hereby shall not be exercised
at or before 5:00 p.m., Eastern Time, on the Expiration Date, this Representative&rsquo;s Warrant shall become and be void without further
force or effect, and all rights represented hereby shall cease and expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless
Exercise</U>. At any time after the Exercise Date and in lieu of exercising this Representative&rsquo;s Warrant by payment of cash until
the Expiration Date, the Holder may elect to receive the number of Common Stock equal to the value of this Representative&rsquo;s Warrant
(or the portion thereof being exercised), by surrender of this Representative&rsquo;s Warrant to the Company, together with the exercise
form attached hereto, in which event the Company shall issue to Holder shares of Common Stock in accordance with the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD ROWSPAN="2" STYLE="width: 7%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD ROWSPAN="2" STYLE="width: 4.62%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">= </FONT></TD>
    <TD STYLE="vertical-align: top; width: 6.54%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Y(A-B)</FONT></TD>
    <TD STYLE="vertical-align: top; width: 7.26%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 74.58%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7.76%; text-align: justify"><FONT STYLE="font-size: 10pt">Where,</FONT></TD>
    <TD STYLE="width: 1.92%; text-align: justify"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 1.5%; text-align: justify"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="width: 88.82%; text-align: justify"><FONT STYLE="font-size: 10pt">The number of shares of Common Stock to be issued to Holder;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Y</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The number of shares of Common Stock for which the Representative&rsquo;s Warrant is being exercised;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The fair market value of one (1) share of Common Stock; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Exercise Price.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">For purposes of this <U>Section 2.2</U>, the &ldquo;fair
market value&rdquo; of a share of Common Stock is defined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 18pt">(i)</TD><TD STYLE="text-align: justify">if the Common Stock are traded on a national securities exchange, the value shall be deemed to be the
weighted average of the closing price on such exchange for the five (5) consecutive trading days ending on the day immediately prior to
the exercise form being submitted in connection with the exercise of the Representative&rsquo;s Warrant; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.7pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 18pt">(ii)</TD><TD STYLE="text-align: justify">if the Common Stock are actively traded over-the-counter, the value shall be deemed to be the weighted
average price of the Common Stock for the five (5) consecutive trading days ending on the trading day immediately prior to the exercise
form being submitted in connection with the exercise of the Representative&rsquo;s Warrant; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.7pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 18pt">(iii)</TD><TD STYLE="text-align: justify">if there is no market for the shares of Common Stock, the value shall be the fair market value thereof,
as determined in good faith by the Company&rsquo;s Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.7pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Le</U>g<U>end</U>.
Each certificate for the securities purchased under this Representative&rsquo;s Warrant shall bear the following legends unless such securities
have been registered under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;) or are exempt from registration
under the Securities Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt">(i)</TD><TD STYLE="text-align: justify">&ldquo;THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD ENDING ON, AND INCLUDING,
THE DATE THAT IS ONE HUNDRED AND EIGHTY (180) DAYS BEGINNING ON THE COMMENCEMENT OF THE SALES OF THE COMPANY&rsquo;S COMMON STOCK, PAR
VALUE $0.001 PER SHARE, PURSUANT TO THE REGISTRATION STATEMENT OF THE COMPANY&rsquo;S SECURITIES (FILE NO. 333-272110) AND MAY NOT BE
(A) SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED TO ANYONE OTHER THAN CRAFT CAPITAL MANAGEMENT LLC, OR BONA FIDE OFFICERS OR PARTNERS
OF CRAFT CAPITAL MANAGEMENT LLC, OR (B) CAUSED TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT OR CALL TRANSACTION THAT
WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THE SECURITIES HEREUNDER, EXCEPT AS PROVIDED FOR IN FINRA RULE 5110(E)(2).&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt">(ii)</TD><TD STYLE="text-align: justify">Any legend required by the securities laws of any state to the extent such laws are applicable to the
Common Stock represented by a certificate, instrument, or book entry so legended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.4 <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(i) <I>Delivery of Shares Upon Exercise</I>.
The Company shall cause the shares of Common Stock purchased hereunder to be transmitted by the transfer agent to the Holder by crediting
the account of the Holder&rsquo;s prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system
(&ldquo;<B>DWAC</B>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration statement
permitting the issuance of the shares of Common Stock or resale of the shares of Common Stock or (B) this Representative&rsquo;s Warrant
is being exercised via cashless exercise, or otherwise by delivery to the address specified by the Holder in the exercise form by the
date that is one (1) trading day after the latest of (A) the delivery to the Company of the exercise form, (B) surrender of this Representative&rsquo;s
Warrant (if required), and (C) receipt by the Company of the aggregate Exercise Price as set forth above (including by cashless exercise,
if permitted) (such date, the &ldquo;<B>Share Delivery Date</B>&rdquo;). The shares of Common Stock shall be deemed to have been issued,
and the Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares
of Common Stock for all purposes, as of the date the Representative&rsquo;s Warrant has been exercised and payment to the Company of the
aggregate Exercise Price (or by cashless exercise, if permitted) has been received by the Company and all taxes required to be paid by
the Holder, if any, pursuant to <U>Section 2.4(iv)</U> prior to the issuance of such shares of Common Stock have been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(ii) <I>Rescission Rights</I>. If
the Company fails to cause its transfer agent to transmit to the Holder the shares of Common Stock pursuant to <U>Section 2.4(i)</U> by
the Share Delivery Date, unless such failure was not caused by the fault or negligence of the Company, then the Holder will have the right
to rescind such exercise upon written notice to the Company within one (1) trading day after the Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(iii) <I>Compensation for Buy-In
on Failure to Timely Deliver Shares Upon Exercise</I>. In addition to any other rights available to the Holder, if the Holder has taken
all actions necessary under the terms of this Representative&rsquo;s Warrant for such Holder to receive the shares of Common Stock, if
the Company fails to cause the transfer agent to transmit to the Holder the shares of Common Stock pursuant to an exercise on or before
the Share Delivery Date, unless such failure was not caused by the fault or negligence of the Company, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases,
shares of Common Stock to deliver in satisfaction of a sale by the Holder of the which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions and any other applicable fees, if any) for the shares of Common Stock so purchased
exceeds (y) the amount obtained by multiplying (1) the number of shares of Common Stock that the Company was required to deliver to the
Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was
executed, and (B) at the option of the Holder, either reinstate the portion of the Representative&rsquo;s Warrant and equivalent number
of shares of Common Stock for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to
the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery
obligations hereunder. The Holder shall provide the Company with written notice indicating the amounts payable to the Holder in respect
of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Representative&rsquo;s
Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(iv) <I>Charges, Taxes and Expenses</I>.
Issuance of shares of Common Stock shall be made without charge to the Holder for any issue or transfer tax or other incidental expense
in respect of the issuance of such shares of Common Stock, all of which taxes and expenses shall be paid by the Company, and such shares
of Common Stock shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <I>provided</I>,
<I>however</I>, that, in the event shares of Common Stock are to be issued in a name other than the name of the Holder, this Representative&rsquo;s
Warrant when surrendered for exercise shall be accompanied by the form of the Assignment Notice attached hereto as <U>Exhibit B</U> duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer
tax incidental thereto. The Company shall pay all transfer agent fees required for processing of any exercise form to satisfy the required
Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><U>Transfer</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Restrictions</U>. The registered Holder of this Representative&rsquo;s Warrant agrees by his, her or its acceptance hereof, that such
Holder will not: (a) sell, transfer, assign, pledge or hypothecate this Representative&rsquo;s Warrant or any of the shares of Common
Stock exercisable hereunder for a period ending on, and including, the date that is one hundred and eighty (180) days beginning on the
commencement of sales of the Offered Securities (the &ldquo;<B>Effective Date</B>&rdquo;) to anyone other than: (i) the Holder or another
underwriter or a selected dealer participating in the Offering, or (ii) a bona fide officer or partner or registered persons or affiliates,
of the Representative or of any such underwriter or selected dealer, in each case in accordance with FINRA Rule 5110(e)(1) and subject
to the exceptions set forth in FINRA Rule 5110(e)(2), or (b) cause this Representative&rsquo;s Warrant or the securities issuable hereunder
to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition
of this Representative&rsquo;s Warrant or the securities issuable hereunder, in accordance with FINRA Rule 5110(e)(1), except as provided
for in FINRA Rule 5110(e)(2). On and after the Effective Date, transfers to others may be made subject to compliance with or exemptions
from applicable securities laws. In order to make any permitted assignment, the Holder must deliver to the Company the form of the Assignment
Notice attached hereto as <U>Exhibit B</U> duly executed and completed, together with this Representative&rsquo;s Warrant and payment
of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) business days transfer this Representative&rsquo;s
Warrant on the books of the Company and shall execute and deliver a new warrant or purchase warrants of like tenor to the appropriate
assignee(s) expressly evidencing the right to purchase the aggregate number of Common Stock purchasable hereunder or such portion of such
number as shall be contemplated by any such assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions
Imposed by the Securities Act</U>. The securities evidenced by this Representative&rsquo;s Warrant shall not be transferred unless and
until: (i) the Company has received the opinion of counsel for the Company that such securities may be transferred pursuant to an exemption
from registration under the Securities Act and applicable state securities laws, the availability of which is established to the reasonable
satisfaction of the Company, (ii) a registration statement or a post-effective amendment to the Registration Statement relating to the
offer and sale of such securities that has been declared effective by the U.S. Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
and includes a current prospectus, or (iii) a registration statement, pursuant to which the Holder has exercised its registration rights
pursuant to <U>Sections 4.1 and 4.2</U> herein, relating to the offer and sale of such securities has been filed and declared effective
by the Commission and compliance with applicable state securities law has been established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><U>Re</U>g<U>istration Ri</U>g<U>hts</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Demand
Registration</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">4.1.1 Grant of Right.
Unless all of the Warrant Shares are included in an effective registration statement with a current prospectus or a qualified offering
statement with a current registration statement, the Company, upon written demand (a &ldquo;<B>Demand Notice</B>&rdquo;) of the Holder,
agrees to register, on one occasion, all or any portion of the Warrant Shares that are permitted to be registered under the Securities
Act. On such occasion, the Company will file a new registration statement or post-effective amendment to the registration statement with
the Commission (a &ldquo;<B>Demand Registration Statement</B>&rdquo;) covering such Warrant Shares within sixty (60) days after receipt
of a Demand Notice and use its best efforts to have the registration statement declared effective promptly thereafter, subject to compliance
with review by the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice if the Company
has filed a registration statement with respect to which the Holder is entitled to piggyback pursuant to <U>Section 4.2</U> hereof and
either: (i) the Holder has elected to participate in the offering covered by such registration statement; or (ii) if such registration
statement relates to an underwritten primary offering of securities of the Company, until the offering covered by such registration statement
has been withdrawn or until thirty days after such offering is consummated. The demand for registration may be made at any time during
a period of five years beginning on the date of commencement of sales of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">4.1.2 Terms. The Company
shall bear all fees and expenses attendant to the Demand Registration Statement pursuant to <U>Section 4.1.1</U>, but the Holder(s) shall
pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holder(s) to represent the Holder(s) in
connection with the sale of the Warrant Shares. The Company agrees to use its best efforts to cause the filing of a Demand Registration
Statement required herein to become effective promptly and to qualify or register the Warrant Shares in such states as are reasonably
requested by the Holder(s); provided, however, that in no event shall the Company be required to register the Warrant Shares in a state
in which such registration would cause: (i) the Company to be obligated to register or license to do business in such State or submit
to general service of process in such State, or (ii) the principal stockholders of the Company to be obligated to escrow their Common
Stock of the Company. The Holder(s) shall only use the prospectuses provided by the Company to sell the shares of Common Stock covered
by such registration statement, and will immediately cease to use any prospectus furnished by the Company if the Company advises the Holder(s)
that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding the provisions of this <U>Section
4.1.2</U>, the Holder(s) shall be entitled to a Demand Registration Statement under this <U>Section 4.1.2</U> on only one occasion and
such demand registration right shall terminate on the fifth anniversary of the commencement of sales of the Offering in accordance with
FINRA Rule 5110(g)(8)(C). The Company shall cause any registration statement or post-effective&nbsp;amendment filed pursuant to the demand
rights granted under&nbsp;<U>Section 4.1.1</U><I>&nbsp;</I>to remain&nbsp;effective&nbsp;for a period of twelve (12) consecutive months
from the&nbsp;effective&nbsp;date of such registration statement or post-effective&nbsp;amendment or until the Holders have completed
the distribution of the Warrant Shares registered under such Registration Statement, whichever occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&ldquo;Piggy-Back&rdquo;
Registration</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">4.2.1 Grant of Right.
Unless all of the Warrant Shares are included in an effective registration statement with a current prospectus or a qualified offering
statement with a current offering circular, the Holder shall have the right, for a period of five years commencing on the date of commencement
of sales of the Offering, to include the remaining Warrant Shares as part of any other registration of securities filed by the Company
(other than in connection with a transaction contemplated by Rule 145 promulgated under the Securities Act or pursuant to Form S-3 or
any equivalent form).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">4.2.2 Terms. The Company
shall bear all fees and expenses attendant to registering the Warrant Shares pursuant to <U>Section 4.2.1</U> hereof, but the Holder(s)
shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holder(s) to represent them in connection
with the sale of the Warrant Shares. In the event of such a proposed registration, the Company shall furnish the then Holders of outstanding
Warrant Shares with not less than 30 days&rsquo; written notice prior to the proposed date of filing of such registration statement. Such
notice to the Holder(s) shall continue to be given for each registration statement filed by the Company until such time as all of the
Warrant Shares have been registered under an effective registration statement. The holders of the Warrant Shares shall exercise the &ldquo;piggy-back&rdquo;
rights provided for herein by giving written notice, within ten days of the receipt of the Company&rsquo;s notice of its intention to
file a registration statement. Except as otherwise provided in this Representative&rsquo;s Warrant, there shall be no limit on the number
of times the Holder may request registration under this <U>Section 4.2.2</U>. Notwithstanding the provisions of this <U>Section 4.2.2</U>,
such piggyback registration rights shall terminate on the fifth anniversary of the commencement of sales of the Offering in accordance
with FINRA Rule 5110(g)(8)(D).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall use its best efforts to maintain the effectiveness of the registration statement and a current prospectus relating to the
registration of the Warrant Shares until (i) all Warrant Shares have been disposed of pursuant to such effective registration statement,
(ii) all Warrant Shares are sold under circumstances in which all of the applicable conditions of Rule 144 under the Securities Act are
met, or (iii) all Warrant Shares become and remain eligible for sale pursuant to Rule 144 without volume or manner-of-sale restrictions
and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144(c)(1).
During any period when the Company fails to have maintained an effective Registration Statement or a current Prospectus relating thereto
and a holder of this Representative&rsquo;s Warrant desires to exercise such warrant and, in the opinion of counsel to the Holder, Rule
144 is not available as an exemption from registration for the resale of the Warrant Shares, the Company shall promptly file a registration
statement registering the resale of such Warrant Shares and use its reasonable best efforts to have it declared effective by the Commission
within thirty (30) days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><U>New Purchase Warrants to be Issued</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Partial
Exercise or Transfer</U>. Subject to the restrictions in <U>Section 3</U> hereof, this Representative&rsquo;s Warrant may be exercised
or assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Representative&rsquo;s
Warrant for cancellation, together with the duly executed exercise form or assignment notice and funds sufficient to pay any Exercise
Price and/or transfer tax if exercised pursuant to <U>Section 2.1</U> hereof, the Company shall cause to be delivered to the Holder without
charge a new Representative&rsquo;s Warrant of like tenor to this Representative&rsquo;s Warrant in the name of the Holder evidencing
the right of the Holder to purchase the number of Common Stock purchasable hereunder as to which this Representative&rsquo;s Warrant has
not been exercised or assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lost
Certificate</U>. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction, or mutilation of this Representative&rsquo;s
Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Representative&rsquo;s
Warrant of like tenor and date. Any such new Representative&rsquo;s Warrant executed and delivered as a result of such loss, theft, mutilation
or destruction shall constitute a substitute contractual obligation on the part of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><U>Ad</U>j<U>ustments</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments
to Exercise Price and Number of shares of Warrant Shares</U>. The Exercise Price and the number of shares of Common Stock underlying this
Representative&rsquo;s Warrant shall be subject to adjustment from time to time as hereinafter set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">6.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Share
Dividends, Split Ups</U>. If, after the date hereof, and subject to the provisions of <U>Section 6.3</U> below, the number of outstanding
Common Stock is increased by a stock dividend payable in Common Stock or by a split up of Common Stock or other similar event, then, on
the effective day thereof, the number of Warrant Shares purchasable hereunder shall be increased in proportion to such increase in outstanding
Common Stock, and the Exercise Price shall be proportionately decreased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">6.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Aggregation
of Shares of Common Stock</U>. If, after the date hereof, and subject to the provisions of <U>Section 6.3</U> below, the number of outstanding
Common Stock is decreased by a consolidation, combination or reclassification of Common Stock or other similar event, then, on the effective
date thereof, the number of Warrant Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding shares,
and the Exercise Price shall be proportionately increased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">6.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Common Stock upon Reorganization, etc</U>. In case of any reclassification or reorganization of the outstanding Common Stock other
than a change covered by <U>Section 6.1.1</U> or <U>Section 6.1.2</U> hereof or that solely affects the par value of such Common Stock,
or in the case of any share reconstruction or amalgamation or consolidation of the Company with or into another corporation (other than
a consolidation or share reconstruction or amalgamation in which the Company is the continuing corporation and that does not result in
any reclassification or reorganization of the outstanding Common Stock), or in the case of any sale or conveyance to another corporation
or entity of the property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved,
the Holder of this Representative&rsquo;s Warrant shall have the right thereafter (until the expiration of the right of exercise of this
Representative&rsquo;s Warrant ) to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately
prior to such event, the kind and amount of Common Stock or other securities or property (including cash) receivable upon such reclassification,
reorganization, share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such sale or transfer, by
a Holder of the number of Warrant Shares of the Company obtainable upon exercise of this Representative&rsquo;s Warrant immediately prior
to such event; and if any reclassification also results in a change in Common Stock covered by <U>Section 6.1.1</U> or <U>Section 6.1.2</U>,
then such adjustment shall be made pursuant to <U>Section 6.1.1</U>, <U>Section 6.1.2</U> and this <U>Section 6.1.3</U>. The provisions
of this <U>Section 6.1.3 </U>shall similarly apply to successive reclassifications, reorganizations, share reconstructions or amalgamations,
or consolidations, sales or other transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">6.1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction.</U> If, at any time while this Representative&rsquo;s Warrant is outstanding, the Company enters into the following transactions
with another Person or group of Persons whereby such other Person or group acquires more than fifty percent (50%) of the outstanding Common
Stock (not including any Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with,
the other Persons making or party to such stock or share purchase agreement or other business combination): (i) the Company, directly
or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)
the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance, or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any direct or indirect purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent (50%) or
more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spinoff or scheme of arrangement) with another Person or group of Persons (each a &ldquo;<B>Fundamental Transaction</B>&rdquo;),
then, upon any subsequent exercise of this Representative&rsquo;s Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, the number
of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional or
alternative consideration (the &ldquo;<B>Alternative Consideration</B>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of Common Stock for which this Representative&rsquo;s Warrant is exercisable immediately prior to such Fundamental
Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternative Consideration based on the amount of Alternative Consideration issuable in respect of one (1) share of Common Stock in such
Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternative Consideration in a reasonable manner
reflecting the relative value of any different components of the Alternative Consideration. If holders of Common Stock are given any choice
as to the securities, cash, or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as
to the Alternative Consideration it receives upon any exercise of this Representative&rsquo;s Warrant following such Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<B>Successor
Entity</B>&rdquo;) to assume in writing all of the obligations of the Company under this Representative&rsquo;s Warrant, and to deliver
to the Holder in exchange for this Representative&rsquo;s Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Representative&rsquo;s Warrant which is exercisable for a corresponding number of
shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Common Stock acquirable and receivable upon
exercise of this Representative&rsquo;s Warrant prior to such Fundamental Transaction, and with an exercise price which applies the Exercise
Price hereunder to such shares of capital stock (but taking into account the relative value of the Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the
purpose of protecting the economic value of this Representative&rsquo;s Warrant immediately prior to the consummation of such Fundamental
Transaction). Furthermore, the foregoing adjustment of Exercise Price in consideration of the Alternative Consideration should be completed
prior to the issuance of and reflected in the security of the Successor Entity issued in exchange for this Representative&rsquo;s Warrant.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and
after the date of such Fundamental Transaction, the provisions of this Representative&rsquo;s Warrant and the other transaction documents
referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of, the Company
and shall assume all of the obligations of the Company, under this Representative&rsquo;s Warrant and the other transaction documents
with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">6.1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes
in Form of Representative&rsquo;s Warrant</U>. This Representative&rsquo;s Warrant need not be changed because of any change pursuant
to this <U>Section 6.1</U> and any warrants issued after such change, in exchange or replacement of this Representative&rsquo;s Warrant
may state the same Exercise Price and the same number of Warrant Shares as are stated in the Representative&rsquo;s Warrant s initially
issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new warrant s reflecting a required or permissive change
shall not be deemed to waive any rights to an adjustment occurring after the date hereof or the computation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Substitute
Representative&rsquo;s Warrant</U>. Except as otherwise provided in <U>Section 6.1.5,</U> in case of any consolidation of the Company
with, or share reconstruction or amalgamation of the Company with or into, another corporation (other than a consolidation or share reconstruction
or amalgamation which does not result in any reclassification or change of the outstanding Common Stock), the corporation formed by such
consolidation or share reconstruction or amalgamation shall execute and deliver to the Holder a supplemental Representative&rsquo;s Warrant
providing that the holder of the Representative&rsquo;s Warrant then outstanding or to be outstanding shall have the right thereafter
(until the stated expiration of this Representative&rsquo;s Warrant ) to receive, upon exercise of such supplemental Warrant, the kind
and amount of Common Stock and other securities and property receivable upon such consolidation or share reconstruction or amalgamation,
by a holder of the number of Common Stock of the Company for which such Representative&rsquo;s Warrant might have been exercised immediately
prior to such consolidation, share reconstruction or amalgamation, sale, or transfer. Such supplemental Representative&rsquo;s Warrant
shall provide for adjustments which shall be identical to the adjustments provided for in this <U>Section 6</U>. The above provisions
of this <U>Section 6</U> shall similarly apply to successive consolidations or share reconstructions or amalgamations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Elimination
of Fractional Interests</U>. The Company shall not be required to issue certificates representing fractions of Common Stock upon the exercise
of this Representative&rsquo;s Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being
the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may be, to
the nearest whole number of Common Stock or other securities, properties, or rights, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to <U>Section 6.1.1</U> above, if at any time during which this Representative&rsquo;s
Warrant is outstanding the Company grants, issues or sells any securities of the Company which by their terms are convertible into or
exercisable for shares of Common Stock (&ldquo;<B>Share Equivalents</B>&rdquo;) or other rights to purchase shares, warrants, other securities
or other property, pro rata to all of the record holders of the shares of Common Stock (the &ldquo;<B>Purchase Rights</B>&rdquo;), and
not the Holder, then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase
Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Representative&rsquo;s Warrant immediately before the date on which a record is taken for the grant, issuance or sale of such
Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights. The provisions of this <U>Section 6.4</U> will not apply to any grant, issuance
or sale of Share Equivalents or other rights to purchase shares, warrants, other securities or other property of the Company which is
not made pro rata to all of the record holders of shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
and Listing</U>. The Company shall at all times reserve and keep available out of its authorized Common Stock, solely for the purpose
of issuance upon exercise of this Representative&rsquo;s Warrant, such number of Common Stock or other securities, properties or rights,
as applicable, as shall be issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of this Representative&rsquo;s
Warrant and payment of the Exercise Price therefor (either with cash or through cashless exercise pursuant to <U>Section 2.2</U> hereof),
in accordance with the terms hereby, all Common Stock issuable upon such exercise shall be duly and validly issued, fully paid, and non-assessable
and not subject to preemptive rights of any shareholder. The Company further covenants and agrees that upon exercise of this Representative&rsquo;s
Warrant and payment of the exercise price therefor (either with cash or through cashless exercise pursuant to <U>Section 2.2</U> hereof),
all Common Stock and other securities, as applicable, issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable
and not subject to preemptive rights of any shareholder. As long as this Representative&rsquo;s Warrant shall be outstanding, the Company
shall use its commercially reasonable efforts to cause all Warrant Shares and other securities, as applicable, issuable upon exercise
of this Representative&rsquo;s Warrant to be listed (subject to official notice of issuance) on all national securities exchanges (or,
if applicable, on the OTCQB Market or any successor quotation system) on which the Common Stock issued to the public in the Offering may
then be listed and/or quoted (if at all).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><U>Certain Notice Requirements</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">8.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Right to Receive Notice</U>. Nothing herein shall be construed as conferring upon the Holder the right to vote or consent or to receive
notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the
Company. If, however, at any time prior to the expiration of the Representative&rsquo;s Warrant and its exercise thereof, any of the events
described in <U>Section 8.2</U> shall occur, then, in one or more of said events, the Company shall give written notice to the Holder
of such event at least fifteen (15) days prior to the date fixed as a record date, effective date or the date of closing the transfer
books (the &ldquo;<B>Notice Date</B>&rdquo;) for the determination of the stockholders entitled to such dividend, distribution, conversion
or exchange of securities or subscription rights, or entitled to vote on such proposed reclassification, consolidation, merger, compulsory
share exchange, dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing of
the transfer books, as the case may be along with the proposed effective date of the event triggering such notice. Notwithstanding the
foregoing, if such information not otherwise publicly available the Company shall deliver to the Holder a copy of each notice given to
the other stockholders of the Company at the same time and in the same manner that such notice is given to the stockholders stating (x)
the date on which a record is to be taken for the purpose of any such dividend, distribution, redemption, rights or warrants, or if a
record is not to be taken, the date as of which the holders of the shares Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the shares Common
Stock of record shall be entitled to exchange their shares Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; <I>provided</I> that the failure to provide such notice or any defect therein
or in the provision thereof shall not affect the validity of the corporate action required to be specified in such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">8.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Events
Requiring Notice</U>. The Company shall be required to give the notice described in this <U>Section 8</U> upon one or more of the following
events: (i) if the Company shall take a record of the holders of its Common Stock for the purpose of entitling them to receive a dividend
or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as
indicated by the accounting treatment of such dividend or distribution on the books of the Company, (ii) the Company shall offer to all
the holders of its Common Stock any additional shares of capital stock of the Company or securities convertible into or exchangeable for
shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) if the approval of any stockholders
of the Company shall be required in connection with any reclassification, any consolidation or merger to which the Company is a party,
or any compulsory share exchange whereby the shares of Common Stock are converted into other securities, cash or property, or (iv) a dissolution,
liquidation or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a
sale of all or substantially all of its property, assets and business shall be proposed. The Holder shall remain entitled to exercise
this Representative&rsquo;s Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein. Notwithstanding the foregoing, no notice need be given to the Holder
if the Company makes a public announcement of the applicable event via nationally distributed press release or via a publicly available
and legally compliant filing with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">8.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Change in Exercise Price; Notice of Exercise Price</U>. The Company shall, promptly after an event requiring a change in the Exercise
Price pursuant to <U>Section 6</U> hereof, send notice to the Holder of such event and change (&ldquo;<B>Price Notice</B>&rdquo;). The
Price Notice shall set forth the Exercise Price after such adjustment and any resulting adjustment to the number of shares of Common Stock
and describe the event causing the change and the method of calculating same and shall be certified as being true and accurate by the
Company&rsquo;s Chief Executive Officer and Chief Financial Officer. The Company shall, within five (5) business days after receipt by
the Company of a written request by the Holder, send notice, in the manner as set forth in the Underwriting Agreement, including by email,
to the Holder of the Exercise Price then in effect and the number of shares of Common Stock or the amount, if any, of other shares, securities
or assets then issuable upon exercise of this Representative&rsquo;s Warrant and shall be certified as being true and accurate by the
Company&rsquo;s Chief Executive Officer and Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">8.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transmittal
of Notices</U>. All notices, requests, consents, and other communications under this Representative&rsquo;s Warrant shall be in writing
and shall be deemed to have been duly made if made in accordance with the notice provisions of the Underwriting Agreement to the addresses
and contact information set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><B>If to the Holder:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">Craft Capital Management LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">377 Oak Street, Lower Concourse</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">Garden City, NY, 11530</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">Attn: Stephen Kiront, COO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="font-size: 10pt">Email: </FONT>skiront@craftcm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><B>With a copy to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">Ortoli Rosenstadt LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">366 Madison Avenue, 3rd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">Attn: William S. Rosenstadt, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: 0.5in">Mengyi &ldquo;Jason&rdquo; Ye, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">Email: wsr@orllp.legal; jye@orllp.legal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">Phone No.: (212) 588-0022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><B>If to the Company:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">689-85 Xiaodong Road, Yongkang District<BR>
Tainan, Taiwan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0.5in">Attn: Yi Lu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">Email: [&mdash;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><B>With a copy (which shall not constitute notice) to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0.5in">VCL Law LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0.5in">1945 Old Gallows Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0.5in">Suite 260</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0.5in">Vienna, VA 22182</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0.5in">Attn: Fang Liu, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">Email: fliu@vcllegal.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>.
This Representative&rsquo;s Warrant may not be amended or modified unless in writing by all of the parties hereto, and no condition herein
(express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning
or interpretation of any of the terms or provisions of this Representative&rsquo;s Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
A</U>g<U>reement</U>. <FONT STYLE="background-color: white">This Representative&rsquo;s Warrant (together with the other agreements and
documents being delivered pursuant to or in connection with this Representative&rsquo;s Warrant ) constitutes the entire agreement of
the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings of the parties, oral
and written, with respect to the subject matter hereof. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Representative&rsquo;s Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the
Company and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Representative&rsquo;s Warrant or any
provisions herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding
Effect</U>. This Representative&rsquo;s Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company
and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Representative&rsquo;s Warrant or any
provisions herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law; Submission to Jurisdiction; Trial by Jur</U>y. This Representative&rsquo;s Warrant shall be governed by, construed, and enforced
in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby
agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Representative&rsquo;s Warrant shall
be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District
of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection
to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process or summons to be served upon the Company
may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to
it at the address set forth in <U>Section 8</U> hereof. Such mailing shall be deemed as personal service and shall be legal and binding
upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing party(ies) in any such action
shall be entitled to recover from the other party(ies) all of its reasonable attorneys&rsquo; fees and expenses relating to such action
or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by
applicable law, on behalf of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted
by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Representative&rsquo;s
Warrant or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver,
etc</U>. The failure of the Company or the Holder to, at any time, enforce any of the provisions of this Representative&rsquo;s Warrant
shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Representative&rsquo;s
Warrant, any provision hereof, or the right of the Company or any Holder to thereafter enforce each and every provision of this Representative&rsquo;s
Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Representative&rsquo;s Warrant shall
be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver
is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other
or subsequent breach, non-compliance or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Agreement</U>. As a condition of the Holder&rsquo;s receipt and acceptance of this Representative&rsquo;s Warrant, Holder agrees that,
at any time prior to the complete exercise of this Representative&rsquo;s Warrant by Holder, if the Company and the Underwriter enter
into an agreement pursuant to which they agree that all outstanding warrant(s) of the Company held by the Representative will be exchanged
for securities or cash or a combination of both (such, an &ldquo;<B>Exchange Agreement</B>&rdquo;), then Holder shall agree to such exchange
and become a party to the Exchange Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution
in Counterparts</U>. This Representative&rsquo;s Warrant may be executed in one or more counterparts, and by the different parties hereto
in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the
same agreement and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to
each of the other parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder
Not Deemed a Shareholder</U>. Except as otherwise specifically provided herein, the Holder, solely in its capacity as a holder of this
Representative&rsquo;s Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company
for any purpose, nor shall anything contained in this Representative&rsquo;s Warrant be construed to confer upon the Holder, solely in
its capacity as the Holder of this Representative&rsquo;s Warrant, any of the rights of a shareholder of the Company or any right to vote,
give or withhold consent to any corporate action (whether any reorganization, issue of share, reclassification of share, consolidation,
merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance
to the Holder of the Warrant Shares which it is then entitled to receive upon the due exercise of this Representative&rsquo;s Warrant.
In addition, nothing contained in this Representative&rsquo;s Warrant shall be construed as imposing any liabilities on the Holder to
purchase any securities (upon exercise of this Representative&rsquo;s Warrant or otherwise) or as a shareholder of the Company, whether
such liabilities are asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Common Stock acquired upon the exercise of this Representative&rsquo;s Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">9.12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severabilit</U>y.
Wherever possible, each provision of this Representative&rsquo;s Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Representative&rsquo;s Warrant shall be prohibited by or invalid under applicable law,
such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision
or the remaining provisions of this Representative&rsquo;s Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.15in; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Company has caused this Representative&rsquo;s Warrant to be signed by its duly authorized officer as of the ____ day of _______,
2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.15in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADVANCED BIOMED INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Yi Lu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exercise Form</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Form to be used to exercise Representative&rsquo;s Warrant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: __________, 20___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned hereby elects
irrevocably to exercise the Representative&rsquo;s Warrant for ______ Common Stock of ADVANCED BIOMED INC., a Nevada corporation (the
&ldquo;<B>Company</B>&rdquo;) and hereby makes payment of $____ (at the rate of $____ per share of Common Stock) in payment of the Exercise
Price pursuant thereto. Please issue the Common Stock as to which this Representative&rsquo;s Warrant is exercised in accordance with
the instructions given below and, if applicable, a new Representative&rsquo;s Warrant representing the number of Common Stock for which
this Representative&rsquo;s Warrant has not been exercised. Capitalized terms not defined herein shall have the meaning ascribed to them
in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned hereby elects
irrevocably to convert its right to purchase ___ Common Stock under the Representative&rsquo;s Warrant for ______ Common Stock, as determined
in accordance with the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR>
    <TD STYLE="vertical-align: top; width: 38.45pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="width: 82pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;X</FONT></TD>
    <TD ROWSPAN="2" STYLE="width: 15.95pt"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 196.05pt; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Y(A-B)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 149.45pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Where,</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">The number of Common Stock to be issued to Holder;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Y</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">The number of Common Stock for which the Representative&rsquo;s Warrant is being exercised;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">The fair market value of one (1) share of Common Stock which is equal to $_____; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">The Exercise Price which is equal to $______ per share of Common Stock</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned agrees and acknowledges
that the calculation set forth above is subject to confirmation by the Company and any disagreement with respect to the calculation shall
be resolved by the Company in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please issue the Common Stock
as to which this Representative&rsquo;s Warrant is exercised in accordance with the instructions given below and, if applicable, a new
Representative&rsquo;s Warrant representing the number of Common Stock for which this Representative&rsquo;s Warrant has not been converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Craft Capital Management LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">[Signature]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 0.75pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">[Signature Guaranteed]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">INSTRUCTIONS FOR REGISTRATION OF
SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Print in Block Letters)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOTICE: The signature to this
form must correspond with the name as written upon the face of the Representative&rsquo;s Warrant without alteration or enlargement or
any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Assignment Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Form to be used to assign Representative&rsquo;s Warrant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(To be executed by the registered Holder to effect a transfer of the within
Representative&rsquo;s Warrant):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FOR VALUE RECEIVED, _______________does hereby sell,
assign and transfer the Assignee named below all of the rights of the undersigned the right to purchase ______ Common Stock of ADVANCED
BIOMED INC., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), evidenced by the Representative&rsquo;s Warrant and does hereby
authorize the Company to transfer such right on the books of the Company with respect to the number of shares of Common Stock set forth
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of Assignee</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address and Phone Number</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of Shares</B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">The undersigned also represents that, by
assignment hereof, the Assignee acknowledges that this Representative&rsquo;s Warrant and the shares of Common Stock to be issued upon
exercise hereof or conversion thereof are being acquired for investment and that the Assignee will not offer, sell or otherwise dispose
of this Representative&rsquo;s Warrant or any shares of Common Stock to be issued upon exercise hereof or conversion thereof except under
circumstances which will not result in a violation of the Securities Act of 1933, as amended, or any state securities laws. Further, the
Assignee has acknowledged that upon exercise of this Representative&rsquo;s Warrant, the Assignee shall, if requested by the Company,
confirm in writing, in a form satisfactory to the Company, that the shares of Common Stock so purchased are being acquired for investment
and not with a view toward distribution or resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dated: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Holder&rsquo;s Signature: _____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Holder&rsquo;s Address:&#8239;&#8239; _____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Signature Guaranteed: ___________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOTICE: The signature to this
form must correspond with the name as written upon the face of the within Representative&rsquo;s Warrant without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange. Officers of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Representative&rsquo;s Warrant.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>vc051_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Exhibit 5.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; font-size: 10pt"><IMG SRC="vc051_ex5-1img01.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; width: 3%">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">9275 W. Russell Road, Suite 240 <BR>
Las Vegas, Nevada&nbsp;&nbsp;89148 <BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif">PH</FONT> (702) 692-8026 <FONT STYLE="font-family: Times New Roman, Times, Serif">| FX </FONT>(702) 692-8075 <BR>
fennemorelaw.com </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">January 7, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">689-85 Xiaodong Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yongkang District</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tainan, Taiwan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left"><B><I>Re:</I></B></TD><TD STYLE="text-align: justify"><B><I>Advanced Biomed Inc./Registration Statement on Form S-1</I></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as special Nevada
counsel to Advanced Biomed Inc., a Nevada corporation (the &ldquo;Company&rdquo;), in connection with the registration by the Company
of up to 4,160,625 shares of its common stock, $0.001 par value per share (the &ldquo;Common Stock&rdquo;) including: (a) up to 1,875,000
shares of its Common Stock (the &ldquo;Firm Shares&rdquo;) on a firm commitment basis; (b) up to 281,250 shares of its Common Stock (the
&ldquo;Additional Shares&rdquo; and, collectively with the Firm Shares, the &ldquo;Offered Securities&rdquo;) in connection with an over-allotment
option granted to the underwriters (the &ldquo;Over-Allotment Option&rdquo;); (c) up to 129,375 shares of its Common Stock (the &ldquo;Warrant
Shares&rdquo;) to be issued upon exercise of Common Stock Purchase Warrants (the &ldquo;Representative&rsquo;s Warrant&rdquo;) granted
to the underwriters in connection with the issuance of the Offered Securities; and (d) up to 1,875,000 shares of its Common Stock (the
&ldquo;Selling Stockholder Shares&rdquo;) to be sold by certain selling stockholders (collectively, the &ldquo;Selling Stockholders&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Offered Securities, the
Representative&rsquo;s Warrants, the Representative&rsquo;s Warrant Shares, and the Selling Stockholder Shares (collectively, the &ldquo;Securities&rdquo;)
are to be offered under a Registration Statement on Form S-1 Registration No. 333-272110 (the &ldquo;Registration Statement&rdquo;) in
accordance with the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), as filed with the Securities and Exchange Commission
(the &ldquo;Commission&rdquo;) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Offered Securities, the
Representative&rsquo;s Warrants, and the Representative&rsquo;s Warrant Shares are being offered, sold, and issued under the terms of
an Underwriting Agreement (the &ldquo;Underwriting Agreement&rdquo;) by and between the Company and Craft Capital Management LLC, acting
as the representative of the several underwriters. The Selling Stockholder Shares were issued to the Selling Stockholders and other persons
pursuant to a Debt-For-Equity Swap Agreement dated June 30, 2022 (the &ldquo;Swap Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="vc051_ex5-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 7, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of these opinions,
we have examined originals or copies, certified or otherwise identified to our satisfaction, of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Registration Statement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">a form of Underwriting Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">a form of Representative&rsquo;s Warrant;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">the Swap Agreement; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">certain resolutions and actions of the Board of Directors of the
Company relating to the issuance of the Securities and registration of the Securities under the Securities Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have obtained from officers
of the Company and from public officials, and have relied upon, such certificates, representations, and assurances as we have deemed necessary
and appropriate for purposes of rendering this opinion letter. We have also examined such other corporate charter and other documents,
records, certificates, and instruments (collectively with the documents identified in (a) through (d) above, the &ldquo;Documents&rdquo;)
as we deem necessary or advisable to render the opinions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our examination, we have
assumed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the legal capacity of all natural persons executing the Documents;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the genuineness of all signatures on the Documents;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the authenticity of all Documents submitted to us as originals,
and the conformity to original documents of all Documents submitted to us as copies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">that the parties to such Documents, other than the Company, had
the power, corporate or other, to enter into and perform all obligations thereunder;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">other than with respect to the Company, the due authorization
by all requisite action, corporate or other, of the Documents;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">the execution, delivery, and performance by all parties of the
Documents; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">that all Documents are valid, binding, and enforceable against
the parties thereto.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have relied upon the accuracy and completeness of the information,
factual matters, representations, and warranties contained in such Documents. We note that the Company has reserved, and assume that it
will continue to reserve, sufficient authorized shares of its Common Stock to allow for the issuance of the Offered Shares pursuant to
the terms of the Underwriting Agreement and exercise of
the Over-Allotment Option, as applicable; and the issuance of the Representative&rsquo;s Warrant Shares upon exercise of the Representative&rsquo;s
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="vc051_ex5-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 7, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opinions expressed below
are limited to the matters specifically set forth herein and no other opinion shall be inferred beyond the matters expressly stated. We
disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed for purposes of delivering these opinions
expressed herein or any changes in applicable law that may come to our attention after the date the Registration Statement is declared
effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the basis of the foregoing
and in reliance thereon, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the issuance of the Offered Securities has been duly authorized
and upon issuance in accordance with the terms of the Underwriting Agreement and the Over-Allotment Option, as applicable, the Offered
Securities will be validly issued, fully paid, and nonassessable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the issuance of the Representative&rsquo;s Warrant Shares has
been duly authorized and upon issuance of the Representative&rsquo;s Warrant Shares upon exercise of and in accordance with the terms
of the Representative&rsquo;s Warrant, the Representative&rsquo;s Warrant Shares will be validly issued, fully paid, and nonassessable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the issuance of the Selling Stockholder Shares was duly authorized
and such Selling Stockholder Shares were validly issued and are fully paid and non-assessable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While certain members of this
firm are admitted to practice in certain jurisdictions other than Nevada, in rendering the foregoing opinions we have not examined the
laws of any jurisdiction other than Nevada. Accordingly, we express no opinion regarding the effect of the laws of any other jurisdiction
or state, including any federal laws. The opinions we express herein are limited solely to the laws of the State of Nevada, other than
the securities laws and regulations of the State of Nevada as to which we express no opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hereby consent to the filing
of this opinion as an exhibit to the Registration Statement and we consent to the reference of our name under the caption &ldquo;Legal
Matters&rdquo; in the Registration Statement. In giving the foregoing consent, we do not hereby admit that we are in the category of
persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="vc051_ex5-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 7, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; padding-right: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">/s/ Fennemore Craig, P.C.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-transform: uppercase">Fennemore Craig, P.C.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>5
<FILENAME>vc051_ex5-2.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="vc051_ex5-2img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">1945 Old Gallows Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Suite 260</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Vienna, VA 22182</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">(301) 760-7393</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 7, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 235.5pt 0pt 0"><B>Advanced Biomed Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 235.5pt 0pt 0">689-85 Xiaodong Road, Yongkang District</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 235.5pt 0pt 0">Tainan, Taiwan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 235.5pt 0pt 5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 123.1pt 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as United States counsel to Advanced
Biomed Inc., a company incorporated under the laws of the State of Nevada (the &ldquo;Company&rdquo;), in connection with the registration
statement on Form S-1 initially filed with the U.S. Securities and Exchange Commission (the &ldquo;Commission&rdquo;) on May 22, 2023,
as amended (the &ldquo;Registration Statement&rdquo;), under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).
The Registration Statement relates to the following securities of the Company: (i) 1,875,000 shares (the &ldquo;Firm Shares&rdquo;) of
the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), (ii) up to 281,250 Common Stock, issuable
upon the exercise of an over-allotment option granted to Craft Capital Management LLC, the underwriter named in the underwriting agreement
(the &ldquo;Over-Allotment Shares,&rdquo; and together with the &ldquo;Firm Shares,&rdquo; the &ldquo;Offered Shares&rdquo;), (iii) warrants
exercisable to purchase additional Common Stock in an amount equal to 6% of the Offered Shares (the &ldquo;Warrants&rdquo;), (iv) the
Common Stock underlying the Warrants (the &ldquo;Warrants Shares&rdquo;), and (v) up to 1,875,000 Common Stock offered by certain selling
stockholders. The Firm Shares, Over-Allotment Shares, and Warrant Shares are collectively referred to herein as the &ldquo;Securities.&rdquo;
This opinion is being given in accordance with the Legal Matters section of the Registration Statement, as it pertains to the portions
of New York law set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In rendering the opinions set forth below, we
have assumed that (i) all information contained in all documents reviewed by us is true and correct; (ii) all signatures on all documents
examined by us are genuine; (iii) all documents submitted to us as originals are authentic and all documents submitted to us as copies
conform to the authentic originals of such documents; (iv) each natural person signing any document reviewed by us had the legal capacity
to do so; and (v) the certificates representing the Securities will be duly executed and delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also assumed that (i) the Company has
been duly incorporated, and is validly existing and in good standing; (ii) the Company has requisite legal status and legal capacity under
the laws of the jurisdiction of its incorporation, (iii) the Company has complied and will comply with all aspects of the laws of the
jurisdiction of its incorporation, in connection with the transactions contemplated by, and the performance of its obligations under the
Warrants; (iv) the Company has the corporate power and authority to execute, deliver and perform all its obligations under the Warrants;
(v) the Warrants have been duly authorized by all requisite corporate action on the part of the Company; (vi) except to the extent expressly
stated in the opinions contained herein, the opinions stated herein are limited to the agreements specifically identified in the Exhibit
1.1 Form of Underwriting Agreement (the &ldquo;Underwriting Agreement&rdquo;), and the Exhibit 4.1 Form of Representative&rsquo;s Warrant
(the &ldquo;Form of Warrant&rdquo;) to the Registration Statement without regard to any agreement or other document referenced in such
agreement (including agreements or other documents incorporated by reference or attached or annexed thereto); (vii) as provided in Section
9 of the Form of Warrant, all questions concerning the construction, validity, enforcement and interpretation of the Warrants shall be
governed by the internal laws of the State of New York, without regard to the principles of conflicts of law thereof; (viii) service of
process will be effected in the manner and pursuant to the methods of the State of New York at the time such service is effected; and
(ix) at the time of exercise of the Warrants, a sufficient number of Common Stock that have been reserved by the Company&rsquo;s board
of directors or a duly authorized committee thereof will be authorized and available for issuance and that the consideration for the issuance
and sale of the Warrants Shares in connection with such exercise is in an amount that is not less than the par value of such Common Stock.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this matter, we have examined
the Registration Statement, including the exhibits thereto, and such other documents, corporate records, and instruments and have examined
such laws and regulations as we have deemed necessary for purposes of rendering the opinions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are members of the Bar of the State of New
York. We do not hold ourselves out as being conversant with, or expressing any opinion with respect to, the laws of any jurisdiction other
than the federal laws of the United States of America and the laws of the State of New York. Accordingly, the opinions expressed herein
are expressly limited to the federal laws of the United States of America and the laws of the State of New York and are based on these
laws as in effect on the date hereof. <FONT STYLE="background-color: white">We are not rendering any opinion as to the compliance with
any other federal or state law, rule or regulation relating to securities, or to the sale or issuance thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon and subject to the foregoing, we are
of the opinion that <FONT STYLE="background-color: white">when the Registration Statement becomes effective under the Securities Act of
1933, as amended, and when the Warrants have been duly executed and authenticated in accordance with the Underwriting Agreement and issued,
delivered, as contemplated by the Registration Statement and the Underwriting Agreement,</FONT> such Warrants will constitute valid and
binding obligations of the Company in accordance with their terms under the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinions set forth above with respect to the
validity or binding effect of any security or obligation may be limited by (i) bankruptcy, insolvency, reorganization, fraudulent conveyance,
marshaling, moratorium or other similar laws affecting the enforcement generally of the rights and remedies of creditors and secured parties
or the obligations of debtors, (ii) general principles of equity (whether considered in a proceeding in equity or at law), including,
but not limited to, principles limiting the availability of specific performance or injunctive relief, and concepts of materiality, reasonableness,
good faith and fair dealing, (iii) the possible unenforceability under certain circumstances of provisions providing for indemnification,
contribution, exculpation, release or waiver that may be contrary to public policy or violative of federal or state securities laws, rules
or regulations, and (iv) the effect of course of dealing, course of performance, oral agreements or the like that would modify the terms
of an agreement or the respective rights or obligations of the parties under an agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter speaks only as of the date
hereof and we assume no obligation to update or supplement this opinion letter if any applicable laws change after the date of this opinion
letter or if we become aware after the date of this opinion letter of any facts, whether existing before or arising after the date hereof,
that might change the opinions expressed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter is furnished in connection
with the Registration Statement and may not be relied upon for any other purpose without our prior written consent in each instance. Further,
no portion of this letter may be quoted, circulated or referred to in any other document for any other purpose without our prior written
consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this opinion
as an exhibit to the Registration Statement and to the use of our name as it appears under the caption &ldquo;Legal Matters&rdquo; in
the Registration Statement. In giving such consent, we do not thereby admit that we come within the category of persons whose consent
is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder. This opinion
is expressed as of the date hereof unless otherwise expressly stated, and we disclaim any undertaking to advise you of any subsequent
changes in the facts stated or assumed herein or of any subsequent changes in applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.45pt">&nbsp;</TD>
    <TD STYLE="width: 40%; padding-right: 0.45pt">Very truly <FONT STYLE="letter-spacing: -0.1pt">yours,</FONT></TD>
    <TD STYLE="width: 10%; padding-right: 0.45pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.45pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.45pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.45pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ VCL Law LLP</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><B>VCL LAW <FONT STYLE="letter-spacing: -0.25pt">LLP</FONT></B></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>vc051_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM
OF EMPLOYMENT AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
EMPLOYMENT AGREEMENT (the &ldquo;Agreement&rdquo;) is entered into as of November 1, 2022, by and between ADVANCED BIOMED INC., a Nevada
State corporation (the &ldquo;Company&rdquo;) and Mingze Yin an individual (the &ldquo;the Executive&rdquo;). Except
with respect to the direct employment of the Executive by the Company. the term &quot;Company&quot; as used herein with respect to all
obligations of the Executive hereunder shall be deemed to include the Company and all of its subsidiaries and affiliated entities (collectively,
the &ldquo;Group&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECITALS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company desires to employ the Executive as its Chief Financial Officer to assure itself of the services of the Executive during
the term of Employment (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Executive desires to be employed by the Company as its Chief Financial Officer during the term of Employment and upon the terms
and conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">POSITION</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Executive hereby accepts a position of Chief Financial Officer (the &ldquo;Employment&rdquo;) of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DUTIES
    AND RESPONSIBILITIES</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive&rsquo;s duties at the Company will include all jobs assigned by the Company&rsquo;s Board of the Directors (the &ldquo;Board&rdquo;).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive shall devote all of his working time, attention and skills to the performance of his duties at the Company and shall faithfully
    and diligently serve the Company in accordance with this Agreement. the Certificate of Incorporation and Bylaws of the Company. as
    amended and restated from time to time (the &quot;Charter Documents&quot;). and the guidelines. policies and procedures of the Company
    approved from time to time by the Board.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive shall use his best efforts to perform his duties hereunder. The Executive shall not, without the prior written consent
    of the Board, become an employee of any entity other than the Company and any subsidiary or affiliate of the Company. and shall not
    be concerned or interested in any business or entity that engages in the same business in which the Company engages (any such business
    or entity, a &ldquo;Competitor&rdquo;), provided that nothing in this clause shall preclude the Executive from holding any shares
    or other securities of any Competitor that is listed on any securities exchange or recognized securities market anywhere if such
    shares or securities represent less than 5% of the competitors outstanding shares and securities. The Executive shall notify the
    Company in writing of his interest in such shares or securities in a timely manner and with such details and particulars as the Company
    may reasonably require.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
    BREACH OF CONTRACT</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Executive hereby represents to the Company that: (i) the execution and delivery of this Agreement by the Executive and the performance
by the Executive of the Executive's duties hereunder shall not constitute a breach of, or otherwise contravene, the terms of any other
agreement or policy to which the Executive is a party or otherwise bound, except for agreements entered into by and between the Executive
and any member of the Group pursuant to applicable law, if any; (ii) that the Executive has no information (including, without limitation,
confidential information and trade secrets) relating to any other person or entity which would prevent, or be violated by, the Executive
entering into this Agreement or carrying out his duties hereunder; (iii) that the Executive is not bound by any confidentiality, trade
secret or similar agreement (other than this) with any other person or entity except for other member(s) of the Group, as the case may
be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPENSATION
    AND BENEFITS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Base
    Salary</U>. The Executive's base salary shall be USD20,000.00 annually, paid&nbsp;by&nbsp;the&nbsp;Group&nbsp;in
    accordance with the Company's regular payroll practices, and such compensation is subject to annual review and adjustment by the
    Board.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bonus</U>.
    The Executive shall be eligible for Bonuses determined by the Board.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equity
    Incentives</U>. To the extent the Company adopts and maintains a share incentive plan, the Executive will be eligible to participate
    in such plan pursuant to the terms thereof as determined by the Board.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&nbsp;Benefits</U>.
    The Executive is eligible for participation in any standard employee benefit plan of Company that currently exists or may be adopted
    by the Company in the future, including, but not limited to, any retirement plan, life insurance plan, health insurance plan and
    travel/holiday plan.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses</U>.
    The Executive shall be entitled to reimbursement by the Company for all reasonable ordinary and necessary travel and other expenses
    incurred by the Executive in the performance of his duties under this Agreement; provided that he properly accounts for such expenses
    in accordance with the Company's policies and procedures.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERMINATION
    OF THE AGREEMENT</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>By
    the Company</U>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>For Cause</U>. The Company may terminate the Employment for cause, at any time, without notice or remuneration (unless notice or remuneration
is specifically required by applicable law, in which case notice or remuneration will be provided in accordance with applicable law),
if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Executive is convicted or pleads guilty to a felony or to an act of fraud, misappropriation or embezzlement,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Executive has been grossly negligent or acted dishonestly to the detriment of the Company,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Executive has engaged in actions amounting to willful misconduct or failed to perform his duties hereunder and such failure continues
    after the Executive is afforded a reasonable opportunity to cure such failure; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Executive violates Section 7 of this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination for cause, the Executive shall be entitled to the amount of base salary earned and not paid prior to termination. However,
the Executive will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination, and the
Executive's right to all other benefits will terminate, except as required by any applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>For death and disability</U>. The Company may also terminate the Employment, at any time, without notice or remuneration (unless notice
or remuneration is specifically required by applicable law, in which case notice or remuneration will be provided in accordance with
applicable law), if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Executive has died, or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
the Executive has a disability which shall mean a physical or mental impairment which, as reasonably determined by the Board, renders
the Executive unable to perform the essential functions of his employment with the Company, with or without reasonable accommodation,
for more than 120 days in any 12-month period, unless a longer period 1s required by applicable law, in which case that longer period
would apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination for death or disability, the Executive shall be entitled to the amount of base salary earned and not paid prior to termination.
However, the Executive will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination,
and the Executive's right to all other benefits will terminate, except as required by any applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
<U>Without Cause</U>. The Company may terminate the Employment without cause, at any time, upon a prior written notice. Upon termination
without cause, the Company shall provide the following severance payments and benefits to the Executive: (1) a lump sum cash payment
equal to 12 months of the Executive's base salary as of the date of such termination; (2) a lump sum cash payment equal to a pro rated
amount of his target annual bonus for the year immediately preceding the termination, if any; (3) payment of premiums for continued health
benefits under the Company's health plans for 12 months following the termination, if any; and (4) immediate vesting of 100% of the then-unvested
portion of any outstanding equity awards held by the Executive. Upon termination without, the Executive shall be entitled to the amount
of base salary earned and not paid prior to termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
<U>Change of Control Transaction</U>. If the Company or its successor terminates the Employment upon a merger, consolidation, or transfer
or sale of all or substantially all of the assets of the Company with or to any other individual(s) or entity (the <U>&quot;Change of
Control Transaction</U>&quot;), the Executive shall be entitled to the following severance payments and benefits upon such termination:
(I) a lump sum cash payment equal to 12 months of the Executive's base salary at a rate equal to the greater of his/her annual salary
in effect immediately prior to the termination, or his/her then current annua1 salary as of the date of such termination; (2) a lump
sum cash payment equal to a pro-rated amount of his/her target annual bonus for the year immediately preceding the termination; and (3)
immediate vesting of I 00% of the then-unvested portion of any outstanding equity awards held by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>By
    the Executive</U>. The Executive may terminate the Employment at any time with a prior written notice to the Company, if (1) there
    is a material reduction in the Executive's authority, duties and responsibilities, or (2) there is a material reduction in the Executive's
    annual salary. Upon the Executive's termination of the Employment due to either of the above reasons, the Company shall provide compensation
    to the Executive equivalent to 12 months of the Executive's base salary that he is entitled to immediately prior to such termination.
    In addition, the Executive may resign prior to the expiration of the Agreement if such resignation is approved by the Board or an
    alternative arrangement with respect to the Employment is agreed to by the Board.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
    of Termination</U>. Any termination of the Executive's employment under this Agreement shall be communicated by written notice of
    termination from the terminating party to the other party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIALITY
    AND NON-DISCLOSURE</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Confidentiality
    and Non-disclosure</U>. The Executive hereby agrees at all times during the term of the Employment and after his termination, to
    hold in the strictest confidence, and not to use, except for the benefit of the Company, or to disclose to any person, corporation
    or other entity without prior written consent of the Company, any Confidential Information. The Executive understands that &quot;<U>Confidential
    Information</U>&quot; means any proprietary or confidential information of the Company, its affiliates, or their respective clients,
    customers or partners, including, without limitation, technical data, trade secrets, research and development information, product
    plans, services, customer lists and customers, supplier lists and suppliers, software developments, inventions, processes, formulas,
    technology, designs, hardware configuration infom1ation, personnel information, marketing, finances, information about the suppliers,
    joint ventures, franchisees, distributors and other persons with whom the Company does business, information regarding the skills
    and compensation of other employees of the Company or other business information disclosed to the Executive by or obtained by the
    Executive from the Company, its affiliates, or their respective clients, customers or partners, either directly or indirectly, in
    writing, orally or otherwise, if specifically indicated to be confidential or reasonably expected to be confidential. Notwithstanding
    the foregoing, Confidential Information shall not include information that is generally available and known to the public through
    no fault of the Executive.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company
    Property</U>. The Executive understands that all documents (including computer records, facsimile and e-mail) and materials created,
    received or transmitted in connection with his work or using the facilities of the Company are property of the Company and subject
    to inspection by the Company at any time. Upon termination of the Executive's employment with the Company (or at any other time when
    requested by the Company), the Executive will promptly deliver to the Company all documents and materials of any nature pertaining
    to his work with the Company and will provide written certification of his compliance with this Agreement. Under no circumstances
    will the Executive have, following his termination, in his possession any property of the Company, or any documents or materials
    or copies thereof containing any Confidential Information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Former
    Employer Information</U>. The Executive agrees that he has not and will not, during the term of his employment, (i) improperly use
    or disclose any proprietary information or trade secrets of any former employer or other person or entity with which the Executive
    has an agreement or duty to keep in confidence information acquired by Executive, if any, or (ii) bring into the premises of the
    Company any document or confidential or proprietary information belonging to such former employer, person or entity unless consented
    to in writing by such former employer, person or entity. The Executive will indemnify the Company and hold it harmless from and against
    all claims, liabilities, damages and expenses, including reasonable attorneys' fees and costs of suit, arising out of or in connection
    with any violation of the foregoing.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Third
    Party Information</U>. The Executive recognizes that the Company may have received, and in the future may receive, from third parties
    their confidential or proprietary information subject to a duty on the Company's part to maintain the confidentiality of such information
    and to use it only for certain limited purposes. The Executive agrees that the Executive owes the Company and such third parties,
    during the Executive's employment by the Company and thereafter, a duty to hold all such confidential or proprietary information
    in the strictest confidence and not to disclose it to any person or firm and to use it in a manner consistent with, and for the limited
    purposes permitted by, the Company's agreement with such third party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Section 7 shall survive the termination of this Agreement for any reason. In the event the Executive breaches this Section 7, the Company
shall have right to seek remedies pem1issible under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFLICTING
    EMPLOYMENT.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Executive hereby agrees that, during the term of his employment with the Company, he or she will not engage in any other employment,
occupation, consulting or other business activity related to the business in which the Company is now involved or becomes involved during
the term of the Executive's employment, nor will the Executive engage in any other activities that conflict with his obligations to the
Company without the prior written consent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITHHOLDING
    TAXES</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything else herein to the contrary, the Company may withhold (or cause there to be withheld, as the case may be) from any amounts otherwise
due or payable under or pursuant to this Agreement such national, provincial, local or any other income, employment, or other taxes as
may be required to be withheld pursuant to any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSIGNMENT</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement is personal in its nature and neither of the parties hereto shall, without the consent of the other, assign or transfer this
Agreement or any rights or obligations hereunder; provided, however, that (i) the Company may assign or transfer this Agreement or any
rights or obligations hereunder to any member of the Group without such consent, and (ii) in the event of a Change of Control Transaction,
this Agreement shall, subject to the provisions hereof, be binding upon and inure to the benefit of such successor and such successor
shall discharge and perform all the promises, covenants, duties, and obligations of the Company hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SEVERABILITY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any provision of this Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or applications
of this Agreement which can be given effect without the invalid provisions or applications and to this end the provisions of this Agreement
are declared to be severable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENTIRE
    AGREEMENT</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement constitutes the entire agreement and understanding between the Executive and the Company regarding the terms of the Employment
and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter, including any prior agreements
between the Executive and a member of the Group. The Executive acknowledges that he or she has not entered into this Agreement in reliance
upon any representation, warranty or undertaking which is not set forth in this Agreement. Any amendment to this Agreement must be in
writing and signed by the Executive and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GOVERNING
    LAW; JURISDICTION</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be governed by and construed in accordance with the laws of the Nevada State.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMENDMENT</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may not be amended, modified or changed (in whole or in part), except by a formal, definitive written agreement expressly referring
to this Agreement, which agreement is executed by both of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WAIVER</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the failure nor any delay on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall operate
as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other or further
exercise of the same or of any right, remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with
respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No
waiver shall be effective unless it is in writing and is signed by the party asserted to have granted such waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICES</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices, requests, demands and other communications required or permitted under this Agreement shall be in writing and shall be deemed
to have been duly given and made if (i) delivered by hand, (ii) otherwise delivered against receipt therefor, or (iii) sent by a recognized
courier with next-day or second-day delivery to the last known address of the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COUNTERPARTS</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature
appears thereon, and all of which together shall constitute one and the same instrument. This Agreement shall become binding when one
or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the
signatories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Photographic
copies of such signed counterparts may be used in lieu of the originals for any purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
    INTERPRETATION AGAINST DRAFTER</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party recognizes that this Agreement is a legally binding contract and acknowledges that it, he or she has had the opportunity to consult
with legal counsel of choice. In any construction of the terms of this Agreement, the same shall not be construed against either party
on the basis of that party being the drafter of such terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[remainder
of this page left intentionally blank]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, this Agreement has been executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Yi Lu </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi
    Lu</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">/s/Mingze Yin</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0pt 0">Mingze Yin</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>7
<FILENAME>vc051_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***] Certain information in this document has been excluded pursuant
to Regulation&nbsp;S-K,&nbsp;Item (601)(b)(10). Such excluded information is not material and private.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Advisory Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Party A: Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Party B: LIN CHIEN HUANG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Date of Signing: November 1, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Party A: <U>Advanced Biomed Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Party B (Appointee): <U>LIN CHIEN HUANG</U> Certificate
number: [***]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In view of the work needs of Party A and the professional
level of Party B in the industry, it is voluntary, equal and negotiable to the principle, establish a consulting service relationship,
and sign this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Article 1: Term of Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The duration of the agreement is <U>3</U> years,
from <U>November 1, 2022</U> to <U>October 31, 2025 </U> If you want to continue the employment, you must negotiate <U>3 months</U> in
advance and re-sign the employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Article 2: Engagement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A engages Party B at Advanced Biomed Inc.
as an Advisor, to provide services to Party A (see Article 3 for details), and Party B shall perform service duties according to Party
A's requirements to achieve the goals of the work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Article 3: Service</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Party A hires Party B as Party A's expert Advisor,
and Party B must provide corresponding consulting services according to Party A's needs, the main service content is: <U>Provide consultation
on the company's development plan and overall plan formulation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The main service methods are as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regularly participate in the meetings of the company's
strategic development committee and provide professional guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4: Remuneration </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Party A is responsible for Party B's participation
in the work of the travel expenses and other related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Party A agrees to grant Party B shares within
the range of 0.5% of the total number of issued shares in the first year of listing, and to pay one-third of the above shares at the end
of each service year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. When this agreement is terminated for any reason,
when Party A and Party B have not defaulted, the shares in the preceding paragraph shall be paid in proportion to Party B's term of office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Party B may cede the rights of Party B to a third
party as stipulated in this article, but Party A shall be notified first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Article 5: Post discipline and technical confidentiality
requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Party B confirms that Party A has informed Party
B of the relevant rules and regulations that Party B should comply with, and Party B has fully understood Party A's rules and regulations
and undertake to comply with Party A's rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Party B shall strictly abide by national and local
laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. If Party B violates the rules, regulations, laws
and regulations stipulated in the preceding two items, Party A has the right to unilaterally terminate this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Party B is responsible for keeping Party A's confidential
for any information, documents and data (whether written or electronic) that Party A comes into contact with in the course of work, as
well as any deliverables formed for Party A's services. Without Party A's written consent, Party B shall not provide or disclose to any
third party in any way. After the end of Party B's service, Party B shall return Party A in a timely manner, and the electronic documents
shall be permanently deleted from its own computer and other storage devices. When Party B violates the above confidentiality provisions,
Party B shall bear the corresponding legal responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Article 6: Modification, Termination and Termination
of Employment Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. After the employment agreement is signed in accordance
with the law, both parties to the agreement must fully perform the obligations stipulated in the agreement, neither party shall change
the agreement without authorization, and if it is necessary to change the agreement, the two parties shall reach a consensus and change
the agreement in writing according to the original signing procedure, and if the two parties do not reach an agreement, the original agreement
shall continue to be valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The employment agreement shall be terminated by
itself when the employment agreement expires or the conditions for termination of the agreement agreed by both parties appear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. If Party B has any of the following circumstances,
Party A may terminate the employment agreement without bearing the liability for breach of contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">(1) Seriously violating the relevant
rules and regulations of Party A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">(2) Intentionally failing to
complete the work, causing serious losses to Party A, serious dereliction of duty, malpractice, and causing major damage to Party A &#65307;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">(3) Disclose Party A's trade
secrets (including technical information, business information, marketing network, customer list, etc.). Causes or may cause significant
damage to Party A's interests</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">(4) Those who are investigated
for criminal responsibility in accordance with law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7: Liability for Breach of Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once this agreement is signed, both parties shall
strictly perform, and either party shall bear the liability for breach of contract if it violates the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8: Other matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. In the event of a dispute between Parties A
and B arising out of the implementation of this engagement agreement, they may file a lawsuit in the Taipei District Court of Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. This Agreement shall be made in duplicate,
one copy for each Party A and Party B, and shall take effect after being sealed and signed by both Parties A and B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 7%; text-align: justify"><FONT STYLE="font-size: 10pt">Party A :</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 39%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/
    ADVANCED BIOMED INC.</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 8%; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 7%; text-align: justify"><FONT STYLE="font-size: 10pt">Party B:</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 39%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/
    LIN CHIEN HUANG</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(Signature and Seal)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(Signature and Seal) </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Representative:&nbsp;&nbsp;&nbsp;&nbsp; YI LU </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">LIN CHIEN HUANG </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">November 1, 2022</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Date:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">November 1, 2022 </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>8
<FILENAME>vc051_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***] Certain information in this document has been excluded pursuant
to Regulation&nbsp;S-K,&nbsp;Item (601)(b)(10). Such excluded information is not material and private.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Advisory Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Party A: Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Party B: ZHOU CAICUN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Date of Signing: November 1, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Party A: <U>Advanced Biomed Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Party B (Appointee): <U>ZHOU CAICUN</U> Certificate
number: [***]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In view of the work needs of Party A and the professional
level of Party B in the industry, it is voluntary, equal and negotiable to the principle, establish a consulting service relationship,
and sign this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1: Term of Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The duration of the agreement is <U>&nbsp;&nbsp;3&nbsp;&nbsp;&nbsp;</U>
years, from <U>July 1, 2022</U> to <U>June 30, 2025 </U> If you want to continue the employment, you must negotiate <U>3 months</U> in
advance and re-sign the employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2: Engagement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A engages Party B at Advanced Biomed Inc.
as an Advisor, to provide services to Party A (see Article 3 for details), and Party B shall perform service duties according to Party
A's requirements to achieve the goals of the work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3: Service</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Party A hires Party B as Party A's expert Advisor,
and Party B must provide corresponding consulting services according to Party A's needs, the main service content is: <U>Provide consultation
on the company's development plan and overall plan formulation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The main service methods are as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regularly participate in the meetings of the company's
strategic development committee and provide professional guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4: Remuneration </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Party A is responsible for Party B's travel expenses
and other related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5: Post discipline and technical confidentiality
requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Party B confirms that Party A has informed Party
B of the relevant rules and regulations that Party B should comply with, and Party B has fully understood Party A's rules and regulations
and undertake to comply with Party A's rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Party B shall strictly abide by national and local
laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. If Party B violates the rules, regulations, laws
and regulations stipulated in the preceding two items, Party A has the right to unilaterally terminate this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Party B is responsible for keeping Party A's confidential
for any information, documents and data (whether written or electronic) that Party A comes into contact with in the course of work, as
well as any deliverables formed for Party A's services. Without Party A's written consent, Party B shall not provide or disclose to any
third party in any way. After the end of Party B's service, Party B shall return Party A in a timely manner, and the electronic documents
shall be permanently deleted from its own computer and other storage devices. When Party B violates the above confidentiality provisions,
Party B shall bear the corresponding legal responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6: Modification, Termination and Termination
of Employment Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. After the employment agreement is signed in accordance
with the law, both parties to the agreement must fully perform the obligations stipulated in the agreement, neither party shall change
the agreement without authorization, and if it is necessary to change the agreement, the two parties shall reach a consensus and change
the agreement in writing according to the original signing procedure, and if the two parties do not reach an agreement, the original agreement
shall continue to be valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The employment agreement shall be terminated by
itself when the employment agreement expires or the conditions for termination of the agreement agreed by both parties appear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. If Party B has any of the following circumstances,
Party A may terminate the employment agreement without bearing the liability for breach of contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">(1) Seriously violating the relevant
rules and regulations of Party A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">(2) Intentionally failing to
complete the work, causing serious losses to Party A, serious dereliction of duty, malpractice, and causing major damage to Party A &#65307;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">(3) Disclose Party A's trade
secrets (including technical information, business information, marketing network, customer list, etc.). Causes or may cause significant
damage to Party A's interests</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">(4) Those who are investigated
for criminal responsibility in accordance with law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7: Liability for Breach of Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once this agreement is signed, both parties shall
strictly perform, and either party shall bear the liability for breach of contract if it violates the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8: Other matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. In the event of a dispute between Parties A
and B arising out of the implementation of this engagement agreement, they may file a lawsuit in the People&rsquo;s Court, where Party
A is located.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. This Agreement shall be made in duplicate,
one copy for each Party A and Party B, and shall take effect after being sealed and signed by both Parties A and B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 7%; text-align: justify"><FONT STYLE="font-size: 10pt">Party A :</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 39%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/
    ADVANCED BIOMED INC.</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 8%; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 7%; text-align: justify"><FONT STYLE="font-size: 10pt">Party B:</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 39%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/
    ZHOU CAICUN</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Signature and Seal)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Signature and Seal) </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Representative:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;YI LU </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Zhou Caicun</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">November 1, 2022</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">November 1, 2022 </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>9
<FILENAME>vc051_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="vc051_ex10-5img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***] Certain information in this document has been excluded pursuant
to Regulation&nbsp;S-K,&nbsp;Item (601)(b)(10). Such excluded information is not material and confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>National Taiwan University</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Industry-Academia Cooperation Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">NATIONAL TAIWAN UNIVERSITY (&ldquo;Party A&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">ADVANCED BIOMED INC. (&ldquo;Party B&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B will provide funds for the purpose of
research and development, and entrust Party A to handle the &ldquo;Identifying Novel Biomarkers for Early Detection of Lung Cancer&rdquo;
industry-academia cooperation plan, which will be executed by the project leader designated by Party A. Both Party A and Party B, as well
as the project leader designated by Party A, agree to cooperate in handling the matters related to this contract as agreed, and agree
to establish the following terms and conditions, and fulfill them in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1: The Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the contract period, the project leader
designated by Party A shall provide advisory and consulting services to Party B and participate in Party B&rsquo;s internal meetings at
Party B&rsquo;s invitation, and provide opinions or assist Party B in planning, modifying, or improving product design and development
processes based on their expertise and experience. The plan details are outlined in Annex 1, which is an integral part of this contract
and has the same legal effect as this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2: Term</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of this agreement shall start from April
15, 2023 and end on April 14, 2024, a total of one year. The agreement may be extended for one more year upon written request by Party
B, to be made within one month prior to the expiration of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3: Payment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total amount of funds for agreement is NTD
3 million. This includes 15% of the total amount of funds designated by Party A as management fees. The funds will be disbursed in two
installments by Party B&rsquo;s subsidiary (Advanced Biomed Inc. (Taiwan)) registered in Taiwan to the bank account designated by Party
A after the contract is signed, in the following manner:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">First installment:
Within 30 days after the execution of this agreement, Party B shall pay Party A a1 total of NTD 1.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Second installment: Party B
shall pay a total of NTD 1.5 million on October 15th, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="vc051_ex10-5img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4: Ownership of Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both parties acknowledge that the purpose of this
agreement is for the project leader designated by Party A to provide advisory and consulting services to Party B and does not involve
actual research output. Therefore, any results, such as reports or works produced as a result of executing this agreement (hereinafter
referred to as &quot;research and development results&quot;), shall be attributed to Party A as the author and Party A shall own all copyright.
However, Party B shall enjoy the rights of the funder under Article 12 of the Copyright Law of the Republic of China and may use the research
and development results without limitation on the region, duration, frequency, or method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5: Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. If this agreement cannot continue due to force
majeure or termination of the appointment relationship between Party A and Party B, either party may terminate the agreement at any time.
Party A shall refund the unused funds previously paid by Party B in proportion, without objection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. After the termination of this agreement, the
provisions of Article 4, Article 6, Article 7, and Article 10 of this contract shall remain valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6: Liability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. If any third party accuses Party B of infringement
regarding the &ldquo;research and development results&rdquo; produced by this agreement or Party B&rsquo;s use of the &ldquo;research
and development results,&rdquo; Party B shall promptly notify Party A, and Party A shall fully assist in the necessary defense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. Party A guarantees that the &ldquo;research
and development results&rdquo; produced by this agreement are created independently and without any plagiarism. The main content of the
&ldquo;research and development results&rdquo; is based on Party A&rsquo;s advice or technical guidance provided at any time during the
term of this agreement. Party A guarantees to assist Party B in using the &ldquo;research and development results&rdquo; to the best of
its ability, but does not guarantee the patentability, applicability, or commercialization of the &ldquo;research and development results.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="vc051_ex10-5img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. If Party B suffers specific damages as a result
of being accused of infringement by a third party, and such damages are caused by Party A&rsquo;s act of plagiarism, Party A agrees to
bear the compensation liability for Party B&rsquo;s damages, but Party A&rsquo;s compensation liability shall not exceed 30% of the fee
received by Party B under this contract. If the infringement in the first item is not attributable to Party A, Party B shall be responsible,
but Party A shall make every effort to provide technical identification, consultation and other technical support to assist Party B in
handling the matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7: Confidentiality </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. The &ldquo;confidential information&rdquo;
referred to in this agreement is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(a) Confidential Information
of Party A: including any items, documents, or materials related to the &ldquo;research and development results&rdquo; produced by this
project, which were originally owned by Party A and have been disclosed as a result of the execution of this project, regardless of the
medium to which they are attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(b) Confidential Information
of Party B: including any items, documents, or materials related to this project that were originally owned by Party B and have been disclosed
as a result of the execution of this project, regardless of the medium to which they are attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. The confidentiality obligations of the &ldquo;recipient&rdquo;
under this Article do not include the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(a) Information that the &ldquo;recipient&rdquo;
already possessed prior to obtaining it from the &ldquo;disclosing party&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(b) Information that has been
made public and for which the &ldquo;recipient&rdquo; is not at fault for the disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(c) Information obtained legally
from a third party, and for which that third party has no confidentiality obligation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(d) Information disclosed by
the &ldquo;disclosing party&rdquo; to a third party without a confidentiality obligation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="vc051_ex10-5img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(e) Information developed independently
by the &ldquo;recipient&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(f) Information that must be
disclosed due to legal or government agency requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(g) Information disclosed by
the &ldquo;recipient&rdquo; with the prior written consent of the &ldquo;disclosing party.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. The &ldquo;recipient&rdquo; shall be responsible
for maintaining the confidentiality of the other party's &ldquo;confidential information&rdquo; in a manner consistent with the care of
a prudent manager, and shall not disclose or reveal it to any third party for their own benefit or for the benefit of any third party.
The &ldquo;recipient&rdquo; shall also return, delete, or destroy such information at the request of the &ldquo;disclosing party.&rdquo;
The period of confidentiality obligation shall be five years from the date of receipt of the confidential information or from the date
of Party B's product launch (whichever is later). This period shall be an unchangeable period and shall not be affected by the expiration,
termination, revocation, or invalidation of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8: Public Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Party A or the project leader designated by
Party A intends to publicly disclose the research and development results domestically or internationally, they shall notify Party B in
writing of the content to be disclosed thirty days prior to the publication. Such public disclosure can only be made after obtaining Party
B&rsquo;s written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9: Use of University Name and Protection
of Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. Without the prior written consent of Party
A and relevant government agencies, Party B shall not use the name, emblem or other representation of Party A or relevant government agencies
when using or promoting research and development results for commercial purposes (including but not limited to public marketing, promotion,
or advertising of products, goods, or services), nor shall it in any way imply any connection between Party B and relevant government
agencies or Party A. If Party B intends to use Party A&rsquo;s emblem, it shall follow the procedures set out in the &ldquo;National Taiwan
University Trademark Usage Management Regulations&rdquo; and the &ldquo;National Taiwan University Trademark Usage Application and Management
Rules,&rdquo; and the authorization conditions shall be negotiated separately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. If Party B violates the above provisions, in
addition to compensating Party A for any losses incurred, Party A may terminate this agreement without notice and shall not refund any
fees already collected by Party A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="vc051_ex10-5img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10: Interpretation and Dispute Resolution
of the Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. This agreement shall be interpreted and governed
by the laws of the Republic of China (Taiwan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. Any legal disputes arising from this contract
shall be submitted to arbitration in Taipei with the consent of Party A, and resolved in accordance with the rules of the arbitration
institution and the Arbitration Law of the Republic of China (Taiwan). In the event of litigation, both parties agree to submit to the
jurisdiction of the Taipei District Court as the court of first instance and resolve the dispute in accordance with the laws of the Republic
of China (Taiwan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11: Miscellaneous</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. Any matters not covered in this agreement shall
be handled in accordance with the &ldquo;National Taiwan University Building Education Cooperation Plan Processing Guidelines&rdquo; formulated
by Party A and related laws and regulations, or shall be added in writing with the agreement of both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. This agreement is executed in duplicate, with
each party holding one original copy. The duplicate copies shall be held by Party A&rsquo;s project leader and the relevant units for
Party A&rsquo;s copy, and by Party B for Party B's copy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="vc051_ex10-5img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Party A</B><FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 38%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">/s/NATIONAL TAIWAN UNIVERSITY (Seal)</FONT></TD>
    <TD STYLE="width: 54%; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(Signature and Seal)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Representative<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>Wen-Chang Chen, Ph.D.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Title&#65306;President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Address&#65306;No. 1, Sec. 4,
Roosevelt Rd., Taipei 106216, Taiwan (R.O.C.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0 0pt 0.25in">Project leader designated
by Party A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.25in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; width: 50%; text-align: justify; text-indent: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name&#65306;[***]</FONT></TD>
    <TD STYLE="padding-top: 0pt; width: 50%; text-align: justify; text-indent: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature and Seal&#65289;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; text-align: justify; text-indent: 0in; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: justify; text-indent: 0in; padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; text-align: justify; text-indent: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title&#65306;[***]</FONT></TD>
    <TD STYLE="padding-top: 0pt; text-align: justify; text-indent: 0in; padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; text-align: justify; text-indent: 0in; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: justify; text-indent: 0in; padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; text-align: justify; text-indent: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Department:
[***]</FONT></TD>
    <TD STYLE="padding-top: 0pt; text-align: justify; text-indent: 0in; padding-bottom: 0pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Party B</B>:</FONT></TD>
    <TD STYLE="width: 38%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">ADVANCED BIOMED INC. (TAIWAN)</FONT></TD>
    <TD STYLE="width: 54%; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(Signature and Seal)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Representative<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>YI LU&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Yi Lu</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0">(As a joint guarantor, I agree
to guarantee that Party B will fulfill the debts arising from this agreement. When requested by Party A, I will assume joint and several
liability for the repayment of all or part of the debt, and I will not refuse or object for any reason)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; margin: 0pt 0">Title&#65306;Chairman of the
Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; width: 40%; text-align: justify; text-indent: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Office&#65306;</FONT></TD>
    <TD STYLE="padding-top: 0pt; width: 60%; text-align: justify; text-indent: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3305 SPRING MOUNTAIN RD STE 104, LAS VEGAS, NV 89102, USA</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Registration Number<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>54566067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact Person<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>Zhenyi
Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>689-87
Xiaodong Road, Yongkang District, Tainan, Taiwan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone Number<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="vc051_ex10-5img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identifying Novel Biomarkers for Early Detection
of Lung Cancer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>A. Scope of the Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lung cancer is the leading cause of cancer-related
deaths in worldwide, including in Taiwan. Because of the poor early detection of lung cancer, even under the most advanced treatment strategies,
about 85% of lung cancer patients die within 5 years of diagnosis. Thus, early detection of lung cancer is crucial and beneficial for
patients to receive appropriate and curative treatment, which may result in a longer survival period. To avoid unnecessary invasive diagnostic
procedures, a predictive model of malignant nodules based on clinical and radiographic parameters had been proposed recently. A recent
study demonstrated that Protein X was up-regulated in patients with lung cancer compared to healthy controls. In this study, we aim to
validate and evaluate the potential of Protein X as a biomarker for diagnosis of lung cancer. We will collect urine samples from patients
with lung cancer and from healthy controls. Blood samples will be also collected. The expression levels of Protein X in urine and serum
samples of patients with lung cancer and healthy controls will be validated by Western blot analysis and quantified using enzyme-linked
immunosorbent assay (ELISA) assay. We will also analyze the expression of Protein X in tumors tissues from 100 patients with lung cancer
using immunohistochemical analysis. According to our preliminary findings, the expression levels of Protein X in urine, serum and tissues
specimens were significantly elevated in patients with lung cancer when compared to healthy controls (p&lt;0.05), correlating with histology
cancer types, and suggest that Protein X expression in lung cancer may be release from tissues to serum and excrete to urine. In this
study, we propose to develop a novel biomarker, Protein X, for early detection and prognostic prediction of lung cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We aim to apply the protein biomarker, Protein X, as an adjunct to
lung cancer LDCT screening project, in order to improve the accuracy of early lung cancer detection. We also will explore more novel biomarkers
in this regard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>B. Fee Schedule</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">NTD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-top: 0pt; text-align: center">Item</TD><TD STYLE="padding-top: 0pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-top: 0pt; text-align: center">Description</TD><TD STYLE="padding-top: 0pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid; padding-top: 0pt">Unit</TD><TD STYLE="padding-top: 0pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid; padding-top: 0pt">Quantity</TD><TD STYLE="padding-top: 0pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid; padding-top: 0pt">Unit Price (NTD)</TD><TD STYLE="padding-top: 0pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid; padding-top: 0pt">Total Price (NTD)</TD><TD STYLE="padding-top: 0pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid; padding-top: 0pt">Note</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0pt; width: 13%; text-align: center; padding-bottom: 0pt">1</TD><TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 2%; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; width: 11%; text-align: left; padding-bottom: 0pt">Research Fee</TD><TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 2%; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 11%; text-align: right; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 2%; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 11%; text-align: right; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 2%; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 10%; text-align: right; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 2%; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 10%; text-align: right; padding-bottom: 0pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">2,550,000</P></TD><TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 2%; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; width: 10%; text-align: right; padding-bottom: 0pt"></TD><TD STYLE="padding-top: 0pt; width: 1%; text-align: left; padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 0pt; text-align: center; padding-bottom: 0pt">2</TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Management Fee</P></TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">450,000</P></TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">15% of overall fee</P></TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0pt; font-size: 12pt; text-align: center; padding-bottom: 0pt"><FONT STYLE="font-size: 12pt">Total</FONT></TD><TD STYLE="padding-top: 0pt; font-size: 12pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; font-size: 12pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; font-size: 12pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; font-size: 12pt; text-align: right; padding-bottom: 0pt">3,000,000</TD><TD STYLE="padding-top: 0pt; font-size: 12pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: right; padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-top: 0pt; text-align: left; padding-bottom: 0pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>10
<FILENAME>vc051_ex10-6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><FONT STYLE="color: Black"><B>Exhibit 10.6&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><FONT STYLE="color: Black">[***] Certain information in this
document has been excluded pursuant to Regulation&nbsp;S-K,&nbsp;Item (601)(b)(10). Such excluded information is not material and confidential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><FONT STYLE="color: Black"><B>PRIVATE &amp; CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>Non-Disclosure Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ADVANCED BIOMED INC. (hereinafter referred to
as &ldquo;Party A&rdquo;) and Unimold Technology Inc. (hereinafter referred to as &ldquo;Party B&rdquo;), both parties have commissioned
processing of [***] for injection molding mold kernels required for [***] Injection Molding Foundry &quot;Establishment of Contract Manufacturing
Program (hereinafter referred to as the Project), in order to ensure the confidentiality of information related to this Project and maintain
the inherent rights and interests of both parties, the two parties agree to conclude.&quot; The confidentiality agreement (hereinafter
referred to as this Agreement) stipulates the following terms to ensure that both parties can abide by it together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>I. Definition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">One of the parties
                                            disclosing information for the purposes of the Project is referred to as the &quot;<B>Disclosing
                                            Party</B>&quot;; One of the parties to whom the information is received is called the &quot;<B>Recipient</B>&quot;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">For the purposes
                                            of this Agreement, &quot;<B>Confidential Information</B>&quot; refers to all tangible or
                                            intangible expressions (including but not limited to oral, written messages, writing, notes,
                                            drawings, models, e-mails, computer programs, audio-visual content, electromagnetic recordings
                                            and vehicles), information or materials of a technical, commercial, non-technical or other
                                            nature that are not disclosed by the disclosing party ( Including but not limited to patent
                                            rights, copyrights, trademark rights, technology, inventions, research records or achievements,
                                            financial, personnel, procurement, sales or customer information of the disclosing party
                                            or its shareholders now or in the future, products, products, etc. Information relating to
                                            or derived from the foregoing, including original or copies of analyses, research reports,
                                            compilations and other documents produced by the disclosing party or its agents (e.g. lawyers,
                                            accountants and financial advisors) or on behalf of the disclosing party that contain or
                                            reflect such confidential information or those who have commented on it.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">When the &quot;Confidential
                                            Information&quot; referred to in the preceding paragraph is disclosed in the form of a tangible
                                            object, the disclosing party shall mark the object as &quot;Confidential&quot; or &quot;confidential&quot;.
                                            If there is no such indication or inability to indicate the information (e.g., dictation,
                                            viewing, hearing), the disclosing party shall declare that the disclosure is &quot;confidential&quot;
                                            at the time of disclosure, and shall submit the disclosed confidential information to the
                                            recipient for confirmation within ten days from the day following the date of disclosure,
                                            and submit it to the recipient for confirmation after adding the foregoing confidential marking.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">For the purposes
                                            of this Agreement, &quot;<B>disclosure</B>&quot; means the disclosure of confidential information
                                            by:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">(1) Written;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">(2) email;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">(3) delivered
together with other projects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">(4) Access at
the behest of the disclosing party (e.g. access to confidential information in the database, including but not limited to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">watching, hearing
or reading);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">(5) Verbal disclosure,
audio or video broadcast, or delivery to the recipient for viewing, knowledge or possession.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; color: red"><FONT STYLE="color: Black"><B>PRIVATE &amp;
CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><FONT STYLE="color: Black"><B>PRIVATE &amp; CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt; text-align: left"><FONT STYLE="color: Black"><B>II.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Confidentiality
                                            Obligations</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The Recipient shall
                                            use the Confidential Information only for the purposes of the Program or the original disclosure,
                                            and shall take such reasonable steps as may be necessary to process, keep and use the Disclosing
                                            Party's Confidential Information with the same care as it does with its own Confidential
                                            Information to protect the confidentiality of confidential information from improper disclosure,
                                            disclosure, misappropriation or dissemination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The Recipient agrees
                                            that its employees will only know or use the Confidential Information only to those who do
                                            not know or use it in their duties, and the Recipient shall enter into a confidentiality
                                            contract with the employee that is substantially the same as the content of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">If the Recipient
                                            needs to deliver or inform a third party of confidential information due to the performance
                                            of the work within the scope of the agreed purpose, it shall obtain the prior written consent
                                            of the disclosing party and shall sign a confidentiality contract with the third party that
                                            is substantially the same as the content of this agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Except as otherwise
                                            provided in this Agreement or with the prior written consent of the Disclosing Party, any
                                            information, content, plans, meetings, meetings, or negotiations regarding any consultations,
                                            discussions, or negotiations relating to the Program or the Confidential Information, in
                                            whole or in part, in respect of the Disclosing Party's Confidential Information, the Recipient
                                            shall keep the confidentiality of the existence and content of and in accordance with the
                                            provisions of this Agreement, and shall not provide or disclose it to the media, the public,
                                            institutions, trade names, or a third person other than a group, corporation or a party other
                                            than both parties to know, possess or use.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt; text-align: left"><FONT STYLE="color: Black"><B>III.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Exclusions to
                                            Confidentiality Obligations</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">The Recipient shall not
be liable for the confidentiality of the Confidential Information as defined in this Agreement if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">It has been disclosed
                                            as a well-known document or information and the disclosure of such information is not caused
                                            by the recipient's negligence or violation of the provisions of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Documents or information
                                            was known or held by the Recipient in a lawful manner.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The Recipient obtains
                                            or knows from a third party who provides or discloses the information from other lawful sources
                                            by lawful means.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Documents or information
                                            that the recipient proves to be independently developed on the basis of confidential information
                                            provided by the disclosing party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The disclosing party
                                            agrees in writing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Those who provide
                                            or disclose it based on the provisions of the law, the order of the court or the order of
                                            the government. However, the provision or disclosure of such provisions shall be limited
                                            to the scope of the law or the order of a court or government agency, and the situation shall
                                            be notified in writing to the disclosure in advance before it does not violate the relevant
                                            laws or orders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; color: red"><FONT STYLE="color: Black"><B>PRIVATE &amp;
CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><FONT STYLE="color: Black"><B>PRIVATE &amp; CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black"><B>IV.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Obligation
                                            to return or destroy data</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The Recipient shall,
                                            within ten days after termination or rescission of this Agreement or the day following the
                                            written notice from the Recipient, return to the Disclosing Party all confidential information
                                            delivered by the Disclosing Party, as well as all originals, copies, photocopies thereof
                                            and copies thereof, including without limitation, tangible or intangible objects of any finished
                                            products, templates, documents, diskettes, diskettes, CDs, e-mails, electromagnetic records,
                                            reports, abstracts, excerpts, text exchanges, audio tapes, videotapes, notes, drawings, models,
                                            specifications, compilation files, computer programs and other media presentation or preservation
                                            of Confidential Information).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">If the information
                                            cannot be returned (including but not limited to electromagnetic records such as software
                                            programs installed on the hardware device), the recipient shall immediately delete and destroy
                                            it.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black"><B>V.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>The meaning
                                            of not authorized</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The Recipient acknowledges
                                            and respects that the Confidential Information disclosed or provided by the Disclosing Party,
                                            or the Confidential Information of the Disclosing Party known or held by the Recipient through
                                            negotiation or partnership, is the property of the Disclosing Party or the original owner
                                            of the Confidential Information, and is not the property of the Recipient.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The disclosure, provision,
                                            knowledge, possession and use of confidential information shall be in accordance with the
                                            provisions of this Agreement, unless otherwise agreed by both parties, and the parties shall
                                            not transfer the rights and obligations of this Agreement to a third party without the written
                                            consent of the other party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Unless otherwise
                                            agreed by the parties, the Disclosing Party shall not be deemed to have consented to authorize
                                            or transfer part or all of the rights in the Confidential Information to the Recipient; or
                                            the Recipient obtains any authorization or other legal right as a result of the receipt,
                                            knowledge, possession or use of the Confidential Information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Unless otherwise
                                            agreed by the parties, this Agreement does not represent an obligation between the parties
                                            to purchase, sell, license or transfer products, services or technology, nor does it create
                                            an agency or partnership.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black"><B>VI.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Validity,
                                            Modification and Duration of the Agreement</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The term of this
                                            Agreement shall be from the time the Parties sign this Agreement to the end of the relationship
                                            between the Parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">After the termination
                                            or cancellation of this Agreement, the Recipient shall not be exempted in advance from its
                                            confidentiality obligation to know and hold confidential information during the effective
                                            period of this Agreement, and the Recipient shall continue to perform its confidentiality
                                            obligations until three after the termination or cancellation of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black"><B>PRIVATE &amp; CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>PRIVATE &amp; CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">If a part of this
                                            Agreement is deemed invalid, illegal or unenforceable, the invalid, illegal or unenforceable
                                            provision shall not affect the other provisions of this Agreement. The foregoing invalid,
                                            illegal or unenforceable provisions shall be deemed not to have been included in this Agreement
                                            from the beginning.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The signing of this
                                            Agreement supersedes any prior oral or written agreement between the parties relating to
                                            this Agreement. Any subsequent additions, deletions or modifications to the terms of this
                                            Agreement must be in writing and shall be effective after being signed by both parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">During the litigation
                                            arising from this Agreement, except for the disputed part, the parties shall still abide
                                            by and perform the other parts of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black"><B>VII.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Breach
                                            of the Agreement</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Unless otherwise
                                            agreed by both parties, if either party violates this Agreement (such as non-performance
                                            or performance in a manner not in accordance with this Agreement), the other Party shall
                                            notify the violating Party of the breach or obligation to make corrections. If the correct
                                            notice is not made within 10 days after the arrival of the written notice, the other party
                                            may, without notice, within 20 days after the period of correction has elapsed Terminate
                                            this Agreement directly by written notice to the breaching party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The Disclosing Party
                                            shall ensure that the source of the Confidential Information is lawful and does not infringe
                                            the rights of any third party or breach the confidentiality obligation to the third party,
                                            and that the Disclosing Party shall bear the losses and additional expenses incurred by the
                                            Recipient in the event of infringement and damage to the Recipient.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="color: Black"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">During the term of
                                            this Agreement and for a period of two years after the termination or termination of this
                                            Agreement, neither Party shall directly or indirectly employ employees of the other Party
                                            or its subsidiaries or employees who have been separated for less than two years without
                                            the written consent of the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">If the other party
                                            suffers damage due to the breaching party's violation of the provisions of this agreement,
                                            the breaching party shall be liable for the damages, lost benefits and reasonable expenses
                                            (including but not limited to attorney's fees and other expenses incurred in asserting rights)
                                            suffered by the other party. If the breaching party thus derives any benefit, the breaching
                                            party shall return all the benefits to the other party as part of the damages.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black"><B>VIII.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Governing
                                            Law and Court of Jurisdiction</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">If any dispute arises
                                            from this Agreement, the two parties shall negotiate and resolve it in accordance with the
                                            principle of good faith.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The interpretation,
                                            validity and other matters not specified in this Agreement shall be governed by the laws
                                            of the Republic of China.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; color: red"><FONT STYLE="color: Black"><B>PRIVATE &amp;
CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><FONT STYLE="color: Black"><B>PRIVATE &amp; CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black">3.</FONT></TD><TD STYLE="text-align: justify">In connection
with the dispute arising out of this Agreement, the parties agree that the Tainan District Court of Taiwan shall be the court of first
instance.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24pt"><FONT STYLE="color: Black"><B>IX.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>This confidentiality
                                            agreement shall be executed in two copies by each party.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>The above is the content
of the confidentiality agreement followed by the signing page</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>The person who signed
the agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A<B>: <U>ADVANCED BIOMED INC. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representative: Yi Lu /s/Yi Lu (Seal)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Uniform number: 54566067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: No. 689-87, Xiaodong Road, Yongkang District,
Tainan City</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B: <B>Unimold Technology Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representative: Chairman of the Board: Jinxing
Xu /s/Jingxing Xu (Seal)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Uniform number: 80487659</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: No. 162, Zhengnan Third Road, Yongkang
District, Tainan City</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; color: red"><FONT STYLE="color: Black"><B>PRIVATE &amp;
CONFIDENTIAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>11
<FILENAME>vc051_ex10-7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 10.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***] Certain information in this document has been excluded pursuant
to Regulation&nbsp;S-K,&nbsp;Item (601)(b)(10). Such excluded information is not material and confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">CONFIDENTIAL</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">Industrial Cooperation Research</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">National Applied Research<BR>
Laboratories</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">Advanced Biomed Inc. (Taiwan)</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">Design and Verification for Pilot Run of<BR>
Thin-layer nano-channel Fabrication (II)</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Contract No.: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Execution period: August 1, 2022 to July 31, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-size: 10pt">Confidential</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Industrial Cooperation Research Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advanced Biomed Inc. (Taiwan) (hereinafter referred
to as &quot;Party A&quot;) and Taiwan Semiconductor Research Institute of National Applied Research Laboratories (hereinafter referred
to as &quot;Party B&quot;). Party A and Party B cooperate on &#8220;Design and Verification for Pilot Run of Thin-layer nano-channel Fabrication
(II)&#8221; Study, and hereby makes this agreement and agree to the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 1: Both parties agree</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Party A agrees to entrust Party B and Party B agrees
to accept party A to conduct the &#8220;Design and Verification for Pilot Run of Thin-layer nano-channel Fabrication (II)&#8221; (hereinafter
referred to as &#8220;the Study&#8221; and &#8220;the Agreement&#8221;) in accordance with the terms herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 2: Research content</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The contents of this study are included in the annex
&#8220;Design and Verification for Pilot Run of Thin-layer nano-channel Fabrication (II)&#8221; (hereinafter referred to as the &#8220;Agreement&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 3: Study period</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The implementation period of this study is one year
from August 1, 2022 to July 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 4: Research progress</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Party B shall support the study according to the schedule agreed in the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The form of the research report shall be written according to the format determined by both parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">If Party A has to change the contents of the Agreement due to actual needs, it shall put forward the comparison
table between the proposed changed project and the project of the Agreement, the impact on the Agreement funds and the completion time,
and state the reasons, and the change shall be made with the written consent of Party B. The increased Agreement funds due to the Agreement
change shall be paid by Party A, and the amount shall be separately agreed upon by both parties in accordance
with the principle of good faith.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 5: Research costs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total cost of this study is NTD (the same below)
1,300,000 (tax included), as detailed in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 6: Payment method</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The research fee shall be paid to Party B by Party
A in two periods according to the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">After the effective date of this agreement, the first installment of NT$ 650,000 shall be paid before
August 31, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The second installment of NT$ 650,000 will be paid within 30 days after 7 months since the commencement
of the project.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 81pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Party B shall, after the effective date of this agreement, deliver the invoice of each installment to
Party A within the time specified in this agreement for payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The above payment shall be handled by the tax withholding reporting authority in accordance with the provisions
of the tax law at that time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: -42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: -42pt">Article 7: Expenditure
voucher</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: -42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify">Party B shall properly keep all the original
vouchers of expenses related to this study. If Party A needs to check, photocopy and copy the aforesaid vouchers, Party B shall provide
all necessary assistance to the personnel assigned by Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 8: Confidentiality obligation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The parties agree that during the execution of the Agreement and after the completion, neither party shall
not publish the research results of the Agreement, the reports, files, charts, data, and the knowledge of the business and technical information,
or in any other way.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Party A agrees that Party B shall use and disclose the written consent of Party A for the academic creation
of any relevant materials developed by Party A (the consent shall not be rejected without justifiable reasons).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">The parties agree to observe the confidential information upon the completion of this Agreement. It does
not apply to the following information:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
a public source or domain recipient; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
or disclosure from the third party without violation of the confidentiality agreement with the third party; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is proved to have been developed independently or obtained by the party of the other party, or known by the party of the secret information
from the other party; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A third party who is required for the execution of this agreement, but who is also subject to the same confidentiality obligation: or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If it is disclosed by an order or requirement or law, such disclosure shall not constitute a breach of this agreement, provided that the
party required to disclose the confidential information shall immediately notify the other party and shall assist the other party to obtain
the necessary protection order or protection measures under the current legal system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The period of the confidentiality obligation in this article shall be valid for ten years from the date
of disclosure or knowledge, and the validity of this article shall not be lost due to the failure to formation, cancellation, invalidation,
termination or rescission of this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 9: Intellectual property rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Any technical data, special technology, design, business secrets, information, data, and other intelligent
property, business secrets, copyright, patent rights, trademarks or any other protected intellectual property rights under the purpose
of the study shall be owned by the party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The intellectual property rights arising from the implementation of the Agreement shall be completed by
Party A (whether Party B provides any assistance or not), and Party A shall have the relevant intelligent property rights and application
rights; the developer (whether Party A provides any assistance or not), and Party B shall have the relevant intellectual property rights
and application rights. If both parties jointly complete it, or it cannot be confirmed by either party, both parties shall jointly own
the relevant intellectual property rights and application rights. In case of any need to apply for the registration or registration of
copyright, patent rights or other legal rights in any region, unless party B agrees otherwise, party A shall apply for the application
in the name of both parties and register as a joint owner. The expenses for application and maintenance shall be paid equally by both
parties, but Party B agrees to pay all the expenses due to the insufficiency, and the relevant documents and instructions shall be approved
by Party B in advance.As for common wisdom property rights, if party A did not apply for the intellectual property rights, the party B
notice still shall not be the applicant, as party A agreed to its common part unconditional abandon to party B, party B to apply, party
A shall not to the application right or the wisdom of the property rights for any claim.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">In addition to the common intellectual property rights, any patent right, copyright and other intellectual
property rights developed based on the intellectual property rights generated by the Institute after the termination of this agreement
shall be separately owned by such party and may independently apply for the protection of the relevant intellectual property rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Party A and Party B agree that the rights of joint ownership shall not authorize any third party to use
or transfer to any third party without the written consent of the other party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">This section applies to any intellectual property rights arising prior to the expiration of this agreement
or early termination during the execution of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">If either party has a paper or work published based on the intellectual property right of the joint venture,
both parties shall be named.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify">Based on the needs of the cooperation project, Party A shall provide any registered intellectual property
right to Party B for use, but only Party B shall use it in the cooperative research project.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 10: No guarantee liability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Party A agrees and acknowledges that Party B shall
not be liable for any infringement of the patent rights, copyright, business secrets, or other intellectual property rights caused by
the use, implementation, restructuring, modification of the results of the study, or the manufacture, assembly or sale of the products
of the research results. Party B does not guarantee the liability of the products manufactured or sold by Party A after using, implementing
and modification of the research results, nor does it guarantee the patent ability, availability and possibility of commercialization
of the research results. If the third party charges Party B of infringing upon its intellectual property rights and other rights, Party
A shall assist Party B in the defense and defense free of charge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 11: Liability ceiling</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If Party B is responsible for the loss or damage to
Party A, it shall be liable for the research cost set in Article 5 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 12: Liaison and management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any notice or request herein shall be served in writing
on the premises and persons (hereinafter referred to as the &quot;host&quot;) and the person shall be deemed to have been served on the
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To Party A: Host name: Zhaohong Chen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To Party B: Host name: Yifang Zheng</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 13: Agreement period</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This agreement, when signed by both parties, shall
be effective from the date of commencement of Article 2 of this agreement to the date of expiration of the study period. If the parties
otherwise agree with or have other circumstances agreed herein, it may be extended according to the actual circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 14: Termination of the agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One party hereto may terminate the other party on
any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">If a party refuses or fails to perform its obligations as agreed herein or has a material breach, it shall
correct within 30 days by written notice, and fails to correct within the time limit; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Party A will declare or have declared bankruptcy; or conduct liquidation according to law; or transfer
its assets to creditors; or assign its assets to the property manager; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Party A's business activities are collected, suspended or intervened by the government or other units
or organizations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except for the above provisions, this agreement shall
be terminated by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 15: Termination effect of the agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.1pt">If any party considers that the
continuation of the study cannot achieve the intended purpose, either party shall stop the execution of the Agreement in writing to terminate
the agreement from the date of termination and submit the part of the research funds from Party A to return the research funds to Party
A without interest, or request the research expenses that have not been paid to Party B according to the execution schedule, and Party
B shall submit the completed and completed research results to Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.8pt; text-align: justify; text-indent: 0.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 16: Force Majeure clause</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any party shall not be liable for any breach of agreement
in the event of God, government order, riot, war, strike, fire, flood, explosion, court order, or any event not under the reasonable control
of the party. The implementation period of the Agreement shall be extended according to the duration of the force majeure period, but
the extension shall not exceed three months. If it exceeds three months, this agreement shall certainly be terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 17: Transfer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Without the written consent of the other party, neither
party shall assign all or part of its rights and obligations under this agreement to any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 18: Contract integrity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The annexes attached hereto constitute the entire
provisions of this agreement and supersedes all relevant oral or written communications, agreements or representations of the parties
previously made hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 19: Jurisdiction courts and quasi law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.1pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regarding the dispute arising from the execution of
this agreement, the parties agree to take the Taiwan Taipei District Court as the jurisdiction court of first instance. The parties agree
that this agreement shall be subject to the laws of the Republic of China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 20: Amendment of the agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This agreement shall be modified or amended in writing
by the consent of both parties. Any article or part of this agreement deemed invalid shall not affect the validity of the other provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Article 21: Number of agreement copies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The original and duplicate copies of this agreement
are made in duplicate, and each party holds the second original and the second copy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 60pt"><B>Promiser</B></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A: Advanced Biomed Inc. (Taiwan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representative: Yi Lu /s/ Yi Lu (Seal)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: No.689-87, Xiaodong Road, Yongkang District,
Tainan City</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unified number: 54566067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B: Taiwan Semiconductor Research Institute
of National Applied Research Laboratories</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representative: Jiasong Qiu /s/Jiasong Qiu (Seal)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: No.26 Zhanye 1<SUP>st</SUP> Road, Science
and Industry Park, Xinzhu City</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unified number: 80778283</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">August 1, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>12
<FILENAME>vc051_ex10-8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Investment Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ADVANCED BIOMED INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>HANYU ASSETS CO., LTD.</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>June 6, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Investment Agreement (the &quot;<B>Agreement</B>&quot;)
was signed by the following parties on June 6, 2022 (the &quot;<B>Signing Date</B>&quot;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21pt">1.</TD><TD STYLE="text-align: justify"><B>ADVANCED BIOMED INC </B>(the &quot;<B>Corporation</B>&quot;), a limited liability corporation validly
incorporated and legally existing under the laws of the State of Nevada, U.S.A., With A Certificate Number: B202107161840981;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21pt">2.</TD><TD STYLE="text-align: justify"><B>HanYu Assets Co., Ltd. </B>(the &quot;<B>Investor</B>&quot;), a limited liability company validly established
and legally existing in accordance with the laws of Taiwan, unified number: 90230708</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: -21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any of the foregoing parties is individually referred
to as a &quot;<B>party</B>&quot; and collectively as the &quot;<B>Parties</B>&quot;. In this Agreement, &quot;laws&quot; refers to all
<B>laws</B>, administrative regulations, rules, regulations, policy documents, regulations, decisions, policy documents, etc. of local
governments or local government departments in force at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Whereas:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">1.</TD><TD STYLE="text-align: justify">The Company is undergoing restructuring and intends to become the sole holding company of Advanced Biomed
Inc. (Taiwan) (&quot;<B>Advanced Biomed Taiwan </B>&quot;), a Taiwan limited corporation under the actual control of the Company&#8217;s
existing shareholders, the main business of which is principally engaged in the manufacture of in vitro diagnostic reagents (&#8220;<B>Main
Business</B>&#8221;) .</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify">The Investor intends to invest in the Company in accordance with the terms and conditions of this Agreement,
and the existing shareholders and the Company are willing to accept the Investor's investment in accordance with the terms and conditions
of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 18pt">Thus, the Parties have reached
the following agreement on this transaction based on the principle of equality and mutual benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">I. Arrangements for this transaction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Arrangements for this transaction</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">1.1.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investment</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">The investor agrees to invest USD2.5 million
(the &quot;<B>Investment Funds</B>&quot;) in the Company as set forth in this Agreement to acquire an aggregate 2.5% equity interest in
the Company following the Transaction (the Transaction &quot;<B>Investment</B>&quot; or <B>&quot;This Transaction</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">1.1.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investment valuation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">The parties confirmed that the valuation
of the Company upon completion of the investment was USD100 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholding structure after investment</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">From the completion date of registration
of the change of registration (see definition below), the amount of capital contributed by the investor and the shareholding ratio in
the company will be changed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Shareholder name/title</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Amount of capital <BR>
contribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Shareholding ratio</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: center">Investors</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: center">USD2.5 million</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">/</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.5</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Corporate Restructuring</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">The parties expressly acknowledge that
the Company is undergoing restructuring and that Advanced Biomed Taiwan will become a wholly-owned subsidiary of the Company after the
restructuring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholder Rights</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">The equity acquired by the Investor pursuant
to this Transaction shall enjoy the rights granted to the Investor by laws and regulations and the Transaction Documents (as defined in
paragraph 1.6). After the closing date of this transaction, if any rights conferred on the investor in the transaction documents cannot
be fully realized due to the restrictions of the laws of Taiwan, the existing shareholders and the company will use other methods permitted
by the laws of Taiwan to realize the rights and interests of the investor specified in the transaction documents to the fullest extent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The purpose of the Investment Funds</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.6pt; text-align: justify">Except as otherwise provided in this Agreement
or otherwise agreed by the parties, the Company shall use all of the Investment Funds obtained from this transaction in accordance with
the Company's budget plan approved by the Board of Directors of the Company for the day-to-day working capital and other purposes approved
by the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Document signing and change registration process</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">1.6.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The existing shareholders and the Company agree
to sign other ancillary agreements, resolutions and other documents (the above documents and this Agreement are collectively referred
to as the &quot;<B>Transaction Documents</B>&quot;) in accordance with the provisions of this Agreement at the same time as or at such
other time as the investor agrees to enter into for the investment under this Agreement to complete the transaction. The existing shareholders
and the company are responsible for the registration and filing procedures of this transaction, and the investor will provide necessary
cooperation. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">1.6.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For matters not stipulated in this agreement
related to this transaction, applicable laws, articles of association and other transaction documents shall apply and comply with the
provisions of applicable laws. If there is any conflict or inconsistency between the provisions of the articles of association and the
matters stipulated in this agreement, and the articles of association of the company are not stipulated, the provisions of this agreement
shall apply and comply with the provisions of this agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">II. Payment of investment funds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 34.5pt; text-align: left">2.1</TD><TD STYLE="text-align: justify">Payment of investment funds</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">2.1.1 The Investor shall pay all of the
Investment Funds of USD 2.5 million (&quot;<B>Closing</B>&quot;) in accordance with Article 1.1.1 of this Agreement before June 30, 2022
to the company's designated bank account. Existing shareholders shall provide bank account information to investors five (5) business
days prior to the closing date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">2.1.2 The company shall confirm in writing
to the investor on the day of receipt of the investment payment from the investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 34.5pt; text-align: left">2.2</TD><TD STYLE="text-align: justify">Registration of changes</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">2.2.1 The Company shall commence the registration
of the change of registration in relation to the Transaction after the Investor has paid the investment amount in accordance with Clause
2.1 above, and then obtain a new registration document of the Company as soon as possible (the &quot;<B>Registration Change Registration
Completion Date</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 34.5pt; text-align: left">2.3</TD><TD STYLE="text-align: justify">Closing date</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34pt; text-align: justify">The Closing date (&quot;<B>Closing Date</B>&quot;)
shall be the date on which the Investor actually pays the investment amount in accordance with Article 2 of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">III. Representations and warranties
of the Company and existing shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company and the existing shareholders shall separately
and jointly make the following representations and warranties, and ensure that the following representations and warranties are true,
complete and accurate as of the date of execution of this Agreement, the date of delivery and the date of completion of the registration
of the change of registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.1 <U>Authorization</U>. The Company has obtained
or will obtain sufficient and necessary authorizations for signing the transaction documents, performing all obligations under the transaction
documents and completing the transactions under the transaction documents; Each existing shareholder has full capacity for civil conduct
and civil rights, signs each transaction document and performs its obligations under each transaction document. Once signed, the transaction
documents are legally binding on the Company and existing shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.2 <U>Invest</U>. As of the date of completion of
the registration of the change of registration, the Company does not have any other subsidiaries, partnerships, branches or offices in
Chinese mainland, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan or overseas, and does not directly
or indirectly hold shares or have similar interests in any other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.3 <U>No conflict</U>. The execution and performance
of each transaction document does not violate or conflict with any provision of the articles of association or other constitutive documents
of the company; The Company and the existing shareholders have obtained all third-party consents or authorizations necessary for the transaction
under the trading file. Material agreements or <FONT STYLE="letter-spacing: -0.15pt">contracts</FONT> between the Company, existing shareholders
and any other entity will not be terminated by or materially affected by the execution or performance of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.4 <U>The company is valid</U>. The company is an
entity established and effectively existing in accordance with the law. The registered capital of the company has been paid in full and
on time in accordance with the provisions of its articles of association. All articles of association have been legally and validly registered
(if required) and are valid and enforceable. The business scope of the company detailed in the articles of association meets the requirements
of U.S. law. The company conducts its business activities in strict accordance with the scope of business stipulated in the articles of
association and the provisions of the laws of the United States. All licenses, approvals and permits required by the Company to carry
out business activities under the laws of the United States have been applied for and obtained in accordance with the law; And all of
these licenses are valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.5 <U>Financial reporting</U>. As of the date of
this Agreement, all of the Company's audited and managed accounts are prepared in accordance with the laws of the United States and are
true, complete and accurate reflections of the Company's financial and operating conditions as at the date of such accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.6 <U>Share capital structure</U>. The structure
of the company's capital equity contained in the articles of association and the amendments to the articles of association registered
with the Registrar of Companies is completely consistent with the records of the articles of association and the amendments to the articles
of association provided by the company to investors, and it is true, complete and accurate to reflect the company's share capital structure,
and there is no false capital contribution. The Company has never promised or actually issued any interest, shares, bonds, stock options,
options or interests of the same or similar nature to any person in any form and in any way other than the above shareholders' interests.
There is no nominee or similar arrangement in the company's shares, nor are there any security interests such as pledges, mortgages or
any kind of encumbrances, or any other third party rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.7 <U>Taxation</U>. The Company has completed all
tax registrations required by U.S. law, has paid all taxes due, and has not been involved in any tax violations, irregularities, or any
tax-related disputes or litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.8 <U>Assets</U>. The company legally owns and uses
all fixed and intangible assets owned by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.9 <U>Real Estate</U>. The company's own real estate
or construction projects, or leased real estate, are legally owned or leased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.10 <U>Contracts</U>. All material agreements or
contracts currently in force of the company are legally valid and can be performed in accordance with the law, and there is no material
breach of contract by the company or any other trading party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.11 <U>Intellectual Property</U>. The Company owns
the legal ownership or use rights of all intellectual property rights (including but not limited to patents, trademarks, copyrights, know-how,
domain names and trade secrets, etc.) necessary to engage in business activities, such intellectual property rights are valid and enforceable
in accordance with the law, and to the knowledge of the Company and existing shareholders, there is nothing that may cause any intellectual
property rights to be invalid or unenforceable. The Company has not infringed or unlawfully used any intellectual property in which any
third party has any right, title or interest, nor has it licensed or permitted any third party to use any of the Company's intellectual
property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.12 <U>Environment, health and safety</U>. Since
the date of its establishment, the Company has complied with and not violated any applicable U.S. laws relating to all environmental aspects
of its business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.13 <U>Litigation and other legal proceedings</U>.
The Company does not currently have the following legal proceedings that could materially and adversely affect the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.4pt; text-align: justify">3.13.1 Penalties, injunctions or directives
imposed by government departments on existing shareholders or companies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.4pt; text-align: justify">3.13.2 Civil litigation, criminal litigation,
administrative litigation, arbitration and other procedures or disputes and claims against existing shareholders or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.14 <U>Employees</U>. The Company employs its employees
in compliance with applicable U.S. laws relating to labor applicable to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.15 <U>Provision of Information</U>. All documents,
materials and information provided by the Company and the existing shareholders to the Investor before and after the signing of this Agreement
are true, accurate, free from omissions and not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">IV. Prerequisites for investing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4.1 Unless exempted by the investor in writing, the
obligation of the investor to pay the capital increase shall be subject to the satisfaction of all of the following prerequisites:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.4pt; text-align: justify">4.1.1 There is no judgment, ruling, ruling
or injunction of U.S. law, court, arbitration institution or relevant governmental authority that restricts, prohibits or nullifies the
Transaction, nor does there be any pending or potential litigation, arbitration, judgment, award, ruling or injunction that has or will
materially adversely affect the Transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.4pt; text-align: justify">4.1.2 The Company made the resolution of
the shareholders' meeting and the resolution of the board of directors in relation to the consent to sign the transaction documents and
approve the transaction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.4pt; text-align: justify">4.1.3 The Company has obtained all third
party licenses, if any, to enter into and perform the Transaction Documents and the Transaction, and such execution and performance will
not cause Company to violate any applicable U.S. law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">V. Transaction fees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.1 Unless otherwise agreed, the Company, existing
shareholders and investors shall bear all tax costs incurred as a result of the transactions agreed in this Agreement in accordance with
the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">VI. Confidentiality</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6.1 Unless otherwise provided by law or agreed by
all parties to this Agreement, the parties to this Agreement shall keep the matters agreed in this Agreement confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">VII. Entry into force, supplementation,
modification, variation and dissolution of the Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.1 This Agreement shall enter into force upon signature
by the Parties to the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41.8pt; text-align: justify; text-indent: -41.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.2 This Agreement may be modified or varied by consensus
of all parties to this Agreement. Any modification or variation must be in writing and shall be effective upon signature by all parties
to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.3 This Agreement may be terminated by mutual written
agreement of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.4 Effect of rescission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.5pt"></TD><TD STYLE="width: 34.5pt">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">When this Agreement is terminated, unless otherwise
agreed by the parties at that time, the parties to this Agreement shall return the consideration under this Agreement obtained from the
other party in accordance with the principles of fairness, reasonableness and good faith, and try to restore it to the state in which
this Agreement was signed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.5pt"></TD><TD STYLE="width: 34.5pt">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon termination of this Agreement, all rights
and obligations of the parties hereunder shall cease. A party shall have no other claim against the other party under this Agreement or
for the termination of this Agreement, except for its liability under Article 7 of this Agreement. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">VIII. Liability for breach of
contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8.1 If one party to this Agreement breaches the other
party, the non-breaching party shall be entitled to bring a claim and the breaching party shall indemnify.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">IX. Governing Law and Dispute
Resolution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: justify; text-indent: -23pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.1 The formation, validity, interpretation, performance
and settlement of disputes herein shall be governed by and construed in accordance with the laws of the State of New York, U.S.A..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.2 All disputes arising out of or in connection with
the implementation of this Agreement shall be settled through friendly consultations between the Parties. If any Dispute cannot be resolved
through negotiation within fifteen (15) days of the Dispute arising, either party shall have the right to submit the Dispute to the American
Arbitration Association Center for International Arbitration in accordance with the Center's then-current arbitration rules. The arbitral
award shall be final and binding on the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.3 During the Dispute Resolution Period, each Party
shall continue to have its own other rights under this Agreement and shall continue to perform its corresponding obligations under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">X. By-laws</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.1 The headings used in this Agreement are for informational
purposes only and shall not affect the meaning or interpretation of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.2 This Agreement and other transaction documents
constitute the entire agreement of the parties with respect to the Transaction and supersede any prior agreements, letters of intent,
memorandums of understanding, representations or other obligations (whether written or oral, including all forms of communication) and
this Agreement (including its modifications, agreements or amendments, and other transaction documents) are contained by the parties The
only and entire agreement with respect to the subject matter hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.3 If any provision of this Agreement is invalid
or unenforceable due to the laws of the State of New York, U.S.A., USA.S., such provision shall be deemed to have ceased to exist ab initio
without affecting the validity of the other provisions of this Agreement, and the parties hereto shall negotiate new terms to the extent
lawful to ensure maximum realization of the intent of the original provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.4 This Agreement shall be effective against the
successors and assigns of the parties, and such successors and assigns shall have an interest in and beyond hereunder. Investors have
the right to assign and assign their rights, interests and obligations under this Agreement to its affiliates or any other third party.
Except as provided above, neither party may assign or transfer any of its rights or obligations under this Agreement without the prior
written consent of the investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.5 Except as otherwise provided in this Agreement,
a party's failure or delay in exercising its rights, powers or privileges under this Agreement shall not constitute a waiver of those
rights, powers and privileges, and the exercise of such rights, powers and privileges alone or in part shall not preclude the exercise
of any other rights, powers and privileges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.6 This Agreement shall be executed in duplicate,
one copy for the Company and one for the Investor, and each copy shall have the same legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[No text below].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[This page has no text, it is the signed page of the
Investment Agreement].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43.15pt; text-align: center; text-indent: -43.15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><B>ADVANCED BIOMED INC (Stamp).</B></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Yi Lu</P><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yi Lu</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Position:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chairman of the Board</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43.15pt; text-align: center; text-indent: -43.15pt">[This page has no
text, it is the signed page of the Investment Agreement].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43.15pt; text-align: center; text-indent: -43.15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><B>HanYu Assets Co., Ltd <FONT STYLE="font-size: 10pt; letter-spacing: -0.15pt">(Stamp)</FONT></B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Tingyu Zheng</P></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name: </TD>
    <TD>Tingyu Zheng</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Position:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chairman of the Board </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>13
<FILENAME>vc051_ex10-9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.9</B></P>

<P STYLE="font: 18pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Investment Agreement</B></P>

<P STYLE="font: 18pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ADVANCED BIOMED INC</B></P>

<P STYLE="font: 18pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and</B></P>

<P STYLE="font: 18pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NEWLINK TECHNOLOGY INC</B></P>

<P STYLE="font: 18pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center"><B>June 6, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">This Investment Agreement (the &quot;<B>Agreement</B>&quot;)
was signed by the following parties on June 6, 2022 (the &quot;<B>Signing Date</B>&quot;):</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21pt">1.</TD><TD STYLE="text-align: justify"><B>ADVANCED BIOMED INC </B>(the &quot;<B>Corporation</B>&quot;), a limited liability corporation validly
incorporated and legally existing under the laws of the state of Nevada, U.S.A, with the certificate number: B202107161840981&#65307;</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21pt">2.</TD><TD STYLE="text-align: justify"><B>Newlink Technology Inc. </B>(the &quot;<B>Investor</B>&quot;)<B>,</B> a Hong Kong listed company incorporated
in the Cayman Islands under stock code 9600 and registered office at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">Any of the foregoing parties is individually
referred to as a &quot;<B>party</B>&quot; and collectively as the &quot;<B>Parties</B>&quot;. In this Agreement, &quot;laws&quot; refers
to all <B>laws</B>, administrative regulations, rules, regulations, policy documents, regulations, decisions, policy documents, etc. of
local governments or local government departments in force at that time.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Whereas:</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">1.</TD><TD STYLE="text-align: justify">The Company is undergoing restructuring and intends to become the sole holding company of Advanced Biomed
Inc. (Taiwan) (&quot;<B>Advanced Biomed Taiwan</B>&quot;), a Taiwan limited corporation under the actual control of the Company&#8217;s
existing shareholders, the main business of which is principally engaged in the manufacture of in vitro diagnostic reagents (&#8220;<B>Main
Business</B>&#8221;) .</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify">The Investor intends to invest in the Company in accordance with the terms and conditions of this Agreement,
and the existing shareholders and the Company are willing to accept the Investor's investment in accordance with the terms and conditions
of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt">Thus, the Parties have reached
the following agreement on this transaction based on the principle of equality and mutual benefit.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23pt">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>I.</B> <B>Arrangements
for this transaction</B></P>


<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.1</TD><TD STYLE="text-align: justify">Arrangements for this transaction</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">1.1.1</TD><TD STYLE="text-align: justify">Investment</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">The Investor agrees to invest HK$8,000,000
(the &quot;<B>Investment Funds</B>&quot;) in the Company in accordance with this Agreement to obtain a total of 1% equity interest in
the Company following the transaction in the Company (the Transaction, the &quot;<B>Investment</B>&quot; or the &quot;<B>Transaction</B>&quot;).</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">1.1.2</TD><TD STYLE="text-align: justify">Investment valuation</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">The parties confirmed that the valuation
of the Company after the completion of the investment was HK$ 800 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.2</TD><TD STYLE="text-align: justify">Shareholding structure after investment</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">From the completion date of registration
of the change of registration (see definition below), the amount of capital contributed by the investor and the shareholding ratio in
the company will be changed as follows:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Shareholder name/title</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Amount of capital contribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Shareholding ratio</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: center">Investors</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: center">HK$8,000,000</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">HK$8,000,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.3</TD><TD STYLE="text-align: justify">Corporate Restructuring</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">The parties expressly acknowledge
that the Company is undergoing restructuring and that Advanced Biomed Taiwan will become a wholly-owned subsidiary of the Company after
the restructuring.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.4</TD><TD STYLE="text-align: justify">Shareholder Rights</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">The equity acquired by the Investor
pursuant to this transaction shall enjoy the rights granted to the Investor by laws and regulations and the Transaction Documents (as
defined in paragraph 1.6). After the closing date of this transaction, if any rights conferred on the investor in the transaction documents
cannot be fully realized due to the restrictions of the laws of Taiwan, the existing shareholders and the company will use other methods
permitted by the laws of Cayman and Taiwan to realize the rights and interests of the investor set forth in the transaction documents
to the fullest extent.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.5</TD><TD STYLE="text-align: justify">The purpose of the Investment Funds</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 34.6pt; text-align: justify">Except as otherwise provided in this Agreement
or otherwise agreed by the parties, the Company shall use all of the Investment Funds obtained from this transaction in accordance with
the Company's budget plan approved by the Board of Directors of the Company for the day-to-day working capital and other purposes approved
by the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">1.6</TD><TD STYLE="text-align: justify">Document signing and change registration process</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">1.6.1</TD><TD STYLE="text-align: justify">The existing shareholders and the Company agree to sign other ancillary agreements, resolutions and other
documents (the above documents and this Agreement are collectively referred to as the &quot;<B>Transaction Documents</B>&quot;) in accordance
with the provisions of this Agreement at the same time as or at such other time as the investor agrees to enter into for the investment
under this Agreement to complete the transaction. The existing shareholders and the company are responsible for the registration and filing
procedures of this transaction, and the investor will provide necessary cooperation.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">1.6.2</TD><TD STYLE="text-align: justify">For matters not stipulated in this agreement related to this transaction, applicable laws, articles of
association and other transaction documents shall apply and comply with the provisions of applicable laws. If there is any conflict or
inconsistency between the provisions of the articles of association and the matters stipulated in this agreement, and the articles of
association of the company are not stipulated, the provisions of this agreement shall apply and comply with the provisions of this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="text-align: center">II. Payment of investment funds</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">2.1</TD><TD STYLE="text-align: justify">Payment of investment funds</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">2.1.1</TD><TD STYLE="text-align: justify">The Investor shall pay the investment amount (&quot;<B>Closing</B>&quot;) in accordance with Clause 1.1.1
of this Agreement before September 10, 2022. HK$8,000,000 will be transferred to the company's designated bank account at one time. Existing
shareholders shall provide bank account information to investors five (5) business days prior to the closing date.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 80.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">2.1.2</TD><TD STYLE="text-align: justify">The company shall confirm in writing to the investor on the day of receipt of the investment payment from
the investor.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">2.2</TD><TD STYLE="text-align: justify">Registration of changes</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">2.2.1</TD><TD STYLE="text-align: justify">The Company shall commence the registration of the change of registration in relation to the Transaction
after the Investor has paid the investment amount in accordance with Clause 2.1 above, and then obtain a new registration document of
the Company as soon as possible (the &quot;<B>Registration Change Registration Completion Date</B>&quot;).</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">2.3</TD><TD STYLE="text-align: justify">Closing date</TD></TR></TABLE>






<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34pt; text-align: justify">The closing date (&quot;Closing <B>Date</B>&quot;)
shall be the date on which the Investor actually pays the investment amount in accordance with Article 2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="text-align: left">III. Representations and warranties of the Company and existing shareholders</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company and the existing shareholders shall
separately and jointly make the following representations and warranties, and ensure that the following representations and warranties
are true, complete and accurate as of the date of execution of this Agreement, the date of delivery and the date of completion of the
registration of the change of registration.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.1</TD><TD STYLE="text-align: justify"><U>Authorization</U>. The Company has obtained or will obtain sufficient and necessary authorizations
for signing the transaction documents, performing all obligations under the transaction documents and completing the transactions under
the transaction documents; Each existing shareholder has full capacity for civil conduct and civil rights, signs each transaction document
and performs its obligations under each transaction document. Once signed, the transaction documents are legally binding on the Company
and existing shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.2</TD><TD STYLE="text-align: justify"><U>Invest</U>. As of the date of completion of the registration of the change of registration, the Company
does not have any other subsidiaries, partnerships, branches or offices in Chinese mainland, Hong Kong Special Administrative Region,
Macau Special Administrative Region, Taiwan or overseas, and does not directly or indirectly hold shares or have similar interests in
any other entity.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.3</TD><TD STYLE="text-align: justify"><U>No conflict</U>. The execution and performance of each transaction document does not violate or conflict
with any provision of the articles of association or other constitutive documents of the company; The Company and the existing shareholders
have obtained all third-party consents or authorizations necessary for the transaction under the trading file. Material agreements or
<FONT STYLE="letter-spacing: -0.15pt">contracts</FONT> between the Company, existing shareholders and any other entity will not be terminated
by or materially affected by the execution or performance of the Transaction Documents.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.4</TD><TD STYLE="text-align: justify"><U>The company is valid</U>. The company is an entity established and effectively existing in accordance
with the law. The registered capital of the company has been paid in full and on time in accordance with the provisions of its articles
of association. All articles of association have been legally and validly registered (if required) and are valid and enforceable. The
business scope of the company detailed in the articles of association meets the requirements of U.S. law. The company conducts its business
activities in strict accordance with the scope of business stipulated in the articles of association and the provisions of the laws of
the United States. All licenses, approvals and permits required by the Company to carry out business activities under the laws of the
United States have been applied for and obtained in accordance with the law; And all of these licenses are valid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.5</TD><TD STYLE="text-align: justify"><U>Financial reporting</U>. As of the date of this Agreement, all of the Company's audited and managed
accounts are prepared in accordance with the laws of the United States and are true, complete and accurate reflections of the Company's
financial and operating conditions as at the date of such accounts.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.6</TD><TD STYLE="text-align: justify"><U>Share capital structure</U>. The structure of the company's capital equity contained in the articles
of association and the amendments to the articles of association registered with the Registrar of Companies is completely consistent with
the records of the articles of association and the amendments to the articles of association provided by the company to investors, and
it is true, complete and accurate to reflect the company's share capital structure, and there is no false capital contribution. The Company
has never promised or actually issued any interest, shares, bonds, stock options, options or interests of the same or similar nature to
any person in any form and in any way other than the above shareholders' interests. There is no nominee or similar arrangement in the
company's shares, nor are there any security interests such as pledges, mortgages or any kind of encumbrances, or any other third party
rights.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.7</TD><TD STYLE="text-align: justify"><U>Taxation</U>. The Company has completed all tax registrations required by U.S. law, has paid all taxes
due, and has not been involved in any tax violations, irregularities, or any tax-related disputes or litigation.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.8</TD><TD STYLE="text-align: justify"><U>Assets</U>. The company legally owns and uses all fixed and intangible assets owned by it.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.9</TD><TD STYLE="text-align: justify"><U>Real Estate</U>. The company's own real estate or construction projects, or leased real estate, are
legally owned or leased.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.10</TD><TD STYLE="text-align: justify"><U>Contracts</U>. All material agreements or contracts currently in force of the company are legally valid
and can be performed in accordance with the law, and there is no material breach of contract by the company or any other trading party.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.11</TD><TD STYLE="text-align: justify"><U>Intellectual Property</U>. The Company owns the legal ownership or use rights of all intellectual property
rights (including but not limited to patents, trademarks, copyrights, know-how, domain names and trade secrets, etc.) necessary to engage
in business activities, such intellectual property rights are valid and enforceable in accordance with the law, and to the knowledge of
the Company and existing shareholders, there is nothing that may cause any intellectual property rights to be invalid or unenforceable.
The Company has not infringed or unlawfully used any intellectual property in which any third party has any right, title or interest,
nor has it licensed or permitted any third party to use any of the Company's intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.12</TD><TD STYLE="text-align: justify"><U>Environment, health and safety</U>. Since the date of its establishment, the Company has complied with
and not violated any applicable U.S. laws relating to all environmental aspects of its business operations.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.13</TD><TD STYLE="text-align: justify"><U>Litigation and other legal proceedings</U>. The Company does not currently have the following legal
proceedings that could materially and adversely affect the Company:</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">3.13.1</TD><TD STYLE="text-align: justify">Penalties, injunctions or directives imposed by government departments on existing shareholders or companies;</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">3.13.2</TD><TD STYLE="text-align: justify">Civil litigation, criminal litigation, administrative litigation, arbitration and other procedures or
disputes and claims against existing shareholders or companies.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.14</TD><TD STYLE="text-align: justify"><U>Employees</U>. The Company employs its employees in compliance with applicable U.S. laws relating to
labor applicable to them.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">3.15</TD><TD STYLE="text-align: justify"><U>Provision of Information</U>. All documents, materials and information provided by the Company and
the existing shareholders to the Investor before and after the signing of this Agreement are true, accurate, free from omissions and not
misleading.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="text-align: center">IV. Prerequisites for investing</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">4.1</TD><TD STYLE="text-align: justify">Unless exempted by the investor in writing, the obligation of the investor to pay the capital increase
shall be subject to the satisfaction of all of the following prerequisites:</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">4.1.1</TD><TD STYLE="text-align: justify">There is no judgment, ruling, ruling or injunction of U.S. law, court, arbitration institution or relevant
governmental authority that restricts, prohibits or nullifies the Transaction, nor does there be any pending or potential litigation,
arbitration, judgment, award, ruling or injunction that has or will materially adversely affect the Transaction;</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">4.1.2</TD><TD STYLE="text-align: justify">The Company made the resolution of the shareholders' meeting and the resolution of the board of directors
in relation to the consent to sign the transaction documents and approve the transaction; and</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 46.5pt">4.1.3</TD><TD STYLE="text-align: justify">The Company has obtained all third party licenses, if any, to enter into and perform the Transaction Documents
and the Transaction, and such execution and performance will not cause Company to violate any applicable U.S. law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="text-align: center">V. Transaction fees</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">5.1</TD><TD STYLE="text-align: justify">Unless otherwise agreed, the Company, existing shareholders and investors shall bear all tax costs incurred
as a result of the transactions agreed in this Agreement in accordance with the law.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="text-align: center">VI. Confidentiality</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">6.1</TD><TD STYLE="text-align: justify">Unless otherwise provided by law or agreed by all parties to this Agreement, the parties to this Agreement
shall keep the matters agreed in this Agreement confidential.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="text-align: center">VII. Entry into force, supplementation, modification, variation and dissolution of the Agreement</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">7.1</TD><TD STYLE="text-align: justify">This Agreement shall enter into force upon signature by the Parties to the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 41.8pt; text-align: justify; text-indent: -41.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">7.2</TD><TD STYLE="text-align: justify">This Agreement may be modified or varied by consensus of all parties to this Agreement. Any modification
or variation must be in writing and shall be effective upon signature by all parties to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">7.3</TD><TD STYLE="text-align: justify">This Agreement may be terminated by mutual written agreement of the parties.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">7.4</TD><TD STYLE="text-align: justify">Effect of rescission</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.5pt"></TD><TD STYLE="width: 34.5pt">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When this Agreement is terminated,
unless otherwise agreed by the parties at that time, the parties to this Agreement shall return the consideration under this Agreement
obtained from the other party in accordance with the principles of fairness, reasonableness and good faith, and try to restore it to the
state in which this Agreement was signed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.5pt"></TD><TD STYLE="width: 34.5pt">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon termination of this Agreement,
all rights and obligations of the parties hereunder shall cease. A party shall have no other claim against the other party under this
Agreement or for the termination of this Agreement, except for its liability under Article 7 of this Agreement. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">VIII. Liability for breach of contract</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">8.1</TD><TD STYLE="text-align: justify">If one party to this Agreement breaches the other party, the non-breaching party shall be entitled to
bring a claim and the breaching party shall indemnify.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21pt"><FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="text-align: center">IX. Governing Law and Dispute Resolution</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both">
</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">9.1</TD><TD STYLE="text-align: justify">The formation, validity, interpretation, performance and settlement of disputes herein shall be governed
by and construed in accordance with the laws of the State of New York, U.S.A..</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">9.2</TD><TD STYLE="text-align: justify">All disputes arising out of or in connection with the implementation of this Agreement shall be settled
through friendly consultations between the Parties. If any Dispute cannot be resolved through negotiation within fifteen (15) days of
the Dispute arising, either party shall have the right to submit the Dispute to the American Arbitration Association Center for International
Arbitration in accordance with the Center's then-current arbitration rules. The arbitral award shall be final and binding on the parties.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">9.3</TD><TD STYLE="text-align: justify">During the Dispute Resolution Period, each Party shall continue to have its own other rights under this
Agreement and shall continue to perform its corresponding obligations under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>X. By-laws</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">10.1</TD><TD STYLE="text-align: justify">The headings used in this Agreement are for informational purposes only and shall not affect the meaning
or interpretation of any provision of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">10.2</TD><TD STYLE="text-align: justify">This Agreement and other transaction documents constitute the entire agreement of the parties with respect
to the Transaction and supersede any prior agreements, letters of intent, memorandums of understanding, representations or other obligations
(whether written or oral, including all forms of communication) and this Agreement (including its modifications, agreements or amendments,
and other transaction documents) are contained by the parties The only and entire agreement with respect to the subject matter hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">10.3</TD><TD STYLE="text-align: justify">If any provision of this Agreement is invalid or unenforceable due to the laws of the State of New York,
U.S.A., USA.S., such provision shall be deemed to have ceased to exist ab initio without affecting the validity of the other provisions
of this Agreement, and the parties hereto shall negotiate new terms to the extent lawful to ensure maximum realization of the intent of
the original provision.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">10.4</TD><TD STYLE="text-align: justify">This Agreement shall be effective against the successors and assigns of the parties, and such successors
and assigns shall have an interest in and beyond hereunder. Investors have the right to assign and assign their rights, interests and
obligations under this Agreement to its affiliates or any other third party. Except as provided above, neither party may assign or transfer
any of its rights or obligations under this Agreement without the prior written consent of the investor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both">
</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">10.5</TD><TD STYLE="text-align: justify">Except as otherwise provided in this Agreement, a party's failure or delay in exercising its rights, powers
or privileges under this Agreement shall not constitute a waiver of those rights, powers and privileges, and the exercise of such rights,
powers and privileges alone or in part shall not preclude the exercise of any other rights, powers and privileges.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34.5pt">10.6</TD><TD STYLE="text-align: justify">This Agreement shall be executed in duplicate, one copy for the Company and one for the Investor, and
each copy shall have the same legal effect.</TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center">[No text below].</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 43.15pt; text-align: center; text-indent: -43.15pt">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 43.15pt; text-align: center; text-indent: -43.15pt">[This page
has no text, it is the signed page of the Investment Agreement].</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.1pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 6pt; padding-right: 15.5pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt"><B>ADVANCED BIOMED INC.</B></FONT></TD>
    <TD STYLE="padding-top: 6pt; padding-right: 15.5pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Yi Lu</P></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 43.15pt; text-align: center; text-indent: -43.15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 43.15pt; text-align: center; text-indent: -43.15pt">[This page
has no text, it is the signed page of the Investment Agreement].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 15.5pt 6pt 0; text-align: justify"><FONT STYLE="letter-spacing: -0.05pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 6pt; padding-right: 15.5pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt"><B>Newlink Technology Inc. </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.35pt">(Stamp).</FONT></B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Shuchun Zhai</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name: </TD>
    <TD>Shuchun Zhai</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board </FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 1.1pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> &#8239;/ 12</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>14
<FILENAME>vc051_ex10-10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***] Certain information in this document has been excluded pursuant
to Regulation&nbsp;S-K,&nbsp;Item (601)(b)(10). Such excluded information is not material and confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DEBT-FOR-EQUITY SWAP AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ADVANCED BIOMED INC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>HUNG TO PAU</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>YIMIN JIN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>XIAOYUAN LUO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NANZHEN SHEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>JIAN WANG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>QIANG CHEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> &#8239;of&#8239;6</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>BORROWER (HEREINAFTER REFERRED TO AS PARTY A): </B>ADVANCED BIOMED INC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration number:</B> NV20212175095</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registered address: </B>401 Ryland St., Ste 200-A, Reno NV, 89502,
USA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LENDER (HEREINAFTER REFERRED TO AS PARTY B 1): HUNG TO PAU</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Passport number: </B>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lender (hereinafter referred to as Party B 2): YIMIN JIN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Passport number: </B>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lender (hereinafter referred to as Party B 3): XIAOYUAN LUO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Passport number</B>: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lender (hereinafter referred to as Party B 4): NANZHEN SHEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Passport number</B>: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lender (hereinafter referred to as Party B 5): JIAN WANG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Passport number</B>: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lender (hereinafter referred to as Party B 6): QIANG CHEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Passport number: </B>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Party B1, Party B2, Party B3, Party B4, Party B5, and
Party B6 are collectively referred to as &quot;Party B&quot;, and Party A and its direct or indirect holding subsidiaries are collectively
referred to as &quot;Party A Group&quot;, and Party A, Party A Group and Party B are individually referred to as a &quot;party&quot; and
collectively referred to as &quot;all parties&quot; in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> &#8239;of&#8239;6</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Whereas, as of June 30, 2022,
Party B loaned RMB22,200,000 and NTD174,020,033 to Party A Group for the daily operation of Party A Group. As of the date of signing this
Agreement, Party A has not repaid the above loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">The parties confirm that in accordance with the principles
of equality, voluntariness and good faith, they have reached an agreement on the borrowing of money from Party A to Party B, and signed
this debt-to-equity swap agreement (the &quot;Agreement&quot;) on June 30, 2022 for all parties to abide by and fulfill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt"><B>Article 1 Debt-for-equity swaps</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">After consensus of all parties, Party A will issue additional
Party A shares to Party B to repay the above loans. After Party A's additional issuance, Party B obtains Party A's shares as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Party B 1: 4,405,625 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Party B 2: 2,193,750 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Party B 3: 2,060,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Party B 4: 1,511,250 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Party B 5: 1,243,750 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Party B 6: 1,230,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt"><B>Article 2 Special Engagements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">2.1 Any tax liabilities arising from the provisions
of this Agreement shall be borne by each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">2.2 Party A shall complete the corresponding change
registration in accordance with the laws of the State of Nevada, USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">2.3 Party A and Party B confirm that once Party A completes
the corresponding change registration, Party A shall be deemed to have repaid all the loans of Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> &#8239;of&#8239;6</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Article 3 Liability for breach of contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 7.1pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">After this Agreement takes effect, if a party fails
to perform its obligations in accordance with this Agreement, the breaching party shall bear the corresponding liability for breach of
contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Article 4 Dispute Resolution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Matters not covered by this Agreement and disputes arising
from the performance of this Agreement shall be resolved through negotiation between Parties A and B; If the negotiation fails, the China
International Economic and Trade Arbitration Commission shall be requested to conduct arbitration in accordance with the arbitration rules
in force at that time, with the place of arbitration being Shanghai and the language of arbitration being Chinese.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><B>Article 5 Entry into force, variation and rescission of the
Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">5.1 This Agreement shall take effect from the date of
signature and seal of both Parties A and B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">5.2 After this Agreement takes effect, none of the parties
shall change or terminate this Agreement without authorization; If it is necessary to change or terminate this agreement, it shall be
agreed upon by all parties and a written agreement shall be reached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Article 6 Miscellaneous</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">This Agreement shall be executed in 7 copies, one copy
for each party, and shall have the same legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 10pt">(There is no text below this page)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 10pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> &#8239;of&#8239;6</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">This page is a signature page with no text</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PARTY A: </B>ADVANCED BIOMED INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Signature of authorized representative</B>: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Hung To Pau</FONT></TD>
    <TD STYLE="width: 35%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> &#8239;of&#8239;6</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">This page is a signature page with no text</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PARTY 1: HUNG TO PAU</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">(Signed): </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 43%"><FONT STYLE="font-size: 10pt">/s/ Hung To Pau</FONT></TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Party B 2: YIMIN JIN</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Signed): </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Yimin Jin</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Party B 3: XIAOYUAN LUO</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Signed): </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ XIaoyuan Luo</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Party B 4: NANZHEN SHEN</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Signed): </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nanzhen Shen</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Party B 5: JIAN WANG</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Signed): </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jian Wang</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Party B 6: QIANG CHEN</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Signed): </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Qiang Chen</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> &#8239;of&#8239;6</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>15
<FILENAME>vc051_ex10-12.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***] Certain information in this document has been excluded pursuant
to Regulation&nbsp;S-K,&nbsp;Item (601)(b)(10). Such excluded information is not material and confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>National Taiwan University</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Industry-Academia Cooperation Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NATIONAL TAIWAN UNIVERSITY (&ldquo;Party A&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ADVANCED BIOMED INC. (&ldquo;Party B&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B will provide funds for the purpose of
research and development, and entrust Party A to handle the industry-academia cooperation plan, which will be executed by the project
leader designated by Party A. Both Party A and Party B, as well as the project leader designated by Party A, agree to cooperate in handling
the matters related to this contract as agreed, and agree to establish the following terms and conditions, and fulfill them in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1: The Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The details of the industry-academia cooperation
plan are outlined in Annex 1, which is an integral part of this contract and has the same legal effect as this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2: Term</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of this agreement shall start from December
1, 2024 and end on November 30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3: Payment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total amount of funds for agreement is NTD
3 million. This includes 15% of the total amount of funds designated by Party A as management fees. The funds will be disbursed in two
installments by Party B&rsquo;s subsidiary (Advanced Biomed Inc. (Taiwan)) registered in Taiwan to the bank account designated by Party
A after the contract is signed, in the following manner:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">First installment: Within
15 days after the execution of this agreement, Party B shall pay Party A a1 total of NTD 1.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Second installment: Party
B shall pay a total of NTD 1.5 million on June 1, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4: Payment Methods</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A shall provide invoices to Party B when
delivering research reports during the term of this agreement to collect payment from Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fees under this agreement has been incorporated
into Party A&rsquo;s university fund, and the fees shall be used in accordance with the plan. The project leader designated by Party A
may make adjustment to particular fee schedules based on the need of the plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5: Extension of the Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Party A believes the term of this agreement
needs to be extended, Party A shall provide supporting materials and obtain Party B&rsquo;s written consent. The plan can only be extended
for one time with no additional fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6: Status of the Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Party B needs to know the status of the plan,
Party A shall provide detailed information and necessary materials. Party B may send staff to Party A&rsquo;s place to inquire about the
status of the plan. During the term of the plan, if Party B&rsquo;s assistance is required by Party A, Party B should cooperate with Party
A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7: </B>All equipment and materials
purchased by Party A using the funds of this plan shall be the property of Party A and managed as university property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8: Ownership of Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B shall not have ownership of any and all
products, such as reports or works produced, as a result of executing this agreement (hereinafter referred to as &quot;research and development
results&quot;). Party B shall not use the research and development results directly for profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B shall not apply for intellectual property
registration or protection using the research and development results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9: Plan Reports</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The payment shall be made in installments. The
project leader designated by Party A should provide mid-term report to Part B before applying for any mid-term funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within two months of the end of the plan, the
project leader designated by Party A shall provide results or a final report to Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10: Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the plan cannot continue because of Party B,
Party A shall terminate this agreement in writing. Party A shall refund the unused funds previously paid by Party B in proportion, and
the agreement is terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this agreement cannot continue due to force
majeure on Party A or the project leader designated by Party A, the agreement may be terminated at any time. Party A shall refund the
unused funds previously paid by Party B in proportion, without objection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11: Liability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. If any third party accuses Party B of infringement
regarding the &ldquo;research and development results&rdquo; produced by this agreement or Party B&rsquo;s use of the &ldquo;research
and development results,&rdquo; Party B shall bear full responsibility without involving Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. Party A guarantees that the &ldquo;research
and development results&rdquo; produced by this agreement are created independently and without any plagiarism. Party A does not guarantee
the patentability, applicability, or commercialization of the &ldquo;research and development results.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12: Confidentiality </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. The &ldquo;confidential information&rdquo;
referred to in this agreement is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(a) Confidential Information
of Party A: including any items, documents, or materials related to the &ldquo;research and development results&rdquo; produced by this
project, which were originally owned by Party A and have been disclosed as a result of the execution of this project, regardless of the
medium to which they are attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(b) Confidential Information
of Party B: including any items, documents, or materials related to this project that were originally owned by Party B and have been disclosed
as a result of the execution of this project, regardless of the medium to which they are attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. The confidentiality obligations of the &ldquo;recipient&rdquo;
under this Article do not include the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(a) Information that the &ldquo;recipient&rdquo;
already possessed prior to obtaining it from the &ldquo;disclosing party&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(b) Information that has been
made public and for which the &ldquo;recipient&rdquo; is not at fault for the disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(c) Information obtained legally
from a third party, and for which that third party has no confidentiality obligation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(d) Information disclosed by
the &ldquo;disclosing party&rdquo; to a third party without a confidentiality obligation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(e) Information developed independently
by the &ldquo;recipient&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(f) Information that must be
disclosed due to legal or government agency requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">(g) Information disclosed by
the &ldquo;recipient&rdquo; with the prior written consent of the &ldquo;disclosing party.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C. The &ldquo;recipient&rdquo; shall be responsible
for maintaining the confidentiality of the other party's &ldquo;confidential information&rdquo; in a manner consistent with the care of
a prudent manager, and shall not disclose or reveal it to any third party for their own benefit or for the benefit of any third party.
The period of confidentiality obligation shall be five years from the date of receipt of the confidential information. This period shall
be an unchangeable period and shall not be affected by the expiration, termination, revocation, or invalidation of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 13: Public Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Party A or the project leader designated by
Party A may publish the research and development results without obtaining Party B&rsquo;s consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 14: Use of University Name and Protection
of Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. Without the prior written consent of Party
A and relevant government agencies, Party B shall not use the name, emblem or other representation of Party A or relevant government agencies
when using or promoting research and development results for commercial purposes (including but not limited to public marketing, promotion,
or advertising of products, goods, or services), nor shall it in any way imply any connection between Party B and relevant government
agencies or Party A. If Party B intends to use Party A&rsquo;s emblem, it shall follow the procedures set out in the &ldquo;National Taiwan
University Trademark Usage Management Regulations&rdquo; and the &ldquo;National Taiwan University Trademark Usage Application and Management
Rules,&rdquo; and the authorization conditions shall be negotiated separately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. If Party B violates the above provisions, in
addition to compensating Party A for any losses incurred, Party A may terminate this agreement without notice and shall not refund any
fees already collected by Party A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 15: Interpretation and Dispute Resolution
of the Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. This agreement shall be interpreted and governed
by the laws of the Republic of China (Taiwan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. Any legal disputes arising from this contract
shall be submitted to arbitration in Taipei with the consent of Party A, and resolved in accordance with the rules of the arbitration
institution and the Arbitration Law of the Republic of China (Taiwan). In the event of litigation, both parties agree to submit to the
jurisdiction of the Taipei District Court as the court of first instance and resolve the dispute in accordance with the laws of the Republic
of China (Taiwan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 16: Miscellaneous</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A. Any matters not covered in this agreement shall
be handled in accordance with the &ldquo;National Taiwan University Building Education Cooperation Plan Processing Guidelines&rdquo; formulated
by Party A and related laws and regulations, or shall be added in writing with the agreement of both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">B. This agreement is executed in duplicate, with
each party holding one original copy. The duplicate copies shall be held by Party A&rsquo;s project leader and the relevant units for
Party A&rsquo;s copy, and by Party B for Party B's copy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Party A</B><FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT></FONT></TD>
    <TD STYLE="width: 43%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">NATIONAL TAIWAN UNIVERSITY (Seal)</FONT></TD>
    <TD STYLE="width: 49%; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Signature and Seal)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Representative<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>Wen-Chang Chen, Ph.D.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center; width: 30%"><P STYLE="margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">/s/ Wen-Chang Chen</P></TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 35%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>No.
1, Sec. 4, Roosevelt Rd., Taipei 106216, Taiwan (R.O.C.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Project leader designated by Party
A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 0.25in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Name<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>[***]</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature and Seal<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65289;</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>[***]</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Department: [***]</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Party B</B>:</FONT></TD>
    <TD STYLE="width: 43%; text-align: center"><FONT STYLE="font-size: 10pt">ADVANCED BIOMED INC. (TAIWAN)</FONT></TD>
    <TD STYLE="width: 49%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Signature and Seal)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Representative<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>Zhenyi Li</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center; width: 30%"><P STYLE="margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">/s/ Zhenyi Li</P></TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 35%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(As a joint guarantor, I agree to guarantee that
Party B will fulfill the debts arising from this agreement. When requested by Party A, I will assume joint and several liability for the
repayment of all or part of the debt, and I will not refuse or object for any reason)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>Chairwoman
of the Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: justify"><FONT STYLE="font-size: 10pt">Principal Executive Office<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;710, 689-85 Xiaodong Road, Yongkang District, Tainan, Taiwan</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Registration Number<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>54566067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact Person<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>Zhenyi
Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>689-85
Xiaodong Road, Yongkang District, Tainan, Taiwan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone Number<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65306;</FONT>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Annex I: Research Plan of Identifying Novel Biomarkers
for Early Detection of Lung Cancer (II)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>16
<FILENAME>vc051_ex15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc051_ex15-1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Stockholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Advanced Biomed Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LETTER IN LIEU OF CONSENT FOR REVIEW REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have reviewed, in accordance with the standards
of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial statements of
Advanced Biomed Inc. and its subsidiaries for the three-month periods ended September 30, 2024 and 2023, as indicated in our report dated
January 7, 2025; because we did not perform an audit, we expressed no opinion on that information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also are aware that the aforementioned report,
pursuant to Rule 436(c) under the Securities Act of 1933, is not considered a part of the Registration Statement prepared or certified
by an accountant or a report prepared or certified by an accountant within the meaning of Sections 7 and 11 of that Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><IMG SRC="vc051_ex15-1img02.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Mateo, California</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 7, 2025</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WWC, P.C.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCAOB ID No. 1171</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="vc051_ex15-1img03.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>17
<FILENAME>vc051_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Significant Subsidiaries of Advanced
Biomed inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 51%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Significant&nbsp;Subsidiaries</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Place&nbsp;of&nbsp;Incorporation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Advanced Biomed Inc. (Taiwan)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Taiwan</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Advanced Biomed (HK) Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Hong Kong</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">People&rsquo;s Republic of China</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>18
<FILENAME>vc051_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc051_ex23-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Consent of Independent Registered
Public Accounting Firm</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the inclusion of our
report dated October 28, 2024 in Amendment No. 14 to the Registration Statement on Form S-1 (No. 333-272110), under the Securities
Act of 1933 with respect to the consolidated balance sheets of Advanced Biomed Inc. and its subsidiaries (collectively the
&ldquo;Company&rdquo;) as of June 30, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss,
changes in stockholders&rsquo; equity, and cash flows in each of the years for two-year period ended June 30, 2024, and the related
notes included herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference
to our firm under the heading &ldquo;Experts&rdquo; in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center">&nbsp;<IMG SRC="vc051_ex23-1img02.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">San Mateo, California</TD>
    <TD STYLE="text-align: center">WWC, P.C.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">January 7, 2025</P></TD>
    <TD STYLE="text-align: center">Certified Public Accountants</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">PCAOB ID: 1171</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="vc051_ex23-1img03.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>vc051_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #! 80# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *IZCJMAI%OY^H7<5O'V+M@GZ#
MJ?PK'\9>+(/"VF"0!9+V;(@B/3W8^P_6O!=3U6]UB]>[O[AYIF[L> /0#L/:
MO1PF!E77-)VC^9YF,S"-!\D5>7Y'L=U\6?#T#[88[RX_VDC '_CQ!_2JW_"X
M-&_Y\+_\D_\ BJ\9I\4,DS;8HV<^BC->K_9N'2UO]YY/]IXEO2WW'L?_  N#
M1O\ GPO_ ,D_^*H_X7!HW_/A?_DG_P 57E*:+>.,E43_ 'F_PJ== E/WIXQ]
M 34/ X1?\.;+%XY[+\$>G_\ "X-&_P"?"_\ R3_XJC_A<&C?\^%_^2?_ !5>
M9C0#WN1^"?\ UZ/[ _Z>?_'/_KTOJ>$\_O97UC'^7X'IG_"X-&_Y\+_\D_\
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M]/>.::]NE5N5$\>58?B*]=\'>)!XGT,7C1K'<1N8YD7IN !R/8@BL7QTBO\
M#%6902J0%2>QRH_D35'X/_\ (&U'_KNO_H- 'I%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5!>?\>-Q_US;^53U!>?\>-Q_P!<V_E36XGLSY=/
M4UU=A_R#[?\ ZYBN4/4UU6GG.G6_^Y7U^(V1\IE_QOT.DTG_ (\S_OG^E=%H
MO^LF_P!T?SKG-(/^B./1_P"@KH=&;%Q*OJG]:\:MU/>I]#H+1=]W&/?-;=8M
MBP6\CSWR/TK:KS*FYV1V"BBBLR@H(R"#T-%% '/,NUV7T)%<_J:[=0D]P#^E
M=#*=TKL.A8FN?U7_ (_V_P!T5WTMSFGL<[K/6$^Q_I7-ZU_R#C_OBNDUG[T/
MT/\ 2N:UK_D''_?%>K0W1YV)_AR]"CX9_P"1ITG_ *_(O_0Q7TK7S5X9_P"1
MITG_ *_(O_0Q7TK7)FWQQ]/U%D_P3]5^1X'XV@-U\1;VW#!3+-&FX]LJHJUX
MB^'-_P"'=+;4EO(KB*)AO"J59<G /OR15;QI.+7XCWEP5W"*>-RN<9PJFM'Q
M5\2F\0:.^FVUA]GCE(\QVDW$@'.!P,<@5XI[AWGP[\0W&O\ A]C>-ON;:3RV
M?NXQD$^_4?A7G-U_R5X?]A1/_0Q7<?"G3)K+PW-=3(4^UR[HP1U0# /YYKA[
MK_DKP_["B?\ H8I@=I\7?^17M?\ K\7_ - >K'PI_P"1./\ U\O_ "6I/BC9
MR7?@UWC4M]GF25L#MRO_ +-7%^"?']GX:T2:PN[6>5O-,L;18P<@#!R>.G7G
MK0(H>&^?BE%C_G]D_P#9JWOC#_Q_Z3_US?\ F*Q/A]#+JGQ BO-GRH9)Y,=!
MD$?S85M_&'_C_P!)_P"N;_S%(9BZE=OX;\8QZDJD+=6(E4#N9(<9_P"^\G\*
MS9K/[/\ #^"Y9<-=Z@2#ZJB8'ZLU=3\0-(EN?#WAV_@B9V6V2%]JY.-H*_\
MLU,\=:?_ &5X#\.V97:T>2X_VBH+?J30!TUC_P D;D_[!TW_ +-7E_A?PI=>
M*KBXBM9X8C"H8F7/.3CL#7J%C_R1N3_L'3?^S5YGX2\62>%+BYFCM$N#.@4A
MG*XP<T >I>!/!MYX4DOFNKB"87 0+Y6>-N[KD#UKB/BU_P C=;_]>B?^A/74
M>%OB/<>(=?@TU].BA64,2ZR$D84GICVKE_BV<>+;<_\ 3HG_ *$],#L?'/\
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M.CZSA/YOS#V>/_E_+_,X@Z_%V@?_ +Z%0R:^Y&(X%!]6;-=[_P *:_ZC@_\
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M0<>AP>1]: +UA>1ZCIUM>Q!A'<1+*H;J PSS^=6*:B+&BHBA44850, #TIU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>vc051_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img02.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0.?:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C$M8S P," W.2YD86)A8V)B+" R,#(Q+S T+S$T
M+3 P.C,Y.C0T(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7!-33TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(@>&UL;G,Z<W12968](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;7!-33I$
M;V-U;65N=$E$/2)X;7 N9&ED.C8R-T$P-T)%,C(S,S$Q144Y.$5%03E%1#$Y
M-$$W1$4T(B!X;7!-33I);G-T86YC94E$/2)X;7 N:6ED.C8R-T$P-T)$,C(S
M,S$Q144Y.$5%03E%1#$Y-$$W1$4T(B!X;7 Z0W)E871O<E1O;VP](DUI8W)O
M<V]F=,*N(%=O<F0@3%130R(^(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII
M;G-T86YC94E$/2)U=6ED.C X,S1%.4)"+48X-#(M-#="0BU!-#DV+3-"0D,W
M,S0P-#=",B(@<W12968Z9&]C=6UE;G1)1#TB=75I9#HP.#,T13E"0BU&.#0R
M+30W0D(M030Y-BTS0D)#-S,T,#0W0C(B+SX@/&1C.F-R96%T;W(^(#QR9&8Z
M4V5Q/B \<F1F.FQI/E-A8F%R:7-H(%,N/"]R9&8Z;&D^(#PO<F1F.E-E<3X@
M/"]D8SIC<F5A=&]R/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \
M+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @
M,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4      !#\
MX1^)R+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @("
M P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@!"@)L P$1  (1
M 0,1 ?_$ -T  0 !! ,! 0             ( P8'"0$"!00* 0$  P$! 0
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MRPOCS@H'V*?5L^KG'>6%\><% ^Q3ZMGU<X[RPOCS@H'V*?5L^KG'>6%\><%
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MWO3"V\\]KV7;V4\>)RD#/XWS#=ELHW';-L3MIN@=,I>U;G64,V(_2< JDJ
M8A0&@N7K)-W^:-JM[[-(7'5PX[@K5W'9]0PC=UP9#C%UTK85?Q4I,,KA:+IN
M6Z!DRJQ?>P-SB'=>Z (#V:#7ED;KC=Q\!@3?]<EI16%[MN[8YEW&F/(;+%F^
M$[FP_F1K?,E#L7\.ND*K8UK7Q;II8IG38BRR:7!^,.M!.>W=WFYW<!N3E-J6
M"GF/K8=8AP=C?(.X/.5T0[B;8,,C9.B"SEL8_L2R2.&J3M$6!5%'JZ[DHH)E
M[0#&$ H(29DZXS=98& ,SS\'A&UY3<KL_P!T<5A;<+AV+,_G8^_,>2352=9Y
M!QNX S>7BE9ZSRA*)M5T3&0(54O; 0!H)9[Y^M89X9P_M)N+;L>UKZR#NWOG
M#:=MMI07$A$VOB7($NSC;@R-+LV9RJ=YPKAT5FV%0Z95G93EYRC0>3DC?/F^
MS-X.ZK;G<^X#;YART\"X9Q5E"V+SR3;0H%N=_D4KCCC94%9=NVCXQK(-RM04
M2445#NH"!1$*#U9#=GO9EM\&*]H-M2>$8-Q?.SM?<?(SDA S,]&A=D;)Q$&\
MMN+?-W3<YK8DG\D"Q7(D,Y32'M4S:!J$D]B.]&^]QTEGW#>>;$AL3;F-L&0"
MV7DNU;;EW4Y:,G"S+%*4LN_[9E7K=HNY@;JBW!3E0.4%452B4?;H(#7!UA6]
M>'P?OWS!;K+&%]3VS_<]*8@LO%[6V'S%]EVW(1Q&]UAO#)GYG4=>\TC(=S:<
M#<R'&4-1Y:#/UG]9%+[@UMH5\X*D8FTK#R7<.1K=W/V=D2W7[C(^&[GQ;93R
MZ;@QZ\C"*-Q@+E8KQZR1SN"B11 Q7!!$HA0?'C;=+O[W5;=+CW@[<K=Q1&V;
M,2\T? N![FC)*1N;)=APEQC%IW7=E]).$2VG-7!$L5W;%BU;.D]3I%44#4:#
M<O;CN2?V] OIED,;+O8:+=RL<(B86$DY8H+/F0F$ $PM71S$UT#7AH/8#F#[
MP4'- H% H% H% H% H*:@ (!J #H8!#4-=! !T$/:$*#7!A+DZRG>H <@?-+
MMV-H'-J9C<'$.GMCIRT&R.@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4&H7JTOY1O6N_Y[2?_ $.X\H-O5 H% H% H% H% H% H%!\AUC 90HD'@
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MT+DC'982/7C)^W9AN!3@@JH5=J<X&-H.@!@7#O5S[Q=LJ6SG.]DWUC/+>Y;
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MIKS_ ,V@Q7FO)ULX1Q;D7,5YNDV5J8TLJ>O&96%(#F[W@F:C_A()0[H*RQD
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MR$S;T,Y?(M2OVZJC9PJ)NYF-PB(!M(H% H% H% H% H% H% H% H% H% H%
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M->1$1[A0.@5LO]6/#7D1$>X4#H%;+_5CPUY$1'N% Z!6R_U8\->1$1[A0<=
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M@?(&QO$VU/)R&]Y4#Y V-XFVIY.0WO*@?(&QO$VU/)R&]Y4#Y V+XF6IY.Q
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M?N=F@I]W#A*/ 8#&$ $AM $FO[O3B *#@JYAYTC@(G.F7G$HB4HF*/%IR$,
M<_8'DH N"@(!PF$P\/"! $P"!A$H#Q: 4 X@'LT%4IQ$P@)= #02CKKQ?NN3
M30-!Y.?EH(U8&_AYN5_RO(?XE6U028H% H% H% H% H% H% H% H% H% H%
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M(&+Q'R^7\V ZG(1.SK:(0YPY@!701#[@4$F_N>SL?AH% H% H% H% H% H%
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M"<Y@Y"=MP'X3"H;A(5,VFBAQ-^U+J(4'V<8#RARAV! 2Z"'MART#B#V"7\-
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MKQ&UX T'0PAV -^+J.G9&@J%,!@ Q1 0'7E#EYAT'^8(4'- H% H% H% H%
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M4Z0#H503::%T  E GQ=S)Q:<7"'$)0T*)OVP@'8 1H.] H% H% H% H% H%
MH% H% H% H ^SV#R4&MG)$I,[F=T$]M9@+\O+'..\%VM:N0\U.+'E%;=NS(L
MW? O/D?8S:ZV1PE8"V6,<R4=OSLSH.G!SI)E.4A3 8,S!LEQ,   77G4
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M1$P\.FIBASB7EY^:@Z]\IZ\( <1U+P@!![<#Z"4Q?;*(#S_<&@[@ND.NAPY
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M^[9EKLM"[+9BKCE[1>7+!2L,A=$ 5GX<@7$@U7:)R\6#])RT[_8IJ 9$QRB
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MF>N&$:1D0A$O[YEHT"HGD'B"P$+J $[8=0Q5/=3AM^FXV^WL1?62K1O')[;
M@WS>T5(0BRKV8P&]AW4=<#*(<11X.*F[R&W619M=L@EWP+-/M2\M!EF"ZO5[
M:F4LNY8LS<MER ?YLR'9>1KMA3V_C.5:DEK1B8V %E$N7UIKRT*UDXN-*FZ!
M%T43@81#2@Q!:O5!8QCHZ[<?7;G++U_8(O?/D[N6N_"-Q%LR.MVY\B2TTA-
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M[A/%]QW59>0+GQ_;5Q7QCY@_C+.NB6CTY.X+<8RS8&<JE%R[@@N&H/F8F37
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M$URHM@+W4R34#F$?QC&$W.-!D?IR6Z.O<L!;FCGT#4"X9N0#"4!]LR !H&M
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M8K< ,82E+J/.-!\TC<$;#-$Y&4DXR/CU.Y_[M?R+5JT**XAP #I=1-!85!,
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M)"IG$ .F<1 FAR")3\7*/(/+R4'DL;FB)"57B6DU#.WS4Z@.(YM*,W<DB0H
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MU@^:H*!VAX8Q2RC=N0WO8.#)FUL.9>5<W2^;V]<=_/H',,->%Y7&Z1DW)&<
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H_&YOVW^J]O[M!WH% H% H% H% H% H% H% H% H% H% H% H%!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>vc051_img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img03.jpg
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M P,# P,# P,# P,# P/_P  1" #% /0# 1$  A$! Q$!_\0 N@   0,$ P$
M              8("00%!PH! @,+ 0$  @,! 0$!             @,!! 4&
M!PD($  ! P,# P($! 0#!@,%"0 ! @,$$04& "$',1((01-182()<8$R%)$5
M%@JA0B.QT5)B,R3!\7+PX247*(*20X,T1$5V&!$  @$"!0(% @,&!0,%
M  $"$0,A,1($!4$&47$R$P=A(H&1%*&Q0B,S"/#!T3054G(6\6*2-1?_V@ ,
M P$  A$#$0 _ -_C0''<!ZC^.ABJ3IU/-3B2GZ%)4:B@[AN0H ]-]M92KY$7
M*#5&U5IM8YT\/Q&W>-'E+QCY56+/\DXM_GW\KXVY8SCAO(3D5J_E$E65X%*9
MB7>1 9_<2 _9Y1DH7&=)2M:#]2$D4UPN"YWC.>MWY\9K<;-UVYU37WK-8^'^
M$>][^^.>Y?C?><?M.Z8PC>Y+B=OR%C2ZUL;E-P;P5&TLOR;'*]R>O</XC7<H
MZTZGA5BJK%'7O1\>G7K^.BQR,:HI5;5 #B#L%IJ/2HKM\NNLT:Q:=#-3L%)/
M10/IL0=_AK S5>@5'Q'\=*,/#%Y!4?$?QT"Q55D<Z - &@#0!H T : - &@#
M0!H T : - &@#0!H T : - &@.#T/X'KTUAJJIXA9D _W).:^9,FYSA<*<$Y
MEE^-2>->,K_R%FQQ"^7&R.RRB ;Y+9GO6QYI;AMF/PVU-(6:>Y*%!W'7Q[O?
MG.X=QR\.([6N^UN-I8E<O/QA%5DOR1^@_P#:K\<_&.Q["N]^_+G'V>0XSEN3
MAL-F[E-=N=R6CW+:=&W;<JNF6E#I<1F\T^:WA=Q;<N#_ "0NOC;RFB=:(V8<
MAV?$+%G%PES<5$NSY'8YEJR!Y$>.U?G@Q-+Z%I=5](-4K5KU,+O*=T]KV%Q.
M\>VW,J*=Z%']T6G)1\6Z--'PGN?A.T/@#YZY+B.[N!V_</9>WD_TNWN796=5
MF\ZQDKD4Y)0=8U54Y)QS&#?9G\:/+/#[URMG68>16=6/C+&_*#GRQ9IP5D'%
MELM,3F+*&1&MTSE<W^Y(:O%H;O5V=;EI1!0J,I<3L0X4*5KP7Q;V[W/LKN\W
M>ZWFYC9AO[R=J[%Q5VM$KJU9USJL/Q/M']W'R7\2\_L.+X7M_A=CN.=O]L\3
M*SO]ON9SEL+%NW.O&NU33.Y;3T7*O5"JPQ-C?L2I+2"D4 3]*J"I%*4!Z[^F
MOO%;BGJK_,47CTR/S_L6IV81=NJM1MND:9-X4:\F:Y'$6$>07E-Y#>3F+VSR
MHY0XRLW&^;Y#)ALQ[]D%P@I@R<LOELB6^% 9OUM:@18;<0!(15(304%-?$>-
MV_<_<7-[W91Y&[LU9N8*'\2DY9_1:</,_3;O6_\ $/P_\2=F<A?[-X_EN>YG
MC(^]*XE2;I"57XR6IF=^ >5/(7QK\P[+XD<T\BN\PX;G=O$G$,IN*G9%TMST
M^%<I=KN#$Z4IZYML2Y%L>BR8LAU]"%A+C:@*UZO ;WN+B.[UV[R.\N;S;7+?
MN:IYI)N-%7IA4^=_)'9'Q7\J_ ]WY[^-N*_XCGN)OJ.]L*:6WBDU8]I6JXNC
M4E/HG1CS+A]Q[Q$LT:YJ<Y'D//VO)?Z5>M\7&<C-V<O!?<CK_;0'K=&<DPF5
MLGW9"?\ 1;%*J)4 ?7WN^>VXW/:]^E_W7;T1Q=4\<$?"./\ [4OF_>*S*UP-
M^WQUS:K<ZW?3@MO*/N0;E6D*QJU"332Z"PY=\Z?&_@N[QK!R/GHBY&\TQ)<Q
MRR6N??[Q ARF@]&DW>);&7$6S]PRL+2T\M#RDFH0>NKN4[MX/B9*-^Y<K1.4
M:8QJJ_<LU58JO1IG"^/O@GY8^3K=W==L<3N'M+<I)2G>LQLW5%N-;5RY**N)
MTZ5Q,Y\.<Y<7<\XNG,.*LLMF4V)#G[24[%]R/-MTT-I<$.YVV4AF=;97MD$(
M>0DJ3NDD;ZV^,YO8<U:=_C+D9V$JN2=:?]W@_,\EWGV1W5\?<Y+M_NS:7=CO
MXUK;G&BHOXH2IIG#PG%N+6*=#,P-0#\0#KKK%56*/*X=,CG0!H#H7&TFBEH2
M?FH#UIZGXZ Q=RUSAP]P1C4C+^9.3\#XPQN.VMU5WSK*+3C<5T(_4W#_ )C)
M9>N$@DT2TPAQU1- DG64F\$"!KR/_N8/"CBFXIL?"&,YYY+W-NXQH4N\8^TG
M ,(;0],9CN+@7_+87\UN[H;6HH]BVEE9"?\ 5 -1-6FXN4L*>('.<$??=\"^
M9/V$#)LTOG!>22TM(=M7*UBDQ;,W*7LIIG-+ J\8X60K]+DER+4=0GIK5MWH
MSKTHS+C)9IDM&#<C8%R996<BX]S;$<[L4@(4S>,-R&U9);%AQ <0/WEIE2V4
MK*#7M)"A\-6IIXHP+/O1W!'<GN(J$U%2!U('J!I55IU!VUD!H T : - &@#0
M!H T : - &@+!?LCM./6.\9!<Y;,:V6*UW"\7*0\?;;8@6R*Y-F.K4OM2E+<
M=HFIU"[<A8C.Y=>F%N-9/P69L;';7N1WMOC]HG/=W;\;,8K-W)-)+ZY]#64\
M:N?>0AS%Y!>1+'C7R)SXQS'(OF,HEV"-*7;,?L<F8J1,LBI(M-Q;D/JM A1E
M)2$]C35""54U\*XGG=]+D]_ST-A<W"W%WV[;25)VI.C:KTIXT\C]7?F/XJX-
M?'W:OQI+NOB>V]]PFTLWKEN]<49W-S=HW>:63C+&K''_ &J.2)^#<@\W^.&8
MV2]8?+=DIY'Q;#[_ !GHMWLY;<8@W*T/1Y#3#ADILLNWO&B05I96Y0#78^,^
M1O[#>[OA-U#3!W'<MVW2L7+-+\/W'SK^]3L[CNX.VNU_F#MO=[3DMA=VL.-W
M%[;N,XW+MF"G[CDL56ZYI5Z^:)WX1#[:74 @ 4H:U-=@3Z5IK["I)1<5%JKS
M/SGTW+;:W$E.=<'X?0H;X_,81%,-CWG2\@%%2GZ0L CNZ)K7UU3>E*,5&&,Y
M52_*I)7K5NU=G-TI##/.ODS6W\?+CY60/)[RR/BK8\$O=W<SS(498UG+K+<=
MFW(S>_+M:[>I^?;TJ=5)#H7N:@#;7P[C]QW5_P"2<G+MAVJZH*YK2?6:C2O7
M,_57Y7XWX/W7PE\>W?F?<\G8M0XRW<L+8T<VU&&O7]LJ8..G+J/J\=?#3GVZ
M^1B?*CRRO^/OYM:XKC6,XIC3K,N'!=_92;=&><7%2W;[;!L\:4[^VC,EU2GG
M2XM==C['MSMGG)<I<[@[GOVY;^%IP@H*B4'CCT]39_-7RK\Z?'>S^*O_ ,)^
M&=KN;?9^YE.5W<;A1C=N?=&[6=%%R>JBJUTPP&]?;"XFX]S_ )!\GLFS/#+!
MEUSQ[,&;58SD%NC76/;&KA>,FFSC%B34.QVWI;D1H*<">^B  0*U\YV!QG&[
MSD>4W.YMQNWH7;FBJK1KJOJ?3O[QN]NZ>.[9[%XKCMWNMCQ\N"M7;CL3<)77
M"W9@U-Q:U1TMX8X5, >*2.>LEY<\BLYP/@WBWG+-G<PN$3*9/*UX::N6,IG7
M:\-JCVNTS'4,EB68GLK?""4)CH;20GZ=<KMK:<[NN:W^YVNSV&[W/N8N_-IT
M2I%..*6"27TH?4_FE_%W%=B=H]L=R=R<OP'#QXRS=V\./VMOV+RTIQNW;ZG&
M<KDJZE&E*RHU5#VO [ASFCC#R=YDO67XOQWQSC.;8Y)DW/CG!<\L^0MXU?F[
MK;Y,%#%@BW"5=+=%:3+E=JGTCVOW'8/I[1KVG9O%<GLN8WG([N-JS:N)N=BW
M*/MZZXQ@JU45C2J6!_-G]R_?W8O>'Q=P.W[?WO,\IS6PO*V]_O\ :JPK]B*T
MJ*DE]U:+!.7XLFN24I0@$_Y!0GJ0$C<TU](3JJTI]/#Z'\3MU=5@F)W)\TQ#
M";',R;,\HQ_$,<M[9=G7_*;O Q^R1&P">^3=+L_$@LIH.JG!K((4O)[^X-\"
M. C<+1@637WR3S.&EUMNS\1P6UXHB8VM3?LW+D:]&'C[;/>!5<!-Q('1)Z:4
MKD#74\H_[CWSEYC5/LG"\+#/&7%) D,-2<5B(S+D5R,Y7L+^99/$5;[?*2V0
M.^WVV,I)K19ZZLA"LONPB"!3DCE'DGF+)968<L\AYIR5E<M:ER,@SK)+ME%S
M*EK4X0U(NTF48J.Y1HAH(0GT ULQC;@ZI@QVMU+$NSI6Y7W[]:6VDUW<69K9
M[0D_4O9'0:C?G'VWB96:\QW\1WM2FJ:K/TJ%#L10$$?+U^&O+2O:92TO"IT8
M*W<56\C)N <F\@\77-F_\9YSF''E]CN!Y%UPO([OC<Q+HI13CEHEQ?>30=%A
M0(]-1]RY+%327@5SLVW.B>)+9P%]]#SPXE,2#EV3XOSQ8V5I"XG*-C;;R!3'
MZ5(8S#&%6:Y]_;T7+1+-=R#O6ZSN9PE][K]1^E1-/PC_ '"OCKF28=OYKXTS
MWAZZN^TT]>+,EGD?$O?((<=6NV-6O)8<:M"*P'B!U.ME[^WXJO\ CZ%#V]RK
M2BZ$P_#GEGXU^0$5J1P_S9QYG+SH03:K5D4)K(&5* ^B1C5P7#O\90)I1R,G
M?6ZKD&LRN=N=OUJ@X/W6^_V^X!>WTFH._2E1N-M6%=3TT,AH T : - &@#0!
MH T!@?R XBN?./%6:<6Q<GDX0WFEJ-EEY';XS4^9$MSTF.Y/88BN/1T'^81&
ME,+)5LA9V.N;S''OD^(W'%1FX>ZL)]?K_IY'K/C_ +H_\([WXSO>6VM[J]Q6
M\=V-B?\ 3O+31:\\GTSPP++XV^/EM\:^(\>XEQZX/7N'97+A+E7Q]MJVS;M<
MKI/>FS)TF-&<6VE2_=2VE/>KM;;2*FE-0X#BH]O\2ME;FKMV*ZQ5&_-Y&U\H
M=_\ ,?)_>_(=\<A8V^UW.ZC9A;LV4YPA&-%*CNU>&-#$V6^%D2]^66*>5MAS
MJX8Q?+)"@VZ^XQ&M,.5!RF+&@S;5)1,N#LEJ1&3.M4E#*PE"Z>RA0K2@YEWM
M79W.Y[?<UN;MWX1^Z*RDZ-8_F>VX7YGWO'?$>Y^(MYQ^SW'&7;GN6MS+4KVW
MN.<9.5N,?LJ]+CBLI.F(^%EDMMA/:E!WJ!2FY)V(UZBI\4E*4IR;R;!UI9""
ME*5%"^ZA-/X$_ Z)+4M7IQ_"J,)R4JKTT=5XX8+\QE'CCX;QO'WE?FSE&-F<
MS(W.8[JY='+/*MD6&WCY>OUSO:V6I;+[JYQ"KF6ZJ2D42#UUY+@NU-OP.[W6
M^L3E._O)IS3R2BY-4_\ DS[%\C_,G)?)'9O =J;O90VJX/:^TIJ>KW:Z4ZJB
MII4%3QJ/0?8>44%"4DI"QNH4"5J 4D CJ4>OIKV2]N5N=N;:U*G[/]3XO=A&
MY?C.<-486YZ76GW-))4^M,^@S+Q/\.8WBY<.5I\/-)V7GE'(V,@?;EVR+:A9
MS'?NKR8C*H\F092%?S2A4H)/^G6F^O*=N=M;;MZ[?NV9:G?N2DZ_4^U?+OS1
MS7RWM>#L\CM;>W7 ;);:S&,J^Y!Q@I.3IG6)@?G'P L[7(N4\\\2\^9#XP7K
M(P_)SNXP)T>'C$Y3P#TVX.2EW2S)M@E.=SKR'5K9+M7 $J)KSN1[+4][=Y+A
M-W/9[V^TYN*JJI)8+#HD?0.T/[F+VQ[3VW8?R/P/&]S]O;%5VD]PJ7MM1N2M
MZJ-SC5NGA&BZ##['YJ_;E^W6<UGVSF/*?*SGG,7*9E?<'C-9$]<'HS[LENVJ
MRN5,8Q2!"5+47'EIFS9#CE"KN[4I3N]N=H6.!E<WEV[<W?(76Y3E-T4I/%NF
M2J^E3P7S%\U<[\OW]EMMUM=IQG:O&)?I-CMX*-NRTDE-R26NB63(YO(_^X9\
MJN0FI]EX$P_#N ,<6'&8]\?;1R#R&J*4^V"+A=X\?%K9(*#6K5O>6A0V<]=>
MMT2>+1\9;;;E+-YFKQRQY0>1'.WDAGZ^:>:^3.48+;>/OQ;9FV9WR^62)-<-
MQCO2K?89<Q=CMCRVFTHK'CM )2 -M7RC:TO3G3P,'%SE0(,9UV0]'ALMH*G%
MO.!EIM(&U5N%*!2G2M=:\?4@-[R7GSCJRR%08UW7D-U0>U-JQN(]>9KKA(2E
M"4Q$+2FM0-SJ\"1&1\V9B K%N/X^&6R04E-ZY!GIA/*02*%%BB)>NI*D= 6M
MSZZ M[O!][RBZ6F+F'+^4/WF;=8S$4XK#9LMFM<A;E$2(Z9#SLZ2IA-:%7M$
MFG35=V%N4=4W2GTS"Q=%FS.[?$_E9Q_M@'-UFSVVM!*6K)R39E?N5-)V2P+H
MTF>_]2=J^\U37&FMGN&W<K%QP5#9=F_:HL,<<RN9YXYWP52D<K>.E[GP&=G[
M]Q?<&\@C+ )[GOY:5RGF4 "M%/)V]-5?\=9N?=;G]OUP)0<XSK--^6)DG$O+
M[@'() @S,O=PN[)46UVG.[7.QJ2TX2D!M<F2VNW=P-1_UNO75<MI<M_;!:HK
MJL3:>XMUIC^0Z^PWRUWN(U/Q^[VZ]0U!*T2K-/B7..I/;L/?A.OH!^1-=:ER
MU<AC).C+5*,E6JHQ?6^Y2X,B/-AR%PY\8MNL3(CCL:;'<22I#C,IA3<AIU!%
M04J!!&I_JFEU_(LC"U/^M_J2(<$?<T\T^#C'C8SSCDF0V".&T#&>2"C/[*EI
MLIHS'_J R+M;V^T4_P"VELD>FL6=_=G)25=*>)!;*S.#<,Z$R'"_W]'74Q('
M//"22%)90_D_%EX (Z!V0[BF3KZ$#N[6KB:= #KI1Y"WJ6INGD:D]E)1K',E
MHX9^X]X=\W(@QL;YDL-BO\U"2,9SY+N$7E#JJ?Z"?YX(]JENA1I2-*?!(V.M
MJWO=O<EIBW7ZIFJ]O=BJM8#VXDZ'.9;D0I+$N,\V'69,9U#\9YM0!2XS(:*V
M74$'JE1&MJJI4I>#H5>@#0!H T : - &@#0!H T : X)I38FOP_\QK*508%Y
MB\H. > ;<_<.8>5L/P1+31<1;[I=X[M_E @]B8..P%3+[,6L[ -QSN1HU0&O
M[Y3_ 'V,P<NUVL'B?C-AAXJEE+5LY1SNUW*;?+FI3*2_.M>&2S!A6IEJ5[B&
MC-$E3B4I66TA79K -?3R"\G_ ""\B;F]/YGY<S;/TEPN,6NZWEYC&X062>VW
MXM;_ -GCT%  (HW&2?B3H34&U4:1-4@**4@?2H=B0!VGZBHA(Z $#5JFDJ$&
MFG03UP4@(D%-25(J!M]/;4T^6I@BHS]/)5RYURNV<=W&R6>3,A6M^XW.\(4O
M]HV)T]AE<1"6WBZ[W*4>T(/Q)&LM55.H%O%\;?YLMJ;RSG^5\A35$..6UJ:]
M8L<3W$K4U^VB.?O'V_2ON-;>F^JXP:=6#,./X=BF%QC&Q/';-CS110KMD%IB
M2Z$CM'[B<4KG2%?-QU9KJ> /2:I("B =Q52D[55M7X&IIK(Z%DMQ"<HQ9XC8
M9';16FX"GNVGX&NJ;[I:<NB1.VM4TT/6B.A:U=0%)4*D[#;\^FO(N[*4I:<J
MG<U0E%*2Q2/:.IQI^J L573N0:>OJ?AIJ;S;+(MT^Q+3]3MDG'V!YO"+.88?
MC&3M.)]LB\V:%.>JH4^F0ZT9#=*]4K21J^.[O6XZ8THO',JG:4Y.4J59@&X>
M$?$#DM=RP.9FW$MW4H+1/P#*[G!:2ZD@H6JWS')<<I%-PDI!&U-60W]VO\U)
MQ*'LK;=:M%1'XU\P,"6K^B.=,4Y/M;';[-CY8QI<.XN-MDTCG(K-[LA2U)%/
M<6M('KJU[C9RSA)5\O\ 4A^GOK*2H*>#Y$\VX:CLY9\8\J_;LD)>R7BBZ1,W
MM)3_ )G_ .6%:+BRU1)-"HE.H7-I;K_(G"G@+%R]!4E&5#,6">9'C_DTEJWJ
MSZ+B]V40V;-G<*=AUS:>K0L$7AEF*5I)I]+I&J);6]%-TR-J-^#DE)-1'>V:
M_6^[QVI-KN%ONT%U*%-2K?*CS8JVU =I;=BN/,J21T-:$:UY^];6I1::9<Y6
M)?;%CI.)/*#R!X0=97Q7R]F^)1VBE1M<*]295A<"2"&W\?N2IME>37J%,4.K
M8[N_1)531HW-LF]25:^!*AP]][[G'&51(',F"8MR?;T!+;MVL:UX/DRDU2%.
M+1%:N&/2G4I!V$6/4^HUN1Y"5*2JVBB6SE+&*TI>/7R)6N'_ +M/B+R=^TA7
MW);UQ1>Y*4!4'D&UKCVQ+IHDH1DMI5<;,$=W^9Y<?8U(&^M[;;NU.+<G1UZF
MK*U*+IF2)XQFF)YK;6+SAV26+*[1)"5,W3'+O;[U;UI6*I4)5NDR&OR)!ULQ
MO6YRTQ:96TU@Q35^7^S_ 'ZLQ\#&'B<ZR T : - &@#0"8S:_.XKAN690S'$
MQW&\9OU_:B**DIEN6>U2[@B,I2/K2E]4<))&XKMOH#3MYV^Z)Y=\N*G1$<C.
M\<8U(2M(QSC6.<<(8<'_ $960I7)R*82E1"O^Z0%?\(UKNZY.D<*&Y;MQAC)
MXLBCY'SVQVEF=D6>9?!B+F!U^5?,JOK:'I+@JXXI^;=))DO+-2:E2CJ49M>K
M$DW!9*HGF\BL.38KB^2XI<X-\QN^8Y;IUKO%M=#T&X-)2[%=>BN@4<;]^*M/
M<-B4G5J>I5*)Q4W588&,KFM(7VJJ2.ZHH?RK_P NLF4J1H(6X)271V;"G=7K
MOOT.VU#H42S8E+HL(:=';_U$E((V]0*_.M-6*Y]#!'/#<)\D,L": ?RRT@ B
MNPO,]7R^--6O!5\ QSTU1"DU-?\ +\.M/]FJU.KI0P6&0H+J>@25)[:]:>OX
M5.I@2TE5%$;T(I0GIN3K(9;X6]]QP?#([2*_C*2/\*ZHOK^4U]"VSZAY\%1#
MRT*^JA/U=-OA3?KKR#MZ)R5<V=9>E>1>TKHZ$@4[:4/Y_#\]8R+X9?B7QI9
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MPAX'1E.]-C4>F]37_=JC5+Q,?0O45+@60I*B E-0?X^OY:5;S&7F7QEDN$$
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MBU=QR+RJN;3"F5 -T)34U Z4]-OCJ<4W)4\2$TW"B)J_!6*^YXWXX^B7(;5
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M(D);+9*0LG6WQUJ-O>Q:=2N_A"B\#?IWI2N].M/6G6FO?]/J<PYUD!H T :
M- &@#0!H T : X/0_@=!G@,TYP:$+#/*-X^[7)^),ZM$QLK4IIF1%XGN3^/O
MI;42EL3V?WC-1^MUM"=S0:DL_P 37@W[TH=$?'[,9*66U=P6% !)'5-.@K^.
MKVJX&P+_  F^V:=;+CQCG,Q,'$<BF"Y63(76U/'CO.$,?LX63^VE*G7<>NC
M1#O<=&[D/LD(!>BM@VIZX^TTJ5K]<"%QR4?L]53'6=0<LL=Q:P?,FW&;A@J)
M-FB0G2Q(3"B2I;MW2W N+22+E99;DY4N&ZE:V5LR XT0AP:U;TG*Y5F8R35/
MXS'2TE8-*4[EBGQ3M3J1K$$FZ^!;"*<M7@9>OT9?)7&=MRB-5_,^)H$'%<T9
M!6J3<^.Q(3#P?,* ][W],OR!8YZJ?Z,<V]2CVE2A?+;N_'76FG UIKV;U(?Q
MXO\ =@8"4VA0*7$(6*G=2$FH^1(K0TUJ*#M_:Z5+BT.V:V/I[G[;#614DF.T
M%"IZU2D*&L@I/Z:M:B"PB1%[5?\ [6;,8 (^"4/A/^%- =5XW6OM72X(K2B7
M7692!^4AAQ9_^]H#K_);JP?^WNT9=>OOV\ @U_47(SS"B0/@-3]Q_0'5FW72
M$^Z^W!L,AUT@N/!<R/(=Z[+=6W)Z$UZTUB5R5 /M\);SG,;)LY@V+%\?DR)-
MAM3[[U\R1R% BL1K@\E+[8@VB?,EJ4Y)[2V$MT _5KA<[&U.*=ZNGZ$HR<):
MEF2=V^Q<E7-257+.<;Q]N@)C8CB:Y<E %#]%TR>?+;6I5: _L13K37F)RV=A
M:K<92;PQQ_R1T;,'>6#28I6N.;.ZU_\ ',BSC*':U*+GE,ZW0Z_*VXP+!!I\
ME(57UKJ/ZW3_ $H)>:-CVI6\9-.HML>Q##;,A"[1BMA@R%;F4W;(BYJE'JXY
M/?;=FN+/J2X3JF[N+EUINBHNF ,@-SE,M-MH61V([4H"R4@5]$DG_?JAZVZZ
MI?F$>3UTEH2I27U(JFB05?F10FFYUE0N-5JV9'.>#USE*\Q/%SN>25)YRXZ^
MKZ2JB[_%;/J1N%4_/73V%5NH)YFGN9M*G0^@1KWISPT : - &@#0!H T : -
M &@#0#?^>L?<_H?/[Y%LT?)(<KC3,;/DF+R M2+]%;L5RDV;L"'XQ[XEP);>
M(6E7[5]PI(4D:E"FM5]-2.F,9.YUIB?)#\@.(QASRLZQ"T7B#QK>KZ_:'[-=
MVG!D?#^=AM4RY\0\@,EM#D.XVRJG+-/6A$:_V?VI,=1<3)::W)VUZ[?H,0N0
ME-1\1K,A?>D]#0+[Z 5]4D4(K6AZ4U6FTZHVU"*=3+-D>;YHQN!@$EUH\HXI
M!,;BVZ/K2AS-K#&#CZ^*+D^LCW+S!*ENXTZLU4HN6XJHN($0E!S]/J.?I4+M
M8YL;8X7&7'&5H6VMIUUMQMQM2'&W&UE#C3B% +0XVI-%)(!210[Z@XRMY]3<
MJXQ36;/*WWB?:),I^U7&;;W94&?:9;L.0]'5)M=TCJBW.W/EHI]^%/C++;K2
MJH6DT(U%RDU2N!5.*G)2EFBU?3W?\M33KTWI\]022P1D\5$]BA_F((_]O3IK
M(.4=H%!U.Y_':N@/0 GIH ((ZZ YJD)!_P P._4[>FHS])F*JZ#W/"1;*LZR
M_N5V=V),$FE.XINS/T[BA_4-<?FFU!?@;$;<'*C1*# N;32"&R2$GU"JBG3T
MV!UYMNN:1L)45%D*!J[!24$*3W+]*;[4_AUU7.W[F2R)*4EDR^M7!(Z*%0CX
M_P"85!'\=:\[$D\"6N1[.3PE54JJ0D$54=Z_B::E#;R:JS&N7^$=7)J' AQ9
M^A -45-%*(WWZ'6W;LS4$D-<AS'@_=&__P#8WBXFB$*7SQQHVD_J[0K*("=O
MF0=7[2S/];$UKC<VU(^B!KVQJ!H T : - &@#0!H T : - &@$%RFTE[C+D9
ML[>[@67M$^O:O'[@D]*'UUE9AJJH\CX^?'OEWR)QVW<,9NUKPSES#;O9W\1O
M&&\KVB3?H-SQ?WUF/CZ[W;I]KRB/!M3U'[8!,6;5*2EZ(&5@D[ENXH.EQTL]
M2,-M[LE;M)JZ\M.=?H+R3CW"O(T)BZ^-_$MFD9T[&:3<N!>6>1\KE9TS=4MC
M]Y(XM<%VQFP\T61UU+BV8+;S-_9;_P!-R#( ]Y6PWMMU+W-FDZ8-&-QM.6XU
MZ>7M7]NY>ER5$UXY#',\RC,)F2K8RFW?TG?<94W;&L:CXVW@SV)KA2%/H@MV
M&+#MLBV2H\C_ %"IU!DESZEK4H5UI7/?MR^Y:466X6KT:VY:IH7.=*1RSADC
ME^"VTWG.,2+?;^:;?$ ;_G#-V<_9X[R]'CM )0+W/[;??^T!M%W6Q(HG]^0F
M]Q4[=9JK11_-C.DFW$;WWIH*&H-3M\]:+S-F:2I3P#O3\=_AM7^&L$ [TG8I
M'X^OI^6@ . =$)_'0'IW$!7;2JJ;_#KT^'70'%:FE3T)W^&AF/J7F=VTU6.G
M:FI(/KJ44I2H\C8TQ62'=^(,SV<YR4))2%XQ5)Z&J;K%IZ] -<OE+?NVJ/.J
M_>3AZB2&!=2W4**>Y2A4@U"NT4ZZX'Z8N+LU=@7%*"^VE-ATKON/X:RMNUD9
M+NW>TI[25=0>AZDG>N^CV\GF8/=5Z!/ZT["E":=/3X:MM[9Z2J<I*5$RA?R)
M*1V^]V@5)'=M7H=JD:VH;9Z2<&W&KS'&>$V3-*\R_%)MIP^XOR%XG;K78^YF
M-K0:>G16MJ&U<*7(X2\2F6$F?2GUUS5#0!H T : - &@#0!H T : - 8B\@L
MA1B7 O-V5N)0IO&.(N2<A<2YW>VI%EPR]7):5]E5]A3&WIO3IH#X?]NSB5+E
MP[H^$%"Y+<QQE *@I*G0^I !4@D*!IU2:?#6)O[77*AN\;N;>SW]G=7G2U;F
MF_(NF6WV+>W;&Y;;=_+_ -K=W9;CR%OA;CBG'WXRBVMYT1S!"NQLMD$  DD[
MZTMA9N;-S2DTY.N#9]%^2N[.*[M6TEM,96;:BUT>&-4*W,.6.1>0H>-PL_S:
M_9BG$(#]KQQW))[EXN%KMDAQMQRWLW>;[MWDV]#C*?::??=0QN&@@*4#T)3G
M+U-OS=3Y9%*&,$D_I@7'BO/&\%S*%=9T?]]C=UA7#%,WM*A[C-ZPG*(ZK5D<
M!;7<CO?:B/?NXAK5N=&9<3]2$ZG9;=V*;^TSGF)&[-P+?=;K;K9=F+Y;8-RG
M0K?>F&GH[-W@QI#C,.Z-,26VGXR)\="7?;6D+;[NU6XU&Y_5EX5!0!5=ZU^8
M-?\ '4 =@HCK4_GH#M[GR_Q_]V@*M*DFM3VTI3UK_LT  I.Z2#Z5'^S0S'U+
MS.Q7V(J*U)IL:>E?_#3ZFSUH.=\5Y:8V9WIPG=6-NBGPI<8G7X@]U=4WX>Y;
M:ZU0ZX#^D7>NW>BH%2:]M3TKK1_2O\!5^)5(O:4"G>"?4@]?]^L_I68JP_J)
M>P[@*[#TI^%=60VN#J*OQ*&1E"FU44[Z$'ZMO3<UIJS],/,3%PS)*$D%X!(/
M^X]02-SK*VWU%7T,\>#N=M#S?\14^_L?)7AALCN( ][D"Q,CNVZ5<_/IK8C'
M3%+J&?53U(U@T : - &@#0!H T : - &@#0%KO5MM]ZM<^R7:#$N=JO4.3:;
MG;;A':F0+A;K@PN+/@S8;Z5L2H<N(XMMUM:2A:%%)!!IH"#_ )^_MNOM \_F
M;-E>+%JX?R*:IQ:\D\?LBOW%,AMQ>X<;QZTS).#%:%;COM2A\J;: @Y\@?[,
M?&GS.G^*GF=?K*X5.*@XIS_@<'(8(!^IIDYO@#]BGMH!-%.+LSZ@!T.@(-?(
M7^V3^[QP,9\VR<&8MY#8["]XIO/ O(-DOMQDLM@$.-87EG](9DZXM!V;9AOK
M)%!4TJ!"ARYPASKX_P!S>LO.G"G+/#-V9=4RY!Y-X]RK"UEQ)*2A#V06J#%?
MHH=6G'$GT)T!A]%P0I"E!:2EW]*@:I(^*36A%= >Z)M6@E"NX@#Y BM:BG6N
M@.[4M9)[JI ^%=ZT/KH"L1(3^HJ*A3?;8'YGY: JE36TMNN+42EEI;IH!7M;
M'<KI\AH#M%N,9](]MPA2@%H"@035((IZ&E= 5GN=^RC4G:M-OPJ-M EX#B/'
M.46<RNE/\]@<01Z=PFQE;=>@IJ,_23@FI#U1,(WW(U7;5)?@7'<3E$'_ %.U
M(Z#:F_6A)&KQB6B9?F8?<5.=M$J!/H#38DDJ--8!AW*N584 +:1(0MPJ4D +
M*NX@5'TBE=!TJ8VLF3YIR+D<#$L'L5_S#)KPXEBUXSB5HN>19%<GG"$I:M]C
ML\>9<9:S44"&SUT,8=<S9/\ MD?8=^X_E?-'!GD'RA@]K\<>/^/.3< Y+4US
M!<'FL^R*%A^2VO)#;+7Q]8FKE?+5*N;$ M(7=S;@V5A120*:"J/HKU^GNH>E
M:>O2M/QT->F-#G0!H T : - &@#0!H T : - >3B"KL4FG<VKN%02#L4GH0>
MAT )<->UQ/MJ^:@4J_\ 2=JZ ]= &@$SD^%XEG%HD8_F^,8]F=AE@IE63*[)
M:\AM$A"DE)0_;;M$EPGDJ2H@]R#4== 1%>1O]OO]H[R7_F<_+_#O \'R6Y>Z
MXYEG"+]VX<O;3[M5+?:BX+.M.-OOJ4:_]Q >23U&@((_(3^S X3O:9\_Q7\O
MN4N-Y)6IRWXOS;B-AY-L("AW(C?U+BKN#Y!%::5]/N.QI:^WXD5($''D)_:K
M_=KX1_FD_!\)XP\E<>@>XIFX<.\C0H.0S(Z2KL6C"^18^&W1R0I(!+4=V2:[
M"M0= 0=\X>+7E'XPW!ZU>0_CGSAPM,:4KO\ _F+QIE>.VUSM44*7'OLJV&R3
M6NX;+9D+0?0Z P$U=XLIIP-NLN-.(4A78XE04D@@@$&M170%1 0PAU+[;A"6
MTD!I10K92:"BOU'?YZ O[<U%-Z==P"*[?#?0E%TDF. X DH;RZ>I/=O8WR *
M5!$F+4'0M<EXH>+_ #%(22>\437KM7YZ&4XO!"2O^6Q+1'=DS)28\=M!65.+
M2A/K4540.HT%4C-7CC]OC[B_G_<([/BWXV9U=\(ER"T[R_FT97'/$D9JE77F
M\XRQ,*%=PA%3[=L1/>52B4$FFAAR7B;,GAQ_9]X=;7[5EWGWY&7SD6X]S$N5
MQ)X_M/XCB#+Q3[KD"]\E9!'>RJ]L=Q"'?Y?;[254/:[0@ZR8<ETR-K?Q;\#/
M#_PMQ]K'?&#Q_P".N(&/9#,Z[X]8V9&87M/8$+5D&<7@W+,+VMWM[E?N)S@J
M30#6"J68[O0P&@#0!H T : - &@#0!H T : - &@.JDI4** /_A\Q\#H#RJZ
MWUHXCU(V4!\2-ZTT![)4E0JD@CXC0'.@#0!H#@@*%#TT!:KK8K+?K?)M-]M5
MOO=JF(4U+M=XB,7.VRFU#M4W(@36WXCS93MVJ01OH"*[R-^QA]J#RC%RE<F^
M$_#UOR&Z!:G\PXNM,CAW+$2'"29HO'&4O%E29?<2>Z2A\$]0= 01>07]F%XH
MY0JX7/Q@\J>;.$)KR5.0\;Y'M.-\TXHT\*E##<QHX'E<:+7;N<F2UI'_ !&M
M0(,/(;^TM^ZWPX)EQXE>X)\H[+$0MYEC ,[<P/,9#*/16,<GQ<?MBY*D=6V+
MK()(HDGKH".7C;[<'W%N->;8?%V?>$?DMCN<9#"F6ZP6AWBS)+A#OTMIUAUY
M%GR2S1;AB\]EIEM2U.HFEI+8*RH)J= ;('BM_;)^8W,#5LR'R2S7%/&'$981
M(D8W&,?D?EIZ*L=X:_E5KFL8;89"A0']Q<Y#K9/U,5!&A*#2>)LH^)OV&?MQ
M^*[]LOZ.%8_./(MJ5$E1^1O(!^'R+<&+DPDE4RR8G)AL8'CJP]]:%1[;[Z-J
M.FA)&9.I,A'M\*(Q&BQ(S,6+":;8B18S:(\6*RRD(::CQV0AEEIM"0$I2D
M  :$"K  Z: YT : - &@#0!H T : - &@#0!H T : - &@#0%)]/NJ_;DA5/
MK[0"U7>G=50W_P#3O\= >A$C_B1^3?\ LJYH#H/<H:E^OI5+5?RHHC^.@.I]
MVA__ %7Y".#_ +3H#GZNP5_= ^OZ2KKZ]M!_#0 CVM^_O[J[^YW=W^!(T!W_
M .W]>W_[5?\ #NT!P/VE13V:UVI2M?2GST!Z'V.TU]NGK7M_\=] <CV^P]M/
H;W_17MZ[T[?2O6F@!KV_;3[5/;H.VG2GI\] >F@#0!H T : - ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>vc051_img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $  4 # 2(  A$! Q$!_\0
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MM.EFCM:_+A(R23VNU626G<_L#!!Z$'/O1N'/7@$^_!(.!^'\J_CLB_X+7?\
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M@84Y^]>W+&>)NUIN^5=N9W/Z4MPY !..O'OC/N"<XQZ'TIV?PZ=?>OY8KO\
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M_*I%_P %=_VWMVTZI\&9"A'F8^$[$C&=W(\6J, = /O9YJQ_P]Z_;4-OYO\
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MGTJQI7_!9/\ :MNM0LX9KSX71HU_I\4R_P#"K7614FNX(G5/^*B#;@&;#8.
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M$]""?GK<MTM[]==?G?S/H'33:=EM:S;_ "MMZEIK^<!V6=\Y4D.2=P+' R.
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MC"MLP95488EGAY"MQM^;&T= <8S4K)JV_7MZ:&BAS*[TZ:K_ (8DMKI9F)+
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M(@8U;!T_]I[X&7,D27OCF;PO).FZ.+QSX0\:^"@%RX(:;Q#X=L;)=NTG:UR
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M^YDEM;>RU6[T#49[A2@=4:-04*!'+G%8MR;Y7>ZUV2^=^I#5[RANFD_RV?\
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MD\$LQ'3C/317@8[D%G-\P1MP'.2J;1@'&0<C!QN!SSDUJV-O:RW=D6LK0O\
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MZ^]?YGTZC)+5-/T>_K9&A@$@]<$#/RL0,DCMDD 'H?O8QUI>3P,XSCY@><
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ME));)(TIVUVO=6VOL]K^?;4RV ;AE(YQR._Y]>N#VSGIFF)(#]\]^0J]<@$
M^F6)!R1G!Z5IG:<[L $DD@!N<G P?^!>^,=,XJ,PP.0=H(&%W#"X.>,@#!(R
M"3D$CW%,MI/=)^I6"9))"[2"5.<'DC!//8-^'7J,T,@R&7[H!) 8CH22=N>?
MQ&.@JV8U&57<I&!O!W;@ .Q4CG&>V, #/-,9&&=IR"2QW \,<C)'ICUX/([&
M@?E_7;]"J!M5#D;=H7/N"YS_ (^Y]J0QHQR1DGG.3_C5C!!VN,G@Y"_+@Y&
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M9P.OITZ5,(G) R,-GYCA3GYOX<Y/(S[],'.*C)7@8?Y>,KCGU)!!!)Z]?QH
MB$;DX  )Z$G('5NG'N>O4_A4D<4B31%F4?O(SG!ZJX(YW'&..W/IU:G!L$$@
MG'8 CD@@Y)[8/ 'XGCEP<,1\I)&#@\<9'/;'09/<G/;%%TFF]D_^ OQ:7S!W
ML[;VT\WT_$_E8_:3\&ZUX3^//Q7EU72=0TS3+_Q_XHU+2=1O;>6TLM1T^ZUJ
M]2WN;*>3$5S%-+#<QAHRS!X),\+@^>Z#?6]RT,$%W;S3?,T@A,>X!F( D59$
M=E(W@@#!)XW8;;[9_P %"+SQ-_PT#\9_"][XHGA\/:/XJ/B'3+6]TV/5X]-L
M]5T73=2DM+!&N+*XM[.:[N9+O[+;7,:_:I'>$Q-=3$_/%@+2V\:^$[+0]-U)
M/"=MX&U6]N]3O+1=+U/4=>FGT:VADU)#_:FG)I;7S:VNE>']%N[>ZM(4%UK&
MJ7]VA)_#,TP\*>/Q\4Y7ABZZDF[\K]I+FOIJU)O1-Z):Z'[WE];$5,'@)N$.
M2IAL,U)/5Q="FU[K^'1=V>X:7(RQ)$KL,$*NWL<@[B9"W4C81R!N4\ $'M]/
MO+BV+9DVKE=F]0ZANG!5@ 2V.H ZK@9K@+1X%VC=+&!LY.X')^7*E5.",=W<
M' )!KK;4P$*#<*2W&V4*<%>>) XR"6W [>H(." 1Y+DEN_/J>O&$I)M*Z6[T
M]?RU.TM-2E8J)#;LP8YW1*7#9^4XV ;=V"0I'&?K75Z3J4,M[IT;Q0RL;VTW
MN)#"3_I,(R<J "".@+ <;<=:X:U )"*6+DDDJ06V'#'9N+@ ] #GZ#@5UFD\
MWUDNUD$=Y:!58;B1Y\0'+ #D@$X P,X/(Q/->W+J[[6?D2TU=/1J]_N9O^-L
MMXK\5&/<Y'BCQ+O=E41J?[=OE$@ )8@_,?F( &,X/7PSQ<J#?&2KY))7D,2Q
M;:H8Y!8Y)8?+UX(S7T5XSB8^*/%Z; JR^)O$ZD-@22 :Y?,'(!(C4GG)^8]
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M.%1RBHQ3E%KDE%IV;4DUYZ'^A@S(I^<L.O4+U'8YYQZ'N5.!P":DBYQN((P
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MDNK_  F\$-,[*9+_ ,+0ZGX#U-G.1YPN/"E_86XD0DD;K-H]Q8E?EYM.,HX
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M<(SZV2[7U79W^=['?VOQ$\;PVHL9M>N-2LV3;)8ZPD&KV1!&TAK?4(YXW7#
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MB^W)V@R18(PQ S4EM*^GZC:1:I9:GIDQU"Q7RKVSGA<O]JB)5HYXXG) )R0
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M=7M<WIR<KJVR7=[-?HC'9.0HRV0P)P 5(!P , Y)P!GOT[U&8F55+%E+8!!
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MT--X323<LZ&(MPH4/)"$ #;BFX.C'D[0^.H KFKSP:Q5SE?ER P()X8;1Y1
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M4%E\0-(T_P 2L&@\J/:-5>*VUI-\3LID.H-(%)PW.3]:> _^"G%VEQ-?^/\
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MG;XS_P ?VG8+!9,G[7!@YD#E<$_(&)Y! /)!STL)EPZ 2L<$99OE).'4%0V
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M[O.]7/.T[7 V@AB-J?<W9R<8KM+2YB9(_.A <%CN12\?]T*R;V=-JDL9!MC
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M@LI+&, GA3G*BNBUK]IG0OAUX@^+/PYT*_LE^+^I?##0_!_@"#[0?M]KJ7Q
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M))(,B.9X@1D! PZC.,$;2^>BX+'&<'.:]5N/!OC23AO!'C)  R;U\)>(W7#
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M=:F>)+F\NM!M_B)X'BG90#/))96C:Q80!AS*=$F"+@M*/D+? 7_"N/'.P*/
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M[9#D'>R[0YR2I(P688QFOKL>!?$SQQ@^"/%\K;R\JKX/\08#E069EDTT.>.
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3K"NT9?\ ,3A7]F6R^LO^MS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>vc051_img05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! B8# 2(  A$! Q$!_\0
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M_P!FS_HOWP=_\.'X6_\ EK0![Q17@_\ PU'^S9_T7[X._P#AP_"W_P M:/\
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M0BXB; \Q"?&.YESG'RJ .>A-?/TVG(CI);MYJ(RGS48;<]<L&R<G'RXQN&,
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M/&/YMXA(_,G\Z=_PX)_X(]CC_AB'P!QD?-XC\<D_B1X@QGZ<?ABCDEY??_P
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MF @%7!C5QC]X&!R,<Y!R QY !P,.UE&G:O.)8\A,0^80 K,NT$A\8R6PQRQ
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MED2V6V@Z@C#S,258<;MIP?4#!\WU;]I;4'9X=+\-P0H/NS7ERTSYX(+)%&J
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M'6V]1\NJ(K'=[#;Z#K]*_P!:%OO-]1^B@?S%8FPE%%% #.I&?^>B'\?-Q_(
M5_CG?M46U\/VJOVG]5TY(_M4'[2?[043%N \"_&'QFKY)(SD=#[D#J,_[&..
M5[?O$_'$A)'Y<_\ U\5_CH_M3+-:_M6_M.W5O(DH3]I7]H W=MY4CK)$WQ@\
M9&2-LMM!*_-D#@\@$8KX?C6?LZ.!ERJ;]M6M%MI/]S&^R=_R\KGHY5"%2I5C
M4:6_*V[->\TVK^5MMSPQ9YI&1Q;R0RW&(G9V^5 S9D8@,P&_&003P.O/.U#!
M]FTV6TV1C=(7:1F0M)$7)+#+'=SDX((' (Z@X^NWL5M;A[,Q;;Q5,,<3'$1(
M&]7)'4.P QT8]>#56QM)8K7[1,\,LT\8#QSS2%X Q&#&.0J\Y]0W!'(Q^?.G
M&K%RO"E'VE[.756M:]G^M]E<].-12E*#DZDH0:<9+1T]7S75_>=W=;-=C3L%
MU+3&E6V#/:W(=C&I7 "OE-N3\I4X(&-S8QZU;=;S4OLZW<ZQ!<AH9(U(D1.2
M6'S97KDD@>@/%1>']01;N;3;YED@E4_9V)/FQ2Y!18P<Y1\_-U;(  Q6#?SS
MW>HO9JUQ;I;F59)D(W[U)V+@' 0A=H8=3P >E8K"SKXJO0^%TH>TYEKS+D3Z
MV5F[*Z;>HX^S5!<E>NZ-:?(J/-:3E:3O!6<E%<LDDG:ZNMRSKIBN[F0P.L?D
M. ML&&R)(R=OD/D*"" "#Q@#([#!F%O<.6+?92% 9XUR9""2\DH7." ,A5 !
MS@#J#9DC4+'DY(D9_,8$DDX.U^<$MG&X 9Z8P<47EO!</+?19BDBB5YX@ (3
MN&U6 ' R%^8*<@YSZ5ZF&DX0I8>7*O>5I1F^=II]M+Z=G]Z.'%J*DW&/+S1;
M:6NOX/K]]V9\-U;P++_9SAWF1T>=\QEMP+?N]P5EP<!@>2#_ '016;!YL+M*
M\N)O,YBS@[2"&D; R5)Z,,DG@$<@2PVUM B7#L+F20F1K<D!%5LX>,_>(&.,
M@!B&!XYI(;F,W\<LJ"51\@0J0I4 X3J>%!(W$X+ \ G)]7V5&-&<VISG)-R<
MZDGMY<JL]%9WTU[G!U2[M+[_ /AC8@^S7DT4+G[+%\SRLFX>8RY7( P" 5&-
MG<XX;..VCU'37AM[&"2&*!+?RTA5,F1V?:\CA=V3]YCG.3R>H(\]O(-EY:PV
MKK'%*T1+KEECCF^8H3G^%CECT4$Y'RD5LV-K96]\XB#3!$PDV[@2J2QR#SC/
M)[XSV->/B\%"I1IS<Y)WNK)/E=]'=M7L^ZTU.[#U6JLZ;2Y4FFVW:UD]5V_X
M'J=MI_A:^BE>YT+4UC3*JJ2%E6.3))VC&TH#W&% !SGG'7Z;HT&@7L'B+Q3K
M=K?W%JL@L;:2XB%E!-( 3<@,@\R:,*"@"E^#@X!QQFF:W-IVHQ6US+&\%U"R
M1E<;8Y5 (,F<<OW!/!/0=:I6]O'XM\27<VL2/%I=DOE06B,S1R3)@!^FS)4.
M.@[CH:^8Q%#$SG552NL/A*=)NI7C3BJ]12=I4X22N^9:734MHK2]_8PT\+3=
M%4J<GB)U90ITG-U*#G92YY0=[QOK+6T=U9I'2:_IFG>-)'U#3]3M)-168M$8
M7=&E(7:!P /E/S8!.!P.M8JZ#XC:!+>\N(Q%;*GF[[AG_=Y93A?XB%Q@ DY&
M?K:U70;33$-WH-V=,:VVSQ%'+&24 E 0< B0D;T'J<=<4:QXN&K^%XY4*VWB
M!&2SNH@-BGAE$H &27 )9=HVL0RG! K7"RQ=.G06!DZ^ IKZM&=:ER5L)%J4
M[OFO*2YI<]US)/5*_+?2K2PSJ5IXVG[#$*,Y3EAI25&LVI.,6Y-^CA?12:ZD
MZ7_A3PQ:R:;#<H+Z[9))9V4O)L,>[:ORL<,<$@8X(XSBL2XL=)UIQ!#?1B<H
MLYVG8'+ XV,^"'P0=HSGIU&:Q9-)TK28+;5M9MA<WUP(_L]K#(_FR8 X8$,V
M^1OE5.Y&,U3DO(A*1+HM_8B<1K"LJF":-R2-RD@.2H(PH Z9/0FO1IX6*DJF
M'K5YXB<HQK5JD_<<[-QIQIS:FWRZ+W;6]Y+2QYE27ME3>(A2<(J*IP3G>FG?
MXY*/*GRKF2;YK/H:3:&UE,!<7TLB6^)"K;V 'S' .#Z 9X'?/6LVZU:R,HBC
M=@(\9RF\3,0 >< -D$$YSDXX! J[J]_>+I:P& 1W$A6UE=G/FN'*[6?@_-L)
M[@\X!Z&LJVTF.VB54Q-*%R[2X(PRD[\D\%>, ''!(/2N^C3]I"K6Q-:HG&HH
M4Z<%&G37+9RG;6[D[*3>CLVK-G+7M&?)37/"*5I1;=D^C>VB7=/0>I2Z?S6$
M4(#'<5)!D'4*XR2"1@$X^\.<'.-8ZK#ID!D>]FD4J$BM%RP1W&U&VX^902S'
M/!ZXZ53@@$Z2(4CBFMCMG=02LD;@C?@GGIG."1@Y' -8L\?F:A)("K1VR*J1
MX_UV,*#D'GH6! S^'-$:"KU)WFU""3Y8J+4DKM7D[-*35M/E8QE-1TY?>M\7
M-)6WZ+3Y_@;:7T%V@CNY&E$A&U2K@*1@!FZ%?H,]^F3GI;+PG973*9M1N%MH
ME,IAC+#<I .$92 0K':48C!P0"0,\5(%A(Y1@P# <9PQPPSDX*[ACY3QU''.
MFFIWD.BS^6^QRQC5^I1200%('7)P  #N&<=ZSKPJQBO93J4*<Y0A+DLU%2;O
M43E>STNE9*]GT-*$Z,IOV\4WR^Y+F<9*UWRWC9OIK>^KUZ'=3^*M!T"U&B6,
MEQ+$L_F/!:*7_>D%3+,Y (F0MA0,'&0<@&LZ"7PWXIF,2^:+J##7<$R$7KPQ
M[=S(Q 5FSZ,"1@Y&<U#X:TFPL8;=Q:Q3W5W$9YS*-Y1W8DLS,6VAB<J=N0<A
ML@"M/6[%Q$=<M46PN=,>+:;9HT,RH0'C="H+HXP#DYX!SC&/'4<%2JRIX>6)
MJXZI5]E'$SJMNI*:48RK6@E&[^*UE9+0]-3KRP\)5:-)X.*M[&<&[.Z<G%^Z
MWO%[:VNW<A;2O"/AT1:G>2W!,3M<K'=*6:W<<Q)$A!5B_ *C.&]/FSE_\)DL
MLKK/H&I2VT\A<3-'D2B0@@I'G*!HL+M  "\$<8$6L;=?U_3K.Y#) +6+4##,
MV%DVE9""W 9LE@N!@@#VKM8V>79^Z@15Q&GS*I7H 3A3DJJXQU]CR:=2E&@J
M?U]5:^*E"3E-591C&'/.-/DY()2YE%MRT:LDK[DTI1K2JRP<H4*,)0C=T;RE
M*4>9JVMDG>R6FFR>A_;Y_P &BG]CR?LT?M=7NC+MMKS]H?PX[J?E*S)\/K-"
MIB^41[$QM^7#XR,Y!K^NZOY&_P#@T?L+:Q_9P_; ^SH$CF_:&\-/M!!4,/A]
MIX&W& !@C''L .#7]<E?MW#4E/(\O<95)P]C:#JR<JB@I-1C.3LY22TYFKOK
MJ>%B5)5ZBE&G&7->4:2M34FDY."N[*3=[7TV6E@HHHKW3 CCZ-_O?^RK3%_U
M"?1/_0A3X^C?[W_LJTQ?]0GT3_T(4 )7\P7_  =Q_P#*(OQ3_P!EC^&?_I==
M5_3[7\P?_!W$"?\ @D9XIQV^,7PT/X"^NS0!_/'_ ,&;'_);OVW?^R2_#G_U
M,+K_ #[]1Q7][Z]!]!_*OX(O^#-O'_"\?VWP.B_"3X=G/LGC"X!_$$BO[W5Z
M#Z#^5:4^IE/?[OU%HHHK0@**** "@D $GH!D_044C#*L/52/TH " 00V,8YS
MTQ_3'KVJ, '@,Q(((50\GW3@K@;CCG)QU STK.UN]N;'1=9OK.$3WMAI=_>6
MENZLR3W-M;O-#&X1E<QLR R;"6"@X!Z'X ?]H'XA^(+=I(-7M=.MKAW16TB&
M,*A5C'(D<I:5B$8%=[-N!'(4\5M1I5*TE"FX)MJ_/S-:M+11:]=?(QK8B%!)
MSC.7-S<JC9:Q5];K7?9:GZ),%C4DR)'\I/[TK @QU):5D7"_=R.N%'(%<Y?^
M+/">D@?VEXGT.T=68-&U_ SYY.W;%(Q/) "^I(Q@\_G#J?B+Q%JZLNHZ]JMZ
M68,?/O;@ DG=]Q'&<<<#'3L!SAQ6YD<B15<')!)9FXY4,SEF;&1UP<@\'%>G
M'*9K6I5BM=>1.UNEDW??SL>=+,I<R]G3BU9?&W:^M[I/FTTL^^I]^ZG\=?AK
MISF*/6I]3G ^[IUE<2)TY_>,$B)!X!Y]\8Q7G^H_M+::K,ND>%[^XPH"S7UQ
M'$CG=@2&,*SC=LSLY"XR"2<'Y8BL5&T"-=I&<LI)+8^;Z=N!VZ$U8&G^<P#?
M+MRH(W#'4 J0<X!]3T..YKJAE=!*\Y5)^[I9J%FGN[WO?M;ON8RS#$-OWJ4-
MU94Y2\K;^=[Z['MFH_M#^.&MIFT^RT6"226&.W4VSW3Q)(2)929I#')Y8P %
M0 ,RMM!VD>::[\;/%$J--KOCV#1[>-<SJNI6&BVD.<X>0))$8@!T>1ESM))Z
M&N1USPUIVM:-<:-K$,MQIE[<6$=_;QW5U9R2VR72SA5N;.:"ZAW31(S>3*C.
MH,3$J"#;M?AM\.[4QM'X&\-//;Y$%U>:<-0O5 '+276HFYED<'IYC. H*@ \
MTU0IQNN2-GKLGNEU>OI;S.?ZU6<$G4DYM:V35W?I;RU=MM3SC5?CE\.XYW_M
M+XA6^NRR/M":-+K/B^9I@Q!5O[&M]26-B,8R0A.,'FLJ?XEWMT8_^$3^$/QI
M\5K.4\NZ'@J7PSH[$GADU7Q1/I5KY9'S!RZ@+@8!( ^E=.M[?3$8:7;6VFJS
M$'^SK:VT]6&!@,+2"'> ?N[@2, $D"I)4,[%I))6*Y8@RL26;'WQ]UL@'TR"
M 02-U7&"3]W31Z<J5N]I;_E8YW4F_B;GY3O+5=;2V?3YM:'S@^I?'+484;2/
MA-H7A^X=EW+XV^(>DAX8U/\ K/LWAJWU@NQZ^69T9@""<X-3+X;^-ETX&I>,
M?AAX=0QJ6@\/^&-9\1W]N^=SL+G5KBUM;ERI 6,(BG'. 0!]!K%&H^2-%SS\
MO&.!@C &<>G3C@\FJ5Q:QI&[JOSJ=P;..2<'.,'/.._'?G Z(T9;MI-/1*S3
M]7T-%>S;];]$G\N_J>&2_#O6[T;=9^+7CFXW*%>/0-,T#PQ:3@$ +) ++4I5
MW?\ 3.YC*-ALY&:1O@]\.9U6/6M(UOQ7&98_,@\5^+?$NKP2RX?]X;<ZA;Q)
MOV &* +!U 55.#Z_/$@8$Y'WR3N[AO;TR>G0_6L^1-TA'(5 C*V"Q+?O<#/N
MO/0XQWQ6\5:*3T-%.5DD_=MIHGT\_P ?+H?H7\"?!5_X!^'?A36O NGF?P;=
MZ>9M<^'$#SRQ:5L9P=2\%>?+)]FEBV>=<:))*8KX^8]M_I#;6]G\1Z797-C9
M>)]"DCN-,O8RUP40QO$Y=5,DL94&&5) UO=V[[)(9E"$#-<5X(^+/PW^&7P;
M\+W/BKQ+;V4UCHL1N+*WCDN]2\^1GD2&*UB S*P(*&26-$^^[!-Q'PYX+_X*
MM_L[^-X_&UAJ>C^/_AS?VGC#Q!X+U.;4?!^IZUX1FCL9!;Z=XLEUC384ATVY
MOMT+7$7V<0J<JTLI"N?A:T:D<57J6:C]9J1;=OMS2Y5&]Y/EO)VC:*N^9;'U
M=-TZF'PZ23FL.M4K+JTVUU]5LC[DW#DYX&<\'C;US[^W4]1D49&<=\9Z'ITZ
M].QXZUP_@WQYH7C2!6T9=>E2*RMKIM0U'P]J6BV5XLRHHFM)=1AA%P9LB6,1
M*1Y3JY)#AAW"DG.<=2!CVX/_ (\#CVQ6ADTT[,6BBB@05X)^U*=O[+_[1QR0
M4^!GQ2R>00?^$3OAN'KD_/U[YSFO>Z\!_:N_Y-9_:5QQ_P 6)^*9)!(X_P"$
M3O,G(YZ?YQ4S^%^J_,J'Q+Y_D?YP?_!,F3'[=_[*; [L_%WPKCD'&_4XV.#S
MU)PV#@[<=J_ULVX8^X!^G4$?IS[YK_(O_P""8$Q;]O+]E!5?<G_"X?"R#.>J
M:BF.O?;ST[^]?ZZ#??;VP/\ V;/YM6)L)1110 T=4_ZZ#_T(U_CJ_M61M%^U
M-^U)=,S*!^TO^T"0^_E@/B]XS 7!89!X 0@XXX :O]BDD90>LJX^OF'^@/Z?
MA_CP_M1Z79Q_M5?M/WVJ7K3Q1?M*_M R-;Q[5@A7_A;WC,K'*"_S2)G:QW<D
M=,+D_"<<W6'P$K.5J]5*,5>3<J44K)6V:UUV[[';E_/S573AS25K2NE&%YM<
MTFVDENNNJ/G"XMUAL+2[<[HI'=3;R@!XD+%WDCP,@G&03SECW J>1HC""CNM
MF^W:SCH=H "2'DCT0YYPN-W%7KFXTV:1I$N%>!P8]C+B-5/  ')0%@,D]>"/
M?._LT0@XN?.M@3((6&Z)5."HC()Z,<8&6YQ@%<5\#2C&HE";Y%S<UY*SO:_+
M)7]W5+75W:[Z>LI5*$G*A36(E./+4:5_)RB^5^[9K5);,JPQ&6^WPB1&BN(L
MW':':?O[CT'OT'7/3*.EO+J.I,T[@S';'<.^?/<9R4(.6PP^4J,MQ@8(%33W
MMM;3-;I&\'VB-MQ ,CS':"I(Q\NTX![YP.V:I16L9> 7*$E0!Y3N5F0.?D(4
MGEFYPOR\$?6NZ$I-UJU1*DZ='EC!KE]I%6@GSZ/6+:];/=(XIPJS;IPO>$KV
MBVN6][V:U5G)JZL*L:"652/F10^YF;RS&%^3!X#EB3R0"N,GFK=I8H=)U"XF
M215=1'; R$,TBG>6"Y8L@SA=V>,<>EA4M+1RMS"UT2K&-)2T/D@D;-S#).WK
M@\#MD9Q!!=7-PT\D=M<W5M&.5A7Y8$ /F,.,-QG;TR0,<D8Q<K-5(6C[.2?M
M'\,EVBW=2;O=+3[RZB]HFY:NR47MN]?N^_R5SG)8?M,"2ASOAPC[<QR+$H("
MD# &3P0,;LY.<8K/AVR2LB+(2"F%:,*$8G(;=C('.3GKR3[=7+;M+")H(S"C
ML=@D'[R;:25,P R%W!0%."",GC.:3W<5GB.*"-+B0$S2*2[/(>&;8P&2,8[#
MCKT:O4I5_:0E#W9M<M[2M[LHIO1>O]=>*I3<'?31JUGL^G].Y'=20+-9>4,/
M %,IB.59SPW0X5,$X!!!//KBTC2K,GER.HE4NC%FV'+%B'*8 !'))''4CGGG
M/(O);AB76&&23$<ARK9!!<NO( <DX]^W(-7H%GLI#',LWDC]XJ2,?]((P#Y;
M8.U,$@@$# "Y[TJT*<Z2I.HH=8V:D[;\O?5]=P@YJ3FKZ_'*VENM]-++7^M>
MPTVSBU+4[2,AGMO.5KNX@!VAE7)!8@D,2#G  &XY  P.@TV^L_#NJW%I<2E+
M:ZF*P2S1Y7G@MO\ E#;N@) Q@'IBN<LO%-K8Q+#;0(P((:W@7:3(1D[WPQW<
M@#;UQR<$FNJA:T\1#9>:<KQ&,!6>0"2*0(5RO&X$#/4D9&,="/F\6JT8U*>)
MP]3ZG.+O4C447%*S4E&]WS6<K)-]DT[+T<*E4J0]E53Q*J>VIIJ3I\T(N/)*
M:MR^TC=65[V;LVM.CUC^PVL[FY>YLT&S?;;Y54*_E_*J@9$DQ8_NU7)!P0?7
MA9_"5Y9>&(_%-PEP;F\O%>&T"'S4@7>5FFB<[@.G+ @[N 017=:9X3\,Z+:2
M:GJ,LILK8?:,7I5H4D7#0M"C'YW4@':Q(R.5XQ5:X^(.@:G*\ ^WR6TD)0W!
M@$5LJJ%VD*=RJH48PBD<@$C(QY-'$8FG:GEOUG$X:.(4\14D_9/E27-AH2FT
M[N#7.X*\.2":M/7UYT98JE_M=2&&G4IW4%*,FKOEYM[K2+TD^JN<#H?B>SC\
M4:+K&O6O]HV=E\ES;G&?E.U"%.-K1MW( R3G'-=%\3?$NB^*-6CO= T[[,9)
M89([-)Q*T8"8\S"E0C-C+;@"3N/').V_@/1-63^T[&^8Q3%GD-LBL(6.#F15
MD&-S9X*\8 P,YK#N;30/!T?G7,AGN&S@[0US*0&VA49B I) 7&-N<XSQ7='$
M9=6Q='$X98N>;4H2H1P<YRY:,9/F<YQE",;Q?NN3E>UH\R1PU:..PV&^JRA1
ME@GB:=;ZU>#G.*A[-\M17E*,4^;E6\E9)M'-:CHDL&E12.9I+N207,N[>[F0
M@!=Y_@ ' !'.?;-84$WGPFUNLI<HN_(<*'(R-KG.<]\'CT &*ZM?$:ZF L>D
M7L4;$9>0GYAZ[<#"XYXY()P.E9UPML\.V",;YIPTXD&)8QG(VG:#MV]03]/2
MO6HNNDZ&)A&,W+GO"2:;;]Z/NMI1AHTW?FUU>YYE>485&Z$W*FU;WHJ[:W:O
M>5G?2]O2VA5T]H+9)WDE,@,;2)"#N?(&&61L-N!^7;D\ 9 .<UB2RQO-YL:'
M$T8VA.%B==J@#)X(W'^N!S3+RZ2*Y%K$S.ZLRN4( VMD[F;YLC#@'KC:."3F
MFPVY.\8+F-BRJIV/C<=QP1SC Z=.?2O3H4'2YI-+WXK9MW6N]UIOYG*VWJ]>
ME_ZT)665U15PVT)N9LEP7(X)/S$@]LC&!Z9,MU>QVUA%8L1]_?(W5F(?.6(S
M\V!C.<@X'<576Z"-(SIG.0!D8XW;2"2,D[L9QTP3Z"D8Y)W.82=Q&T%B=^0,
M;L $$'L!P<D' P=72IM<K6G-%VN]XRO'ST;>GG9F+G)2NG\+=M%INOU9W>A:
M[;6T:F0.L?E[3*060)ELD$\@[NN2-QV8%=/9-!XBAN[95GN1.3Y<TFZ-+5$P
M2ZMA2V,$@,3UR<@"N.\/6Z*6A= P\Q1)!,,(R,Q),>2Q(!SG Z8YSP.EO?%+
MV5U'INB64,EUM56"8%HA)Y\QE3)!4@ 8Z]/?YS,,,ZF,J4\+0:][FE.[@HO6
M6DM$FN6^ZLGO=GMX/$3IT^5UHSI.+Y8RC&3MV2DKIKO=-[!XJL9HKVPU/2HM
M[VEO!;M$YY9(-N2B8!*R,,D8PV,@YZL_X2FP6 -);7D=V2[F)$P6?."4"D["
M2"%! *CC')H@U/Q?;S376H66EWMHZ;Y+:$LLT,8(_P!26 WD*3TXR .><=.M
MSID%C#K,8M&M&A>1F$:R3P/&Q#12;P/G+<A<=.!D;37)4J3@J=+%8=XE*2A3
MJ4*T6XRFW:G4LW)MN_*_AN[)7;OT0BES5(UE0562;I5:?*G96]I9.Z<5?FM=
M*+4G<_N!_P"#1>+45_9F_:VEO;5K%;C]H'PS);6\BD2^0/A]8$.V1E1)D%0W
M. 1QD@?UUU_(M_P:0:Q<ZO\ LX?M>WEQ&8X#^T-X:2R#_>> ?#ZS 8<8!8\X
M&%'3( S7]=-?MG#//_867^TC"#5*248:QC%5))1NY2NX[2?1Z/5-OP<7)2Q-
M9QE*2YVE*45&4E;23BKI)VO%]59]0HHHKWCG(X^C?[W_ +*M,7_4)]$_]"%/
MCZ-_O?\ LJTQ?]0GT3_T(4 )7\OO_!W&S_\ #I+Q, 2$_P"%P_#@-@X!_P!+
MF*@@#DY+8!]S]/Z@J_F%_P"#M\X_X)'^*O?XN_#GOCG[;<X/OB@#^=O_ (,U
MRQ^.O[;0R<-\'/A^[C)))'C*0D8[DY/IV ':O[Y5^ZOT'\J_@8_X,V6"_'G]
MMQLCGX-^ R">A_XK*X(Y[C@U_?..@Z=!TZ=.V>U:4^OR,ZFZ%HHHK0S"BBB@
M I#T/3H>O3\?:EH(R"#T/!H ;'&LLR>8?W;DJ5()(5@$D&W@\HV>,GV'.?RP
MOM(BTS7=>TJ*W@M8[#Q'K<(@BB6.)%_M*X=%58PJ<JP)( !)YW$&OU. P58\
M, O)P?F&"Q^FT$<<YZ<5^;OQ#@BM/B-XRBDDAMB?$=Q<1*[K&628+-\H)#%7
M+9&T8 RQQM!/J96TJT]%)J',D_[K7D][Z^7X>;F<^2C3?+?][&\OY8V:;>CL
MG=7U6B76QS:P)E2H&_=@87C'<8.,\$Y)^GI5Y;5EG3:@7*@GH1R%['TZ9Y)[
MX/%(LUFBLS7MFHX./M,.<G@D_O,Y(/W3C#<'IDJVIZ;N5FU335*D\-?6PV@E
M6P^Z8X &T ]6YX48KW_::?"GZO\ X&IX/,KZ<J]';\V;2VO"C8P)8$,K<'CE
M=P. & YXQCG/<:*0($7 W%CU(P02 V,XR/4=>#C ZUEP:WH6%#:WHXR&&TZI
M8J0Q)W CS\#CCIGJ, =-%=;T,%0VMZ5L'S G4K3[H (&#*?<<GD=.0*SE*W7
MENWHY65FGM=JV^R&O>>CN^K6KWM<E>V@N('1T4!I(06 !.5E+ITY !( V]R3
MT)K7BMX7#;]S8=L$X).,L,Y !)SC'?C@]L:Y\3>&HK"ZEAU?3[J6UAENUM;6
MZMYKNY:WC\WR+>(/NDFD",$0,"6 Z9)KXE\??\%*_P!G;X<0ROKNB?$ZX-F#
M),MAH%B9-ZEUDCVR7ZA-K*R_,03W]O.Q..PF$47B<33I>T?+!2;;DTM;6NK)
M6Z]+LZJ6#KUI-4:<YN,;M\LDDFTM915KZ[;VU/O9H8T5BJ(,*3R%)ST]>>3W
M!],< 53>$L?D.PG&>"!P&!QC@ YSUP#G'&!7XL>(_P#@O_\ LE:-<R6</PA^
M/6K-O\M)+>W\)V0;+ >:T<^JLX7<P!SR,@X/-8=S_P %X?@G/((]'_9Z^+,S
M-!-<K_:7B/PM9JXB4/Y>(_.*LX)(P7.<C'W:YZ>;9?5;4,7!I=>2=M^Z6^VF
MAH\OQ*?OTW';JV[M7ZKM^)^WX12>%7.0,;1UW%<<CKR/?C) %13Q@*Y/("_,
MO+(<D8/!PN<<=#Z=C7X8:;_P7-\/ZG%/<Z/^S5KQ1&<1)JWC[3HG:-/FRZ6V
MEOE\>AVYX)(# _N[\'\_&OX6Z%\3+8:=X7@UGP3I'C Z+?7PEN$&JP>=_9T$
MX2))Y;<_+Y@11)@$*"37=1S'"UJJA3J^TDES245)I132U;L[W:Z/053"U\/A
MHRJ146WRM-ZVWN[ZW3;27XG-7%N77>JY)[@8 SESD]",]1R,#!QFJ/ELO)&&
M+)@8 (QYJ\=>201@GA?J*Z-AE G (<  D' 7 .#CD'Z8)!JC);L2HVYW-U)
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MES>H\<&DW$0<)B4@J@D!.Y@Q'H!DXR.!@]:9BXM+1FNE0RA@L<:D%T!(;Y%
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MFM>7LIY?B:<:.*C%3I:2E!/WHK5.\%KI?9Q\G8W;A69!(%8A0KQY4 L",!5
MP0H!Y.>0QR<\CSK4II1!KUK!'"NE1SVDUP5&6BGE4><JD@'<< 8R1C!QGKUB
M?\)=>LD,>E0VT0^1[Z>4L8PWRR.JG W1X/[H<@XXR,5T*:58V6FC0XY;>\1W
MD>\NGQ&]S*VV0/*H!.Y03'#G.&#;>!7!2DL%5C!SP]6I[:C.=.G)5G3ASJIS
MSY'924;2@W)MMV5M;=4J?UI2C3NK0E>I6O"[4?@BI-)\UK6BTFELUH?V^_\
M!H^B_P##+W[5**4>(?'?PKY+H<A=WP]L<KU(WXW%AG(]NE?UQU_(E_P:,:;=
MZ7^S1^US:3N6A7]H;PRUJ,'Y(_\ A ;,MDX /S#;T&"0<<D'^NVOW7AKV;R3
M 3I3C.E4ISJ0E!6B^>OB)/2RUU2;>KLK]#P\3=8BHFK.U+?2_P"ZCZ;;!111
M7NF)''T;_>_]E6F+_J$^B?\ H0I\?1O][_V5:8O^H3Z)_P"A"@!*_F#_ .#N
M!A_PZ1\4+W/Q=^'?3U6[N6YS[<^M?T^5_+]_P=PC/_!)'Q0?3XQ?#C];FXH
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M_P ./C5K^F+K'BKP%!X5UNYE!NM#?7M+GE3.?WD:VLMS#]GP%"LUT95<LI3
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M5.<FDJM2*G4A)SY>NK3>[OI=7W0ZWUKQ.95NKK3%-DX61D< .8P"=W!W$@<
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M22;=M=2#Q!K4$6DVTUI.KBXC;:BX7;(Q&%SM W,1SCC! [DUY@D6K7SI+<7
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M0G_GBP;KD@8!)4 @X%=O#>J^DW>IF-XY]+/EZFD8P5XR)8D(!.Y%^4I@88<
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MN/Q]Z_OLK^!/_@S;96^/O[;.#D'X,>!C@=2!XR?G!]#^1K^^L=!SG@<^OO\
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MI0IZW]YXJ-5PY6HW322D]HQTO_6;H7_!2VQ\.:E)IOQ<\'375JUW9V.F>(?
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MTW5=3^R0EGGTK1-/,SL5A>= KX4DY1E&]N96;\NJTZ.^O=:7 _S]?CE^Q?\
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M++1K3Q'<WMYI-W_PCJ:=?1O/$JZU&LEH;Y8XWEELW,<BAXS&KLYQ\Q?L[_\
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M$4^H3Q?%_P ;*WV6)GWL&?/,9((7'M7^QV!RN>!OZY'7>K 8Z\XXX_$#FO\
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MA"T=5[B<DIKD5W%+I;LOQ9@>#K=%BO[VX<RS3S2*S3)\\2DE@H+[L<KCDY
MYY-:VI(DL<8NU66WD4 @@-@'(4+M(*L 1@]L9VY^4X#V.H>';V5UMY+BQO#Y
MLP&9=I!)W!A@Y&2.<L,<XZ5(CZQK,R0:7I[1F93&EQ<D+;Q1KAFE^9SR%'"C
MYMQP.1@=-2]7$+%.K%T(PI2ERZ1IJ"525TI*-]7=)*[>JU:.*G/V=*-"M!>T
M@JM.5HZ.7M;0E=IW<%&Z;EM9)O6V6UW?O8V-M*Y-K974MC+?/(Q>6-Y"T:D8
M"R&-1LSG.UOH1ZK8;;9((X4:*VB\IU1<>6S8 W%1DEP2#ECCGMUKE=2\.QS:
M!;Z2$1I+6<RF<,0+B[E!WD;>0022"QX'T%9^G:QK6GC['=Z1>74]N1%$Z$2^
M8JD*N I .=N,DX/ R<G//7C2QU)O".%-T)U77I2G&G"2F^>-1./+!N<=7=-Q
M^TS:C5CAJB]KSSYE=.--U':]^2SNTEH_P[G]W?\ P:B!1^SI^U@ZJ 9/C_X;
M+L,9;_B@+4@L>K'G!)QP#T'7^L"OY*O^#2V75YOV:_VL9-5TMM+$OQ]\-264
M#RAI&MSX!L@TC@,S*V\8V\#!.,KC/]:M?NW!\)4^&\IA*4)2AAN5N$_:1NJM
M5Z33DG9-1T;MR->2\C'SC4QN)J034)U.:-UROE:5M&EOOMK?J%%%%?2G(1Q]
M&_WO_95IB_ZA/HG_ *$*?'T;_>_]E6F+_J$^B?\ H0H 2OY>/^#NG_E$IK__
M &6'X<_^E\M?U#U_+Q_P=T_\HE-?_P"RP_#G_P!+Y: /YVO^#-C_ )+Y^VMZ
M_P#"E_!?_J;FO[] ,# Z#@5_ 7_P9L?\E\_;6_[(OX+_ /4W-?WZ5K3V?K^A
MG4Z?/] HHHJS,*AER 6 /*E3CIC(/YG+ #OFIJ:5R<GG^[D?=XP?J#UP>] '
M^?;_ ,'6/QB\<> _V_\ X?>%_#FH:K)87?[.G@+Q'%8OJ%XNCZ7J\&N:_&-5
M32K<I!<W<4EO#,+JX9FA*QA5(4$_S._$#]I#XE?%Z^LY?$/Q6\1C6M?\.:!H
M/C;5-6N[G3K'5;VPG:WCNKH:0UI'/%!;%)+JXNH)I)@ .&5MW^N!^UC^PW^R
MY^VQ\/==^'W[0_PC\*^+8M;LHK.W\;6^E6%A\3/#TEK&XT^]T#QK';?VS9MI
MQ8M;:?)<3:4ZC9-:/&S!OQ,F_P"#4#_@F;=HL=_XO_:5O%$14#_A,/"=K+&V
MU@DJW%KX91@8VQ)L9O*D8!67'-"A.4G:=.,;*W,I-WZW:V7;KJ^UA_U_7WG^
M=%J4?A+P1_:&C:)=#Q5XXLM;LY]'\9Z;?>3HT-JH1R+6VN(V26]%WN!:9GM_
M+(<?,3M^Q/A-\4OB%\0]1OK/6KJ'Q-/I$)MKCPOHM]INE_$*6UB3:;O2?#EV
M\=GXMMK%E9KV/2+L:G]G$EPMK* HK^W2X_X-(O\ @FM=K''+\4OVIA(F%\R'
MQ3X%$DBAAM$O_%)[)"H.,E2^!D=23ZMX _X->_\ @FWX$\.:SX5N=2^,OC6T
MU?Q#H?B5=>\5:EX.D\9:'?>'&DFTZW\.^*=,\.V6K:)I4URRSZKI]I<)'JRH
M(KS?#E:OV47;GE3GR[^Z[72ULK/1^NP-OEE%2<>;1M:>E^ZOTM?L?Q^_!+P_
MX)^(VLE?#EY/KK:7<V\&KV4<-RNHZ-J$SNOV+6[&>&%[&\5XI UK(I<>6>",
ML?V'^!/[)>KZ]XHT[1]*T'5?&7BK6WB70?#&C6)EF7<%:.YO7PT%C801DO<7
ML[10Q(K-(Y(*U^ZOPC_X-]_V2O@]\0_%_P 2]'^-'[2.NZWX[>UD\4Z?KFI_
M#]=%O);!)(]*N;6STWPI;/97FG13-!'/&QEN82%NWGD5FK]:_@C^SU\+/V>M
M!&B?#CP\EK>7<*IKGB[4I%OO%_B5T().L:P5646H.T1:=9BVL(\'RX K,#RY
MK/$5J-+#Y;2HX1./+7QDDI.G%IQG]7HM-2K3B[1G+W:=W*SE%)]N6+ 4O:U\
MQE7Q$J,J<L/A*/[OZQ.ZNJ]>TN3#P:7M()7K1;IWC&3DOS__ &5/^"6_@KX=
MMI?CWX_C2O'?C2T:WOM%^'%O$)O '@N\5-\=S?EUSXNUV,LBNUS#%I-E)&3!
M!/GS*_6R(+%!##''&%@BB@MHUC2**TMXE"1V]M;Q!8X(HHP%2.)%10!M( %,
M"[CC))R#SDX ]\  #+8!P<C'< 6-N!@$@X SZ8.1@=,>WIP<CBN?!Y?A\)*=
M2E&3JU%%SQ$WS5JLHQLI2;;M:\N6*48J]E'5D8[&U\PM&KRTJ$'+V6&P\8TL
M/2A)WY(4X)1:NDW)_O)-MN<DVA@!SMZ#!^8="/E!&#W.,Y[9XSU+CDJ8CAHR
MNPH5#AE(P5<$%60]"C @@')Z+3Z" >H!^M>@]4T]O+_/7S^3:.5.SNO-[=_N
M/,_$OPA^'7BP%M5\+Z?'<X8"]TQ#I=\&(RK-<VP0/R?N/$XS@\8 KQ/6/V8;
M>%99/"OBB5"Q#+8:_:B8$@ JJZC:O'(H['S()<9SG).?K;;SD<9QG '\.<>^
M??/&!C%0N<,3R3D<D=QT&<9/0X&><;A\Q!K.K0H3IV4%"4MY4TXR6CU4G?7;
M6S].IM2JU(RYHRM)*\6M'%JVL;/1^>N[W/@N[^&WB[P_C^T] OA;1,-MUIZ?
MVA;LP&0SO$Q>)6*XRR?*"25.2!0A,8>4 X;D2(.61^.&4X*C.<@@$D<#T_0+
M+D'#MS@D9.&QR 0" >>_3^=<SK/@[PSK^&U/1;.68 @7<4:6EVN<\_:K7RI"
M!G($F]0>>!FN:>#2UA4YG;[4.75/;=W3.YXUS7)6AS*6G-327+%[Z2;N[ZZ-
M?J?&$+\[1C:<Y)&&).,<DD \],YXYQGC5C.7R3PRKCNI(1<Y'8 @\$\_F3]!
MK\%/"L?GR#4=>/FON2,W$ $()/R1;H6:1%QPSDOUR>*F7X.>&HU!_M'6R%Z?
MZ3;C.25/_+ ''<'D=3UP1M'GIPC%\NE]5MJV]KF,ZE!+W7-><[*]^Z2=GZ.S
MW/EOQ792Z\WA'0H03)K7BJPL&&"RB%F!NF88SA80Q8XPH#$L%7)^_(HH;6*.
MSA"K%:I':VX4$ 10Q+$-OR\+E!G)SP>AZ>9Z=\+?#6FZUHFN)/J<USH-S/=6
M,%Q+"UI)/-:RVIDG2. ,QACF=X\. 902PQQ7I@0J5W'O@<$D_,3R0,<[L$'@
MXS6-"A;&XS$R=E6IT*<''1J%).;B[WOSST>BO'2UU<TQN+I8C"X'#0<E'"QJ
MSDNDJLJT_9]/A5*,';O)NZV+%%%%=AY@4444 %?-/[9YW?L;?M8CH6_9U^+I
M )P<KX.U'</PV_C7TM7S1^VAQ^QS^U@>X_9T^,/MT\$ZF?U))J9_"_E^94/B
M7S/\I3_@D0[I_P %)/V+@6) ^.7A$>O74#CKUQQGTZD\U_M=,/G<^X_]!7_(
M^I]>/\3C_@D9,3_P4F_8J09^;XZ^$,G/4#402#WZ#'4@Y'T'^V0WWV^H_P#0
M5K$V$HHHH 81N*<9Q(A],;7 R?7N<<>P-?X_7[37@K1(OVHOVH-0UBYBPO[2
M?[0=Y<%D C4?\+@\9R 2Y8;7VLN!C'0#Y:_V!QP5STW*/S<$?D2<^O'/8?X]
MO[8VICQ/^T_^T!I\&;?^T?VF_P!H#3]5*MY;D6OQD\8VT;IM!W;XD5RV!N+$
M8)(KX#CVIBHX?+*>&KU,/">,J2Q56DTJJHT<.ZKIPO[K=11DGS6M;=-IGHY9
M]74ZLL1259QC#V4+I7E.M&G>[5DOWD$]5H_4\<G\=^'HHOL]M',UO%*4@>VA
M4PQRJ A4*F[*.#SN(!'.>A%>/3-"U]6U"":6"24!YVA4*8VP075%(V$X/48Q
MCIGGK9?"FDZ);BWTVU3/[CSQ( [D",%I'+D@DOR2O/)!;!(&!=W#:/=V5];^
M1;6_VF*SOU551)H'7+,(,'+HO=020<@XP*_*%7P\FUET,1&M452U2I.3E.=W
M[13IINSYY7DG*SYKIMIV^@JT)45%8Z%&I@W&:5.G"*E3GM%*2BFFVW)\L7HO
MBW1<?5M*\'V#>3&TDDFV)'D ED<$'!VGS,'"C)[#C/)KD9?$-G<"22\M[J*"
M<XFE:-9(><DYX7:<,<8[ KP1@1P1QZWXJN[J6!I;&%7^RVZL2"5. [IP1WR&
M&,=ADYZ&Z"QV\OFP130H"XC(#0A03\D@(^\ .3U &!P.=_987#>RI8C#RJXV
M?))8B,Y4XP]HFU34')-)R;M;1--WUN^9RGB.9T'3P^'I/E2J3;<VDHKVBDXW
MT;?Q-Z:^=6?PU9VZVMR99!;W42/:^4D;QF1P2L8D'20C!;&%!R0,4^UUC1M'
M26PM8'EN9@S7$T85MDN.%FQ]TY^7:>"<'&<UCF\U33=!FMKF(B&;&H:*H);[
M/!,P28*220KJQ;E0%&,=A3=#T]+:!99(%$]RWGN=VX3+M4H\F3EF4\$Y /'&
M<&NFI2C.C7EC:U6I"C65->SDN6I'GU5E.^EE\TVWJT<=.M1=5QAA8PGRM*4N
M5QC)O1M*5VEK>S3UZ)*SD2PUR[C5(VM[MI3N@^42RNA&#V)WY)PN<<'@#C>7
M0]#LFDU"\E$IA8*(CD".=2 T;C.23U7 ;KC&3SGWNG0RRM>1_P"BWD2M<17,
M!:,QR1(3GY<8!^X0>!N!YP:2>\.N:AHX>(KYD(-XB_+%<./O3MZL0 "W<].A
MJ57G4YXT:N(AAUAW*HW-J?LDM(1<7SJ4I045RMRCHVE%W+Y,-!>TJTX3JRDH
MP44TI3DGRO5<ME:\E-\K2?VK,^Y/V#OV]-8_85_:0\%?'3PWI.N>(?#\5GK'
M@GXF>#M$U:?0KKQO\,?%UE)I?B;0;/58S&-,UW3FDM/$7A#5Y24TKQ3HNEWD
MJM;_ &B)_KF\_:@_8V_;POM2TC]M[P;?_!KXG&[N+3P%^WW\#/#6B'XAKIC7
MLW]@Z9^V7\'='@TKPU\;H+/3WLX]:^)7@P^&_&OGV]Q=&U8W-S>/^32?9[,0
ME(8A"R8: Q1A%!.P%MRAF.>IX())!XYYF*<Z1K=RB6\?V;5 JSAE1HF1E;>!
MNRJL  #ZX''',83-JD<.\+A8U?80J*K4PF-FJM'$.I*,:G/)Q4H-J-XU82C.
MG52G&7,VGTUL/37)5KN-JC474II1G91TNXQ<>7FM%IQNXJR>BM]D_M6_L4?&
M;]DG2M!^(%VOA?XN?L\^/6"?#;]JKX-ZBGB_X&^,;>5]D%M+XDLU9O!?B8L/
M)O?!WC.+1]>TZ^2XLI(9Y(&D?XGL]9#0)=);&5HG(N0496(;E28S\Q."I!7@
M_>KZF_92_;'_ &@/V0+[Q,?A#XFTW5_ASXSE;3_BI\ /B9H]K\0?V?/C/H4F
MZ"\T3XE?"KQ +KPWJPO+226R&NV=K8>)+&VF86.K1H7@?,_:4\<_L[_$7X@V
M'C/]G+X#ZI^S9X<UKPSIMQX_^%\GC*?QMX,TSXB/<:A_;DOPMGU*UAUG0?AY
M<6PL6TCPWKLVHWFDSR7-M;7"6$=I%%UXNAEGLUB,&YTL1*5JM"JY2<>9MMTJ
MFD:E)6T]I&-2,7%7EK(YZ2Q$>6"<)T8S;C)0BI;W7,Y)MM=79]5IJ>8Q6J-:
MP:C)+_HLD#7 \Q4VQHN!M;(##!()4E3[@8K:TSQ#\<?V@9OA[\$/ >F_$CXR
M1^"+;Q#I_P -OAOX=L/$/C:Z\.:=JVI#6?$<7A/PQI-O>S:=IUYJTZ:CJLEM
M;+;?:98YKAHR4)\UFN6:SUG2+>W\R!Q;7:/([*UN9@/."KPB1C)D"J/NLQQT
M-?LS_P $>_C99?LQZI^T?=^(OA1^T?XH^%/QG^"^D?!CXD_&W]D33?$9^/G[
M.7_"3^)WU'PSXJ\*^(O#%M)J>C0^(;W3;^*:"WN]-OM2U;0=#N+*>]FTK^SK
MC@RVA"6,H4L7BYJ&-Q,\-#E<G"G'DE6A*LH-N'O0C"\H.RES<C22?37K>T4X
MX6G&$J,+SE/W93;4>=47:,6K<TG[R5ER)W=G^4U_\!OV@;&R^*6I:G\'/B9I
MME\$ET-OC(=4\#Z_I4/PL/B>X^Q^'7\<Q:A96MSX9?6IQ_Q*O[2CB6_4&>!G
MM\25X->37-H$BN-H69B48 *7/\;$@$KN(ZD[?10>*_K?_:._9%U_X/>#/^"I
MVC_%C]HOXW_M.ZT_A3_@ECXF\)?$GXB_$GXE^'O'^L?"WXK_ !?U3PG:> _V
M@?!>F>*M/TWQ?XJ\/Z%HMUI,$?Q'TS7-1L=-O-/\0Z?!HNLZC<F"?]JS]AG]
M@'Q]J?\ P52_9]^#_P"QW%\%O&O["/B?]EO7O 7QF\(?$_QWXF\=^-(OC+XX
MT#3O&G@X:!XPUN?POI_AE/#>H7VC>%-(G>5++4FM-:NM12Y@DF?[6GP[5HU*
M:B\/&'[R,E6J<WM*BC*:=)4X6:=.'->323MRN3;C'QJM=S33=V[:J[VTU=TM
M+[-W3W/Y-?">B:EXP\0^'_!7AK1+_P 1^-_&6NZ-X6\'Z#I*FXU+7/$NNZA!
MI>B:-8P.RB6^U34;JVLK2!BOF7$J+N 8&KOCKPKXS^%OCCQ9\//'_A_5/"WQ
M \#>(-5\)>,?"NJQ+:ZOX:\3:'=RV.L:)JD43RQQ7VF7L4EM=1I))&LL;!9'
MP<_UU?M#?LR_L ?L=_'+X(?#OP;^S;\"_#G[0\7_  4L_9(^&O[.OBGX:>*O
MVG_$/Q'T#X':7XY\"ZUXS\>_M#:AXPNX?A)!\:+_ ,3P:KH,.F6;ZM9:MH&H
MV]QH%L]CIMK=V^[XE_8[_82C\>_MC_M:?M0^%_A1\0;_ .*__!7S]IWX)>.+
MOXOZ5^U!XKLOA]\,O#/BO4?M/AGX1Z3^R_I6M77ACXX>*87D\1^&_%?Q)M#I
M6V*WT[2AYEU'%<ZOAN:YY3K4W)5K3C"_)&DZ<IR:;2;:G:-K6Y6[VDFE,9JR
M2TM'LKIK:W;OYV\S^--=7NHV8&<1PB/S)6=V<"1LH04.<KG&...I)&17O>@_
M!#]H'4_!?AKX@:?\ ?C)K'@'QCJ6GZ-X+\;Z7\*?'-_X6\6ZGJ]Q%::78^'-
M:L]$FLM:N=7O)K>UTM+"6X&J7,L<%A]IED2-ON^S_91_X)VZ9\<;#Q)#^WI\
M/]8^&UK^V1H7A.S_ &6/''PK^,&C?%K6/@9#\>M/\+"'Q9XKU[PSI7AG3FO/
M K+X@UM/$8TR6'P\UU9:PMCJYN+-?M__ (*T?'S_ (*[?"[]O+]M/P_\._&?
M[8GPX_9G^'FEZ/=^!](^$MGX]\._L]_#C]FGPMI'@F;P5X_\'W'AW38OA]X,
MDT[6+2QEF^(_AZXT[QAHGB=;C2(-;L?LXLH>*>0X65+$UZL*T'2Y*=-854JD
MI<RG)UIRE44:--<K5JCC.3:C9-I/55*D;)2>MW[UG>UKVBT[M7T=GM=7MI^,
M&M? /]H/P9H&J>+_ !I\ ?C5X*\+>';=KW6O$?B;X/\ Q!\.:#I%E\J&YU?6
MM7\/6>G:7;AW2/S[VYA0LRH6#$!N2U_X5_M"^$_".B?$[Q#\&/B?X5^&WB@P
M+X7\?^)O 'BG0_!/B)[A?,M%TKQ)J>EVFE7HNT(>S,=R1?1GS+,SI\P_IJ\1
M_'[XE_$JZ_X-R_!O[0O[1?QAUOX(_M$_#G5KC]J#P_XW^+?C/4/!OQXO+#XU
M>$8O#@^-^FZIK<VD_$B,:JNEZ<TGC2#5@EE="TXMYGB;X@_X*??%#_@IUJW[
M1?[?GPW^+&H_M1/^S'I7QAUFTUGP3K?A[QK<_LU>$_A#IOQ,MO\ AGW4/"$>
MHZ*_@;PMHNHVMOX(.B>(O"]SIVJ>)-5N9H=4O;^>>\BKSL?DF P.&KXB,\7C
M)QE1IJFJ%)QI5,1AXXE3K3ISJ<E*,)*FY?;G?EDTF;T<37E.%-5(TN:ZE.RB
MFE)I<W*HN32O%=%%JZ;NS\-TUS4;>[M=/UJW7;J5P#!=0$&-3@$1)D$;69NY
M!Z\?-5C7=9N]/(LM/\I]3"_NX8F0+$"Q*JZ( 6D,9!/7TYSQ6UF.,Z=)(P7R
MF51;)N#3)>+)B/R2>%+%>=O !(%5&66R\4VBZG;L[S6%LF\1Q*(&>)"DAQM.
M]\[2Y);W'&/FJ*PE2$IJBDHPE)X>4G'VDX.TDXJ4(N/-RJS>JC)<UCJJ1<9Q
MI<[;DDU44E:*;U5]+:*WS38VPB\4E?M<ES!]ID1U,,RN45WW$%(\A!C;@DX.
M1M)&2:[G0-4&I17"7$:V.J:0@DOX6(>.>WP-MW:KM8JAQR&++GDD $T01.B.
M&B50,E9"^XRODL.#G#JO .[J".>,9$]M=WNO&UT*Y6UU.VTFZ&L7"!"/L4RB
M2*RW$%?/D0L,#=LRNPC&!RUL3#%N=%TJ6'E"/M?;KEIT:-.-E*G55)QC-25Z
M24^=MVW>IM*A]2<,12KJK4J25-Q;]IRN2=I\C7*E&6LN7[.ETM3^XK_@TYUW
M^W?V>?VNY8P!:VO[0/AFVM0QW2J!X!M'E:0GYMSR9 !)V@D=CG^LZOY$?^#1
M2:$?LN_M9VZ@&YM/VBM#ANAMVOO/@2S:,R'JQ"G /?!)-?UW5_0'"E*G1X?R
MRG27+"&'Y%'HG&K6YI)V2:J.7M$UH^:Y\S5G4J5)U*OQRG)O1JR4FH))ZI*"
MBDGLD%%%%?1&9''T;_>_]E6F+_J$^B?^A"GQ]&_WO_95IB_ZA/HG_H0H 2OY
M?_\ @[B16_X))>)<D_\ )7_AVP&>I6ZN2/RV9P/>OZ@.E?S ?\'<.3_P23\3
M<<I\7_AX#[?Z1=9/?IN_SF@#^=3_ (,V?^3@/VUE(P?^%+^"FQ_LMXW./T_&
MO[\0<@$=" ?SK_*M_P""&G_!6GX;?\$G_B;\??'/Q%^#WC?XPVOQ<^'V@>#]
M+T_P3KNC:%/HM[I'B :J]YJ$FL0S+<031@P1I;A720Y8\BOZ.Q_P>/\ [, Z
M_L4?'K X)'Q%\"@CMMR++C!QQP<\=ZN,E%/1_@1*+E;78_L8HK^.M?\ @\>_
M9>/ _8I^/;$XX;XC>!..<?Q60[D#CGU..#'_ ,1DG[+G_1D_QX_#XB>!#_*P
MJO:+L_P)]F^Z_$_L8HK^.?\ XC)/V7/^C)OCQ_X</P+_ /*^@_\ !Y'^RZ1Q
M^Q/\> >Q/Q#\"XS_ . %'M%V?X![-]U^)_8L5!&"/4Y[\Y[^V3CTS2;   ,8
M [C/YX(Z=O2OXY?^(R+]F#_HRWXY_P#AQO '_P @T]/^#R/]ES(5_P!BWXZ[
MB1C'Q%\ 'KQR/L///;O1[2.S4K=M.@>S?=?-']C&T=^>OX9QTSGN >_/-+M'
M''0Y![Y]?KZ^M?QU_P#$9!^RQPS?L7_'D#I@>/O A /.!N2T )_'/\J>/^#Q
M[]E?_HRSX]X['_A//!'/KG_1\?E1[1)6Y:EO*G)KY--)_P!>0_9O?FI_.I!?
M@]O3==3^Q#:,Y'![>W_UO;W/KP;![?B"1U)]<]^><'N*_CP_XC'_ -E;_HRS
MX]_^%YX(_P#D>FM_P>/_ ++!X'[%WQ\3&<%?'O@<$\#J3:D]>,9XQGOBDZJM
MK&K;M[*37_I0N1]'3?E[2GK^/]>1_8E@]S^7'Y\G/_ZZ6OXZ#_P>/?LL]OV,
M/C\1C(/_  L'P)Z>]F?P/!/&,=U_XC'OV6"!_P 88?'P'W\>^!./RL^:/:Q2
M7NU?)>RE_P#):#5)V^*DNMO:05OPM]Q_8M17\=/_ !&/_LL@$G]C'X]XQ_T/
MW@1>XSAOLF0<=QSVZ9II_P"#Q_\ 99*@I^Q?\?GYY'_"Q/ P./E_Z<CGD@9'
M.#P>N&JB;24:FO5TVDO5W?Y![-]XO_#)27WQT^1_8Q2$ XSV(/XCD5_'/_Q&
M/_LN#@_L7?'H9[-\1_ H/'4<V>>N0>>",<$<2)_P>0_LI#_6_L9_'W."2H^(
MO@0 '/!!^S GV QG@X-5*223]Z7E&+DU\M+>MPY&MG;[S^PT< #TH) Y-?QW
MO_P>/_LH8^3]C3X^*<'C_A8/@/!/O_HW'MQG]*8O_!Y#^RJ !_PQE\?"PSR/
MB%X"/KDX-H><$CVZU"JI_9J*W>#3?I&[;^1I]WS=E\WT1_8B-IZ8_+%2!BHP
M,8K^.P_\'D'[+!Z_L9?'OM@'X@^ U.,<G_CTQU]*3_B,@_96[_L8_'KZ?\+#
M\!<_C]E_H:'-/[%1]4G2F#5]&D_1\R^\_L44!B^>^#@?[60?U&?J:EVC@8Z=
M/\?KQGZU_'2/^#R']E4?\V7_ !\SD?\ -1/ @#<' R+,DYY(V_7IUE'_  >0
M?LK;L2?L6?'Y&P3M7XB^!NF,Y -FK9)[].N,MQ5II+2ZONE&5_NM=M=NFNVI
MFX)O2R[[ZG]B5%?QUR?\'D'[*G&S]B[X_*03NS\1? ^2 <$ &T)SD]<#N,\$
M4B?\'C_[+)<_\86?'T\+@?\ "Q_ N[.<9\LV8)SD8QQZFG=/I-?XJ<HK[W=7
M[+J+V;[K\3^Q6BOX\#_P>0?LH*2'_8S^/JL.H/COP&Q!YXR;8$XZ9Q2?\1D'
M[*75?V,OCV1[^._ (S_Y+Y'IT]Z/Q]$W^@<C[K\?R/[$*^9_VT_^3-OVLO\
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M)=K.]V]'U _NXM_BQ\,KL@6OC_PE<%LE1#K5E)D X. LQ)Y]/0U_/E_P<_\
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M&?7YNOXFO]'X?\%KOV87&!HWB4  8SJ6AC (X&-W89'J,G-3Q_\ !:_]F)
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MP,@\'G(YYU=#E@Y3C)--+EC.$MVDFG9>K5@/\WP?\$WOVNV49_9J^,@R#T\
M^)BHZC(Q:9.1W]2:>O\ P3E_; &%_P"&9OC$PR N? /B@8QQDG[*>O'/%?Z/
ML?\ P6M_9B) DTCQ.RXQA-4T93DG(QM((';:.HZYYRY?^"U_[+N<#1O%:[F
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M /" \3__ "/7^D O_!:W]F AA_8GB3YB59OMV@DMG ).,9SP>, D9SGFGO\
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MIJ),ES*K@)#" 5$.<;1G<ORY&XGY>M<U$EW8"400!X)7)>'JZ*P&[9&1CO\
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M^GX=?3W>BBVM^H'@W_#+?[-G_1 _A!_X0'AG_P"5E+_PRY^S;C'_  H/X/\
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M'_RNI#^RW^S8QRWP$^$)/M\/_#*C\AIV*]Y50Q.<X ' )'7=UQSV'?\ K2.
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MX >'77<#G@GXE[E'0<' ' '%9]U_P: ^![M#$?V^O&Z1BZ:Z1%_9]\-8C=P
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MT:HJ?\,^>&9@7'WY-TOQ(WJ'(8[-S*N<*<8R1X5SN,DUA8)*][5Z-VVK;W]
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M+QG>:H_P^^!GPS:_BO;#PCIEKI&E:C<:OJ5K9R7,%C:(Z![Z\$K?T6?M ?\
M!I=_P3N^(6B^&+;X'>(OC!^S_KND>(_#UQXAU*W\:7WCRQ\5^%[34;9_$EA-
M8^)C--HWB75-+2ZBTGQ'HU[:?V-J,D5\NGS;-@MQBG9R=[=@/Z*?VAOVD_@A
M^RG\*]7^-W[07Q#T;X:_"G0KC2K75?&FL1WUSIEG<:U<+:Z8CC2K2^N76\G=
M(X94MVC+LAW$$5^?5A_P7I_X)":C>6]A!^W1\)H[FY9$B%U;^,+2+,A 4R3W
M'AF.&%&)&7ED14S@LO(KY%_X.)O 'AOX5_\ !$3X@?#+PG'J">%/ -U\#_!_
MA^/6-3O=;U3^Q]!\0Z3I=C_:6K:G+<7VI7KV\"-<WEU*TTTS,YV';C\-/^"$
MG_!$?]A3_@I)^PGXQ^,?[1.@?$Q/B=:_';XD?#?3_%?P^^(=[X5DT[PYX=TS
MP[-HXMM)DL=2T9[VWFU.[EEN;RRN//W1*Z 1?/ ']T'P7_:"^!_[0WAH^,/@
M9\6? 'Q9\,DKOU?P)XGTOQ#;V[.N42]6PN);BQD91Q'>0PR$@A5)#8]C\Q/[
MPK_,5_:8^#/[1W_!M1_P48\ >*O@7\4_$7BSX1>++*W\9>&Y=57[#:?%'X5Q
M:[:6'CKX:_$W0M.-OH>J>(M&A9'M-:L[2WNEF%CJUJ;1I)(&_O _;!_X*2_#
MG]D?]@G3?V^;KP1XA^)G@'5M&^%^N:;X6\+ZA86&LW=I\4Y-,3362^U!)+1!
MI[ZFGVK<A)$;JGS'- 'Z2#H/H*6OY9?CA_P=3_LD?"G]F+X*_&70/A5XK\;?
M%WXVZ5K.N6?P#@\5Z'8ZE\/-"T;5+O26U/XA^*Q;7-CILFIRV?G:-I-I8W.H
MZC;,TZQP0QM*_P"G/@O_ (*U? [3O^":WPS_ ."DG[2NGM^S[X%^)'A6'Q!I
M?@>YUB#Q=XDU34-0O[^TT#P]X36RAL7\1ZQXA2Q^UZ?;16T?D6K&6Z:*"*20
M.S[/[@/UAHK^+.Y_X/)?@NOC[^SK+]B_XFS_  ZBU-[277KCXA>&[;Q6]D6<
MVUV/#PTU]-AO)(BDTFD3:R9%RT*SLX%?U$?L0_MS_L[?\%!?@EIOQW_9O\8'
MQ'X7FOGT/Q'HNHP+IWBWP-XG@MX)[SPUXMT1Y'ETW48(YX9[:0F2RU"UE6YL
MKB>-G91IK=- ?8E%?SE?&'_@Y,_9/_9X_;@^-/['7QS^&OQ"\ :5\$KWQ'IG
MB#XVF^TW6O#>HZEHOAJ#Q!ING:7X9LH#K;WGB.:XBTC3$>01)>R(US*L!<C\
M_P#3_P#@\?\ V>KOXG/I$W[(GQ7A^$B7<4;>-HO%^A7'C!-):Y,4FOCP*=,B
M%S!# /.?3[769KC&(C.2Z@H#^SB/JWT7^;5+7CWP#^.7PN_:6^$/P_\ CO\
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M8[FSL/#OP02[T;5-63Q'XHTF.ZU:W\:W>CW.E> -<&EZ=J6GZT9IIX.AT_\
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MWJFE[T6IZG\O?[/?[(GQ<_:]_9&_:I_8FT[PWX>^ G[*FD_%_P#9T\:_LO\
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M6FCIXAT[3;OPM/=>'XM/M-56VL]$G_L6)/[/B6 _F-^S1_P3?_;)_9#D\/?
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M.HKW2/&EOJFK>*M(\3OJ<B^("=$NKV9O!MAHT.HZO:6M_I5I=W%UJ%M&G[J
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M (T 145)Y2^K?]]&CRE]6_[Z- $;$>6!GG<_'_?=/<'>, D?)R!P,.2?T_\
MKTOE)_M?F:DH BP?-S@XW9SCC_5X_G^';K4:]!]!_*K-1^4OJW_?1H CJK=9
MVC R-LO.1U\F7'7Z9STS[U>\I?5O^^C5:Y4*HP3]V1CEB2 $8<#WR1T[URXU
M7PM==Z<EM?=/U[=F-;KU7YH^*9POVR[R!@7=S@@<@>:P^N3WQU'4YJ(]3CIV
MJ2Z.VZN5PQQ<W'1<\F9CVS@\X(]3[5#N/]R3_OAO\*_X3^/,'C9\;\9N."Q5
MGQ=Q.TXX7$M6_P!8<Z2LUAVFFE=--I[H_I;"M?5L,^9?[O0ZKK2I^?D.HINX
M_P!R3_OAO\*"Q_N29[91O_K5\I_9^.>GU/&*_P#U"8K_ .9T=%UW7WK_ #/S
MR_X*T>(_$/A#_@F=^W+XG\):_K?A7Q-H/[./Q#U/0O$?AO5;_0M?T?4K;38W
MM[[2=9TJXM-1T^]A;F*YM+F*9.0KX+"OQLE^#4G[87[;.N?"#XL?&;]HNQ^%
MNA_\$4_V6?BW+X#^'OQS^(GP_P!"\2?$ZZ;Q5;V7CGQ6OA?7;"[UO6-+O"FM
M 75P8-;U>*VD\2P:S;PK;5_4;JNDZ5K^G7VB:]I&G:YH^JVLMEJ>CZUIMMJF
MD:E9S ":TU'3;^&YL[VUE4;9+>YADAD7AT8=,FV\&^$-/U-]8L?"F@V.LR:-
M:>&YM7L="TVVU63PU8&5]/\ #3ZG!:)>2>'M/:64V&BM.VF6F]S;VJ;VS_=W
MT>?I2X3P*\,,=PG3X(SC'\58C/.+,XRKBC QR2E6RF7$&6>&F6T*,5FW#F;8
MZC/"PX-X@:Q&%G2]D^)8UL'&E7_M"L>!F>3+,,93Q#Q,8TX4J=*=&]1<WLWB
MV[RIU(-J?UF#:V3HQO=VY?RV_P""4WQT\8^-O^"-_P"S?\=?C'XB\;^/O%5C
M^SIXWU3Q=XB@OKW5?B-XET_X=ZKXVT>TFM=3N9Y-1U3QE/X>\.65O9ZI<W,E
M]>:HD%Y<32W#O(WX<_L._&_19_\ @HM_P32\9?L\ZC+\/O G[7W@+]I&_P#C
M!\.H_P!NKXN?M<_$OQAHVD^%HO$'@.^_:J\.>-Y[KPA\./BKINI07UWI6F:!
M<3ZE9-%JFD7,=BOA\1-_8WHF@:%X9T:U\/\ AG0],\-:!IULUOINA^'])L]$
MT72K=F9VM].TG3+6UT^PM_,:29H;6WCB:25V*EG9FXSPW\'?A'X0O6U'PI\*
M?AUX8U*36;SQ$^H^&_ /A;0=1;Q#J-I]@O\ 7OMVEZ/:W"ZQ?:<6L+W4$E2\
MN+$FTFF:!F4_5<%_2L\/>&JWTIL16\*>(:J\?LSXWJ\/9;AJ^2T\DX<RGBO)
M.*LNP&7YWDN(R>&68NOD&;9ODN?9?C,LHU(87%8"MA\OP.6SITLWHY8C)L57
M63\N-H_\)L,/"JJD6YU94JE!U:E.MS.:=2G2=/66JFY.3;:E^//_  48\&ZE
M\:/^"F'_  2M_9RU'XG_ !F\!?"CXR^$/VU;7XL:'\(?BIXS^%MQX]T#PI\)
M+#Q9;>%];U?P=JNEWJ:;JE]I-O87MU:S6^KPZ5<:E9Z3J&GM?S35^(D?P\\5
M_#S]ACXE_M1Z3^T7^U/JOQ5_8P_X*U+^S'^S3/K_ .T!\2-0\,_#WX':1^T'
MX!\.77@=_# UN/2O%T'B>P\;:M;>)=8\70ZUJ=YIMEI'A^WO+30=-_LV;^W.
M^T'0+[5=&UZ^T'2;W7?#\=\F@:Y=Z38W&M:%'J</V745T;59[62^TM-2MV-M
M?#3Y[=;RV/D7*RQY4X(^'?P^_LV]T1_ 7@YM$U36F\3:GHS^$]"?1]2\3/=1
MZ@_B*_TQ]/:RO-?:^@M[PZS<02ZD;F&&X^T^9'$R?3^$_P!.3">&? 'A]P(O
M#_.<?EW"66\)99F].A2X1I8?/88'C7Q-S[C/$RCC^#,7C4^+^%>.,CX,Q57$
M8V5>>79!B<-B/9977I8>7-C>'YXO$XW$K%.$L36Q#BW*M>E">'P=*@Z:C64$
MZ-7#5*VD4KU+.U[O^5/]M3X\_'GP'=_\%W)/"'Q9^+OA/PGX;_;"_P""?OP_
M\6^*/!_B/Q)=ZS\"_P!G'Q_X%\'P?&WQ%\.HX+JZ?P,+FTNC:ZQK/ABWTZXM
MUUB\OC<P7$GVR#M_VO=(_99\+_L@?"'X;_\ !-[]KOXJZE\._&/_  5"_9!\
M">.O'?PI_:I^)7Q6U/P!<_$OP]K=IK.B^#_B;K/BG79])F\2>&Y[/Q/K_A.S
MUW4=)LO$URE_JVE6=ZPL:_J$7P;X123Q+*OA'PZ9/&B&/QI))X>TIW\9)]C.
MF[/%C&S+>)4_LW%@JZT;Y5LA]D \CY3S^E_"7X4Z#HFG>%]#^%OP_P!$\*Z1
MK4/B72O#>C^!?#.G>'M,\36SF2V\1V&BV6DP6%IX@MY3YD&MQ6RZE;N 8+I#
MG/OX'Z=?!>$?"F*POAAQMDRX3XCR#.ZV19-B^ J'#O&KRCPSR7@ZA4XTR[$\
M"UL9F&,R/-LJGF_#'U7&TL'A88S%TLSP^(QT8U,:EPUBE'$7QU&?UFE.FG4=
M=U,.IXN6(G"C-5HN,:L9N%1RCS7C%Q=G9?S1?&;X5_LI_#S]O&X_8E_;3_:)
M^+7P;_8:^ W[$FG?$/\ 92T?QY^U=\4_AEH?C;XA:[\2?&6O_&3QQK7Q5L_%
MNAZS\3?BAX'DN3;>%_#NOZUJ^H:5I$-I9Z)H$UH+>VN?K'_@FI\3O^"FGC#_
M ()X_LA>)_".C_"KXN7>JWWQ-L/%'CG]KWX@?$_PC\4M6^#.D_$B]TKX+^*=
M,?PYX,\1WGB?6=8^'5N]S=W_ (PN-.O[EXM&FE:=;NXN4_;3Q?\ #'X;_$*'
M3;?XA?#KP5\0H-(O#?Z3%X[\&^'O%Z:3>L\<C7.FKXBT[4!93-)$C-+;!&_=
MJ"2%%=Q;10VT$=O#"+>"&)(8K>*!8((((D6*&"W@AC6&WM[>-%2&&)5CC0;%
M4* *_-O$/Z9V&XS\+N&^%\;X7QXMXKP>(X8Q.=5/$G+LDXCX(IYGD>3\89?G
MG%'#63\/Y-P5Q)@.)_$''\54,[XRKYKG^)PD\PR'*GA</B*5"@L+T8;A^IA<
MPKXF.-=/"R]K[.GAG5I5:CJU:52,,1.I6KPE2P\:7LZ*C3IR]G-Q<O=U_$S_
M (+I_$7XG^ _V;OV>[+PMXGOO _PM^(7[7WP6^'_ .TYXQC\?>+_ (5:)IWP
M5UJ_O)-;T7QS\6? 5I>^-/AG\-O%FJV^GZ'XV\;>'X#?:5H%S.'>..XF4_DW
M\;=*^*GP8_X)[_MR0_"[]K#X:1_#34OVL?V$X?@;X4_9#_:^^)7[15_^RE-X
MJ^)WAC0_BAX<LOB[XLCL_$>C6/C5)=(\3:+X1>_U+2[59=61K:.TOFBN?["=
M;T72/$FEW^@^(]"T_P 0:#JUM/8:IH^N:;9ZOH^J6%R-D]GJ6F:C!<6-];2J
M/WEM=021MA3MR 1PVD_!GX-^'O#,W@SP]\'OAKH'@^YU.WUBX\):'\/O">D^
M&+C5[.:&YL]7N="L=(@TNXU2TN;>WGM-0GM)+VUF@C>"='C1E]3P,^F)PMX6
M^%O!? N/\*\3CL9PKQ]5XPS=X#*>$:F5\68>MQ/0XLP-3&5>)\MS/-<NXDR-
MX;_5S+<=A\'G%&>00IY=7Q&"PN(Q>%S",PR'%8VMB*L,:X1JT8PA!UZL73DJ
M"P[DU1J*%2,XIS<'RM2G)M\RC-?S%_$W]E3QUX7_ &L?^"C'[ 7[-/QJ_:02
MP^*O_!+OP'^U-X&/BGX]_%'Q7XN@_:Z\.?%;5K71/&6B>--8\2S:WH%_X_N?
M#-MI'BF+3+ZTTV^@UJYLA:Q:/9Z?IMGYQX3_ &Q?BM_P4(^!'_!0+]O'PYXZ
M^(OA'P=^S?\ \$BH/@1I6DZ%XD\3^%-+LOVO?&_P]O/B5^T%XQT[3;"\TU#X
MH\"W&E:7X>T#Q5:VQN["SUL/97ZRP0&#^NR+P]X?@UV3Q7%X?TR/Q3-IMOHL
M_B:/2+"/Q#+HMI=O?6NC2ZXEN-3DT>VO)9+NWTI[EK*&YDEFC@$DC%LG3OAU
MX T31-7\,:#X!\(:3X9\13W]QXD\-Z9X0\/:?X?\03ZJGEZI+K6BVFG0Z;JL
MFJQDQ:@]_:W#WB'RKEI4^4?7X?Z?&1XBCA\7G_@YB<[XGP6'\*J.&XHQ=#A6
M>8N664^'\O\ &BK6]MPQ:O6\1,CX-X>P>22Q%.I+(*SS.>.M3S#E6$^&:K<U
M3Q\Z=&I]<C*A&=10C&JZ\L%[/GJKDCAIXJLY*[51*%VN51C_ #1?"7X8WO[6
MW_!17]C;X7?%KXQ_M Q_"W0_^"*W['W[0.O> O!WQK\=^#M$^(OQ6TGXO>)5
MT[Q/X^&D:U!<^(;F*0V]]J;W,AO-?N;&Q&LW-W:0B(_GSKOQ3T_Q%^S+\1OV
MI=5_:4^+EA_P76L/V_8_ASX1^"-M\??B!IGC#2+A/VG-'\+V_P "-$_9DLO%
M,GA-_@O!\")?$-]/+)X.F\-RV]HUI=ZM.D[Z?=_VW:?X-\)Z3JD.LZ9X0T'3
M]7M=$M_#-IJUCX?TJTU:S\,V<IFLO#=IJ-O917=OX=M)7DGM-#BE73+61F>"
MTC<ECC_\*L^&A\;+\2V^&7@C_A9$:^6GQ#;P7X;_ .$Z6'R#:^6OB[^S/[>7
M_1F-N6%_N,!,6[R_E/I91^T(R;"9MB'BO##BK_5[!\/<'X+)<DRNOP7AX8C'
MY'G_ (B9SQ1D'$%7&<"5X8O@3Q)7&/#=#C7"X>2SW$TN#,/1P^(C0>$6#F?"
ME>5.*CC:#J2GB/;RJNO-1A5I8.E1J4?9XR"5;"_59RI*:C3<L3.4O@?M/Y9O
MVI_AIKWQ\^/?_!?W7O'WQK_:.T&#]D+X,_L]?%'X&^ ?AS\>OB3X&^'_ (%^
M+-Q^S-K?BM_&UKH'A?7["SU&]T?6/"RVVFV%P)-"\K4]8OKBQGU2Y@O[;T#1
M] \0_MS?M-?\$IOAC\<_C'\>8? OQT_X(A^&OC?\=/#_ ,-_C'X]^&"?%SQY
M?Z7\*]4FO_&U_P"#=:TJ]N_M/B37FU^\DAFM[K4+ZQ@L-2N)]#NM1TV\_IQF
M\'>#Y'\27,OA+PZUSXR@M[3QA/+X?T=IO%]G:6<FG6UGXKG>Q,GB6TM["66R
MMK766O8(;2::UB2.!V1F6O@[P18W>DZAI_A3PQ8:AH6@)X3T&^L_#^D65]H7
MA55@ \+Z'>6UI'<:1X<7[-;*FA:<\&EQBVM@EJ%AB"^/AOIX99A<BP^$P?AE
MF&"SC(.'XY7P'C*='A*G#@K$8SP9X:X!S6ME51<'U,73AB^-,EQ?%]2L_K>9
MNGC\)B/K=/-L%6E'6?#U26(G4>(_=S=/V\'5G)5X+'UL7*$E&NFTX5?8<B5N
M6*VB^5?QG?L^:-XZ\,?LN?\ !+O]M>Z_:,_:=\5_'6?_ (*=:!^R+<ZKXU^.
MGCW7O";_ +,J_$_XF_#B3X47G@2[U8^$KO2'T;P=INJ:CK%[I,NNZKJSW$NI
MZE=64>FVMCI:[J?QJ^.?Q^_;<\0^)OVI/@)^S?\ MH_"/_@HMJ?A'X.>-/C[
M^VY\9_@UXS^$'P=\#_$;PO#\*?AG\-/V8],TF]^%WQ,^$?Q8\#*VCM-''K4/
MQ%U/Q9?7.N-+=F,W']B4?P]^'<>F:9H<7@?P3;Z+H>LGQ%HFBP>%M BTC1O$
M/GS70\0:5IJ6 LM/UX7=S<W0UBSA@U%;F>XN$N!+<2N<O6OA#\(/%'B?2_''
MBKX7_#3Q-XXT3[(NB^-?$O@;PMKGB_2!8E#8'3?$>I:3<ZM;26;1QR6;17:/
M;,BM T9 *_9Q_:)<*U\WSW.L5X19Q1S/-*'&.#RK.(Y5X?9IC<HX>S3CC#<9
M<.\'UL#F'#N7Y;CN&:6"J9GDF>Y?BJL8SJX[$8G#4,TH5Z^6U^1\+8BD^2AC
MH^S7U=5(3KXNG&LU1E1Q&(<Z<ZDHXB[C."5E)TX*4KIR/Y0?VL/AUK'Q?U[_
M (.'OBMXB^.7[2FE:M^Q?K?P[\>_LV^$_!?QY^)?@OP)\-OB%;? >T\47'C*
MR\)^&O$%AI^H:G+/HEII5O9ZFD^BZ=82ZG>6.FP:YJ,FI1^C_$;PM\!/&W_!
M3'_@DA\?OVI_B3XI\%:O^T)_P3U\-^,M1\9:M\=O'_PR\/>*OVA]'M?@O>>!
M?"WA^?3O$VDZ787GBVZO[PZU\/-*DM=(^(^J741\0:1K-_<J;C^IF3P/X(GB
M\3)-X.\*2IXW,?\ PFPD\-Z(X\9"*'[&@\7"6Q8>)=ED3:+_ &X-0 M";5<0
M_(:NK_#GX>>(_P#A'$UWP-X.UZ+P7<VE[X.BUSPGH&KQ>#[NP2&+3[SPM'J&
MG3KX<N;"*WM4LY='%G):K;6ZPLGV>+;\;AOI[9;1R["Y35X&XQRW+L%PYG/"
M&%QO#,^#<GSC*.'L\\!N%?#O'83)%/@ZMAJ;Q'B-PY5X\Q'UWZY#$X?'2PE>
MI/,G4<NA\-N<N>6)IRJJM2K-5O;U:52='-:^.I^T3K;JA6^K^ZHN/+"5[14#
MN1DLY(VMN8.O3#@D-P.!@Y'&1W!. 2\=!]*A4C!*[GR3EB"<DD9R>.<\GCKG
MW)E!P!D$''/RGK^5?Y98K#XFI4G..&Q;C*;DN;#8ARVUYY*ARSFW=SJ1]VI-
MSG&RDDOKHO5MM+YK\-;V[7Z6%IK<8_'_ -!:G5"\J [22,#)('8CJ,@YX/\
MCU%94<)B_:T_]EQ7QK_F&Q-^NUL.RFUIJMX]5_-'S1]._"3_ )%9^2?^)E=G
M'I_J^GXY_P /4H^$F1X7()'-_=..Y(.P9R.!R#@$ @=:*_[6/HD2E'Z+_P!'
M^+BTUX2<$)J49J2?]B4+III-.][II-/='\[9[IG.:?\ 8;B/_2V>HT445_1A
MY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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I_DE%%%?]*'T>/^3$>#__ &;GA/\ ]5&'/Q_-O^1GC_\ L+K?^EL__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>vc051_img06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #! 80# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9C0#WN1^"?\ UZ/[ _Z>?_'/_KTOJ>$\_O97UC'^7X'IG_"X-&_Y\+_\D_\
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M]/>.::]NE5N5$\>58?B*]=\'>)!XGT,7C1K'<1N8YD7IN !R/8@BL7QTBO\
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MS9K/[/\ #^"Y9<-=Z@2#ZJB8'ZLU=3\0-(EN?#WAV_@B9V6V2%]JY.-H*_\
MLU,\=:?_ &5X#\.V97:T>2X_VBH+?J30!TUC_P D;D_[!TW_ +-7E_A?PI=>
M*KBXBM9X8C"H8F7/.3CL#7J%C_R1N3_L'3?^S5YGX2\62>%+BYFCM$N#.@4A
MG*XP<T >I>!/!MYX4DOFNKB"87 0+Y6>-N[KD#UKB/BU_P C=;_]>B?^A/74
M>%OB/<>(=?@TU].BA64,2ZR$D84GICVKE_BV<>+;<_\ 3HG_ *$],#L?'/\
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M.CZSA/YOS#V>/_E_+_,X@Z_%V@?_ +Z%0R:^Y&(X%!]6;-=[_P *:_ZC@_\
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M0<>AP>1]: +UA>1ZCIUM>Q!A'<1+*H;J PSS^=6*:B+&BHBA44850, #TIU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>vc051_img07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img07.jpg
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M/E5XWZFL]/I>T-Z:CUW;-@$9*TJNW3857KDQ9D9-\G%Q3B*82DBW<.&DM**
MU:K=H).7/\),QE/EX1=\CY/^/41MQAH&2W5JMEO&62(M%:C=7ZLM]A2(*,S2
M*:+2K+2!)95^K&$%T1J"?U)VP>Z4@I_-PB[-_P"]==:)I#N;ONT]3:H>S:+Z
M$H<ON6W,:C3Y6[*Q[I>(BG;A=ZSD7K0JB'O/2,NYPBR(HI\H%[@(J.^%GW):
M/L7P \<O+KS!V'HC0DUN@EV:.U#7%O5M<N9>J[$NU2*A2GERF%Y.3CAA:NF]
M.J=944T3BLH*:8]"*WFP/,_Q+U0B#C9_DSX_:]1&"A;1FX[DU] *#6;.Y;-*
MQ8R(2$\BLK V19VD#%V4HH.O<**9C .>$2_=?*3QTUO+5&"V!O#4]-EK\RCI
M.E,;'?JY%+6B+F7[6*A92&^K?)$>1LW*/D&K%P ^P\<K$21.=0P%X14IW)]P
M^G^&U)\P]\^4.T-$6#2^HMHT6GZPK>AIY>S[DBS6N$A6">O=RPLG,!$Q>UI6
M[*R+EBV14:-BP:7NK=IDSCPBM1 ><'B':I.?@ZUY)Z2G)NJ:]4VS:8>-V/6W
M,E6M8(1J4NXV!/LB/!<Q%1;QBQ5SOUBD;@D/=W8S@BDYSOK2[/4K;?+O:>OV
M>E7L#'VECM9Y;85IKY]6Y?V/TF;9VMPZ3B'4;+"Y3!JHFH8KDRA 2[A.4!(F
M0AYA^++BF5_8J7D5HPE"M<U*5NM6]YMBDQL#.62",H6=KL9(2$NU1=3\'[)A
M>LBB+IJ!1%5,@<(NZ.\M/&6P:<5\A:_Y ::F-$(JK-U-RQ>QZH_ULF]0E/T1
M2/\ YN:R*T(>1&8$&H-RK"N9P8J92"8Q0$BK#]M3S'N_F35O*:QW5;4$BWTK
MY>[1T'2K1H^4F9J@W6A4NN46?KMN:RLS(R9Y"0E$K<<KE5 Y&XG2[2$ "]2*
MPT7YN>(DW6%KM#^2FDI.GMMF1VEW%F9;'K3B$1V]+JBWB]8*R*;T6Q+Y(. %
M-**$WUAU [03[NG")=_UK/&MWMM;QZ:[ZT^IO4HN4/[I2;"K1[^#]HR))NHT
MM8)(?JJDLSCS@X6:$(+I)N(*F3 @YX14C\.?/B:N,MY.5?S LV@=46O5GGS;
M/#'4A:S8)6OP.RGS&AZ[M]1B(I:_2:DE/[!G_P"<SE%HB!#*')[:*0@4!,17
M18^8GBO)0\]8&/D9HQ2$J^P!U1999?:U+81U?V< E ->S+M_+-B1UT/W )8Q
M7M=B7Y@)CKPB9L=]P?P=F35,L-Y>^,DJ:^79]K6E$8;SUTY4M>P8QPW:2%,K
MZ:,Z<\K86CIXBF=LEW' ZZ0>JA.XBD^?\G/'NJ;8KVB+/NO55>W1:P:#6]63
M-\KT=>YH9!)PO'(QU;=/4I)P[DV[191J@!/>=)I',D4X%$0(G+MC=>IM$U56
M\[EV-2=7TU%\UBALM[LL768E:5?"<&<4T<R:Z /91U[9A3;H]ZQP*80*(%,(
M$6N+SQ^Z'J+Q\U'XX6+5F\/'L\AY;[IH^J]9;4M5NC;3JVL4N<4EEKUO!XUK
M]DA/YRJVOF<.+95%&39H_JSUJBX72*)P$BL]4_(MOHOQKUALCSQWAXS4>S6(
MK*)EMG52SNJ5HNY34ZY?.J8O1'>PGP2**EJJR3=T5FHNN8')E2(J*IE(<2*4
MW_E'X\1DAL6*D=V:JCY+4-5K]YVJRD;[7F"^N:9;6H/ZK:;J1V[2&N05E8C[
MK!PZ]I-T40]L3"/")M1?FOXCS=)AMD17DGI!_0K!?XW5$/;VNS*HK7WFT)A;
MZ>+UU^H_J((M;M(K"!4(Q?VGBHF+VIB!@R19X>8?BT#+8$FKY$:1;1NJ;FUU
MULE^]VA48]K0[^^.=-E2;<M(234D!:GATS>RQ<"1PL #V%-@>$3PHWD%I+9N
MOY#;.NMLZUO.K8=Q9&TUL>IWBNSU&AUJ:Y<-;:61M<<_7@V@UE=HJ5][BY0;
M=@B<2@&>$3&CO,_Q0EZ!8=J1OD5IAWKFI2T; 6>Y);%K7Z)7Y^:3;KP<%,.3
M/BBPFYY!VBHP:*%!P]363.@10IRB)%EN?,'Q98U"H[ D?(S1,71K^WF7=&MT
MKMNC1E?MS6N).UK"O79*0F6S>6"O$8+_ *@5 3F8F1."P$$I@ B1Z?YR>&VP
MK#KNHT/RG\>[E:]MP[RP:PK-8W!1)N?O\''*.TG\M4HAA-K/YQBT4CW '.@F
M8 %NJ'JF?!%PB_-_P\L^P8?3]9\J/'.?VQ9WDM&5K74)NC7\Q<9N5@5#DF(V
M-KT=.KR;V1C3I'!5!-,RH"0P=HB4V"*KOAUYO7&ZPOG;.>7DOH[54;X@>8U[
M\>_YKK,O+5V@'I4#0]76R FIR9OLD9P-@?N-@^PJ >RF=<"HHI"/:)B+89J_
M:^M=U4Z+V'J2]U#95$FOJ0B;?1K#&6>O/U6+@[-^W0E(I=PV^KCWB1T7"(B"
MJ"I#$.4I@$.$4A<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<
M(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA%A2#Y"-:.'[M0B+1H@LZ=K
MJ"($0;-TS++K&[0,82I)$$P@ ". ].$7@?INL&^R5/,+SKU35K_Y)(^+OW</
M(+R4W!X/VB.VF?7'D[X<W-]5_P!&VO2=,VUM%TRP[2U\XAWM@JK\D>Z._/'*
M).$U#$;%$BN]Y'6SQ@\@O,;R/V+Y1/O-";\2O-[P[T-4_$V1\=JKN<\#N" J
MP7N'W+XHVJK5#7TW*US9;W8LRA(IL)48@G>OWF6)[!5"$5?O)225U)XV?>E\
M7?(+Q^W@3?7D7J[24SX9U=YJ6][\F;)H^I^.^LZCKK7\-M.I5NS0CNQ^.5TK
M<H-@.X?MA92QEY!+W%%Q4.1+_P!P+8:C!+[PE)3T1Y'V6W^?/V\_!22\9JS#
M>.&V)F1N8:]H=NK^P?Y@!K4';>@V#5[Q\BK*,IP[%\W[2%2(HL9(AB*W-?VE
MIV!W'YV>/GFCX?;DWW*^:TSXR[.\6*K_ *OFR)AGY#:0B])ZC@:!I<]E=0*$
M1I^8T/M6H2+Z8;V1[ )PJ[MQ(*_.*G<10EI'4FIW^]]D:/\ +*D><MM\Z:E]
MSZT>3FM=/T>5VG Z,OR$ALMM8=+^3\7L=E3":NA=?Z_U$]0CIA=Y.(J?3PJK
M(K8YW"+<2+9EYD[)C?'3[LFCMY>3U.N=G\1K-X,;=T?K&R06I+=MZOTCR5G]
MJU^PVV!FX.GUZUOX2P;CU=%MXJ,<G:IIOR-E& J844#A%H1\4F%/J-/\!;%Y
M?UGS?T)XH)^%/E%XQP<]KG5V[Z@_UWO.=\M+Q>K7KJY4VKZ[LME"K;HTE.0C
M&+?(,#,'JT0HQ*L(D5*0BGRWZK\0J-Y!1=%EO'67I5)UM]@SR!HE&IOD!K^1
MVEL:GRKS8LG)Z@K5PLZ]8G")[5>:F<_5M(@5SRL,P=_08*=,R?")OR-J39:;
M\/-A:=@[=L?;R?V]/MSZDW#X?[?T_>+%I[SNJU,MSI-EK76-G90+:V:D\K/&
MC:<0[D%5U'!&G8H@J];F:I*+\(N_RZ:UW8FKO\255-)4Q](/IG?'A+MJ/K50
MUS/-PGXO6X:7:[QMU::,(!)M<%J];X68)+KQH.5G#M%PL/N>X)SD5W?NHTRY
M;+O7A]Y(>&"I6!?N64QW]JG=/ZY79JBV.5T7NA=Q?*_N)O4[-&P=H2E=2UJH
MVY5N#IDDJ$3, J/:B4G"*_7W@7M.\?O S7L/$:'8[&HE!WEXIU6O,5J=>[W4
M?'F"JU[@V]>W_/:XUFX96N^5[0[6#0D$H1%0K>1>$;(N0,@8Y!(O/.6>U59J
MA":TWS7=B['L0?XD77V_9J;W[XK7*HR%PT%L.!KC^2VI(5X^KH:HPE3M+*/*
MXE(UNBW(T9JM"OVY#*D[B*5Z#=JIJS>*&T(ZF3[CPE\>/OO>7>Q=Y52CZ8ND
MK7]?UK;'C_&TGQOWL- AJJ=5[JVL[3;3*A)**CW;>-D3%=E AR)FX1;EOLG7
M&M65W]R]6HZ]V30JA;/N,[EVY0#732]ZU#!677VQ:CKTL'8Z<G;ZY7D))M+2
M%>>NEDD" X;^^FHNFF+@G<109$^'VWHK[QLWJAO33-O!!Q=@^[-&S2D8JI76
M/EZ[U^[\<'5 2.1!.-.HK=79MB"U]PJI7R(*E* ")P(J(52E6:V^".I/M]3.
MO+K$_=,TE]RV&V K/N*#9&DT$M'>8+W<-O\ ,PFUCP0P;C5EGT%,NRKS(2BH
MN4U"Q&3KBDAPB;VR]A5JVZH\_P#8]3B;O>*_J#_$%>-7ES;$*SK2\R\^AX]T
MV>\?HNP[9K=>_ETDS;:LR=4Z6(*\2DZ4,1DL8H"G@QB*,_(2YZOVWJW[I-JN
M>EME1E"WE]V?[?6V=4MMN>-NRZ^&P=71IO'F.OE]K$79*$5PHP>T.E6![)IF
M32D$X-<WUB297?M'(D;S,B/%-DK]^MW0M7TYK-R.ZOMKR&@UZMI"3+).W%.;
M:L/L)]IU>(I8N$D8>:@7QY-2&,1(KALJ941$V3$5DHN@Z+O'D3Y;ZQ\I*OYS
M[,\BMA_<.C/*[Q@U?J9QM&#TYY#Z\D'-%L7B_N* V#&U$^N:?#Z?J4<1C..Y
M:;C1A6\0J4R0J* @8BVS_<)D+!I[[@'VU?*?9D+.3_B)K5IY.ZWVA,153EK;
M"Z2V_MZIUAMJC=%QAH:/E'K6OJ-8"2KA9OZ4"0HRAQ5633='$2+3I;6U*TTE
MJ"Z2<-,4KQ_W+_B)JWY:>.E.DM?6Q,('Q<8:_=US:&W&]+1JQWNNM36_;CUS
M+MDWC9B55M)(O/9 BX&X1>G?ST\7:SYJ^&&Z?'>2<LHK^\+7[M6A6<000_D?
M8T DE:=5WJ-6,"8,7%0NT1'O2'()!*FD8O0HCPB\SM1@O)C=7V^M/_<]VYJY
MW>+CMO[CGBUY2^7VK->P+B\25E\/_%=FEH6OMX&OQ[=R\O%9KDI4QV.$<@U=
M [3>'513$"$.)%R\\*<.V9[[CGFKXT4BZ6?Q8E'?VJ++;9.HZ\M""&VMJ^.?
ME"UO6[=K:_I*L"RGKDYUCI1:,CYB2:,CJ.5DU&Q#+&:K D15<\^-@4+?^M_O
M*79/3&W4*#Y#>7/VI[QI-_L7QJVK5TMHTRC-=80NR;C4&]AH31Z?-2@9EPZ2
M5(WDS09CJ*I@DN!3$7JJ\O==^-+/[:7D=7Z[JB66\<;KHNX2$G0/%6G1M4N,
M_4[K$D6?2VL:U7H1!NO<7;1TF]0*9DJJ[41*15-3N$HD7G7FMT7"DT-TMLW6
M%:\DXBG_ '#?#:+I?W4ZQXW;=6,NW@]/69M4?(K:OCC2V;4^P-^>,=?C65,4
M^B:&JKB<E69W;8R[55L8BBC2SO3LU ?;HU/OBD7&QVS67WPO+ZV;%3\AO&ZS
M0%@+0=BOM_7*IW"T1LEKB.J,="V^;NE3>OVS$I(QC+NVR:J2)T"E2(N6L7GB
MY2FFI+%3*% 5>SQ?^)JN5ZCIB&TQ88JT17C7(2EY9L;&E((4Q.8CM.N(BQ-"
MI&$Y(DJ#@H%  *;M(D72NK-%;CU)Y/\ B]I;4\,/GFW^_GLO8NK;'5-.2D3-
M:JUUK'RQJ,[/;)<[?CZBUKE<UW0=6P\TS5:EF"%(9<C!-#WW"29B*2-E7"+V
M!-^1>Q8EWN^6\=M7_?V=>1'D<XT=6MB1>T8C0<MXQU756N?(:H-&-2=SMJH^
MN-XPHOG"T4U?G[8\RY"8(10"+T2?:CI&@JGK[>\_XQUGR!;Z?VQO>?VJTVEY
M$2MP&Q[]N]G@*\2_[6J]2OT17;=5*@_FV0-$U7<<P+,/&KAXBD*1RJJD6UGA
M$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA$<(CA
M$<(CA$<(CA$<(CA$<(CA$<(N!TRG[>[/RCD _;@0Z_U\(OATBGQD3 )?RB4P
MA@>G4/VX#'"+X5("B(]R@B.,Y,/7'0!'&,C@,9_#A%\% O;VE.H0, 'R'$N,
M?ATP'"(% OP.H7YNX>TXAW#@ 'N_'(!^_A%]]DN,9.&?S8-@39# B;&,CCIG
M]G"(]HO;V9/V],!W#@ #X?NZ<(N1B ;XF+Z=2C@>@YX1<01*7.#*?,.1$5#"
M(^O3(CG&!X1<?8+U^=3 B)L ?  81SD,!T'(9X1<O: !$>]3(AU^;UZ &1#'
MY@ /7A%]]H/\XX 'H &[0+@,=   QPBK0/ASXSAY'*>7CC5,&[\BPAF\&EM&
M2?3LE)Q\>TA%*VFI$0\A*N:O"2G\MK*1YW[-B@_.S541,L)%#@8BLB84%# ;
MO$#@& ,43%'M'(X <9Q\1X1=A4R]#%44-ZX$3B;H(Y^(#Z8X1??9#N*;N4$2
M )0$3CZ"("8!_'/:']7"(*D0@G-DXB;\PG.8V ]<%R."%_8& X1=9BH."B;N
M[BE$1'M$< 8 SW8QU-VCT'A%]*FDHF!2G.) 'M_,/PQT'N#/3A%V>V&0'N..
M!$0R;\<_\OA%]!/!A,!E.OP$XB7^@!SCA%U%!-01[55!$O00 Y@QZ_N'A%V
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MV=]Q[4.GXF:LMUJ^Q_Y1KTG>:/*V^!BZS+0)=S:WUS*;/M&EFP?S.A)&N?\
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ME4X6#CBB5HP3D)Q[)2SI- #"!3+N%5,#U-PBDWA$<(CA%Q.!A+\N -D!#(B
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M466CFK10X&*1=6XOME5^X4^_M==[5O-=N]U>;S?'D+A(,+!6"F\G+91;'OE
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M)BF@W12 I2%*!2%*&    ./F(FX$G4%87D&BRV\F58AE"-G10Z?*LB9N8?\
MG@!P*>2Y'UY=S"14!7:V]JR!6<J_D0(7&>IU@$0_>5,JF!XUFF 52'TPI5-V
MQ7:K4UJ9Y<;=5:JT( F.ZL<_%PC8A.T1[C.)1VT2*4 #.1'TYB=*2TZJ >(K
M]* T;60@._EVJI=\^Y!X)ZV%4+?Y7Z:;'2-VG:0=P96M\)B]!*1C5"33H_4!
MR)2B']?(PEASU._E[%8Z>("NI4RO'W\_MV4[Z@(:X;)V0X2(K[:5+UY+D1<'
M3_LD=6US5FY -_G".,#R]ES"RI!<<%:+F%V%52F]_P")KU0S.NUUEXRWRP+
M!O9?7:ZU^LM"8R!?=9PD?:%\YQDH*AC\>1I=U(-(6 ]M2L/SC"2&\%2Z\_XE
M'RMF@62HNF-&T9%05"(O7X6^ZR#8.X"E,8Z\Q7&*IR@/7+7L#]O(DNX7<A!:
M T=W[58Z]+15H!5,+U][3[D5W3>ICOY6IM%.XA6]"I=*K0HE.'=W(R",$YE4
MQ)\# XS^(B/7F$7=VY^DO(/<H[=RE.;6Y]ZJK)>>GFY-/%I:0\K=_+R2Y>Q1
MQ_>A;T2^VI^8"IMY-%!(H &<)IDP(=.5?-.UVD&O>L$E](7G #WI #S<\QQ
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MTX2,3!2"99\DNIGN+GYAZYY#=N$[,W?0/U*ID>'!O!2HP8,VI2I,FS1DB(F
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M.EXC;\).2_1A8N$7;9!VB8#).$4W"1P'H*3@H*IF ?00,0X#_3STF%Q+6?\
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MIS1.YHG].=,3#DIDTL%(8 3(90_<0#]1#M 0P&!R !UY1$[F0+G<93.8Q>T
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M3<S]XXGLJK[?=8KH.# /+^E>3W8^A]'WRV2=KDH_;1G#PY%)"(:[++ 5Q^^
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M;,?N$0[0+W" !D?PSS!YVC2XDK- 3R\>U+*2A<F[DR?E,41[NSM N,$.7'S
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MYUW)Y0T+C6[1.^*D8.NHX*36$)97!4Q")F!34*41!T!$13ZE''\8Z)@$/7T
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M:M"- UF>F+37JNG:ZW&VF,966=B(=\:+D6C%T"OLO7B/N%;#())JG)W$(H<
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M4[CF;;Z9ZW:@[<MW)R]R?MY4 BLF3:.M%&5GD2[#HIV%(<?1W5^G;8$[&GO
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MZ$_BXJ;D$@DF395""AY6=8M7$DJ4D<FY>MTC+@HJ0IB*R@*E G<H8A,9[LF
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M2[A$#$34*!A..#%*':.>[N$!$?P^'3FMP<X@=O!73C"@QH$V5FRY5,& "IG
MYQ*<Q#8.7/R H'<'7(?+USRKK70"3A@HZ30<H"NF@<.I@^41[0%,P%$X@<"@
M!""(] ZB/(M'=B+M44'L,5(P=0ZD$WN&(8YL=W=C 9_8(_ARR1FINDY*E:+H
M4((H@ D*"G<4#ER<!-V!U/\ *8,@ ?M#H/[.1GQ!HJW$JH(.6*ZDS@4XE7*<
MAA5$I.F?X*8E,;.1 ?D'^GKR+(UW854@C/-+ * J8/:[02'J.<=PG3.<WJ/;
MWIF <8 >OKR,0=8.-%)@\K3JPQXI7*K[K3/M'QVG5$_<4Q0((Y I2B;O$_9^
M&1S^SE9RUS: @X*0)' 48"0LZ.4$2$*1,0ZE$JA##W 4P=.\!'':&![Q#. ^
M'-?2F>:SL)<VI%"E] RAU@()#%Z";Y1]<#@H@!<A@O[/7A7)?;*Y 04')DA
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M^X+SR">@[^ZG*9#UC5VLJFFRUA8;&YHE1;QMHO\ M"/+&HM8F'69-HE5X_\
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MB!>H& V?CTZ\Q3 EF&:-#)':*K(%02+"J)E.TO<8"BID/R"(D'MQW]PE# _
M/7FOF+V-J!Q4CDB ^; E?"N 7, $$Y#F^9//S%RH;N.)S#V]IRA^&>8FRX'F
M8=BL<YI(H5DMU.W @9,Q@.8!,8," '*8F2'*)0-G/7(=,\CES0UU>U3HPR45
MKDE]%_[8&[@]"' Z93=<X^42C@?E-Z8Z!^WD,$'%9VL#!0)3;F( E3)\I%/F
M*0QQ$ ,8#=Y1$@@)< &/V<CO>P/H3BA>T8$XI;36%(Z/:H8QC]Q2%$Q3',81
M,(E,H)@+@#].F>GKR@(.(R510XA*Y7HE('</S=H (?*80, X/D<AT#E-;4J
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MF6-)HU;\WJ'&:3MZ=W?6[<S[R%",+K>YDD%V3IA*,V:XJ'=/)MX238MV2(&
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MHM%%.XW43=Q@'.?CS;2.$G3]I(TU:* ^XC]"RQBEV[Q4ZZ] H0":F,=ZIA,
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M?]YHS_M7C\6W/^GN/Z^;_65WX5M7^ZVG_AXD?R_7O_%^"_[S1G_:O'XMN?\
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MRP;ADC*2)B L5H@^8K&!(H@':)A,;GD>\7\T.[S0OD(CC>!AW^U=);,F^4U
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M<QE2=HKAV(G,H)T\ 4 $@82$<Y,(_FSZ (<YJ25[)7Q@4!HI<39=5'E;_/\
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M9'#ME#UB&7=8'Z5I(6*3:IKJX_AH&.;U#GC^Y0,NMYF=)AK=4CP7764Q99'
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MS3:,@6\E&.W31['#+SL8Q^N9.F3EL[24:HN#'/[:A#>V4P=Q0YZSL>P[AO\
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M?33HNZV7>V70WV;>)+ADL#J>1S]0)#@\>P *,J!YU>'#7:6P-R;5C]E7*YW
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M<2%051,02@?GTGZ"6VXVVY[KT1TM(PV^Y6#;FT$;A'\I/-=-M[ES79,#G'F
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MW[311;;"BYFBTJ I$;$PLY%R%FOI[9)O;%%U6-46,T:22#MFL^5*\<DD%"J
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M].6/8US2",%>SXEM(\3W_P"I:>BW0" YF; F./@)) 0Q^WGL'1@#=E:!EJ7
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M4()! S(5?/*N25F-)F0*C8'($V53#=E>C_U)V0IX.[E,HY( F%)H4 ZGQ^;
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MG/91KFOKEVA2LON):UTR'\@FE7EML^*-TA*'$T#Q[9>/C@=MP]^=7I*-5O\
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M71WDC7]H&@ >S)2D;[;^R 1(C&P4I"B!FYCK-+#17*2IT$3(>XHQ=LUFQ3+
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M2\M__!O2G_\ -;XS_P#[V*_PBM9D/Q#^OE*A5H49#\0_KXJ$H557PTR.@60
M&1_O4\C?_P#8_:^?\G,<QD:RL0J_4WW:A7W"I1M*XJ7;I15K<=@9%_\ 0&9
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MC=RT\O-8M7SI5^^;^*&X$7K]P@DU<2#Q/9FA"N7[AL@!46Z[U7*IR$ "%$^
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MEME; C]:5X;I7OU@0K[5O9I1 'IA75.W04!0"' !#A%;0)R',M(MRRT8+B'
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MBL4BL,I9J\1FZ?\ Z]"?1LU2-G3LTLQ*T;.UBHF0:N70K^PW76!RGVD.8IC
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M2.:/&L<_FH)F=,C@'1^$5\]9>4REJ\K8W3S::);=>[O\9&?E7I2;+#!#OZ]
M5^UUW7UXJ$P'TS=9ZS?N+=#2\<JZ(5^@LX?-5NY-)OVD5\>$1PBJ3N?<5HB_
M(GQM\;Z<[/7WNXH?;NR;1<BLXJ1<0]%T>G0R2,#$L)A)RR&6N5AV/&-C.#HK
M_21Z3HQ"%6,DJF1:M?&S[C6W[MK[PCONV[?:H2+NB'EG9_(NS+:-1K^OK%4M
M%U;:UIBCT2RJQ"K05V#2C('73CG"RSM C@0$I@ 2D5PK9]PE[1]G:SCMD::L
MFGM,6.G;DV-<]Q[)G*LA#Q.OM9:GJ&U&UNKS>N3,N[D(HC"TG;3)5DBKQSUB
MHW*FOWD6X12.T\]-:0+)#8.W6HZ%T);7$5&Z9V9M68CXJ3W \>MWTG)6"(U_
M$-I>;INNXZ&12>EF)Y=@8[985EVS1N4JJI%!4E]Q>!V+YE>*>J- ;.U1:-#7
M.W;&J>W+HUL,%(OK5<RZ2OM\H%&H *+E<"VA757;OI:11 2N%)..:-C*>ZX
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ML(E^K7F22CIJFU>N6[<"+J*=Z@G(IWE_$CQXL%T<W^=UM'3%DDDZ^,^:3E+
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M_N%3/*C4XB@-#Q6-VX6;<"\52Y(;2H,2D*TE98]B0N>X'!S)G( >HJ$$O<D
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M[C:$L"K?KZ#]46*^FP/^[Y:=UL0:%XJFMJ<O]X-/[>[]:0#]ADW!#?\ 0F2
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MV1P0A\]J?>4!$AA5 >H@&,^O,1%#0<%*8]ND5.*<+,3H#[A2A[H#C ]4RB0
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M" X PB4P^I1[>T0#J(8-T_JYM8\UK>%>*S4Q[@]LHD[S$$I3&R Y 1$  V,
M(A^SDAC0[-0WRN)IA0+.2$^.PA^S'8 =#CD,%$W<(9 H8_K].7\MO%6<QR5T
MC"7N #Y[<E[@ <& W4OY@S\W'+:JB9[<,*)<: <N# (%$Q0P8, 4! ,F*/P[
MA_#CEM5W/?W)RM%C 1/!N_!BB8H &%1 >H&R(]N!'I@>8G4'@I335H)SHG.W
M7$I"&[ 'J(8Q\1^'J'< ? >45R74A ,=3%'L$P8 <%_8/X&$?Q]./!%FH"41
M/DJ@F,7M' E,.2@  .!R&!#E"*YHE= 3"0"F#MP4,%((!V]?CTQW&^/+2T-!
M(S5*EIJ.U3;LIP*/VZ/(1; AV1<_T]!Q^HUPOX^OS<UO5>K^X>X:?Z$_6%M^
MEVM/6U@75_C!5I^TC05)'7&Q;JJB+9[)6Q-M$/1# @2*:)%.B!NF45%S&S@?
M7GS-M4#(]I;<OKS"WV+TKU"W1KMP-HTU8'NKV\%NJBU5E& F<%,FJGW)J@(B
M BH0.TXB/3("<.@AZ@/+F2F0!X.2\TF:QLC6LQ![4V(RT(+24A$R"B?8DX%!
ML[,<"@4%,"5NH/IW=W0H\VUA?QB7Y:?"N16TN=H=';,N[:I-*N&:5)!-=F3W
M!$3!WAV*ESGM#\HY ,= Z<V-P9+7][J!'<L%M+#,1'3S<:I)&5!P<"^\#9VG
MT!0^2MU0]"E6 ,@7.<=^.GQZ<6NXNN7:6.+7=^2G26/RS>;35&>'$+*1G%62
M@%=I=AN\"GR4H )NN!$Q<%,&/0?3DB*<1.(E.-5C_"OFF:XS7"J=3:615$GY
M0$V! 1$! ?W>H^G)<>Y1,P\NGBM)<6,K!0):*JFH'N)F 0#UZ^@C_5^/)(FA
MD=S8\2%K3$8S1_Q+C[RGO>T9(P)B0#E7 0$HFSU3,7/<40#J _'F=DIE.AP:
M!W!4+ <%]5;IKE[3%STZ#@!Z_ 1SS/R6/8Z,@$N;3']'>KN;)&/*2%&RS8CM
MN_K#SO43(>0(V6' KMC"X46;KH'.!BD5206 2Y# X HY#/-);7L^V2NM]1#6
M$?2>*V,]DR>R;-CS'?J5;[Q5HNF.VC>QV>W3(2(+J, 9^XW,Z30.4BI3MZ_&
M@X(9,YP <G #>H<]-VR]9N4#71$&0#$=J\^O;::UE-=6D]B;S-E$.TS'A=66
M:>^(NI>.6,F %#/>HK8GY1 <=1$2CR> Y]2T$4PQ[5%CE>YM8\17CFD*U[?K
M>KV8K72UZ/T\Q(F8QEM@[1J%7%(A"B83&;&<,CF$ #J4#CCEKK>8G4!@I3#+
M3%K2?!4AV/\ =G\#* *R=J\YM2/'K<3^Y%:F@+%LU\82B(=J#J&833 YR@'3
MYP ?CTY@= 0<6NJI $I H![E1G8W^(4\!H$5$:PCY5;G<I@;VA8P\'K&%7,4
M0#Y5I.492)$SB/R_[V$<?AZ<N^2E.0P*R99YJCUW_P 2#&>XL&I_".GMU2B)
M4)3<6S9ZZNCB(CVN%8V$C(EN90P#D2BZ'KT[N2OPN9OF(90*P1MK2I50[Q_B
M%?N$6,ZS2BN]*:;CS@8$B:_U)"+OD""(CV$DK>O9%LD[OS=H"(\RQV37/ =7
M359N4UGF;6H7#P]^ZSYQVGS)\?I;;>_MG[5J[G9$/'S6N'5MCZK6+8UEBN8X
ML"Y:LVD=78]N\=.4P]Y=$R2 E X] YAOH([:)SXZU':KXI!K =D<%[>?$'R4
MV+N3:U@KUAU9K+7%;CZ6]EF9*_LUYL.ZN)!&8B&:*,D=G!QE;:1GTSHYCBDJ
MJI[H$ OR]P\LZ4OIIK]X?IH(SD.\+97-L^&)KWBA)_0MEGPYZ-J\NI0$<N1'
M"(X1>2W_ !D=UM]4^UUKZ,K%EF8!A<_*F@UZV-8B0<L$K%!(T79,VG#RWTRB
M9GD8$O%-G H'$4S*H$,(")0P1?ET?5.O_93G_A"W_J^$1]4Z_P#93G_A"W_J
M^$7O'_P0=RMKR_>?E)>66<=TZ-IFB;''UAU)NW$$PGWL[L>/>3#*-65.U:2+
MQBV32553*4ZJ:9 ,(@4N"+]"+A$<(CA$<(CA$<(CA%\'T']W*')%%6U__!)3
M_P##VG_UYN?F1_FR_P#^2KW_ /<K3_I!=KT)_P#4'_Z+OJ*C+4?_ (8__D=Y
M_P#=6_/R^_R?_P#_ %#>_P#\?N/J@79=>_\ H$7_ &JM"8P$ 3&S@/P 1_R
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MB5/HF)2@'=W"H.!'N'(^O-@&AN2BS.<QM6FBS@()#%, "'02B(]H@.>HF*
M&0P'KGF:/BH9[5GMVH8 WSX.) +G&#@(]H%Z?*.<?'F7-4"6 1$ *!4R],AV
M!\H@(=!,8 _,8,]/AQ@JI0;MS?,.# D _P 03%-@>TF2C@,"/<?IT].$2JT
M"B4IBF$H_,4"#^7( (%P/7 #RTM:34YJ3 ]SCI)P"=K)0"&3P'<7MZB;/41Z
MB(@/IS"5)3C3 1 IC&+D0#YBER42CD>G4# &<?MY3)$JM29[CB8I1. 9ZC@
M^ ?,/3TXXHE%OZB _,4?RF*(!_T7=^7KZ#CE'?"4IVJ7]R*';_;6\D5OBG"S
MJ@=P_A*5W.?V_+S5]5E_]PMP$7Q\K](6SZ5<W^]MB^3(3BOA0IX?;>KH53Q%
MUX51N9E(S"3R>=I*% IU!E'2KA-7 AW8,D</ZN?-%Y-':[7%:!P:\1 GO)75
M=6-9==33E@_<ZLJJ]9'Y$HP5SG*8ICJ$.8V,")<X[C#^[D#;@[D$N=JJ5SAM
MGON>4W,'#P5:[?)ECE$VH 7ZB7>J/U#AT,5%LH((F 0#H B/0?CS)<"5SP&G
MRCZUV]J*1#5\5*%.^N;/9-BIP=H5.5LOVE8R*OY"9+@I'!NINTHC@!YLK'<X
MV'DW^-<B5JKS9#S/G-O%):U<!^K@G6N5H)SF(X260.7!3I'*<IR=?0<CT$/Q
MY+>8G.);( T]E%EC?/H&MAU4QKVK"<NP5CG#<5!4.V2.=(ZANY11N0,AC/YA
M3_']G,KI8WMTOQHL\5NZ!P?'AJ^L_P J)/BIP544U!4 W9@HB!OPZ>@?CR)4
MG J;+MS'BM,5)43+^Z!2@.0$ Q@?CCFWLGOC;1AH%R&Z;:(W\QPP"<A7:H#D
M1$ QD>X0$, 'P#\>;2*>1KZD\.Q:@01DT Q\2NUG--G#@&P&*50R9S$#NR)A
M2.":Z> _M)"("/[#!S907\+I&M;_ !05@GL9F-+S\"9UW>-:NRF;:X4319L8
M]5==10_:!7."(I%'.>BG0H  9$W3UYI.H(RSF7K^P5X+;[+_ &Z6';W&E7'W
M<5"=NCYG=.JI?743L2XZ<NUTJ#]S7=D4Y"&<7#7[]11-..GHI"?CI.*<N$W>
M/=;KHF(LCW$R01*<KI?>I-OGCE+_ "OQ''#)9NH=A=$V4Q4+8W:3[15?G;_<
MWC_NS^+VX[#J7RV\C?(J[0ISG>4_8,=?KLUU?LBK.'KA"-GX;]"=1\(Q7<@B
M)',6Y*5TR< 9(Q!#M.?WNQO-NO(!. "\\*Y]Z\Z-GRS0"BT[K/I"3<*.YE^[
ME7*JIE%7\J]6>N5! W<!SN':JJQS ;XB/-B&1.%6MTCL5A&@Z2NTT[!-.CV3
MCF_8 ?G>-RE I0   2@H)N_ ?ARO*=]D"G@JZW)'=[4HS$IB*3B*H@41*#0B
MBXY ?\XI,9_IY;\NY6]Z;Z^Z*^IA*'BI^74 Q>T&S$X=YL_+@V1/@V/\W'+S
M;,&;\$JEM"W7J3:B]AZ2(&!1%(&+LSX)'VEN[_?14C-6[11-,0 #_P 8I@R&
M $,CRQK8&'475 X*I<XB@*VO?:<U=K/9GESIEOY.[1G=4UM*\UEU78NHUD)2
M:L]T5EV*%7K2LD7]2:U^,<RRA#/'JY0*FW*8A0$YP$O/7X,LNASJ6Y./Z/I4
MN,6IC >VLH(.9X+],_3/C#KC24TZL%3).*3#Z*5B'3N6E$G1!9K.6KM1--JV
M:,VZ9A79D$#8$0 !#/7FWVG98+"Y,T63F$'$YU'ZE,NKV:Z8&2$$-RP ^I63
M^./ACG4T&FG!0>%5]Y541PB.$6E+[^GV_P"M?<-^W]9]=3E[DM=2NK+I7=SU
M&Q,HI*=9J3L VE:TI$S<0J[8&=Q,C$VQR!C)K)JI+$3.'< &(8B\S(_X'BQY
M''W$(;&>F?'5Z X_;C;6.$0'^!YL8" C]P^%$,^G^KJ]_P!O;(APBW9_X?7[
M-D']JRU^;:JNZG^Y[K/[ HVHG\FE5$J976M>I=%@]DQ[QI$'E9U\>6?/MKJH
M+F.Y%,A&1.P![S#PB],'"(X1'"(X1'"(X1'"+X;\H_N'_8Y:[X32IPX9^Q4.
M2B3:2Z9ZJ8H#D_US,1)W%R ]QLY+W"/[?PY^7W^:Q?;?-^5.^M+AYYK-QLR8
MV2PF5GFSD:'%U.T 57;]"LF&^,);_LC7W8J,]6*E0M?N',! _2W10$1 .[)T
M.@"(@'3UY^7?^4E>V^U?F5N)MPNK6UMW[)= &4@.=Y8: $D89+L>MF.EV.-G
M'FJT"9P4 HY[BF 1#/7/^40_R\_I[MK@7 :_4UP(JUS#5CAVKQI[=#M)S7;V
M$R!NT.X P!OB ?@ ^H!^STY,5J^ BD&<$*&?7IZ]<]?Z>$7(2$,7M$H"7_-$
M.GKGT_?PBX@BD E$$RE$A 3()0 HD( 8 A1# E* ? .$01),GY"%+U$>@8R)
MOS"/XB/"*/J[JFAU6]7[9$#7&<=<]GJ0*MYG4G$@HXL*M8BT82"4<MG#M6/:
MJ,(ELFAW-DD15(F3W>\2%$")_"U;B90PHD$RV/=$0ZJ8'( ?_. !],^G"+N[
M0R(XZB  (AT$0#(@ B'7 "8?Z^$7SM*.!$,B4>XN<C@<"7(9]!P8>$6C#[J0
MXW#JX1S@-</^@&[0 365Z&1, 9*/X#R%/\8\$6L!)%,BA#%/[F50(5+YQ%02
MAD^#F$H8,8?Q'F)%EIF*)2%,!Q[#="8/_#Z]P$#("4V!'/<&<<(LTB8IB) [
M3$. A@O4P ;U$ ZEZCZAPBRL'!)NIVE( D-V"G@IE"@/4RX"(B/:8< (=O3U
MX1<3IJJ  =V  0R'J!B]H?,8 SZFY0@$4.(1=Q$"Y$R@=QC 0I1*0!^;N''<
M7 X+VCCIUY'+6UP"K4]J['*64PR&>T!/@/4/V#GT V>:VZ[%L;;)0!L.J*RS
MB0.@9(IG*!1!%4W;DJ2*9.TH^HC@OX<\KZKV&2ZDYC14C$+T;8=U%K9L8XT!
M("@2@463@+8\>J-4$TEDQ!0X*CDQ05'M$H#@HB =.O.,MNGKIL[2&:<<2%U6
MX[G;26@:'U>1@MH40@J>+:& HY! GJ0!P/9\1P.1P</4<#SW/:P!:QL;AI;0
M]Y7C-U-%\R]]!JKFE4C3N, &*)<Y()Q$PD,)0 PB4PE#Y.OI\.;=@!-%#EE:
M\ #M2HBV4.!P[!["@"8 4P=Y2#@"]>AC=PC_ %<R@ 9*.EALWRF8")&( %
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MB*@=?VASJ)61\QP:!@:>Y;JS;6W#G?$[%),J\2>MT"+_ "I&;*?Q,X[%!ZE
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MO[!Y8_X58_X5K8*@!E,X*0#&#W"]2I@'H.,";N#]G,*PKO20( " "(B CT*
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M [BCU'(E !^'7KS&&/.0/N1-ULBD_6"5?CWN$BBV23%-(Q2$ Q5>P@*$,8F
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MD8P$'!?1L,7-?X/*H)KO:*<);$)B2.X[#O3F=.2G$Y1!83 *IP] 'W#YR'0
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M#\I,8XX!*UA(+=-*TX=Z1ON-_P#_ #[\O.F/_P"WW988QC&*Z]^'[>?UYV(
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MP^@8QD1SR?:2-!H3C1,E#V_X,DQH[<L+VDQ*ZGV&Q*0A>WW#.JG+HI@8"X'
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M$MR72$MR46TM' "*4$,':J169\^F9)U,S:_U;]XI[@%-U*5'  FFB']A-,
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M*-6D/[&FA3:_\<+-N299D).;JLQCQ*RB0E72I=1%:*CBD4, &%!],B[7+@1
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M)\KGD5C;VJ[=;@6]VV.*NMU:]GO6-6YC:, U?R\8LXL!X!JT]J-E5%!_[GJ
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M1%)!!1R!SF,( !0'E\6,S6C-55:]3-M7:AU=KS5M?M=73BJ#4(&JM3$F8_\
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M/3\.6:*"I\SNUV*5I@/A["N0)A\0*/I_9_#\?QY?0>TYJVCS\9K3)<P*4/0
M ?V  <H !EDKJDYYK[RJ(X1'"(X1'"*E_P!Q9XXCO!/RRD6C@S1W'Z*V"^:.
MB&$AFSMG!.7+9<IP$!**2Z139STQS+;#5<MK@*_M55XB7OW7-?QBA(V:I^TU
MI5F@T1E56$UKDC%9[],F+E=HE*/FCH6BBP&$@F$#"40SUYT#GQZCY@L9D>#3
M"@56[1Y$>"6R;#.62R:EWTK.6-PJ\FE(>U5<J"[ETNFLJO\ 1,;^V;HG442
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MRJ4Z38>+5^>**>TFU>32HGQGM #Q8?']_+[IK+C:9F.&#FT_37Z%DD(%\PD
MGO\ %4??[ 9)JJ&!?H7&0 2A\Q1[>X.N ].<$VI 8:<M@H .[/WK:2Z))#J:
M Z@Q&"94SL!H=DX*+OY!$1QW )C9SZ=WH !T]>9FL!RP47EMC)#>*UT>2D11
MMTU"X:NOA'$E3+I$N(2=9MGJT>\49K*I*"=K(-#E<,W**Z!%$U"9$IR@/4.G
M)4$AMSK9_%'%7$U9I6LC7WV:/!FS6B*B7*NX?HG;HB2I2[,<"84A QC"0YXH
M>W %_;R:[=-P>=1=BM9=-9"SF ?O>U339_L:^"$4=0L=)[B*0HF[2NK\W?
M!G&16A"B8/V#R!=;GN('D=0IMKGO=J?0U[EJU^Y-]N'0?C#H!#8^HIN\&LZE
M\@*V9&?E&#R."*E&DLLZ-VMF#5P#HIV)/;-W"4 $<@/3F7:=ROY9^3(ZI[5M
M-Q<&P\U@  7GT4C7Q<BI)/#8 <D!8W9@HCD  H@8!Z?MYUG,[%IM>KRA9T=$
M@I!V:0>*KJ"V2BXUB<ZBH@F\DI KCN(/R]JGT$:XP/X"/*M>PN >*MXJTAT8
MUM.(6TKPGD%->:RK=VA%B1UP0NUDF8Z>!),\DB1FJQCV[4%SA[AF*A6:A5$1
M-[:I%#E,40$>=?'L>W[KL\EG=1:VOI3N(R/L6BN-XOMFW>&^M9-!;GW@YCVK
MTD:AW;2=HZ[:[5/(L(E2LIK$V#&F6*J-8EHY 7+[ZA(3G7(R=MP^I:B8.Y5,
MX%#)NG/EOK#I[^[-[)&YU8L2*"G_ !<ROM+TPO[_ -19K.RZ>MA<]03RQ110
M$U+Y7/:&$$4TAKJ.>2" P.)P6S[QLT2AY=4ISM;>4I,QB]!(6=T3JA!1)&"H
M3:*2-)1UNNL8N19O9;W:4""FM]04R<.R6!!N!%@44YQ'35Q:_B[+RZ!>WF ,
MA=\)J:.+Q]H#"@X+U/UPZEN/3"WO>AO3*Z+KB[+ANF[D_P!MNK@ ,N+.WE90
MV^W12:XN6TETI:7%]" ( TQO.!>>1SZESDJV;SY(Z$?1KI5<AC3C'OE6X-A(
M8_>5\U^GZ#@/>+U#YBB'/=NJ>C?DF1;M;']P^1KM(:0P5&3,?*!Q';BOD_9-
M]DOMLDV6[T\F.(Z!AY:XD,[!7'&I)Q))4Z^5VRT*/Y5R9DUBK-+/6*TC(-53
MBFD\ KUZZ%(/G#*BJ92D_:7I\>>2[WH;N[V.RH#1>D=(6<DFPL:XN<UKG4<X
MUIE@.X<%9705VH-RN=(F(=))M-34=,M'#LR:::QUHMF[$8Q\*7^E0%%=4I0-
MD036$,] Y@M8&F:1T?EJ!]2LWMKG[:]TQU-9*VGLHINU?+5JI;'?NFQEDS.$
MVQ_ICE,*I5FTA[1TRAG E3 1P(?*(!D.:B[D++UAD!#&85[>]:W>&F]VET#:
M-+A@<U#_ -S:M1=QMGCB^6(RD*]8HR\UR=B)-J@ZCI:'=O*A)_0OV[A-0BB!
MEP*8<  Y#U]<^@[[+9[QM]LQP$EH]H;IR((&)K^A><='7^\=+[R[>-GNI;?=
MK%VJ*4$A[37@YI#B,*!KB13"BKQJ)-?Q;VG2M8V*2&RZ-V!+PM=U=8YKW7:V
ML+R\735C]8V:PO(5PXDZ;; (<E<=G<'59N2 Q44$ID!+YTZR=M5^X/)9MKQ1
MA.(). %%]6;Y^'^M/1E]U?806\7J):PMN[^WA $5_$#1VX6\>'*O8G"MY"-7
M[L%XH*K9.I.,$SJD]T %,YT\ 3)<%,(" ''U('H'3TY)-LXY'#@OF0.>)"V0
M%@IY2>)[*<%F,K.Q*<I3.@ H8# @(X$3#^/[!Y,@!CP.5%5S=7^DI\TQ,,Y*
MQ/4FRP*&3AUE#  8P .VA!'^LW/3/3MNG<9&?]23_P YJY/?V:8&G^>/J*LY
M\.>V?87)<5]Y>B.$1PB.$1PB.$1PB.$1PB.$1PB.$2-8(*%L\-(5ZQQ<9-P4
MPV4CY6&FF#24B)5DY**:\?)1K])9F^9N2CVG24(8IPZ"'&/#-%4>EZ%\(MFI
M3\E5?&KQTLD7 3\K5UYXFA]?C&R<O7E?HIDL').ZH1K/,(V2(JR.Z:*+-@>-
MET 4$Z*@!4%PXJS1C51Q(5_[;U>TO9O(66T;XR5W5-)-*HW:RRVA:+$K4]]7
MI\:M88BS1#NFMYJ&FH.Q +1RT7;D634P/:)#%,+4[M30%/JOB;X?^TFN;QI\
M;!!YV(MCGTUK'VWIUB"JDDB<:YAS[I0[B 7(F ,AD.-3^!Q01CCB%6B$;?;(
MGM@)ZS2T9X[L;@.R[!IQ%M.^+T57HQUM:LUIK<9;7L=9YS6S"LO;:2J/4I%%
MFF\%5XT$3M@6 A^VFN?^D<JED?!H!5FS^&7A\80.KXK>-IL= %31NL!QGI@!
M-6.F>-4_](Y6\MF3L0OG^IAX=A@!\4O&KKGM =&:OZB 9'M :O\ A^'*A\XS
M>XIRHONA9\7XC^*=>DXZ>@/&KQ]K\W#OFTE$3</IK7$7*Q4FR6*NQD(V29UQ
M!VP?,W)"G252.11,Y0$H@( /*F21PH\DJYK&L^$45AP,7H(& 0,/RCD/F' C
MT_'H \L I7O5R;EPM#&E5:?MLFUF7T=7(IY,/FE>@Y>RSCAJQ1%=9&)K\"SD
M)J9D#IE$$FS5!5=4V"E*(CRJ)H[+W'1M/TAML'8<DYA*RYGZC6/KV\/,S'LS
M-ZLL74*PV=-XA@]<L47UAFFK<ZZY$V[<RN5CD !'A%*)1$2@)@ #8#N* Y[1
MP B&?CC/"+[D!R&0R X$,^@B " #^ B \(D=[8(2-DX>&D)6/8RMA7=-H".>
M.T&[V;<,62TF_0B6JIRK2"K&-;*+K%2*84T2&.;!0$0(EGA%IE^Y:H0-GZ](
M;N((4!V=-4I@[0-_,3L#%.0V>\.T.F.N1Y?'\2L?\*UO@X2**F" "F0'M#)2
MF >@@!0P!<AUSGX8YF6%<#* !A#!P+^8H'4^;N$,"<,% <=/CP$7:W=%+@AE
M3@F(B&"&$V!QTS\WH(_LSP42E]04%,"8OM@4.XV0*41#J43!ZF-GA6.8'&JY
M@Y*<$P!82"B!Q Y@R7 9Z$ ?CCX_CS&X-)Q.*N H*+&65:^W@#B(*@8H]XY
M@ &>X0#/J(=/V<QG/#)53-DWI2]_<(B!A* =.A>TP"!@'\!QTY FD,>0JI(Q
MHO,#]Z1,'6WX-<Q0$2ZZB#]P#\4WDT0!+\!$/<#DC;OX1\%E>P1O !JO/94B
M I;*^@(&,H>7:)G$?0N'"8'$F!Z_P@'.>2P[6=)PJL@-,5[./L-N"_ZI>P&
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M4??*BX4;$;G$@B)P$O)=W^1G9O3WJ.TW+J7JC;3TPZY;%S3#(Q[1(UQ#Z/\
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M@L2Q4;5^FJ0]N33'M(2X5IXYKEG I1$.TIYJ+6,4, ':8,  <TFW5N-O:Z0
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M<RUCI!Y%SKM^9I),68K(@)3&]LB?%?\ -;Q=V#,-Z=JGR#TGL/84N$NA5Z3
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MIG_P=O<G1KGS)N^DJC/N*E%UU^>,OLC#+_KD3^J$31L#?]0]X6JCQ-J?O4A
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M=9M(MU4@PDJ(7JB@>\^#_D7M%#:-"VO+:W.W\I=_>+^S]B6W2B4_3HW4U/\
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MDH!FZYD91BHD<#)'26%LJFHD8#]2F Q<" ^@]/AS<[Q=&\VATH=S0UU </,
M X2>!KI[/*O.>@QN6U=;2PWD7)O&W3Q)S/(X2?"\4/V6$<MIXANK,DJ6DIAV
M+1LC_%468N"8*4ICF+U7#!A)@,@) 'I\,?CSA)-MN]QAUQPR&HJXM%149>&"
M^W^E.H6V&X.ADGMA;O;0AT@!Q[,:I8\F[*^L-<0G'I2@FK-54!.4ZAF_OIUZ
M>*Z0:G$1*H9 JY!/VB)0$X<V'1\,UK=2OB+@UPT.!'9W'QS&*\9_,9N%I=[9
M8VUO+$98Y9- 8[4 V0#5CC4FG'+@H*KDB!V$6*!A*11H1$HF, ?G*=#M$PX
M.H@'.IWB-GX<Z+$L?B:DFI'>5\]>G.X2[1U79S1.+) QS:]U2./=[4O!,OFD
M<=HX.<JS=]@0[P, =OMB8"]N2F*'N8 0Z=.G//Y=O!AJ' -<%]=;7U-*W<6R
M12.$8SQ6UKP=VD[3NU!8N#*$1_ENR0Z =X9<$(0BP+E3*?N,)3(B3H'PYRUS
M:265RQ@8=#35OB>*F^JNX6V[="W3P\%S)6R_\<"E?=PR[EN4N&S!A8]](LC.
M7#MRFB2';)F>@J]EY)'VV+<OL)'3]Q1]G/4! I1'/3EW4%RVVMS&W"\F:6-/
M\YPH,,LRO _1KH&XZ_ZRMMLD<V#:H'/FOYW&C+2PC:;A]V7<961M<R.(X/?0
M$$E.6HR2-8J\% )+J'_3XUN1PNKE-5P^7+]5(NU"&Z@H[?+J*#_NN:[;+9UI
M81V\@_>@U=XJ[U5ZWF]1NOMQZRA@;#MUY,U]HVN/R,<8M8G.'!](]1!Q\V*7
M36\X#DJHB "']L/Z?AS9 !U0[*B\_J[A5;>OLQ3_ .K>35^0[^X2:5EE<".1
MR%SJ!!''[C<Z?HH W[WG/E$?2%I][)-JVOWQ]17IL^'/4_L+EN*^&(0P@)BE
M$0]!$ $0ZYZ#^\.7HOGMD$P'[2]P>AL=0Z"'^P/"+GCX_'A$8#\.$1CA$<(N
M)2%+^4H!U$>@?$>H_P!8\(ON _ /ZN$7WA%\P'X!_5PB^\(CA$V;G!/+/4['
M6F$P\KSJPP4Q!I6"-]D92"-+QKJ/+-10.4EVII.+,Y!= %2&2%5, , ER'"*
MD,%]O:@U65@#U+8VT:C2T]):JT'L;6,#-0J%3V[1M+,YAC0@MCM>NKV6'D"L
M["_;2QX1[&EFF+LS=T!TP#A$UX/[:-!AI+3LVIM79LO.>/)M:0VE)B5&G.I.
MFZYU&6X%I>NGKLU4 ;1&@6Y*%D7[PHR<B2/8@HL!T#G6(FE _::U37=>7'3C
M#=._RZ>V'6:['W/7[2V5R&:2EYJ--CJ)6MKMYR)IZ%BCK3&PM>B%S,$7)(%U
M*0[-XLR.=,Y5"*0+%]N^*O,RI;-B>0>ZKQ=I2DZ\HMJL\L.OF9[!&ZTW+7MW
MUU=O"Q-(90-7-_-=9;)+H1;=JV6:F7$2 X6.OPB;(_:^I*59OU68;WW?$L;K
MJN\Z<CW$2]I48_I5*NNW)#=0MH)\PI[9V_<Q=NDUT!-('=$D(M=5J[*J0^0(
MFW"_:?H\*:ZE;[\W*#/8KI9W;H]..U&V:O#!O5[Y%QC9BG'ZT8)0T?$;*EGI
MTD6I$B#'N0:C@B27:1.]?[7VIEXRK5X=@;%"LZPL,Q/Z0A#&J2Z>FOYHW)4-
MZ6R+K3UW6'#^9C)BY4ADU0+*J.U8Z"%5@W4*0_>!%<S0^E(?0E,EZ7"3\]9&
MLUL?:>T'TI8QC/U$]AV_L*Q[-M2*98>.BV*,8C9;2Z!HD5+N1;"0AC'$O<)%
M-'"(X1'"(X1'"(X1:\O,&L3]@NU67A8":E2-*PJBLXC(U\]324/*N3E3,HT1
M5(0_:.1*80' YQR;;N#&%QRJH4W\15'/KR]D4^6EVH2& 1$1KDQ^8"].A68X
MY(^89W+%X+""@WWN,8*/;LEZ!FLS0"!N@Y##+CYAJM?$9!4<%U!K^]B!BC2;
MCU$!* 5F9QZ" ]PBS#U'CYABAM@?4U)S7,-?7SL HTFWY$^1 *W+B AV]H>C
M3/\ DX%R KOEW+D;7E^$! :1;\A\I0&MRXE*4?S9 &N!$?A\>5^:':G(<NHV
MN;\8/GI%N-U#'_%N8R !T+@/H\!T_#']/,PN64%:)R'+#6UG?#8*2C6\HE*8
M1S69<Q0((" B4#-1^?/[N5UVN>O%1RRZK31@H[F_'^Y30G%6B6\3CDP"%9FP
M..!'!2@9D*89#\1]<<I6T.;L%*$4K15E:I!A?&2SQRR3Q/7UO47!0#%.:LRX
M=H . $R?T@E[B"&0S@.G* 60-0X*C_G"P@MJ%-,=JR\-$\*4BX"4@ !$QKDP
MH/843 )#"+, -W9]/AZ\NUVI^VL+&7#CI>*,3@#7=V4*7%-M20X4*8JE=E^T
M.T1$F"%8A@#)G[?7U#CG0-Q8ZI68V[BL =7W00'-'M!C )C%5/6Y83 4?0@?
M[S'/YASGU#\! !Y7G0O^-U$$#VFH-')O.]-6QR!2A1;7WAVB!AK$L<OMF^42
M#W,R@3MQD?Q#EO,MVGR$%9HS*QU"XXKH0T;9TEA,% M9$\IJ"!JW)F V"%[B
M@'T0#UP(>H=>8GW$>JH JIV(Q&9"?4=K:[HAVA3K0F(@42F/7)<"&(80$$A*
M=F41.4P=<@ ?Y.4^:&/8<TJ=(;]@<$YT*+<P$0&I6D/F2(3OKDH/:">1$Q1!
ML!2@.1#\,#RP7# *<%&9%(Z5U2=-4IMJ1;! R1ZC94N@C[AX.4-@ ,./:(#;
MM$0*;T]0^'QY=\PQ5((*STJ7:@ZFJUF-V'P4 @Y4@&(8.W!@! ,B8 ^;KRWG
M1]@0?$$IHTJTD[B&JM@.02B/R0TF B8H?(42_3=Q#%Z8$!'TX,D4GD- #Q4A
M+K6H63'8M7K  B7HE^BRB"10#M[B"(ML9QCT$>H<M,4 %0ZO<B9GG'4[?*?:
M[\M*M7:I9YNUR]%F4(.L0L%)R=DF%S2M=$B,7"L6JTB_74*F82D23,80*(XP
M \TNY-U6SVMPP4FT<&W#2[*J\#TAXN^79SF$OBWY'@'3J&D]E=?Q]*X/ISC1
M:3.C'+;4U-5TKI8#(=1#< D-+Q:\P"./JC>*WDH8&HBL4H:0V9A94H@").XE
M9$0*)QZ]!].71P74;\68JQ[[8$4>GI#ZL\[ZXJ=S7O%GR+C%REZ*&\>-A2O<
M4V $,2%070,(YZY)S9@S,SC%5"FCMIGZB^N"DVKUK[AAUU33'CQY!JI"7N[7
MGB_.B0WJ'M@0^NBE  Z#CDEM[<-:!R&N/;1:V;;[;F-?&ZA)QHH=V=XS^8=G
MM)+"Z\6O(91\Z8I.'QXSQ^V Q8KOQ,J0BB$='U-LP9*$;%(4W80!Z9^(\ULK
M)I972<H"IK1;AGRT+0T/H0**IFW?##S'?5Z;<M/$'RADI)RW29I&2T/M%RNB
MV463!4C=%*K'^7'4W3(\6K+E]UHE9RV=RR7$L ;Y9,:*EP>"?GA_])9Y:?\
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-(X1'*&GVJ41'*HO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>vc051_img08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img08.jpg
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M+_6#]H:H7- W$@-5*CM3N+\P_:&@<UWPD%5YTYIW%^8?M#2H[4YTYH)BAXF
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M1SQU9^6](Y:\@/;?M?+6\9!B;5QB/F/#7(2>K=3<Y<Q;(>J:-WK9ZDBW1B+
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M=LRH@W;>7)N'2P"8Y# 9/?74]-=*8[.QW>%S>#QMLXP.W2;VB[CD8 :NCKO
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M>Q2SI=NZ9OG#Z*%RNZ2*<RZSA01*'T[:6WZ[RH;EF7'F_60!,>3=O#V#EX+
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MR1D[A+E:UYFO,[9N&3R5D$).?C(62F,P24Q'1;-[)W&11.Q3BGRJ\858QFB
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MR-;N]:A+97I!$R9TGT)88UM+13Q,Z*BJ1R.6+M,X"4QBB ]!'6SAE$S/4:"
M>U2*K-2HFB)HB:(FB+K.%R()G56.1)!(AU%E3CVD223+WF4.8=BE(0I1$1'H
M !JU^\C^G\2H'-#7.>: * >=L^<;;8VA&Z6=,0NE8YZ[\Q,N0*X91!0"^2JF
MJF1^)B"10FP@.VP@.O*?JMTEE^H<=$RT961FHH.?X+T'Z9=56&"OY9I)VL;(
M*&IY=W!1W)D+CX?8"9CQ<?</Z%T@S!^K9Z(:\5;]*.JJ F+6@_E7L!^JF$:?
M^I&A_,NT%NP>Y()&>5\=@H8H^4JVM\+YJ*@]"+)F*\W Y!V$/AJ:W^EO5EM<
MB[;$=[7 _":::\%CW7U8Z?FB<TW#:EIYJ@ZA1,%PB;U-;)5*LKI^Z>NDW#V;
MKPIL?7KF<.$V;=H!&[8ZS@XG.H!>\YMA,(CX;JYZ!ZZR,C)Y&2 1\-H(_%:1
MGU*Z58'NGNF/>X4&YP(;_A[%T7&,\,UJLW.1L6:()G NG*\\^GWMH@X1O6Q%
M(J!I!671%J4.Q+8@K+F.82 !1';IK+GZ$Z\:&7<T;O3CH*[3P[]5!%U]TC/+
ML%SO>[AYQH>1'80K1XPIG$^HR86F(Y/8SG&SX1<$!G<J&P9OP$X&*I(+0@-%
M)44S]0,L8X".X^.L7)XKJ6_C^3:UK&@:G:0>SC5=*[J<G8^XNI98@/*'/J/'
M]ROK9K9QRL4/)0Y,]8LBRR359FNX9WFL'$6ZVY#I]B[A5!9-0G[Q#E$H_+7/
MX_H;-XZ8SL+O5)%#S"R7]7V]S"8'2AK>T&A]A5F:=0>,5*G23*/)G'KPY$E4
M/(/;J$W(9NN7M50!5@DV<D15+T,0IR@8/'717V+ZJOX!;OV-8.8:02>TFNJB
M'4=M)$(I[J62$<&N?4#V+HR6-.*LA;3VK_.5Q\W,;M*5NC<:4$DDV+T] WL@
M]T^V9=@B3L(X#8@[ (!JV/&=3VED;=E'/-14@G0^U0_ZDM87N8ZZF= X 4+_
M "CP')>AD*A\4+R,61/D)BV!:1Q$0*P_.%)F8\RB!0(5TFQFA?MF[[L+L*Z8
M%5-XB81U#A,/U/:AX< 6:\03QU[5?_J2V _Y2=T<5* -=3Q/C7FO8DJQQ-=4
MU.J)<B,>-5A+LXL"F1*PZDI$IP[3(/R.7*[)Y']I"E],HD*.P  %#;47Z-U0
M+QUT_5FXD @TIRTJHF=2V$-O\O%/(;@&IDW_ -2O/S=GL6_&<)Q0QBD!D>0N
M*95=%-1-EYUVID7'QI%1*+C[=$Q2K.-:K.C%W45*F!S^ CJS*=,]2Y9FRZ(V
M<@!3]Y63!U2R"X^:,^^2E/.=P\:=JO*;*_&0FW=GC#H#N [#D.MA]([=>KX-
M<O)]/L^UA=M&@KP6PAZ]M913U3N\5+W"G)7C&QKT-6&7('#KF6>R)V;&+;Y#
MK"KYV]=KB#=LV;%D?.66<&. $(4!$PCL'77TI]/[1V(Z=BL3H\:FO;S7S[UM
M?'*YU]\34TIIPHIJI#^]^.PA^(;!U#7H#'%S03Q7(KFU>B:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB^<?*;H&^4\F=JR!P-?[9YC910ADSE";>]Y#$$VQ3CVC
ML/00'7S1F9FMSETQG-WCS7J]FTOQL%..W3W*VA[#Z"2330/N@[0!5$>_<-RF
M[1)UZ%,7Y:UWJ.6Q;;-$>YXJKA0-D%P4"F.7??8VXAN4-M^G3KJ:&<L<23R6
M+=6S'M  Y]ZJH)!-$WJ#D(4#)[G.(!W'*&_4P '<8 #]FLMET#6O[EKGV@&G
MXKM'7;3<:]015 HF[T#]H@()N$^Q5(#CX!WAL8H]-RFU)+MN;1T;0-P/[E:(
M_1>TC1U59R4GH6<=3="E$U",6!(F)</$C*HG3G7I4S()-E4CI+=R(B0RI2&#
MN3#81#??6JL+QUA?,E82(J@$<14<>*W&7PS,C9!YIN+5\TGN#<H?<KX8WF3B
M)K&6%(S&#QTH-&S76,=S5RJU@CW"XHQZ3^8M4M((5RU$,()K1SPB:HJAND*J
M?U:]MQMQC,FUL@D:9G#5O9[EY+?=.R6#G$< >*Q&V?W0><-H!4DER1GZRB<!
M!5K3&-9I"!"COT24A(MJY*  /0>_</GK??(VHTV_>M5Z8&AXJ,=JY*9&N@JJ
MWK/61K6=0QCJEF<@V:53/N.YP].62.@)3"/4.W;5/T^/B&IL;V*SC^XPJR+U
M1).3DUS(+ 51..>.E50$A]S&6<!N.^^VXF'58XG->' "H(/ *1O$+]G[V^E/
M.X'\+E>PZ8*<5./R@)J%[%" ?%55,!3D_HG* ]0^ ZW49+F GBLA2^U>B:(F
MB)HB:(J9N0 -2M6_QKDYO\?_ *,=?#XZNBTN&@<"1]Z@N # ^O8?N7YH"T$U
M"R6,09M]SV6?,(BW)]6\N]W$0 OB(Z[^VBC<T!S011>&Y*817,FQS@=Y_F/;
MXJZM9KK184B&9-O$0 1;@(!X;[%*7KOK;"./\K?<%@_.R$?&[_Q%27IM/;"9
MN)6:0B8 ,44VY"_2 ^/4O> #\-9MM96[R-Q8?8%IKJYNFL(:]_#M*F50::@'
ME"9FE]6P=42!ML(@&XB !\-=+!:0B$L:64/_  M_!<A?7%Z 7 R5'_$[\5Z?
M,FE-G?![DZS4:(&*KB2QJ@!B)&V].@5??MW$#?V>F:%NW!2Q ,+Z5^$<O8IN
MD+V^DZD@CD=)Z>O,]R^:SCI#,3X9I ^F0[@CCE, -D]@ %C]NVY.FVX[A\]?
M)L\KWW4C74H''D!]P7W+'-+Z,;=QIZ85\_L<?\6Z0A\O)3V_'H)1VW_#5H<1
MR'N5'ES_ (B=.\K@/!QIS=&J !T -T4__4 -6N >:N ]W\%05' N]Y_%<(UQ
MH(&*#9J(#X!Y)!']7T[:H&M' *XN<6["3M\2NBM76@!L#5N(@'TAY"8>'B&_
M;J02. +0  >.@5HJT;033Q*\]S$,P  *S:E  #<3($';;;J7M+U#IJCGES!&
MX#:-. 5658[<TFOB5XKN"8F*?_)$/+$?J*""0B?Y;;%Z;" ^/SU&&M[%4N<>
M)/O*I&0B&A@[/1-S#OL4?(3 =@W >G:'4H_#QU5QJ#H#IPHK65A\\9(([RJL
MP)'@CR$X^-&$<F+UQG'&YU7*;4@J-F2-G8**G _9N!C &P_';2%TL;@ TM:2
ML6<E[7/<?.?Q7ZG+;]PFX[B":?7]*91_9UUU#"1M X$+ 7:U,J)HB:(FB*B[
MQD6CXTB L%^L\34H,SM!@$M-N2LV O7)5#-VOJ#AV LL5$W:7X]HZM>]L;=S
MS1J*U <N>,ABG,&<<= "8E!3NL+0HE$X;E 2F$#?5^C4(N8"*[PBVCR\XQE#
MN-G''@!V@?<9]N'TCX&Z_ =5^8@_.$7(/+;C07LWS;CW^(0JA/\ ?YL/>0X"
M8IB@'4VY2B/3Y:?,0?G"+C)R[XQG'8F<,>&'N$NP3[;<# .P@/RV$-/F(/SA
M$#EYQB,4Q@SCCL0( &/_ -L#7Z2B.P&,'B!1$-M_#?3YB#\X1/\ .\XQ[@'\
M\<=[CML 6!L(_4 &#H'7P'3YB#\X1/\ .\XQ[=W\\<=B7;?N"?;"7;Y]P=-N
MGCJUUW;-^)X5S6N=\(0O+SC&<"B3.&/# 8!,42SS<0, " "(" ;#L(AJWYVT
M_P#V#]O8KO2D[%O#EQQF$W:&;L>]VY2B SS<.TQAV*4PCL!!$?GMJ\75NX5#
MQ1/2D[%<&B9?QGE TH3'=VK]R-"^F"5&!?)OBQXNP4,U!R=,.TGJ2HG[/'N[
M!^6KF3QN=0$$*P@M-#Q5MH_-=@LLSR$JU1J1)6VX3GXVO1<5(3K2'C;B^F:1
M 7*-+]Y.P=?8"'"<%NH=1%<$Q2[]C ;M"[)&WPIQSLS,Z*TOV3O$C6AVP-EV
M-J*4T:.?'FL&"]^:==0PL_J0"@UYT.J]+&5YSA/LK&KE+$<#CEXQ10/66L1D
MIC>RV%8R#HZZ;IRUK<&6%*DNFD0!,5;N!03=.W;6/F<STI9W38<+D+B[9_,3
M:/%.TBA%>:KCVYB5FZZAC'EJ/-QTTX'FO/QGD'/]DEWK;*.$Z]B^#0C/4LIB
M'RM&Y =/I0'C=((M2*;5B#4:(F9**J^H%0P=R8$[=S;A7/9?I;'6K+W"Y">\
M8[XFFTD#F#F: UT5N/?F)G.%W;,;0:>?G[UUJK?^14M>3Q%NP96:I02KS!$[
MRQR\PL<BJW:@O]E6&HHU2/72-+&*GYA1="+8#COW]O62_P QTG!A8\C8W\TU
M\X F(V[F4U%:N)\M._P2%V8==>G+;QB&O'=W>-5R+9"Y"HY&+7TL&UE3&7WU
M)F;(YLOQI)4( Y"&6F@HWY5.Z,Z25,)"L_6]QM@'OZ[:B=G>BFV'S4F1F;D-
MM1"(P0?^]QT0_K3KH1-MV-M_S;J_97FK8Y8Y2W['>5VV/(C'-,G(-9G7WKNX
MS^54J>E")3;A1OY5@;+TV3AX)TJ9NM]M1?23525\D_DEZ:OQF:Z/N\/+?W5_
M+#=,!VQF,5=V4X4]RMG?F([EL,=NQT;N>Y73R3D7/$')QJ.)\,5W*<,YC3.'
M\M+Y5CL?*,9 '!R(LD&+JLSQI!!=H!5?/*<A2]W;L.V^L+&=2=&WEL^6_O[B
MUG:?(TQ [_$FE*=W:I+IN;AD;Z-O&]CN/FIM^WG^Y>AD:ZYS@HFKN<:XD@,A
MS$@B<ULB93);&DMJRH#1LJ1-C*N:W+DGP,[451$2IM]BI ?^D!0R\1F^EKZ^
M-O?WDMM:AIVO$+I-WB00&GN]JNNSE8XFN@@C+B-?/P]Y6R;NV;V&/("?K^(H
M*?R2[,P"QX\<Y-8P\3!%73<#(&9W=6N.FTT+%0B92 5FCYP*"(=O;MJVQS/3
M-WEY;*XOIH<7'6D_RK_-W $T]RMG.799B5EO'\P3PW?QHM[:\YO6Q:\LSG$4
M RRHDNH1EC ,F,'$.\;DDD6Y%CW\*VFV:J*QPG<B46)NTQ03WW'N"*YZBZ-9
MDOEA?S-Q-0!/Z6USM!4^FZM*.J!7B!7FKXOU1UCZKH&"\H:MW<-=-:TX:KCJ
M%]SA*4RSRMSQ' 5&[,?6!4:>PR4QM$?9S(QY5V8/;0A7(Q"O^LD1%N/>V7\L
MH>9U#Z=17O4?2%ODXK2TOYYK)]*R^F!0'M &BCM!F9L?+<30,;=-KM9N^*GM
MYJVM Y065U;9^CYLI-4P_8(YI$?9@:Y*)=HF3FY9)PX1K,K8T:C UNMV%5H5
M%PW8+NS/G3=P51-'L$HFGRF<Z2M*?I&0EO'<PZ,,IV@4XTUYZT5,<[,7 )O+
M9L=!^8ZE5SC6_P#(*R6!TTR9A"O8WK"+!PNTL,5EIC>GCM\FX1(V9*03:K0B
MS9-TT,=45A6$""4"]H[[ZGSF9Z1M<5'?8+(3W,SB-['6D@<T<R!76BMLW9F>
MX/KV[&6Y&GFY\N:VUW(/(AYD$T#8\&5N QQ]TET"9":9=CIF4/%-".AAI U+
M)56SA):8,DD!T!>"+4%1$3G[-C37&7Z1APT5[;7\LV1>!6(V[V4/,%Q-&^U5
MB?F!>>C);,,%?BW</M6Z6R'R':9%)7XG!M:E<<#,1S4^15\O1D?*!"N"MS24
ML%(-55G!G,<910I&WK0%?RP$#E[NF(,_T5\DZXER4S,@!I"(P0?^]QT5)'YP
M70CCM6&W)U=OX#MI5;,@Y$Y$0=H0CL<X.K.0*FJW8*+6B5R[&TE\W=K+*)R+
M0M><U6856)'(%*<BGGE!<3"78NVXQXO/=%WN,EO<CDY[6=A.QGI-)D/)NHTK
MVJ2Y_5H+ML4,$<MNX:NW4H>SBO5RE?,ZUEU#)8JPU7\HM'C)RK,.YC*3#'JD
M.^242*W9I(.JS.C)).DSF,*H"D"8EV$HB.X2X3-])Y .;D[Z>UK_ &R(#(7$
M5KN IM'"A/'V)=_J\<C/EH(WM/Q>:E/>=5MO%SSC#UNK2./\20=YM,BF@:V5
MJ2R6PJ3&KJGCTEW";&P+UV42L -Y(QFX"5!#S"E\SH ]NJXK,]-W65EL<G>3
M6]HSX)/E9*/';\5!X!7WHRS8&_+01^L>/FX>\KGD+MG)OC",L4;B*!D\I+K-
M22V-%\F1\?$1R*CI9)VJWOIJVLU?^E:$(J  Q)YHG$@=HEW&&+/=,2922TEO
M9&8YITE,1:?'8[B.P\#[%:\Y46H>VW8;CLW?OK1<,5>\Y.<:2]AE\10$5D]N
MJ\+"XW1R6PDHF4206;$9J.;VG7&[6.%Z@HJ<2BQ4\D4@ 1-W!M'<9_I6'*,M
M8,A/+AG. ]=MJYQ H-Q.T[?*ZHX<!KJK;89J2U]::",3Z^7=PH=->_BN2AW?
M.,W7;2^O^)("B61@DJ-3K\9DN/N#2QJECU5TBOIM"NQ:< 521*1N(G07[2G%
M3P+VC+F<_P!%X[(QVN/R4UU9OI_4,093_$VE6^!5UJ<I)$730,#^S=^!5+5/
M-.4&ASKY^QQ4L(0CJ2KU=KDPVRJPO@6*W6253B(RN%;M:O!F8NGSQ=)-L<14
M\]50" 4/'6PGFP62D9:](7US>W;'R22CY1P A@8'S &M- ?B'(5"CMYLEZI?
M?01Q6X--7UK[BI3;C^/[F_A\?]?2H6>M^JHFB+Y ,YW64B<X9F8@=)PB&4KZ
M5$WF]BZ0#9I+LZB!B_PM^@#T'PU\N9>)S>H+EVM XKVW%>B[%P>5N[;^Y6R2
MNZ\,]CT920(8[G==N7O#N(41^KZ>XY2]P^/XZQUFR,W,VMX55^ZS=$%G"?EK
MD,4_;])/$=@#<#!TT6(^W=17_C9I!VWV%4/J( ;B/@4VQ0W'<=BB/35"2&DA
M8SX'%S1JK>P]C=UNUSL6JL91@9 $A25/N!%6JI%HQT4-AW$S)51$_P P2 1\
M-8\.0=;OV%QU4\EDTLW$"JK:UUEG=$2.H]XK$V%LU,YB9)OY8BZ.F!C>G.FL
M((#)I$[B(+*;@F(_5N'A#>RLE\L0H>.G;VJ>TF>&B&<5C',_<HT62\XTO=/L
M^%N1E1CIF@OXXS2UT+)#,SAK+BJIY::BB:I$E'4HU7,!F[IJ;S"*CYB!PV#5
M^'R-UAY_F6$ND/>LN?!P9"%^QK7,Y&B^7_W&O9[@\!Q:O(3BK RUXX^&:>IN
M==DWOYFN.*GYW2A#O2D*@+Z6Q\8AB@#E3O<,!#M7'LV.'LW3W6MGEQZ%X[TL
MD-&L_-WT[UY3U#TQ)8-^:M]6CB.55AE9QL<DF46S-DD78#%,BV0*!@-UZ"!/
MPUW/J24XE<;5>FIVE0<E "__  =40[    >PWRVV\-0-D>7@5-%<WXAXK]DG
M@1__  ;X<?\ ]6\!_P"/%E6WUNH?[860>*EGJ5431$T1-$31%3MMV_*UEWZA
M]@F=P^8?;G.JQ?\ 4L\1]Z@G_L/\#]R_.%]*FI8[ !@$/^V2=V'8/ 9=[T_1
MKTN%K1$T@"NT+P'+#_FY?_Z.^]7IJL. "D8IP#O'N >O0!\-^FLWTI".)6C!
M(*L;G.(LT+<:XYI]TMT.VF:\H]EH]&;638I3#2:DH]T9HD!1\A%=%NF8" (@
M [ZP86SBY<T..T<JK85MW'SM;Q6VJ*Y;7$J2E\L?D#L(&-.2!U [Q$0$1$Q0
MV'Y? ==!;LNG-H'NKXK"G;8E]-'=ROI=*C<9; 68D9*T6*32)C6V+*(.9N16
M07(C#NE3IJ(F6\I4AA*/00VVUL+^QE_1YI23OV'7GP6OQK[>'.0NC:UOG T\
M5COXXH';8=I@*)G(D=DH""AB"5-8 4^L2&']X2&Z"&^X;Z^5=X=+*W_\@D-2
MOL2%KC#%(3Y3&%?@B1#]W0 [1VW  V$?CM^C5CR12A4RW>E3#P+N/X%#_#?5
M6$D:E*KD%F<OU]G:4  1'8.X-_P /QU:\D.T.BI5>:JS.8PAV[@;?8PA\!^'
MAON'AJFYU:U1>2[8!W"&P '@&X?X==4W'M**/F=;1;,?55.:J3*.>O\ U8I'
M2E"JBT,B"!U# 4R0@)5!, ;"/350232NBH5C]FL[YXM, \?_ '&OTU)*319F
M6BX_UC]0%.\3)IF5$Y4P'MVW#KUUNK:&V/FW5=R6.]Y:TFNE%</AMES,$;RL
MXVP#RV'GB2N><9^<K)1;7STFKJUQZ:B!%@[5"%\L!VZ>.M@(V.-' $+ ,^\;
M:\5^Q0@42ID$1 =TT^H?@0H"/RZCK)H/<K%SZJB:(FB)HBQQ^Z";MXU$V*01
M_F/4 V4[>PW>WFBE VX&$0Z> !W;^&L#($^E3DI8FAS]5\]#9N?SMUP)W&+Y
M9"FW3*X,8O;Y1E"E!0#!^\8X@("!=MMQUSP:TCDLHVU34#1=9?U$?Y!$T2N%
MCO4TG#983H)+MOJW*W6!$3 K](B4I^P#;^(:KL;7@D\;&C0 %>M9T7J5C44C
M*PXC(Z32]4T0\R*1C&S8R1!5(U5D#.I(P$'\1.)M]AV'4YCCH30*#:WL7E.4
MG1)N0CEDTP0;,VBK44CLGG:+D>PR %;F(0#G.3N[P+T VW7IJ#8WL5"T'DJA
MC"%/%6A-1FV574AEUV1A6.13S&KAMY"I5SF%DV,1<# 8RI1(">X;"(Z;6]@3
M:U4U3$Y6?9RJ:Z\<E]O8OW)3-S%?'.9#MW(D[CFA 3.!Q#81[MPWVWZ%U7:W
ML0M:N!JH9S&-GPD1(JY01,J1!43I$[CG.*29Q23 P )>TW3;<>NK#%&[X@"I
MH@!6B]DC5)0" W*9<B2(G I!2 #*!L"@@H"/FB8P&+OL82]WZ]1/AB!T: LI
MG UU0J2I/+[ 4 Y"F,FIW=2K =0Q5#D'</, @[B8=]_GUU)&Q@;2@5]![5F4
M]I=,Q$\VG/W"*GY&,0W<!BB44[&(AN'],JAAW^'RUM+#^<<AP6NN@ XD<5D1
MQW+8UE,D9ZCZ5#GC[?!W*N,LLR*K19N6;M"]'@'L$[274<K$?$;5!PS0[TR)
M%**?8)1,43#KNL8^H)(+,23,%@V,B,.Y-<2XC_O'4]ZUN+N+22:XBA8ULX>6
MO(%"X]_:KV"4!  $-]@VUY\]\I?5SG%XYU*W6QM "."T["[[]H;_ #U;O>7^
MIN=O/.I_%5H*[OYEKVE#?8 Z^/XZL VUI7S<=3KXI0<5Y$_#IST-)PJCQ_'I
M2C%U'JO8IVHPDVR3Q!1LJO'/T?XS%\D103)+$^M)0 ,'4-2>JYM"=0."$ C:
M>"Q^'P]F'C<6=5QKZ/,6.K$Z!Q:*;9VRLK89!,L<C'.%5P<>LE)!V,<Q10+Z
M$[IH5)+8L+OW''8>JRX ?*[^HW@>=53GWKJXUR_7'MZQY3,,.+%1Y>=FGI;U
MAZYIG>46 KT*@#JSO*2^55%2-LR:RQ$645$."I@8RBKZ+:I(J'+647+O/<U<
MW^6H_;N5145(Y\5DC\L!+L8O=\1\1#?X?L#6N<Q\@+2'%E>&M/L5*-X%/**.
MWT!T\.GAJABD> '!Y X?%HA#32O)/++ON)0W_$/V:2!SB/5J7#M_BFQNXNIY
MCQ5+W:JH7:IS]1<OI2*9V.*?0[R2@I%:'FV360;G;KKQ4DW(=5D]*0_T* '3
M\=7B:1K"P$ACN([50L:7!Q'F;P[E MUC;,_'".F8RN0T9GK#4[(/Y"QTZ5CS
MO["89'M5DG;M%5O.3#M==4I0,8I9IF"1 (FP8HE*))_7&T T-%>XE_Q:KU,,
MY6@9_(M)I6%YRRQ4.[9S,YD#&&0MWT148*( S+R\:32[Y=^ZE5+ Y03%C'O9
M"(9,2JG709*>2FI<^V)>;@EQFI6M373VJA[^"R$@F4-Q FV_CL'CK":Q^XR@
M.W'B==52C1IVH*93=1( COOX?$/ ?TZD FX@'W?P5P<0* Z+3RR=/H#IN/@'
M01\?UCJDCY'R"24UE;P)XA1LBC8W8P ,K7VK42E$1$0 1$  1V\0#P#]6AFE
M<7.+CN?Q[Z<*JYK0TDMT)3M+X;=-]_UZC<2]GIO)+!RJ?Q50 #4<4[2[[[!O
MX;Z<]W\P%.W3LU5-HK7FM 3(7<2E !'QZ>.KF.=$7&,EN[C0D55::D\R@$(7
M?8H!W;]W3QW\=_TZM;Y&EC0 UW$=JM$;!4@<>*L3GK&T7E& ID))V1*K)5_*
MN,,A-7BR394DC(4.YQED:00%<NV9"*3B\>5L!RF,H3OW(0QM@UW/0>=OL'U
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MFZ[ZUEZ]KV!P !JLN"V)8:U.JN/"Y2:/(Z*%D]!RJK.NR-%2*EW426<)M!3
M#;"8HN4U0*/RU!/\ /.BLN+7RK=>;7BN^TM[%Y#9(R[BNV4(>"EDCE0GXTQC
MQ!O,CY(@>H*1L65\HY!$Q3)AMMOU#-QEQZD3H)P/3 T//MXK5 7EA6XM2XD\
MJFGNX*LX:IU:CJ-J[ 69P6,^WN(^-AY]!K,-9)O*( JX2>&4!$7J8$44()%4
MS$4WV/N CK-MK6T$GJM)$@X'G[^(43LS<7?].]LZMKQTU[_:OFCYK^R[E ;K
MDO,7$I6JW#'DG+SMF)A9)P,#>ZLH'F2$U"U!FY 8JSQC=<RIV+=)5)R5,02
MAA N_K&+ZKM'6C;&\)$E0 >?8-5YKE>G7!SKVRKM-=.SV+Y^'9%FY'[=9)5L
MX;D=H.$5R&27;N$/,26;KI' ITED%2"4Y1V$I@$!ZAKMF?&/%<LT'<*]J_9.
MX#;CP9X;;^/^:U@+_P EE6UO(O@'@IU+74J)HB:(FB)HBIBX"(5FQ]1_[GIS
M_@USJL7_ %+/$?>HY_\ HY3_ ,)^Y?G7(HD_,$\40 ?,L,Z CL'3NE'@[AT\
M0UZG;@>@S_"%\Z7Q)O):D_W'?>KSP:C"-:.'DBX2:,&391T]=N#%2;M&;<AE
M7#E=01[4TD42"8PCL  &L[YEH;K2@"UK07NVMU<30*%>4.7'%25F(H6^<Z Y
M2C?O+999&3.OV$6E5'"9@,1(>XIO-,(;;^&M+)D[%LH?7RUUIV+>MZ:S>X5;
MI7L7H5+F7Q!9'3,^SQ1TB)]O</F.CCL7_P"2[ZW5GGL-$=Y)H/P6/<=,9HNT
M9KX*YB'N0\4+96,CXKJ=A6L\_.TJVPK-2-[/2.Q<0KM KIJ=5),QVW<H!OGL
M ZRYNHL?>XN>WMR?5VD@'L"PY.CLY;9&VO0-&RMK[]5>_P!OKBO5<Z<7(!:=
MGY6%=5V2=&8?;46Q_-:.&[4ZJ2BBP"8P&,8#?\MMKY2N[FE[+04\Y7V)90.N
MK*$OTD$8K3@I&..#^/F2JJ'YJMIA3.<FX@R /H,)0'8$=]A^.H!<E7RXTAN[
ML7D.N'%3:-7BQ+3.J@V:KK)E!!H7N,FD=0A3" "8>I0W^(ZN9=>>BP&<P1P*
MAD[JKYL0Q1;JB4H"'<8O;N &$ ,;H'4=M_#6>7[_ #*UX\W!4>ZC%2@8PD,3
MLW#<2F[=_D ^&^BLU5+ND V_=,<Q0W$ WWWWVZ_+J.BSV ;!4#@%9S,54<3M
M+E")H'.5D079OI[_ "BBF9,3" CX"80#6/?DMIM/8KMHIH L84=3IN=K$U#P
M8BC*(S\4L1;RQ5,"0R!$U@,0-_[0FY0'\=;6UNVL(>0--5K2W3AR5U./-*DZ
MUSCXZ14NAV/V><\4J'W*)1V7M4:JD!@$"@  EL(=/CKHX)1<,]1M*+53- ?H
M*+]@]$P^6D40Z^4GN/X]@#X:F42Y]$31$T1-$6.KW.13#C>D90=@3R13S!L8
M"B8WD3!B !A =AW#]/RUKLA_:4T/Q57S] 1%$"&.!1*<CE4VZ29^U8QS=G<!
MOK P@/CX!N'RUH@#0:+:#@O'F5041*UV*1-SL5-0ZASE*H4P*%44'HI])C@7
M8 'X^.JZU6/<Z\%W[%$R,,[J\T]:1K)C)LR(LDUP;#,N$4&Z!//<R1$5%@;K
M"MNF %W$![1\!'60?A-5C*HIM@])(DGAB'C.*L2(!!3,FQ11+(-8XIFSQ%JD
M8ITCMFSDI]S (F 1#N^&L=%XT8\1,]6;D29H+.$WS!N=9PV;,@<N3;-GS@[H
M2-/2M [SF[P$H$V+VF^#@E5XM50FT[?:*+%/&=CDU9)Q6F3U@=FVK[U=VLV
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M!L#Y?QA&333$MUY'8WKE8F).*=LQ5<5R3B$7;D6P-S))M7#M$WD['$QB;&V
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MB @ ;_LUK"#7N437-#0*KVH63*Z<'[/J1;LUU.XW]HH8AT2G,*AMP,GWG
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M(_C_ +,W_/:?)?\ !%_YDT['_P#B_BMIDE.TP%$P")1 -CCXC\>IMA\ U+'
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M&9#M('('5?H3].8#BNE+>PGKO9$!P[!1?5I_=K8NSV##W)5E+)+KR#7)58<
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MMQG&6UY UUW),\M-L;>28S/AF:[U(P2'$$!>=V'2.$CR<]Y'CA!G9V!S[AG
MNK\)(TTTKIXT"SB8?JYZ1BS']2<"47T#5(5C*G*'16:*R2/-K] #<SB646.(
M_$3;Z^7IY;4R;;5K6VS0 T#A0"G$5!/,D:$UIHO0V![6-;(09  "? 45R-6
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M"EU3N;>$Z77ZLUCZ5+L)N$C8MB_G(:-C6,C()H,RI2"2SQ!V@H\1.X#S$P5
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MPT7[;Z(;$2VW$/+)L/S_ (8?+IK*5B[&B)HB:(FB*&W.8J9L*)^;OV#=*YN
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M-V%3(7>NP5G;,CAB!(:36I!.O <!W#V%4]1W<K3X<]XCEC5\@6^ZYJFGEOQ
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M6]O<N/966F).Z0^6L?VZ,54CGBK52(2D9>#=+NY0H>D:.2D?G*!-P$Y@V^(
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M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%H( /00 0^0]=$01 H"(B
M>(] #1%L3625[O*4(IV&,0_88#=IRB)3%-L([&*8! 0^ AHBVBNB4Y$S*ID4
M4,<B:9CE*=0R9?,.5,@B!E!*F'<.V^P==$7 ,E'@Y!D+YGZT0[@9^I1]4)=N
M[N!OW^<)>T-]^WPZZ(NYT'Y=?A_R-$7$*S<IRI&51 YNI$Q.0#FV#<1*01W'
M8.H[> :4KQ1;S'(7L QBE$YNT@"(!W&V$W:4/B/:41Z? -4H#Q 1;N@_(=*
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MTO?!GZ78-L9V_P!U\5Q-*Z84  <PAS8]NI!:!6M#6@4MG%D((W.FE$I?H#0
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M*8;D+J3&,Z7M,8^UEQK7Y&5FMQ)<2@NKP\AI3:*#@*TKS5]S:Y"6Y$UO.(H
M0=A /C4]YU6[+W&NQY(F)AW3K_3\=Q%LAV,;D"#?8 QCD<,@N(MPY-&OK=*6
MYHH[F21S18B+=LY\Y%$""8@ )AU3!6G3^,LWQ9/&P7FIV[;B1K@/\0-52]M\
ME=3-FAN6-:WB !0^*];)/&E>]1.'JM6[X&-:5BZZ4JZ2=1J%(KC2-M[NAS<5
M8(6,0]/Z(E0BC24<H*R+!,$U".#%$NQ2Z8-V,PUY>7EM:/K>,+6ASR[T@10A
MI-=*:'ANXE0Y"SNL@P,;<AM*5H*5(4K-UOZG]#?]\?'^IJ5;:GW+LZ*J:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBQ[>ZWG/(_&OV[>6>;<1IK#
MD:C8HDEZL^;I NO7WLY)1=87MR*8_2*E-83:TJ41 2E%F!A 2@(:(O13R+G+
M!JD'0<?</KAEW$$'!UBLP&0J?F3'!KO*R18AD"]CM=*OTA57"=>?2+DQW,N2
M8D9)94%W"C$ ,7O(L='NPNN#DOF7BA5<Q\A\;<>>7BN7<-9(Q[D*>R](UJ^8
MSQECS($1-7F'QQ#LY1/[A*9E624J+:/38_[^*2*JZY5$6(@0B\O"N$)"L^[N
M\Y9,Y?C9RW@N0%FSMAN6RQC^ FZYG?AM8L;U)=XTQ7=G+#(%GI%MIS>OU9*L
M.EG,;$3C62.V-L8CHY3$5M>6'N8\M,-\Y>06(J5?L._RIQ3RA]K?"T75[7CQ
MJ^L#N#YUHVBOWYW(6UC:89V@:AR;!O)L?\E.H;M].J<B1A,)%:>B^X/FO+F2
M^ 4Y=Y#$+B^?S)]ZW$$W>X^EM&"J,GPZJEIC,?Y"I\6M9'K.JN+LP@6(3;!8
M\@S=)!VHBEW]XD76XW>Y!R?Y4\?<YP&<+YCY:R./9DQK[C] O6,*L;'5DQ7F
M20<Y@8*,6R[:RS1)1.(G<=QDH14R;4R*JRS8R1VZFPD7TD<2<DV;,O%KCEE^
M[0HURZ95P9B?(]O@11*V&(L]VH<#8YUB#8@B5L5"3D5 *G_0+L7X:(OGFH2'
M?[I'N]J"4AO_  J<9"%$P%[D]N/,*)^PPAN4! P;_/7+]0G0#P6XQ7Q'P4W%
M%FD>Q<R4DL1K&Q[95R\<GW\INW;$%19=00 P@1,@"(B #KF' BI/!;-GPKDK
M5@J5L0<N*O.L9I%F9('JC(YS@U,N!S) H"B9=N\$QVV^6LR-]H8@2*Z"IY*Y
M6#YOT4E^X7\K:6BCZH]@X^Y6:H)'*;8[I"H2D@R$=PZBF\9)F+\0$-9]K;M#
M@[@*A4</*6_S4*NE_=F3;^R]Q'W_ 'N_,>^_CO\ SMR$(]/GN.NTJ#J%RE"-
M#Q6>G1431$T1-$4$^>_,2R\-J5A.<IN&ULZ7#.O)3%G&BHTA*[QN/2C:,L%L
M"$'*N[-+Q<O'M(Y@_AR>I[T@$K<YSE$QR%3.10RP+[N]CR/D+"V#LD<=4,?Y
MLL_.+/O!7-4% Y++<JGC:^8/P<^SNG<*E9ORG#JWNJ7"K"Q(@55M&.6JCD_F
MEW2[3$5#XZ]X_*>>9'A]3\(\/V-KO/+&W<QHH(^R9P852O8SJG#+-T9BV[7"
M=F%*0]<SOY@A'2CYFP:MBK@^,BU,)DS*.$R* #/E5RLSUFSV\L<8]MF;285O
MW,#W,C9.DICD^WI^3[F;B1D6SQ;.J/)RG8HC_.Q/0X9D$I$5PX&+,)')%OUQ
M*B+I0BN/C?WT)7&O'?CPQJF*[OGZ^O.(BG+G)!LS93D'F6[+2I/+M]HT#CJA
M2&.<+2\;D?-4XI4GZC%%W'UV'2:MVR!G)EE0'1%Q^XS[I?)#(M1R-&\7L86;
M%F','<R>!N"LB\E"Y8_).5T;SE6\83OMTH#;$:5=-(+T4U.R(TKDRJK+).3O
M7B@>E4;$5,0BD=[CN7^3D9[FG$S#U/E[E6..<+Q6Y6<EKBWQEGE[BJPW.PXB
M:5A )"QQ;*CSQ;)'X^"8;A'0#IP,;,KRBJSGRP9=BQ%9*!][/+V)>-]4F:CQ
M?M?("OX8]N/BUSRSIE7+'(NLQ-]#&&85+4SL,<L6.QF@E?\ +$>A5EG*!V[2
M+C9 Q%@4%H8$4UB*:>>O> 1P=RFP9AY6@XHMN,\Q9:XZX;</J_F]Y(<@:=-<
MF(EL]I=MM6'(['+VMU>KQ+UV5)PVDK,VEWK;_*VK8R(E[B*CN)7-3(6(O;%Y
MR<O\JOK+G:?XX<B?<;F6L58K,HE*RU+PAGW)C*I4%G873.1^TQ4/7(9%@QW0
M5*U;D(4""4H!HBI&W^]YD_#]6Y+.<Y\*S4[(N(N/G'+E=BS'%7SI"W4V4<,<
MB<MPV&HR,G+6E2XJ)H^3*K:Y4I7;/RWT<MWD\IV) .J!%ZV6?=\Y18D2SR25
MX+51_)<&L+T;/'.^+:\EXT%,?5;)1[=8JS4L(NQQT=IEF[Q>*ZL:<E#/#048
MFX4%@W<+* "AB*+GN0^ZAR'R)1<K1/$['L]0<+80Y9<!</7WE-&Y@+3\BC;L
MS7O!>1)RIP6+&];5?2= D*!D=C RKE26175<R9P*U4;IK&*19&'ONP(1CMLQ
M_D>Z%);W=?\ 16$5+=$^TC@T?]P#-';^7C"9J4H]HP@;J?'U73;1%%_,ONK<
MR[C[?W+_ )O<<N,&/*AB.@U+*;_C;E7(&86DS:IT^)LH.\96FWWW#2='!G%-
M9((:0DX.-3F'2CE%J5%X=JHJ0=$6<GC_ &;)-QP]C^SYAJ5<HV3IRLQ<G<JI
M4[2K=:]#2CQL5<$8RS+P=;5E&[AH=-?N%DAY9E12 # 3O,17DT1-*!$T1-$3
M1$T1-$32@1-$31$T1-*!$T1-* (FG'BB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HBIBZ4ZMY"J-FHEQB&%@J5Q@9:L6> E&Z;
MN-FZ_.L%XR8B9!LH E69R#!RHDH7H(E-T$!T1=>BTV/H-2@:9%/)9]$UN)8P
M44O./1DI4L5%MRLHQL[D3E*L^49L$DT065[EE (!E#'4$QS$70F<58RL<RC8
M[%CRC3]C;%:%:V&<J->EIQJ6/4%9@5O*OXUP^2*Q6$3H@!]DC#N78=$7M1E1
MK<*\E)&)A(B-D9QV5_-OX^*C6#Z9?%1*W!Y+NV;1!Q)NO((4GF+F4/VE -]@
M#8B\"2Q+C"8D'TM+8]H\G*2;ID]DI*0I]:?2$B]C0$(UV^?.XI9T[=1VX^0H
MH<QT=_H$-$772PWBA$$ 2QO04_2J2:S04Z55DA:K3:8I3*S84X@HHKRZ0]KH
MY=C."]%.X-$5'7?C)A.^5"=H<I0*W&5:V0R=5MT?5X*#K*UFHXKD6?T*4D8>
M.:2(4^;(3R7K-!5(%VYSI]P <VY%?%BQ:QK5!DR01;-&R23=LV;HHMV[9L@F
M1%NV;H()I(HMVZ"92)D*4"D(4     #1%\Q^,&A%O<T]WM;L,8X9EXTD,/T]
MO;_FX5TQ #X]#;[_ *0US>;C8][:GS+<XL$5>?A[5-&5A5Y6NSD.DDF RD8_
M8H^8;L*8[IJ=$@'';8""H;81\-M:F> 3POMFC:^G'MT6Q#FL'F-%3F*,<R-*
M;RR$F@T1!^2/[?3.4W'<=F5T0P'[4R; )%BB'3;?<-0XJP=9P.9<>;L"QS.Z
MOE^%7'LE<;S]7M%?7("J,]69Z$62,4.TZ4M$/(]1,P"!@$#%<" _';6S%*BG
M!4]=WS.[^6BMI_=P8L\'[0G&B$5*)%8:R9_B%2"':8JD7R#R8P, @/7<HM]N
MO773P?VZ\JK2S_WW>U9T=3*!-$31$T18\/<;X/*<]*'Q_P :N;(A6ZSC'EAA
MK/MW$)*SP4S/5#&YK$$O7:C9:<_C+!5K@]^])JQ\DBX1%HN@!^\!V'1%0CCV
M=N$BV&J/A5&MY3C(_'^;K%R/@\EPV;\HQ.>7.;+FT?15XR#.YN8VA'(<W.76
M DEHR3.N],#B/$J.Q2D()2*[&#?;8XD\<)?!<WA^AR]7=<<(S/4/B-%2XV:8
M:5V-Y*6B/N&66SE&8DWIIO[S.Q:*B!WAUE692B5(P 8VY%S4#VX^*V,[!B:S
MU&GSS*8PE=^3^1,>N'5PL#\D7:N8<@\DL\/7:+E\=.41LKE^J+9%<#I1P#LW
M @ &B*UK/VB>(%>AL0Q6.PS=AUWA3%SG"%4M.&<^92QE<Y;#KJVO[T?&MXL]
M6L3"1N=81MLHY?-RO3'7:K+G\E4@&-N1=?*_L[<&<TY;M&:+W2,@.+1=+/B_
M(%M@X;,>3*[CZSY0PXO!C0,KV#'T-9FM3G,EQ4=76K!27=M5G+AF4Q5!,8YC
MZ(I79+XD83RWEFMYLO$#)R&0JIAW+F"8>5:3\I'-$,<9Q/ 'R+%J1K-PDT7>
M2AJRT\ET8HKM>P?*,7N-N11R0]IOA0VQS?<5)4"R?DO)7$C&?!^VQQK_ &TS
MA[QVQ'^9/R/5&[\TGZMC*QPVQZ*DHD<K]QY@>8J;M+L1<-F]IKAO;,M)YDE*
MYD5*P%R=A/-JM;BLMWZ*QP^S-QZBX&OXKRI)X\93B56DKM!5FMM8Q1VL@<'+
M,IBJ$$QS'T1=G-OM[TR4X$\O>%W'I5OCLO*& Y(O?O5K=S=HBHG)O)&1L5DM
MUFD"J+KR9H9:UV5PY]&@(%12'RT2E*!2Z(K7XQ]E[A=3L09#QE8:O?+<[S33
ML&T_+%DLN7LG6N:>0. Y>$MM I%(G;99)>=H^,ZY=H<7[.$8KHMBBJ8ARB38
MI2*[W(WVL>'?*C*,MES+51NJMFN57JE%RW&T[*>0*%3L\42BRZDW3Z9G&G5*
M?BH#)==K[Y=4$$7Z)A%NL=!0QT#>7HBI'+GL\\&,UY9M.8KM0[R2?N]@Q7=+
M;6:KEO(U-QC8L@X56@@QKD69QC6['&TJ2O-9BZXTCTI!=FHH9@GY1@$?J B[
MLE[1G":6Y$N.3SNEWS^9*N?*SRD:Q:.7,C(XSBN0=:2:-C99B<5DL@41E<+&
MS8(H2SH&0F?(D[#; <_<1<]?]I;AA687D+38NJ9$#&/)B R+6L@8;=YDR<\P
MW"1F7)D++DHV,L:+6@U6QK(6VR$*_7=1+=NNDY 11,D4QRF(ILX1P_6<!XKI
M&(*?*W2<K5!@FU>AI;(ESG\A75Y'M#JF;C/W.TO)"?GG2)5?+*JY6.8J12)E
MV(0I0(KJZ(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(@^ [>
M/PT1?-OAA@7_ $C7N^/U-MCYYXW-R=W: #Y?&2JJ" "(AN(>;N(?#??6HR$;
M9)!^846^Q[@+;7\Q4M[E;8VDP2]A>MUWC)HNW;K(QQ4UW8&<&$I!(B B)AW#
M\ Z^(:UN0?%;Q^HVM:<@3]RON=6Z*.2W,2I$25.E5)DYB.%6Y 4F(8B'<D"H
M&*H\;*/45'?>3;T[0'JP"( 8I1WUI&7[I!Y62D_X'?@M897C0<E+^$70E6L7
M($7;I(R+5B^!)=9(ATD7J*2_E*@)RB51,BG:8! !W#P#6\;;RN -.-%GACB
M4]EVJEHW!2%IH !0K'(3F!#$*&W:";;E1ESR0+MT[10,40_#71PL<R(,=Q"U
M-Q_?=3O65_4J@31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:"/: B.^P (].H]
M-$7S)YVX9^Y;#\R>8&5L 86PCDS#O(C)..K[#O[5R->XOL[-2G8@JV.WC5Y
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MU&Z0X6"O-:HS+(6H9!$ZQ6A7%58*%6ED"JF7C$3@HZ(D0>[1%[>)N6O&[.M
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KB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>vc051_img09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img09.jpg
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M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5'?\
M6)GYI_SEJ['^)ZD3/TLKCJ8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*CO^L3/S3_G+5V/\3U(
MF?I97'4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5'?]8F?FG_ #EJ['^)ZD3/TLKCJ8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*CO^L3/S3_G+5V/\3U(F?I97'4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*5T8?4%WMMZZ]Z- ]"J-V7==-]<S^C[AV,VYNN$
MD:M7[O8X^#L3BLPM"IMFN"*\;"),31SE_(G0+\PJF9,!,1(A_+V/L;9L3"[(
MW#OU]K3>MTCW*# Q\>199((3)$TTF1-'"RM(2-$,*LP366)#'2!R/<69,V[8
M.P1Y+8<.1#-/+,ND.4B*JL,;/=4=F+/(=+,(U&FUVJIK[ZMG8;1>SXSKE2@U
M3V/I.M>R&M.G#S<FY-@&BNQ&Y;M821]EN.R(JB4-@VKKVGT>HOS-UI("I).E
MTTG0GX5]D_4#TVV'=-GR>Z-[3-V_<)=GR]W$&'C ;?BP0N\,.,TTTC.L^1-'
M=4\V@-H/'BNFF[AW#;IUVG:FBRXX<K%Q.ID2?EYILO1(&1(U >.%)5UOP! )
MO<<==8?7C[(6)A8)YGIGKO%4FUZB[D7_ %',L]CV2?N,*UZV*2AZW=MK51DU
M<$K]2N*;=%B@B!RN',EY'(8B/)"RLGT6[:Q-&#/E[M],1;ALV+D XZ1PO)N8
M3K0XDCM>67'NSDD! @XZCQK)#WGGR[AJAAQ7VIWW+IGJ,9-& DC++,BB\<;L
MBQFUV))*V\H/(UK]9?LEH#2L!'=KT=%W:^17T_YSM@C>6EJ/%R>PK?:[02L]
M?:&ZAXPC"'&QVZ31=-YEI%HB=$R9#H@0I%!&S</2G8.YNXI/Y%P[GC[9-W2F
MUI&\>H0PQ1&7.R6;S,(HHS&\)E(+ MK-R (VV]VYVW[7CS=PR8K2MM&1N#LK
M!3I!5<>$ Z5ZLDA>,@"PTJ+7N3F]V?5C[96_57;Q2,T-K:+U5IRIZJT[<K="
M[4O]/V6MV W_ $G7\>E4=>/*^9%]''JUWOJI!>HN$GR#=$GA_3$.<=?L'IYV
M@V?L0;-S?I3<YLG+C5H()((MOPI\DB:?6;2--!BLPBT&,D^<Z.!EYW<V]PXN
M?,,?'Z&!M\+3'5(&.3DXR,(8@HN DL\0+Z@RK<B[BXS%?^L7O35VQ*U2Y/2E
M/LO5BE[_ +]U4<;2D=@VBP;WMI]$:;<738%S;L'#08B;6J;BN.R23M=83/SK
M)  )J"=4V(>FO;VY[!)N,F9EKWK/LV/NG0$$4>(AS\U8,6!G!!1IEFC956,+
M&-7$BRC*=]W/#W--LQX8FV>#<HMO>5I'>4NN-U<AK&^H0:)-;,Q9CI6UR7J<
M/I_?5D[!]P.SE"U%;]0:'KE"V3H:=[&,7NM]ESEWOFO:5(3"$7KBM;.:G:(0
M41=)E BKER@F("9!1,Q4D@#E2%Z@>FG;G9_;DVXX>1NDFYXV[_1I]XQT@@R)
M8HV?)GQ3J:1X$8"-2P!U&Y)O84V+NK<-YW3'AZ6*N!E8CY2Z9&>:*$,$B690
MH19)"P8 '@H86X GK)VQW0[PWCZF=G)J[?&U];Z,4[KRFCM:R;BTUQUUR>0O
M6^BQ\OO'74KKM>L24Q-W&XDAWZ[-R+QH@*BABE.*@% /0MN[>[)V?TH,^=@X
M.=W&G;GOL\)AE7.5MQR7CP,E<KJK$D$"M%U(Q&\EB"19KUIMUR]^W'O$X>!/
MD8V =TQ\*.173W=)8X5DR8Y8]#N[R-J5265=0*7X58B$^O\ [TD5']U>Z/Z_
M(ZJG.N>_NS-+C83:%ALFU:U1M= Y@-7L=MQ+-LA#UV<V-<U6@ @F8JORAE2)
MD Y2*GTF7Z';+CA-K3*W3Z?3?,#:I'DQTCQ)<C)_*93XKEC))%BPK)=F #-H
M:X4D"=C]\9&1.N4L>*-EDQ<W*7\J3D)CXB/9ID"Z8S/)TU07.D:P02!6;VM]
M;+O1JV:USJE]U!TH]WO9M>U#=MAJS/85Q7K[;7VT91"*UC1XV2.Q: QV1+*M
M'QWSQ\L2*;#["*::RIC!F'8O2?T[WC'R-].[;E'VK'FR8<4A@BZSRX\?5GR#
M&K,?=PCQ".- T[W9F$:BL.X=W]R8$$$#X>,=XFQ/>BO4?II&S"..-F('Y5Y0
M^HDK%&H4%F8U=GZDO97>"=ZZ&]4=:;0/U%E.X\S<9;:6Y73BNELNN*GK>IPM
MBF:#3YNR(*U]C=)Z3G"M@>>T*Y4VI@0 #*\AQ'IUL>V2[9O_ '?DX/TN-E@Q
M^ABL).G+)E3-$D^0D1$AA@1&=D# ,S(&8 &_1=R;AF01[;ML<@Q,C<LEHWE!
M4F%8HNK(J%AH,DA*QQL00#<A22+4Y[#ZG[$U[L3]/7KWJ_ZIG;J\M^R\GM52
MQW.!NU" I-*:W@BV$ML8NZU6S1DY8E)NSM6)910ZI7+5 I3 )R^6==LO<&V#
MMWN;N#=^UMBBR-N3#6*-L?( 7+R91%H*O/J"=&&:4Q#3:3C>QM6EW/ R8YMI
MP<'=<]QEY4JEQ+$2T,4;S2FXCXLKF*,/QLK6(N+C:OIPV;L7W,M:V]KM]1>_
M4]/7>^+=JC6O5R/?ZT +GK[1DFI79<NYZL\C0M%GNUVBF!I&6D$Q27057%5'
MVDRE#(WJ!!@=G8G\G\+M[#E7)VO'R<C<9(YR1/G(LVK#=9%AAQX&<00)I<,5
M(<LUZS;3UMTS97FW.>-<3.?&A@#1AG3&-B<C4I>66<*TCVTV0W4  $5J[H=N
M>P&N/JE;:W"O%0.P:-U5D=%]8>OU ;;?O>NJ&UWGV:@G5CAK)L])K_W-2@)P
MDB[)8P<H*D29-6*;4Q%?-0O1=G]M[!G^F&%LL<F5C;INXW#<<Z5<:">1L#:V
M$9A@#?E@7D0& (R:I6E:4F,*IA=R;EG8W=$N6ZQR;9MD&(D<?4=+Y>>Q$;R%
M?*-(MK+AE6#25&MBPL?2_K)=O=F3-'T)KCK]UVN/:2P]E]TZ*=O(79-M?]>Y
M:KZ?HT+9)C9=3MS9H>:=QL5.SZ4<\2_V0D=5!0J2P"<!3T.X>EW9.UQS;]N&
M9N\/;$6RX6:8W@A&>LV=D/%%BO&7$:L\<4DP8D60JQ4C@TJ/NG>Y;[?%#AR;
MR=S?%0I))[NRQXW7EDUZ-8,)9$< &[$J/-\V3/K)[YWWJAGUZLD#V'G])Z5J
MKE,>X45UMN^MD.R=4D;\:$@=76RN5N]HNI"Y:]C+*H_*XC6B2+J2*4#<*$3$
M"1O1;8MHWG(S\:7;X,K?IU VYL^&>3;V,.N7*AF>!D$4S0B/1*Y,<7&X4NI.
M?OG<,[;MK@R5F:+&AU29@@=$R#$0$C:#J@W59=>I;!GX &ZM:LT;]37?5*W5
MLJ*T97XS?%UV-OF^Z+@9;<&S[G$:U>47J#H2"D;YO1"IL$WD9KM[)VZ6,,NS
MAVZ#1[X&Y*1Q_2%D+V/L$VR09O<L\V)MF-M./G.F)C0M,9]WSW3%Q%9BKRCW
M>/4C32,8EMINEP:'=LY-S.'M:]?/DSHL",S2.B,,?#$^3.Z@%$9'D4.R(.IQ
M!NP%N#:/]()WLXU)6;Y0= Z)CIZL]<*!NW=,1L_:%@@0F;'MVU2=4UE0="Q+
M!DI.6^2FR,$Y50'!3&*U7!$1(*9W&;["]"NW6[BGVG-S-T?!EWK*P,63'QXY
M.FN%&DF5DYS,ZI%'&7Z0"\2RL_*RG5R]^;@FS1[@(<5,E-O.9,))&52AFDBA
MC@L&9Y9NGK XJH=%))-ZB6Q_5;W'HKLMVQVU6:4UOVQ=X[6HG7O7U%M-FMAM
M/:[:=9-(5J?W7/DCX8KB1>.S7B\J,T4VGRQE!,99TL!$3<MJ].]I[B[:VC!S
M)FQ=DP=MDW*=T6+WJ9MTSY8<&/4Y501C8RNQ<D*/+&A9Q5^;W!F;?N^3DZ1)
MN4DF+@1QW?HQR0XOO>:UE#-Y'R-.D#4QMY@JFNP_9GUC=DT3I/=]H6KJAM_6
MW8R'ZS!MIJ\>4QS9.LC"SSZK"*K8L]L-I'VIN.25FV\DHU%$H^RFHW,N)B^X
M/&[7Z6;'O'?F/L6V;QBS=OS[W[FJENGN#1(29']U9/)<(Z(S&Q;2VBQTUNE[
MISL;8FW'<,&;WY-ODR3TUUX]U#&-#*&YO9"RJ25#$:KB]5MW74NPFJOIV[M[
M5/OJX=@-E;.@-1538LK ZVMVJ$JU";;MP-2T6NP?[.0"\A6:=8I2THM31A3$
M([12343^\GY#T7;VX;?N_J)M?;4G:&TX6SS;B\(6:'*,K8JD=8RO),!+-#$C
M2&32-#Z@0 ;5JYH)X^V\O>IMYRI<I=O,[=)HA&LFAGCZ:JA*1N]HP-1UKPOJ
MK4:R[[6+=C-=]%KY]3+=>I*NTZJTSN%NC<]UMFNXS:<Y;[X):XEK37EOM,,W
M0BM<TU6+,\<MTRF5.Y<*"L<4R\9>)MIR.V9O4/;NV-MS,N;>GVW%QHX,AL6"
M"-!/UIXHY=4N5.)4BC9W"!4)5=58E3.QLS#[<R]SR8C+MWOF1,[QB1G#='HP
MEDM'&K*\KD L00+V%Q>;ZCO8_:'T_:=].F^3^\[G<*;5=QS53WY9#HQ$?([Y
MK[/1E]EH1K9XR'9DBW,S8YZ!;"B#5-),TDL10A0] #D/3_MZ+O\ S>X]NPL#
M&3>9]NZN)&H;IXKG/Q$<IK8LL<4,KZBS$K$&X^-;_>\L;#M.WY61ER>X0Y\"
MSS,07DAZ.06U%0 Q8JIL!9FM85U(:2^H?WNN<9L#K[LC;MOKN[:?V1V%VCWG
M9V9VB3C2O4G6FJ*]NE?5<:L9@!6$!:+)-M(%JDH B+%N[(!A XCGI/=/9O96
M)!A]T=M8D<W;V7LV/M^WAP?[LW7(RI\(Y3C5YC#%&^4PY!VQQ8<JYO9=YWS-
MW'(V;=',&X3;BF0X!!]UVY<>'*D"\+J267'6][EI3QM6Q=*_JQ]C.FG65WK[
M>>H8784TOI77._-033W9UA<6*:M_;3=TQ!4N#W%,6!J\84ZMNWTBXDTQ9BH+
M&,;>UP8ZA#$R]Y>F_:G>7=?O/;6;DQ0#=LS!F4X\8C3'V? CDG?#CC;7.P5%
MC&O299GU<%O>)L/<^[;5M+96[PH\4V VX*1*QD9LO,Z<*2%P%C5S(2#:T<4?
MBWE&[=@/J?;AWK%TK1NWX>GZ^O.F>^]1D=E7'JWL&?M6O[OJGK[J&8[&;"C:
MO/KBW?.Y*">QS*+E6_OKLSN1]LPAP8N:O;NP=FV)9.X>WCE2Q9G:\C00[A#'
M%D096X9J;7BM(JEE42"26:)K:@JAQ?@:V&1OFX[CKV+<>C'*-VQ(6DQG9XVB
M6)L_)4$@,7BC@5)%%C^4MPMQ[)?I<?5"[#=]]G7B-O77"J:[U"CK^+V!2[I5
MK5+RTO"GG999."IMZ93;=F$G*RE?)\V22CD$&!E$E$TP5#[Y>(]4O3SM?L'
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M"!CF$GCR.9\+N?N7;=KFV3;MPS8-FR"3+!'-(D4A("G6BL%.I0%:X\P #7
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ME!T,<5P0% ;G,9$%.3@4#"(CAVCN?N3M^";%V'<,W"QL@6E2":2)9 !8:@C
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M0?FKY18$BD^S[3DHL>1BX\D:2M*H:-2!(YU.X!'!G;BQYL>)O6P1/2+J;!N
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M?"W/QY5DB5)9LX%4KNT*@U7CE$_==UD$'155"F="()1:;@J3  'W0^X90/\
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M46HV,IU?H\Y<H^7C+A!2\A*:JVE7MNS3&QZIFEW[!0%91 57S9LFD<C0#*G
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M!]E<MK97$:F[B&K%-RK'JNF3$5%C)E=/DY=0AV8@1,_@1O&N45?+D1'D0X
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M405,D#AH=&E:Y*T:*HD,<3JO_P ,<> E$>/ /0?+T\ZS'$N)NTG+\K#P//\
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M++<:9AK(7B0!I\C7'!BLB/POP8<;W%:K-6'YZ:K\Z9!9HE4S+/W:'NB8/E;
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M2*O(5^%K-*K<H[EZO6EI*Z&H,9&QL!.W0[:(:M;!8$!BD5P<K)"8C@OF3Q$
MXV6\=R[OO6[R;SD32)DO/)*H1W"Q-*S,PB!8E%\Q%@>7 U9)E9,LAEDD<N0P
MYG@KDED''@AN1IY6X5NDI7-53<M';"FH'7TO.U)15I$WB4BZY(2U95(N*:S:
M.LKM!5Y#*%<J^)B)+IB!S<"'(YKH<K<L>)L+'DGCAG U1JSJL@MPNH(#BW*X
M/"@ER1&<4,_1)N4N;7YW*\N7C:N8&N-=&F9ZS%H=*-8;9&C$6>P!5X(9FRPY
MTRIC&3TL#'YZ9C3I% OLN%%$A* !X\9;[_GC'7#ZTWNL;ZE36VA7O?4JWL&O
MQN #>J>]9!"?E'M'Q3S'R_N>/#[%JP0:4THTA8R%#4NK6U=KDFI8H:)"AU-&
M%@9G@IE9V,8?A16,7)^*0"9TD1-7@H<F],SG>]Y,[91R\KWEDT%^J^HI^"6U
M7*_V)-O@J\968[-:20O+8-YF)?V!N/FY\ ;\ZR5.@]5NW+S9FOX?7[IY>FZ3
MF0V#3H^N+.;BU3.((KO+7"(F5L+=-1/@ICN%B@)?0>0S'ES;I%&-KSGR%BA-
MQ#(7 0GCPC;@I(-^0O>K)I,AB(<AG)BNH5B?);@5 /S;6L1PM:U<5XZU'L>S
M2U&D_P!@KQ;-6R%7LDO5Y-O!V*9H4K,-W$C3YUQ&/4G;BO2+YLU568.?%)4Q
M2&,F;TYRZ)=UV_&3<X.O#BY'4B65=2+)IL)4#BP8#4H=;GF 15Q&5C1B^M(<
MA#;F!(@;2WP,H8:3S / UDTM9ZW01,W1U]2$6YX6;K9T$JI IHGKMF?GE;)
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MBPLH&O+1$G$VR:=C+7%([M\A&+MT'[!BS]UZD@#AK[U<3)]Y@,TJ/ 51&*R
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M#:YM>UZRI/&[]*_Y;3JM\%[?LU&3U(CNV3PG .)]T,&4?3A0L(XIX&2-Z\B
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MXD(80 .1'Q].1],H-V)Y1_=_K57H#VUPDOJZI+HF71T<F<B8'$Y V.4%B@0
M\S>R:F@?P*8?4?R>N5;=&47:/_QOZU.A\/W*\3?5R4*3D="'\A,4I"_O$)P?
MD.1$I@IYN0#@0Y^ \99],?[']W^M5RXU^9^Y7)#ZM@^?@.AU/B4G(;"*( H;
M@/:/_P!R >)@./ X^F/]C^[_ %JN]T_LON4_Y6TOAY?N+/Y>12@7]O\ CGT,
M"@\#3N0\%."ASQR)@^S'TQ_L?W?ZU/=/[+[G]>NXYDX^;9M'?A[?S39!Q[8C
MY"3WDBJ> FX#GQ\N.> S= W%ZAUR<K2F*4Q2F*4Q2F*4Q2NCWZKQ0-L/4'/I
MQ3+(//\ <G& _DS3[G\]?;I-;+!("M?G<5U0&1YY_*/VA^3\GV?;FF-C4U'U
M</&LK'1*+HHG5>E;@4X!X"@LJH;T\N2@3Q( #_*8!'-E@;3-N"EXRJHIMQO?
M[51,S<XL,Z'5BQ'A6T-F$:W$. >NS< '(^RT3$?L#T!P?C_5#-W%VO MNK*S
M'^Q%OV;UJFW^6WY*,#]T;_L6K,H.Q1'Q;,&B7B!?O*@JZ/P(?D55]OGU^PF;
M.+8MNC/S"Q_LB?V.51)-YSWY.%^(#^O63_%)WVP33?N42#Z DT\6B?K\/$&Y
M4^,V,6)BP#R1H/L"M?)E3R'\K(Q^R:]*22RBGFL<ZQO!01,L8ZIC#[9N2F,8
M3&$#? >/7,A:YL/FU'+CXS6&0KMG79M??L$)&K&23,J$97G<@5,3$ ?%):3F
M6X'$.?B9  _DRW@/$ZOL4#WX6KV#17"_ O[Q<5B\>J48> @$#<_RQ\(=^3T]
M/1P A^7*>6PX'5\=-;@^%Z]*>K*6)S*/(V3FU#\@8]DM%IGR#SZ#_L62F5F
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MD&4='O9>;8+$3?H7MPV!\<I458E01H,>U"+4?-Q<E64<)^9_0? @\ABTR%N
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MY?$UUW]C^W>V](S-DAHNM4AT2!=*)M7$BVEW!EFHIE5;+*BA)-2',*9@ PE
MI1, \ 'PSELO><R'+;&*II4\#8_+70X^V8<V*L^I]3#B+CG]JNN+_E:NTDK,
M_AC2 U,R1_IS%%*J2SE0"I)F-SY.+"<H^A?4>,+O&=J"KH /P?UZR?1N(HOY
MC]FOPWU.>SS]VT;DG*&S4,HJ#U)E1&0F0+Y&%(0.[<N #R3#\H_#)*[GG<]0
M'V!5ON6+RTG[==NG2;;U]W?J:P6O8DDRE99E=WT.Q=,HMG$I?AB,/$/$TC-V
M1$T3F3<.U.#"'EP/ _#-WM>1-DP,TQNP>W*WARX5K=RABQY D7 %:M@H0/'X
M"/'_ +'V\?DY#-E6MU<+>-;=KB_3.J[.2_5XS(DQ LW)F1Y!,BK1,9 H1JIU
M2* )#&*@Z.)/(! #\#P.8LA.I"R_!4K#;^Z!<\*M;;>Y3E>)GOG1MAXBTU%\
MQ1!Y.J/TWDTYC"K-4&**#2/B"-I!^E[(D21(<$%!*(B'ESSN+!.,A#.H'FXV
M%Q;XZZ5U@8%,9M1\">!^U7S]_4&ZUP/:MY*;XNVMJ3LB2A-<U^LLH>12@RV^
MN5^J0*IDJPWD%W45)*F%RHJNBT Y^5'*AB?SQYMWC$W:\DNTY""W-#:X/'QY
MW(L;>-:^3'W%9%*W17' L#IYVOP!X7K[=-1IHI:IUBDV:BR;I:]I::#,Q#)F
M:(DK<:5)J9,PB9,4" !!*/J''&4344!?Y]A?X_&I!!!L>)%2%EU*8I4>7[;6
ML]5J4]/9%XK='"_6E&DT]>SR:$0SG;:YBY2::P#1\\,DS+).XZ&<G1(HH3WC
M)>!/)0Q2FPS9&/CZ!D21QF20(FI@NMVOI1;D:G:QTJ+L;&P-7I'))?IJS:5+
M&P)LHYDVY >)/ 5(>9JLIBE,4IBE5/WQIC9=MM%?V/KJ^OOQ2H'BY"/UI8W'
MO:_?2L(>569RY(DWC%N9LQY/D#/B"<JR#=5L\CU$05&T@DW%7 BUC4 *;KKU
M9>V%_9XNQ]<-U,D@?2;&(AUIK7NT9511)HQ;RM354;,7$G89!0&[=Z95DL=1
M4A&\VY(4V4N!SX&KK7X<Q78E5W%A=UN =6V/CXFT.8>-7L47$O5)&,CIM5HB
MI)L8]^JDBH\:-7ACD35$A1.4H#]N7UC^*J1;,U]NNG;"FMF+,V78^BOV\['E
MU]9HYJLXIM<L#Y%S)1=9AF4<X,*BC1JV9G>)(2RSMLW*15FF(KNE+""#?G5X
M((MR->JB[J@6B]5C].V&4D7%@L,= &ZY[".X6L,0V.N4+!,T2V"O(N6==IT0
MW7>.BG7EH=%-'Y5,S%P=-(0(\*$>W[=7'V/49.]4V7K$/<;!0I*1^2,UM%96
M%O+,#LI!J_%(BJ:C=S\E(%;"W=%07;.#ME5"I+(G$JA;S5HX&J KHVC1L'#T
M7?&O1O.MH)^Y=5?<%+<.6UUK$I).U'KJ>4LS96*E0L,A(NC+.G2RT9)NECG
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MFFT$4#-EU'@.%DDRAX<E1,!>#& <ME95:RCRU4!CQ)J/:E76UJ9S,U :]KL
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M0CZZFZ+KI?86BI>L:^K-]0E:);HT4YZ6?PAXI^>P1ARJE?LHZ3.5H[;D\5"
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MIF.F9,BJ1P]LQ?0Q#?W\T/2F"D<;W]M;038S-Q (/MK$E:7M@H -I&PH 4
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ME 0\Q$(P!XZOPA:WL\;^TVY$6%^8-7]/;F93)[PP5KCS(.-B/P#PXT;ZQN3
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MG58D6Y7^"I!=]:MA[#>)N]M[BF)]XL=8%$4'DE-HE<)I'4]C\4G5_ET/O<
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M'$Q0Y'@ 'CGC^YR'VY>1<50&L(XJZ3N<A7RZ93 H#M+P.4!'[C-4Q#&Y14\
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M0FX^<#P)N;\+VX7M7=%I%!LDON(6"*+>+_?)-L(Q!N4I&Z#6N5"D50[9!,@
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M$DBHU)[*I5#G(3DP;[=^UNY]@V[;]WWS;L[#VK=H&GPIIH7CBRX4D,3RXSN
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M:/ 7<-#&$??1(=0R8B ?8&EV[W> /)#.)4(N?[$"_@/@K<[@,B8QI-"8Y!P
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M*3TR3:>/]\!.GFU[6//X*PYYNRGA;$VDJIL5TZ?L(@K#W*W(/ERO7KDLA/(
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MK(.E1\EG+EVI*+K.7BY^1.LL<QAY],\BWCL+U-W%]7N\1'@.O$% \ !JX >
M%>DX/??8&&OEFDU<S>&0DGQN;7)-6EC/H9]W(Q,J:>K:8)"?S"ALZE^7IZ>2
MQOQ'[YS<<^GIG+GTA]2#\[%A)_\ *(OEK;_YTNR0-(GDM_M,GR5G1^BEWJ3
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MV\.UV=K>A;&:UZ51G8!M?*?7K>W@YMOQ[$Q#HV".D$XR50\0\'"($6+QZ&#
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MP2 <665(XY2I'M:.1&7XR#9@0,4<@DD@C (7)@$T3$65T+M&2&_L'4AO#BK
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M5^[[=_\ U#(J!F?\ZX?Q3?Z@5?3/G6MM3%*8I3%*8I3%*8I5<>XO_%&[3_\
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M02@*K=(%TR+$$2B ^/[CG;9N61@[O--!GXZ[?FPS%@RJ\N+ \D9=7TN&:-E
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MN9NP8V)W%G8N'D^_8D>;,J9)YY"B1@)S[3*/.3XDW\:[]?\ 1ZS>7:+MT/\
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M/(>N?3_9G]#%ZC[#H]^]2O1WR_@;GW"?M7[8%>"]R97<V[:O=<2;C^$T8_\
MKFJ[6>H]S9<#E:=#NTX%'R\ 6#0! #SX\O0-]'\0-XAR ?$ SZP[-_HR]UV'
M2<_U)]*KBU].;OY_^'!7@7<GI[ZE[MJ]UQH^/X4R#]LU7:S]?.^<O[GR?1#L
MB'GR >\[T&F(!^3[N\3" ?R!Z9]9]F?4VV'8='O_ *C^F_E_!R-];]G8!7@7
M<?U<?6_==7NN/A<;_.R@/_JFH%F>E7U#I58QQZ+]@ 3$1$"C*Z( 1Y]/O?\
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MBA]?M.TZQOE+*H]FZUKNK0TF[_;%!%K:4W3QA&(++MYYLW(FY2.(IJD#Q$O
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M/S_??Y> &'GCGCG*?YJO1S_M1V'_ !1W'_%55]]W#^\I?X2'^WK])V4[6)E
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M<*WM!IU+EV:=95NM/D[L6!L^SGE$;F@D[5*I/I%-N8JBPKJ$*8,F.1!N,>8
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M4IBE,4KC/4W2K-VDQ<ILWJK9=-H[5;_-I-71TC%;N5&GO-_FDT%1 PI^X3S
M./(.>0QRB1HF6)@LI4Z21< VX$BXN >-KB_*XJ^,H'!D!:,$7%[7'B+V-K^V
MQM[*Z\NH.G^TT_9I+?W?HU 7W?6OQ;6&H*7K%VY=ZOH]!B%QBYC;T/&NW;\8
M[9G8=PT"4D"J+.G$!!?)0R2P>#\7,B!UCPQ( 5S\E%,P)!$(%O[FC8 :D# R
MN_.1V56NL,=89P[Y317!P('/2-K&4F_Y>07-FT-TDCO:,*[CC,UMZ^I!46%^
MZ.]CJ3)[JM?75E::">%6W13*Y:[;,T3YV7BDTWR]=HX!:Y2NR*OBQF$V2C=;
M\)=.1]]N "LGK\VVB,DI<9$+!74M&Y65&$4H6QZ<MNF_$#2QOPX&;B&TC_/X
MPRBZ$"1-4;+U(RP(ZD=^HG G4HMQKYH8CL1VLUSK&M[1T7UMKVG+EJ;IC]1F
M-UA8=3:DV[8M/7Z>J79WJC'4;:^H=?[5:K6NLZ[V_'3,P_CZM+H&='*S749J
M';)D7'<=1W=Y;F-YX=H0QMYC$DF[9$,B%K*67H$3I<(\<4B:PND6U\BI%A"X
M$IQ\K/*NMU$NC:%F1M/F <3@0.1K225'TEBQO*W<'ZB'U)]#NMD:!@MJSJUO
MK'8SL77*UV"+UTJ[67/J*A=5M';EKU^M\ AK38-)+I?6&R-KOFUIF8VOJ/%H
M*,(B5ZB_3657TV/D'+C1W(QQ$N:)';C&%Q]P@QXIICI!57QY'/DT*\JJZG1J
M2IO2,:*0K323#"*(H\Y?(P\B:6&(:N+K+$E@VME1F5N.EAHME[)]T]"V7L3/
M]<;?'QM([&=X!G+EW.L]"E)/7\HTC?IN=5YW5-GBA@-(;A@6M%W??R/!%\QJ
MZC5P# T8T=1KI<BR>TR1)"B;=%'[M''D;R\<4@8L91N*+%#):[7$+/)I#HTN
MDF.2R%6A8W3GF?<)7&1*^)LR.\9 '3;#F,TL=[#RRK''J96$>M>I'YKKV(]Z
M-C]O;_U=T"WW5I6W5W1S+>?32:[I[)Z_VFR3*6V^O$PS!]OX]<UE4V+'L'2]
M3,KJM&GGF3QHC-'J@.TE4>/F"9AS$Q4W['ZPT;2N9D*R2><7&/D#$:5EU(4&
M4(0P:Z%BA?R!JNQ6SCLLPA8/NK8<3!XR%/&>#WE8M85NI[J9BC* W!M%CI-1
MENGJUT>W!V'^D=:NO77V&M.B;/V"[!U:ZOD]<[$8UAY2JKUYW'8:["V%E;XV
M/79Z\A=K((NH5%PDE#$D2)BQ#@2@:3@K/'OFN?@#LV5*A)_UU)<00,3SZBC6
M(]7G"7T^6U1MQ*2;*4Q[$_2N+&X'YN1,@S*!^ QT=33PU?.XZJEWZ1P:F1GI
M=OV!@=BM_JIEOO93^T+,;!K>XBSJ\'^]NQ_LPG$VM_'_ +L'.D":U"O!3&S1
MT:+28BG\DF5T+H1C;69&V'&,!77]'P>]\PYR3I]XZNOB9?>==B+VBMHM%<5+
MSTT[QDC(_>AFR>ZVMH&-I(@$6G@$$%@X-ORNHO>2QJIUP[:?5A=)7RQ5W<MF
MKK-Y"?6#L5:K"74:G3(U8O0G9R;;K-"1TF_KQWLPOO. ?_)O%7R;@\Q'MRFB
M")/!4?&B022)MD61+Y\CZ#@SFN+7G.9[N^.5%B%:(AV M(I74I"'36PEB@E[
MB&V1?D\%MW7#U7OIBDPUG,X+<+QRW5228R"58%@#5<ZA7]_6/ZB3'M?==<3U
M"J%H[_\ 3U&[[IIL)MP-S54VPOIYZTD&^H2P"R*-65Z>7[;LU^!VAT=1Z:#E
M5@.NV!0HNFL\XT>VR9V!CF\7OW<44)U7ZVA'&/',?P=&J;$=5(;(B1 R"0%M
M )\C<L>++GU=9<'8Y9!:PB!E!G>$'[Z]H\F,D$02,Q#:"*QW36=W1TYK7TR"
M[%JO8"SZN8TKLSWI2<NZ]LJQ2=;ER=0]XQN\-%6<AV,A(-)%UM9*(GZU'OR
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M 790HN;CP)Y"]KGA6?#QWS<F#&A*ZLF14C)-E8L0!8^(%[FU[#C57>N7U%=
M]G(#8-GHC6_0\-K/0>@NQ]H<VZMM8XR6N^Q>KYK;=(!FA&3$RL[GHVJP+@)-
MJ4H W=>*:1U@-Y9GW4KLV/F96<0(,":6.4BYXPP0Y#E1:Y7ISI;Q+!A;@"8N
M&WO^=!MV."<G(C5T!X"S9$V, 3X'J0/\&DJ;\2!PNLGU,NJ':E"4/3+/:: \
MC-<:SW*E%[TI<WIM[-Z>W(UEW>L=HUE6ZI1\;8:5;RP#Y-NZ:N%!26:J)K$2
M. %'(8R(GENMHI1&XN-2.T?64,.8U17<'D0&XW4@6+,K/&JW(E1G1K'2ZI)T
M7TMR)22R,.8++P\PO:.U;\TI28BZSEFVK0HUAKJ@O]I78O[41#N0KFNXV)&<
M=7*1B&+IS+)P'X3PNFX! Q%R'+[8G$Y0&/D2IB12SY%UC@X/P/E/X)',,3P"
M_.)L "34K&ADRYHL?'LTLY CX@!K^()(&GVM>P )) !KB:][%:*VI4-57N@[
M9H5AK&\(%E9=2OD++%M7%^B7S%"0(I7(I^X:RS]XU;N2@Z:E0^:9J^2:Z::A
M3%"7/C38^2^'*MLF.^I18\ 2"W"X*\#YA=3:X-JBQ3Q30#)C8&!B #R%S;RF
M_)N(\I\PY$5MP;/UJ9[9HTNPZ,:1I1FI+DP"VP O:D=\J1!D2S-0D/?@3/%E
M"D2!T5(5#" %Y$<C@@IU!QCU:;^&J]M-^6J_"W._"LQ!#:#\_3JMXZ0+EK?@
M@<;\K<:UU_O?432$EYN/V#4[2$35;9<@AZ;88:U6.8@Z0DZ/95J] PKYW)3J
MT:NS.W.1N0XE=<(CP<>,Q3S+CXTF6P9HHHC(VD%CHL2" .>JUE_"/ <:R11-
M-.F.I DDEZ8N;#7PN"3R(N"WL'$\*T";L'6GLAK_ %VUV,%-F8&V0FNNR-3H
M.SEF$%9V3.H2$+LZDWR0ILN\:S,6O1YV*:/SK*I>VP>-/Z00%,<DS1^Z9G48
MK[UA2:]8(/2:Q37J' <&*@GVU$CD3.PM&ECBYB:-# CJ+<,4TGB>*@VY\ :L
M#7[%7[9#,+%59V&LU?E41<1<[7Y-E,PTDW!0Z0KL)..7<LGB(*IF+Y)G,7R*
M(<\@.4960V8$&P/'V$7!^R.(^"LH96^:0;$C[(X$?&/&LSEM5IBE:K>:-3MF
MTVTZ[V'6(2Z42[P$K5K?4;+'-I>OV2N3C-:/EX68C'B:K5]'R#)<Z:J9RB4Q
M3#F.6&*>,Q3*&C-N!]H((/P$$ @CB" 1Q%9(I9()!+"Q60>(^$6/V"+@CD02
M#PJ--#=9="=8*_,UC0>K:OK*(L<NG/6,D W<'D+#+H1[6(:/YZ;DG+^;F5H^
M(8HM&OS+A4&K5(B*0$3*!0D--*Z"-V)C4L0/[)C=F/M9C;4QNS6%R;"T=(HD
M8NB@,0!_X*WTJ/8JW.E191<V N;SKF.LE1W_ %B9^:?\Y:NQ_B>I$S]+*XZF
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5QWC1K(-'3!\V0>,GK==H\:.4B+MG35RF9
M%PV<(J 9-9!=$XE.4P"!BB(#Z99+%'-&T,H#1.I5@>1!%B#\!'"KD=XG$D9*
MR*001S!'$$?"#52^G'2?371ZAV>A:?-;9)K;KI*V^7L%^L3BVVH6:GC'4RBM
M9UZF5VWU]JFFM&=?K,6 BC&1+,A"^2IUE5,RR.,.##)+)"@&H\7D:P#2RG[^
M5PJJS\"51%Y*!6-U5\N;, LTK7TCYJ+<L(XU^]C#,[A1]\[MS:I$[.ZS<[FT
M+LS5;>@ZDVF2]UX:[(:[WJ67'5-PAGSUH2;A+8K QDU,,T'40"WRSENT<*-G
MH(J@0?#(>5$9HU32K)U$)!)!LK DJPXJZVU(?!@#<<Q)QY3"YD5BKZ& ( /$
MJ19@?G(;V=?%21QY5\^MB^AQV2LVFY76\AO+73IL^ZX=V=%TVG6:R;9V%7M+
MUCLKO/KUL?5VH:E>[LUE=@7/5NIJCIY\P,\EQ3D#KOTTV[9-JF4J<]9. &03
M--IVP22L &F.%N4F9(7'$$F%U@C))+=,-(1<VC,&]V>#&_(J9LQXU4G3#[QM
MGN2A.1'Y>^0X "KJ(0<.-9?J3_3%W93+G8V>J=()[+T3MO=?:C<L9K/2&IY:
MPUFO1EVZB]?=&QVE)R"K4*^3U78]U6>E3GLVR.B/DX,K@7AY-DZ$?<U>()U;
MW;,!R D>8RAB0)!D;GCY<4 E_P!:Z:QLS$E%-V568,PJ6P0P1F*3HDG"CD8#
M4R>[X63!)D&/_7;M(@5;.Y.DLHT@U9[9/T7-X[Q7+LZ14U?4X^W[TE]URG4N
M6O5N@:E 5/9O171W623H$SLBITNWD+=]06/7#\C!ZSAWS.0AWJQ"+M5UO<+M
M<]%;)DB>3WI"^YJ93=-0S,Y,I)D Y$K'HD3R<"-##38P-OD=,9)$C]V?H[60
MGSRIPL6:!XF+<U)E#HQU>9/.K7N+Q;W^F;M"X:3Z\T6C;@:WMEUYV9UIV%"=
M:NP[EO:>L\Q":'JCRJ/=:.;%'4!UMV7BI$K\DDRDK.O:%B2L8S77;F$#"6F3
M,TV\+NCA9K39+'J  VR()H P">0/$91(ITDZE(U G55V+"D&UOMJ7B4P0H-)
M+"\4\,QN6.HK((C&UB!I;YE@%JNZ'T;=C.^W-R[$65YIU]%W!S4[Q46=7NVS
M*.EU[MU=ZINNNQ];:]HT-3OP:YZB:/G2SB-2>RD2V1C'[I)Q$K+ B?($D#?1
MF;@1L3/-'G*DK<2XS(1':53<#ID:009+1I%I"NFJIJY"MN.%F2H!!COA,T:&
MP!Q,DSZD;@29.;"R R%]1*.5JP?2+Z:FV.L.O-]4ZW7_ %[87VU^DG3?K%"N
MJ\E8@9QMNZX]=+=IRUV&4+)1S94:Y.SUB2=1Y4@.Y^43-[I"*<%S+W0AWW;-
MWPL?R2;CD9,B%N2B;"Q<90UN-P\#,;?>E;<;VB[./H[>L+<Y?-%C0QHP',E,
MW*RB5OP^9.JB_P!\&\+&H3J/T-ZQ6NL/4[6,O,P&S-S:]NOT_7?9:\;?L-QV
M75[_ *IZ9/CRB^EM<PED9N&5;UD60E)-2$@_P]FQ.9Z8S_W#B)LDY#1MNF-E
MXH"8T64T\G#SR2>X38:,3QN4,BE+FR*&*@,3>&F/-]%3X<C?W4\'1C(N$C1L
MV/)<*!8CJ!"'(\S,1<Z0+:\O]%K8LUN6[/IFQ=>&&M9#;_>;;L5M&)I\ZY[#
MWF'[B:;NNJ*[HC9S9W'-JN?56EBW1-1L1&2>(/F5;A6Z#!@9N=0-6^+-+M!P
MG<C+7:\O$!!)6:3(R!.N5D<F,L=@>&INK:17 &FMW%E1P;K'FHFK&&Y8>45-
MATDQ8A&<:'@0(I+6XZ0(V=&5R=5:!4/HA;>3O_5:W;)D='V&%T_H'J%I:R5"
MD["VMKF*H5FZD[-E;LWVUJ=>!H!']@?;5%PWEI.+=*5XR-@2X</9%J=0#;XY
M:R;UE;HP:/WG,3*4J;M"PA:(P(ILK1*6)C)(%GE#1'4*TLF.6VF';O*1#C38
MY!X"57D5UF9A=EE-@)+!B=,9612*TZR?0<WY:-8WC6+B_=:X=RSTCVATW [3
M@X*Z-=A=F%NR79&@;M3NG;!?\$#W7U!A*:JV0;M7,^+J8?*NDUVC?AN.OVM(
M\./&7)16CB3:(GB4?DF3;<B.664!C^^Y"QD:2+!I9=3L&X;?*R>KES3P^77+
MN4RORD5L[$GQTAN#^]1-,K$WN5AA"HI6K"2_T591AM6Y;'UF7KSKT\[W$[+[
MNB%:Y3W5<F([2>[N@DOU<A-4@Z@:VV!LWCMLRAK$^C43_A!VYCKD [T>!UJX
MF0-LR<!WU-/M^[07))&O/R5F@9K\UA1=+>*FV@6I'-"F:N25\B96TRIP%T&"
MA3(T^QIK\"/G#YYK :\^C=M:ETK;^LKQ"=4.P%6W;U:T#IN:MM\D-ITW;.OI
M;3W5JL]>IW7&L;[5JQ)SE<U':9:O*S+)\T<,GL>:5?$7C7HK#Y;K<94S1EJJ
M:.KN3Y2,ITNP=\5U64V(_(G'O&#U$:T:LFD,3J]L@?;TPP7UF# 3&96&J-=
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MGZ/T_BWC]<>GZ/T_BWC]<>GZ/UK?_AU_WR?^K_\ N'/F'_\ W_\ ]9W]7_\
0F-;G_%7_  +^K_\ IZ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>vc051_img10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img10.jpg
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M P,# P,# P,# P,# P/_P  1" $S 0X# 1$  A$! Q$!_\0!!     0' 0
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M+8V:L%4:4M+9(^P^[1(QV!/C2O03I<8)4VLS)^"):TP.+.Q[EK.T^S^YX_\
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M,]G[3-Y#%_,8!EP<EIMW'7.7S<TF6BA-K MC8V<KN';OH(!J".G]E=.*5>6
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MG-S<3X^'XI);(ZB%6DBNM)4ZS:;IMWKK3)V]U!6S0]0 ":&O3)#>M/U7AY0
MX<IJ,<(KK)N3H2L[HV8E=SV$^Y*MH')O."9Q=9&);*3B52(PGX;)^%>:.,/4
M)Q_B.3.)]S6FY]K95=#2PGRLAB,@B(USA=P8YS\QB,U9L^F6"4 @]U+*0QXG
MNG:=[VE<GK;?F.15MKTB0DT[("2V59+2K S'$D1W?:>XK3NNVMUEDJA5I4C4
M9N:W&Y_5>,AI*/5Q&  BYS_"[*!6GA^0_P!3K5A/ZP*5=AS'<8V.:09$B?=B
M/1W02F6A!KXBG^Y_JUZ'.,2BJ&4Q LI />OOH!U<T[H\LH:%&VG>578_$!V
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MY2J8W9G,4<(FE%O:Q$1Q9 DZ50L&E2J1=]K]K[7ZOTSNX-EH%'U 9:"JNBD
MV\,)NM(&$Y343+$ QPFU;HW3T??:L&]7#6=/GG2*2MF5.,G&33BS,RG)($Y
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M11I[&HK7Q^VE/;T/43TX1'A ]Q_03>/]&_\ $>A33J G^GR03,=HCU^>+/\
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M5Y;7-C-A;+;-AC-ZM'+%C<CBDR=[L:7&UBAPN8O$O[)+ZSRA_.22PQR2QD4
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M(/9*+Q;/G,MK'&CDZ7 *@GX3XGP[TZ/2ZDI![1 BQI64YD$Y9>B'Y<?T$O\
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MQ)<5/FJ9<-MQM3,VHFD<?8D^WV]/R$Q*9:5-F04.W*)9CT?>EO.*3+QCQ;,
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M4!6?$EFATP[OWE9LQ.E4W7N*!&%?%=&5%*GI<MK[>'A^S#PO_JOO[.$"/?\
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M^G/B>E[0[VP^@=\37_5^?I-*:_LMP'[&Y.Y<(_PY'2]H=[86@0)_V?[Z3?\
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M1VJ/9WZF=I*6/O5&499-!2% F9F"OZV;@R2K#Y*BFHF.&%J#XJR(TA#_
M5/<GV#I?@YL"94KXXD*-I/[R1CG ?ZV<A+$OEW+UH6IHC$9D)_K1("H^"A '
M5B=HTZ)@Y3BQJA0/,$IU3SD( /)N1<$_,SZRVGXIB% HK-\"@DDD^UJ4]G4A
MM.D ^K+P@MMH!S2L GOQA/;D>[=DU2R2M0DF6X.@RD,"%TF-R53N:5]G?HI.
MU6]/E2-/A%JVV@H^5/P"$V3>E_\ G)?F=:$BD3O*[-(=7<IJ(<!3X-X 'HL;
M>II 8!7'+X((32"4\,H37W?DF(82*ZK']U(U B+$J5C0(78L1W[]NB?<U'*6
M$/[*8';=63,;,UPY%$*,[:).Y"_!2E-%:U/L\1U4+33)4"G,>F)(8*5!7880
MI,S<O(6EED(JY+,ZLI!!)^_V&JG>@[=J^/6;H&TT3S=6VD%3;B5##L,/64(N
ME(Y;G%%+;J"DGNEC'1]@^%\,O^J6;QXJ.=OVPSY&#(+F#:V_SR#]N_9^[C"+
M?S/EM)N4,.O570=7CVZ]YM[X6_T\7ND( Y#03+M*I(^+5'R1<Z=6VG_,,WLA
M-0LVRHN!67)XI*0IP =@)3*.U"7[H_*3^YI;KJHSCSVOU#X&/*.^M#DKB'ZK
M7KNC5VB1.=+H Z7(8?HAM(E@5H13[/W3UY[WQ2)7N-XD8E(GW3''Q[X^C?0"
MM]FZ<,)'$_/&L9L^6<(;CS-*.58K*@C*4HXE'8%ZT]OAWZU 6U($\([1[R"S
MIP@,90F1EDG0B@2&0@%$ JRAI H)/LJ*'[>I>PI F@8\918W5XS!PBF7,*L9
M<S(2Q94T^8QK]PNI;X4/A7IA1:CIEE$G:\(3/.<)%QFSI;7>Q1HB1ZB[)J+*
M0Q\:T=0"-/B:]9%NV@@2$YQB57-K4>8#+N@*+)W%U-%''*US/(ZQ)%:AYG8S
M,L*)#' &EEFE=@J(H)9C0"O1;%O0T)!)YRC).&<(7*@4A;KQ+;+:9J<^S^Q&
M?F3^F_\ 40VEQ+=\^;J](G.^W>'['$/N*^W?E=E7-BF)VU;6:WLNY,QAWF_2
M+%82*U'FO=SV<4 0:F('1M3L^O:IO:%T\TYDG"7H,I1IUOZN=/U5[E&;O[16
MIP2V9 */!*3]8]PQAE<^^G'G7TK[EV?M;G7;$.U,UOG8&V>5-L6L>>P^:3(;
M(W<D[[<S$EWB+VZAM)\A\NY^6?3,FGX@*CK3[K9UT*4%Q)0M:9R[/@F)2QC=
M-N;QMFYK6;K9=*0S4%AY/>%$&4\Y<2.,6FMLI)'I1I$0NX95\Y#-\*HSHH=@
M2)=7@U:^SK7'*(F:I$I!E.1E\.4;L*1UMU?**13!1TDD2EPQ/="U'ET41RR7
M4D*R$%(V92-%0=0^,=O+8$:A0#MT&JV$S 'F\(OYK$U)TJU)]; X>/9/A.%Z
M+,3Q)')#<Z5^+XA)\+E'&E#(0RQ]C4]Z]8LT84"A8)GGA$5-,O(Y;8(4LZ4G
MAJ.$I]L&AN&Y1!_=OG'6P"I+^<5B31OB:A ;W^S[>W5)M-/FI) (["(LIZ=U
M@%G6E2DY@$$CQ Q'IA7BW#<(=0O111YDQ66.7RA'&Q8D&04('B"O0JK8TT20
MVH:DZ02D@&9&1ECZ(L44)Q<64,:I+4!.2>(/9.,A.9N#^<O3Q#Q=?<L[<.U+
M?FOC;%<N\;M^.XO*RYW86=_-V.9*XV[NFQHNV0 03A)U]J@=9&];3>ME.P_5
MI/)<:!098?IWQK^UMYV#=E36#;M4I/L+_(45)D$KX:B<,>$\XNEP=Z-?6MZE
MMM3;RX+].W*/(^RHI9K>'=N'PT5KMV_N;1PDUKCLOF+S%V68NXI*H8[265]0
M*^-1U;;.G5[N[*'Z9@J95VB7P3S^.!-Q=6NG6V:TVR^W&G1>T>N%H*R .(")
MZ0.,Y<(LAR!MGE'A_>.5X]Y5V?NSCG?N&9%S&UMXX>[V[G+ 2%G65['()'(\
M$ZJ6BG37%(!5&8"O6N7C:[EJJ335K"FE)X2./Q8QL]EW%M[<U"+IMVKIZNA/
MK+:!"4JSD9\9$8Y<(:29Z\T _-L YHIDF! 1C]Y@2]"*FE!0D]^L2;72SD4D
M2[I1G4,A: OMA]<?;4WQRSOC:_&FP+(;AWYO3*QX/:F"@OK"PN<YEKE&:UQU
MO<Y2\LL<+R\:,I&))%#N0BG40.C:+;[UPJ44E$QK6O $\8Q]WO%NL% Y<+LZ
M::C:$^8D:L!C,RG*,D-\^@OUY<8%Y-[>DOU!8R&/67GMM@9W/X^.-$)F9;S:
M\&9M]"OW[/W KUL-5TVW-1E27Z!Q>G@E"CAPG(81SZV]9^GMVU&V7ZV(T^LI
MP2([UDR /;PG&'F1GS.%R%WBLY99'#93%R-;9'%Y:QO,=D[&[4CS8<EC;V""
M\L[I3_,EC5J>(ZU5^SN4KA:?;+;L\E"1'<)QU:GJJ:LIDUM(ZV[2*R<0I*D'
MP4DE)^&":YH3.T2SAS\3!@SPNP^Z8PRE1X#MV[^_J HE @D02,X+OD5!BEAF
M4?"%59-#2*0-,IJ)?A"*>U:]_;U<*7#+&!%@\P?9@DV=BK(5E0#4$$B&J>:!
MV8 _S@O8GVGPZM31*!&!RA:PCS8023,Q'S"KR(S,?,:OF L*J:!02E /'L>_
M5QHE&4QPB;=2 3,"#(S'QQD=Q4!69GJC2? Y130*"OOJ.HFD,7!T.8X0<L\P
M"K-%$'0:@SNS/60UU:AYJBI;V4Z&J*(ZA,8R_3A#S[,H,19:5RL02)0&%?,*
MK&TA)'PEGK\ '85[]4&C&>.,7(/EQBNZRKHAD"Q*133K[JK+JU21D*S*:>SV
M#W])FDFY+S>B)3[)0"F7D8:S*RET!;220KJ::B)2NJ/2_B.WNZFJC ,I<86H
M=L1;WR"7^G60 AE:E0')8.@1G(H .IJIL,N$$>U#M@6;+L 9'E]I56*Z=94>
M I4%.X'5**.:A(0_M4 0WRW$@.CL0%D0O0ZBM10L5 [CW#JY5.4))' '&)(J
M-3J$GBM/RQUQ85@/]5KW:^IB&E@EKI.H4]9>U6\O36O<C3UZA93_ .!;R<)\
MH?\ MHCYP5>G_?%I<M/MZOX%R.O69J4':A!K_$?;UZ%)2003A*/%JO5/@8\]
M?ZB6R=I9GU[^LC)9C:F!R=VW/>Z$>_OL9:W%RZ+B-OQ(KR20.\JQ@ #4?A'A
MX4Z^;GYA=RWNV]3;C2VVL?:92Q3G2%$">&7Z8Q]'.@**8]-V)I\TXP8O./MD
MQ7D=M9[(V>;JX#"$28C%NBB0ZM9B2W1=*&HTD@GKC;&\=S<DU3U;4EI.)$SX
M1U\)I%DH; #L5P\3<?13I--M; 3W*.KNWZ/8N*UU-I<1) +=JDDT\#U)6^=T
M.HG35E0 >.H_3%]%3M-M*YHXY0L8WCSCJ^N+U8-A[:^7N5$"V]QM[&Z1<Q/1
MKB-/E]8+.A'PT'0E1NS=K#:7%5U0I9.8421AV"+GFJ9: I*)IGC";N+'>G3:
M%A\MN_#\7X":*6>>6XR./P,<UTC,GF1>1)$MS+("U*HKGQH*CK,VH=7[Z>9;
M%U[U/ACK6@)],Q,'XHK<%D9;\RV^8?JS$SZ(N+Z ^:_0OCO7IZ9%W5MS:=[M
M&+ES;4=UN>XV/8V&SL!DM<T6V<SELKFK>Q@&.L]S-;223A'2/2') %>O0O2?
M:G42V;HHZ_=E?HMR7P5-K?+AX8DDG3+LPQQCD?5E#]=L"OI]O4]4U<5)]9"3
M):.*9CB<8RX];7I;^I+C_71ZQ_4'N;:?J W3QO<W?*&YK#>N+W9N:'@J[]/;
MX:X_#L:,C^DEKM!MN1[,"02X<*#+,KKY+LU6ZIU%HNH]?7O4-J6XB@YR5AR7
ME4V3/RGL PC!=&;UT)M>U:&GO197N8N )86R''D/)3)3A!$Q-6/=&W?D?<'$
M'*/U&_0MZ..4O2SZ=N3MC\]>A_94F\=\[\V7/G^44PMGQ]NW,;?PNSL_<9".
M#9^.VW?X(R#Y2#YF8W#LTJZ$IT&G^]O5JV[5M-/MJM^MU9Q.J2C\@P]$<-I[
M/<*/9%^ZB6>Z5;%527YQ')D4-*"G"1I3EB")C@9\8PH]!OHIQG'^W.+LEN#B
MKTX\B\3<M>K7EGB&UMF]'.Y?4_S!G]I;3Y*S&V[W&<O<J-N>RVGZ?]N8?!XC
MR[*\\DLB()9O.<E>B+-8FZ42J4TJZ%=6L@ STC5@#C*#-\[O5>*I:>;74UV9
MM++H6:E3*>8IL*/+IY?>S)PSF!#2R?I\]+WI>PWUX=]XCTO\,\IVWI*YRX2F
MX*VQRYA+S<NVMB)O2:SDEQ$!@O+++R;6QV0W'YXQANEAO([6&"<O'JKCDT%K
MMOOJI+(6[2K ;'ZQ_0'NC8W;YN3=WX(MCUTN5&]=6'C5.M:A[3R@= $L%$2
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MM#WZA,2(BM;:M40!+YBJ5&C4DBSKK1DB*T,:R*R%?B-0>]?=TX*0)\8(;F$
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M4-04E1'V3X900VDA8\8Z]<$9/^RH;R.J/7Y\'Q:O@I^VGM#MJI3P_<KUZ.8
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M7'67Q-];6W"]EMW9YVW/>XN]M9KG\6E,8,<3R2.NP5%QMGM;-4*SF,F1+?+
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MI39:=DMLY"0 2.Q.F6 X0>;S3J64IHIYP>A#+*CJ/SJ]E-&!^Y44/3)+*0L
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MQ-IE;VVQDTIA7S;B>TBG%M+((J$ZPP/;MT72;LW)3T;5'25E0XU2N!Q"')D
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M[?EVCN>3#V6S[C%8OB"]SF&S$N5D;?\ ^F<.)Q;98Y&S6],T/X7EKBX6&&2
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MX#=0JLD8J[.-?G"NO2@4@M)7RV4'LP&FA[=^K4J4HS4<.Z,:XXM]<U2PBJ.
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MEOM^Y83+\N QTZFHPD6,T[ *K*%)'L[]8URZ-HP!BO2I7KPH6FT;N0B$0"C
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M6IE-5"*Q[#4K:2GP*/W1VZXL7TJ3*<A'9RH)$U90H'#QSNJ2PNRB,EIXF/P
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M]_2_G=_(_P 4$D_5CY\O_1HKY$5?(_:\K_1FGG?S?#[VG[*]^K?]'/\ 8?\
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G5+U?[;I_M>J/*51[3_393_\ S/VGG*_Z/[9/EKR_M&O^ME/NC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>vc051_img11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $? 38# 2(  A$! Q$!_\0
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M ",^AJ*^:Q^T7I.\QR^'=6C<%0?WMOPO&23G!/7MP6 YK0A^/FCSY"Z9>JP
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MB[WG&VJ>E[I7?9M,NZEKS:*^CT3>ZO>ST:Z'6-)@C<WS=>@( SW QG< <>N
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M$8 7<-AVY&3G:N023TSD$Y(Y4#C.X>B[2P&5.?X0V5Y )(7(! ! &2,=.<C
M@9!+ERC=",8&#N7.XL0<XW ]\;3C&#1*:3LVEUUN].^E]!63U4EKT;L^O?3\
M7W78\\CN;ZVQC=B,G((.&3!'3G&2,@X&.I/(SH1ZT@(,L98%1@#(PV"Q)XZ$
M[\YQGCM71S:6A,C*"N3N (YSC.UO8].JGGCYN*H2:1*"1Y:DENS@8)/!((R
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MK"4TX[.I]G_IY)]O,\W$Q;JR:YMH[6['D'Q^*_\ "SK\DJ<:/I>?F.5(#@G
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MJL,6 6>%22V,;F+8#FHQ2>OF]7Z[)]=/ZN3JKI_UK\[_ "T/T=_X)<?MCO\
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MV:C*+=G]>?LH:7??L(WNLZKX5^*]]\5_V3/%&JZ:NKZ5X@TF_L_'GPSU'7'
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MTP<<YYJ.:Y6XIQS3+&F_LYE@&G\UC7?72^K0-U=W1EI_T[J)^J7(MOGW:/.
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M^-S-EF\DZ'=*5Y. ORG ZCC&<'GH*HW'P&^-$UA? ?"WQL2D-T %T2Z8Y".
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MAB/JU3$_5L/B'PQ0_P!LJ3PF58RBL'0JT8U).N\XPU*G"K]749TZKG6Y$IG
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MGB;<OUB<Z_+>_+[:<ZO+?KR^TY;];)]PHHHKTB HHHH **** "BBB@ HHHH
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M?"[PQX3\5:EXJUS1O!7@D>(-(TN#3[D6TT?]OZOJVGDQ8WM8V/GQ\ *&Q7X
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M;HR[CG/0\XZ8J,D9(!"L/0\@8YY[<G! ZC&.>*UIH=,M),+(UR#Q$?\ 512
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MVBVGB=!)$VT@.IP<DJ6&,<#H#DYYC4M2\-7=Q/>32R2S7-S-<S$9)>29MTF
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M.T$^I3+N(A8,A)K-\2?\%<_VK;+1K32/@5<_"7]F73+ZUFM-4TC]G_X)^!_
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MVDY5)*FI3DTG*<I2>K9]5'X8_P"&/_I*"BBBNPH**** "BBB@ HHHH ****
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MM?"WC3])T*,_8XH) J [EC'SMP2P)RW([\Y(/'%$FMW!1EAQ;(^U2S8&% Z
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MM)6N[7/R\G\2V-@QCWB65@P1$)F5CD949^[GH >H;/2JL=UX@UG"6T;10R'
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M]'S_ ,%,OV!@#G]H6#&,<_"7XUG@*<\?\*](Y4=,8SV/4M7_ (*8?L!E@_\
MPT+ 3&H.\?"3XU JK N0&/P]+[3C.T<9SD=JTK\"_2VQM+'T\3^SJRY+$Y)F
MV3Y?*AP]P7AZN5QS.G@Z"JQE3J4:&)EA:>786DJV+IUL:L/1PL\!C\!4AB)8
M^5B\@227%]2UXRE^^Q%YRBI+F<N1SBVY7<82C3D[\T'>Q^"OQ3N_^"A?BO\
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M,\5P]77+B>*E6A[&-+D?MX)N$<1!591:G"52HJ[=63C=SC%P<(7IG@7[)7Q
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B:,_"GXOQ8B62.,OOE\"1H?GE1=H8L<Y  #$E?W8?,G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>vc051_img12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G 9H# 2(  A$! Q$!_\0
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MD[==7K;6WZGZK^,/VT_$'ABU:[D\18MU=4-W+9VJHS'(V6]NL9ED9CQE@B9
MR0.:Z3P)^U'XW\=:<M_I?B4L#E6C:QLD<8'RN4V/G=CH&) '4U^%5QJ$NJ:G
M8Q>)M<U/Q!X@U*9(=-T*V+WNJ73NP$8M[&U1VBCR<%D@10#RX'-???P8^ _B
M_P .Z[H%YKOQ%L/AWJ>HVKZK8> ;BZM9M9OM-ABEEN)Y=+N[A9I%BACD>8QP
M2!"C@L"IQ$/K%2:5.%:K+65HPG)<MTGS*,=(ZKWFUOO92L2C1A&/-[-+;FE-
M).UY._O13:2D]-4EL[6/OKQ'^T1XV\'0KJ>O^,+>UL7EA@BCDL;-KBZFE(VV
M]M"J>8\C'H6*+SU%=OX6^-WBCQ?X?LO$>E:U.EC?F01QW-G:Q743PLT;I-&B
MR*/G5OXCTS[U^'_[0OC[P5\2_!WPY^-'PQ\3>)/$7A[7;O6;WPIKFOPSV$=_
M>>#M:N=,OKRSL)&$<=E?75C=BT5(5$L8BVC#J*^E/V3_ (X:OXHU^ZTK4Q!'
MI?B^P%]H"1M&L,>K62^;=6L,*X$)N(VN7VC879 =I/%15EB:&*K83$T_85Z,
MY4ZE.2:J0G"ZE%J[M)25FKJST-*+P]2C&M#V<J4X1Y*L4Y1E&4?<:=^MUK:S
M75*Y^I/_  LWQRJ[O[<?UV_9H>220.2AR<@*>WMBHV^*'CI=N[6W)8, /LUN
M<<'G_5]1@8ZCJ>>,><V]Y*TKQSHT+X&T-T8$\E0.,@@G ..?6K<C?,-P.XC@
M'MUY'&6XSQG& >^*ESG)6<YVTW_X9/7UVV?:)0HST7+%JUW%M-):;2=MK7;=
M]F=E+\4?'\?37G8,H"G[-;]<D$Y\O(SUZ^GXUE^*WQ R0=>8 ' W6MJ1D'&!
M^[XZ=N" <\9K@W9SO4R-@,=H& !GD#E<=?P&.O6H5!8[>,_-V#$-QN!QC)&X
MG(Z#GH:A\_2I-=FVGKU:3MHNMV_)ET:4*DM:<7&,HKF5U[K5[N[LW;6ZNFUH
MK-'N_P .OB%XOUOQKHNE:GJQNK*[^V&: V\$8?R[2XDC.Y%W*%D1"N"N"![Y
M^MH\[%SU(&>IYQ[\],5\,?":.4?$/PZ<X53?YX& /L%UP<@XP3VY_K]S+(&
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MBZS^)MKJ.A76KW6E":>QN-0T'4+=;8P^<_M+P?\ !3KX'_#GXE?$OXQ_%_\
M: LM>^(W[9>O_#/P5INA^);.R\.:+^S3:>#O$_B;1_%6AZ9X-4W&CZ]/KNE:
M<]LMYJJWVJ7%M:>&P\-IJEZER70']D22JQ(/#!BN,'!( R0<8QS_ (U+GK['
M'Z _UK^>3]BSPA^WSK/[6_@'XG>._B=\:1^SK>?#G0;CPWI7BGP_:76B>.?A
MW?\ PF\)PZ5%X^CU'Q=;7G@?XIV?Q!AU?7-8:W\%WFK7,]S<V,^L'3&@CB_H
M6B),:;R=Q!SGKD$]<9&:3:6K=@):*A,Z!G!XVC(/][CD#Z'COFG"0,SJ 3M
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MDXVDY*Z2ZKBQ=:NL/45!N,X4YN*3]ZI._,HN2[I.-VY)73::5CN?VM_B%?\
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M7WN'DZ%&GAVHN%.E3IJ\>7^'",+I;*[CS6MHG;38_P!'V\\3:@ MQY%M*T
M6!0R/)GEDWA_E8D87/.2,ALG/9Z=J<>KV=O>VRNB.) Z2#]Y!-&!NCDW*"OR
MD8&U20V1QS7R[\'OB#;_ !7^''@[QG82(R:YHMO+?+&H9;?5+'-CJUM(PY$U
MMJ5M.A) 9EVM_%S[MX7FNO[<U."1Y&@N=,L[HQD%EBN;6XD@+*6(51-#,F[
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M.>I/J3S2%\R+&& &X;R?X5YR<]#C)X'7DC-:QS#&.-U7<M-&HPL[+757[/\
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M<DY3I3@G&*:C%)-I7OH?U20_\'</_!4>6#[0OA;]FSRD^5B/ ?B<Y&5RV?\
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M?-\_HPS*M0XBS.KC*F-I8G$3JTI9?AL=A\'B:6">$PE5.I0PU*O.G[2K-O\
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M3!%:2RQ^2J*'<HX(*G/\$VKWVJ:W*=7U&=[AW14A:5P[^6I*JC294;D! W8
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M46N3!_P1^_X(QC9OC?1_VG\ ] 1\3P P!'8$'&?0#FOY^)99KF4*$VE,@+G
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MTD_[TS.?-(KQ_P#;:\9Z9X'UZ'6;QI]>B\(^&-;\9:]92W$ES.]O821W#DQ
M2&21C<001DQR;47 5@IK^:;7/VT-?^-O[7WPJUCXG^(?%7AKX<W6N:7X:L4T
M/Q#?:+)\/=+U.\6Q.O:7;Z>L%E+?6CS&_NX[^PNX[VW46LL)7FI>'K5FXU9W
M5.,9)OEDF^1/9<NJV3U:L[E0FH>\HZ-6:OYNW1Z?<T?Z87@;X@Z9+X#\!_\
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M=6?SUMK8^5XII5*V6RA2A*4WB*5DEJUS3YO72W1_@?@ /F R"K=3DDD].F>
M#W ]NF<4[ YQUQTSCKD_ASGFOK[_ (=W?M_Y7_C"S]I8'' 'PD\:'(['G1N
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M#;_@G9_P4"&<?L6_M*LY."3\)/&;\'/R_P#('P !R0><]<XJ$_\ !/#_ (*
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M[58%N2!DXQG&0,'&.1G'JMA>>&O#-E+<W,$9#QR+'(P#R2S$;HXU7;\S,2,
M #@UDWFDS"1HWC4(KM^^4@ENIP1U&01GG(^@KS3Q2-2%S;0P6\DL*,CH 2%!
M4'&,9R6)P,#[O<@F@#\WM+\(#XF>#OBY=-:R?VA=?$W77U&6X)DGB$"E[2W
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M68;N*72_AUX$MXM>ULO?A86O?$UY%*--T>QL8I)6,4T\EY(5!B@.,&E^V?\
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M5\8;U(R-H8ZJ<D<]L9Z$UGW'[<O[844J1G]JCX_PRAL2?\76\8X4=\$ZJ-V
M!T[=R:^5K77HDMEC*-O0ELCNI P",YQD= #U. <<U-2O[>^$9BBVNH.XX&2Q
MR,Y')'3&3UX&<$5_47$5;P<?!^!J\-X;A*KF>%PF7JGD>8Y3E^+DZ<JE)XK"
MX+$T,JPN,HXNE5@YU?K6(Q?-1JSA3]WE:\:E''*O+VSK*,Y-^TA4J12:O9RC
M*<E).]KQY;:,^I+S]N3]L?=_HO[5O[0#_-@$_%/QB,\8QQJQZ@]N.,5''^V_
M^VJDL0F_:D_: *D@@?\ "U/&0W*0#C/]J@9..AYSW-?)D#(DBB;<H5U.<;L\
M@<X(_P X-;&HW_FM!]G8E8U 4G*[CU Z]/ISSQT(K\PPF0<!9K0S;BC&Y9D^
M5X[ X[*GA<@RS+LMDJT9UN?$\^"QF&J5G2HPC=3YI4ZDY*,ERR<#ME5Q,'3H
M1E4G&<9\]64Y>[H[7:>^J5MTMMCZ_P!/_;:_; OM>\/Z?=?M,_'J2RO=8TJV
MO+6Y^*?B^>VNH)M0MDFBEC?5"CQ2Q.R.C JRG:1@U_4/_P %4OC1^T5X5_;F
M^-MAX0^-'Q;\-^%K"S^%26.EZ#X]\2:7I5FT_P *O"-Q<_9;.UOX8(?M%S+)
M/+Y4:F6:5Y')9B3_ !J>#UNM0\6>&T9A\FN:0^2W VZC;$GG)Z#IGG\*_L(_
MX*DZM<1_M[_'>VNX5N=)M[3X2220Q >>Q;X1>#,#:[!=H;DYYZG'&:_!O'KA
M/+.)>,N':V%R+,L)E.;Y#G=3+I9/EN69>J.+RS&990Q6-GE^7T(47A\+'$\F
M)5*C2G*56+BU%31]EP13P]:OB:&+Q,:;A22A.JI5:2JU+*E"K.?,X4I+GDY)
MKEY4F_>/@6?]J']IL,(S^T3\;HW^1RP^)7BP[@"2=P_M3YN>K$XQC ZU"?VI
M_P!IIB%C_:)^. 5G&QQ\3O%V#GKD?VF?ER23GD'@9ZUP?C"\TS5+TW&EV#6$
M?EQ(80$'F')!(V   <;L@8)SG!S7$$G !4K(<!05 C58SC=DD9R%Y('<X)Q7
M\5Y_E-')\TQE# XFIF6!PM?ECC(4JE"%2-E>52R7(W)RC)5'=.G+[3N?9XK"
MT*.(JT83HXB-*<H1Q%!+V56]FI06W(HN-MW9ZK8^FK']H?\ :DE^SN?VA_C=
MY=Q*=AD^)_BPJS!=Q50=3 "\;@Q^;J/6NEC_ &@?VA6>!-2^/7QHMXGE5;G4
M(?B+XGD,*@9Y/]HKG)Y8[L8 //.?E:RU*YB,44KLT"/YFX$GY3N#JJDY *\A
MCD' &!N%=G_PE&GL8XPDOV=%99%?&&8J O)X.=I.2!R..M?TSX;YGX23X?S#
M#8G%4\CS">$P.'K2SK$8''4L1BI4;5JT<#B,!5Y<NI8BU53P]:GCJ='F]I6<
MN24>.$/9U:52I3HUX4JL)NA4BO95(QDW*G)TXJ;4X+E;NG%OF5[(]]D_:$^/
MK7UW86G[4'QG-I!&3!.?B1XJ2&0Q@,,9U0;6!Y RRL!C&:XNZ_:/_:3DO2(?
MV@?C1=R0L5AN%^)'BMW;:<;@!JA S_"01P<\]1X1=W$$\LLEL@6%F=HD .?5
MMRKP".0,\$YYQ75>#Q;332^;<+:/!:RS(9"HW )D\%AGIC@ENX4\U^?8K$9)
MQ!G.'R'&4,IP.6_VM653B7+YSPM"K@_:U(Q5#ZS6EAJ-/V5*,Z$:Z<DZK4W*
M*BCW*-'#XZK&& P6&H8FM4K.&'E4<Z48*-2LZ<95MU3IPG&,IR<ZEDM6TG]%
M^!_VG_VA4U.&/6_C7\;M6MQ<*LMH?B=XQ1EB&/,(,&IB0';E@.3D  8K]/O^
M"/WQ]^*_C7_@J;\%O".L_&;XI>*?"$^E?$V0>%_%_C77M8M&AM_"EW);FZL;
MV[DMYS;3#,$DT9DCPK<-DU^%T.KW=MJ;7]I, Z3[@Z$X."-N\@AL$$9X&5)X
MSFOUV_X(<:9J5U_P4[^ GB.\M%C6ZT;XI.+H%6\XOX3O ^Q@20@;@!\'@GG.
M#YV+P>6SRS'99DE3%8RIE>*QN,J8BGAJ-*,\MPJ5)U:N)O*=:ER\LY0C-03F
MY1C)5(V]G'9BZG!N)RA97@YU,/B98VIC8Y51CC:%/V$:/)_:.'IQJ?5G6DW*
MCB)2BVH33Y[M_P"A=$FT*21@JN-O(//0]/;UQQST!LU%$"8UZ#Y0 ><^_P#]
M:I:^&3OVLM+KOLU\K'Y(K]7UTTZ'\_?BB6-=>UYL%C_;VM;E4*0%&H3@9!/&
M?O9!Y''TXY[T*S[&(QY8!P"> 2>HQQG!&XX]^:ZCQ1_R']?!7E]>UH CA0!?
MS$ D9/3@YR<UP5PAB/ .TE@=O))& 2,]#@''.>< 5P 79[HE7V'*&,D$YW*Q
M0MAB00<\G(Q@< XKA-9NHP5DV@M"V"VW+* /EZD#!W$ X#8Z]*ZN60;5(!_>
M[00/N@$=2>_R\$  8]N3R^LZ7/<6TTL("Y5B^X%2=BDQN%SWQ@@X[,!0!YKK
M/B2XOY!X?TP)=-J"R?:HV0L6@&/.:X5LC[.@Y? +L2JJ,%F'R]^T/\-+[Q!X
M,N],75=8@MA$KMI$%W- EVZ(64I#$ZJL#)PJ%@FWC:3DCU*RCURQ\5+>V[,)
MD9H][X">0[,'C92.593DCG&!R>*]A;3]&NK:XN?$LZ7+M EK&9 -L0VE51$4
M O+M(B4*&+ Y/J #\+_A3X2TD>+M1^'_ (XU&?PIX9M=VKW7B<V/]KWFE:7$
MP2[M[73S-#]MO9G9$M4DGB@21]\DN%V/^J'[%GP<U37_ (A7DGP@^#VN_$3X
M/W&KQV0U7QI?Z9IGV>]6+:?$6J1+)]C>-)G2XO;2WANV%M;+$BR2DJ?/?A-^
MR;K/[4WQ7^)\'@V)M)T?3?%^C^$;C4/*+_9=+LK*#5-7D$0929KJ6YC"(3T@
M ;"J:_=OQ)X[^$O[!?PAC\ _#]++4?%5AH3SG36FC%Q>Z@8RCRWK)N>-990[
MR38!(+*@&P5A[*S:@W*;E>2?1/J[=-=GMOU(G55TERWMHEY76VSNUJ[W?XG\
MQ_\ P<^_';PY\*?V<HOV8_ASXF6\\7Z]X\\'R?%R6Q@6WBF\/6>E76I:9X>9
M%"I9Z2=5BBN(=+@)22.TBFN#(S9/\;G[!WB:^\/?M%>'(H=8?0]-\0V.M:+J
M]VEI/>QBVN;&9[8?9+57D>2/4HK-[=U7$5PD4I("9K^B3_@MAX \2?''Q1XL
M^-%AHWB?5_!_Q-L="U2^U/3]*OM>7P/XY\/V_DG3=2BL87FATV[MI)+>&Z4"
M)58NWS@*?RG_ .">?[)VK:M\>?"^IZAH/B*;3-(:SUCQ%K=UHVI:7H?A[1H;
MZTEN+UHKJ#[;>6\J;87E\J"-(Y7?>3Y8/?&$*-*233YTYS>_OR7O16KT6B6E
M[O;O-*<IPO)<LKM-+I9M+?R_JY_<3^RA\0/&GBS]GS6/@O\ $/4M=?XS_#RW
MDL]<\0:IID%@ESI7BB,:WH=E:&WN[LW%QI.BZA#8^?((#+&(P(EEBG1?R$_;
M7UO3? VJ^$O#:)<:=92^*K'4=:U&55,AM+*=&G\^8'<D=W-Y4+,!B&,M(P.,
M5^S?AK6/#/A?P%K7B72?$/A^[\8>(!#>ZMXRN9)8[#4[\2/8:4@C4,]OIMG9
M/%:VRS*LA6(-,0% KX!^-O[''Q*^,^J7VK>*FT8QC199=(-U.&T/7_MDR)BT
MU"R<^7A@%21/,9)E*-'7"IP47*5H^]9=?1[;.U_3\=XJ[6]N_P#P3^+/]H3X
MT_$S2OVO+O7H/.\-:UX5\2:?I=CI.G:DU[:FPCU!;I+62X7]UJ-O="?+.R&.
M=&4LI[_Z)'_!.+7O"UI\.;#P;X;T&+PM)KGB2;59])EEN7LM,@U&WBN;@6$B
M02(!'J$K6ZV\HMX$ 4-)%A*_DS^-W_!*KXLZ)^V!HGBWQ1\*M8UKPEJMKX6U
M32[R'Q3H.E>&)-=B,$=Q;^(=<O%DN)-/L'AQ<?8]/\ZXMFC82Q3*Z5_1#H/C
M?QE\)O%OP>^$/P\TV'4=<MM2T"]\8:]IJ2R7'B2^U>YA;5;'38FPUKHL=S)Y
M&GEU,L\<*3R;5;%9XJJIK#RI:N&LK7T=XKDDHI-IZNWY.QI"+Y9R?2-E>^^C
MOY>I_3K\)[2.U\;^'((=H2WAU%2(\A2W]FW>YB#_ 'F.2/[QZ=Z_RX/^"AG'
M[=G[8 ^;:?VC_BLO'!_Y&W401@G &._KCUX_U'_A#)/)XR\/27<(MKJ6UN7N
MX-X?R;I])G,T.Y1M/ER;E)'&1W'-?Y<G_!0Q=O[=G[808#C]H[XJDMN!VY\6
MZB<A1R>.OICM7QGB$V\LRYVM?%NZ[/ZOK;?_ (?ST/R3Q=?_  FY7M_O\O\
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M_P#"IB_Q T(*V1Y>HNV<Y8G3KOIR>A'.>O))SFO\N7_@H21_PW;^V(&.\/\
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M8O,I8;%SG7>&I2FJ2>'M'FDK*,I7T3U:5^Y_(*T8P1)DD(=N,@>8,[0H4 $
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M%/V#2O#GB2RU6/5=,\/_ !)NO %HB2ZA!H\D6N3)%#J]_I:0S"SM9D!N)'8
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MW%ZY^Z!S^5%%/V-.S7)'7=VBW][BV.[[O[W_ )AL7^ZO_?(Z4;$_NK_WR/\
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L>PI?R+\.R7\O9)>B2VT"[[O[V*%4=% SUP *6BBM4E%)1226R227W)(#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>vc051_img13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img13.jpg
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MIM_]GT?F%S[*];*I;:,72K%D^>3+B:?<3&N']=[G_0^C\PN?97K%\NNME_\
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M/G[]6VXR4JT99;P>/4$MR-Z430TJ:ZMTRZF6U0070:"E?4=5SL2N8TR*YXO
MN#RDB@2:'O\ FU#Y1]171A3;HY 2 ./KXGLU%PT/3U%\+TH1TE_BUX ?/O\
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MZB6M0WI&N 5W<JHCH-=;=M)5>(*I,O)$35V2\M067GY;EHNK<-EAUMAYV6Y
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M5C[;3G4*^XG>9CS=ZL?2_P#=RPW#[\32VTEA,!Q<];*G QX:Z.I94CEAB_G
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M"!1'AQV4\O$]]=9KEU5TTQ(%W:3V$U'JU1.2ED)FW>@9_P =G2<#8?I$Q?\
MW5B=G^AT6_Q(OM7TBDL'W,])6NR<\K0!6@#AK\5N>U$ZF]*4+4 I> WM2:FG
M#($#\.N5S#\2/=]9JV_A?><I/MAHD%3J>7M%1^$@GCK!0T4Z0H7EC85138<?
MU] 4%#=XX_9)I7OKH"@FN[L&G*H#OH:?A&@,"S[4;(W6@^GFX?3I/)L*=1(_
MHE(4JP7UP\H0W=VGTK/LH*7X,=NO,HTH%-FNM.UG54EX2*XC=%!U-GR[C%"2
M?>(SAH:)0ZAP$FM-T*4*U[..NBKL%'3T$U"ZO%!T&-R:W5*DN-!"S]:HY1Z
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M?RNLMYZ,%D,B7C&8)?DO N*3XCBU_6V!4XNG?L>[6=I/#H D]]N#[F\W,/\
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M2YR+CU/ZB71F0\$S<ZR>0DAYP>RN\S5(IRKY4T[*4X:IO04L>D9L# .N/4+
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M,I+RR$5575FU:C>4GDCG;[9-QHEC4]RGEC$RZ>5SRVY(\\[+CWOH5T;GQK;
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MR(E927$-<Q*DM@C85IW:\UOE&$J7N)=EUREEVXFRU.]=^&&B,7T*-*DNBBH
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M:BNB'5$G@!3^F(&CY+KFO4R:WFKPP?K1F%E^#I;[5&2P?.5@+O*D)JWT3ZG
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M.D?06^$3OOOO]74/F.SV_N W5Y:@?T]],Q0[7V5O3^P=VU;8N<2]'"E&5W?
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MWUIG.Q*T[<DI)9-Y]XOI'Q68=.LTO>-](<ORZP1L"R[H/TD>?R 7>W*@XOU
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M94^@[=NLO]SJ'@*^$GW/ZNWN->/9]O?@KI_W*9= L*D$<A2#EV5[?WSY ?\
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MYT@C>N_9OJD=:BP<2=Q7YM&0Q9"SMQY=]MO3^/4XMMXB#FG"-B24D5 /$'L
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M9C_M\6O_ '>NGI74O4-2EUL43.C*J ]'!'YST< _+XU-&E=@A5B?$+J![U"
M40*JGP1RUKNH"0I0 IW:*!0/;DMK "5DBE0L'F0H5-%)6DE*@:;'2EX14'7Q
MA[E];^IW&I_P@X_BU55TSZ/K%0YU9C+5]\,MJNM,IR*GLC;]V)O?72EXGWC2
MP,>3*54$*/$;\HH#Z](82B4X5"IKQWV[CZ#H ,1*/+NJA'90;U/J&@,R[WLG
M@HG_ $(TLLQT?47OW%J,P]*D/H8CQVEO/O.T0VTRVDK<=6NE$MMH25*/8!73
M6.0C9L7IGFTIEB0W A(:?:0^TI=RA-<S:QS(*D..A:2I.X! V.GP+]S&U@@[
MPY/3#-6P2N+;0#M7[8MO?7_7QH>UW:S: 43TXS--.5BV5'#]V;;OO7AX_P"/
M3^4WJ>(=G27JP7,$&BXUL!&Q_=NV<?5XXTOEMU6E54>ETK3 (1BF2-I"2Q!)
M'&EWM7'Y96^CY7=]:%@%)QZ\@'G:B$]@%TMA^3:7QKIK;;M/4Z:5F((CV6ZH
M)+D=A">_[2@$_)1]0U?0:84J#/;  9:5Z?M"%Z^/C4T4Q N1&G#]@T-N FPE
M4^9ZNAX!4(2)212C).P/\]Q>SO\ VW?3C74J!CTA[;SBE *3%2-J4E1B>/9^
MVC?6N>2[@"P^EO9:F4]H/O#"M_4%UU !9,Q('-XR"!Q"5M*] K^V:*/HJ 4B
MX1TA!*G"14D(4WVFM111H-"KTY %(O$($\Q=!V_8)/T\XKIT8'U%]@+4$\[@
MYMJ\J>[^3T4 *^TX(H?&)H1^Q [?Y/2QZ4Z 7&[0@*^)]*!_JJZ,@+/MB&>#
MB:^E20/]-H ^,7R"_)7$;4I3[;")"Z));#:EJ;H715 <YDGV:UIOJNYBE031
M(?RR/)7UZZ9 #^KLKM_L'=N'?I;?\:/>5W/ SNCKKF(K0!6@#BM\5Q[PLJZ,
M '=5@S#;_P"\+&/QZY7,/''N-6W\+[SDBJ2H&G,#_*_DU@-'H+?>SVJ^@'\6
M@"Y,GF-.<?,-9Y-U>8&\N@9I:<O:0:4SB<^LT_9S+)9GUJ[A58.NQM:4] &Z
M;[?[3C-KD7F^SA!MD9<9IV2IMYX^+-DM0HC#3$9IY]]^3+?0VA"$*4I2@ #K
M;9M3OW8V;"K>DU1+%]].KM,=V[;V]J5^\]-F*JWU)8OT]@UV?-L4O\:Z2K->
MHEP19');%XCMK#<^V2(/B"3'GVYT-3H;K:VU) =;1S*20*D'6R]R[F.WNJWN
M+<N))T3TNGT&2QS?EV\M2GMMY_9BJR6%?W&/(ZL].'<?N>5IRRV-X_9E11=I
M[RWFDV[WY$-<)4EE37O*&I29[/(YX9;//QJ% 3CR#F5N[';QMZKEUU46J5]?
M4)<_Y9<MRW,MTW;LJC:6'I?O&W".L/3/J:_.B8'E]KR.=;V%2;A$A&4F3#C>
M\)C(D/LR([/*P\XM/AJ!(6E04/9()OYOY?YER1Q^=L<*U/)];SH+E/F'EG.X
MREL;_%G!XKH2[UTF?/ %(2"I)/$I5O\ K:X4Z41V4ZC>M)*2:DT2>._9Z]5\
M31@(!4H<I%=SV!0[^[?1JUXL8,0-_:IMPKMP[M%$ ,I- ?:V%?E^GMT )Z +
M.7O4H_+^6N@*%BJ5V-=N^NBB ^;?FI/I(J= 'RE2-AN:<-A6I_%H"@LI(4!6
MM!VGE/H_9)(&^C #X&P-_3^:CYOJ:, %DH2H5H"17>B?P 4[=%$!>$@;4'S
M?@ T %) Y1L/F&L\D]3$RY3=$E5*]M.75ZR0Q,IK4*"!4'BVFO ]^B2P8&56
MQZL")[/+1E":5IL/DUG$ZU,C\8>X</ZE4X]OWC]6BF'[=8CF[F,I7WSR\*)
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M' ?>K(Z<?Z\S:ZRS\3[R^,XN*Q,=;)"30D5._P E*:B-SBT\<:#JPX"*UJ2
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M"250)214BFU#M\E?PZA/PD -7U3ZCJEY#&Y\D\Q_-H!_*UTP&U9(-.PC\N@
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ME=CQ#+.D]HNL6_\ 3/-7+]9(SLK/<(RBQW?"I]I#;!C12V51TJBRO>&RHD#
M;LU\B?F@NF%]"L=Q2RX9;V<.PR^87E4.]=7IL6X0,>8ZS0<WQ.(].M6&W+&K
MS>58A[_!FO1+;&CQS,"8WLM(&@ &Z^13KSD_1CI#TMO/3[ L?/0NZ]2'+$[A
M^;18[.7._:^.P>G>:W5$.VVN4YF[]M=FS'G93ZXB(\!IB3'?==0$ #-G?D)\
MP+O2;/\ IOB^!8GD$^[=?K+EV)91FN4XXW=8V*8;B,ZWM9*MJ,M;<.7F>1S_
M  G(GBJ6+<EQ4A 4I*  2W^')Y=>K7EUL75FT=6\*PJQ73+,GM%]M628O=;9
M=+C>8,>U_9KMGNWN"EJAQ;0N,EZ,V"&N>2\0D*4I2@L5NJK4Z7C@/4-(J>#/
MNF HV@+50F@H3Z32FP])T $!MM.QJ2L&@/';C4_)W:!@CH#1H#S</1Q%:=O#
M0(U?-ELKO$]L+2%(E+0H<U2*(1N104WU5=\ R3OD^5S>93I$:4_?'.]/][UZ
MUDVOXZ[_ *BN[X&>CG79,)6@"M '##XOTI$7*>A_,H@KQ_-Z )KLF?CX_P!7
M]&N5S#\2/W7])JV_A?><9UW5LG99I3M 'ZN.L!HP_:HJW<T$ <W&N]$GM.@,
M ANX(YOYH/E'>0/V-3VZ!0^.3B<+/,GYUNM>(=:>K.(V;/,AQFQ6&_2,=M%M
MQR<[9DN6R*W'<"9TB&_%DS%.OU=*E*)!.VW'EQO7+>X=I-M'T_DG)N7WMNKU
MQ)NBZ"!.3>>#K:]*=",\O3:E*VE?;%Y=F*/85O.S7N9STUK770MW97(UR.CO
M+.PV\6E%-T[CH+Y.?B#=<V4VB#DF7W3+K4NX",["O<A<Q]F*AU+:/=YSJQ+2
MZE*J@+4H* UTMJY4Q>!XKF,+<ZN&#/3]TFS=G.,<BW9A:BEQA#CC#FSK"U(2
MKPW!O3ZW'@=;3SSU1EI:P-GJ?613@.S@?Q#49+4J"E'4@)Q7,E:J4^J*<>\?
MCU'A]I#A]H$M-1QX$'YM^\'1P^T.%VD)LN\CG1S+LMOO4:;=^I4/JM<\TAYE
M:NJD',*YOA2K:B:Q Q7"94ZVS;58<*8C3W4+MZ8BTR"4K>4XM"%)-#Z&'#[3
M$<D^';T#RJ)8;9>+MU7<MEEQ#$\%EQH_4&;%DY)C6'9'=LRML6^7EF(B^(E2
MLMNQN,F3"DQ)"Y$=GD6A#81I?,NV^&U6G25R5)4&J[_#UZ+7?I+;>@T_*^LS
M_2BRW^[7RQ8NO.HKHLR+M%7%<M$6ZR,??NB[;%]XDN,N..KG!V8\I<A?/M8M
MS55I[1!F$?#[Z$8)B/5;!+==.J%VQ7K19;C9<\MM_P U$UR=]I7-Z[KO46XQ
M[3"N<?(8MPD.N1Y)>6EDNK"6PE1&H.Y7H R^Q>4K%K7D6+Y%?^K77[J(O"WI
M<W&+)U ZC,77'+7=9-CGXZW=Q;+98+,J;.@6NZ/HC^\..M-J<YR@K 4*TZ-/
MM TC#^%EY2+78C8K-;^J%I29N)S$7*-U<S1^?&&'RI4B!#@HFW&3;H$.8BXS
M&9 :82Y[O.D--+:0X1J]WZJE -SRO)GTBDW7)\@1/SF/DF6M=01=,E1D,:7>
MFIO42XXG.EW6WR;E:IS,6X8LS@]KB60^&INW18:$I2I8Y]5RFVJ9 :VS#X:W
MEESUG#HN4(ZFS8N#8'C_ $TQF(SU"FQHENQ7'(MRC08[;'N+O\^257B6]*>"
M@J1(D+6JA">6*DTP)0="NA>#>77!OT<]-EY&G%Q?;SD;,3)+Z]D#\2Y7^3[[
M=A!D/LL*BPI4Y2W_  $CPTNN+4*<U-.4M0&ZP/"4@4Y^95.&P]--]]52AJZ0
M"1[1 X?JKIQCI5 "VD* %*'8]M#Q[M]2 70% [@ 4[Z]WHT *Z &#(U)CV>8
MXM1 "4;T[?%;'?V5KI77H=%B!A\.>TOE"%$A55G8<2:D>CCJESJJ 9?SI^SN
M/]1N;AV?>JGX=0H1ICZ3EOGG6/$F<[SAI>104K:S+*6EI#A!2IN^W!"DFB=R
M"*:QSF]3HEFQK(Q']->%'ZV26]1[*K=5^!O4>(ZY8#%FNM>$#FKD=N IQ+CJ
M?PMZFYQZ,PP%1UIP8[C)+:1WAU=/^YZAQ'U $IZX8(A 3]Y[<D]M5K-#OL/8
M.I1FY.@,N/7?I^GCD]M&QKRN.$FFY%/#XZGPYW/ \@^+^!M2[#E#\6]N79O,
MWCE\7(F-0>HW0_IKD6-R6+9=%0IK-EL#EJN+*;DJ*BWNSFEPO%6VVXXIMI:"
MJA5362]MI:U&:3P/J?EKFMFWL7MY3TW*_4<'\VS1F=-;:8E/R7?> V/=VGTC
MF*RCPR7FVN85XD#6NSMHVUAF4[[G6XA<DK<VXTH2E@7V1;<?Q4SIRH:A$5#A
M!YT,K=E!F&X&FR"270V. W/"FI7K</&U63'Y:YO&QNG+<-/'"O2:]S?*W ^^
MS-N;;$MI2O$#KH1(96*#PUA:0ZVL5%0=]<M6N)<>"I4]#SCG\9N4EIC5]'03
ML\I6172%B.//QKA.9?<N$Z7'D1Y#S7.ER6"V\%H4@D*Y33:GKUT=JFG3H1\R
MYINX;G=_W5%X'IQ\L75:ZS+3C]OR&4[/"V4);F\]7$410"25#F<(X5UVU.#=
M*GGEF=$6I#;D=LI?0I"VTD?6((4*T^J.S4VH=#Q+Y*JH8O=,]PFQ.^[7C*\=
MM+XXLW&\VZ$Z#V@M29+;@W[QJ-"'#7;4^Q<UQ.[I4BTY1C]P5W0;O EJW&P*
M6'UTKH#AQ%#<82Z<LE"SONFB@>'<=.@N&@E \9M8-%'B#QH"-ODKI#X:ZQ)4
M<( 40FM>%>[YM!"2TNF(DIM"^*1MP]'J]>@A5B?@-]V@L5QI4% RK:E.78;D
M@CT[)5MH*WCB&^[ <0D?+H'Z3ZB.D+K['U2./?\ CT 7K9H4@<FU>!T !R&%
M*'-0"E*$=H/ ^HZ ="#%YZKXY%ZIY?BZ[O&;N5KO3D1Z(XKW=U#I2WS)3XH0
MASEYN"2=8YW9-N-%0#H+Y*+XW,\RG1Q'.%*>R.8$GF!YQ]V[X00*DTH-1V\4
MKR[7]1"[^&STOZZY@*T 5H \Y7QT^I5IP',?+JQ<O>N:Z8SU%6R6&%.I BW/
M%4JYE!2:&KXVURN8?B1[F:]OX7WG!$>8_#%?65<PL42H"&:52D5V*SOKF2FX
MO#(UQA6-15/F3PU/L)5<JCM]QJ=]^Q1[]1XDL\!.W*N&0JWYE,/YOKW(&AJ1
M ))[#MS#3XDNI%*5RW)M)9G!SSTR&D>86XY1;&42;#U80[=;.XIUQNXM7^W6
MF#$NT.=&>0Q$B15R6PII:'5T0KA4ZRNQ%W.+5ZO8>TY)S[A6N!<2IZ3F!?\
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M1R4H10U!)KWBFU*:25%00*ME::;C?O!U( )32MN:O;P!]'?70!;X7H5^KY-
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M$CVC35M[REY15O#;[:M5_P!N'N*I>:>=R>J5ZZWVSE[QJ>ZR^<)<9^4YU/\
M,&IF+.1:Y:W,QS@"-<EJ90F!("YH\&2526P$JH3XB>\:A<\I^38V5.Y8VZ5?
M_''W$H>9>>S=+5RZW3[3]XI(R[SM3)9MZLK\QRI:(B+A[JYDN>)>3#7R4EI;
M<G-E3'MBJ@:<1Q! YL.5>0XSE#@[?#_Z</<6?G_/G^+.XNKXG[S%_OKYL9$=
MQXYIUY>B)F_9KCR<ES0Q_M#Q51Q%\?W_ ,)3A>04>R5)YQ2M=M:[7*O)C3X%
MFQ3I_MQS]0OSGG4\5=N_U2]X@_?O-0)+<65D/79,R08X:CO9#FA??]Z?>BQ2
MA/OX)1(D1UH0K@5(/9OJ]\H\I<*O!L5_^W'W#_/.=6_AXMW^N7O&\S?,K<1;
MW/MGK5*%VD.1+:I60YB439#+JHRV8ZU7$-K6B0VI!H>*%4KRFF9;+RI!:>#8
M_HC[A_G_ #K_ ,M[^N7O&J\)Z\6^7(MM\N/5)B9&ALW"3!N-\R=;S,.0):X\
MA3*Y[A*7DP'RFE5$-+V]DZN7+O+DHIPV]C2__IQ]PGSWG&?%N_U2$KO9.K=E
MLD#(\A<S"+9+BJ,W"N,R_P QQJ09D=R5&'A?:;DII+S+2E)*T)!]>JGRGD<J
MO@V>SX(^XPO<<PD]3OW:MU\<O>;9\M4JX2\RN[TR=<)7@6+E2B3-DR$5>G,A
M2^5YU8YN5-*TKKX7^N.UVVUY/M[FUMPMW)357&*BWCDVDCZW^F=V[>W=R-V4
MI12=$VW3UDZ8RP5T*:[$[T('9K\PO'%YGVHV#X?[@]G]RM?E_21IUP_;K$:;
MZCK*^I/4<GLS_- !_P"4MTUGGXWWL[4/ NY&#.K]GAZ./?MW:B2I7#K&UU7.
ME0I3E)'?6GS'10. H_$-WB <U=JTWKPX#N]&@Y^Y3KZ2WQ$?G#Z=&!EHRP;K
M'<5;GNXD&G=^#5UF24G%NE8LE&F'WHG7GR0=7NFW3*=-N&?=0,,P=&;=,>GV
M+8[/S#)&,;M<_*<9R1J4]8G;L\0W:[F]:XKCD;Q2AIXIY>:I /U??;2%K]/]
MG=K%SXN.*;]/2>"Y?*2\_P"[C%/3*UG3#UFA?B9>:/H=:[1<1-ZD]%3!\7J"
M9EOLN;,Y_E5_NUPC1$6.;;['9[Q>&TN7%]#B9"'4,,-)".6@&O%1N*[=;PH>
MPN[1J#3KX#BU\#W(+=(\_O3*/-E.L0+G#SUB4TQ&C3YIB7'%;RHA%OD/-IFN
MMM_62%; $@B@.M]RS&5NM4><V.UI?;>#J>LWJ7+1D'4;IA)L<_"Y&,MY;U##
M :L=P;R-R[1$PXMR3;'Y4528<>-22)*BZ@ON%M0)Y:ZXTXZ9M=IZ1+3\)RP^
M%^X+GYH?BV1X4VYI:'5>TJ<5C;\>9=)-;KU'5X,.W+:D0KKX99)<2LT: *Q4
MH(,#GV-L]<I95;.P76B[W2ZWO%8E]?GRICN=O62VK&+M/-V>._8F[5%:F2OL
MN>;7$3,4")"7(RI:%A ]C<)TTG:V_A.;G7FW.8-&\H6!2WV;M=+?Y]/+$F=>
MDHCQG;C-?S.1*:7[BTVA,=MIAY3:"5'9'#VM4Q;U(GS#\*!U:RS(<^L4C+UX
MQ?+%-RF\)Z;VB7#R*Q>&N-;%7^>[<8$FX0I#<!=PEV*W/(8=;<\-AUA*B55*
M=7G,MQURTK,YW9Q:6KG%NN=H;Q"58\5S?J9"3:K-"DH"[A<I-OEVXB1>%R%-
MN,2:NRGRI")"G X$A("1=M[G#OQ?1J1>]LN%<KGH?U'B_LU\MHRB^R)=PMT<
MR+K=GE%4QE*0X[<9"N3F6L$CV^--?HSRGOMG&U"5^4%1+I2^L^2\\V<W!T3S
M?1^XF+TAZAVW$9L:]V_)<:C7"*EUME$^X6J1&<;D-K9>2_$DNE#Z%-J(H1MQ
M&^OO_*O,G)W95JY<MJWA7XH^\^/<RY?N5?XEO;3NS5:825,21+OF:O*HTR&U
MG&%0X=PEPIDN+!<LD>(Z[ 9;9C),5+Y8\-'@MK^KSAQI!"A2A[WYGY-SXUNO
MWXY^LQ+_ ' UAL)T74G[@<^96Y)O2LB.7=/W[HY;GK.])?8QYY3]JE./O38#
MY=<65-SI$EUQQ>SQ6XHA::BE,M[Y/F]2WMN'\M8NGM](5\PK#Y&:]8Y(\X^8
MQ(N-06>H>&HAXE&5%L$52[*8]O;5","C;7CA/,B.?8.W(I*2F@%-996_(UR3
MG/F$-3Q>,?>:(;KS#&*7"G&BRTR=/881<O,K<KC<&;F_G>(HEL7N/?V51YMI
M:;3/BW5V]I2MDOEIZ(_=GB^ZTL*2M:4UV2-9G+R@FTN80T_>CEZR7#\PR^);
M.XZXU^(=9/G'SAZ5-E.=3\9YKG;D6JX-%['Q&EVY FI,=V,5K97SB>Y59!7]
M6A 2-52L>18Q<H[^WJ2JL8FI/S$W3Y.:[<<.TQQ/FIR6*Y#?:ZJV9AVWQ'H4
M.2;E9'I3,61$@P7& ^Z7'%-B/;60FIJGDVWUACN?)[DD]_;IWQ]Y<]OYAG%Q
M4)>B+,4E^8A#R8Z7>H^/L.1ILFX19<678XTUB3-5/5+<;G1F4RUJDFYOA?,L
MA07P]E--/YSY0L_VEOK=.^)3'EO/W*KL2N/JTOW D7(6.IM_>7;LBMV47^:&
M7'FK>^Q)EK:92U%2M;$042VVA"4E7*   5&N^LN_\Q>5K>RN<'=PN3<&E&J7
M0\<S;L^4\YN;^PKNUE;@KJ=:-]>&1U0M%O668Z%#E#+##)3Q*5--ALI/9MR=
MFOP!S*\KW,MU.'X;W$Z>L_5^SC=AM+=NZDJ061T;^&(TEKS\>6$)_P .KJ#Z
M?WC99K+9==Q#O++_ .#(]V&NR<DK0!6@#RM_YQG_ ';>5;_Q4ZL?)^ZN#[ZY
M?,/''N.CL+7$J^BIYJ) Y%%7&IX\.P=N^N3<:U>@[FA0P&Q\\QJ.!21MN!Q&
MJ^FI5>5(5&)]2D%T#M ]K\FF8KOX:KU$M_(MF.-8-U?R"Z9EDF.8M8)'3;*X
M;][S"<BT8O$F2'K6FV"^75Q246^"[<?#075%*4J4*D"IT;?/TF=)O)$\?-3U
MZZ7V>VW>>_GOETLT4YC9[[=,IN/4?'YMQR7'3:[G'NMUAP[7D5PEW*YP69#+
M,-IA@I=9KRH!!UTFT#C+J9(K!NI;TFRX)U P;(\.N-JNO2J?<,,CW^UR;4Y+
ML$Y-HE09\=2'H*1;U09#;$5QQ'BNO2$>(4I20H30J$<L\DY-U,R').G=RNV&
M1[D]@^&72/C[L\W:ZP7(BK.Y/6] DPU0%6]I5P4&@ZMY2F5@\@Y^?6&ZOCP)
MP7Q9'/;S_P 23B]J\K\)UQR>J\^>3H'>)!#C(BVZ7 NT:U*M]OAM'FCV_P )
MA3@64H2I:MD\U2;-NGKZ<BK=XP7>>@7/)US<ZH6^]IQN&\QCO4?.6)EPM.2T
M1_.S%N>ALSXJV9TIV9+?C-F1&:+"64@N':H/6>$50Y[2(*==,CR7J+;F;%'M
M=HM,G-<1Z@/'';ZM<B6W<7)?.B$7_!C!V(II@*></B!#:>3E'$P[RVW@F>87
MXK2!!ZM]); IEJ/+L72.) N3K+;3<5^ZM7R:B>J'RJ"W&1(94 I0"E"FOHWD
MB48P;;26I]G4><\P/5%)9X$$L,2M3#9&Y2KG![:@GLI37W;R]C.TXXQJ\?2S
MYISZNA]=/J)?X\R'[5'7N E&PI6M37CMK] <JV[E&,GX6D?*-\T[DJ9U8\*C
M)4DI"2/4FNNXT\GD<CC23I3V SD2@Y!S"O:4"O=38)VUE6V-'S&G&F1M''^I
M]RQO$D8FU8+#-88:G,LW*4+JW<$,SEWI2D4BW%B(HM&_R0E1;YB%)J?933%N
M.1?,O5J]HX<RT23TY=AETGS&YG*N;EX?LV,N2W;8U:"XJ-,:<5";=1,4T](8
MDM.R Y=&@_[=5)W;"@@TU@N>6EII4O\ S?5\+CAW&.,=;K_$M5WM'V'9G8=W
MO@R21XT_()"VKR)[4\JBIDW-V,Q:E+CM@PDMAA19;4L*Y -8K_E>U<MZ;K>F
MIIVG-E;N-T6*,_G><KJ3<\A.33[%C<BXHLYLL8*1<$LL1?M.7<N8-HD!+RZS
M7&^5P+:Y35*4D"G#?E.S;N5LIXFRYSA7$NBAK/\ 3SEK9M*6(<5F%:KO9KG]
ME*E7%ZTW"+8[A<KK$M%P@.2/#>B+N5T6ZZO9UPMMA2CR ZW2\NV(V^'<6,NH
MC#F$7-7,/A-B)\XO4AN^&^,V+$@X[:H5HD0I,*=-B2X\"9<);#C_ (\LO+=1
M]I+0FB@$I (WWUEAY2VB6<LRR_S979ZL,%0P]OS'YXW$M4,6S''H]DN4*X6G
MWF"ZZJ+[@Y?GF8BSXR3(CEZ_K*O$JI8:0%$DJ)E;\G[2%QWL6F4_F<0.]^8'
M*LBN-WN5[L>/S)=U8A,)6E5ZB_9*[>BXIB2[0J)=6%19S*[ASAW=7.RV> (5
MJ?(DL(^'H*);M3;E7,PS(^I>3Y?88&-W@P'8UO=AJC2&HZH\GW>!%7$C1%\K
MO@K11Q3BE%'B*<-:@;:@^6QVVYJFGA]1>MTJ=!N?RQ0G&[CE,LH5S)AV^.D$
M"H\1^0M>]"=PV/FU^=/_ .AK\IV-CM$G2$*O#Z?WGV/]*HN_N+UR2I2+?5T$
MW[?%*4\ZDU)%=P13@=J]NORS6I]E,[V^POJ'^YFE*G_G%IW=^^I]'H^L#174
M-T?I+ZCI(J#U S;ZNYVR:Z:C-K4\5F=F'@7<C#U*"Q2A&_;L?DXZC5=:)#<M
M)05FAH5$BO;4Z &MX .5KN4]X[R=,C.*G'2\A/2*?EH"P 20I( 4#6O;\_IK
MJ4+=J[)0NJJ?3U X6K<7&47)2(+>:Z9<9]ULL'PEBTVF=:UJ'+^U.R9,A/B/
M*!^LXAL!(.] =M;)W]].U\DKB6V3#E^TVFVW/SBC\2PH<TNHUN=E7V]LQ(CK
MCGVI,JF,R.:BGE %5*&GI.M]B2>FF450T\Q=N=7:6>-.T+Z:1>H/33+<>ZBX
MGD=\PC*,5FQ[OC^18]<I-IOUIGM&C<F%/B.(>C/@*(-#1224D$$C3O;C1<<>
MA'%V%NU<O\*]!ZJ]1T0ZH_$=\Z657"U8]EWF3ZC2,:,6U.3VX,FTV:X26Y\1
MM4]<J\V.U6^ZNB62?%'C>W4\Q.H?,2Z#T]WE^SM6E*W&LJ9(ZB_YMU(D'(?.
MZY<7Q$M^3P^FRDW2YIEJ::D.3<]>-WE3H@7=HZ&E%*EOLFKBEE"B>96A24LL
MSR-V$HS=4TJL]"?4I=Q<SW"(5LBKOUMB]3LGF7+*(G4$AN%-C0%6YV))M34D
M*OJY:7'2N,XVH15(!(05$AM?"6;>4:4;2.8OG$R"S6_JQY6[;-NULMCSGGU\
MLMQYYD@0W!$M5XD2)LAR3+4VCW:.'$D\A"&:U*JJ&J(>)(MWRUVXZ<6CN%U
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MO'8Z7_(GG*"_N;W<-^D:\J<CIAM+'L$_NYFO^'65_P!LI(^D$'2_Y&\W/_\
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MU).P^<:HUQ#1+J+'<< 4>5(YC0#V33L[=&N/6#C<6,5B)C&RI0"F16G+S5%
M:\>6ATZVY>)X E=?B6!1QAQ)H2:^ANOX-/\ L=?TAHEU"0QI1-5I.PVH.WY!
MJJ<;$G@QZ)=17W:/YI_ZK4-%GK]@:&5]VZ#=L?*#IZ+77[ T/J$%8YN3RT%3
M^<!^'1HL]?L#1(^-V=#:T)2GEYU<>51[-Z[=NL^B5>PM1T9\NL7[)Q$,*'*9
M#P= W I78'T@#7(YE^)V5->V\)(U3YXJ!X?G=E/737/P- \^\#[!X?WM4_\
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M^IF>VWR09ZA"1^E#R<'8@%OSV^3MP;\:E/6E5::W68[A1>7K1'6NWU/W#M_
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MHH&M=3]04KIY+ _ICA"AMQZF],P?IS ?@T8AJ[&?1T\F[4GX/7_WG=,JU_\
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DT_NVP>E?TD\]:_>.E>7;U[<=M2X>'BCEU]H<15\,L^KL/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>vc051_img14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #1 4 # 2(  A$! Q$!_\0
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M]E_SXS_]]K_\71_PE]E_SXS_ /?:_P#Q=<+_ , 7\UI <\!!^8_PH_M7'?\
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M?H?PHU#X%:+\#OAOIGP8U6"6VU+X7V>@)%X,OX)IUNI8;C2/.9722X59F&\
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M,@$GY02,?Q8!/7'-6U\,>&WQCQ%,,X^]$B]<=<XY&>G7/0&C^PLT_P"@=?\
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M?^$]?_Y \HHKU?\ X5M:_P#04N?^^(?\:/\ A6UK_P!!2Y_[XA_QH_L+-/\
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M; _A7V[N3^/.34R5UNXVUNOU#^MK_@5OD]?_ !T?_$TY,>8,="IW$#'0KMY
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MW^*&N0D$7\X*G()EW<X"DX^@R!ZDY/'/!2:'R3L;)P/NJ2,+P>_  ' R,\5
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M] IX8<X]<],,?XL9Y!'7IG-=M$4,,+QCMCDY(/1\#'&.N>IR,9XFT^/7@&7
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M"D@#K@<#YBU-.2&/7=A!NP#W5' 7/.6SV.#DC@"GKSSWR0>_0D''MG./Z=
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M,$4 ?L-X9URV\2:'IVM6C;H;ZVCF7U#%1O!R!C#9&.1[GK6[7SA^S'JDVH>
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MD'YB1G@X''7&4%QUP<8QQ[<GZDYZ=L#M0 @4>B@ =@0<E5!'7H,8^OIC+/\
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MI3E'X9->C?XJ]CZ%TG]I;XFV!$>HP:'KT0QN\VW-G.ZJ<?ZZ-F&\,?FX_B(
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M>W7L3F$L_(W$KEL'@L>0 N2I'S+\PR!G.">!EO.U2&.3UY'W@C$Y)XZ@#G@
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M:+:R3G)-U$/(G;.TF1I(\;FRV1NR6/7UKTZ61 !N(Z$ELX*D;1E<XYZ#GL<
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ML<@@KU^4 #LI4$Y"V"0>./E[DX'/XCC [UQ\GB.\F(6RTV1B"&#S,44D$#A
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MD8^PS=",X<G!.3R0<\\\YJ,ZVF.+&<]<[M^#D@] ,=<GI@=J/K^%_P"?C_\
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M<_2O6HS:(.+*0'&#A9.1[_+W[U86Z@7&VSE&,=5D/3IU7_(Z\TOK^%_Y^/\
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M3_Y6'UFA_P _%]TO\C1BMBNW"G&U<  DAA@8SC')^\2?<@-\HOQQ,/E!Z<L
M4W<L^=WS;5P3\HW$GUR& Q1X@A"@?8)LX )Q)S@8QC '_P!;KD\T_P#X2.+
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M@ J%_O\ _ 5_FU%%1+KZ+_TIDR^%^G^0VBBBLC$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
<F3[B_P"ZO\A116E/K\OU-*?7Y?J.HHHK0T/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>vc051_img15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #G B8# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"*SQZ^MQ:_ [_A7_BC6/"MM?:NS6B/=KXAO=*26QCG2UQ!=!@SX&5\-_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCX;ZGXOT#3_'.OV%QJNC^&;W5;2UU74K"WF6&:>TM)YDEG"NP4)&K2/ABBL
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M @C!XP1QR, =#^9[CFO)?B+XK\.?#_21J_BF2XM[)YO)66TM9+IE8 ,%9$Y
MQWQ][%?3M_IKV\DR2?*R90C^'@XZ]\9.3VX]\> ?';P'<>*?AOK<UO ;A-)A
M-W.54MY8.5&1M;'08W=SCH<4YU53CS5+<BG!/["_>3L^J5[Z[7;^\=/#NI%R
MC%>[I9I7VOII>VZV_4^-/$'[3_@*&>W-AH_B74;:>-9DU!=.C@A2%G*^8(YI
MDD=5P3\JG\37]^G_  ;6^)=!\6?\$[[76/#[W;6<_P 3O&!D:_C\F=YUO5,C
M;-S97((5@Q!&,'%?YYY^!_BGQ+X%N_&>GV<KZ)X?\.S)?;;-V1'AOFB+&<)\
MAPV-N,'#8)/%?UL_\$R_VHOB7^Q%_P $+D^+?PJL/#MUXNL?CIJVD6T/BNPN
M+[23;:G?N+EFMK>>VE:4*H,;"5<'+'.,5[;Q.6Y?@<7F]:<HT,MP=?%XN4(N
MHZ5&C0E5JN-.+;E+V<':$;2D]%J=O#?"V>\;<5\.<%</8:GB,]XMSW*^'<DP
MM?$4<'A\1FV<8RGE^7TJV,Q%J&&I5<36IQJ5ZK5.C%N<](L_MG!!Z'/;\JH6
M&J6&IBX:PO+6[2VN)+69[:XBG6*XA8K+!*8F;RYHF&UXWPRG&1S7\-/_ !$:
M?MZJ<#PY\"L \C_A#]8&?7IKPZ^O7'>O#OV7O^"SO[2G[/\ \=/&WQ1\5K:>
M._AY\4O%LGBGXD_"VT::SL+0W<ZOJ-W\/S<SW']CZI'%N:UM79K6\D58)0AD
M$B_GD/'/P_JXG!8:CCL=-XO$0P\JD\NQ-&GAG425*K6=2[E3E6E3HR]E&<J?
M/[6473A(_O3$_LJ/IA9?D?$6=9CPAPSAWD>3ULVP>78?C3(LRQN?3PLG4Q66
MY<L&X4:6.A@*>)QN'^O5\+AL4\/+"0Q-'$5:3E_;)^W'L/[+/Q;W#<O]@1D@
M=_\ 3K;'ZCK]:_F64HH+K$S[E^<MP5&6++GC*  8Q][KQGC^AK]I#XG:#\6?
MV$/%7Q5\,QZE;^&_'7P_T/Q1H\.MV-QI.JP6&K/97<,&I:?>*EQ9W<(E,4\,
MB\2(61G1E)_G)36HF5V+QJ%< 8?*,@8 KZD]1@#C'3M7Z5CJ,J]2G.#4HNE%
MJ2NDU)N2:ND_A:NK)IZ65FC_ #I2G1E6H5(2IU:56I1JPFN6=.K2G*G5ISC>
M5I0J4IQ=I23M>,I1:DY?-MMFN+<7@TT"UV(_ERS+-,C"146./"AWQM#.X"CD
MYYK4BEM[S2=*U'?;>=&K:>;=BSWC!BTANS'M*"%@/+)9RVX@@ 50O6BO=+F,
M:!)+A_, ?'(4L!D@=QD@ ^@.<9.?%(+33XF0KNA\I7&=J[MS!QG!)7H ??CT
MKD^JU'%1:NO6VM]/S_X85[]?O?\ F2:MJ5G%HNH6FH&XLC)_I%A)!;_:$ENH
M6(BMB&(6!9_O/.0?+"X Y(%^VF2^TO2=0FN8I;CR'LIK!89$FM(8PKPEYSF%
M_/?=A5^Z%!8@MBL;4@FI::D3F,,S;XT;[K%'#+@]N"<$CG)/H:9;W@M+(1MM
M!6:)>&(3=L;@$ G  YQ@G^:EA9M)6BK>:?E_7??J5&23?GYV^XZ6#9A]L:Q'
M  &[HX+$'G.X$?>Z =AT-:6AL#K>EJP.V/5+($\#.ZYB(*@$#'7 SU/H>.&.
MMAT9F9. 4*J1O^4]QZX+ $CN,CTV-'URW;5M)&0N=3L,?,"P N8%^;C&U,C"
M]B<=!4?5)QU:5DU?1/[4=;6?]>AHJG1Z)WZZ;/T_KT/[#_"'_(J>&<=/^$?T
M?_TWV]="2!U(KG?!Q!\(^%R.0?#VBD'V.G6Q'Z5\:?MW_MZ?"K]@/X?^&?B/
M\6/#WC7Q)HWBOQ9%X0TZS\"Z=::CJ<>I26$]^LT\=[=V<2VRPV[J[B7<&*@(
M1DCW,3B\+@,'5QF-Q%+#83"TO:XC$UI*%*C2CRISJ3=U"*<HIR>D;W>ATY#D
M&=\4YWE?#G#658[/<_SO&T<NR?)LLP\\7F.9X_$.:H8/!86DG4Q&(JN$^2E3
M3G)0GRIN-C[NR.N>/6J.I,O]G7_S#_CRN_TMY"??@ Y^E?SJI_P<L_L7 *K_
M  I_:*'9A_PBN@G@]>!XA&3@]B.>X/-<W_P3;_X+;>&/C[XK\6? S]HJ>#P;
MXBU37?%U]\'O'NLRVFDZ?XF\/7NJ:A-X>\'^)T\S[-I?BVRTJ:SMXY4D:UU
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M+)+LFG-S=,H=B/EAM\DCH,]<"OV U&.Q8.C64<$F,;HU^1B,G)! P>F!P,8
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M0S#+\SR[$3P>-P&/PE=5\)B\'B</*%;#XG#U:<*M&M2E"I2G%2C-25SVI?\
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M?^">?_!#?Q[\9/%7B7X@_M)RZKX+^$7@#Q9XAT;0M'L(I=-\3?%&]\*:O?6
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M5[IH_6;X#?&0WWP-^%-T+@.)OA[X;DWAV;)338XNN<_P]2>HYXP:_<#P9/\
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M-?AY>_#WPQ>>&;&R\+V.EW4%Y!>7[7S7%P]\C2+(KN4"H0NT#.<FOQ^\1?\
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M.<ZCYIR<G91N^R5DM+;!1116A!QWQ$F6W\ >.;A_N0>#_$TSG.,)%HM\['\
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MIZ*O0?2EI%Z#Z#^5+7Z@?F*5DEV27W:?H%%%% PHHHH **** "BBB@ HHHH
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-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>vc051_img16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img16.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1" !O F0# 1$  A$! Q$!_\0
MK  !  $$ @,!              @&!PD*!0L! @,$ 0$  04! 0
M     P$"! 4&!P@0   & @$# @0$! 0%!0$   $" P0%!@ '"!$2"1,4(934
M53$B%0I!42,687$R%X&A0B08\)'1,R49$0 " @$" P4&!0,"!P$!     0(#
M$1($(1,%,9'1(@9!45)3!PAA<8$R%*$C,T(5\+'!X6)R%O$E_]H # ,!  (1
M Q$ /P#?XP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@&-/EAO=Y*+2.MJE8J,S@R%DX*_P !MOC5
MRQN"$I(LY%JHV_MVV:C3K\>C'HE0-W*)J.P6/V&3.!0$#1N3S@J0[IUP*:>B
M*M'*:+5EIN1CX2-80SCR0ZJ!T]?N"MF351=[!R\?&D6<& I5%U2HIAU$Q@*
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MO5GB&Y1W:0IW]WP\/K>FS@(/)B:6G8F5G(./59JN$3K5IN^(X7<F5$B9FXJ
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M5(DW$YRVY@S-2\;<A$(&6_7W]\@W36L;-DE"IG%8SBY:W8,C*'_$BUK1$0'
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M45;N%B+7ZU?JMM'4&\(6'.J@Y=-G^TXND3[2?H$:J@V$AGC=O,QZ#@035<D
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MQW46G1*VVM/*XSI<5:DNUJ+E'S8TO*PV70UUS*XX;80U,M0=B?K9]V3M\JM
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M(RL75YJYOFKE9DP<(0_HURO/%^]X9NF8R/IE,*IB$-#9.%,YUV-*==-ELO\
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M[$UF V-M)&.*K<[/7Z<S(QK4 ZFG1UW+2!BT4RF*R;"@V46*"JA#JAWX!>7
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M)B@;UCJ=Y1+S_IOK>ZZCO=Y3/S;6IK0\+AGM7X_J9O7^E4]/A4T]-\HK,?\
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M :OI=\/6.^GQ'M/,C]UX&?+;@^FQR_N%^9Z7[MUX#5]+OAZQWT^(]IYD?NO
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M27-:S-XXR;][]OZG)=7ZC9U3?3W-G9^V/X1782IS<&L& , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8!ZF !_$>G\_B(?Y=>@AC R_9@\=OQ#\WP_E^/\ '^8B.4P_?P+6I.66
M^'N/?*EQXZ#_ #_]?^^"W#]YZ]"]0^)>O7X?SZ]/\_QZ93'XL+&>&#WRI<,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>vc051_img17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img17.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  < @H# 1$  A$! Q$!_\0
MG@ !  (" P$! 0            4&! <" P@) 0H! 0 " P
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M941PAW)?,^<>RMC?2^'0;3[;G@:P%;CK%$RHCA#N2^9\X]E;&^E\.@VGVW/
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M[ZZ#<X^8X@?RT4-G#FD8P-#F>SN:MY=&R-*VMJ;4+@E- :K4'%)0A*&9U.F
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MI<CNTLFJ5(T:9WF)RI<O,:DZ>EI+P 45=B6LA[-9AIS8" \#X4S***QHO+F
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D'2_3,8 ^Q^ & & & & & & & & & & & & & & & & & /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>vc051_img18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_img18.jpg
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MV(:T[ 9&KE8N^*K'!4AC(2+&FYV7FFT)<J))2R*D>>RL&\>D,K78=^B5,BX
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M._\ ML(UF.H>TMNDTTS93NO8[N/)YE>&-\SU>\,;ZWC"MW3H_LX6(TA4&WQ
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M9!WPHD^H'3I;N>D_:5L3Y&]5*?MCO_!?U4_^)YN_YXY"YT?*_NG&_P#Y>/\
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M--F6C5\EU;3C9;">6UH@QC1;_(6*<?35>=6%@8YCC]M<X#].FB@'Y2#(B0
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MFZ;8L@XY=Y$<34M074H]J[DEMR+:+='A'N9F.B9!0R+";3(K[MT_"I3 'D
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M7\#RPRC0JOR^+!9 *54HN"B4JK9H"2/@!*85/KYVI$1]M8WZ7\JBTUNJ)0(
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M).M8:E&PC-LI+/H!=@NP(HLJZ$BSJ.5=)IHG\&*:?QV4W'9L66+':VOV>/\
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MA,:5PMAN=X]VU 38%G.U 3U(%Z?E*1>Z^4X3!-HDYB:%"Q)LJ[%!<@=% NQ
MZ FU4S7[$.?[]JC'?N7L?4RQQ&XK?<EUM=^A&</5GK?K5K35?"\3B=*K_?E9
M/(4F)H5*>DA /G>MG+MRF<"BF4)6+FY7\/FX5.=CBVY"NO,'U6+<G8K>P5A'
MCJ8(L>P)A9UFD+LA9=.1Q^'[VR.6AX=Y6$&T<4- 2W'$EB 01WLE^^\@/I8H
MN.JC<0UX_P"X4O5-RYT0;"Y*J$BTLM"R14==[G6I1DX [2:JUMS!BJ7C';9R
M@8?4KZ*?E$IRCY+[>?Q#E7[IX^7"YOC>+SE*R1\[!$XU!ZNK6^T7L?(WK9P/
M(19W#9?)X;*4?BII%/4 [00#\5;0@]""" ;BM#]>MLD.GS;JG]5N1%[?(:3[
M;,CY6ZU\P7!T>:5J%^F8AG-Y2U)MUE)\:!G#28,M(5U11)%1;[PA#?(H]#X>
MECRAGR9?MSD) ?<O&/(8#>WU/'+))M.TWM+B_(UB08P21&!"CTIC?&QL/W%B
MJ%X+.CB7('7Z?.:-?4&L+195MP4BXD-E+[9G&U^MYPDX[V.^@R0@()ET;;G\
M>/\ K6^')5-4!\?Q P?7E-[5!'LG))Z'W+GG_6(_HKIO="E>>X\'_P#G\8_I
M=S6BMF];Z]W@[][SX;R) +3>NO79KS-:]8'FV[Z1AHU#??/%;C;;<,A$D6KA
M#]3L&%HJ#AH]) ?9LQ6.8ZA#BX\!$3$SFX'DO<^,2,^><8_'L+!D& XFR&CZ
MB\V4$@D=M&@_#558,YTRY6#'R_'<!+KBQQ?59ZD7#C*#0XZ'IZ$Q^Y,@7U=^
MY+%0JU*W23L=R/,](&0]I\P(JJ[.Z:X?V!QQGV =L$TY5CGK6".L4(LC8(LI
MSE3DIU&)BY)X'@J:AGIS%*4@@4-_OKG%EX+_ *NX5$6/E<:*6 #<B";)=8#:
MX)15R68[-=BV6^EZU^R^ E'N!?9/).>_@9?8DW'<W91>[&Q*V+;L?:%?^\(W
MWN36R^E#37&>M&A&'LT6^,B[ML;L71(W9_8W/=G9,;-D6Z7C*T&VN\D1Q;E6
MBTRI 5J)?(L6+-)3X"$0,H!!565,?J/<^)B>ULF7VUA';Q?%J8FL"-\D:COR
ML#=F9Y Y!:[; JW-KGG.!SY_=,8]RY5WSN0=F4M:ZQ%V$$8U(4+'MNH-@Q;P
ML!I?63LTZ,=P-^\5OL!?H<[O-+5+(N/\=75;7W)M!L)ZNFS=6.[Q2EFG*= 0
M*HJLX9P*:[DZCD$S+(HJ%*NJ12JXN*62+(/&JH6?&62:P +11D.+WU%B5) L
M6*K>^P6L^6FBA?'')N6,644BN20)9 8]+== 0";A;DBQ:YK9Q?N_JAIUW8=V
MQ=FZ-DFZ_P!>W/50U3+C_6NZ; I1R<!AELG+#+N*56;.YJYG"TDW^%-PFBFZ
M]#&*8QDQ *SVOEXY]FR88#?4CW#R3$[;#:9Y  &Z$W!TZ@:VL:NO<D4HYW&G
M)'9/"X:VOK?:#\OE\?'I5Y&"]X-1-Q\.;:DUBQWD2EOL?X<L 7!U?M:;Q@$T
MBWL=1MQHA",<W.I5D]C!N>)6%9-(5!;^Q#&  4*(Q_<22?\ 2W(3@CM?33"U
M_P!;LN0;?9I?[O&O/ 2QGW-@0&_=.1$U[&UA,@(W=+W(TOKU\*YMOVQ:LSHS
M9]9ZQ:KA(EUT[;]<+!D?$19EP16*B]S==+_9:KDG'[,2II)P[VTXJ(E(M!/Y
M_42M$D"G,J@!>==C2Y.;%E^UR-TF#CP\ACDVN^/-%&N8L?BS0RB-Y$_4B'=&
MC/;F<M,?&D@]S7_>,J3 R +_ (<BR,^&T@N1LE!DCC>U^ZYC.FTUF_[FRZ7K
M<NR;)ZNUN3EHO7#K2U/8[;Y\EH-=-%O8-GLHRS.K:_XUL"BI5@=-(ND33R8*
MW2*4WAVJHH<!23#GS[-Q\C9D>[G9#@X6=@\;C+J;Y&9D0_5R#2S&/&(2^Z\)
M)!%Y@*[?!GQ>YC^V$O\ F&=AYV=/Z1=<;"QY6QU#$W429(#,-I[BJMM(V(E#
MV=9:QY@B;_;;Y;RU$6&?QY2+.\DK3$U.@RN4;$_:KZJ5R.;HQ=!@F$I,V-;[
M]XD8R;9NLLD0!5*01)RSY&2.'^+3,]]OY3R@&E]3/C@?8+FY/AXZ7-57&JTO
M\,&VV!_,N).IMH(LLD?>- /$Z=:LJP!VR=;6<\U8SQ'B[#&;8C(M\LJ$13I6
MS:)Y;QY!QDT1LX>H/)&[6#'$5$5M%%-L;_BE7"9$S>/)@\^>7>-%+/(4A8!Q
M&[:MM]*(687/B5! 'ZQLHU(%5F1-''&#+=E+HMK;M68*NGD"02? :G0&J*]D
MM&,D;1=TO;EGW5NVV"C;UZ/UO1?-^JLBQF56E4NLN.&&R]UP]>X8H$3E8;*4
M+7R19#F62(11;XU_9LJL7E=Q&3G<-P<_N3C1W)(.<EBR(2 1D8<D;=Z(7N X
MMW$-CN*[!M8K(F_,AP>3YF+@>4].-D<29(90;-CY<<J]F:_BEV"O?Y5]8O8J
MTSNT_>3'W8/^VOS[LA2F#RL24\CBJI9-QQ,)K-K'BG,52S[C:*R)C>P,W)$G
M;=]7IQNI\)E2$.X8J(+^I05\!$]UPXD?+>W\CC7,W$97-X4N/(;>N)BY!)6Z
M[ELR/M)7>K;25L3:^SILMX>9Q.31(N9Q.(SX\B-22$D6%AI?7:]PR7UVFQ]0
M:NC0V-\>S^&F<I.T6G34JOA]BU7E9>LPDE)K-TZ01LFDJ^>L5W*B9&XB0"F,
M( 4?'CQ].3O<O[OR-M"R3W_0U57 ']Q!Z#L_[M5!?MO,=8]FNG'3B9F*%2I2
M8(TR6L65?U. =27SLLS7L&C@SY:/,Y,Y; @3T4$PG+Z%\#^4/'7^Y28I>.DB
MNLGY-@&XT-_IDN?M/4^9))U)KG^%]61RT;:Q_G6:+'46[I%K>5M+=+:=*MQW
M4_['&V/_ ':LZ?\ +"T<^4^_?^S.4_R4O^R:[SVM_P!R\?\ YV#_ )BU7G^W
M;_\ !<T%_P#I-,?^3(MUY](Y_P#?(O\ )8G_ +6&N#]N_NN1_G\O_P!Q)6N2
M_P#]+1O_ -/BW_Y5,?\ S\X_VQ^_>Z/^-QG_ "9*Z[W'_P#7^V__ %<C_N5M
MOOSV3RKJSU:[$Y"PC8G-.RG9E\<8?J-R9$\OZDMF#(U9Q_+V"-7$0^PE6%>F
MW@LW0"!VKH4U2>#D+SWGXC\ID87!@D0Y^='!(0VQNV0SNJL-07";#T.UF((.
MHW<6YQ5RN654:3!PY)U5QN4NNU$N""#M9PX#!ENHW*RW4RUT7T/UNT3U_HV&
M,&XSK5=;QL$P7M]I.P;R5RR'<'K)NI9;A=;6]36F;%,SLE[JG.NJ9-$@E11(
MFBFFF7I^8RUR<EL>!%BXV'\.*)5"HL:$A00/F8C5W:[.Q+,237,<7"Z8RY.0
MS/GS 22NQW,78 MKX*+V4   =!UKP6?5WH%'Y9L>;6FKF+DLA6S+M+SS/O@A
MC&A'^7<>T:_8\J-Z-4#KFJ2,W$U[)TV<#ILBE4DGHR"A3/DTW!*$XD!XX<38
M_EPRCD=O<VWN&W775+BXB_9@DV34U>_6S_5?7>GZSZ;L;]J[NW?I>WSV]/<_
M:;++NVBU;2W(VVQII9@NR9JR4X.N5H/Z%1ZDR\C-Y#R%(LGSBM4>"(!3@5Y+
MJL5#+.#@"#)FBLY5$$TC#R342OS]+Y?K;F'(-TRQD^45L^0<AV.2M-HF7ZQW
MQA>2*QC-HF.,J %9U^N1_P ,?'-4BIH-V;=,I"%^O)21V%#\*\1LD@B8/B;H
M)C_B1%,H^!^@AY OGQS._2UJP-#>LD9J"7P'D?     B/@/Q#Z?X?7GDBCK>
MLKAYZ6KTG$6& EW]?L->E&$[79^*<&:RD)/1+@CR*EHYR #\+UBZ2*<@B @/
M@2F 2B(#@D :UH-U.E6UV"H84[PH6MUJP3,/@?L>QK6GC1_<XFA/YC&6QM'C
MXU<64;>WD/\ ;&A%6;IL1PD"KLC^#<&5%@5VT6,W);<+SK\3*5E7NXC:;;G2
M_B/CUTZ&JGE^&BY:.ZD)EKT:P/W'_P >HKZZ=M\_QO0Z[UG=\&&+[18H(.6)
MBS<.6EE9EQ%EA'2@U)XPR;3HZ0*]L$"T;"DULD4\5>*-FQ$II@4JC@ZDW,XN
M'/'U_%.C/(?V0^8'QT\/T6-5V)S,W&2?E_+(ZH@_:GY;>&OB/YJZ2]-=:]7L
M)8MJDEKHA6KI#V"':RB.:B/H>Y6;(2+QLD'ZXO>F*1DW35\4GL#=F*+)(1$"
M)$^O.9D[B,8I 0ZFQ!TL1X'XUT\120++&08R+@C6X/2QJ9?T_A^'-1J17^\4
MIQ2G%*<4IQ2G%*<4IQ2N:#0?165SU@SO2UHV4QS>\=47;3L(VC&LR-HK+R%=
MR],MM8IC:IY2I 2R*2,RQC)Z.3?QSQ+V;J.&A?!A\#XYGC>-R9_X:<9Q:L<?
MEHQD,I9=8I1F22Q%T87V[@NX6&]+[38AJZKFN3QH?X@Y?)(JY''F'$1@"0LB
M'#2*5%<=#8LNX:HUCU%J\/H_UVW;G,D;";3=AU!?5G)N%\343KJUE8S,%)Q[
ME[B37]J_:7_+-=:6&0E)-+^^5J1CWKF1;G3;3"C8QDO9N1+G2<HLC>U.3Y4,
M?SOW)OR<B!=6B6*$QP8]MH8+WFGD6%B2&M*1>137*8J1ISN#Q UXO@_PH96%
MED>:7<\]P=I=8%AB,BK81_AAM'40"Q5@_<6U=.VF_5M%X)SGC>5WDW$V'INS
ME\=X]L$6^U]U2CMCK?D*]62?4DHHT97)+(E><-6D.,B8B#]JLN"95O<@&@<9
MQC<CB^W.*S7>'CL+A,?(RK6!9\>("+&NS+9WF*L5L7&P K8M:UY;D$P>4]R<
MKB(L^9E<M/!BWN5'U!"ODV!!>..,. 20A+;@UU%[!T/VP6$VE/)CUGV0=JC6
M@HUX]1;TA#:4B500JIH\T46LIUI*H$A"U\L<;[<60( V%#^7Z>@^.6&;_P#(
M+*,VTQF!W=S\0-Y;PU]]K#KUL*K,/;A&,XX[?;((V>BQO=BNWY2Q)U'B35<]
MXU\W$QYT'[\=5]FPSG;)>6-0\^4ZCX-G(N@V>?0SUK78]@J7D7'5TQH[:-7+
M:QM:_"F?HR;%@=48)%!)%4I *(%C9^3F>X,'VWSN5&8^1AY2*#+C/S1-B!U6
M4^+8[1&-(9NC!-2-!7N'&Q^(S^:XK$??Q\_'R9&,X^5AD*I>$V%EG24.TL=[
MEI"5N+UT[;Q:(T_L'T6D]8KM).Z%99*J4F?QKDMI'_-;,,Y?I:,7,4R^0 E7
M9OV,I!S++X'0-G#9PLQ6<(%53%3V"5S\>0_*MR?$R+'R^+EO-CRZV#!R;;E]
M020>EBM]"&L2H%:O;LR8_%QX/(HS\;/B)%D1:>I"@!!5@5+(WJ4,+;A8Z$US
M-=>EY[--:[9WI;?Y_P!-,J*;3'Q=KA0\<URLX]N\Y!;!9LQE7+%A>(NM!5*R
M?N[K!6.30CK)++QQG#=)DY5.!RE\>-$K/D>R)\3C6./RO)\Y(Z(%"G&;-!,A
M4>E53'9F*LUD]*C=:K$O$ON3"7E1WN-XOADA:0-^\QXS%D+,-UI)TVH0MV!)
M) -Q4B]./VTDF&O])O.>M^^QK$&R.9&A\R;'5+".Q(4"F-\SY#-_4%M!2(C(
M!U]].QZSHC1Z]6775<N&YC>P$]"EL\K!PN%,?!<5,TW%X$:PPMN)4!0-_;N3
MZ#)N*M>[_.22QJGASLGF7EYSD85AY#-D:1UVA6VW(B#BYU6+:-M_PQZ  %K+
M]..MFZ]=N_\ M+II)26R.PNAW9KK)+R9LWY/,]R8M5=AX-I.5O(,!EFUL(AO
M"L;!=Z387#EE)R2*!Y+XVK45%E$#"%:D$7/^VN5]C9D44&#C_P"*QO0JHZ3@
M).(C<?CI*$E>($$B(3 7:IL\S\1S7&>[L21Y<R1OIY_4QD1H3W,<L!<F INC
M5R+(TC)\H-9AIYN=L#TZ8PK.B'9+K7L-9\/8%%W0,!]@6 L;6O.^(LE8I;NG
MCO',5D>KT2.FK]C6XP=>.G%?;F:/@.+0I! A"E<+V$_.'GE3*Y@'']Q")(Y5
M(9XYVB18^['+<[FD559@X#$EG<JS&-8<?$+Q#O#Q![_"-(\B&X62+NN9&C>/
MP579[%3M LJ J U?P_W0D^QGM_ZS=D-6=7MF(O635" VB:96V!RO@BPX%Q\_
MD<KX^;1M<85!MD5G6[?:5&\C&^C@Y8XB95'9 )[>%3$]<'%)A<EG9^:.UBS<
M48(PQ&YWWLP(4$D+J "0-;] +F-S^W-X_"P<,]W)AY6.>2P-E15L;L0!N\=H
MOI;6YL,+Q!L+=-!.WKN$R3E33#?;(^.]E+OKLYQ/=M?=8K9EFH3C;'.+"PUA
M=FEXYU'H 4'LH0B)T16(?XU"F$IR>HU?MW+6+VE)Q$R2)E#G,^?U"P[<DT@0
MCQ]0LPTL5*D'RO\ GT67F\?-C=&A'$8L1L;D.J#<#;I;4$$W!!N.E[><9=@L
M'NE5-B<94O4_>G$DU7\"W:PM9/8[6BQ8>K]M<R45(P3*K4R2EY1X:?MJ[MP4
MP,B)D,*0^P"/CQR/S>+)D>W<]H;-)]/(@0'ULSQ26VKXBXL?B0/&L</E18_N
M# $MQ&<E&+V]"!)$)+M^KH=/.Q\JI(Q?USYZR_\ MQM)J_7J+<\8;S:/RCW:
MS E.M==EZU=2Y5QAE?(]E1QY+0SL8FPQY,EU*14:I(^R"BCE=H<P>H>!F\WG
M\CP_(\=[GX,M)F8"0[XU 8RP21K'D1$'K9;2&/7N=OM%?7I X7"P.4Q>3]O\
MT F%R#S*DC=(I@=T$W0Z;KQEOU$D:13=160S&F>U$;^W4WYF<RXVMEPWZWV2
MO.S^9J'7*B_E,C!<<B7JIJU'&J%?8ED; L&/<=PC-!&*#Y31107;)D*"8EY$
M]V\7C<=PG&^V.'9I\7"RL-V(.\-/+FPY&7*6!.]KG9+-<[S%O)VV-6?M?DY.
M0Y_/]Q\DBP2Y.)F1(#==L$6#/C8L84VVJ?FB3K^* ;N36XNP]KE3$T_^W\SD
MVUTV/RY6M7)U[8\VU[!.)IW)E_I;)WK77:81M)5:+^)9N["=>&242642'P@L
M4HBH4"&\YY9/XH/R.US@'C.1C$@%T+RSP;%W=-0"WV"XN :T<<@/\-S@LRKF
M?7\8^PFS;88LDR&W7TEE4_$@&UZGY3NYW'MUN=+I+/0WM0@W5UM4#5$)ZVZ1
M7.N5*O+3\@A')S-KL#V=^VA:]&&7^5XZ$#E01*8X@(!RYPL;ZW+CQ%>.-I&M
MN<[4&A-V:V@TM?SM55FY286'+F,KR+$F[;&I9VU LJZ7.O2M8:4XORC7^[_N
M,RE9<:WBMXTR)0M)8W'>0)NMR4=3[VXJ6+',=8R5*P.$21TZ>%?&^)T5N<XH
M*!ZG]1\!S7PI$7MC,QY/3.W--(%.A*&-P& ZE?CTU%.11G]P8DZ"\2\6R%AT
M#&6,[2>E]#IUT-5 _N$>OS:G%*&T.6-$\/VS.F)>S!CC2D[<8-H=8G9U_B[,
M.*[75K91=EJ;7*HLH9V]N;*ONHJ>668G(FY7^==81<D^+G8\ KF8?#.=G$)S
M,'(8[*#^!/%N$T-C=%BRE?>2-AWI8G1 >B&7''%+S4(!Y9>,R,*96(_'@F0B
M)[@!R^,P"A;N"K A1ZS787'M'R6%6+$[%Y^I)XN;-#Q@(&^_^^)4R(F8_;?Y
M_O/G#X_C_'W^G+CW"#+!G"(;BR36MK>X:UO._A51PGX1Q.[Z=O:O?2UMM[^5
MO&JKOV]^,\C8?ZD-4\=Y9H=NQG?J\SR6G/4J]0,A6;1#G>Y:O$BR+)0LHBW?
MLA=Q[M)=,%"%$R2A3 '@0YU'N.>#(/'M ZN%XC"4V\&7'164^(8$6(.H.A .
ME47#PRQ97*&5642<QF.MQ\R-*2K#S4^!&A\-*L7W B9B>U,V?@J]#R5AGYO7
MK,\1!P,,T5?R\W,2>.;&RC(F+8H@*SR0D7JY$44B )CJ'  ^H\^:>]<>?+]I
M<CBXJ-)D28DBJJBY)(L  .M=M[;DCA]PX,TS!8DRXF8DV  =222>F@KG ZF>
MR$VE'7/J[J]F/KU[4QR;AF@OJ];BU/2*\6&OKR;BTV&=]X28"58_>LU&TJGZ
MF421. ^2F* @/.XY;,ARYUFBOM3&@0Z:[HH(XV^[<IL?$6KDN)PY,.&2*4KN
MDRIY!:_RR2LZWTZ@,+^1O609$VNLV,^WO%O8#):2]@-KP1ESJRA,;13/'FK=
MIMV0J3?IW/;NZJ5')U29OTQJ4]&0L,)G+8SE55$RZ7DHE/[!2\=B/PO->X\+
M+(9\B7CFB=/5$ZKB!VVOH"R-+VW ^61'0Z@7NL_)3EN'X/)@#(,:3D!(CC;(
MI,O;4E=?2^S>A-MR,C#0FTJ\Z96QQW>:^[!]>J&O.^^KS_(>,4[;7LT[%ZL3
MV*Z%7;A0[E6++2Q:3$Y,K?JLJ2TQK115@D5)9>.(X^-4A@ P;,WC,S-XZ3DN
M-F@CY#CYX)HA):[ON;TJIU(*AD=QK&'#V:VTL/D,3#SH\3.BEFP<N.:*39>R
MH4U+-T!!(:,&ZNR;38&]8]@SN7NNME#@L.=K^HFRFL^?:1&-*JTNV+\-Y+V4
MP=L$C6FZ<*>]8WNF&ZS<3P[R=7: Y7AY,"J- <IC]P?W$J4[(S\/E96S,-)H
M\N4EWQW2SHSDDJC:)(M[@$$6Z78#>T#&P,SC(QB9+128$0")D(?2RJ+ R)JT
M;VL;>K=JUD/H'JL.VS?-9M:L_O>H79AMII'98H%-K(%;'-N/-8GF:5DJ?O.P
M:NN)4SO$*M5YJ"KR"<.9PE(*MY<YBJJJIG(CJ^BY(<>9R(/S0Y MCB1=W9"D
M-N>^T3]PKM0 @C>ILH$QW'*X_P"M$*M+] (B&F,;[>Z6!4JNVY@[8?>_4'80
M"28A7GWP3NTT]GRK&R=29JCZQP+EY6]>B*RE4E8R\7)I&)N[MD22/5YR;=Q,
MW+-7?V<4PE@9NTHIFHJ1N519T!?*VOK7JJ-D $0^ADRC]?JI[^/^GXR'-]?]
MW)J4\:V93*9'V9\DE,Y7Q1CID=1,IWUN1S)*N$$Q$OR*GBZ'AZUD5$@B/@I7
M8>P!^(>>:V"CH;FL5-BGZRZ9.P)_6_9?4H;R!14"CZJ;!3!@$?/N1)2T5R.(
M(E'_ "G,GX'\1)_#GDD^5>C\:L1P-C[H9H3IDTOV>++G*V*&2\S.9:KFZHTQ
M-T41]C,8B,Q[3J2U;G 0]B/5WO@ ^I_'GFM]WW5X.SQZUT.:Q?Z5/[=H_P"D
MC^S7]MON5_;^S/\ 3/Z)^H?*?[K]2_IWZ_J?R^?D^Z_G^?QYKK/I\*\C</\
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6*4XI3BE.*4XI3BE.*4XI3BE.*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>vc051_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  : 'T# 2(  A$! Q$!_\0
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M&2>-;?Q% ^J7/BF36;:[T633O^$@9DM8-'OTN?LJAIH?-8IQ?_!4G_@FJ/\
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M^!&L_P#!"W2-7_X)B^ ?^";C?M,ZY!8^!OC9+\91\8%^%^E/J.ISR^(O%?B
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0KSC*DL7[&;5.4H7@E+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>vc051_ex5-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex5-1img02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  + $X# 2(  A$! Q$!_\0
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M/B3Q'??%KX-^+]$N_&OQST;QGK_A^76;?1/ASJEAJ>E7FGZP=1E==9TQ;?\
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M-HD'A'QGX6\*>'="UC2'L)+>33M)MH(5A'F&0 _F=U7Q7_P4L^)O_!1GX1?
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.--U/Q =3U"SM[F, _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>vc051_ex5-2img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex5-2img01.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ; )T# 2(  A$! Q$!_\0
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3M>,4[3M[M._LZ>OLXQN[_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>vc051_ex10-5img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex10-5img01.jpg
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M$0$#$0'_Q "Q   " @(# 0             ("0<*!08  P0" 0 !! ,! 0
M           '! 4&"  ! P()$  !! (! P,"! ,%"0$    % @,$!@$'"!$2
M$P 4"2$5,2(6%U%A&$&!,B,9D:'!T4(S)#0E-1$  0($! ,%! <& @L
M 1$"  ,$!2$Q$@9!$P=187$B%(&1,D+PH;'!(Q46X5)B,T,DHA?1<I)31"4U
M165&"/_:  P# 0 "$0,1 #\ O[*5A..N?[OYY_AC^>?7A[Q+"G*,B+-G[7H&
MI:T8N>QK4'I]5$14O3C1J8W$B-JRVZZF.UE75R1-?;:5XV6L+=7T^B?4<O\
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MR5KLOBFZ\X[UAY-PB60,D!-IXL)!DOSR)R,W(D,J>=>AR$NJP^M]Z8VXA?\
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MMPEK#37<[8"HN%0VY"QEIYM-/<'/X/4,0_45^BSVT=/95JV16;KN834T:/\
M$OW0Z+<G+'B[?ZOR\:JFZ3^=IKT[?*#C75RF6B%2(Z:-]^'3;E4Z?*A-"6''
M#Y]L<4+X4B4[V0V%MIRY&\R#JA,I;=L2XSJA[F'TWQ-^(*YHP3%8&FRY;OU7
M;:N6W52S*V6O80'*>WLBN[^T^Q_VV[ON ?W7]'?L^[[A-\/B_JQ\7WGS_<.W
M[O\ 9OR]?^YY_P#)\G=]?5#.10>GU^LJT7G\?]]I7+MP\(^E7ZMMGYNG)_\
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%61D?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>vc051_ex15-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex15-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K J8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>&[D+:Z7.?NH(V/M@_\ UJ^B48.H93E6&0:PHMZIFM5+1H=BBBBN@Q"BBB@
MHHHH *J7E@M[LW3W,6W_ )X3&//UQUJW10!E?V%'_P _^I_^!C_XU>M+5;2'
MRUEFEYSNFD+M^9J>B@ J&\M(;^RGL[A \$\;12*>ZL,$?D:FHH ^7[7Q3<>
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M48Y/;(K:!! (.0:\HTOX+K>:L-7\;ZY<>(+L?=B?*Q#]<D>PP*UOBK%=:?\
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M9;FWL[63S40XR-QE(![<BK.F7_C75K674+6YT(VXGFCCMI+:578)(R &02$
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M\*/[-\<_]![3_P#P&'^%8^VE_(_P_P S3V:_F7]?(Z^BN0_LWQS_ -![3_\
MP&'^%']F^.?^@]I__@,/\*/;2_D?X?YA[-?S+^OD=?17(?V;XY_Z#VG_ /@,
M/\*/[-\<_P#0>T__ ,!A_A1[:7\C_#_,/9K^9?U\CKZ*Y#^S?'/_ $'M/_\
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>vc051_ex15-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex15-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E 'P# 2(  A$! Q$!_\0
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M*** "BBB@""2QM);R&\DMH7N8 RQ3,@+H#UP>HS4]%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>vc051_ex15-1img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex15-1img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K G,# 2(  A$! Q$!_\0
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MEZ]_T,7_ )(I_C1_9>O?]#%_Y(I_C6YD>M&1ZT>S7G]["[,/^R]>_P"AB_\
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M]EZ]_P!#%_Y(I_C6[D4F1ZT>S7G]["[,/^R]>_Z&+_R13_&C^R]>_P"AB_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 4O['TWRC%]@MMC$$CRQR1T_F?SI7TC3I+:.W:PMC#$<QQ^4,)]!V_"KE%
M%9-.LHRI2T@4JH1=J 8 ;<!^?/UJ6&"*VB$4$:QQ@DA4&!DG)_4DU)10 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>vc051_ex23-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex23-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K J8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>&[D+:Z7.?NH(V/M@_\ UJ^B48.H93E6&0:PHMZIFM5+1H=BBBBN@Q"BBB@
MHHHH *J7E@M[LW3W,6W_ )X3&//UQUJW10!E?V%'_P _^I_^!C_XU>M+5;2'
MRUEFEYSNFD+M^9J>B@ J&\M(;^RGL[A \$\;12*>ZL,$?D:FHH ^7[7Q3<>
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M48Y/;(K:!! (.0:\HTOX+K>:L-7\;ZY<>(+L?=B?*Q#]<D>PP*UOBK%=:?\
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M9;FWL[63S40XR-QE(![<BK.F7_C75K674+6YT(VXGFCCMI+:578)(R &02$
MG;UVGKTJYI?A[Q+I\UH)?%%O<6L&U6A&EI&SH/X=P<XZ=<57M?"/B&Q26UM?
M%OD6$DTL@CCTY/,02.S$"0L><L<$@U3WT)6VIT>DZFFLZ';ZA&C1K/%NV,>4
M/0C/L<BO*="U'0[G1;26[\2>,6U5TRZP27CJ9/11M*'G\*]<L=/@TW3(;"T7
M9##&(T!.3@#J?4U7T#2O[#T&RTPSF?[-&(_-*[=V/;)Q2>['T,KPWJFL37=O
MI^K*BSKI<-Q,-F'\UF93G!QT4< =<U4\2>)[_2-,U>YCGL8/LM[!;I-<QL8X
MT?9N9\,"<;R>,=*T]8\/WUWJ:ZGI.L-IM[Y(MY"UNL\<B!BPRI(P02>0>]5+
MKPA<W.A36AUESJ,]W'=R7TENK#S$*E0(P0 OR 8S^=#UU_K<%I_7D9/AWQI=
MZCKD=@-:T#64DBD=FTR-T:WVC(9@78%22!V.2.M=5X9U*?6/#.G:C=",3W,"
MR.(P0H)] 2:R[/POJQU.VO-8\0)?"U+-!'#8I;@,RE26(8DC!/''/TJMI?A7
MQ1I-I:V5OXNA-G;!46)M*7)0=MV_T[XI@.M/%&JWNF6,5K;6LFJWL]RB;]R0
MQ1Q2%2[<DGC;P.I/85KZ2GB>.YVZQ/I-Q;E2=]I%)$X;C VLS CKSD?2J2^#
MA'I5M;PZC-!>VEQ-/;7L2 ,GF.S,I4Y#*=V"#UP#P:N:3I&JVUR+G5M?EU"1
M5*I'' L$0![E1DD^Y/X4D OBK64T30I9_.BBGF9;>W:5PBB1SA22>@')/L#6
M/X/URW@L=3TR?6!J;:0?,-X9Q,\L# LK,03DC#*?]WWK;U'0+?5]6MKG4!%<
MVEO&X2SEA#+YC8^<YX)"Y &.YJN?">GP:M:WVG06MBJ1R0W,,-LJK<QN!\K8
MQT(!!Y[^M %*WNO&>IP1:C:#1;2UF3S(K2YCD>0J>5W2*P"DC&0%./>I[S4]
M=O-2DTK1DL(KBVA1[NZN@[QH[C(1$4@MP"<DC QUJ&+PKJ]H%L['Q3<P:2HV
MI;FV1Y8T_NI*>0 .!D$CUJSJ'AJY>Y2]T?6)].OO)6"61HUG2=5^[O5L989.
M&!!Y/6C0!)=4UO1M(EFU:*QN[MI(X+1++=&)I'(4!@^=G)]3QGZ54N=0\7:+
M;2:GJ2Z/=V,0WSP6B21RQ)_$RLS$/CK@A<XK07PT]SI=Q:ZMJEU?37!5C.,1
M>4RG*M$J\(0<'N<]<U2;PKJU[_HVL>)Y[W3<C=;):I"TH'\,CKU![@!<_2CJ
M!J:=J<]YK^K6;>6;>U6!H2JD,=ZDG)SST]!6+J7B'78DC&G06D\YU62V,3J1
MOA168A3N^^0N 3QGM5[4O#FHOJLVHZ)KATR:X1$N$>U6='V9VD D%3@XZX]J
MDMO#)MUT\F_DFFMKM[N:61!F=W5E/ P%'S<8]!3 BFUZ?4_L T.>!?MD4^&N
M(B3'(@& RY!&"2".OTK*T^\\<7>OW^G2:AH(2Q,)D9+&4&17!.!F4X.![UNG
MPU"GBN+7;>=H?W;K/;*OR2NP $G7A@!C..1C/2K-GI!M-;U34A<;C?"(>64_
MU>Q2.N><Y]J- ,R^\17-MXG@MU6$Z2KK:W,I!WK.XR@!SC;]T'CJZ^]1:AXE
MO=,\630W$4)T*"WB,\RJ?,ADD+ .W./+^7!..,@GC-1R?#C0+JUF>]LK:XU:
M;<SZD80)?-))#CG@@XQSQ@5LV.C/!>W%U=W2W3W-K#!*#$%#%-V6QD_>W'BA
M 4+FZ\07][?6^CW>FP?9ID :ZMWE#(T8;^%UYR>OIVK)T77?%4GAI_$6HMIM
MU;"VDE6SLK61)6920!N+MD<'H,UT'A_PZGA]K]8;IY;>XF$D,3C_ (]T"A1&
M#GE1CCT'':G:7H']F^&(M%^VS'8C+]IA_=N,L3D=<'FEZ O,P?#_ (JO=3U"
M%3KOA>^BF?:;>SD=)H^.<;F.\C_=6NWKE%\(WMQJ4,^JZY]MM[>9)HHQ91Q2
M%D.5WR#D\\\!?RKJZ8@HHHI#"BBB@ HHHH **** "BBB@ HHHH XOXJZ/)K'
MP^OXX1F6WVW*CUV')_3-?*QY[U]M31)/"\,BAHW4JRGN#P17R+XRT"7POXKO
M=,:,B*.0M 6_CC/*G\N/J*3&C9\(W@N-+,#$;X&V@?[)Y']:^@_!FK+JF@0@
MG]];@12#//'0_B*^4]'U%M+U!)QS&>'7_9KUSPSXC?2;^*^@826\H D4='3_
M !KF;]G4OT9T6YX6ZH]QHJKI^H6VIV<=U:R!XG&1ZCV([&K5=2=SF"BJ&LZS
MI^@:;+J&I7*P6T8Y9NY] .Y]JP%^(_A^2-9(Y+AU89!6+J/SJ7)+<:3>QUU%
M5=/U&UU2S2ZM)1)$_<=0?0CL:M4T[B"N-\4_$G1O".NVVF:DLY\Z'S3)"N_R
M^< ,O7G!Z>E=5?WUOIMA<7MW*(K>",R2.>R@9-?(GBWQ#-XG\37NJR_\MI,1
M+_=C'"C\OUH8'U=HWB71M?MTFTO4K>Y##.U7&\?53R*U:^,=&AN+C5H$MGDB
MEW9\R-BK(!U.1TKZJ\$7U_?^'XY+X[MIV1R$_,ZCN??W[U/-K8IQTN=)116/
MKEMKMP8/[%U"WM N[S?.BW[NF,<<=Z<I<JO:XDKNQL45R']F^.?^@]I__@,/
M\*/[-\<_]![3_P#P&'^%8^VE_(_P_P S3V:_F7]?(Z^BN0_LWQS_ -![3_\
MP&'^%']F^.?^@]I__@,/\*/;2_D?X?YA[-?S+^OD=?17(?V;XY_Z#VG_ /@,
M/\*/[-\<_P#0>T__ ,!A_A1[:7\C_#_,/9K^9?U\CKZ*Y#^S?'/_ $'M/_\
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>vc051_ex23-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex23-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E 'P# 2(  A$! Q$!_\0
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M*** "BBB@""2QM);R&\DMH7N8 RQ3,@+H#UP>HS4]%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>vc051_ex23-1img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vc051_ex23-1img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K G,# 2(  A$! Q$!_\0
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MEZ]_T,7_ )(I_C1_9>O?]#%_Y(I_C6YD>M&1ZT>S7G]["[,/^R]>_P"AB_\
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M]EZ]_P!#%_Y(I_C6[D4F1ZT>S7G]["[,/^R]>_Z&+_R13_&C^R]>_P"AB_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 4O['TWRC%]@MMC$$CRQR1T_F?SI7TC3I+:.W:PMC#$<QQ^4,)]!V_"KE%
M%9-.LHRI2T@4JH1=J 8 ;<!^?/UJ6&"*VB$4$:QQ@DA4&!DG)_4DU)10 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
